Text

Rev. 23 to Offsite Dose Calculation Manual
	ML081260684
Person / Time
Site:	Limerick
Issue date:	04/30/2008
From:	; Exelon Nuclear
To:	; Office of Nuclear Reactor Regulation
References
	CY-LG-170-301, Rev. 23
	Download: ML081260684 (261)
	v • d • e

CY-LG-170-301, Rev. 23 Page 1 08/07 LIMERICK GENERATING STATION UNITS 1 AND 2 OFFSITE DOSE CALCULATION MANUAL Revision 23 EXELON NUCLEAR DOCKET NOS. 50-352 AND 50-353

CY-LG-170-301, Rev. 23 Page 2 08/07 Limerick Generating Station Offsite Dose Calculation Manual PURPOSE:

The OFFSITE DOSE CALCULATION MANUAL (ODCM) shall contain the methodology and parameters used in the calculation of offsite doses resulting from radioactive gaseous and liquid effluent, in the calculation of gaseous and liquid effluent monitoring alarm/trip setpoints, and in the conduct of the Radiological Environmental Monitoring Program.

CnPE

The ODCM shall also contain the Radioactive Effluent Controls Programs, the Meteorological Monitoring Program, the Radiological Environmental Monitoring Program required by Tech.

Spec. Section 6.8.4 and the descriptions of the information that should be included in the Annual Radiological Environmental Operating and Annual Radioactive Effluent Release Reports required by Tech Spec. Sections 6.9.1.7 and 6.9.1.8, respectively.

CY-LG-170-301, Rev. 23 Page 3 08/07 Change Matrix The following details the linkage between the Revision 21 of the ODCM and Revision 23 regarding the renumbering of the various sections. The purpose of this section is to permit a cross-reference from the old to new revision of the ODCM for procedures and surveillance tests. Changes to procedures to address the new numbering will occur as the procedures are revised on their normal revision process cycle.

Revision 21 - Old Revision 23 - New Part I 1.0 Definitions 1.0 Definitions Table I1-1 Table 1-1 Figure 12.2-1a Figure 1-1 Figure 12.2-1b Figure 1-2 2.0 Bases Bases 3.0 Applicability 3.0.1 3.0.2 3.0.3 3.0.4 4.0 Surveillance Requirement 4.0.1 4.0.2 4.0.3 4.0.4 3.1 Meteorology 3.3.4 Meteorology 3.1-1 4.3.4 Table 13.1-1 Table 3.3-3 Table 13.1-2 Table 4.3-2 Table 13.1-3 Figure 13.1-1 Figure 3.3-1 3.2.1 Radioactive Liquid Effluent Monitoring 3.1.1 Radioactive Liquid Effluent Instrumentation Monitoring Instrumentation 3.2.1-1 4.1.1 Table 13.2-1 Table 3.1-1 Table 4.1-1 Table 13.2-2 3.2.2 Concentration in Liquid Effluents 3.2.1.1 Concentration Liquid Effluents 3.2.2-1 4.2.1.1.1 3.2.2-2 4.2.1.1.2 Table 13.2-3 Table 4.2-1 3.2.3 Dose due to Liquid Effluents 3.2.1.2 Dose Liquid Effluents 3.2.3-1 4.2.1.2 3.2.4 Liquid Radwaste Treatment System 3.2.1.3 Liquid Radwaste Treatment System 3.2.4-1 4.2.1.3.1 14.2.1.3.2

CY-LG-170-301, Rev. 23 Page 4 08/07 Revision 21 - Old Revision 23 - New Part I 3.3.1 Radioactive Gaseous Effluent 3.1.2 Radioactive Gaseous Effluent Monitoring Instrumentation Monitoring Instrumentation 3.3.1-1 4.1.2 Table 13.3-1 Table 3.1-2 Table 13.3-2 Table 4.1-2 3.3.2 Site Boundary Dose Rate 3.2.2.1 Dose Rate 3.3.2-1 4.2.2.1.1 3.3.2-2 4.2.2.1.2 Table 13.3-3 Table 4.2-2 3.3.3 Dose - Noble Gas 3.2.2.2 Dose - Noble Gas 3.3.3-1 4.2.2.2 3.3.4 Dose - Iodine-133, tritium and 3.2.2.3 Dose - lodine-131, lodine-133, radionuclides in particulate forms tritium and radionuclides in particulate forms 3.3.4-1 4.2.2.3 None 3.2.2.4 Gaseous Radwaste Treatment System 3.3.5 Ventilation Exhaust Treatment System 3.2.2.5 Ventilation Exhaust Treatment System 3.3.5-1 4.2.2.5.1

- 4.2.2.5.2 3.3.6 Venting or Purging 3.2.2.7 Venting or Purging 3.3.6-1 4.2.2.7.1 3.3.6-2 4.2.2.7.2 3.3.7 Total Dose 3.2.3 Total Dose 3.3.7-1 4.2.3.1 3.3.7-2 4.2.3.2 3.3.8 Dose - Incineration of Radioactive 3.2.2.6 Incineration of Radioactive Waste Oil Waste Oil 4.2.2.6.1 3.3.8-1 4.2.2.6.2 3.3.8-2 3.4.1 Radiological Environmental Monitoring 3.3.1 Radiological Environmental Monitoring Program Program 3.4.1-1 4.3.1 Table 13.4-1 REMP Table 3.3-1 REMP Table 13.4-2 Reporting Levels Table 3.3-2 Reporting Levels Table 13.4-3 Lower Limit of Detection Table 4.3-1 Lower Limit of Detection 3.4.2 Land Use Census 3.3.2 Land Use Census 3.4.2-1 4.3.2 3.4.3 Interlaboratory Comparison Program 3.3.3 Interlaboratory Comparison Program 3.4.3-1 4.3.3

CY-LG-170-301, Rev. 23 Page 5 08/07 Revision 21 - Old I- Revision 23 - New Part I 6.0 Administrative Controls 3.5 Annual Radiological Environmental 6.1 Annual Radiological Environmental Operating Report Operating Report 3.6 Annual Radioactive Effluent Release 6.2 Annual Radioactive Effluent Release Report Report 3.7 Major Changes to Radioactive Waste 6.3 Major Changes to Radioactive Waste Treatment Systems Treatment Systems Part II 1.4 Liquid Effluent Dose Projection 1.3.2 Liquid Effluent Dose Projection Appendix A Technical Specification/ODCM Deleted Matrix Appendix B - Radiological Environmental Appendix A - Radiological Environmental Monitoring Program - Sample Type, Location Monitoring Program - Sample Type, Location and Analysis and Analysis Appendix C - ODCM Revision Process Part I, Section 6.4 Changes to the ODCM

CY-LG-1 70-301, Rev. 23 Page 6 08/07 Table of Contents PART I - RADIOLOGICAL EFFLUENT CONTROLS 10 1.0 DEFINITIONS 11 3.0 APPLICABILITY 18 3.1 INSTRUMENTATION 20 3.1.1 RADIOACTIVE LIQUID EFFLUENT MONITORING INSTRUMENTATION 20 3.1.2 RADIOACTIVE GASEOUS EFFLUENT MONITORING INSTRUMENTATION 25 3.2 RADIOACTIVE EFFLUENTS 30 3.2.1 LIQUID EFFLUENTS 30 3.2.1.1 CONCENTRATION 30 3.2.1.2 DOSE 34 3.2.1.3 LIQUID RADWASTE TREATMENT SYSTEM 35 3.2.2 GASEOUS EFFLUENTS 36 3.2.2.1 DOSE RATE 36 3.2.2.2 DOSE - NOBLE GASES 40 3.2.2.3 DOSE - IODINE-131, IODINE-133, TRITIUM, AND RADIONUCLIDES IN PARTICULATE FORM 41 3.2.2.4 GASEOUS RADWASTE TREATMENT SYSTEM 42 3.2.2.5 VENTILATION EXHAUST TREATMENT SYSTEM 43 3.2.2.6 INCINERATION OF RADIOACTIVE WASTE OIL 44 3.2.2.7 MARK II CONTAINMENT VENTING OR PURGING 45 3.2.3 TOTAL DOSE 46 3.3 RADIOLOGICAL ENVIRONMENTAL MONITORING 47 3.3.1 MONITORING PROGRAM 47 3.3.2 LAND USE CENSUS 60 3.3.3 INTERLABORATORY COMPARISON PROGRAM 61 3.3.4 METEOROLOGICAL MONITORING INSTRUMENTATION 62 BASES 66 6.0 ADMINISTRATIVE CONTROLS 76 6.1 ANNUAL RADIOLOGICAL ENVIRONMENTAL OPERATING REPORT 76 6.2 ANNUAL RADIOACTIVE EFFLUENT RELEASE REPORT 77 6.3 MAJOR CHANGES TO RADIOACTIVE WASTE TREATMENT SYSTEMS 79 6.4 CHANGES TO THE ODCM 80

CY-LG-170-301, Rev. 23 Page 7 08/07 PART II - CALCULATION METHODOLOGIES 81 1.0 LIQUID EFFLUENTS 82 1.1 RADIATION MONITORING INSTRUMENTATION AND CONTROLS 82 1.2 LIQUID EFFLUENT MONITOR SETPOINT DETERMINATION 83 1.2.1 Radwaste Discharge Monitor 83 1.2.2 Service Water Radiation Monitor 86 1.2.3 RHR Service Water Monitor 87 1.3 LIQUID EFFLUENT DOSE CALCULATIONS - 10 CFR 50 87 1.3.1 Member of the Public Dose - Liquid Effluents 87 1.3.2 Liquid Effluent Dose Projection 90 2.0 GASEOUS EFFLUENTS 90 2.1 RADIATION MONITORING INSTRUMENTATION AND CONTROLS 90 2.2 GASEOUS EFFLUENT MONITOR SETPOINT DETERMINATION 91 2.2.1 North Vent Noble Gas Effluent Monitors 92 2.2.2 South Vent Noble Gas Effluent Monitors 94 2.2.3 Noble Gas Effluent Fractional Contribution 96 2.2.4 Noble Gas Effluent Default Setpoints 96 2.2.5 WRAM Noble Gas Effluent Monitor 98 2.3 GASEOUS EFFLUENT DOSE EVALUATIONS 100 2.3.1 Site Boundary Dose Rate - Noble Gases 100 2.3.2 Site Boundary Dose Rate - Radioiodine and Particulates 101 2.3.3 Noble Gas Air Dose 102 2.3.4 Radioiodine and Particulate Dose Calculations 103 2.3.5 Incineration of Contaminated Oil 108 2.3.6 Gaseous Effluent Dose Projection 110 3.0 ANNUAL DOSE EVALUATION 111 4.0 SPECIAL DOSE ANALYSIS 112 4.1 TOTAL DOSES TO MEMBERS OF THE PUBLIC 112 4.2 DOSES DUE TO ACTIVITIES INSIDE THE SITE BOUNDARY 113 5.0 RADIOLOGICAL ENVIRONMENTAL MONITORING PROGRAM 113 5.1 SAMPLING PROGRAM 113 5.2 INTERLABORATORY COMPARISON PROGRAM 114 REFERENCES 260

CY-LG-170-301, Rev. 23 Page 8 08/07 LIST OF TABLES PART I 1-1 Surveillance Frequency Notation 15 3.1-1 Radioactive Liquid Effluent Monitoring Instrumentation 21 4.1-1 Radioactive Liquid Effluent Monitoring Instrumentation Surveillance Requirements 23 3.1-2 Radioactive Gaseous Effluent Monitoring Instrumentation 26 4.1-2 Radioactive Gaseous Effluent Monitoring Instrumentation Surveillance Requirements 28 4.2-1 Radioactive Liquid Waste Sampling and Analysis Program 31 4.2-2 Radioactive Gaseous Waste Sampling and Analysis Program 37 3.3-1 Radiological Environmental Monitoring Program 49 3.3-2 Reporting Levels for Radioactivity Concentrations In Environmental Samples 56 4.3-1 Detection Capabilities For Environmental Sample Analysis 57 3.3-3 Meteorological Monitoring Instrumentation 63 4.3-2 Meteorological Monitoring Instrumentation Surveillance Requirements 64 PART II I1-1 Bioaccumulation Factors For Freshwater Fish 116 111-2 Ingestion Individual Dose Factors for Adult (Daipj) 117 111-3 Ingestion Individual Dose Factors for Teen (Daipj) 121 111-4 Ingestion Individual Dose Factors for Child (Daipj) 125 I11-5 Ingestion Individual Dose Factors for Infant (Daipj) 129 111-6 Dose Factors for Standing on Contaminated Ground 133 111-7 Usage Factors (Uap) 137 111-8 Assumptions Used In Limerick Liquid Effluent Dose Evaluations 138 112-1 Dose Factors for Noble Gases 139 112-2 Ingestion Individual Dose Factors (Ri) For Gaseous Effluent 140 112-3 Stable Element Transfer Data 237 112-4 Assumptions Used In Limerick Gaseous Effluent Dose Evaluation 241 112-5 Nearest Gaseous Effluent Dose Receptor Distances 242 A-1 ODCM - Limerick Generating Station Radiological Environmental Monitoring Program 254

CY-LG-170-301, Rev. 23 Page 9 08/07 LIST OF FIGURES PART I 1-1 Map Defining Controlled Area for Radioactive Gaseous and Liquid Effluents 16 1-2 Map Defining Low Population Areas for Radioactive Gaseous and Liquid Effluents 17 3.3-1 Meteorological Tower Location 65 PART II 111.3.1-1 LGS Dilution Vs River Flow (Station Outfall) 244 111.3.1-2 LGS Dilution Vs River Flow (Pennsylvania American Water Company) 245 111.3.1-3 LGS Dilution Vs River Flow (Phoenixville) 246 111.3.1-4 LGS Dilution Vs River Flow (Philadelphia Suburban) 247 111.3.1-5 LGS Dilution Vs River Flow (Crew Course) 248 Il1-1 Liquid Effluent Flow Diagram 249 112-1 Gaseous Effluent Flow Diagram - North Stack 250 112-2 Gaseous Effluent Flow Diagram - South Stack 251 112-3 Gaseous Effluent Flow Diagram - Hot Maintenance Shop 252 A-1 Environmental Sampling Location on Site or Near the Limerick Generating Station 257 A-2 Environmental Sampling Locations at Distances Less Than Five Miles from the Limerick Generating Station 258 A-3 Environmental Sampling Locations at Distances Greater Than Five Miles from the Limerick Generating Station 259

CY-LG-170-301, Rev. 23 Page 10 08/07 PART I RADIOLOGICAL EFFLUENT CONTROLS

CY-LG-1 70-301, Rev. 23 Page 11 08/07 1.0 DEFINITIONS The following terms are taken from LGS Unit 1/Unit 2 Tech Specs. unless otherwise noted:

1.1 ACTION ACTION shall be that part of a specification, which prescribes remedial measures, required under designated conditions.

1.2 CHANNEL CALIBRATION A CHANNEL CALIBRATION shall be the adjustment, as necessary, of the channel output such that it responds with the necessary range and accuracy to known values of the parameter which the channel monitors. The CHANNEL CALIBRATION shall encompass the entire channel including the sensor and alarm and/or trip functions, and shall include the CHANNEL FUNCTION TEST. The CHANNEL CALIBRATION may be performed by any series of sequential, overlapping or total channel steps such that the entire channel is calibrated.

1.3 N EHCH K Q

A CHANNEL CHECK shall be the qualitative assessment of channel behavior during operation by observation. This determination shall include, where possible, comparison of the channel indication and/or status with other indications and/or status derived from independent instrument channels measuring the same parameter.

1.4 CHANNEL FUNCTIONAL TEST A CHANNEL FUNCTIONAL TEST shall be:

a. Analog channels - the injection of a simulated signal into the channel as close to the sensor as practicable to verify OPERABILITY including alarm and/or trip functions and channel failure trips.

b. Bistable channels - the injection of a simulated signal into the sensor to verify OPERABILITY including alarm and/or trip functions.

The CHANNEL FUNCTIONAL TEST may be performed by any series of sequential, overlapping or total channel steps such that the entire channel is tested.

1.5 CONTINUOUS SAMPL ING Per ASTM Standard (1987)Section II (Water and Environmental Technology),

Volume 11.03, Article D1 356; is defined as "sampling without interruptions throughout an operation or for a predetermined time." A CONTINUOUS SAMPLE is

CY-LG-1 70-301, Rev. 23 Page 12 08/07 1.0 D_.INJTLI__ iS the opposite of a GRAB SAMPLE. The time period involved to secure (shut-down) ventilation or re-establish sampling of the release pathway shall meet the intent of CONTINUOUS SAMPLING. Consistent with industry standards, the time allowance shall not exceed 8 hours9.259259e-5 days 0.00222 hours 1.322751e-5 weeks 3.044e-6 months .

1.6 CONTROLLED AREA CONTROLLED AREA means an area, outside of a restricted area but inside the site boundary, access to which can be limited by the licensee for any reason.

1.7 DOSE EQUIVALENT 1-131 DOSE EQUIVALENT 1-131 shall be that concentration of 1-131, microcuries per gram, which alone would produce the same inhalation committed effective dose equivalent (CEDE) as the quantity and isotopic mixture of 1-131, 1-132, 1-133, 1-134, and 1-135 actually present. The inhalation committed effective dose equivalent (CEDE) conversion factors used for this calculation shall be those listed in Table 2.1 of Federal Guidance Report 11, Limiting Values of Radionuclide Intake and Air Concentration and Dose Conversion Factors for Inhalation, Submersion, and Ingestion," ORNL, 1989, as described in Regulatory Guide 1.183. The factors in the column headed "effective" yield doses corresponding to the CEDE.

1.8 FREQUENCY NOTATION The FREQUENCY NOTATION specified for the performance of Surveillance Requirements shall correspond to the intervals defined in Table 1-1.

1.9 MEMBER(S) OF THE PUBLIC MEMBER(S) OF THE PUBLIC means any individual except when that individual is receiving an occupational dose.

1.10 OPERABLE - OPERABILITY A system, subsystem, train, component or device shall be OPERABLE or have OPERABILITY when it is capable of performing its specified functions(s) and when all necessary attendant instrumentation, controls, electrical power, cooling or seal water, lubrication or other auxiliary equipment that are required for the system, subsystem, train, component or device to perform its function(s) are also capable of performing their related support function(s).

CY-LG-1 70-301, Rev. 23 Page 13 08/07 1.0 DEFINITIONS 1.11 OPERATIONAL CONDITION - CONDITION An OPERATIONAL CONDITION, i.e., CONDITION, shall be any one inclusive combination of mode switch position and average reactor coolant temperature as defined in the Technical Specifications.

1.12 PURGE - PURGING PURGE or PURGING shall be the controlled process of discharging air or gas from a confinement to maintain temperature, pressure, humidity, concentration or other operating condition, in such a manner that replacement air or gas is required to purify the confinement.

1.13 RATED THERMAL POWER See current LGS Tech Spec definition.

1.14 REPORTABLE EVENT A REPORTABLE EVENT shall be any of those conditions specified in Section 50.73 of 10 CFR Part 50.

1.16 RESTRICTED AREA The RESTRICTED AREA means an area, access to which is limited by the licensee for the purpose of protecting individuals against undue risks from exposure to radiation and radioactive materials (Figure 1-1).

1.17 SITE BOUNDARY The SITE BOUNDARY shall be that line beyond which the land or property is not owned, leased, or otherwise controlled by the licensee (Figure 1-1).

1.18 SOURCE CHECK A SOURCE CHECK shall be the qualitative assessment of channel response when the channel sensor is exposed to a radioactive source.

1.19 THERMAL POWER THERMAL POWER shall be the total reactor core heat transfer rate to the reactor coolant.

CY-LG-170-301, Rev. 23 Page 14 08/07 1.0 DFINITIOLNS 1.20 UNRESTRICTED AREA UNRESTRICTED AREA means an area, access to which is neither limited nor controlled by the licensee.

1.21 VENTILATION EXHAUST TREATMENT SYSTEM A VENTILATION EXHAUST TREATMENT SYSTEM shall be any system designed and installed to reduce gaseous radioiodine or radioactive material in particulate form in effluents by passing ventilation or vent exhaust gases through charcoal absorbers and/or HEPA filters for the purpose of removing iodines or particulates from the gaseous exhaust stream prior to the release to the environment (such a system is not considered to have any effect on noble gas effluents). Engineered Safety Feature (ESF) atmospheric cleanup systems are not considered to be VENTILATION EXHAUST TREATMENT SYSTEM components.

1.22 VENTING VENTING shall be the controlled process of discharging air or gas from a confinement to maintain temperature, pressure, humidity, concentration or other operating condition, in such a manner that replacement air or gas is not provided or required during VENTING. Vent, used in system names, does not imply a VENTING process.

CY-LG-1 70-301, Rev. 23 Page 15 08/07 1.0 DEEINJTI*INS TABLE 1-1 SURVEILLANCE FREFUENCY NOTATION NOTATION EREQUENCY S (Shift) At least once per 12 hours1.388889e-4 days 0.00333 hours 1.984127e-5 weeks 4.566e-6 months .

D (Daily) At least once per 24 hours2.777778e-4 days 0.00667 hours 3.968254e-5 weeks 9.132e-6 months .

W (Weekly) At least once per 7 days.

M (Monthly) At least once per 31 days.

Q (Quarterly) At least once per 92 days.

SA (Semi-annual) At least once per 184 days.

A (Annual) At least once per 366 days.

E At least once per 18 months (550 days).

R At least once per 24 months (731 days).

S/U Prior to each reactor startup.

P Prior to each radioactive release.

N.A. Not applicable

CY-LG-170-301, Rev. 23 Page 16 08/07 1.0 DE IIIN FIGURPE 1-1 EXCLUSION ZONE

. mpoundinig./I t:'.

' COOLINGowR NULA TRINN

"."***-;-c CETR(ý.

TOWERS. .:':

~~RC&LIMERICK .

_ot GNRATING STATION !!

-- *-NF'.CENTER ETH SITE :"

P~~~~ARKN LOTý...

0 ,0.V. ..

IN .!

o_.._ u n.d;"

CY-LG-1 70-301, Rev. 23 I Page 17 08/07I 1.0 DFE.INITI.ONS EIG.URE1-2

CY-LG-1 70-301, Rev. 23 Page 18 08/07 3/4 CONTROLS AND SURVEILLANCE REQUIREMENTS 3/4.0 APPLICABILITY 3.0.1 Compliance with the Controls contained in the succeeding controls is required during the OPERATIONAL CONDITIONS or other conditions specified therein; except that upon failure to meet the Control, the associated ACTION requirements shall be met.

3.0.2 Noncompliance with a Control shall exist when the requirements of the Control and associated ACTION requirements are not met within the specified time intervals. If the Control is restored prior to expiration of the specified time intervals, completion of the ACTION requirements is not required.

3.0.3 When a Control is not met, except as provide in the associated ACTION requirements, within 1 hour1.157407e-5 days 2.777778e-4 hours 1.653439e-6 weeks 3.805e-7 months action shall be initiated to place the unit in an

a. At least STARTUP within the next 6 hours6.944444e-5 days 0.00167 hours 9.920635e-6 weeks 2.283e-6 months

b. At least HOT SHUTDOWN within the following 6 hours6.944444e-5 days 0.00167 hours 9.920635e-6 weeks 2.283e-6 months , and

c. At least COLD SHUTDOWN within the subsequent 24 hours2.777778e-4 days 0.00667 hours 3.968254e-5 weeks 9.132e-6 months .

Where corrective measures are completed that permit operation under the ACTION requirements, the ACTION may be taken in accordance with the specified time limits as measured from the time of failure to meet the Control.

Exceptions to these requirements are stated in the individual controls.

This control is not applicable in OPERATIONAL CONDITIONS 4 or 5.

3.0.4 When a Limiting Condition for Operation is not met, entry into an OPERATIONAL CONDITION or other specified condition in the Applicability shall only be made:

a. When the associated ACTION requirements to be entered permit continued operation in the OPERATIONAL CONDITION or other specified condition in the Applicability for an unlimited period of time; or

b. After performance of a risk assessment addressing inoperable systems and components, consideration of the results, determination of the acceptability of entering the OPERATIONAL CONDITION or other specified condition in the Applicability, and establishment of risk management actions, if appropriate; exceptions to this Control are stated in the individual Controls; or

c. When an allowance is stated in the individual value, parameter, or other Control.

CY-LG-1 70-301, Rev. 23 Page 19 08/07 3/4 CONTROLS AND SURVEILLANCE REQUIREMENTS 3/4.0 APPLICABILITY SURVEILLANCE REQUIREMENTS 4.0.1 Surveillance Requirements shall be met during the OPERATIONAL CONDITIONS or other specified conditions in the Applicability for individual Controls, unless otherwise stated in the Surveillance Requirement. Failure to meet a Surveillance, whether such failure is experienced during the performance of the Surveillance or between performances of the Surveillance, shall be failure to meet the Control. Failure to perform a Surveillance within the specified Surveillance time interval and allowed extension per Surveillance Requirement 4.0.2, shall be failure to meet the Control except as provided in Surveillance Requirement 4.0.3. Surveillances do not have to be performed on inoperable equipment or variables outside specified limits.

4.0.2 Each Surveillance Requirement shall be performed within the specified surveillance time interval with a maximum allowable extension not to exceed 25% of the surveillance interval.

4.0.3 If it is discovered that a Surveillance was not performed within its specified Surveillance time interval and allowed extension per Surveillance Requirement 4.0.2, then compliance with the requirement to declare the Control not met may be delayed, from the time of discovery, up to 24 hours2.777778e-4 days 0.00667 hours 3.968254e-5 weeks 9.132e-6 months or up to the limit of the specified Surveillance time interval, whichever is greater. This delay period is permitted to allow performance of the Surveillance. A risk evaluation shall be performed for any Surveillance delayed greater than 24 hours2.777778e-4 days 0.00667 hours 3.968254e-5 weeks 9.132e-6 months and the risk impact shall be managed.

If the Surveillance is not performed within the delay period, the Control must immediately be declared not met, and the applicable ACTION requirements must be entered.

When the Surveillance is performed within the delay period and the Surveillance is not met, the Control must immediately be declared not met, and the applicable ACTION requirements must be entered.

4.0.4 Entry into an OPERATIONAL CONDITION or other specified condition in the Applicability of a Control shall only be made when the Control's Surveillance Requirements have been met within their Surveillance time interval, except as provided in Surveillance Requirement 4.0.3. When a Control is not met due to its Surveillance Requirements not having been met, entry into an OPERATIONAL CONDITION or other specified condition in the Applicability shall only be made in accordance with Control 3.0.4.

CY-LG-1 70-301, Rev. 23 Page 20 08/07 3/4.1 INSTRUMENTATION 3/4.1.1 RADIOACTIVE LIQUID EFFLUENT MONITORING INSTRUMENTATION COXNTROLS 3.1.1 The radioactive liquid effluent monitoring instrumentation channels shown in Table 3.1-1 shall be OPERABLE with their alarm/trip setpoints set to ensure that Control 3.2.1.1 is not exceeded. The alarm/setpoints* of these channels shall be determined and adjusted in accordance with the methodology and parameters in ODCM Part II, Section 1.2.

APPLICABILITY: At all times.

ACTION:

a. With a radioactive liquid effluent monitoring instrumentation channel alarm/trip setpoint less conservative than required by the above control, immediately suspend the release of radioactive liquid effluents monitored by the affected channel, and declare the channel inoperable.

b. With less than the minimum number of radioactive liquid effluent monitoring instrumentation channels OPERABLE, take the ACTION shown in Table 3.1-1.

Restore the inoperable instrumentation to OPERABLE status within the time specified in the ACTION or explain in the next Annual Radioactive Effluent Release Report why this inoperability was not corrected within the time specified.

c. The provisions of Controls 3.0.3 and 3.0.4 are not applicable. Report all deviations in the Annual Radioactive Effluent Release Report.

SURVEILLANCE REQUIREMENTS 4.1.1 Each radioactive liquid effluent monitoring instrumentation channel shall be demonstrated OPERABLE by performance of the CHANNEL CHECK, SOURCE CHECK, CHANNEL CALIBRATION and CHANNEL FUNCTIONAL TEST operations at the frequencies shown in Table 4.1-1.

Excluding the flow rate measuring devices which are not determined and adjusted in accordance with the ODCM.

CY-LG-1 70-301, Rev. 23 Page 21 08/07 TABLEW3-1A-RADIOACTIVE LIQUID EFFLUENT MONITORING INSTRUMENTATION MINIMUM CHANNELS.

INSTRUMENT OPERABLE ACTION

1. Gross Radioactivity Monitors Providing Automatic Termination of Release

a. Liquid Radwaste Effluent Line 1 100

b. A/B RHR Service Water Effluent Line

1/loop 101

2. Gross Radioactivity Monitors Not Providing Automatic Termination of Release

a. Service Water Effluent Line 101 1

3 Flow Rate Measurement Devices

a. Liquid Radwaste Effluent Line 1 102

b. Discharge Line 102 Termination of the release is accomplished by auto trip of the RHRSW pumps and remote manual closure of isolation valves.

CY-LG-1 70-301, Rev. 23 Page 22 08/07 TABLE 3.1-1 (Continued)

ACTION STATEMENTS Action 100 - With less than the Minimum Required Channels operable, effluent releases may continue for up to 14 days provided that prior to initiating a release:

a. At least two independent samples are analyzed in accordance with SURVEILLANCE REQUIREMENT 4.2.1.1.1, and

b. At least two technically qualified members of the facility staff independently verify the release rate calculations and discharge line valving; Otherwise, suspend release of radioactive effluents via this pathway.

Action 101 - With less than the Minimum Required Channels operable, effluent releases via this pathway may continue for up to 30 days provided that, at least once per 8 hours9.259259e-5 days 0.00222 hours 1.322751e-5 weeks 3.044e-6 months , grab samples are collected and analyzed for radioactivity by gamma isotopic analysis (Principal Gamma Emitters, 1-131, and Dissolved/

Entrained Gases) at a Lower Limit of Detection as specified in Table 4.2-1 or gross radioactivity (beta or gamma). Gross Beta is analyzed at an LLD of at least 1 E-7 uCi/mI. Gross Gamma is analyzed at an LLD of at least 5E-7 uCi/ml.

If the A or B RHRSW Process Rad Monitor should become inoperable, sampling is required at least once every eight (8) hours at a sample point common with the inoperable A and/or B RHRSW Process Rad Monitor(s). If a monitor is inoperable but will still continuously sample and annunciate on high activity, i.e. rad monitor bypass switch placed in "Bypass", Chemistry sampling is not required as the continuous monitor sampling complies with the periodic sampling requirement.

Action 102 - With less than the Minimum Required Channels operable, effluent releases via this pathway may continue for up to 30 days provided the flow rate is estimated at least once per 4 hours4.62963e-5 days 0.00111 hours 6.613757e-6 weeks 1.522e-6 months during actual releases. Pump curves generated in situ may be used to estimate flow.

CY-LG-1 70-301, Rev. 23 Page 23 08/07 TABLE 4.1-RADIOACTIVE LIQUID EFFLUENT MONITORING INSTRUMENTATION SURVEILLANCE REQUIREMENTS CHANNEL CHANNEL SOURCE CHANNEL FUNCTIONAL INSTRUMENT CHECK CHECK CALIBRATION TEST Gross Radioactivity Monitors Providing Automatic Termination of Release

a. Liquid Radwaste Effluent Line D* D* R(3) Q(1)

b. RHR Service Water System Effluent Line D M R(3) Q(1)

2. Gross Radioactivity Monitored Not Providing Automatic Termination of Release

a. Service Water System Effluent Line D M R(3) Q(2)

3. Flow Rate Measurement Devices

a. Liquid Radwaste Effluent Line D(4) N.A. R Q

b. Discharge Line D(4) N.A. R Q

Daily when in use

CY-LG-1 70-301, Rev. 23 Page 24 08/07 TABLE 4.1-1 (Continued)

TABLE NOTATIONS (1) The CHANNEL FUNCTIONAL TEST shall also demonstrate that automatic isolation of this pathway and control room alarm annunciation will occur if any of the following conditions exists:

1. Instrument indicates measured levels above the alarm/trip setpoint.

2. Circuit failure.

3. Instrument indicates a downscale failure.

(2) The CHANNEL FUNCTIONAL TEST shall also demonstrate that control room alarm annunciation occurs if any of the following conditions exists:

1. Instrument indicates measured levels above the alarm setpoint.

2. Circuit failure.

3. Instrument indicates a downscale failure.

(3) The initial CHANNEL CALIBRATION shall be performed using reference standards certified by the National Institute of Standards and Technology (NIST) obtained from suppliers that participate in measurement assurance activities with NIST. These standards shall permit calibrating the system over its intended range of energy and measurements range. For subsequent CHANNEL CALIBRATION, sources that have been related to the initial calibration shall be used.

(4) CHANNEL CHECK shall consist of verifying indication of flow during periods of release.

CHANNEL CHECK shall be made at least once per 24 hours2.777778e-4 days 0.00667 hours 3.968254e-5 weeks 9.132e-6 months on days on which batch releases are made.

CY-LG-1 70-301, Rev. 23 Page 25 08/07 3/4.1 INSTRUMENTATION 3/4.1.2 RADIOACTIVE GASEOUS EFFLUENT MONITORING INSTRUMENTATION GQNTROIS 3.1.2 The radioactive gaseous effluents monitoring instrumentation channels in Table 3.1-2 shall be OPERABLE with their alarm/trip setpoints set to ensure that the limits of Control 3.2.2.1 .a are not exceeded. The alarm/trip setpoints of the applicable channels shall be determined in accordance with the methodology and parameters in ODCM Part II, Section 2.2.

APPLICABILITY: As shown in Table 3.1-2.

ACTION:

a. With a radioactive gaseous effluent monitoring instrumentation channel alarm/trip setpoints less conservative than required by ODCM Part II, Section 2.2, immediately suspend the release of radioactive gaseous effluents monitored by the affected channel or declare the channel inoperable.

b. With less than the minimum number of radioactive gaseous effluent monitoring instrumentation channels OPERABLE, take the ACTION shown in Table 3.1-2.

Restore the inoperable instrumentation to OPERABLE status within the time specified in the ACTION or explain in the next Annual Radioactive Effluent Release Report why this inoperability was not corrected within the time specified.

c. The provisions of Controls 3.0.3 and 3.0.4 are not applicable. Report all deviations in the Annual Radioactive Effluent Release Report.

SURVEILLANCE REQUIREMENTS 4.1.2 Each radioactive gaseous effluent monitoring instrumentation channel shall be demonstrated OPERABLE by performance of the CHANNEL CHECK, SOURCE CHECK, CHANNEL CALIBRATION AND CHANNEL FUNCTIONAL TEST operations at the frequencies shown in Table 4.1-2.

CY-LG-170-301, Rev. 23 Page 26 08/07 TABLE_3--29 RADIOACTIVE GASEOUS EFFLUENT MONITORING INSTRUMENTATION INSTRUMENT MINIMUM CHANNELS OPERABLE APPLICABILITY ACTION

1. SOUTH STACK EFFLUENT MONITORING SYSTEM

a. Noble Gas Activity Monitor 1

111

b. Iodine Sampler 1

112

c. Particulate Sampler 1

112

d. Effluent System Flow Rate Monitor 1

113

e. Sampler Flow Rate Monitor 1

116

2. NORTH STACK EFFLUENT MONITORING SYSTEM +

a. Noble Gas Activity Monitor 1

114

b. Iodine Sampler 1

112

c. Particulate Sampler 1

112

d. Effluent System Flow Rate Monitor 1

113

e. Sampler Flow Rate Monitor 1

116

3. HOT MAINTENANCE SHOP VENTILATION EXHAUST RADIATION MONITOR++

a. Iodine Sampler 1 ** 115

b. Particulate Sampler 1 ** 115

c. Effluent System Flow Rate Monitor 1 ** 113

d. Sampler Flow Rate Monitor 1 ** 116 TABLE NOTATIONS

+ The (A or B) North Stack Normal Range Radiation Monitors OR the Wide Range Accident Monitor (Low Range) may be used to satisfy requirements for the North Stack Effluent Monitoring System.

++ Particulate filter and Iodine cartridge replacement does not affect the operability of the system.

At all times.

- During operation of the hot maintenance shop ventilation system.

CY-LG-1 70-301, Rev. 23 Page 27 08/07 TABLE 3.1-2 (Continued)

TABLE NOTATIONS ACTION STATEMENTS ACTION 111 - With less than the minimum Required Channels (SS Noble Gas) OPERABLE, effluent releases via this pathway may continue for up to 30 days provided grab samples are taken at least once per 8 hours9.259259e-5 days 0.00222 hours 1.322751e-5 weeks 3.044e-6 months and these samples are analyzed for radioactivity by gamma isotopic analysis within 24 hours2.777778e-4 days 0.00667 hours 3.968254e-5 weeks 9.132e-6 months .

IE monitor readings are available from local computer output, IrEtN GRAB SAMPLES ARE NOT REQUIRED. Obtain monitor readings at least once per 8 hours9.259259e-5 days 0.00222 hours 1.322751e-5 weeks 3.044e-6 months .

ACTION 112 - With less than the minimum Required Channels (NS and SS OPERABLE, effluent releases via this pathway may Iodine & Part.) continue for up to 30 days provided samples are continuously collected with auxiliary sampling equipment as required in Table 4.2-2.

ACTION 113 - With less than the minimum Required Channels (Effluent Flow Rate) OPERABLE, effluent releases via NS, SS or HMS may continue for up to 30 days provided the Effluent System flow rate is estimated by adding the nominal flow rates indicated in P&ID M-26 for each in-service fan. This shall be documented in the MCR operations Shift Log at least once per 4 hours4.62963e-5 days 0.00111 hours 6.613757e-6 weeks 1.522e-6 months .

ACTION 114 - With less than the minimum Required Channels (NS Noble Gas) OPERABLE, effluent releases via this pathway may continue for up to 30 days provided grab samples are taken at least once per 8 hours9.259259e-5 days 0.00222 hours 1.322751e-5 weeks 3.044e-6 months and these samples are analyzed for radioactivity by gamma isotopic analysis within 24 hours2.777778e-4 days 0.00667 hours 3.968254e-5 weeks 9.132e-6 months . The Mechanical Vacuum Pumps may not be operated while in this action statement.

IE monitor readings are available from local computer output, "rHEN GRAB SAMPLES ARE NOT REQUIRED. Obtain monitor readings at least once per 8 hours9.259259e-5 days 0.00222 hours 1.322751e-5 weeks 3.044e-6 months .

ACTION 115 - With less than the minimum Required Channels (HMS) OPERABLE, then secure Hot Maintenance Shop Ventilation.

ACTION 116 - With less than the minimum Required Channels (Sample Flow Rate) OPERABLE, the sample pump shall be documented in service by recording the air pump local flow indicator value in the MCR operations Shift Log at least once per 8 hours9.259259e-5 days 0.00222 hours 1.322751e-5 weeks 3.044e-6 months .

CY-LG-170-301, Rev. 23 Page 28 08/07 TABLE_4.1-2 RADIOACTIVE GASEOUS EFFLUENT MONITORING INSTRUMENTATION SURVEILLANCE REQUIREMENTS MODES INWHICH CHANNEL SOURCE CHANNEL CHANNEL SURVEILLANCE IS INSTRUMENT CHECK CHECK CALIBR. FUNCT. TEST REQUIRED

1. SOUTH STACK EFFLUENT MONITORING SYSTEM

a. Noble Gas Activity Monitor D M R(2) Q(1)

b. Iodine Sampler W(3) N.A. N.A. N.A. *

c. Particulate Sampler W(3) N.A. N.A. N.A. *

d. Effluent System Flow Rate Monitor D N.A. R Q *

e. Sampler Flow Rate Monitor D N.A. R Q *

2. NORTH STACK EFFLUENT MONITORING SYSTEM #

a. Noble Gas Activity Monitor D M R(2) Q(1) *

b. Iodine Sampler W(3) N.A. N.A. N.A. *

c. Particulate Sampler W(3) N.A. N.A. N.A. *

d. Effluent System Flow Rate Monitor D N.A. R Q *

e. Sampler Flow Rate Monitor D N.A. R Q *

3. HOT MAINTENANCE SHOP VENTILATION EXHAUST RADIATION MONITOR

a. Iodine Sampler W(3) N.A. N.A. N.A. **

b. Particulate Sampler W(3) N.A. N.A. N.A. **

c. Effluent System Flow Rate Monitor D N.A. R Q **

d. Sampler Flow Rate Monitor D N.A. R Q **

TABLE NOTATIONS

+ The (A or B) Wide Range Accident Monitor (WRAM) surveillance is specified in Technical Specification 3.3.7.5.

At all times.

- During operation of the hot maintenance shop ventilation exhaust system.

CY-LG-170-301, Rev. 23 Page 29 08/07 TABLE 4.1-2 (Continued)

TABLE NOTATIONS (1) The CHANNEL FUNCTIONAL TEST shall also demonstrate that control room alarm annunciation occurs if any of the following conditions exists:

1. Instruments indicate measured levels above the alarm/trip setpoint.

2. Circuit failure.

3. Instrument indicates a downscale failure.

4. Instrument controls not set in operate mode.

(2) The initial CHANNEL CALIBRATION shall be performed using one or more of the reference standards certified by the National Institute of Standards and Testing (NIST) or using standards that have been obtained from suppliers that participate in measurement assurance activities with NIST. These standards shall permit calibrating the system over its intended range of energy and measurement range. For subsequent CHANNEL CALIBRATION, sources that are traceable to the initial calibration shall be used.

(3) The iodine cartridges and particulate filters will be changed and analyzed at least once per 7 days.

CY-LG-1 70-301, Rev. 23 Page 30 08/07 3/4.2 RADIOACTIVE EFFLUENTS 3/4.2.1 LIQUID EFFLUENTS 3/4.2.1.1 CONCENTRATION C.ONROLS 3.2.1.1 The concentration of radioactive material released in liquid effluents to UNRESTRICTED AREAS (see Figures 1-1 and 1-2) shall be limited to 10 times the effluent concentration limits (ECL) specified in 10 CFR Part 20, Appendix B, Table 2, Column 2 for radionuclides other than dissolved or entrained nobles gases. For dissolved or entrained noble gases, the concentration shall be limited to 2E-4 microcuries/ml total activity (NUREG 0133, Section 2).

APPLICABILITY: At all times.

ACTION:

a. With the concentration of radioactive material released in liquid effluents to UNRESTRICTED AREAS exceeding the above limits, immediately restore the concentration to within the above limits or terminate the release.

b. The provisions of Controls 3.0.3 and 3.0.4 are not applicable.

SURVEILLANCE REQUIREMENTS 4.2.1.1.1 Radioactive liquid wastes shall be sampled and analyzed according to the sampling and analysis program of Table 4.2-1.

4.2.1.1.2 The results of the radioactivity analyses shall be used in accordance with the methodology and parameters in ODCM Part II, Section 1.2 to assure that the concentrations at the point of release are maintained within the limits of Control 3.2.1.1.

CY-LG-1 70-301, Rev. 23 Page 31 08/07 TABLF 42_-9 RAniOAG-Tl\F I lotJIn WA5RTF RAMPI INr, ANfl ANAl Y~ql5q PRC)CRAM Minimum Lower Limit of Liquid Release Type Sampling Analysis Type of Activity Detection Frequency Frequency Analysis (LLD)a (uCi/ml)

A. Batch Waste Release P P Principal Gamma 5E-7 Tanksb Each Batch Each Batch Emittersc 1-131 1E-6

1. Floor or Equip. Drain p M Dissolved and Entrained 1E-5 Sample Tanks One Batch/M Gases (Gamma Emitters)c

2. Laundry Drain Sample P M H-3 1E-5 Tank Each Batch Composite _

Gross Alpha 1E-7 P Q Sr-89, Sr-90 5E-8 Each Batch Composited Fe-55 1E-6 B. Continuous Releasee W W Principal Gamma 5E-7 Grab Sample Emittersc 1-131 1E-6

1. RHR Service Water W W Dissolved and Entrained 1E-5 System Effluent Linef Grab Sample Gases (Gamma Emitters)c

2. Service Water System W M H-3 1E-5 Effluent Linef Grab Sample Composited Gross Alpha 1E-7 W Q Sr-89, Sr-90 5E-8 Grab Sample Composited Fe-55 1E-6

CY-LG-1 70-301, Rev. 23 Page 32 08/07 TABLE 4 2-1 (Continued)

TABLE NOTATIONS

a. The LLD is defined as the smallest concentration of radioactive material in a sample that will yield a net count, above system background, that will be detected with 95% probability with only 5% probability of falsely concluding that a blank observation represents a "real" signal.

For a measurement system, which may include radiochemical separation:

4 6 6 (2.71 + . aii) (?,At2)

LLD (Composite) =

E V 2.22E6 Y [exp (-?,t,)] (1-exp(-XAt2))

(2.71 + 4 .6 6 OR)

LLD (Grab Samples)=

E V 2.22E6 Y (exp - XAt,)

Where:

2.71 is a statistical term to properly calculate the LLD as the background approaches zero (see reference 17). When background is greater than 70 counts the factor is not necessary for the calculation.

LLD is the a priori lower limit of detection as defined above ( as microcuries per unit mass or volume). The LLD for composite samples contains a correction to account for the decay of radionuclides during the collection time

{(XAt2) / [exp(-XAtl)](1 -exp(-XAt2))}.

OR is the standard deviation of the background counting rate or of the counting rate of blank sample as appropriate (as counts per minute),

E is the counting efficiency, as counts per disintegration, V is the sample size, in units of mass or volume, 2.22E6 is the number of disintegrations per minute per microcurie, Y is the fractional radiochemical yield, when applicable, x is the radioactive decay constant for the particular radionuclide, Ati for the plant effluents is the elapsed time between the end of the sample collection and the start of sample count.

At2 for the plant effluents is the elapsed time between the start and the end of sample collection.

CY-LG-1 70-301, Rev. 23 Page 33 08/07 TABLE 4-2-1 (Continued)

TABLE NOTATIONS It should be recognized that the LLD is defined as an a rkorm (before the fact) limit representing the capability of a measurement system and not as an after the fact limit for a particular measurement.

b. A batch release is the discharge of liquid wastes of a discrete volume. Prior to sampling for analyses, each batch shall be isolated, and then thoroughly mixed to assure representative sampling.

c. The principal gamma emitters for which the LLD specification applies include the following radionuclides: Mn-54, Fe-59, Co-58, Co-60, Zn-65, Mo-99, Cs-134, Cs-137, Ce-141 and Ce-144. The dissolved and entrained noble gases (gamma emitters) for which the LLD specification applies include the following radionuclides: Kr-87, Kr-88, Xe-133, Xe-133m, Xe-135, Xe-135m, Xe-138. This list does not mean that only these nuclides are to be considered. Other gamma peaks that are identifiable, together with those of the above nuclides, shall also be analyzed and reported in the Annual Radioactive Effluent Release Report pursuant to Administrative Control 6.2.

d. The term "Composite Sample" means a combination of individual samples obtained at regular intervals over a time period. Either the volume of each individual sample is proportional to discharge flow rates, or the sampling interval (for constant volume samples) is proportional to flow rates over the time period used to produce the composite.

e. A continuous release is the discharge of liquid wastes of non-discrete volume, from a Volume of a system that has an input flow during the continuous release.

f. Whenever effluent releases are in excess of the monitor's setpoint.

CY-LG-1 70-301, Rev. 23 Page 34 08/07 3/4.2 RADIOACTIVE EFFLUENTS 3/4.2.1 LIQUID EFFLUENTS 3/4.2.1.2 DOSE CONTROLS 3.2.1.2 The dose or dose commitment to a MEMBER OF THE PUBLIC from radioactive materials in liquid effluents released from the site to UNRESTRICTED AREAS (See Figure 1-1) shall be limited:

a. During any calendar quarter to less than or equal to 3 mrem to the total body and to less than or equal to 10 mrem to any organ, and

b. During any calendar year to less than or equal to 6 mrem to the total body and to less than or equal to 20 mrem to any organ.

APPLICABILITY: At all times.

ACTION:

a. With the calculated dose from the release of radioactive materials in liquid effluents exceeding any of the above limits, Initiate an Issue Report that identifies the cause(s) for exceeding the limit(s) and defines the corrective actions that have been taken to reduce the releases and the proposed corrective actions to be taken to assure that subsequent releases will be in compliance with the above limits. This Issue Report shall also include: (1) the results of the radiological analyses of the drinking water source, and (2) the radiological impact on finished drinking water supplies with regard to the requirements of 40 CFR Part 141, Safe Drinking Water Act.*

b. The provisions of Controls 3.0.3 and 3.0.4 are not applicable.

SURVEILLANCE REQUIREMENTS 4.2.1.2 Cumulative dose contributions from liquid effluents for the current calendar quarter and the current calendar year shall be determined at least once per 31 days.

The requirements of Action A. (1) and (2) are applicable only if drinking water supply is taken from the receiving water body within 3 miles of the plant discharge. In the case of river-sited plants this is 3 miles downstream only.

CY-LG-1 70-301, Rev. 23 Page 35 08/07 3/4.2 RADIOACTIVE EFFLUENTS 3/4.2.1 LIQUID EFFLUENTS 3/4.2.1.3 LIQUID RADWASTE TREATMENT SYSTEM Q0NTRQLSR 3.2.1.3 The liquid radwaste treatment system shall be IN SERVICE and appropriate portions of the system shall be used to reduce the radioactive materials in liquid waste prior to their discharge when the projected doses due to the liquid effluent, from the site, to UNRESTRICTED AREAS (See Figure 1-1) would exceed 0.12 mrem to the total body or 0.4 mrem to any organ in a 31-day period.

APPLICABILITY: At all times.

ACTION:

a. With radioactive liquid waste being discharged without treatment and in excess of the above limits and any portion of the Liquid Radwaste Treatment System not in operation initiate an Issue Report that includes the following information:

1. Explanation of what liquid radwaste was being discharged without treatment, identification of any inoperable equipment or subsystems, and the reason for the inoperability.

2. Action(s) taken to restore the inoperable equipment to OPERABLE status, and

3. Summary description of action(s) taken to prevent a recurrence.

b. The provisions of Controls 3.0.3 and 3.0.4 are not applicable.

SURVEILLANCE REQUIREMENTS 4.2.1.3.1 Dose due to liquid releases from the site to UNRESTRICTED AREAS shall be projected at least once per 31 days.

4.2.1.3.2 The installed Liquid Radwaste Treatment System shall be considered OPERABLE by meeting Controls 3.2.1.1 and 3.2.1.2

CY-LG-1 70-301, Rev. 23 Page 36 08/07 3/4.2 RADIOACTIVE EFFLUENTS 3/4.2.2 GASEOUS EFFLUIENTS 3/4.2.2.1 DOSE RATE

_QNIO_5;LS 3.2.2.1 The dose rate due to radioactive materials released in gaseous effluents from the site to areas at or beyond the SITE BOUNDARY (See Figure 1-1) shall be limited to:

a. For noble gases: less than or equal to 500 mrem/yr to the total body and less than or equal to 3000 mrem/yr to the skin, and

b. For iodine-1 31, iodine-1 33, tritium, and for all radionuclides in particulate form with half-lives greater than 8 days: less than or equal to 1500 mrem/yr to any organ (Inhalation pathway only).

APPLICABILITY: At all times.

ACTION:

a. With the dose rate(s) exceeding the above limits, immediately restore the release rate to within the above limits.

b. The provisions of Controls 3.0.3 and 3.0.4 are not applicable.

SURVEILLANCE REQUIREMENTS 4.2.2.1.1 The dose rate due to noble gases in gaseous effluents shall be determined to be within the above limits.

4.2.2.1.2 The dose rate due to iodine-1 31, iodine-133, tritium, and all radionuclides in particulate form with half-lives greater than 8 days in gaseous effluents shall be determined to be within the above limits by obtaining representative samples and performing analyses in accordance with the sampling and analysis program specified in Table 4.2-2.

CY-LG-1 70-301, Rev. 23 Page 37 08/07 TABLE 4-2-2 RADIOACTIVE GASEOUS WASTE SAMPLING AND ANALYSIS PROGRAM Minimum Lower Limit of Gaseous Release Sampling Analysis Type of Activity Detection Point Frequency Frequency Analysis (LLD)a A. North Stack/ Continuousd Q Gross Alpha 1 E-1 1 uCi/cc South Stack Comp. Part. Sr-89, Sr-90 1 E-1 1 uCi/cc Sample Mb Grab Smpl. Mb Noble Gas 1E-4 uCi/cc H-3 1E-6 uCi/cc Continuousd Wc Char. Smpl. 1-131 1E-12 uCi/cc 1-133 1E-10 uCi/cc Part. Smpl. Principal Gamma Emitterse 1E-11 uCi/cc Continuousd Continuous Noble Gas 1E-6 uCi/cc Noble Gas Beta or Gamma (Based on Xe-1 33)

Monitor B. Hot Mainten: Continuousd Q Gross Alpha 1E-1 1 uCi/cc Shop Vent Comp. Part. Sr-89, Sr-90 1E-1 1 uCi/cc Exhaustf Sample Continuousd. W Char. Smpl. 1-131 1E-12 uCi/cc 1-133 1E-10 uCi/cc Part. Smpl. Principal Gamma Emitterse 1 E-1 1 uCi/cc C. Auxiliary Boiler Prior to batch P 1-131 1E-6 uCi/ml release for Each batch Principal Gamma 5E-7 uCi/ml burn. Emitterse Q Gross Alpha 1 E-7 uCi/ml Composite Sr-89, Sr-90 5E-8 uCi/ml Sample H-3 1E-5 uCi/ml Fe-55 1E-6 uCi/ml

CY-LG-1 70-301, Rev. 23 Page 38 08/07 TABLE 4-2-2 (Continued)

TABLE NOTATIONS

a. The LLD is defined, as the smallest concentration of radioactive material in a sample that will yield a net count, above system background, that will be detected with 95%

probability with only 5% probability of falsely concluding that a blank observation represents a "real" signal. It should be recognized that the LLD is defined as an a priori (before the fact) limit representing the capability of a measurement system and not as an after the fact limit for a particular measurement.

For a particular measurement system, (which may include radiochemical separation):

(2.71 + 4 .6 6 a;) (XAt2)

LLD (Composite) =

E V 2.22E6 Y [exp (-,AtI)](1-exp(-?,At2))

(2.71 + 4.66 a*)

LLD (Grab Samples)=

E V 2.22E6 :Y (exp -XAti)

Where:

2.71 is a statistical term to properly calculate the LLD as the background approaches zero (see reference 17). When background is greater than 70 counts the factor is not necessary for the calculation.

LLD is the aprior lower limit of detection as defined above (uCi/cc or uCi/ml). The LLD for composite samples contains a correction to account for the decay of radionuclides during the collection time {(XAt2)/[exp(-XAt1)](1-exp(-XAt2))},

OR is the standard deviation of the background counting rate or of the counting rate of blank sample as appropriate (as cpm), shall be based on the actual observed variance of the background counting rate or of the counting rate of the blank samples (as appropriate) rather than on an unverified theoretically predicted variance.

E is the counting efficiency, as counts per disintegration, V is the sample size, in units of cc or ml, 2.22E6 is the number of dpm/uCi Y is the fractional radiochemical yield, when applicable, XL is the radioactive decay constant for the particular radionuclide, and Ati for the plant effluents is the elapsed time between the end of the sample collection and the start of sample count.

At2 for the plant effluents is the elapsed time between the start and the end of sample collection.

CY-LG-170-301, Rev. 23 Page 39 08/07 TABLE 4-2-2 (Continued)

TABLE NOTATIONS

b. Sampling and analyses shall also be performed following shutdown, startup, or a THERMAL POWER change exceeding 15% of the RATED THERMAL POWER within a 1-hour period. This requirement does not apply if (1) analysis show that the DOSE EQUIVALENT 1-131 concentration in the primary coolant has not increased more than a factor of 3; and (2) the main condenser offgas pre-treatment radioactivity monitor shows that effluent activity has not increased more than a factor of 3.

c. Samples shall be changed at least once per 7 days and analyses shall be completed within 48 hours5.555556e-4 days 0.0133 hours 7.936508e-5 weeks 1.8264e-5 months after changing, or after removal from sampler. Sampling shall also be performed at least once per 24 hours2.777778e-4 days 0.00667 hours 3.968254e-5 weeks 9.132e-6 months for at least 7 days following each shutdown, startup or THERMAL POWER change exceeding 15% of RATED THERMAL POWER in 1 hour1.157407e-5 days 2.777778e-4 hours 1.653439e-6 weeks 3.805e-7 months and analyses completed within 48 hours5.555556e-4 days 0.0133 hours 7.936508e-5 weeks 1.8264e-5 months of changing. When samples collected for 24 hours2.777778e-4 days 0.00667 hours 3.968254e-5 weeks 9.132e-6 months are analyzed, the corresponding LLDs may be increased by a factor of 10. This requirement does not apply if (1) analysis shows that the DOSE EQUIVALENT 1-131 concentration in the primary coolant has not increased more than a factor of 3; and (2) the noble gas monitor shows that effluent activity has not increased more than a factor of 3.

d. The ratio of the sample flow rate to the sampled stream flow rate shall be known for the time period covered by each dose or dose rate calculation made in accordance with Controls 3.2.2.1, 3.2.2.2, and 3.2.2.3.

e. The principal gamma emitters for which the LLD specification applies include the following radionuclides: Kr-87, Kr-88, Xe-133, Xe-133m, Xe-135, Xe-135m and Xe-138 for gaseous emissions and Mn-54, Fe-59, Co-58, Co-60, Zn-65, 1-131, Cs-1 34, Cs-137, Ce-141 and Ce-144 for particulate emissions. This list does not mean that only these nuclides are to be considered. Other gamma peaks which are identifiable, together with the above nuclides, shall also be analyzed and reported in the Annual Radioactive Effluent Release Report, pursuant to Administrative Control 6.2.

f. Required for the hot maintenance shop ventilation exhaust only during operation of the hot maintenance shop ventilation exhaust system.

CY-LG-170-301, Rev. 23 Page 40 08/07 3/4.2 RADIOACTIVE EFFLUENTS 3/4.2.2 GASEOUS EFFLUENTS 3/4.2.2.2 DOSE - NOBLE GASES CONTRO.LS 3.2.2.2 The air dose due to noble gases released in gaseous effluents, from the site to areas at and beyond the SITE BOUNDARY (See Figure 1-1) shall be limited to the following:

a. During any calendar quarter: less than or equal to 10 mrad for gamma radiation and less than or equal to 20 mrad for beta radiation, and

b. During any calendar year: less than or equal to 20 mrad for gamma radiation and less than or equal to 40 mrad for beta radiation.

APPLICABILITY: At all times.

ACTION:

a. With the calculated air dose from radioactive noble gases in gaseous effluents exceeding any of the above limits, initiate an Issue Report that identifies the cause(s) for exceeding the limit(s) and defines the corrective actions that have been taken to reduce the releases and the proposed corrective actions to be taken to assure that subsequent releases will be in compliance with the above limits.

b. The provisions of Controls 3.0.3 and 3.0.4 are not applicable.

SURVEILLANCE REQUIREMENTS 4.2.2.2 Cumulative dose contributions for the current quarter and current calendar year for noble gases shall be determined in accordance with the methodology and parameters in the ODCM at least once per 31 days.

CY-LG-1 70-301, Rev. 23 Page 41 08/07 3/4.2 RADIOACTIVE EFFLUENTS 3/4.2.2 GASEOUS EFFLUENTS 3/4.2.2.3 DOSE - IODINE-131 IODINE-133. TRITIUM. AND RADIOACTIVE MATERIAL IN PARTICULATE FORM 3.2.2.3 The dose to a MEMBER OF THE PUBLIC from iodine-131, iodine-133, tritium and all radionuclides in particulate form with half-lives greater than 8 days in gaseous effluents released from the site to areas at or beyond the SITE BOUNDARY (See Figure 1-1) shall be limited to the following:

a. During any calendar quarter: less than or equal to 15 mrem to any organ and,

b. During any calendar year: less than or equal to 30 mrem to any organ.

APPLICABILITY: At all times.

ACTION:

a. With the calculated dose from the release of iodine-131, iodine-133, tritium and all radionuclides in particulate form with half-lives greater than 8 days in gaseous effluents exceeding any of the above limits, initiate an Issue Report that identifies the cause(s) for exceeding the limit and defines the corrective actions that have been taken to reduce the releases and the proposed corrective actions to be taken to assure that subsequent releases will be in compliance with the above limits.

b. The provisions of Controls 3.0.3 and 3.0.4 are not applicable.

SURVEII LANCE REQUIREMENTS 4.2.2.3 Cumulative dose contributions for the current calendar quarter and current calendar year for iodine-1 31, iodine-1 33, tritium and radionuclides in particulate form with half-lives greater than 8 days shall be determined in accordance with the methodology and parameters in the ODCM at least once per 31 days.

CY-LG-170-301, Rev. 23 I Page 42 08/07 I 3/4.2 RADIOACTIVE EFFLUENTS 3/4.2.2 GASEOUS EFFLUENTS 3/4.2.2.4 GASEOUS RADWASTE (OFFGAS) TREATMENT SYSTEM CONTROLS 3.2.2.4 Section is not applicable. See UFSAR Chapter 11.3.

CY-LG-1 70-301, Rev. 23 Page 43 08/07 3/4.2 RADIOACTIVE EFFLUENTS 3/4.2.2 GASEOUS EFFLUENTS 3/4.2.2.5 VENTILATION EXHAUST TREATMENT SYSTEM CONTROLS 3.2.2.5 The VENTILATION EXHAUST TREATMENT SYSTEM shall be OPERABLE and appropriate portions of the system shall be used to reduce releases of radioactivity when the projected doses in 31 days due to gaseous effluent releases, from the site to areas at and beyond the SITE BOUNDARY (See Figure 1-1) would exceed

a. 0.4 mrad to air from gamma radiation, or

b. 0.8 mrad to air from beta radiation, or

c. 0.6 mrem to any organ of a MEMBER OF THE PUBLIC.

APPLICABILITY: At all times.

ACTION:

a. With gaseous waste being discharged without treatment, and in excess of the above limits, initiate an Issue Report that includes the following information:

1. Identification of any inoperable equipment or subsystems, and the reason for the inoperability.

2. Action(s) taken to restore the inoperable equipment to OPERABLE status, and

3. Summary description of action(s) taken to prevent a recurrence.

b. The provisions of Controls 3.0.3 and 3.0.4 are not applicable.

SURVEILLANCE REOUIREMENTS 4.2.2.5.1 Doses due to gaseous releases from the site to areas at and beyond the SITE BOUNDARY shall be projected at least once per 31 days in accordance with the methodology and parameters in the ODCM, when the Ventilation Exhaust Treatment System is not being fully utilized.

4.2.2.5.2 The installed VENTILATION EXHAUST TREATMENT SYSTEM shall be considered OPERABLE by meeting Controls 3.2.2.1, and either 3.2.2.2 or 3.2.2.3

CY-LG-170-301, Rev. 23 Page 44 08/07 3/4.2 RADIOACTIVE EFFLUENTS 3/4.2.2 GASEOUS EFFLUENTS 3/4.2.2.6 INCINERATION OF RADIOACTIVE WASTE OIL CQNIROI S 3.2.2.6 Incineration of radioactive waste oil shall be allowed in accordance with the requirements of 10CFR20.2004. The exhaust stack of the affected auxiliary boiler will be a release point for the radioactive effluents. Doses calculated will be based on the radioactive content of the oil prior to incineration. Dose calculated shall meet the limits specified in Controls 3.2.2.3 and 3.2.2.5.

Radioactive effluents from this pathway shall be summed with other effluents from the site and reported to the Commission in the Annual Radioactive Effluent Release Report.

APPLICABILITY: At all times ACTION:

a. With the radioactive content of waste oil not determined as specified in Table 4.2-2, do not incinerate waste oil.

b. With the calculated dose from the incineration of radioactive waste oil exceeding limits specified in Controls 3.2.2.3 and 3.2.2.5, do not incinerate waste oil.

c. The provisions of Controls 3.0.3 and 3.0.4 are not applicable.

SURVEILLANCE REQUIREMENTS:

4.2.2.6.1 Doses due to gaseous effluent releases at or beyond the SITE BOUNDARY shall be projected for Each Batch.

4.2.2.6.2 The dose rate due to iodine-131, iodine-133, tritium, and all radionuclides in particulate form with half-lives greater than 8 days in gaseous effluents shall be determined to be within the above limits by obtaining representative samples and performing analyses in accordance with the sampling and analysis program specified in Table 4.2-2

CY-LG-1 70-301, Rev. 23 Page 45 08/07 3/4.2 RADIOACTIVE EFFLUENTS 3/4.2.2 GASEOUS EFFLUENTS 3/4.2.2.7 MARK II CONTAINMENT CONTRT.LS 3.2.2.7 The VENTING or PURGING of the Mark II containment drywell shall be through the Standby Gas Treatment System.

APPLICABILITY: Whenever the drywell is vented or purged.

ACTION:

a. With the requirements of the above control not satisfied, suspend all VENTING and PURGING of the drywell.

b. The provisions of Controls 3.0.3 and 3.0.4 are not applicable.

SURVEILLANCE REQUIREMENTS 4.2.2.7.1 The containment drywell shall be determined to be aligned for VENTING or PURGING through the Standby Gas Treatment System within 4 hours4.62963e-5 days 0.00111 hours 6.613757e-6 weeks 1.522e-6 months prior to start of and at least once per 12 hours1.388889e-4 days 0.00333 hours 1.984127e-5 weeks 4.566e-6 months during VENTING or PURGING of the containment.

4.2.2.7.2 Prior to use of the purge system through the standby gas treatment system assure that:

a. Both standby gas treatment system trains are OPERABLE whenever the purge system is in use, and

b. Whenever the purge system is in use, only one of the standby gas treatment system trains shall be used to prevent damage to both trains should a LOCA occur (LCO 3.6.5.3 ACTION a applies during this configuration).

Except after Containment is deinerted and purged DR for the one inch/two inch vent valves to the Reactor Enclosure Equipment Compartment Exhaust Filters when used for containment pressure control and nitrogen make-up operations.

CY-LG-1 70-301, Rev. 23 Page 46 08/07 3/4.2 RADIOACTIVE EFFLUENTS 3/4.2.3 IOIAL DOSE 3.2.3 The annual (calendar year) dose or dose commitment to any MEMBER OF THE PUBLIC, due to releases of radioactivity and radiation, from uranium fuel cycle sources shall be limited to less than or equal to 25 mrem to the total body or any organ, except the thyroid, which shall be limited to less than or equal to 75 mrem.

APPLICABILITY: At all times.

ACTION:

a. With the calculated doses from the release of radioactive materials in liquid or gaseous effluents exceeding the limits of Controls 3.2.1.2.a., 3.2.1.2.b., 3.2.2.2.a.,

3.2.2.2.b., 3.2.2.3.a., or 3.2.2.3.b calculations shall be made including direct radiation contributions from the reactor units (including outside storage tanks, etc.)

to determine whether the above limits of Control 3.2.3 have been exceeded. If such is the case, initiate an Issue Report that defines the corrective action to be taken to reduce subsequent releases to prevent recurrence of exceeding the above limits and includes the schedule for achieving conformance with the above limits. This Special Report, as defined in 10 CFR 20.2203, shall include an analysis that estimates the radiation exposure (dose) to a MEMBER OF THE PUBLIC from the uranium fuel cycle sources, including all effluent pathways and direct radiation, for the calendar year that includes the release(s) covered by this report. It shall also describe levels of radiation and concentration of radioactive material involved, and the cause of the exposure levels or concentrations. If the estimated dose(s) exceeds the above limits, and if the release condition resulting in violation of 40 CFR Part 190 has not already been corrected, the Issue Report shall include a request for a variance in accordance with the provisions of 40 CFR Part 190.

Submittal of the report is considered a timely request, and a variance is granted until staff action on the request is complete.

b. The provisions of Controls 3.0.3 and 3.0.4 are not applicable.

SURVEILLANCE REQUIREMENTS 4.2.3.1 Cumulative dose contributions from liquid and gaseous effluents shall be determined in accordance with Surveillance Requirements 4.2.1.2, 4.2.2.2, and 4.2.2.3, and in accordance with the methodology and parameters in the ODCM.

4.2.3.2 Cumulative dose contributions from direct radiation from the units (including outside storage tanks, etc.) shall be determined in accordance with the methodology and parameters in the ODCM. This requirement is applicable only under conditions set forth in Action a. of Control 3.2.3.

CY-LG-1 70-301, Rev. 23 Page 47 08/07 3/4.3 RADIOLOGICAL ENVIRONMENTAL MONITORING 3/4.3.1 MONITORING PROGRAM 3.3.1 The Radiological Environmental Monitoring Program shall be conducted as specified in Table 3.3-1.

APPLICABILITY: At all times.

ACTION:

a. With the Radiological Environmental Monitoring Program not being conducted as specified in Table 3.3-1, prepare and submit to the Commission, in the Annual Radiological Environmental Operating Report required by Administrative Control 6.1, a description of the reasons for not conducting the program as required and the plans for preventing a recurrence.

b. With the level of radioactivity as the result of plant effluents in an environmental sampling medium at a specified location exceeding the reporting levels of Table 3.3-2 when averaged over any calendar quarter, initiate an Issue Report that identifies the cause(s) for exceeding the limit(s) and defines the corrective actions to be taken to reduce radioactive effluents so that the potential annual dose to a MEMBER OF THE PUBLIC is less than the calendar year limits of Controls 3.2.1.2, 3.2.2.2, or 3.2.2.3. When more than one of the radionuclides in Table 3.3-2 are detected in the sampling medium, this report shall be submitted if:

concentration (1) + concentration (2) +... >__1.0 reporting level (1) reporting level (2)

When radionuclides other than those in Table 3.3-2 are detected and are the result of plant effluents, an Issue Report shall be initiated if the potential annual dose* to a MEMBER OF THE PUBLIC is equal to or greater than the calendar year limits of Controls 3.2.1.2, 3.2.2.2, or 3.2.2.3. An Issue Report is not required if the measured level of radioactivity was not the result of plant effluents; however; in such an event, the condition shall be reported and described in the Annual Radiological Environmental Operating Report required by Administrative Control 6.1.

The methodology and parameters used to estimate the potential annual dose to a MEMBER OF THE PUBLIC shall be indicated in this report.

CY-LG-170-301, Rev. 23 Page 48 08/07 3/4.3 RADIOLOGICAL ENVIRONMENTAL MONITORING 3/4.3.1 MONITORING PROGRAM CONTROLS ACTION (Continued)

c. With milk or fresh leafy vegetable samples unavailable from one or more of the sample locations required by Table 3.3-1, identify locations for obtaining replacement samples and add them to the radiological environmental monitoring program within 30 days. The specific locations from which samples were unavailable may then be deleted from the monitoring program. Pursuant to Technical Specification 6.14, submit as a part of or concurrent with the Annual Radioactive Effluent Release Report, a complete, legible copy of the entire ODCM, including a revised figure(s) and table for the ODCM reflecting the new location(s).

d. The provisions of Controls 3.0.3 and 3.0.4 are not applicable.

SURVEILLANCE REQUIREMENTS 4.3.1 The radiological environmental monitoring samples shall be collected pursuant to Table 3.3-1 from the specific locations given in the table and figure(s) in the ODCM and shall be analyzed pursuant to the requirements of Table 3.3-1, with the detection capabilities required by the Table 4.3-1.

CY-LG-170-301, Rev. 23 Page 49 08J07 TABLE3.3-1 RAflini 0Q.1IfAI FNVIRO)NMFNTAI MON ITC)RIN( PRO(RAM*

NUMBER OF REPRESENTATIVE EXPOSURE PATHWAY SAMPLES AND SAMPLING AND TYPE AND FREQUENCY AND/OR SAMPLE SAMPLE LOCATION(a) COLLECTION FREQ. OF ANALYSIS

1. DIRECT RADIATIONb 40 routine monitoring stations either Quarterly Gamma dose quarterly.

with two or more dosimeters or with one instrument for measuring and recording dose rate continuously placed as follows:

(1) An inner ring of stations, one in each meteorological sector, in the general area of the SITE BOUNDARY:

(2) An outer ring of stations, one in each meteorological sector, in the 3-9 mile range from the site; (3) The balance of the stations placed in special interest areas such as population centers, nearby residences, schools and in 1 or 2 areas to serve as control stations.

The number, media, frequency, and location of samples may vary from site to site. This table presents an acceptable minimum program for a site at which each entry is applicable. Local site characteristics must be examined to determine if pathways not covered by this table may significantly contribute to an individual's dose and should be included in the sample program.

CY-LG-170-301, Rev. 23 Page 50 08/07 TABLE 3.3-1 (Continued)

RADIOLOGICAL ENVIRONMENTAL MONITORING PROGRAM NUMBER OF EXPOSURE PATHWAY REPRESENTATIVE SAMPLING AND TYPE AND FREQUENCY AND/OR SAMPLE SAMPLES AND COLLECTION FREQ. OF ANALYSIS SAMPLE LOCATION(a)

2. AIRBORNE Samples from 5 locations: Continuous sampler Radioiodine canisters:

Radioiodine and 3 samples from close to the 3 operation with sample 1-131 analysis weekly Particulates SITE BOUNDRY locations (in collection weekly, or more different sectors) of the highest frequently if required by dust calculated annual average loading. Particulate Sampler:

ground-level D/Q. Gross beta radio activity analysis following filter 1 sample from the vicinity change: d community having one of the Gamma isotopic analysis of highest calculated annual ground composite (by location) at level D/Q. least quarterly 1 sample from a control location, as for example 15-30 km distant and in the least prevalent wind direction.

CY-LG-170-301, Rev. 23 Page 51 08/07 TABLE 3-3-1 (Continued)

RADIOLOGICAL ENVIRONMENTAL MONITORING PROGRAM NUMBER OF EXPOSURE PATHWAY REPRESENTATIVE SAMPLING AND TYPE AND FREQUENCY AND/OR SAMPLE SAMPLES AND COLLECTION FREQ. OF ANALYSIS SAMPLE LOCATION(a)

3. WATERBORNE

a. Surfacee 1 sample upstream Composite sample over 1- Gamma isotopic analysisd 1 sample downstream month periodf. monthly. Composite for tritium analysis quarterly.

b. Ground Samples from 1 or 2 sources only Quarterly. Gamma isotopicd and tritium if likely to be affected analysis

c. Drinking 1 sample of each on 1 to 3 of the Composite sample over 2- 1-131 analysis on each nearest water supplies that could week periodf when 1-131 composite when the dose be affected by its discharge. analysis is performed; calculated for the monthly composite otherwise. consumption of the water is 1 sample from a control location greater than 1 mrem per h

year. Composite for gross beta and gamma isotopicd analysis monthly. Composite for tritium analysis quarterly.

d. Sediment from 1 sample from downstream area Semiannually. Gamma isotopic analysisd shoreline with existing or potential semiannually.

recreational value.

CY-LG-1 70-301, Rev. 23 Page 52 08/07 TABLE 3.3-1 (Continued)

RADIOLOGICAL ENVIRONMENTAL MONITORING PROGRAM NUMBER OF REPRESENTATIVE EXPOSURE PATHWAY SAMPLES AND SAMPLING AND TYPE AND FREQUENCY AND/OR SAMPLE SAMPLE LOCATION(a) COLLECTION FREQ. OF ANALYSIS ND/O S PLE AMPE L ATIN'a'COLECTIN FEQ O N Sd

4. INGESTION Samples from milking animals in 3 Semimonthly when animals Gamma isotopicd and

a. Milk locations within 5 km distance are on pasture, monthly at 1-131 analysis semimonthly having the highest dose potential. other times. when animals are on pasture If there are none, then 1 sample (April 1 - Oct. 1): monthly at from milking animals in each of 3 other times.

areas between 5 to 8 km distance where dose are calculated to be greater than 1 mrem per year.h 1 sample from milking animals at a control location (15-30 km distance) and in the least prevalent wind direction.

b. Fish and 1 sample of each commercially and Sample in season, or Gamma isotopicd analysis on Invertebrates recreationally important species in semiannually if they are not edible portions.

vicinity of plant discharge area. seasonal.

1 sample of same species in area not influenced by plant discharge.

CY-LG-170-301, Rev. 23 Page 53 08/07 TABLE 3.3-1 (Continued)

RADIOLOGICAL ENVIRONMENTAL MONITORING PROGRAM NUMBER OF EXPOSURE PATHWAY REPRESENTATIVE SAMPLING AND TYPE AND FREQUENCY AND/OR SAMPLE SAMPLES AND COLLECTION FREQ. OF ANALYSIS SAMPLE LOCATION'a)

4. INGESTION (Continued)

c. Food Products 1 sample of each principal class At time of harvest' Gamma isotopicd and of food products from any area 1-131 analysis.

that is irrigated by water in which liquid plant wastes have been discharged Monthly during the growing Gamma isotopicd and 1-131 Samples of 3 different kinds of broad leaf vegetation grown analysis.

season nearest each of 2 different offsite locations of highest predicted annual average ground level D/Q if milk sampling is not performed.

1 sample of each of the similar Monthly during the growing Gamma isotopicd and 1-131 broad leaf vegetation grown 15-30 season analysis.

km distance in the least prevalent wind direction if milk sampling is not performed.

CY-LG-1 70-301, Rev. 23 Page 54 08/07 TABLE 3.3-1 (Continued)

TABLE NOTATIONS

a. Specific parameters of distance and direction sector from the centerline of the two reactors and additional description where pertinent, shall be provided for each and every sample location in Table 3.3-1 in a table and figure(s) in the ODCM. Deviations are permitted from the required sampling schedule if specimens are unobtainable due to hazardous conditions, seasonal unavailability, malfunction of automatic sampling equipment and other legitimate reasons. If specimens are unobtainable due to sampling equipment malfunction, every effort shall be made to complete corrective action prior to the end of the next sampling period. All deviations from the sampling schedule shall be documented in the Annual Radiological Environmental Operating Report pursuant to Administrative Control 6.1. It is recognized that, at times, it may not be possible or practicable to continue to obtain samples of the media of choice at the most desired location or time. In these instances suitable alternative media and locations may be chosen for the particular pathway in question and appropriate substitutions made within 30 days in the radiological environmental monitoring program.

Pursuant to Technical Specification 6.14, submit as a part of or concurrent with the next Annual Radioactive Effluent Release Report a complete legible copy of the ODCM including a revised figure(s) and table for the ODCM reflecting the new location(s).

b. One or more instruments, such as a pressurized ion chamber, for measuring and recording dose rate continuously may be used in place of, or in addition to, integrating dosimeters. For the purpose of this table, a thermoluminescent dosimeter (TLD) is considered to be one phosphor; two or more phosphors in a packet are considered as two or more dosimeters. Film badges shall not be used as dosimeters for measuring direct radiation.

c. Airborne particulate sample filters shall be analyzed for gross beta radioactivity 24 hours2.777778e-4 days 0.00667 hours 3.968254e-5 weeks 9.132e-6 months or more after sampling to allow for radon and thoron daughter decay. If gross beta activity in air particulate samples is greater that 10 times the yearly mean of control samples, gamma isotopic analysis shall be performed on the individual samples.

d. Gamma isotopic analysis means the identification and quantification of gamma-emitting radionuclides that may be attributable to the effluents from the facility.

e. The "upstream sample" shall be taken at a distance beyond significant influence of the discharge. The "downstream sample" shall be taken in an area beyond but near the mixing zone.

CY-LG-1 70-301, Rev. 23 Page 55 08/07 TABLE 3-3-1 (Continued)

TABLE NOTATIONS (Continued)

f. A composite sample is one in which the quantity (aliquot) of liquid sampled is proportional to the quantity of flowing liquid and in which the method of sampling employed results in a specimen that is representative of the liquid flow. In this program composite sample aliquots shall be collected at time intervals that are very short (e.g.,

hourly) relative to the compositing period (e.g., monthly) in order to assure obtaining a representative sample.

g. Groundwater samples shall be taken when this source is tapped for drinking or irrigation purposes in areas where the hydraulic gradient or recharge properties are suitable for contamination.

h. The dose shall be calculated for the maximum organ and age group using the methodology and parameters in the ODCM.

If harvest occurs more than once a year, sampling shall be performed during each discrete harvest. If harvest occurs continuously, sampling shall be monthly. Attention shall be paid to including samples of tuberous and root food products.

CY-LG-1 70-301, Rev. 23 I Page 56 08/07 I IABLE3.3.-2 REPORTING LEVELS FOR RADIOACTIVITY CONCENTRATIONS IN ENVIRONMENTAL SAMPLES ReportinogLevels AIRBORNE FOOD WATER PARTICULATE or FISH MILK PRODUCTS ANALYSIS (pCi/I) GASES(pCi/m 3 ) (pCi/k.q wet) (pCi/I) (pCi/k. wet)

H-3 20,000*

Mn-54 1,000 30,000 Fe-59 400 10,000 Co-58 1,000 30,000 Co-60 300 10,000 Zn-65 300 20,000 Zr-Nb-95 400***

2**

1-131 0.9 1,000 3 100 Cs-134 30 10 2,000 60 1,000 Cs-137 50 20 70 2,000 Ba-La-140 200*** 300 For drinking water samples. This is a 40 CFR Part 141 value. If no drinking pathway exists, a value of 30,000 pCi/I may be used.

If no drinking water pathway exists, a value of 20 pCi/I may be used Total for parent and daughter.

CY-LG-1 70-301, Rev. 23 Page 57 08/07 TABLE 4.31 DETECTION CAPABILITIES FOR ENVIRONMENTAL SAMPLE ANALYSIS(a) (b)

Lower limit of Detection (LLD)(c)

AIRBORNE FOOD PARTICULATE or FISH PRODUCTS SEDIMENT WATER GASES (pCi/kg, MILK (pCi/kg, (pCi/kg, ANALYSIS (pCi/I) (pCi/m 3 ) wet) (pCi/I) wet) dry)

Gross Beta 4 0.01 H-3 2,000*

Mn-54 15 130 Fe-59 30 260 Co-58 15 130 Co-60 15 130 Zn-65 30 260 Zr-95 30 Nb-95 15 1-131 1** 0.07 1 60 Cs-134 15 0.05 130 15 60 150 Cs-137 18 0.06 150 18 80 180 Ba-140 60 60 La-140 15 15

If no drinking water pathway exists, a value of 3000 pCi/I may be used.

- If no drinking water pathway exists, a value of 15 pCi/I may be used.

CY-LG-1 70-301, Rev. 23 Page 58 08/07

-TABLE 4-3-1 (Continued)

TABLE NOTATIONS (a) This list dose not mean that only these nuclides are to considered. Other peaks that are identifiable at 95% confidence level, together with those of the above nuclides, shall also be analyzed and reported in the Annual Radiological Environmental Operating report pursuant to Administrative Control 6.1.

(b) Required detection capabilities for thermoluminescent dosimeters used for environmental measurements are given in Regulatory Guide 4.13.

(c) The LLD is defined, for purposes of these controls, as the smallest concentration of radioactive material in a sample that will yield a net count (above system background) that will be detected with 95% probability with only 5% probability of falsely concluding that a blank observation represents a "real" signal.

For a particular measurement system (which may include radiochemical separation):

LLD = 4.66 sb E

V

2.22 9 Y

exp(-'*

Where:

LLD is the a proori lower limit of detection as defined above (as picocuries per unit mass or volume),

Sb is the standard deviation of the background counting rate or of the counting rate of blank sample as appropriate (as counts per minute),

E is the counting efficiency (as counts per disintegration),

V is the sample size (in units of mass or volume),

2.22 is the number of disintegrations per minute per picocurie, Y is the fractional radiochemical yield (when applicable),

x is the radioactive decay constant for the particular radionuclide, and At for the environmental samples is the elapsed time between sample collection (or end of the sample collection period) and time of counting.

Typical values of E, V, Y and At should be used in the calculation

CY-LG-1 70-301, Rev. 23 Page 59 08/07 TABLE 4-3-1 (Continued)

TABLE NOTATIONS (Continued)

It should be recognized that the LLD is defined as an a priori (before the fact) limit representing the capability of a measurement system and not as an after the fact limit for a particular measurement. Analyses shall be performed in such a manner that the stated LLDs will be achieved under routine conditions. Occasionally background fluctuations, unavoidably small sample sizes, the presence of interfering nuclides, or other uncontrollable circumstances may render these LLDs unachievable. In such cases, the contributing factors shall be identified and described in the Annual.

Radiological Environmental Operating Report pursuant to Administrative Control 6.1.

CY-LG-1 70-301, Rev. 23 Page 60 08/07 3/4.3 RADIOLOGICAL ENVIRONMENTAL MONITORING 3/4.3.2 LAND USE CENSUS CONTROLS 3.3.2 A land use census shall be conducted and shall identify within a distance of 8 km (5 miles) the location (in each of the 16 meteorological sectors) of the nearest milk animal, the nearest residence and the nearest garden* of greater than 50 m2 (500 ft2 ) producing broad leaf vegetation.

APPLICABILITY: At all times.

ACTION."

a. With a land use census identifying a location(s) that yields a calculation dose or dose commitment greater than the values currently being calculated in Control 3.2.2.3, identify the new location(s) in the next Annual Radioactive Effluent Release Report, pursuant to Administrative Control 6.2.

b. With a land use census identifying a location(s) that yields a calculated dose or dose commitment (via the same exposure pathway) 20% greater than at a location from which samples are currently being obtained in accordance with Control 3.2.2.3, add the new location(s) to the radiological environmental monitoring program within 30 days. The sampling location(s), excluding the control station location, having the lowest calculated dose or dose commitment(s) (via the same exposure pathway) may be deleted from this monitoring program after October 31 of the year in which this land use census was conducted. Pursuant to Technical Specification 6.14, submit as a part of or concurrent with in the next Annual Radioactive Effluent Release Report a complete, legible copy of the entire ODCM including a revised figure(s) and table(s) for the ODCM reflecting the new location(s).

c. The provisions of Controls 3.0.3 and 3.0.4 are not applicable.

SURVEILLANCE REQUIREMENTS 4.3.2 The land use census shall be conducted during the growing season at least once per 12 months using that information that will provide the best results, such as by a door-to-door survey, aerial survey, or by consulting local agriculture authorities.

The results of the land use census are included in the Annual Radiological Environmental Operating Report pursuant to Administrative Control 6.1.

Broad leaf vegetation sampling of at least 3 different kinds of vegetation may be performed at the SITE BOUNDARY in each of 2 different direction sectors with the highest predicted D/Qs in lieu of the garden census. Controls for broad leaf vegetation sampling in Table 3.3-1 item 4.c. shall be followed, including analysis of control samples.

CY-LG-170-301, Rev. 23 Page 61 08/07 3/4.3 RADIOLOGICAL ENVIRONMENTAL MONITORING 3/4.3.3 INTERLABORATORY COMPARISON PROGRAM 3.3.3 In accordance with LGS Technical Specification 6.8.4.f, analyses shall be performed on radioactive materials supplied as part of an Interlaboratory Comparison Program traceable to NIST, that correspond to samples required by Table 3.3-1.

APPLICABILITY: At all times.

ACTION:

a. With analyses not being performed as required above, report the corrective actions taken to prevent a recurrence to the Commission in the Annual Radiological Environmental Operating Report pursuant to Administrative Control 6.1.

b. The provisions of Controls 3.0.3 and 3.0.4 are not applicable.

SURVEILLANCE REQUIREMENTS 4.3.3 The Interlaboratory Comparisoh Program shall be described in the ODCM. A summary of the results shall be included in the Annual Radiological Environmental Operating Report pursuant to Administrative Control 6.1

CY-LG-1 70-301, Rev. 23 Page 62 08/07 3/4.3 RADIOLOGICAL ENVIRONMENTAL MONITORING 3/4.3.4 METFOROLOGICAL MONITORING INSTRUMENTATION QQNTROILS 3.3.4 The meteorological monitoring instrumentation channels shown in Table 3.3-3 shall be OPERABLE.

APPLICABILITY: At all times.

ACTION:

a. With less than the minimum required instrumentation channels OPERABLE for more than 7 days, initiate an Issue Report outlining the cause of the malfunction and the plans for restoring the instrumentation to OPERABLE status.

b. The provisions of Controls 3.0.3 and 3.0.4 are not applicable.

SURVEILLANCE REQUIREMENTS 4.3.4 Each of the above required meteorological monitoring instrumentation channels shall be demonstrated OPERABLE by the performance of the CHANNEL CHECK and CHANNEL CALIBRATION operations at the frequencies shown in Table 4.3-2.

CY-LG-1 70-301, Rev. 23 I Page 63 08/07 I METEOROLOGICAL MONITORING INSTRUMENTATION INSTRUMENT TOWER 1 TOWER 2 MINIMUM (PRIMARY) (BACKUP) INSTRUMENT OPERABLE

1. Wind Speed

a. Elevation 1 30 feet 159 feet 1

b. Elevation 2 175 feet 304 feet 1

2. Wind Direction

a. Elevation I 30 feet 159 feet 1

b. Elevation 2 175 feet 304 feet 1

3. Air Temperature Difference (AT)

a. Elevations 266 feet 300 feet 26 feet 26 feet 1

CY-LG-1 70-301, Rev. 23 Page 64 08/07 TABLE_4.3-9 METEOROLOGICAL MONITORING INSTRUMENTATION SURVEILLANCE REQUIREMENTS INSTRUMENT CHANNEL CHANNEL CHECK CALIBRATION

1. Wind Speed

a. Elevation 1 (Tower 1 and Tower 2) D SA

b. Elevation 2 (Tower 1 and Tower 2) D SA

2. Wind Direction

a. Elevation 1 (Tower I and Tower 2) D SA

b. Elevation 2 (Tower 1 and Tower 2) D SA

3. Air Temperature Difference (A T)

a. Elevations 266 - 26 ft (Tower 1) D SA

b. Elevations 300 - 26 ft (Tower 2) D SA The meteorological towers shall be located as shown on Figure 3.3-1.

CY-LG-1 70-301, Rev. 23 I Page 65 08/07 e igure3-31a Meteorological Tower Locations

CY-LG-1 70-301, Rev. 23 I Page 66 08/07 3/4.0 QDNTROIS GENERAL It is expected that releases of radioactive material in effluents will be kept at small fractions of the limits specified in Section 20.1302 of 10 CFR, Part 20. At the same time, the licensee is permitted the flexibility of operation, compatible with consideration of health and safety, to assure that the public is provided a dependable source of power even under unusual operating conditions which may temporarily result in releases higher than such small fractions, but still within the limits specified in Section 20.1302 of 10 CFR, Part 20. It is expected that in using this operational flexibility under unusual operating conditions the licensee will exert his best efforts to keep levels of radioactive material in effluents as low as practicable.

MAPS DEFINING UNRESTRICTED AREAS AND SITE BOUNDARY FOR RADIOACTIVE GASEOUS AND LIQUID EFFLUENTS Information regarding radioactive gaseous and liquid effluents, which will allow identification of structures and release points as well as definition of UNRESTRICTED AREAS within the SITE BOUNDARY that are accessible to MEMBER(S) OF THE PUBLIC, shall be as shown in Technical Specifications Figures 5.1.3-1a and 5.1.3-1b.

The exclusion area and low population zone shall be as shown in Figures 1-1 and 1-2.

10 CFR20 Per Technical Specification Section 6.8.4.d, the Radioactive Effluent Controls Program must conform with limitations specified in 10 CFR 50.36a, 10 CFR Part 50, Appendix 1,10 times the ECL limits of 10 CFR Part 20, Appendix B, Table 2, Column 2 and 40 CFR 190. (See Reference 14)

CY-LG-1 70-301, Rev. 23 Page 67 08/07 3/4.0 CONTROLS RASES 3/4-0 APPLICABILITY Compliance with the controls is required during the OPERATIONAL CONDITIONS or other conditions specified therein; except that upon failure to meet the controls, the associated ACTION requirements shall be met.

Non compliance with a Control shall exist when the requirements of the control and associated ACTION requirements are not performed within the specified time intervals. If the control is restored prior to expiration of the specified time intervals, completion of the ACTION requirements is not required.

There are no actions in the ODCM which would require an operational condition change.

There are no restrictions on changing operating conditions in any of the controls on the ODCM.

Surveillance Requirements shall be met during the OPERATIONAL CONDITIONS or other conditions specified for individual controls unless otherwise stated in an individual Surveillance Requirement.

Each Surveillance Requirement shall be performed within the specified interval with a maximum allowable extension not to exceed 25% of the surveillance interval.

Failure to perform a Surveillance Requirement within the allowed surveillance interval defined by Surveillance Requirement 4.0.2.a, shall constitute noncompliance with the OPERABILITY requirements for a control. The time limits of the ACTION requirements are applicable at the time it is identified that a Surveillance Requirement has not been performed. The ACTION requirements may be delayed for up to 24 hours2.777778e-4 days 0.00667 hours 3.968254e-5 weeks 9.132e-6 months to permit the completion of the surveillance when the allowable outage time limits of the ACTION requirements are less than 24 hours2.777778e-4 days 0.00667 hours 3.968254e-5 weeks 9.132e-6 months .

Surveillance requirements do not have to be performed on inoperable equipment.

The associated bases from the LGS Technical Specifications apply to this section.

CY-LG-170-301, Rev. 23 Page 68 08/07 3/4.1 INSTRUMENTATION BASES 3/4- 1.i RADIOACTIVF LIUolID EFFLUIENT MONITORING INSTRUMENTATION The radioactive liquid effluent instrumentation is provided to monitor and control, as applicable, the releases of radioactive materials in liquid effluents during actual or potential releases of liquid effluents. The alarm/trip setpoints for these instruments shall be calculated in accordance with the procedures in the ODCM Part II to ensure that the alarm/trip will occur prior to exceeding the limits of 10 CFR Part 20. The OPERABILITY and use of this instrumentation is consistent with the requirements of General Design Criteria 60, 63, and 64 of Appendix A to 10 CFR Part 50.

3/4.1.2 RADIOACTIVE GASEOUS EFFLUENT MONITORING INSTRUMENTATION The radioactive gaseous effluent instrumentation is provided to monitor and control, as applicable, the releases of radioactive materials in gaseous effluents during actual or potential releases of gaseous effluents. The alarm/trip setpoints for these instruments shall be calculated in accordance with the procedures in the ODCM Part II to ensure that the alarm/trip will occur prior to exceeding the limits of 10 CFR Part 20. The OPERABILITY and use of this instrumentation is consistent with the requirements of General Design Criteria 60, 63, and 64 of Appendix A to 10 CFR Part 50.

CY-LG-170-301, Rev. 23 Page 69 08/07 3/4.2 RADIOACTIVE EFFLUENTS BASES 3/4-2-1 LIQUID EFFLUENTS 3/4.2.1.1 CONCENTRATION This control is provided to ensure that the concentration of radioactive materials released in liquid waste effluents to areas at and beyond the UNRESTRICTED AREAS will be less than 10 times the effluent concentration limits (ECL) specified in 10 CFR Part 20, Appendix B, Table 2, Column 2. This instantaneous limitation provides additional assurance that the levels of radioactive materials in bodies of water.in areas at and beyond the SITE BOUNDARY will result in exposures within (1) the Section II.A design objectives of Appendix 1,10 CFR Part 50, to a MEMBER OF THE PUBLIC, and (2) the limits of 10 CFR 20.1302 to the population. The concentration limits for dissolved or entrained noble gases are based upon the assumption that Xe-135 is the controlling radioisotope and its ECL in air (submersion) was converted to an equivalent concentration in water using the methods described in the International Commission on Radiological Protection (ICRP) Publication 2.

The required detection capabilities for radioactive materials in liquid waste samples are tabulated in terms of the lower limits of detection (LLDs). Detailed discussion of the LLD, and other detection limits can be found in HASL Procedures Manual, HASL-300 (revised annually);

Currie, L.A., "Limits for Qualitative Detection and Quantitative Determination - Application to Radiochemistry"; Anal. Chem. 40, 586-93 (1968); and Hartwell, J.K., "Detection Limits for Radioanalytical Counting Techniques", Atlantic Richfield Hanford Company Report ARH-SA-215 (June, 1975).

3/4-2.1.2 DOSE This Control is provided to implement the requirements of Sections II.A, Ill.A, and IV.A of Appendix 1,10 CFR Part 50. Control 3.2.1.2 implements the guidance set forth in Section IL.A of Appendix I and provides the required operating flexibility and at the same time implement the guides set forth in Section IV.A of Appendix I to assure that the releases of radioactive material in liquid effluents will be kept "as low as reasonably achievable". Also, for fresh water sites with drinking water supplies which can be potentially affected by plant operations, there is reasonable assurance that the operation of the facility will not result in radionuclide concentrations in the finished drinking water that are in excess of the requirements of 40 CFR Part 141. The Surveillance Requirement 4.2.1.2 implement the requirements in Section III.A of Appendix I that conformance with the guidance of Appendix I be shown by calculational procedures based on models and data, such that the actual exposure of a MEMBER OF THE PUBLIC through appropriate pathways is unlikely to be substantially underestimated. The equations specified in the ODCM for calculating the doses due to the actual release rates of radioactive materials in liquid effluents are consistent with the methodology provided in Regulatory Guide 1.109, "Calculation of Annual Doses to Man from Routine Releases of Reactor Effluents for the Purpose of Evaluating Compliance with 10 CFR Part 50, Appendix I,

CY-LG-170-301, Rev. 23 Page 70 08/07 3/4.2 RADIOACTIVE EFFLUENTS "3/4-2-1.2 DOSE (continued)

Revision 1, October, 1977 and Regulatory Guide 1.113, "Estimating Aquatic Dispersion of Effluents from Accidental and Routine Reactor Releases for the Purpose of Implementing Appendix I," April, 1977.

This control applies to the release of radioactive materials in liquid effluents from the site.

3/4-2-1-3 LIQUID RADWASTE TREATMENT SYSTEM The requirement that the appropriate portions of this system be used when specified provides assurance that the releases of radioactive materials in liquid effluents will be kept "as low as reasonably achievable". Control 3.2.1.3 implements the requirements of 10 CFR 50.35a, General Design Criterion 60 of Appendix A/to 10 CFR Part 50 and the design objective given in Section II.D of Appendix I to 10 CFR Part 50. The specified limits governing the use of appropriate portions of the liquid radwaste treatment system were specified as a suitable fraction of the dose design objectives set forth in Section II.A of Appendix 1,10 CFR Part 50, for liquid effluents.

3/4-2.2 GASEOUS EFFLUENTS 3/4.2-2-1 DOSE RATE This control is provided to ensure that the dose from radioactive materials in gaseous effluents at and beyond the SITE BOUNDARY will be within the annual dose limits of 10 CFR Part 20 to UNRESTRICTED AREAS. The annual dose limits are the doses associated with the concentrations of 10 CFR Part 20, Appendix B, Table 2, Column 1. These limits provide reasonable assurance that radioactive material discharged in gaseous effluents will not result in the exposure of a MEMBER OF THE PUBLIC, either within or outside the SITE BOUNDARY, to annual average concentrations exceeding the limits specified in Appendix B, Table 2 of 10 CFR Part 20. For MEMBERS OF THE PUBLIC who may at times be within the SITE BOUNDARY, the occupancy factor for that MEMBER OF THE PUBLIC will usually be sufficiently low to compensate for any increase in the atmospheric diffusion factor for above that for the SITE BOUNDARY. Examples of calculations for such MEMBERS OF THE PUBLIC, with the appropriate occupancy factors, are given in the ODCM. The specified release rate limits restrict, at all times, the corresponding gamma and beta dose rates above background to a MEMBER OF THE PUBLIC at or beyond the SITE BOUNDARY to less than or equal to 500 mrem/year to the total body or to less than or equal to 3000 mrem/year to the skin. These release rate limits also restrict, at all times, the corresponding thyroid dose rate above background to a child via the inhalation pathway to less than or equal to 1500 mrem/year.

CY-LG-170-301, Rev. 23 Page 71 08/07 3/4.2 RADIOACTIVE EFFLUENTS BASES This Control applies to the release of radioactive materials in gaseous effluents from all reactors at the site.

The required detection capability for radioactive materials in gaseous waste samples are tabulated in terms of the lower limits of detection (LLDs). Detailed discussion of the LLD, and other detection limits can be found in HASL Procedures Manual, HASL-300 (revised annually);

Currie, L.A., "Limits for Qualitative Detection and Quantitative Determination - Application to Radiochemistry"; Anal. Chem. 40, 586-93 (1986); and Hartwell, J.K., "Detection Limits for Radioanalytical Counting Techniques." Atlantic Richfield Hanford Company Report ARH-SA-215 (June 1975).

3/4-2.2-2 DOSE - NOBLE GASES This control is provided to implement the requirements of Sections II.B, II.A, and IV.A of Appendix 1,10 CFR Part 50. Control 3.2.2.2 implements the guidance set forth in Section II.B of Appendix I and provides the required operating flexibility to implement the guides set forth in Section IV.A of Appendix I to assure that the releases of radioactive material in gaseous effluents will be kept "as low as reasonably achievable". The Surveillance Requirement 4.2.2.2 implement the requirements in Section III.A of Appendix I that conformance with the guides of Appendix I be shown by calculational procedures based on appropriate pathways is unlikely to be substantially underestimated. The dose calculation established in the ODCM for calculating the doses due to the actual release rates of radioactive noble gases in gaseous effluents are consistent with the methodology provided in 3/4-2-2-2 DOSE - NOBLE GASES (Continued)

Regulatory Guide 1.109, "Calculation of Annual Doses to Man from Routine Releases of Reactor Effluents for the Purpose of Evaluating Compliance with 10 CFR Part 50, Appendix I,"

Revision I, October 1977 and Regulatory Guide 1.111, "Methods for Estimating Atmospheric Transport and Dispersion of Gaseous. Effluents in Routing Releases from Light-Water Cooled Reactors," Revision 1, July 1977 with site specific dispersion curves and deposition methodology.

The ODCM equations provided for determining the air doses at and beyond the SITE BOUNDARY are based upon the historical average atmospheric conditions.

3/4.2.2-3 DOSE - IODINE-131, IODINE-133- TRITIUM AND RADIONUCLIDES IN PARTICULATE FORM This control is provided to implement the requirements of Sections II.C, Ill.A, and IV.A of Appendix 1,10 CFR Part 50. Control 3.2.2.3 implements the guidance set forth in Section II.C of Appendix I and provides the required operating flexibility to implement the guides set forth in Section IV.A of Appendix I to assure that the releases of radioactive materials in gaseous effluents will be kept "as low as is reasonably achievable." The ODCM calculational methods specified in the Surveillance Requirements 4.2.2.3 implement the requirements in Section III.A

CY-LG-1 70-301, Rev. 23 Page 72 08/07 3/4.2 RADIOACTIVE EFFLUENTS BASES of Appendix I, that conformance with the guides of Appendix I be shown by calculational procedures based on models and data, such that the actual exposure of a MEMBER OF THE PUBLIC through appropriate pathways is unlikely to be substantially underestimated. The ODCM calculational methods for calculating the doses due to the actual release rates of the subject materials are consistent with the methodology provided in Regulatory Guide 1.109, Calculation of Annual Doses to Man from Routine Releases of Reactor Effluents for the Purpose of Evaluating Compliance with 10 CFR Part 50, Appendix I," Revision I, October 1977 and Regulatory Guide 1.111, "Methods for Estimating Atmospheric Transport and Dispersion of Gaseous Effluents in Routine Releases from Light-Water-Cooled Reactors," Revision 1, July 1977 with site specific dispersion curves and deposition methodology. These equations also provide for determining the actual doses based upon the historical average atmospheric conditions. The release rate specifications for iodine-1 31, iodine-1 33, tritium, and radionuclides in particulate form with half-lives greater than 8 days are dependent on the existing radionuclides pathways to man in areas at and beyond the SITE BOUNDARY. The pathways which were examined in the development of these calculations were: (1) individual inhalation of airborne radionuclides, (2) deposition of radionuclides onto green leafy vegetation with subsequent consumption by man, (3) deposition onto grassy areas where milk animals and meat-producing animals graze with consumption of the milk and meat by man, and (4) deposition on the ground with subsequent exposure of man.

3/4-2.2.4 AND 3/4-2-2.5 GASEOUS RADWASTE TREATMENT SYSTEM AND VENTILATION EXHAUST TREATMENT SYSTEM The requirement that the appropriate portions of this system be used, when specified, provides reasonable assurance that the releases of radioactive materials in gaseous effluents will be kept "as low as is reasonably achievable." Controls 3.2.2.4 and 3.2.2.5 implements the requirements of 10 CFR 50.36a, General Design Criteria 60 of Appendix A to 10 CFR Part 50, and the design objectives given in Section II.D of Appendix I to 10 CFR Part 50. The specified limits governing the use of appropriate portions of the systems were specified as a suitable fraction of the dose design objectives set forth in Section II.B and IL.C of Appendix 1,10 CFR Part 50, for gaseous effluents.

3/4-2.2-7 MARK II CONTAINMENT This control provides reasonable assurance that releases from drywell venting or purging operations will not exceed the annual dose limits of 10 CFR Part 20 for areas at or beyond the UNRESTRICTED AREAS.

3/4.2-3 TOTAL DOSE This control is provided to meet the dose limitations of 40 CFR Part 190 that have been incorporated into 10 CFR Part 20 by 46 CFR 18525. Control 3.2.3 requires the preparation and submittal of a Special Report whenever the calculated doses due to releases of

CY-LG-170-301, Rev. 23 Page 73 08/07 3/4.2 RADIOACTIVE EFFLUENTS BASES radioactivity and to radiation from uranium fuel cycle sources exceed 25 mrem to the whole body or any organ, except the thyroid, which shall be limited to less than or equal to 75 mrem.

For sites containing up to four reactors, it is highly unlikely that the resultant dose to a MEMBER OF THE PUBLIC will exceed the dose limits of 40 CFR Part 190 if the individual reactors remain within twice the dose design objectives of Appendix I, and if direct radiation does from the units (including outside storage tanks, etc.) are kept small.

The Special Report will describe a course of action that should result in the limitation of the annual dose to a MEMBER OF THE PUBLIC to within the 40 CFR Part 190 limits. For the purposes of the Special Report, it may be assumed that the dose commitment to the MEMBER OF THE PUBLIC from other uranium fuel cycle sources is negligible, with the exception that dose contributions from other nuclear fuel cycle facilities at the same site or within a radius of 5 miles must be considered. If the dose to any MEMBER OF THE PUBLIC is estimated to exceed the requirements of 40 CFR Part 190, the Special Report with a request for a variance (provided the release condition resulting in violation of 40 CFR Part 190 have not already been corrected), in accordance with the provisions of 40 CFR 190.11 and 10 CFR 20.2203, is considered to be a timely request and fulfills the requirements of 40 CFR Part 190 until NRC staff action is completed. The variance only relates to the limits of 40 CFR Part 190, and does not apply in any way to the other requirements for dose limitation of 10 CFR Part 20, as addressed in Controls 3.2.1.1 and 3.2.2.1. An individual is not considered a MEMBER OF THE PUBLIC during any period in which he/she is engaged in carrying out any operation that is part of the nuclear fuel cycle.

CY-LG-1 70-301, Rev. 23 Page 74 08/07 3/4.3 RADIOLOGICAL ENVIRONMENTAL MONITORING FIASES 3/4-3-1 MONITORING PROGRAM The Radiological Environmental Monitoring Program (REMP) required by this control provides representative measurements of radiation and of radioactive materials in those exposure pathways and for those radionuclides that lead to the highest potential radiation exposures of MEMBER OF THE PUBLIC resulting from the station operation. This monitoring program implementsSection IV.B.2 of Appendix I to 10 CFR Part 50 and thereby supplements the radiological effluent monitoring program by verifying that the measurable concentrations of radioactive materials and levels of radiation are not higher than expected on the basis of the effluent measurements and modeling of the environmental exposure pathways.

The required detection capabilities for environmental sample analyses are tabulated in terms of the lower limits of detection (LLDs). The LLDs required by Table 4.3-1 are considered optimum for routine environmental measurements in industrial laboratories. It should be recognized that the LLD is defined as an a phar (before the fact) limit representing the capability of a measurement system and not an after the fact limit for a particular measurement.

Detailed discussion of the LLD, and other detection limits, can be found in HASL Procedures Manual, HASL-300 (revised annually); Currie L.A., "Limits for Qualitative Detection and Quantitative Determination - Application to Radiochemistry," Anal. Chem. 40, 586-93 (1968),

and Hartwell, J.K., "Detection Limits for Radioanalytical Counting Techniques", Atlantic Richfield Hanford Company Report ARH-SA-215 (June, 1975).

3/4.3.2 LAND USE CENSUS This control is provided to ensure that changes in the use of areas at and beyond the SITE BOUNDARY are identified and that modifications to the monitoring program are made if required by the results of the census. The best information from the door-to-door survey, aerial survey or consulting with local agricultural authorities or any combination of these methods shall be used. This census satisfies the requirements of Section IV.B.3 of Appendix I to 10 CFR Part 50. Restricting the census to gardens of greater than 500 square feet provides assurance that significant exposure pathways via leafy vegetables will be identified and monitored since a garden of this size is the minimum required to produce the quantity (26 Kg/year) of leafy vegetables assumed in Regulatory Guide 1.109 for consumption by a child.

To determine this minimum garden size, the following assumptions were used: (1) that 20% of the garden was used for growing broad leafy vegetation (i.e. similar to lettuce and cabbage),

and (2) a vegetation yield of 2 kg/Square meter.

CY-LG-170-301, Rev. 23 Page 75 08/07 3/4.3 RADIOLOGICAL ENVIRONMENTAL MONITORING 3/4-3.3 INTERLABORATORY COMPARISON PROGRAM The requirement for participation in an Interlaboratory Comparison Program ensures that independent checks on the precision and accuracy of the measurements of radioactive material in environmental sample matrices are performed as part of the quality assurance program for environmental monitoring in order to demonstrate that the results are reasonably valid for the purpose of Section IV.B.2 of Appendix I to 10 CFR Part 50.

3/4.3-4 METEOROLOGICAL MONITORING INSTRUMENTATION The OPERABILITY of the meteorological monitoring instrumentation ensures that sufficient meteorological data is available for estimating potential radiation doses to the public as a result of routine or accidental release of radioactive materials to the atmosphere. This capability is required to evaluate the need for initiating measures to protect the health and safety of the public. This instrumentation is consistent with the recommendations of Regulatory Guide 1.23 "Onsite Meteorological Programs," February, 1972.

Site data compiled since January 1972 provide correlation between Elevation 1 (Tower 1) and Elevation 1 (Tower 2), and between Elevation 2 (Tower 1) and Elevation 2 (Tower 2). This correlation serves as justification for the use of the appropriate Tower 2 instrument as a back-up to the Tower I instrument as shown in Table 3.3-3.

CY-LG-170-301, Rev. 23 Page 76 08/07 6.0 ADMINISTRATIVE CONTROLS 6.1 ANNUAL RADIOLOGICAL ENVIRONMENTAL OPERATING REPORT 6.1 Routine Annual Radiological Environmental Operating Report covering the operation of Unit 1 and Unit 2 during the previous calendar year shall be submitted prior to May 1 for each year. The initial report was submitted prior to May 1 of the year following initial criticality (1984). A single report is submitted for a multiple unit station. The Annual Radiological Environmental Operating Report shall include summaries, interpretations, and an analysis of trends of the results report period, including a comparison (as appropriate), with preoperational studies, operational controls and previous environmental surveillance reports and an assessment of the observed impacts of the plant operation on the environment. The reports shall also include the results of land use census required by Control 3.3.2. The Annual Radiological Environmental Operating Report shall include the results of all radiological environmental samples and of all environmental radiation measurements taken during the report period pursuant to the locations specified in the tables and figures in the OFFSITE DOSE CALCULATION MANUAL, as well as summarized and tabulated results of these analyses and measurements in the format of the table in NUREG 1302. In the event that some individual results are not available for inclusion with the report, the report shall be submitted noting and explaining the reasons for the missing results. The missing data shall be submitted as soon as possible in a supplementary report. The report shall also include the following: a summary description of the radiological environmental monitoring program and at least two legible maps. One map shall cover stations near the SITE BOUNDARY; a second shall include the more detailed distant stations.

Covering all sampling locations keyed to a table giving distances and directions from the centerline of the reactor plant; the results of licensee participation in the Interlaboratory Comparison Program, required by Control 3.3.3 discussion of all deviations from the Sampling Schedule of Table 3.3-1; and discussion of all analyses in which the LLD required by Table 4.3-1 was not achievable.

The Annual Radiological Environmental Monitoring Report shall include a summary of Issue Reports detailing level of radioactivity as the result of plant effluents in an environmental sampling medium exceed the reporting levels of Table 3.3-2.

CY-LG-1 70-301, Rev. 23 Page 77 08/07 6.0 ADMINISTRATIVE CONTROLS 6.2 ANNUAL RADIOACTIVE EFFLUENT RELEASE REPORT 6.2 A Routine Annual Radioactive Effluent Release Report covering the operation of Unit 1 and Unit 2 during the previous year shall be submitted in accordance with Tech Spec section 6.9.1.8. The period of the first report shall begin with the date of initial criticality.

A single unit submittal is made for the 2-unit station. The submittal combines those sections that are common to all units at the station. The Annual Radioactive Effluent Release Report shall include a summary of the quantities of radioactive liquid and gaseous effluents and solid waste released from the facility as outlined in Regulatory Guide 1.21, "Measuring, Evaluation, and Reporting Radioactivity in Solid Wastes and Releases of Radioactive Materials in Liquid and Gaseous Effluents from Light-Water-Cooled Nuclear Pdwer Plants," Revision 1, June 1974, with data summarized on a quarterly basis following the format of Appendix B with the following exception: (1)

Gaseous dose rates rather than effluent concentrations are used to calculate permissible release rates for gaseous releases. (2) ODCM Control 3.2.2.1 limits the dose equivalent rates due to the release of noble gases to less than or equal to 500 mrem per year to the total body and less than or equal to 3000 mrem per year to the skin. Therefore, the average beta and gamma energies (E) of the radionuclide mixture in releases of fission and activation gases are not applicable. (3) Achieving doses of less than the limits of 10 CFR Part 50, Appendix I demonstrate that Limerick's gaseous effluents are ALARA. Therefore, calculations of total body doses to the population out to 50 miles from gaseous effluents are not performed.

The Annual Radioactive Effluent Release Report shall include an annual summary of hourly meteorological data collected over the previous year. This annual summary may be either in the form of an hour-by-hour listing on magnetic tape of wind speed, wind direction and atmospheric stability, and precipitation (if measured), or in the form of joint frequency distributions of wind speed, wind direction, atmospheric stability. The licensee has the option of retaining this summary of required meteorological data on site in a file that shall be provided to the NRC upon request. This same report shall include an assessment of the radiation doses due to the radioactive liquid and gaseous effluents released from both units during the previous calendar year. This same report shall also include an assessment of the radiation doses from radioactive liquid and gaseous effluents to MEMBER OF THE PUBLIC due to their activities inside the SITE BOUNDARY (Figures 1-1 and 1-2) during the report period. All assumptions used in making these assessments shall be included in these reports. The assessment of radiation doses shall be performed in accordance with the methodology and parameters of the OFFSITE DOSE CALCULATION MANUAL (ODCM).

The Annual Radioactive Effluent Release Report shall also include an assessment of radiation doses to the hypothetically highest exposed MEMBER OF THE PUBLIC from reactor releases and other nearby uranium fuel cycle sources (including doses from primary effluent pathways and direct radiation) for the previous calendar year to show conformance with 40 CFR Part 190, Environmental Radiation Protection Standards for Nuclear Power Operation. Dose contribution from liquid and gaseous effluents is

CY-LG-1 70-301, Rev. 23 Page 78 08/07 6.0 ADMINISTRATIVE CONTROLS 6.2 ANNUAL RADIOACTIVE EFFLUENT RELEASE REPORT calculated based on Regulatory Guide 1.109, Rev 1, October 1977.

The Annual Radioactive Effluent Release Reports includes the following information for each type of solid waste (as defined in 10 CFR Part 61) shipped offsite during the report period:

1. Total volume, activity and estimated total % error for each waste type:

a. Spent resins filter sludges, evaporator bottoms, etc.

b. Dry compressible waste, contaminated equipment, etc.

c. Irradiated components, control rods, etc.

d. Others (describe).

2. Activity and percentage of each principle radionuclide (>1%), for each individual waste type as defined in 1. (a-d) above.

3. The disposition of solid waste shipments (identify the number of shipments, the mode of transport, and the destination).

4. The disposition of irradiated fuel shipments (identify the number of shipments, the mode of transport, and the destination.

The Annual Radioactive Effluent Release Report includes a list and description of unplanned releases from the site to UNRESTRICTED AREAS of radioactive material in gaseous and liquid effluents made during the reporting period.

Changes made during the reporting period to procedure RW-AA-100 (formerly the PROCESS CONTROL PROGRAM) and to the ODCM, as well as a listing of new locations for dose calculations and/or environmental monitoring identified by the land use census pursuant to Control 3.3.2. shall be submitted in the form of a complete, legible copy of the entire ODCM as part of or concurrent with the Annual Radiological Effluent Release Report for the period of the report in which any change to the ODCM was made.

The Annual Radioactive Effluent Release Report shall include an explanation as to why the inoperability of liquid or gaseous effluent monitoring instrumentation was not corrected within the time specified in Controls 3.1.1 or 3.1.2, respectively; The Annual Radioactive Effluent Release Report shall include a summary of Issue Reports detailing why discharge of liquid radwaste or gaseous radwaste without treatment exceeded the time specified in Controls 3.2.1.3 or 3.2.2.4, respectively.

The Annual Radioactive Effluent Release Report shall include a summary of Issue Reports for exceeding the calculated doses from the release of radioactive materials in liquid or gaseous effluents exceeding the limits of Controls 3.2.1.2.a., 3.2.1.2.b.,

3.2.2.2.a., 3.2.2.2.b., 3.2.2.3.a., 3.2.2.3.b., 3.2.2.5.a., 3.2.2.5.b., 3.2.2.5.c., and 3.2.3.

CY-LG-1 70-301, Rev. 23 Page 79 08/07 6.0 ADMINISTRATIVE CONTROLS 6.3 MAJOR CHANGES TO RADIOACTIVE WASTE TREATMENT SYSTEMS 6.3 Licensee-initiated major changes to the radioactive waste systems (liquid, gaseous, and solid):

a. Shall be reported to the Commission in the Annual Radioactive Effluent Release Report for the period in which the change was made effective. The discussion of each change shall contain:

1. A summary of the evaluation that led to the determination that the change could be made in accordance with 10 CFR 50.59;

2. Sufficient detailed information to totally support the reason for the change without benefit of additional or supplemental information;

3. A detailed description of the equipment, components, and processes involved and the interface with other plant systems;

4. An evaluation of the change which shows the predicted releases of radioactive materials in liquid and gaseous effluents and/or quantity of solid waste that differ from those previously predicted in the license application and amendments thereto;

5. An evaluation of the change which shows the expected maximum exposures to individual in the UNRESTRICTED AREA and to the general population that differ from those previously estimated in the license application and amendments thereto;

6. A comparison of the predicted releases of radioactive materials, in liquid and gaseous effluents and in solid waste, to the actual releases for the period prior to when the changes are to be made; and

7. An estimate of the exposure to plant operating personnel as a result of the change.

CY-LG-1 70-301, Rev. 23 Page 80 08/07 6.0 ADMINISTRATIVE CONTROLS 6.4 CHANGES TO THE ODCM 6.4 Licensee-initiated changes to the Offsite Dose Calculational Manual

a. Shall contain the program elements described in Technical Specifications 6.8.4.d, e and f.

b. Shall be revised in accordance with the requirements described in Technical Specification 6.14.

c. Shall be revised per applicable procedures detailing other requirements for making changes to the ODCM.

d. Shall be reviewed and accepted by PORC and signed by the Plant Manager prior to implementation.

CY-LG-170-301, Rev. 23 I Page 81 08/07I PART II CALCULATION METHODOLOGIES

CY-LG-170-301, Rev. 23 Page 82 08/07 CALCULATION METHODOLOGIES 1.0 LIQUID EFFLUENTS 1.1 RADIATION MONITORING INSTRUMENTATION AND CONTROLS The liquid effluent monitoring instrumentation and controls at Limerick for controlling and monitoring normal radioactive material releases in accordance with the Limerick ODCM Controls are summarized as follows:

1) Liquid Radwaste System: The liquid radwaste discharge monitor (RISH63-0K604) provides an alarm and automatic termination of radioactive material releases from the liquid radwaste system as required by ODCM Control 3.1.1.

Additional design features of the liquid radwaste system which prevent inadvertent releases to the environment include 1) redundant discharge valves, 2) single discharge line with loop seal and siphon breaker to eliminate probability of inadvertent discharges, 3) Low Cooling Tower Blowdown flow interlock which isolates the radwaste discharge line.

2) Service Water System: The Service Water discharge monitor (RISH10-1 K605 AND RISH10-2K605) provides an alarm upon indication of activity in the service water system as required by ODCM Control 3.1.1. While the service water system is not a normal release pathway, the monitor provides an indication of potential problems due to excessive leakage of the heat exchangers. In addition, the service water side of the fuel pool heat exchangers is kept at a higher pressure than the shell side to prevent potential radioactive contamination of the service water.

3) RHR Service Water System: The RHR Service Water Radiation (RHRSW)

Monitors (RISH12-0K619A, RISH12-0K619B) provide alarm and automatic termination* of radioactive material release from the RHRSW system, as required by ODCM Control 3.1.1. While the RHRSW system is not a normal release pathway, the monitors provide indication of potential problems due to excessive leakage of the heat exchangers.

Termination of the release is accomplished by auto trip of the RHRSW pumps and remote manual closure of isolation valves.

CY-LG-1 70-301, Rev. 23 Page 83 08/07 CALCULATION METHODOLOGIES 1.2 LIQUID EFFLUENT MONITOR SETPOINT DETERMINATION Per the requirements of ODGM Control 3.1.1, alarm setpoints shall be established for the liquid effluent monitoring instrumentation to ensure that the release concentration limits of ODCM Control 3.2.1.1 are met. The concentration of radioactive material released in liquid effluents to UNRESTRICTED AREAS shall be limited to 10 times the effluent concentration limits specified in 10 CFR 20, Appendix B, Table 2, Column 2, for radionuclides other than noble gases and 2.OE-04 gCi/ml for dissolved or entrained noble gases (NUREG 0133).

1.2.1 Radwaste Discharge Monitor and Discharge Flow Rate - RISH63-0K604 The setpoint for the liquid radwaste discharge monitor and flow rate element are determined by the following equations. The radwaste discharge monitor high-high alarm/isolation setpoint is evaluated at least monthly based on isotopes detected in the liquid radwaste sample tanks released during the previous month or on any specific sample tank being released (Y-Cigamma), the required minimum cooling tower blowdown rate during discharge (CTBD), and average liquid radwaste discharge flow (RR). The flow rate determination is calculated for each release and the ECL fraction calculated includes, in the concentration mix, the most recent results from

1) the quarterly composite for SR-89, SR-90 and Fe-55, and 2) the monthly composite for H-3, and 3) the sample(s) for dissolved and entrained noble gases.

If the calculated setpoint is less than the existing setpoint, the setpoint will be reduced to the new value. If the calculated setpoint is greater than the existing setpoint, the setpoint may remain at the lower value or be increased to the calculated value.

The actual setpoint may be reduced to a value less than the calculated setpoint at the discretion of supervision.

If there were no sample tanks released or no activity detected during the previous month, then the calculation is performed using release data from the most recent month during which isotopes were detected. In addition, if there were no sample tanks released during the previous month, supervision may substitute more restrictive values (e.g., tritium) based on the plant sampling data.

1.2.1.1 Setpoint Determination - RISH63-0K604 The setpoints for the liquid radwaste discharge monitor is determined by the following equations:

CY-LG-1 70-301, Rev. 23 Page 84 08/07 CALCULATION METHODOLOGIES I (S)(RR)[VE(Cg)/ECLfi)][ (YCry)a(R+CTBD) 1+BKGaLRD)

Hi-Hi Setpoint = CPM(Llr9 * (RR+CTBD) (S)(E)(RR) (ZCr/ECLty)

Hi Setpoint = (F)(Hi-Hi Setpoint) + BKG(LRD) (1-la) where:

CPM(LRD) = calculated liquid radwaste discharge monitor (RISH63-0K604) count rate attributable to the gamma emitting radionuclide, cpm Y ciX = the sum of the concentration of the identified gamma emitting nuclides (gCi/ml),

CTBD = the required minimum cooling tower blowdown rate during discharge (gpm),

RR = average liquid radwaste discharge flow (gpm),

BKG(LRD) = background count rate of liquid radwaste discharge monitor (CPM),

E = the gross detection efficiency of the liquid radwaste discharge monitor (g.tCi/ml/cpm), and S = 2; margin of safety factor to assure that the release is terminated prior to 10 CFR 20 limits being exceeded. Included in this factor are errors associated with monitor uncertainty, sampling uncertainty, flow rate uncertainty, and the contribution of other release paths (Service Water and RHRSW) which are not normally contaminated.

F = a factor less than 1 that is used to calculate the Hi-Setpoint. The value of F is controlled by a procedure.

JCir/ECLir = the effective gamma ECL ratio for the mixture of radionuclides in the liquid radwaste discharge line (unitless).

where:

cir = the concentration of each identified gamma emitting radionuclide 'i' in the liquid effluent (undiluted) (gCi/ml)

ECLir = the ECL value for radionuclide 'i' corresponding to 10 times the ECL limit from 10 CFR 20 Appendix B, Table 2, Column 2 (dissolved and entrained noble gases ECL = 2.OE-4 jiCi/ml) xCip//ECLif = the effective nongamma ECL ratio for the mixture of radionuclides in the liquid radwaste discharge line (unitless)

CY-LG-1 70-301, Rev. 23 Page 85 08/07 CALCULATION METHODOLOGIES where:

Ci,8 = the concentration of each identified nongamma radionuclide 'i' in the liquid effluent (undiluted) (gCi/ml) *

(See note below)

ECLi, = the ECL value for radionuclide 'i' corresponding to 10 times the ECL limit from 10 CFR 20,-Appendix B, Table 2, Column 2

NOTE: The concentration mix must include the most recent sample data for H-3, Sr-89, Sr-90, Fe-55 and gross alpha.

1.2.1.2 Flow Rate Determination The maximum liquid radwaste tank flow rate discharge to the river is determined by the following equation:

CTBD FLOW(LRD) <

(1-2) where:

FLOW(LRD) = flow limit for radwaste discharge line (gpm).

CTBD = required minimum cooling tower blowdown flow during discharge (gpm).

S = 2; margin of safety factor to assure that the release does not exceed 10 CFR 20 limits.

X(Ci/ECL) - the effective ECL ratio for the mixture of radionuclides in the liquid radwaste discharge line (unitless) for x(Cj/ECLi)>1. If j(CI/ECLj)<1, then no flow rate determination is necessary.

where:

Ci = the concentration of each identified radionuclide 'i' in the liquid effluent (undiluted) (pgCi/ml)* (See note below)

CY-LG-1 70-301, Rev. 23 Page 86 08/07 CALCULATION METHODOLOGIES ECLi = the ECL value for radionuclide T corresponding to 10 times the ECL limit from 10 CFR 20 Appendix B, Table 2, Column 2, (dissolved and entrained noble gases ECL = 2E-4 gCi/ml)(gCi/ml).

NOTE: The concentration mix must include the most recent sample data for H-3, Sr-89, Sr-90, Fe-55 and dissolved and entrained noble gases.

1.2.2 Service Water Radiation Monitor - RISH1 0-1 K605 -2K605 The Service Water Radiation Monitor maximum (High-High) setpoint is determined by the following equation. The setpoint is evaluated every 24 months to assure that a high background count rate does not prevent adequate monitor sensitivity in order to meet the requirements of ODCM Control 3.2.1.1.

The High Setpoint shall be administratively controlled to a value that is less than the High-High setpoint.

1.2.2.1 Setpoint Determination The setpoints for the Service Water Radiation Monitor is determined by the following equations:

Hi-Hi Setpoint = CPMsw= (S)(ECL cs137)(CF) (1-3)

Hi Setpoint = (F)(Hi-Hi Setpoint) (1-3a) where:

CPMsW = Calculated Maximum Service Water Radiation Monitor (RISH12-1K605, -2K605) count rate, cpm.

ECLcs-137 = ECL limit for Cs-1 37 (1.OE-05 gCi/ml)

CF = Monitor calibration factor - in cpm/gCi/ml S = 0.5; Safety Factor, F = a factor less than 1 that is used to calculate the Hi-Setpoint. The value of F is controlled by a procedure.

CY-LG-1 70-301, Rev. 23 Page 87 08/07 CALCULATION METHODOLOGIES 1.2.3 RHR Service Water Monitor -RISH12-OK619A, -OK619B The RHR Service Water Radiation Monitor maximum High-High setpoint is determined by the following equation. The setpoint is evaluated every 24 months to assure that a high background count does not prevent adequate monitor sensitivity in order to meet the ODCM Control 3.2.1.1.

The High Setpoint shall be administratively controlled to a value that is less than the High-High setpoint.

1.2.3.1 Setpoint Determination The setpoints for the RHR Service Water Radiation Monitor is determined by the following equations:

Hi-Hi Setpoint =CPMRHRSW = (S)(ECLcs_1 3 7 )(CF) (1-4)

Hi Setpoint = (F)(Hi-Hi Setpoint) (1-4a) where:

CPMRHRSW = Calculated maximum RHR Service Water Radiation Monitor (RISH12-0K619A, -0K619B) count rate, cpm.

ECLcs-137 = ECL limit for Cs-1 37 (1.0E-05 gCi/ml)

CF = Monitor calibration factor - in cpm/jiCi/ml.

S = 0.5; Safety Factor F = a factor less than 1 that is used to calculate the Hi-Setpoint. The value of F is controlled by a procedure.

1.3 LIQUID EFFLUENT DOSE CALCULATION - 10 CFR 50 1.3.1 Dose to Members of the Public Control 3.2.1.2 limits the dose or dose commitment to MEMBERS OF THE PUBLIC from radioactive materials in liquid effluents from Limerick Generating Station to:

During any Calendar Quarter During any Calendar Year

< 3 mrem to total body s<6 mrem to total body

<10 mrem to any organ. <_20 mrem to any organ

CY-LG-1 70-301, Rev. 23 Page 88 08/07 CALCULATION METHODOLOGIES Per Surveillance Requirement 4.2.1.2 the cumulative dose contribution from liquid effluents for the current calendar quarter and calendar year shall be determined at least once per 31 days in accordance with the following calculation methods. The monthly results are accumulated to give the quarterly doses and the quarterly results are accumulated to give the annual doses.

Pathways Receptor Location Dist. Potable Fish Shoreline (mi) Water LGS Outfall 0 X X PA. American Water 2.5 X X X Phoenixville Water 9.0 X X X Phil. Sub. Water 13.6 X X Crew Course 37.8 X 1.3.1.1 Potable Water Pathway (1-5)

Ua.pF i 'D'jx(*P (1-5)

R.pj =1100 MP 1.3.1.2 Fish (Aquatic Food) Pathway Rapi =1100

='110UP MU o MR---F Q Bip D.ipjexp(-11-tP)

Lp.aj(16 (1-6) 1.3.1.3 Shoreline Deposition Pathway Rapj = 110,000 ipj[--7 M F1 where:

Bip =equilibrium bioaccumulation factor for nuclide I in pathway p, expressed as the ratio of the concentration in biota, in pCi/kg, to the radionuclide concentration in water, in pCi/liter (liters/kg). Values are in Table Il1-1.

Daipj = dose factor specific to a given age group a, radionuclide 'i'. pathway p, and organ j which can be used to calculate radiation dose (1) from an intake of a radionuclide, in mrem/pCi, or (2) from exposure to a given concentration of a radionuclide in sediment, in mrem/hr per pCi/m 2 . Values are listed in Table 111-2 through Table 111-6.

F = flow rate of liquid effluent from site, cfs.

CY-LG-1 70-301, Rev. 23 Page 89 08/07 CALCULATION METHODOLOGIES Mp= dilution factor at point of exposure or at point of withdrawal of drinking water (dimensionless). Values are graphically listed by receptor location in Figures 111.3.1-1 to 111.3.1-5. Value will be based on average monthly river flow. Mp appears in the equation denominator because river flow graphs display Mp as dilution flow and not the mixing ratio.

Q = total release of nuclide 'i' for time period (Ci).

Rapj = total dose for calculation time period to organ j of individuals of age group a from all nuclides 'i in pathway b (mrem).

Ti = radioactive half-life of nuclide 'i' (days).

Uap = usage factor specifying exposure time or intake rate for an individual of age group a associated with pathway p (hr/yr, liters/yr, or kg/yr) as indicated in Table 111-7.

W = shoreline width factor (dimensionless) = 0.2. Ref: Regulatory Guide 1.109, Rev. 1.

tb = time period during which sediment is exposed to contaminated water (1.752E+5 hrs) (midpoint of plant life = 20 yrs)

= radioactive decay constant of nuclide 'i' (hr-1) tp = 12 hours1.388889e-4 days 0.00333 hours 1.984127e-5 weeks 4.566e-6 months for delay time for water pathway in hours to allow for nuclide decay during transport through the water purification plant and the water distribution system, Ref: Regulatory Guide 1.109, Rev. 1, App. A.

tp = 24 hours2.777778e-4 days 0.00667 hours 3.968254e-5 weeks 9.132e-6 months for delay time for fish pathway to allow for nuclide decay during transport through the food chain, as well as during food preparation. Ref: Regulatory Guide 1.109, Rev. 1, App. A.

tp = 0 hours0 days 0 hours 0 weeks 0 months for delay time for shoreline pathway. Zero hours are assumed as shoreline activities can occur at the outfall.

1100 = factor to convert from Ci/yr per ft3/sec to pCi liter.

110,000 = factor to convert from Ci/yr per ft3/sec to pCi/liter and to account for proportionately constant (100) used in sediment radioactivity model.

CY-LG-1 70-301, Rev. 23 Page 90 08/07 CALCULATION METHODOLOGIES 1.3.2 Liquid Effluent Dose Projections Control 3.2.1.3 requires that the liquid radwaste treatment system shall be operable and appropriate portions of the systems used to reduce the radioactive materials in liquid waste prior to their discharge when the projected doses due to the liquid effluent to UNRESTRICTED AREAS would exceed:

0.12 mrem/31 days to the total body or 0.4 mrem/31 days to any organ.

Dose projections are made at least once per 31-days by the following equations:

Dtbp = (Dtb/d)

31 days (1-8)

Dmaxp = (Dmax/d)

31 days (1-9) where:

Dtbp = the total body dose projection for the current 31-day period (mrem).

Dtb = the total body dose to date for the current calendar quarter as determined by equations 1-5, 1-6, and 1-7 (mrem).

Dmaxp = the maximum organ dose projection for the current 31-day period (mrem).

Dmax = the maximum organ dose to date for the current calendar quarter as determined by equations 1-5, 1-6, and 1-7 (mrem).

d = the actual number of days in the current calendar quarter at the end of the release (days).

31 days = the number of days of concern 2.0 GASEOUS EFFLUENTS 2.1 RADIATION MONITORING INSTRUMENTATION AND CONTROLS The gaseous effluent monitoring instrumentation and controls at Limerick for controlling and monitoring radioactive material releases in accordance with the ODCM Part I are summarized as follows:

1) North Vent (Common): The plant gaseous discharges via this vent are monitored by two Particulate, Iodine and Gas (PIG) monitors (RY26-075A and RY26-075B) in parallel and by the Wide Range Accident Monitor (WRAM)

CY-LG-170-301, Rev. 23 Page 91 08/07 CALCULATION METHODOLOGIES (RY26-076). The PIGS have separate Particulate, Iodine, and Gas sampling and monitoring channels but the Controls require only particulate and iodine sampling and noble gas monitoring. The WRAM has extended range (via three channels) noble gas monitoring and particulate and iodine sampling capability. In addition, the WRAM provides an isolation (Group 6A) of the large Drywell Purge and Vent valves.

2) South Vent (one per unit) The plant gaseous discharges via each South Vent are monitored by two redundant PIG monitors (RY26-285A,B). As is the case of the North Vent, each PIG has separate particulate, iodine, and gas sampling and monitoring channels but the Controls require only particulate and iodine-sampling with gas monitoring.

3) Hot Maintenance Shop (Common): Due to the composition of the radioactive materials in the effluent steam (i.e., very low potential for noble gas), this release point is sampled by a particulate and iodine (P&I) monitor (RY26-025).

The P&I monitor has a separate particulate and iodine sampling and monitoring channels but Controls require only particulate and iodine sampling.

4) Auxiliary Boilers (Common): Waste oil with some amount of radioactive particulate content may be burned in the site auxiliary boilers, as allowed by 10CFR20.2004. In this case, the exhaust stack of the affected auxiliary boiler will be a release point for radioactive effluents. Doses calculated will be based on the radioactive content of the oil sampled prior to incineration. The radioactive effluent will be summed with other effluents from the site and reported to the commission in the Annual Effluent Radiological Release Report.

2.2 GASEOUS EFFLUENT MONITOR SETPOINT DETERMINATION Control 3.1.2 requires that an alarm setpoint be established for the noble gas effluent monitoring channels (RY26-075A(B), RY26-185A(B), RY26-285A(B), and RY26-076) to ensure that the release rate of radioactive materials does not exceed the limits of Control 3.2.2.1 .a, which corresponds to a dose rate at the SITE BOUNDARY of 500 mrem/yr to the total body or 3000 mrem/yr to the skin.

Control limits are expressed in terms of dose rate, while the instruments that monitor effluents produce data in units of concentration or release rate. It is therefore necessary to identify the isotopes and calculate the corresponding release rate that will result in the dose rate limit being reached at the site boundary. This calculation is made more complex by the use of multiple release points at LGS.

Calculation Bases The alarm setpoint calculation is performed monthly and is based on analytical results of grab samples from the appropriate release point. The concentration of each identified radionuclide in the grab samples is determined, and the data is used

CY-LG-1 70-301, Rev. 23 Page 92 08/07 CALCULATION METHODOLOGIES to perform a setpoint calculation for that nuclide mix and release point.

The highest calculated annual average concentration (X/Q) for an area at or beyond the site boundary (1.1 E-5 sec/m 3 , NE sector) is used in the setpoint calculation.

Maximum flow rates through the North and South vents are used in alarm setpoint calculations. This is necessary since flow can vary. By using maximum values, any flow less than the maximum will assure that the monitor will alarm before release rate limits are exceeded.

The fractional contribution of noble gas is calculated for each release point. The fractional contribution to the whole body and skin dose rates due to noble gases for the north stack and south stack vents are calculated by taking the product of this fraction and the limiting release rate. A comparison of the release rate for whole body and skin dose rates due to noble gas release is made to determine if the whole body or skin dose limit will be most restrictive. It is expected that the whole body limit will always be most restrictive, but the comparison is necessary to assure compliance with Control 3.2.2.1. The sum of the contributions from each release point, independently calculated for noble gases, will equal the maximum instantaneous release rate allowed from the site.

2.2.1 North Vent Noble Gas Effluent Monitors - RY26-075A RY26-075B and RY26QT0762 The North Vent Noble Gas Effluent monitor high-high setpoint is calculated monthly based on the grab sample results performed in accordance with Table 4.2-2.

Release point grab samples may not identify any radionuclides. In this situation, use the results of the last grab sample that identified radionuclides or use the default setpoint which is based on expected concentration ratios as reported in the UFSAR.

If any calculated alarm setpoint is less than the existing monitor setpoint, the setpoint will be reduced to the new value. If the calculated setpoint value is greater than the existing value, the setpoint may remain at the lower value or be increased to the new value.

2.2.1.1 Setpoint Determination The High-High setpoint is calculated per equation 2-1 or 2-2. The High-High setpoint for the North Vent Noble Gas Effluent Monitor is set at or below the lesser of the NVSP(Hi-Hi)NGWB OR NVSP(Hi-Hi)NGSK value. (per equations 2-1 or 2-2)

[VF.,G ][500][_Cij]

NSVP(HI-HI)NGWB < [3.4475E9]X[(Civ)(K 1)] (2-1)

CY-LG-1 70-301, Rev. 23 Page 93 08/07 CALCULATION METHODOLOGIES 3

NVSP(Hi-Hi)NGSK< [VFNYNGC-[ OOO]1CiNv]

(2-2)

[3.4475E9]Y [(Cij,) (Li + 1.1 Mi)]

The High Setpoint shall be administratively controlled to a value that is less than the High-High Setpoint.

Hi Setpoint = (F)(Hi-Hi Setpoint) (2-2a) where:

NVSP (Hi-Hi)NGSK = North Vent High-High Setpoint - Noble Gas Skin (ptCi/cc).

NVSP (Hi-Hi)NGWB = North Vent High-High Setpoint - Noble Gas Whole Body (tCi/cc).

VFNVNG = fractional contribution to site boundary noble gas dose rate from the North Vent. (unitless).

500 = total body dose rate limit (mrem/yr) 3000 = skin dose rate limit (mrem/yr) yCiNV = total noble gas activity from North Vent grab sample (ptCi/cc)

F = a factor less than 1 that is used to calculate the Hi-Setpoint.

The value of F is controlled by a procedure.

/ (pCi)(cc) 3.471 E+9 = Conversion factor, units are (,,Ci)(m3)

(1.1E-5secy1.0E+6pCP(66&450ft3Y 1min y2.83Z'+4cc" (2-3) where: uCi mi )6Osec &

where:.

1.1E-5 sec/m3 = highest annual average X/Q (NE Sector) 1E+6 pCi/lCi = units conversion 668,450 cfm = maximum North Vent flow rate for two unit operation 1 min/60 sec = units conversion 2.832E+4 cc/ft3 = units conversion CiNV concentration of noble gas nuclide T as determined by radioanalysis of North Vent grab sample (ptCi/cc)

CY-LG-1 70-301, Rev. 23 Page 94 08/07 CALCULATION METHODOLOGIES K= Total body dose conversion factor for noble gas nuclide 'i' (mrem/yr per pCi/m 3 , from ODCM Table 112-1).

Li= Beta skin dose conversion factor noble gas nuclide 'i' (mrem/yr per pCim 3 , from ODCM Table 112-1).

M= Gamma air dose conversion factor for noble gas nuclide 'i' (mrad/yr per pCi/m 3 , From ODCM Table 112-1).

1.11 = The average ratio of tissue to air energy absorption coefficients (mrem/mrad) (Ref: Regulatory Guide 1.109, Section 2.0).

2.2.2 South Vent Noble Gas Effluent Monitors -RY26-185A-3. RY26-185B-3, RY26-285A-3 and RY26-285B-3 Each unit's South Vent Noble Gas Effluent monitor High-High setpoint is calculated monthly based on the grab sample results performed in accordance with ODCM Part I, Table 4.2-2. Release point grab samples may not identify any radionuclides. In this situation, use the results of the last grab sample that identified radionuclide or use the default setpoint which is based on expected concentration ratios as reported in the UFSAR. If any calculated alarm setpoint is less than the existing monitor setpoint, the setpoint will be reduced to the new value. If the calculated setpoint value is greater than the existing value, the setpoint may remain at the lower value, or be increased to the new value.

2.2.2.1 Setpoint determination The High-High setpoint for the South Vent Noble Gas Effluent Monitor is set at the lesser of the SVSP(Hi-Hi)NGWB and SVSP(Hi-Hi)NGSK value. SVSP(Hi-Hi)NGWB and SVSP(Hi-Hi)NGSK are calculated for each unit's South Vent.

The High-High setpoint is calculated per equation 2-4 or 2-5.

[VFSVNG][ 5 0 0 ][ Y-Cis v ]

SVSP(HI-HI)NGWB < [1.2149E + 9]X[(Cisv)(Ki)] (2-4)

[VFSVNG][ 3 0 0 0 ][-,Cisv]

SVSP(HI-HI)NGSK < [1.2149E + 9]X[(Cisv)(Li + 1.11 Mi)] (2-5)

The High Setpoint shall be administratively controlled to a value that is less than the High-High Setpoint.

Hi Setpoint = (F)(Hi-Hi Setpoint) (2-5a)

CY-LG-1 70-301, Rev. 23 Page 95 08/07 CALCULATION METHODOLOGIES where:

SVSP(Hi-Hi)NGWB = South Vent High-High Setpoint - Noble Gas Whole Body (RCi/cc)

SVSP(Hi-Hi)NGSK = South Vent High-High Setpoint - Noble Gas Skin (RCi/cc)

VFSVNG = Fractional contribution to site boundary noble gas dose rate from the Unit's South Vent. (unitless) 500 = Total body dose rate limit (mrem/yr) 3000 = Skin dose rate limit (mrem/yr)

F = a factor less than 1 that is used to calculate the Hi-Setpoint.

The value of F is controlled by a procedure.

YCisv = Total noble gas activity from each unit South Vent grab sample (pgCi/cc).

Cisv = concentration of noble gas nuclide 'i' determined by radioanalysis of South Vent grab sample (pCi/cc)

Ki = Total body dose conversion factor for noble gas nuclide 'i' (mrem/yr per pCi/m3, from ODCM Table 112-1).

Li = Beta skin dose conversion factor noble gas nuclide 'i' (mrem/yr per pCi/m3, From ODCM Table 112-1).

Mi = Gamma air dose conversion factor for noble gas nuclide 'i' (mrad/yr per pCi/m3, From ODCM Table 112-1).

1.11 = The average ratio of tissue to air energy absorption coefficients (mrem/mrad) (Ref: Regulatory Guide 1.109, Section 2.0)

(pCi)(cc) 1.2149E+9 = Conversion factor units are in (fCl)(m3)

(EuCi)(m3) 1 m3. uCi mi )60sec ft3) (2-6)

(LIE

.1E 5secy 1.0E +6p CQ ý 23 4 +5ft3 . min 28 2 +4 c where:

3 1.1 E-5 sec/m = highest annual average X/Q (NE Sector) 1E+6 pCi/jiCi = units conversion 2.34E+5 ft 3/m = maximum South Vent flow rate 1/60 min/sec = units conversion 3

2.832E+4 cc/ft = units conversion

CY-LG-170-301, Rev. 23 Page 96 08/07 CALCULATION METHODOLOGIES 2.2.3 Noble Gas Effluent Fractional Contribution The three release points will be partitioned such that the sum does not exceed 100 percent of the limit (500 mrem/yr whole body noble gas, 3000 mrem/yr, skin noble gas.) The default fraction will be set at 80 percent for the North Vent, 10 percent for the Unit-1 South Vent and 10 percent for the Unit-2 South Vent.

These percentages can vary should operational concentrations warrant such change.

However, the sum of the percentages shall be equal to or less than 100%. The following relationship shall be met:

VFNVNG + VFISVNG + VF2SvNG _*1 (2-7) where:

VFNVNG = fractional contribution to site boundary noble gas total body dose rate from the North Vent (unitless).

VF1SVNG = fractional contribution to site boundary noble gas total body dose rate from the Unit 1 South Vent (unitless).

VF2SVNG = fractional contribution to site boundary noble gas total body dose rate from the Unit 2 South Vent (unitless).

2.2.4 Noble Gas Effluent Default Setpoint This methodology may be used when grab sample results from either the North Vent or the South Vent do not identify any radionuclides. This methodology is based on expected release concentration ratios as outlined in Section 11.3 of the Limerick UFSAR.

2.2.4.1 North Vent Noble Gas Monitors (RY26-075A-3 and RY26-075B-3). The default High-High setpoint for the North Vent Noble Gas Effluent Monitor is set at or below the NVSP(Hi-Hi)NGD value.

NVSP(Hi - Hi < [8.00E-1][500][1 .31E-6] (2-8)

-[3-.47-1 E+9] [4.37E -9]

NVSP(Hi-Hi)NGD _ 3.45E-5 gCi/cc where:

NVSP(Hi-Hi)NGD = Default North Vent High-High Setpoint - Noble Gas Whole Body (pICi/cc) 8.OOE-1 = Default fractional contribution to site boundary noble gas total body dose rate from the North Vent (unitless)

CY-LG-1 70-301, Rev. 23 Page 97 08/07 CALCULATION METHODOLOGIES 500 = Total body dose rate limit (mrem/yr) 1.31 E-6 = Total noble gas concentration from North Vent (gCi/cc)

Ref: a) Based on UFSAR Table 11.3-1.

b) Based on maximum North Vent flow of 668,450 cfm 3.471 E+9 = Conversion Factor, units are in (pCi)(Cc) See Equation 2-3.

4.37E-9 = Summation of the North Vent concentration of noble gas nuclide T multiplied by the corresponding whole body dose (fuCi)( mrem)( m3 )

3) factor. Units are in I(Cc)(yr)(p (cc)(yr)(pCi)

Ref: a) Based on UFSAR Table 11.3-1.

b) Based on maximum North Vent flow of 668,450 cfm.

c) ODCM Table 112-1.

2.2.4.2 South Vent Noble Gas Monitors (RY26-185A-3, RY26-285A-3, RY26-185B-3, and RY26-285B-3). The default High-High setpoint for each Unit's South Vent Noble Gas Effluent Monitor is set at or below the SVSP(Hi-Hi)NGD value.

SVSP(Hi - Hi)NGD ! [1.OOE - 1][500][1.02E - 7] (

[1.2149E + 9][2.71E- 10]

SVSP(Hi-Hi)NGD < 1 .54E-5 pgCi/cc where:

SVSP(Hi-Hi)NGD = Default South Vent Setpoint - Noble Gas (pgCl/cc) 1.00E-1 = Default fractional contribution to site boundary noble gas total body dose rate from the South Vent (unitless) 500 = Total body dose rate limit (mrem/yr) 1,02E-7 = Total noble gas concentration from South Vent (ptCi/cc)

Ref: a) Based on UFSAR Table 11.3-1.

b) Based on maximum South Vent flow of 234,000 cfm.

1.2149E+9 = Conversion factor, units are in (pCi)(Cc).. See Equation 2-6.

SeeEqatin -6

CY-LG-1 70-301, Rev. 23 Page 98 08/07 CALCULATION METHODOLOGIES 2.71 E-1 0 = Summation of the South Vent concentration of noble gas nuclide 'i' multiplied by the corresponding whole body dose factor.

(ylCi)(mrem)(m3 )

Units are in (cc)(yr)(pCi)

Ref: a) Based on UFSAR Table 11.3-1.

b) Based on maximum South Vent flow of 234,000 cfm.

c) ODCM Table 112-1.

2.2.5 Wide Range Accident Monitor Noble Gas Effluent Monitor (RIX-26-076-4)

The Wide Range Accident Monitor (WRAM) noble gas total effluent channel displays the North Vent noble gas release rate. This monitor has Main Control Room Annunciation as well as a group 6A isolation function on the primary containment purge and vent valves. The isolation setpoint value of <._2.1 gtCi/cc specified in Technical Specification Table 3.3.2-2 is based on the accident dose limits for containment purge during an accident (Ref: UFSAR Section 1.13). For routine operations the total effluent high and high-high setpoints are based upon the methodology of Sections II 2.2.5.1 and II 2.2.5.2. The setpoint units are in microcuries per second using the two-unit maximum North Vent flow rate of 668,450 scfm. The total effluent channel High-High setpoint is set at a value less than or equal to ten times the High setpoint (not to exceed the 2.1 jtCi/cc equivalent using the two-unit maximum North Vent flow rate). These values are always more conservative than the Technical Specification Table 3.3.2-2 required value of < 2.1 iRCi/cc.

If the calculated setpoint value is less than the existing monitor setpoint, the setpoint will be reduced to the new value. If the calculated setpoint is greater than the existing value, the setpoint may remain at the lower value, or be increased to the new value.

2.2.5.1 Routine Operations High Setpoint Determination For routine operations, the High setpoint for the WRAM Noble Gas Total Effluent Channel is set at or below the lesser of the NVSP(Hi-Hi)NGWB or NVSP(Hi-Hi)NGSK value when activity is detected. When no activity is detected, the High setpoint is set at or below the NVSP(Hi-Hi)NGD. This setpoint is calculated to ensure compliance with Control 3.2.2.1 .a.

The setpoint values are converted from gCi/cc to gCi/sec using the maximum two-unit North Vent flow rate:

NVSPTEWB = [NVSP(Hi-Hi)NGWBor NGD] [3.155E+8] (2-10)

CY-LG-1 70-301, Rev. 23 Page 99 08/07 CALCULATION METHODOLOGIES NVSPTESK = [NVSP(Hi-Hi)NGSK] [3.155E+8] (2-11) where:

NVSPTEWB = WRAM total effluent channel North Vent High Setpoint -

Noble Gas Whole Body (gCi/sec).

NVSPTESK = WRAM total effluent channel North Vent High Setpoint -

Noble Gas Skin (pgCi/sec).

NVSP(Hi-Hi)NGWB = North Vent High-High Setpoint - Noble or NGD Gas Whole Body (lgCi/cc) from equation 2-1 or 2-8.

NVSP(Hi-Hi)NGSK = North Vent High-High Setpoint - Noble Gas Skin (gCi/cc) from equation 2-2.

3.155E+8 = Conversion factor (cc/sec).

668,450sft 3 1min J(2.832E + 4cc Smin J60secJ*( 0t (2-12) 2.2.5.2 Routine Operations High-High Setpoint Determination For routine operations, the High-High setpoint for the WRAM Noble Gas total effluent channel is set at or below ten times the lesser of the routine operations NVSPTEWB or NVSPTESK value.

NVHPTEWB = [NVSPTEWBI [10] (2-13)

NVHPTESK = [NVSPTESK] [10] (2-14) where:

NVHPTEWB = WRAM total effluent channel North Vent High-High Setpoint Noble Gas Whole Body (gCi/sec).

NVHPTESK = WRAM total effluent channel North Vent High-High Setpoint Noble Gas Skin (IjCi/sec).

NVSPTEWB = WRAM total effluent channel North Vent High Setpoint -

Noble Gas Whole Body (gCi/sec) from equation 2-10.

NVSPTESK = WRAM total effluent channel North Vent Setpoint -

Noble Gas Skin (gCi/sec) from equation 2-11.

CY-LG-170-301, Rev. 23 Page 100 08/07 CALCULATION METHODOLOGIES 10 = multiplication factor to calculate High-High value (unitless) 2.3 GASEOUS EFFLUENT DOSE EVALUATION Monthly dose calculations are performed based on limiting sector average annual meteorological dispersion parameters. For the noble gas monthly dose calculation, effluent release data are based on the latest grab sample analysis for radionuclide composition. For the iodine and particulate monthly dose calculations, the effluent release radionuclide composition and release activity are based on weekly continuous samples.

The quarterly dose calculations are a summation of the applicable monthly dose results.

2.3.1 Dose Rate - Noble Gases Control 3.2.2.1.a limits the dose rate in gaseous effluents from the site to areas at or beyond the SITE BOUNDARY due to noble gas releases to <500 mrem/yr total body and <3000 mrem/yr skin. Radiation monitor alarm setpoints are established to ensure that these release limits are not exceeded.

Simultaneous releases from the North and South Vents are considered in evaluating compliance with the release rate limits of Control 3.2.2.1 .a. following any releases exceeding the alarm setpoints. Monitor indications (readings) are averaged over time periods not to exceed 60 minutes.

NOTE: For administrative purposes, more conservative alarm setpoints than those required to meet 10 CFR 20 Dose Rate limits are imposed. However, conditions exceeding these more limiting alarm setpoints do not necessarily indicate radioactive material release rates exceeding the dose limits of Control 3.2.2.1.a. Provided actual releases do not result in radiation monitor indications exceeding values based on the dose rate limits of Control 3.2.2.1 .a., no further analyses are required for demonstrating compliance with the limits of Control 3.2.2.1 .a.

In the event of a noble gas effluent release exceeding the setpoint value specified in ODCM Part II, Sections 2.2.1 or 2.2.2, the site boundary dose rate from the release is calculated using the methodology stated below.

This methodology is based on worst sector (NE) annual average meteorological dispersion but, if further refinement is required to meet the requirements of Control 3.2.2.1 .a, actual meteorological data from the time period of concern may be used to calculate actual meteorological dispersion.

CY-LG-1 70-301, Rev. 23 Page 101 08/07 CALCULATION METHODOLOGIES DTB= X/Q (1E +6 QLj (2-15)

Dr= /Q (1E+6f+/- (Lz+1.11M )Qj (2-16) where:

DTB = Total Body Plume Dose Rate (mrem/yr)

Dr = Skin Plume Dose Rate (mrem/yr)

X/Q = 1.1 E-5 highest annual average relative concentration (NE Sector) (sec/m3)

Qi = The in units of mrem/yr/per pCi/m 3release rate of noble gas nuclide I from all vent releases averaged over one hour (uCi/sec)

Ki= Total body dose factor for noble gas nuclide 'i' in units of mrem/yr per pCi/m 3 . Values are listed in ODCM Table 112-1.

Li= Skin dose factor for the beta contribution for noble gas nuclide 'i' in units of mrem/yr per pCi/m3. Values are listed in ODCM Table 112-1.

1.11 = the average ratio of tissue to air energy absorption coefficients (mrem/mrad) (Ref: Regulatory Guide 1.109, Section 2.)

Mi = Gamma air dose factor for noble gas nuclide 'i' in units of mrad/yr per pCi/m 3 . Values are listed in ODCM Table 112-1.

1E+6 = Units conversion pCi/jaCi 2.3.2 Dose Rate - Radioiodine iand Particulates Control 3.2.2.1 .b limits the dose rate to <1500 mrem/yr to any organ (inhalation pathways only) for 1-131, 1-133, Tritium, and all radionuclides in particulate form with half-lives greater than 8 days in gaseous effluents. Compliance with Control 3.2.2.1.b is determined monthly.

Simultaneous releases from the North and South Vents are considered in evaluating compliance with the release rate limits of Control 3.2.2.1.b. Release activity is based

CY-LG-1 70-301, Rev. 23 Page 102 08/07 CALCULATION METHODOLOGIES upon the results of the weekly continuous sample analysis performed in accordance with ODCM Part I, Table 4.2-2.

n DH = X/Qdepl , RiQi (2-17) i=1 where:

DIH = Inhalation dose rate (mrem/yr)

X/Qdepl = 1.OE-5 highest average annual depleted X/Q (NE Sector) (sec/m3)

Ri = Dose factor for radionuclides other than noble gases for the inhalation pathway only (mrem/yrl.Ci/m3). Values are listed in ODCM TABLE 112-2. See equation 2-22a.

Qi= The release rate of radionuclide 'i' other than noble gases from all vent releases (gCi/s).

2.3.3 Noble Gas Air Doses Control 3.2.2.2 limits the air dose due to noble gases released in gaseous effluents (from both reactor units) to areas at or beyond the SITE BOUNDARY to:

< 10 mrad gamma for any quarter

< 20 mrad beta for any quarter

< 20 mrad gamma during any calendar year

< 40 mrad beta during any calendar year As required by Surveillance Requirement 4.2.2.2, these doses are calculated at least once per 31 days using the results of the most recent grab samples for isotopic composition performed in accordance with Table 4.2-2. The monthly dose calculation is performed using the most limiting average annual meteorological dispersion values. The quarterly doses are based on the summation of the applicable monthly results. The monthly dose calculations are performed in accordance with the methodology below.

DAR= (317E-8X1.OOE+6) QZ MiQi (2-18)

Q (=18

CY-LG-1 70-301, Rev. 23 Page 103 08/07 CALCULATION METHODOLOGIES n

D,6AIR=(3.17E-8X1.00E+6) Q3NiQi (2-19)

=1 where:

DAIR = Gamma air dose from noble gas releases in MRAD DPAIR = Beta air dose from noble gas release in MRAD 3.17E-8 = Units conversion [year/sec]

1.00E+6 = Units conversion pCi/uCi X/Q = 1.1 E-5, Highest average 3 annual relative concentration (NE Sector) in sec/m Qi = The release of noble gas radionuclides 'i' from all vents in uCi. Releases shall be cumulative over the period of interest.

Mj = Gamma air dose factor for noble gas nuclide 'i' in units of mrad/yr per pCi/m 3 . Values are listed in ODCM Table 112-1.

Ni = Beta air dose factor for noble gas nuclide 'i' in units of mrad/yr per pCi/m 3 . Values are listed in ODCM Table 112-1.

2.3.4 Radioiodine and Particulate Dose Calculations Control 3.2.2.3 limits the dose (from both reactor units) to a MEMBER OF THE PUBLIC from 1-131, 1-133, Tritium, and all radionuclides in particulate form with half-lives greater than 8 days in gaseous effluents released to areas at or beyond the SITE BOUNDARY to:

<15 mrem to any organ during any calendar quarter

<30 mrem to any organ during any calendar year As required by Surveillance Requirement 4.2.2.3, these doses are calculated at least once per 31 days using the results of the weekly continuous sample analysis performed in accordance with ODCM Part I, Table 4.2-2. The monthly dose calculation is performed using the most limiting average annual meteorological dispersion values. The quarterly doses are based on the summation of the applicable monthly results. The monthly dose calculations are performed in accordance with the methodology below. Total organ dose is obtained by the summation of the organ dose from each pathway.

CY-LG-1 70-301, Rev. 23 Page 104 08/07 CALCULATION METHODOLOGIES 2.3.4.1 Ground Pathway DOPAR = 3.17E -8 D/QY.RiQi (2-20) where:

DGPAR = Dose from ground pathway due to release of particulates and iodines (mrem).

3.17E-8 = Units conversion (year/sec).

i= 1 = Tritium, H i = 2 thru n = all other isotopes (particulate and iodine)

D/Q = 1.78E-8 highest average annual deposition (ESE Sector)

(1/mr)

Q= the release of nuclide T from all vents in uCi. Releases shall be cumulative over the time period of interest.

Ri= dose factor for organ type, age group, and pathway (for radionuclides other than noble gas); dose factors are calculated based on the methodology given in NUREG-0133. - Values of Ri are provided in ODCM Table 112-2 and calculated per the following equation.

RP [D/Q] = (k')(k")(SF)*

I (DFG)i I (1-e-kit,1-

)/kj(2-20a) where:

RP [D/Q] = m 2-mrem/yr per uCi/sec 3

k'= mrem/yr per uCi/m k"= 8760 hr/yr SF = Shielding Factor (see Table 112-)

DFGi = Dose Factor for Standing on Contaminated Ground (see Table 111-6.

2, = Decay constant for Nuclide I in seconds t = 4.73E+8 seconds (15 years per NUREG 0133) 2.3.4.2 Vegetation, Meat and Cow Milk or Goat Milk Pathway 2 n DIAR = 3.17E- 8 [X/Q-RiQi,+D/QIRiQ, (2-21) 1 i=l i=2

CY-LG-1 70-301, Rev. 23 Page 105 08/07 CALCULATION METHODOLOGIES where:

DvpAR " dose from vegetation, meat, cow milk, and goat milk, pathways due to releases of particulates, iodines, and tritium (mrem).

3.1 TE-8 = units conversion (year/sec).

= Tritium, 3H 2 thru n = all other isotopes (particulate and iodine)

QI = the release of nuclide 'i' from all vents in uCi. Releases shall be cumulative over the time period of interest.

X/Q = 1.1 E-5 highest average annual X/Q (NE sector) (sec/m3)

D/Q = 1.78E-8 highest average annual deposition (ESE Sector)

(1/m2)

= Dose factor for organ type, age group, and pathway (for radionuclides other than noble gas); dose factors are calculated based on the methodology given in NUREG-0133. - Values of Ri are provided in ODCM Table 112-2 and calculated per the following equations.

Vegetation Pathway Ri Rv [D I Q] = (k')y (r) * (DFLi)a* [uL*(fL )e-XitL +US*(fg)e-Xith] (2-21 a)

IYv 2 + xW where:

Rv [D/Q] = m2 -mrem/yr per uCi/sec k' = 1.0 E+6 pCi/uCi r = fraction of deposited particulates retained on vegetation (Table 112-Yv = Vegetation area density kg/M2 (Table 112-4) xi = Decay Constant for the ith radionuclide, in sec-1 xWXw

= Decay constant for removal of activity on leaf and plant surfaces by weathering, in sec-1 (Table 112-4)

(DFLi)a = Ingestion Dose Factor, in mrem/pCi (Table 111-2)

UL = Consumption rate of fresh leafy vegetation by the receptor in age group (a), in kg/yr (Table 112-4) fc = Fraction of the annual intake of fresh leafy vegetation grown locally (dimensionless) (Table 112-4)

CY-LG-1 70-301, Rev. 23 Page 106 08/07 CALCULATION METHODOLOGIES tL = Average time between harvest of leafy vegetation and its consumption, in seconds (Table 112-4)

Us = Consumption rate of stored vegetation by the receptor in age group (a), in kg/yr (Table 112-4) fg = Fraction of the annual intake of stored vegetation grown locally (dimensionless) (Table 112-4) th = Average time between harvest of stored vegetation and its consumption, in seconds (Table 112-4)

The concentration of tritium in vegetation is based on tritium's airborne concentration rather than the deposition. Therefore, the Ri is based on [x/Q] as follows:

rtium [xI/Q] (k'). (k-')

LUL *(fL) +Us*(fg) J* (DFL)a * [0.75*(0.5/H)] (2-21b) where:

3 Rvtium [x/Q] = mrem/yr per uCi/m k'= Constant of unit conversion, 103 gm/kg H = Absolute humidity of the atmosphere, in gm/m 3 (Table 112-4) 0.75 = Fraction of total feed that is water 0.5 = Ratio of the specific activity of the feed grass water to the atmospheric water All other values as previously defined above.

Cow Milk / Goat Milk / Meat Pathway RVIM [DI/Q] = (V) (Q *UAP) * (Fm) *(r)*(DFLi)a L fS + (1 - fpfs)e-th ]e-itf (2-21 c)

(X.+ ?,XýY Y where:

RM [DIQ] = m -mrem/yr per uCi/sec k' = 1.0 E+06 pCi/uCi QF = Cow/Goat consumption rate kg/day (wet weight) (Table 112-4)

UAP = Receptor's milk consumption rate or meat consumption rate for age (a), in liters/yr or kg/yr (Table 112-4) xi = Decay Constant for the ith radionuclide, in sec-1

CY-LG-1 70-301, Rev. 23 Page 107 08/07 CALCULATION METHODOLOGIES xW = Decay constant for removal of activity on leaf and plant surfaces by weathering, in sec-' (Table 112-4)

Fm = Stable element transfer coefficients in days/liter or days/kg (Table 112-3 r = Fraction of deposited particulates retained on vegetation (Table 112-4 (DFLi)a = Ingestion Dose Factor, in mrem/pCi (Table 111-2) fp = Fraction of the year that the cow/goat is on pasture (dimensionless) (Table 112-4) fs = Fraction of the cow/goat feed that is pasture grass while the animal is on pasture (dimensionless) (Table 112-4)

Yp, = Agricultural productivity by unit area of pasture feed grass, in kg/M 2 (Table 112-4)

YS = Agricultural productivity by unit area of stored feed, in kg/M2 (Table 112-4)

Th (milk) = Transport time from pasture to harvest, to milk animal, to milk, to receptor, in sec (Table 112-4)

Tf(milk) = Transport time from pasture to milk animal, to milk, to receptor, in sec (Table 112-4)

Th (meat) = Transport time from crop field to ingestion receptor, in sec (Table 112-4)

Tf (meat) = Transport time from pasture to ingestion receptor, in sec (Table 112-4)

The concentration of tritium in milk and meat is based on tritium's airborne concentration rather than the deposition. Therefore, the Ri is based on [x/Q] as follows:

Rrm- [x/Q] = (k')* (k"')

Fm

QF*U,,p*(DFL,)a * [0.75*(0.5/H)] (2-21d) where:

3 Rtmium [x/Q] = mrem/yr per uCi/m All other values as previously defined above.

2.3.4.3 Inhalation Pathway F' ~n 1 D,IPA = 3.17E - 8 I/QZ RiQi +X/Qde, _ RiQI (2-22)

Si=1 i=2

CY-LG-1 70-301, Rev. 23 Page 108 08/07 CALCULATION METHODOLOGIES where:

DIPAR - dose from inhalation pathway due to release of particulates, iodines, and tritium (mrem).

3.17E-8 = units conversion (year/sec).

i= 1 = Tritium, H3 i = 2 thru n = all other isotopes (particulate and iodine)

Qi = the release of nuclide 'i' from all vents in uCi. Releases shall be cumulative over the time period of interest.

X/Q = 1.1E-5 highest average annual X/Q (NE sector) (sec/m3)

X/Qdepl = 1.OE-5 highest average depleted X/Q (NE sector) (sec/m3)

R= dose factor for organ type, age group, and pathway (for radionuclides other than noble gas); dose factors are calculated based on the methodology given in NUREG-0133. - values of Ri are provided in ODCM Table 112-2 and calculated from the following equation.

R:i[x/Q] = k'(BR) (DFA,) (2-22a) where:

R! [x/QI = mrem/yr per uCi/m 3 k' = 1.0 E+6 pCi/uCi BR = Breathing Rate from Table 112-4 DFAi = Inhalation Dose Factor Reg. Guide 1.109 Table E-7 to E-10 and NUREG/CR - 1276 Append C Table 2 to Table 5.

2.3.5 Incineration of Contaminated Oil 2.3.5.1 Site Boundary Dose Rate The dose rate (mrem/yr) to any organ (inhalation pathway only) for 1-131, 1-133, Tritium, and all radionuclides in particulate form with half-lives greater than eight (8) days from the incineration of contaminated oil from the auxiliary boiler shall be calculated in accordance with the methodology below.

The dose rate from radioactive particulate release shall be determined by either of two methods. Method (a), total instantaneous release, assumes that the total activity contained in the contaminated oil is released in the first minute of incineration.

Method (b) uses the activity release over the entire time of incineration.

CY-LG-170-301, Rev. 23 Page 109 08/07 CALCULATION METHODOLOGIES For normal operations, it is assumed that Method (a) will be used, since the total activity from the waste oil is expected to contribute an insignificant dose compared to the annual limits. However, in the event that the dose rate calculated is higher than administrative or regulatory limits, then Method (b) may be used, because it uses the actual time of release, which results in a more accurate dose and dose rate calculated.

Since the auxiliary boiler stacks are at approximately the same height as the reactor vents and discharge from the auxiliary boiler will also be heated, the use of the reactor vent dispersion values for the calculations is considered conservative.

a. Instantaneous Release Rate Method Q =- "n (Civ)(3785XZ) (2-23) 60 where:

= The release rate of radionuclide 'i' in gaseous effluents from the auxiliary stack releases, uCi/s.

Civ = activity concentration measured in oil for nuclide 'i' in uCi/ml.

3785 = unit conversion (milliliters / gallon).

Z = gallons of oil consumed.

60 = number of seconds used for release.

b. Constant Release Rate Method

= n (CivX3785)(Z) (2-24) i=1 T where:

Qi = The release rate of radionuclide 'i' in gaseous effluents from the auxiliary stack releases, uCi/s.

Civ = activity concentration measured in oil for nuclide 'i' in uCi/ml.

3785 = unit conversion (milliliters / gallon).

Z = gallons of oil consumed.

T = number of seconds used to burn oil for release.

The dose rate (mrem/yr) is calculated using equation 2-17. The dose rate calculated must comply with the limits stated in Control 3.2.2.1.

CY-LG-170-301, Rev. 23 Page 110 08/07 CALCULATION METHODOLOGIES 2.3.5.2 Radioiodine and Particulate Dose Calculations The dose to an individual from radioactive materials in particulate form and radionuclides other than noble gases with half-lives greater than eight days in gaseous effluents released to areas at and beyond the SITE BOUNDARY from the incineration of contaminated waste oil from the auxiliary boiler stacks shall be calculated in accordance with the methodology below. Doses calculated are based on the radioactive content of oil sampled prior to incineration.

Total curies released:

n a E (Civ) (3785) (Z) (2-25) i=1 where:

QI = the release of radionuclide i, uCi Ci= activity concentration measured in oil for nuclide, 'i'. in uCi/ml.

3785 = milliliters per gallon.

Z = gallons of oil consumed.

The dose (mrem) is calculated using equations 2-20, 2-21, and 2-22. The dose calculated must comply with limits stated in Controls 3.2.2.3 and 3.2.2.5. The doses will be summed with cumulative dose contributions for current month, calendar quarter, and calendar year.

2.3.6 Gaseous Effluent Dose Pro jection Control 3.2.2.5 requires the VENTILATION EXHAUST TREATMENT SYSTEM be used to reduce radioactive material levels prior to discharge when projected doses from both units to areas at and beyond the SITE BOUNDARY would exceed in a 31 day period:

a. 0.4 mrad to air from gamma radiation, or

b. 0.8 mrad to air from beta radiation, or

c. 0.6 mrem to any organ of a MEMBER OF THE PUBLIC A dose projection is performed at least once per 31-days by the following equations:

Dmax aamma = (Dmaxg /d)

31 (2-26) f

CY-LG-1 70-301, Rev. 23 Page 111 08/07 CALCULATION METHODOLOGIES Dmaxbet = (Dmaxb / d)

31 (2-26a)

Dmax organ - (Dmaxo / d)

31 (2-26b) where:

Dmaxgamma = maximum gamma air dose projection for current 31-day period (mrad)

DmaXbeta = maximum beta air dose projection for current 31-day period (mrad)

Dmaxorgan = maximum organ dose projection for current 31-day period (mrem)

Dmaxg = maximum gamma air dose to date for current calendar quarter as obtained by equation (2-18).

Dmaxb = maximum beta air dose to date for current calendar quarter as obtained by equation (2-19).

Dmaxo = maximum organ dose to date for current calendar quarter as determined by summing the organ dose obtained from equations (2-20), (2-21) and (2-22) (mrem).

d = number of days in current calendar quarter at the end of the release.

31 = the number of days of concern.

3.0 ANNUAL DOSE EVALUATION The assessment of radiation doses for the radiation dose assessment report shall be performed utilizing the methodology provided in Regulatory Guide 1.109, "Calculation of Annual Doses To Man from Routine Releases of Reactor Effluents for the Purpose of Evaluating Compliance with 10CFR Part 50, Appendix I", Revision 1, October 1977. Any deviations from the methodology provided in Regulatory Guide 1.109 shall be documented in the radiation dose assessment report.

tp The meteorological conditions concurrent with the time of release of radioactive materials (as determined by sampling frequency of measurement) or approximate methods shall be used as input to the dose model.

CY-LG-1 70-301, Rev. 23 Page 112 08/07 CALCULATION METHODOLOGIES 4.0 SPECIAL DOSE ANALYSIS 4.1 TOTAL DOSE TO MEMBERS OF THE PUBLIC Control 3.2.3 requires that the annual dose or dose commitment to any MEMBER OF THE PUBLIC, due to releases of radioactivity and radiation, from the uranium fuel cycle shall be limited to:

< 25 mrem whole body or any organ except thyroid

_<75 mrem thyroid Surveillance Requirement 4.2.3.2 requires that cumulative dose contributions from direct radiation from operations be evaluated when the calculated dose from the release of radioactive materials in liquid or gaseous effluents exceed the limits of Controls 3.2.1.2.a, 3.2.1.2.b, 3.2.2.2.a, 3.2.2.2.b, 3.2.2.3.a, or 3.2.2.3.b. The direct radiation contribution shall be determined by the methodology described below. This methodology calculates the direct radiation contribution, which then must be added to the dose or dose commitment determined in accordance with ODCM Part II, Sections 1.3.1, 2.3.3, and 2.3.4 to determine total dose from all pathways. This evaluation of direct radiation contribution is in accordance with ANSI/ANS 6.6.1-1979 Section 7. The error using this method is estimated to be approximately 8%. The following evaluation is performed for each receptor of concern.

DDR1 = DTTLD1 - Dx BKG - DIEFFL (4-1) where:

DDRI = cumulative dose contribution from direct radiation at the appropriate receptors (mrem).

NOTE: Due to the statistics of radiation measurements and to the conservative nature of effluent calculations it is plausible the DDR1 may yield a negative value. In this situation the value for DDR1 shall be reported as zero (0).

DTrLD = total dose at receptor of interest (as evaluated by TLD measurement)(mrem).

NOTE: If there is not a TLD location at the actual receptor location, a more conservative location will be used to evaluate Total Dose.

DXBKG = mean of the background dose as evaluated by TLDs at background sites (mrem).

D1EFFL = effluent contribution to dose (as evaluated in ODCM Part II, Sections 2.3.3 and 2.3.4.1).

CY-LG-1 70-301, Rev. 23 Page 113 08/07 CALCULATION METHODOLOGIES 4.2 DOSES DUE TO ACTIVITIES INSIDE THE SITE BOUNDARY In accordance with Administrative Control 6.2, the Annual Radioactive Effluent Release Report shall include an assessment of radiation dose from radioactive liquid and gaseous effluents to MEMBERS OF THE PUBLIC due to their activities inside the SITE BOUNDARY.

There are three locations within the SITE BOUNDARY that are accessible to MEMBERS OF THE PUBLIC for activities unrelated to the operation of Limerick Station. These locations are: 1) the railroad tracks which run along the river within the SITE BOUNDARY; 2) the Limerick Information Center, on Longview Road next to the 500kv substation; and 3) Fricks Lock. Of these three locations, the railroad tracks are the closest to the plant confines. Sectors and distances of these locations are provided below:

Sector Distance to Location (in)

Railroad Tracks:

S 300 SSW 225 SW 225 WSW 225 W 225 WNW 345 NW 450 Information Center-ESE 884 WSW 450 Annual doses will be calculated in accordance with Reg. Guide 1.109 and assume an occupancy factor of 0.25. The maximum dose calculated will be reported in the Annual Radioactive Effluent Release Report.

5.0 RADIOLOGICAL ENVIRONMENTAL MONITORING PROGRAM 5.1 SAMPLING PROGRAM The operational phase of the Radiological Environmental Monitoring Program (REMP) is conducted in accordance with the requirements of Control 3.3.1. The objectives of the program are:

CY-LG-1 70-301, Rev. 23 Page 114 08/07 CALCULATION METHODOLOGIES To provide data on measurable levels of radiation and radioactive materials in the site environs.

To evaluate the relationship between quantities of radioactive materials released from LGS and resultant radiation doses to individuals from principal pathways of exposure.

The sampling requirements (type of samples, collection frequency, and analysis) and sample locations are presented in Appendix A.

5.2 INTERLABORATORY COMPARISON PROGRAM Control 3.3.3 requires analyses be performed on radioactive material supplied as part of an Interlaboratory Comparison.

Participation in an NIST traceable Interlaboratory Comparison Program provides a check on the preciseness of measurements of radioactive material in environmental samples. A summary of the Interlaboratory Comparison Program results is provided in the Annual Radiological Environmental Operating Report pursuant to Administrative Control 6.1.

CY-LG-1 70-301, Rev. 23 Page 115 08/07 TABLES

CY-LG-170-301, Rev. 23 Page 116 08/07 TABLE 11-DIlA (tCI 1AI II ATItdI CAC"T'IDQ ICnD I:DQLJAIATI:D M1Q1- I ;"ILI, n r N f"i/f r1 I

Ul~ "I*.ttJU

%.Jll VI L/II

/*,J,-, I",*,*l~l,.* 1 % 1% I I\ __L~i VV -I I LI i i i ..-W ,-,i W .I E-li W L/ SIIIt L

NUCLIDE FISH NUCLIDE FISH NUCLIDE FISH NUCLIDE FISH H-3 9.OE-01 NB-93M 3.0E+04 1-132 1.5E+01 W-187 1.2E+03 C-14 4.6E+03 NB-95 3.0E+04 TE-132 4.0E+02 U-232 2.OE+00 NA-22 1.0E+02 NB-97 3.0E+04 1-133 1.5E+01 U-233 2.OE+00 NA-242 1.0E+02 ZR-93 3.3E+00 CS-134M 2.OE+03 U-234 2.0E+00 P-32 3.OE+03 2 ZR-95 3.3E+00 CS-134 2.OE+03 U-235 2.0E+00 CA-41 4.OE+01 ZR-97 3.3E+00 1-134 1.5E+01 U-236 2.0E+00 SC-46 2.0E+00 MO-93 1.OE+01 1-135 1.5E+01 U-237 2.0E+00 CR-51 2.OE+02 MO-99 1.0E+01 CS-135 2.OE+03 U-238 2.0E+00 MN-54 4.OE+02 TC-99 1.5E+01 CS-136 2.OE+03 NP-237 1.0E+01 FE-55 1.0E+02 TC-99M 1.5E+01 CS-137 2.0E+03 NP-238 1.OE+01 MN-56 4.0E+02 TC-101 1.5E+01 CS-138 2.OE+03 NP-239 1.0E+01 CO-57 5.0E+01 RU-103 1.0E+01 CS-139 2.OE+03 PU-238 3.5E+00 CO-58 5.OE+01 RU-105 1.OE+01 BA-139 4.OE+00 PU-239 3.5E+00 FE-59 1.OE+02 RU-106 1.0E+01 BA-140 4.OE+00 PU-240 3.5E+00 CO-60 5.OE+01 RH-105 1.0E+01 LA-140 2.5E+01 PU-241 3.5E+00 NI-59 1.0E+02 PD-107 1.0E+01 BA-141 4.0E+00 PU-242 3.5E+00 NI-63 1.0E+02 PD-109 1.0E+01 LA-141 2.5E+01 PU-244 3.5E+00 CU-64 5.0E+01 AG- 110M 2.5E+00 CE-141 1.OE+00 AM-241 2.5E+01 NI-65 1.0E+02 AG-111 2.5E+00 BA-142 4.0E+00 AM-242m 2.5E+01 ZN-65 2.0E+03 CD-1 13M 2.0E+02 LA-142 2.5E+01 AM-243 2.5E+01 ZN-69M 2.0E+03 CD-1 15M 2.0E+02 CE-143 1.OE+00 CM-242 2.5E+01 ZN-69 2.0E+03 SN-123 3.0E+03 PR-143 2.5E+01 CM-243 2.5E+01 SE-79 1.7E+02 SN-125 3.0E+03 CE-144 1.0E+00 CM-244 2.5E+01 BR-82 4.2E+02 SN-126 3.0E+03 PR-144 2.5E+01 CM-245 2.5E+01 BR-83 4.2E+02 SB-124 1.0E+00 ND-147 2.5E+01 CM-246 2.5E+01 BR-84 4.2E+02 SB-125 1.OE+00 PM-147 2.5E+01 CM-247 2.5E+01 BR-85 4.2E+02 SB-126 1.0E+00 PM-148m 2.5E+01 CM-248 2.5E+01 RB-86 2.0E+03 SB-127 1.0E+00 PM-148 2.5E+01 CF-252 2.5E+01 RB-87 2.0E+03 TE-125M 4.OE+02 PM-149 2.5E+01 RB-88 2.0E+03 TE-127M 4.OE+02 PM-151 2.5E+01 RB-89 2.0E+03 TE-127 4.OE+02 SM-151 2.5E+01 SR-89 3.0E+01 TE-129M 4.OE+02 SM-153 2.5E+01 SR-90 3.0E+01 TE-129 4.OE+02 EU-152 2.5E+01 Y-90 2.5E+01 TE-1 33M 4.0E+02 EU-154 2.5E+01 SR-91 3.0E+01 TE-134 4.OE+02 EU-1 55 2.5E+01 Y-91M 2.5E+01 1-129 1.5E+01 EU-156 2.5E+01 Y-91 2.5E+01 1-130 1.5E+01 TB- 60 2.5E+01 SR-92 3.0E+01 1-131 1.5E+01 HO-166m 2.5E+01 Y-92 2.5E+01 TE-131M 4.OE+02 W-181 1.2E+03 Y-93 2.5E+01 TE-131 4.OE+02 W-185 1.2E+03 1 Reg. Guide 1.109 Table A-1 and NUREG/CR - 1276 Append D Column 13,14,16,17 2 Letter LTR 881209L001, from R.J. Clark, U.S.N.R.C., to G.A. Hunger, Philadelphia Electric Co., December 9, 1988, transmitting evaluation of Limerick ODCM.

CY-LG-170-301, Rev. 23 Page 117 08/07 TABLE 111-2 INGESTION DOSE FACTORS FOR ADULT (Daipj) mrem/pCi Reg. Guide 1.109 Table E-1 1 to E-14 and NUREG/CR - 1276 Append C Table 6 to Table 9 NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG GI-LLI SKIN H-3 O.OOE+00 1.05E-07 1.05E-07 1.05E-07 1.05E-07 1.05E-07 1.05E-07 0.OOE+00 C-14 2.84E-06 5.68E-07 5.68E-07 5.68E-07 5.68E-07 5.68E-07 5.68E-07 0.OOE+00 NA-22 1.74E-05 1.74E-05 1.74E-05 1.74E-05 1.74E-05 1.74E-05 1.74E-05 O.OOE+00 NA-24 1.70E-06 1.70E-06 1.70E-06 1.70E-06 1.70E-06 1.70E-06 1.70E-06 O.OOE+00 P-32 3.OOE-05 1.20E-05 7.46E-06 0.OOE+00 0.OOE+00 0.OOE+00 2.17E-05 O.OOE+00 CA-41 1.85E-04 0.OOE+00 2.OOE-05 0.OOE+00 0.OOE+00 0.OOE+00 1.84E-07 O.OOE+00 SC-46 5.51E-09 1.07E-08 3.11E-09 0.OOE+00 9.99E-09 0.OOE+00 5.21E-05 O.OOE+00 CR-51 0.OOE+00 O.OOE+00 2.66E-09 1.59E-09 5.86E-10 3.53E-09 6.69E-07 0.OOE+00 MN-54 0.OOE+00 4.57E-06 8.72E-07 0.OOE+00 1.36E-06 0.OOE+00 1.40E-05 0.OOE+00 FE-55 2.75E-06 1.90E-06 4.43E-07 0.OOE+00 0.OOE+00 1.06E-06 1.09E-06 0.OOE+00 MN-56 0.O0E+00 1.15E-07 2.04E-08 0.OOE+00 1.46E-07 0.OOE+00 3.67E-06 0.OOE+00 CO-57 0.OOE+00 1.75E-07 2.91E-07 0.OOE+00 0.OOE+00 0.OOE+00 4.44E-06 O.OOE+00 CO-58 0.OOE+00 7.45E-07 1.67E-06 0.OOE+00 O.OOE+00 O.OOE+00 1.51E-05 O.OOE+00 FE-59 4.34E-06 1.02E-05 3.91E-06 0.OOE+00 0.OOE+00 2.85E-06 3.40E-05 0.OOE+00 CO-60 0.OOE+00 2.14E-06 4.72E-06 0.OOE+00 0.OOE+00 0.OOE+00 4.02E-05 0.OOE+00 NI-59 9.76E-06 3.35E-06 4.72E-06 O.OOE+00 0.OOE+00 0.OOE+00 6.90E-07 0.OOE+00 NI-63 1.30E-04 9.01 E-06 4.36E-06 O.OOE+00 0.OOE+00 0.00E+00 1.88E-06 0.OOE+00 CU-64 0.OOE+00 8.33E-08 3.91E-08 O.OOE+00 2.1OE-07 0.OOE+00 7.1OE-06 0.OOE+00 NI-65 5.28E-07 6.86E-08 3.13E-08 0.OOE+00 0.OOE+00 0.00E+00 1.74E-06 0.OOE+00 ZN-65 4.84E-06 1.54E-05 6.96E-06 0.00E+00 1.03E-05 0.OOE+00 9.70E-06 0.OOE+00 ZN-69m 1.70E-07 4.08E-07 3.73E-08 O.OOE+00 2.47E-07 0.OOE+00 2.49E-05 0.OOE+00 ZN-69 1.03E-08 1.97E-08 1.37E-09 0.OOE+00 1.28E-08 O.OOE+00 2.96E-09 0.00E+00 SE-79 O.00E+00 2.63E-06 4.39E-07 0.OOE+00 4.55E-06 0.OOE+00 5.38E-07 0.00E+00 BR-82 0.OOE+00 0.OOE+00 2.26E-06 0.00E+00 0.OOE+00 0.OOE+00 2.59E-06 0.OOE+00 BR-83 0.OOE+00 0.OOE+00 4.02E-08 0.OOE+00 0.OOE+00 0.00E+00 5.79E-08 0.OOE+00 BR-84 0.OOE+00 0.OOE+00 5.21E-08 0.00E+00 0.OOE+00 0.OOE+00 4.09E-13 0.OOE+00 BR-85 0.00E+00 0.OOE+00 2.14E-09 0.OOE+00 0.OOE+00 0.00E+00 0.OOE+00 0.OOE+00 RB-86 0.OOE+00 2.i1E-05 9.83E-06 0.00E+00 0.OOE+00 0.00E+00 4.16E-06 0.00E+00 RB-87 0.OOE+00 1.23E-05 4.28E-06 0.OOE+00 0.OOE+00 0.OOE+00 5.76E-07 0.OOE+00 RB-88 0.OOE+00 6.05E-08 3.21E-08 0.00E+00 0.OOE+00 0.OOE+00 8.36E-19 0.00E+00 RB-89 0.OOE+00 4.01 E-08 2.82E-08 0.00E+00 0.00E+00 0.00E+00 2.33E-21 O.OOE+00 SR-89 3.08E-04 0.00E+00 8.84E-06 0.00E+00 0.OOE+00 0.00E+00 4.94E-05 O.OOE+00 SR-90 7.58E-03 0.OOE+00 1.86E-03 0.OOE+00 0.OOE+00 0.00E+00 2.19E-04 O.00E+00 Y-90 9.62E-09 0.OOE+00 2.58E-10 0.00E+00 0.OOE+00 0.00E+00 1.02E-04 O.00E+00 SR-91 5.67E-06 0.OOE+00 2.29E-07 0.OOE+00 0.OOE+00 0.OOE+00 2.70E-05 0.OOE+00 Y-91m 9.09E-11 0.00E+00 3.52E-12 0.OOE+00 0.OOE+00 0.OOE+00 2.67E-10 0.00E+00 Y-91 1.41E-07 0.00E+00 3.77E-09 0.OOE+00 0.OOE+00 0.00E+00 7.76E-05 0.00E+00 SR-92 2.15E-06 0.OOE+00 9.30E-08 O.OOE+00 O.OOE+00 0.00E+00 4.26E-05 O.00E+00 Y-92 8.45E-10 0.OOE+00 2.47E-11 0.OOE+00 0.OOE+00 0.OOE+00 1.48E-05 0.00E+00 Y-93 2.68E-09 O.OOE+00 7.40E-1 1 0.OOE+00 0.OOE+00 0.OOE+00 8.50E-05 0.00E+00 NB-93m 2.55E-08 8.32E-09 2.05E-09 0.OOE+00 9.57E-09 0.00E+00 3.84E-06 0.OOE+00 NB-95 6.22E-09 3.46E-09 1.86E-09 0.OOE+00 3.42E-09 0.OOE+00 2.1OE-05 0.OOE+00

CY-LG-170-301, Rev. 23 Page 118 08/07 TABLE 111-2 (Continued)

INGESTION DOSE FACTORS FOR ADULT (Daipj) mrem/pCi Reg. Guide 1.109 Table E-11 to E-14 and NUREG/CR - 1276 Append C Table 6 to Table 9 NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG GI-LLI SKIN NB-97 5.22E-11 1.32E-11 4.82E-12 0.OOE+00 1.54E-11 O.OOE+00 4.87E-08 0.0OE+00 ZR-93 4.18E-08 2.34E-09 1.09E-09 0.OOE+00 8.87E-09 O.OOE+00 2.43E-05 0.OOE+00 ZR-95 3.04E-08 9.75E-09 6.60E-09 0.OOE+00 1.53E-08 0.OOE+00 3.09E-05 0.OOE+00 ZR-97 1.68E-09 3.39E-10 1.55E-10 0.OOE+00 5.12E- 10 0.OOE+00 1.05E-04 0.OOE+00 MO-93 0.OOE+00 7.51 E-06 2.03E-07 0.OOE+00 2.13E-06 0.OOE+00 1.22E-06 O.OOE+00 MO-99 0.OOE+00 4.31 E-06 8.20E-07 0.OOE+00 9.76E-06 O.OOE+00 9.99E-06 0.OOE+00 TC-99 1.25E-07 1.86E-07 5.02E-08 0.OOE+00 2.34E-06 1.58E-08 6.08E-06 0.OOE+00 TC-99m 2.47E-10 6.98E-10 8.89E-09 0.OOE+00 1.06E-08 3.42E-10 4.13E-07 0.OOE+00 TC-101 2.54E-10 3.66E-10 3.59E-09 0.OOE+00 6.59E-09 1.87E-10 1.1OE-21 0.OOE+00 RU-103 1.85E-07 0.OOE+00 7.97E-08 0.OOE+00 7.06E-07 0.OOE+00 2.16E-05 0.OOE+00 RU-105 1.54E-08 0.OOE+00 6.08E-09 O.OOE+00 1.99E-07 0.OOE+00 9.42E-06 0.OOE+00 RU-106 2.75E-06 0.OOE+00 3.48E-07 0.OOE+00 5.31E-06 0.OOE+00 1.78E-04 0.OOE+00 RH-105 1.21E-07 8.85E-08 5.83E-08 O.OOE+00 3.76E-07 0.OOE+00 1.41E-06 O.OOE+00 PD-107 O.OOE+00 1.47E-07 9.40E-09 O.OOE+00 1.32E-06 O.OOE+00 9.11E-07 O.OOE+00 PD-109 O.OOE+00 1.77E-07 3.99E-08 O.OOE+00 1.01E-06 O.OOE+00 1.96E-05 O.OOE+00 AG-110m 1.60E-07 1.48E-07 8.79E-08 O.OOE+00 2.91E-07 O.OOE+00 6.04E-05 O.OOE+00 AG-111 5.81E-08 2.43E-08 1.21E-08 O.OOE+00 7.84E-08 O.OOE+00 4.46E-05 O.OOE+00 CD-113m O.OOE+00 3.18E-06 1.02E-07 O.OOE+00 3.50E-06 0.OOE+00 2.56E-05 O.OOE+00 CD-115m O.OOE+00 1.84E-06 5.87E-08 O.OOE+00 1.46E-06 O.OOE+00 7.44E-05 O.OOE+00 SN-123 3.11E-05 5.15E-07 7.59E-07 4.38E-07 O.OOE+00 O.OOE+00 6.33E-05 O.OOE+00 SN-125 8.33E-06 1.68E-07 3.78E-07 1.39E-07 O.OOE+00 O.OOE+00 1.04E-04 O.OOE+00 SN-126 8.42E-05 1.67E-06 2.40E-06 4.92E-07 O.OOE+00 O.OOE+00 2.43E-05 O.OOE+00 SB-124 2.80E-06 5.29E-08 1.11E-06 6.79E-09 O.OOE+00 2.18E-06 7.95E-05 O.OOE+00 SB-125 1.79E-06 2.OOE-08 4.26E-07 1.82E-09 O.OOE+00 1.38E-06 1.97E-05 O.OOE+00 SB-126 1.15E-06 2.34E-08 4.15E-07 7.04E-09 O.OOE+00 7.05E-07 9.40E-05 O.OOE+00 SB-127 2.58E-07 5.65E-09 9.90E-08 3.10E-09 O.OOE+00 1.53E-07 5.90E-05 O.OOE+00 TE-125m 2.68E-06 9.71E-07 3.59E-07 8.06E-07 1.09E-05 O.OOE+00 1.07E-05 O.OOE+00 TE-127m 6.77E-06 2.42E-06 8.25E-07 1.73E-06 2.75E-05 0.00E+00 2.27E-05 0.OOE+00 TE-127 1.1OE-07 3.95E-08 2.38E-08 8.15E-08 4.48E-07 O.OOE+00 8.68E-06 O.OOE+00 TE-129m 1.15E-05 4.29E-06 1.82E-06 3.95E-06 4.80E-05 O.OOE+00 5.79E-05 0.OOE+00 TE-129 3.14E-08 1.18E-08 7.65E-09 2.41E-08 1.32E-07 O.OOE+00 2.37E-08 O.OOE+00 TE-133m 4.62E-08 2.70E-08 2.60E-08 3.91E-08 2.67E-07 O.OOE+00 6.64E-08 O.OOE+00 TE-134 3.24E-08 2.12E-08 1.30E-08 2.83E-08 2.05E-07 O.OOE+00 3.59E-11 O.OOE+00 1-129 3.27E-06 2.81E-06 9.21E-06 7.23E-03 5.04E-06 O.OOE+00 4.44E-07 O.OOE+00 1-130 7.56E-07 2.23E-06 8.80E-07 1.89E-04 3.48E-06 O.OOE+00 1.92E-06 O.OOE+00 1-131 4.16E-06 5.95E-06 3.41E-06 1.95E-03 1.02E-05 O.OOE+00 1.57E-06 O.OOE+00 TE-131m 1.73E-06 8.46E-07 7.05E-07 1.34E-06 8.57E-06 O.OOE+00 8.40E-05 O.OOE+00 TE-131 1.97E-08 8.23E-09 6.22E-09 1.62E-08 8.63E-08 O.OOE+00 2.79E-09 O.OOE+00 1-132 2.03E-07 5.43E-07 1.90E-07 1.90E-05 8.65E-07 O.OOE+00 1.02E-07 O.OOE+00 TE-132 2.52E-06 1.63E-06 1.53E-06 1.80E-06 1.57E-05 O.OOE+00 7.71E-05 O.OOE+00 1-133 1.42E-06 2.47E-06 7.53E-07 3.63E-04 4.31E-06 O.OOE+00 2.22E-06 O.OOE+00 CS-134m 2.13E-08 4.48E-08 2.29E-08 O.OOE+00 2.43E-08 3.83E-09 1.58E-08 0.OOE+00 CS-134 6.22E-05 1.48E-04 1.21E-04 O.OOE+00 4.79E-05 1.59E-05 2.59E-06 O.OOE+00 1-134 1.06E-07 2.88E-07 1.03E-07 4.99E-06 4.58E-07 O.OOE+00 2.51E-10 O.OOE+00

CY-LG-170-301, Rev. 23 Page 119 08/07 TABLE 111-2 (Continued)

INGESTION DOSE FACTORS FOR ADULT (Daipj) mrem/pCi Reg. Guide 1.109 Table E-11 to E-14 and NUREG/CR - 1276 Append C Table 6 to Table 9 NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG GI-LLI SKIN 1-135 4.43E-07 1.16E-06 4.28E-07 7.65E-05 1.86E-06 0.OOE+00 1.31 E-06 0.00E+00 CS-135 1.95E-05 1.80E-05 7.99E-06 0.OOE+00 6.81E-06 2.04E-06 4.21E-07 0.OOE+00 CS-136 6.51E-06 2.57E-05 1.85E-05 0.OOE+00 1.43E-05 1.96E-06 2.92E-06 0.OOE+00 CS-137 7.97E-05 1.09E-04 7.14E-05 O.OOE+00 3.70E-05 1.23E-05 2.11E-06 0.OOE+00 CS-138 5.52E-08 1.09E-07 5.40E-08 0.OOE+00 8.01E-08 7.91E-09 4.65E-13 0.OOE+00 CS-139 3.41E-08 5.08E-08 1.85E-08 0.OOE+00 4.07E-08 3.70E-09 1.1OE-30 0.OOE+00 BA-139 9.70E-08 6.91E-11 2.84E-09 O.OOE+00 6.46E-11 3.92E-11 1.72E-07 0.OOE+00 BA-140 2.03E-05 2.55E-08 1.33E-06 O.OOE+00 8.67E-09 1.46E-08 4.18E-05 0.OOE+00 LA-140 2.50E-09 1.26E-09 3.33E-10 0.OOE+00 0.OOE+00 0.OOE+00 9.25E-05 0.OOE+00 BA-141 4.71E-08 3.56E-11 1.59E-09 0.OOE+00 3.31E-11 2.02E-11 2.22E-17 0.OOE+00 LA-141 3.19E-10 9.90E-11 1.62E-11 0.OOE+00 0.OOE+00 0.OOE+00 1.18E-05 0.OOE+00 CE-141 9.36E-09 6.33E-09 7.18E-10 O.OOE+00 2.94E-09 O.OOE+00 2.42E-05 0.OOE+00 BA-142 2.13E-08 2.19E-11 1.34E-09 O.OOE+00 1.85E-11 1.24E-11 3.OOE-26 O.OOE+00 LA-142 1.28E-10 5.82E-11 1.45E-11 0.OOE+00 O.OOE+00 0.OOE+00 4.25E-07 O.OOE+00 CE-143 1.65E-09 1.22E-06 1.35E-10 0.OOE+00 5.37E-10 O.OOE+00 4.56E-05 0.OOE+00 PR-143 9.20E-09 3.69E-09 4.56E-10 0.OOE+00 2.13E-09 0.OOE+00 4.03E-05 0.OOE+00

'CE-144 4.88E-07 2.04E-07 2.62E-08 0.OOE+00 1.21E-07 0.OOE+00 1.65E-04 0.OOE+00 PR-144 3.01E-11 1.25E-11 1.53E-12 0.OOE+00 7.05E-12 0.OOE+00 4.33E-18 0.OOE+00 ND-147 6.29E-09 7.27E-09 4.35E-10 O.OOE+00 4.25E-09 0.OOE+00 3.49E-05 O.OOE+00 PM-147 7.54E-08 7.09E-09 2.81E-09 O.OOE+00 1.34E-08 0.OOE+00 8.93E-06 0.OOE+00 PM-148m 3.07E-08 7.95E-09 6.08E-09 O.OOE+00 1.20E-08 O.OOE+00 6.74E-05 0.OOE+00 PM-148 7.17E-09 1.19E-09 5.99E-10 0.OOE+00 2.25E-09 O.OOE+00 9.35E-05 0.OOE+00 PM-149 1.52E-09 2.15E-10 8.78E-11 0.OOE+00 4.06E-10 0.OOE+00 4.03E-05 0.OOE+00 PM-151 6.97E-10 1.17E-10 5.91E-11 0.OOE+00 2.09E-10 0.OOE+00 3.22E-05 0.OOE+00 SM-151 6.90E-08 1.19E-08 2.85E-09 0.OOE+00 1.33E-08 O.OOE+00 5.25E-06 0.OOE+00 SM-153 8.57E-10 7.15E-10 5.22E-11 0.OOE+00 2.31E-10 0.OOE+00 2.55E-05 0.OOE+00 EU-152 1.95E-07 4.44E-08 3.90E-08 0.OOE+00 2.75E-07 0.OOE+00 2.56E-05 0.OOE+00 EU-154 6.15E-07 7.56E-08 5.38E-08 0.OOE+00 3.62E-07 0.OOE+00 5.48E-05 0.OOE+00 EU-155 8.60E-08 1.22E-08 7.87E-09 0.OOE+00 5.63E-08 O.OOE+00 9.60E-06 0.OOE+00 EU-156 1.37E-08 1.06E-08 1.71E-09 0.OOE+00 7.08E-09 0.OOE+00 7.26E-05 0.OOE+00 TB-160 4.70E-08 0.OOE+00 5.86E-09 0.OOE+00 1.94E-08 O.OOE+00 4.33E-05 0.OOE+00 HO-166m 2.70E-07 8.43E-08 6.40E-08 0.OOE+00 1.26E-07 0.OOE+00 1.OOE-24 O.OOE+00 W-181 9.91E-09 3.23E-09 3.46E-10 O.OOE+00 0.OOE+00 0.OOE+00 3.68E-07 O.OOE+00 W-185 4.05E-07 1.35E-07 1.42E-08 0.OOE+00 0.OOE+00 0.OOE+00 1.56E-05 0.OOE+00 W-187 1.03E-07 8.61E-08 3.01E-08 O.OOE+00 O.OOE+00 0.OOE+00 2.82E-05 0.OOE+00 NP-239 1.19E-09 1.17E-10 6.45E-11 0.00E+00 3.65E-10 0.OOE+00 2.40E-05 0.OOE+00 U-232 4.13E-03 0.OOE+00 2.95E-04 0.OOE+00 4.47E-04 0.00E+00 6.78E-05 0.OOE+00 U-233 8.71 E-04 0.OOE+00 5.28E-05 0.00E+00 2.03E-04 0.00E+00 6.27E-05 0.OOE+00 U-234 8.36E-04 0.OOE+00 5.17E-05 0.OOE+00 1.99E-04 0.OOE+00 6.14E-05 0.OOE+00 U-235 8.01 E-04 0.00E+00 4.86E-05 0.OOE+00 1.87E-04 0.OOE+00 7.81 E-05 0.OOE+00 U-236 8.01E-04 0.OOE+00 4.96E-05 0.00E+00 1.91 E-04 0.OOE+00 5.76E-05 0.00E+00 U-237 5.52E-08 0.OOE+00 1.47E-08 0.00E+00 2.27E-07 0.00E+00 1.94E-05 0.OOE+00

CY-LG-1 70-301, Rev. 23 Page 120 08/07 TABLE 111-2 (Continued)

INGESTION DOSE FACTORS FOR ADULT (Dampj) mrem/pCi Reg. Guide 1.109 Table E-1 1 to E-14 and NUREG/CR - 1276 Append C Table 6 to Table 9 NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG GI-LLI SKIN U-238 7.67E-04 0.OOE+00 4.54E-05 O.OOE+00 1.75E-04 0.OOE+00 5.50E-05 0.OOE+00 NP-237 1.26E-03 8.96E-05 5.54E-05 O.OOE+00 4.12E-04 0.OOE+00 7.94E-05 0.OOE+00 NP-238 1.37E-08 3.69E-10 2.13E-10 0.OOE+00 1.25E-09 O.OOE+00 3.43E-05 0.OOE+00 NP-239 1.19E-09 1.17E-10 6.45E-11 0.OOE+00 3.65E-10 0.OOE+00 2.40E-05 0.OOE+00 PU-238 6.30E-04 7.98E-05 1.71E-05 0.OOE+00 7.32E-05 0.OOE+00 7.30E-05 0.OOE+00 PU-239 7.25E-04 8.71E-05 1.91E-05 O.OOE+00 8.11E-05 O.OOE+00 6.66E-05 0.OOE+00 PU-240 7.24E-04 8.70E-05 1.91E-05 0.OOE+00 8.10E-05 O.OOE+00 6.78E-05 0.OOE+00 PU-241 1.57E-05 7.45E-07 3.32E-07 0.OOE+00 1.53E-06 O.OOE+00 1.40E-06 0.OOE+00 PU-242 6.72E-04 8.39E-05 1.84E-05 0.OOE+00 7.81 E-05 0.OOE+00 6.53E-05 0.OOE+00 PU-244 7.84E-04 9.61 E-05 2.11E-05 0.OOE+00 8.95E-05 0.OOE+00 9.73E-05 0.OOE+00 AM-241 7.55E-04 7.05E-04 5.41E-05 0.OOE+00 4.07E-04 0.OOE+00 7.42E-05 0.OOE+00 AM-242m 7.61E-04 6.63E-04 5.43E-05 0.OOE+00 4.05E-04 0.OOE+00 9.34E-05 0.OOE+00 AM-243 7.54E-04 6.90E-04 5.30E-05 0.OOE+00 3.99E-04 0.OOE+00 8.70E-05 0.OOE+00 CM-242 2.06E-05 2.19E-05 1.37E-06 0.OOE+00 6.22E-06 0.OOE+00 7.92E-05 0.OOE+00 CM-243 5.99E-04 5.49E-04 3.75E-05 0.OOE+00 1.75E-04 0.OOE+00 7.81 E-05 0.OOE+00 CM-244 4.56E-04 4.27E-04 2.87E-05 0.OOE+00 1.34E-04 0.OOE+00 7.55E-05 0.OOE+00 CM-245 9.38E-04 8.17E-04 5.76E-05 0.OOE+00 2.69E-04 0.OOE+00 7.04E-05 0.OOE+00 CM-246 9.30E-04 8.16E-04 5.75E-05 0.OOE+00 2.68E-04 0.OOE+00 6.91E-05 O.OOE+00 CM-247 9.07E-04 8.04E-04 5.67E-05 O.OOE+00 2.64E-04 0.OOE+00 9.09E-05 0.OOE+00 CM-248 7.54E-03 6.63E-03 4.67E-04 0.OOE+00 2.18E-03 0.OOE+00 1.47E-03 0.OOE+00 CF-252 2.61E-04 0.OOE+00 6.29E-06 O.OOE+00 0.OOE+00 O.OOE+00 2.88E-04 O.OOE+00

CY-LG-170-301, Rev. 23 Page 121 08/07 TABLE 111-3 INGESTION DOSE FACTORS FOR TEEN (Daipj) mrem/pCi Reg. Guide 1.109 Table E-1 1 to E-14 and NUREG/CR - 1276 Append C Table 6 to Table 9 NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG GI-LLI SKIN H-3 0.OOE+00 1.06E-07 1.06E-07 1.06E-07 1.06E-07 1.06E-07 1.06E-07 O.OOE+00 C-14 4.06E-06 8.12E-07 8.12E-07 8.12E-07 8.12E-07 8.12E-07 8.12E-07 0.OOE+00 NA-22 2.34E-05 2.34E-05 2.34E-05 2.34E-05 2.34E-05 2.34E-05 2.34E-05 0.OOE+00 NA-24 2.30E-06 2.30E-06 2.30E-06 2.30E-06 2.30E-06 2.30E-06 2.30E-06 0.OOE+00 P-32 4.29E-05 1.71 E-05 1.07E-05 0.OOE+00 0.OOE+00 0.OOE+00 2.32E-05 0.OOE+00 CA-41 1.97E-04 0.OOE+00 2.13E-05 0.OOE+00 0.OOE+00 0.OOE+00 1.95E-07 0.OOE+00 SC-46 7.24E-09 1.41E-08 4.18E-09 0.OOE+00 1.35E-08 0.OOE+00 4.80E-05 0.OOE+00 CR-51, 0.OOE+00 O.OOE+00 3.60E-09 2.00E-09 7.89E-10 5.14E-09 6.05E-07 0.OOE+00 MN-54 O.OOE+00 5.90E-06 1.17E-06 0.OOE+00 1.76E-06 O.OOE+00 1.21E-05 0.OOE+00 FE-55 3.78E-06 2.68E-06 6.25E-07 0.OOE+00 0.OOE+00 1.70E-06 1.16E-06 0.OOE+00 MN-56 0.OOE+00 1.58E-07 2.81E-08 O.OOE+00 2.OOE-07 0.OOE+00 1.04E-05 0.OOE+00 CO-57 0.OOE+00 2.38E-07 3.99E-07 0.00E+00 0.00E+00 0.OOE+00 4.44E-06 0.OOE+00 CO-58 O.OOE+00 9.72E-07 2.24E-06 0.OOE+00 O.OOE+00 0.OOE+00 1.34E-05 O.OOE+00 FE-59 5.87E-06 1.37E-05 5.29E-06 0.OOE+00 0.OOE+00 4.32E-06 3.24E-05 0.O0E+00 CO-60 O.OOE+00 2.81 E-06 6.33E-06 O.OOE+00 0.OOE+00 0.OOE+00 3.66E-05 0.OOE+00 NI-59 1.32E-05 4.66E-06 2.24E-06 0.OOE+00 0.OOE+00 0.OOE+00 7.31 E-07 0.OOE+00 NI-63 1.77E-04 1.25E-05 6.OOE-06 O.OOE+00 0.OOE+00 0.OOE+00 1.99E-06 0.OOE+00 CU-64 0.OOE+00 1.15E-07 5.41E-08 0.OOE+00 2.91E-07 0.OOE+00 8.92E-06 0.OOE+00 NI-65 7.49E-07 9.57E-08 4.36E-08 0.OOE+00 0.OOE+00 0.OOE÷00 5.19E-06 0.OOE+00 ZN-65 5.76E-06 2.OOE-05 9.33E-06 0.OOE+00 1.28E-05 0.OOE+00 8.47E-06 0.OOE+00 ZN-69m 2.40E-07 5.66E-07 5.19E-08 0.OOE+00 3.44E-07 0.OOE+00 3.11E-05 0.OOE+00 ZN-69 1.47E-08 2.80E-08 1.96E-09 0.OOE+00 1.83E-08 0.OOE+00 5.16E-08 O.OOE+00 SE-79 0.0OE+00 3.73E-06 6.27E-07 0.OOE+00 6.50E-06 O.OOE+00 5.70E-07 0.OOE+00 BR-82 0.OOE+00 0.OOE+00 3.04E-06 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 BR-83 0.OOE+00 O.OOE+00 5.74E-08 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 BR-84 0.OOE+00 0.OOE+00 7.22E-08 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 BR-85 O.OOE+00 0.OOE+00 3.05E-09 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 RB-86 0.OOE+00 2.98E-05 1.40E-05 0.OOE+00 O.OOE+00 0.OOE+00 4.41E-06 0.OOE+00 RB-87 0.OOE+00 1.75E-05 6.11E-06 0.OOE+00 O.OOE+00 0.OOE+00 6.11E-07 0.OOE+00 RB-88 0.OOE+00 8.52E-08 4.54E-08 0.OOE+00 0.OOE+00 0.OOE+00 7.30E-15 0.OOE+00 RB-89 0.OOE+00 5.50E-08 3.89E-08 0.OOE+00 0.OOE+00 0.OOE+00 8.43E-17 0.OOE+00 SR-89 4.40E-04 0.OOE+00 1.26E-05 0.OOE+00 0.OOE+00 O.OOE+00 5.24E-05 O.OOE+00 SR-90 8.30E-03 O.OOE+00 2.05E-03 0.OOE+00 0.OOE+00 O.OOE+00 2.33E-04 0.OOE+00 Y-90 1.37E-08 0.OOE+00 3.69E-10 0.OOE+00 0.OOE+00 0.OOE+00 1.13E-04 O.OOE+00 SR-91 8.07E-06 0.OOE+00 3.21 E-07 O.OOE+00 O.OOE+00 0.OOE+00 3.66E-05 0.OOE+00 Y-91m 1.29E-10 0.OOE+00 4.93E-12 0.OOE+00 0.OOE+00 0.OOE+00 6.09E-09 O.OOE+00 Y-91 2.01E-07 O.OOE+00 5.39E-09 0.OOE+00 0.OOE+00 0.OOE+00 8.24E-05 0.OOE+00 SR-92 3.05E-06 0.OOE+00 1.30E-07 0.OOE+00 0.OOE+00 0.OOE+00 7.77E-05 O.OOE+00 Y-92 1.21 E-09 0.OOE+00 3.50E-1 1 0.OOE+00 0.OOE+00 0.OOE+00 3.32E-05 0.OOE+00 Y-93 3.83E-09 0.OOE+00 1.05E-10 O.OOE+00 0.OOE+00 O.OOE+00 1.17E-04 0.OOE+00 NB-93m 3.44E-08 1.13E-08 2.83E-09 0.OOE+00 1.32E-08 0.OOE+00 4.07E-06 0.OOE+00

CY-LG-170-301, Rev. 23 Page 122 08/07 TABLE 111-3 (Continued)

INGESTION DOSE FACTORS FOR TEEN (Daipj) mrem/pCi Reg. Guide 1.109 Table E-11 to E-14 and NUREG/CR - 1276 Append C Table 6 to Table 9 NUCLIDE BONE LIVER *T BODY THYROID KIDNEY LUNG GI-LLI -SKIN NB-95 8.22E-09 4.56E-09 2.51 E-09 0.OOE+00 4.42E-09 0.OOE+00 1.95E-05 0.OOE+00 NB-97 7.37E-11 1.83E-11 6.68E-12 0.OOE+00 2.14E-11 0.OOE+00 4.37E-07 0.OOE+00 ZR-93 5.53E-08 2.73E-08 1.49E-08 0.OOE+00 9.65E-08 0.OOE+00 2.58E-05 0.OOE+00 ZR-95 4.12E-08 1.30E-08 8.94E-09 0.OOE+00 1.91E-08 0.OOE+00 3.OOE-05 O.OOE+00 ZR-97 2.37E-09 4.69E-10 2.16E-10 0.OOE+00 7.11E-10 0.OOE+00 1.27E-04 0.OOE+00 MO-93 0.OOE+00 1.06E-05 2.90E-07 0.OOE+00 3.04E-06 0.OOE+00 1.29E-06 0.OOE+00 MO-99 0.OOE+00 6.03E-06 1.15E-06 0.OOE+00 1.38E-05 0.OOE+00 1.08E-05 0.OOE+00 TC-99 1.79E-07 2.63E-07 7.17E-08 0.OOE+00 3.34E-06 2.72E-08 6.44E-06 0.OOE+00 TC-99m 3.32E-10 9.26E-10 1.20E-08 0.OOE+00 1.38E-08 5.14E-10 6.08E-07 0.OOE+00 TC-101 3.60E-10 5.12E-10 5.03E-09 0.OOE+00 9.26E-09 3.12E-10 8.75E-17 0.OOE+00 RU-103 2.55E-07 O.OOE+00 1.09E-07 0.OOE+00 8.99E-07 0.OOE+00 2.13E-05 0.OOE+00 RU-105 2.18E-08 0.OOE+00 8.46E-09 0.OOE+00 2.75E-07 0.OOE+00 1.76E-05 0.OOE+00 RU-106 3.92E-06 O.OOE+00 4.94E-07 0.OOE+00 7.56E-06 0.OOE+00 1.88E-04 0.OOE+00 RH-105 1.73E-07 1.25E-07 8.20E-08 O.OOE+00 5.31E-07 O.OOE+00 1.59E-05 O.OOE+00 PD-107 0.OOE+00 2.08E-07 1.34E-08 O.OOE+00 1.88E-06 O.OOE+00 9.66E-07 O.OOE+00 PD-109 O.OOE+00 2.51E-07 5.70E-08 O.OOE+00 1.45E-06 O.OOE+00 2.53E-05 O.OOE+00 AG-110m 2.05E-07 1.94E-07 1.18E-07 O.OOE+00 3.70E-07 O.OOE+00 5.45E-05 O.OOE+00 AG-111 8.29E-08 3.44E-08 1.73E-08 O.OOE+00 1.12E-07 0.OOE+00 4.80E-05 O.OOE+00 CD-113m O.OOE+00 4.51E-06 1.45E-07 O.OOE+00 4.99E-06 O.OOE+00 2.71E-05 O.OOE+00 CD-115m O.OOE+00 2.60E-06 8.39E-08 O.OOE+00 2.08E-06 O.OOE+00 8.23E-05 O.OOE+00 SN-123 4.44E-05 7.29E-07 1.08E-05 5.84E-07 O.OOE+00 O.OOE+00 8.23E-05 O.OOE+00 SN-125 1.19E-05 2.37E-07 5.37E-07 1.86E-07 O.OOE+00 O.OOE+00 1.12E-04 O.OOE+00 SN-126 1.16E-04 2.16E-06 3.30E-06 5.69E-07 O.OOE+00 O.OOE+00 2.58E-05 O.OOE+00 SB-124 3.87E-06 7.13E-08 1.51E-06 8.78E-09 O.OOE+00 3.38E-06 7.80E-05 O.OOE+00 SB-125 2.48E-06 2.71E-08 5.80E-07 2.37E-09 O.OOE+00 2.18E-06 1.93E-05 O.OOE+00 SB-126 1.59E-06 3.25E-08 5.71E-07 8.99E-09 O.OOE+00 1.14E-06 9.41E-05 O.OOE+00 SB-127 3.63E-07 7.76E-09 1.37E-07 4.08E-09 O.OOE+00 2.47E-07 6.16E-05 O.OOE+00 TE-125m 3.83E-06 1.38E-06 5.12E-07 1.07E-06 O.OOE+00 O.OOE+00 1.13E-05 0.OOE+00 TE-127m 9.67E-06 3.43E-06 1.15E-06 2.30E-06 3.92E-05 O.OOE+00 2.41E-05 0.OOE+00 TE-1 27 1.58E-07 5.60E-08 3.40E-08 1.09E-07 6.40E-07 O.OOE+00 1.22E-05 0.OOE+00 TE-129m 1.63E-05 6.05E-06 2.58E-06 5.26E-06 6.82E-05 O.OOE+00 6.12E-05 O.OOE+00 TE-1 29 4.48E-08 1.67E-08 1.09E-08 3.20E-08 1.88E-07 O.OOE+00 2.45E-07 O.OOE+00 TE-133m 6.44E-08 3.66E-08 3.56E-08 5.11E-08 3.62E-07 O.OOE+00 1.48E-07 O.OOE+00 TE-134 4.47E-08 2.87E-08 3.OOE-08 3.67E-08 2.74E-07 O.OOE+00 1.66E-09 O.OOE+00 1-129 4.66E-06 3.92E-06 6.54E-06 4.77E-03 7.01E-06 O.OOE+00 4.57E-07 O.OOE+00 1-130 1.03E-06 2.98E-06 1.19E-06 2.43E-04 4.59E-06 O.OOE+00 2.29E-06 O.OOE+00 1-131 5.85E-06. 8.19E-06 4.40E-06 2.39E-03 1.41E-05 0.OOE+00 1.62E-06 O.OOE+00 TE-131m 2.44E-06 1.17E-06 9.76E-07 1.76E-06 1.22E-05 O.OOE+00 9.39E-05 O.OOE+00 TE-131 2.79E-08 1.15E-08 8.72E-09 2.15E-08 1.22E-07 O.OOE+00 2.29E-09 O.OOE+00 1-132 2.79E-07 7.30E-07 2.62E-07 2.46E-05 1.15E-06 O.OOE+00 3118E-07 O.OOE+00 TE-132 3.49E-06 2.21E-06 2.08E-06 2.33E-06 2.12E-05 0.OOE+00 7.OOE-05 O.OOE+00

CY-LG-1 70-301, Rev. 23 Page 123 08/07 TABLE 111-3 (Continued)

INGESTION DOSE FACTORS FOR TEEN (Daipj) mrem/pCi Reg. Guide 1.109 Table E-1 1 to E-14 and NUREG/CR - 1276 Append C Table 6 to Table 9 NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG GI-LLI SKIN 1-133 2.01E-06 3.41E-06 1.04E-06 4.76E-04 5.98E-06 0.OOE+00 2.58E-06 0.OOE+00 CS-134m 2.94E-08 6.09E-08 3.13E-08 0.OOE+00 3.39E-08 5.95E-09 4.05E-08 0.OOE+00 CS-134 8.37E-05 1.97E-04 9.14E-05 0.OOE+00 6.26E-05 2.39E-05 2.45E-06 0.OOE+00 1-134 1.46E-07 3.87E-07 1.39E-07 6.45E-06 6.1OE-07 0.OOE+00 5.1OE-09 0.OOE+00 1-135 6.10E-07 1.57E-06 5.82E-07 1.01E-04 2.48E-06 0.OOE+00 1.74E-06 0.OOE+00 CS-135 2.78E-05 2.55E-05 5.96E-06 0.OOE+00 9.73E-06 3.52E-06 4.46E-07 0.OOE+00 CS-136 8.59E-06 3.38E-05 2.27E-05 0.OOE+00 1.84E-05 2.90E-06 2.72E-06 0.OOE+00 CS-137 1.12E-04 1.49E-04 5.19E-05 0.OOE+00 5.07E-05 1.97E-05 2.12E-06 0.OOE+00 CS-138 7.76E-08 1.49E-07 7.45E-08 0.OOE+00 1.1OE-07 1.28E-08 6.76E-11 0.OOE+00 CS-139 4.87E-08 7.17E-08 2.63E-08 0.OOE+00 5.79E-08 6.34E-09 3.33E-23 0.OOE+00 BA-139 1.39E-07 9.78E-11 4.05E-09 0.OOE+00 9.22E-11 6.74E-11 1.24E-06 0.OOE+00 BA-140 2.84E-05 3.48E-08 1.83E-06 0.OOE+00 1.18E-08 2.34E-08 4.38E-05 0.OOE+00 LA-140 3.48E-09 1.71E-09 4.55E-10 0.OOE+00 0.OOE+00 0.OOE+00 9.82E-05 O.OOE+00 BA-141 6.71E-08 5.01E-11 2.24E-09 0.OOE+00 4.65E-11 3.43E-11 1.43E-13 0.OOE+00 LA-141 4.55E-10 1.40E-10 2.31E-11 0.OOE+00 O.OOE+00 0.OOE+00 2.48E-05 0.OOE+00 CE-141 1.33E-08 8.88E-09 1.02E-09 O.OOE+00 4.18E-09 0.OOE+00 2.54E-05 0.OOE+00 BA-142 2.99E-08 2.99E-11 1.84E-09 O.OOE+00 2.53E-11 1.99E-11 9.18E-20 0.OOE+00 LA- 142 1.79E-10 7.95E-11 1.98E-11 0.OOE+00 0.OOE+00 0.OOE+00 2.42E-06 0.OOE+00 CE-143 2.35E-09 1.71E-06 1.91E-10 0.OOE+00 7.67E-10 0.O0E+00 5.14E-05 0.OOE+00 PR-143 1.31E-08 5.23E-09 6.52E-10 0.OOE+00 3.04E-09 0.OOE+00 4.31E-05 0.OOE+00 CE-144 6.96E-07 2.88E-07 3.74E-08 0.OOE+00 1.72E-07 O.OOE+00 1.75E-04 O.0OE+00 PR-144 4.30E-11 1.76E-11 2.18E-12 0.OOE+00 1.01E-11 0.OOE+00 4.74E-14 0.OOE+00 ND-147 9.38E-09 1.02E-08 6.11E-10 0.OOE+00 5.99E-09 0.OOE+00 3.68E-05 0.OOE+00 PM-147 1.05E-07 9.96E-09 4.06E-09 0.OOE+00 1.90E-08 0.OOE+00 9.47E-06 0.OOE+00 PM-148m 4.14E-08 1.05E-08 8.21E-09 0.OOE+00 1.59E-08 0.OOE+00 6.61E-05 O.OOE+00 PM-148 1.02E-08 1.66E-09 8.36E-10 0.OOE+00 3.OOE-09 0.OOE+00 9.90E-05 0.OOE+00 PM-149 2.17E-09 3.05E-10 1.25E-10 0.OOE+00 5.81E-10 O.OOE+00 4.49E-05 0.OOE+00 PM-151 9.87E-10 1.63E-10 8.25E-11 0.OOE+00 2.93E-10 0.OOE+00 3.66E-05 0.OOE+00 SM-151 8.73E-08 1.68E-08 3.94E-09 0.OOE+00 1.84E-08 0.OOE+00 5.70E-06 0.OOE+00 SM-153 1.22E-09 1.01E-09 7.43E-11 0.OOE+00 3.30E-10 0.OOE+00 2.85E-05 O.OOE+00 EU-152 2.45E-07 5.90E-08 5.20E-08 0.OOE+00 2.74E-07 0.OOE+00 2.17E-05 0.OOE+00 EU-154 7.91E-07 1.02E-07 7.19E-08 O.OOE+00 4.56E-07 0.OOE+00 5.39E-05 0.OOE+00 EU-155 1.74E-07 1.68E-08 1.04E-08 O.OOE+00 6.57E-08 O.OOE+00 9.63E-05 0.OOE+00 EU-156 1.92E-08 1.44E-08 2.35E-09 0.OOE+00 9.69E-09 0.OOE+00 7.36E-05 0.OOE+00 TB-160 6.47E-08 0.OOE+00 8.07E-09 0.OOE+00 2.56E-08 0.OOE+00 4.19E-05 0.OOE+00 HO-166m 3.57E-07 1.1OE-07 7.96E-08 O.OOE+00 1.61E-07 0.OOE+00 1.OOE-24 O.OOE+00 W-181 1.42E-08 4.58E-09 4.79E-10 0.OOE+00 0.OOE+00 O.OOE+00 3.90E-07 O.OOE+00 W-185 5.79E-07 1.91E-07 2.02E-08 O.OOE+00 0.OOE+00 O.OOE+00 1.65E-05 0.OOE+00 W-187 1.46E-07 1.19E-07 4.17E-08 0.OOE+00 0.OOE+00 0.OOE+00 3.22E-05 0.OOE+00

CY-LG-170-301, Rev. 23 Page 124 08/07 TABLE 111-3 (Continued)

INGESTION DOSE FACTORS FOR TEEN (Daipj) mrem/pCi Reg. Guide 1.109 Table E-11 to E-14 and NUREG/CR - 1276 Append C Table 6 to Table 9 NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG GI-LLI SKIN U-232 5.89E-03 0.OOE+00 4.21E-04 0.OOE+00 6.38E-04 0.OOE+00 7.19E-05 0.OOE+00 U-233 1.24E-03 0.OOE+00 7.54E-05 0.OOE+00 2.90E-04 0.OOE+00 6.65E-05 O.OOE+00 U-234 1.19E-03 0.OOE+00 7.39E-05 0.OOE+00 2.85E-04 0.OOE+00 6.51E-05 0.OOE+00 U-235 1.14E-03 O.OOE+00 6.94E-05 0.OOE+00 2.67E-04 0.OOE+00 8.28E-05 0.OOE+00 U-236 1.14E-03 O.OOE+00 7.09E-05 0.OOE+00 2.73E-04 O.OOE+00 6.11E-05 0.OOE+00 U-237 7.89E-08 0.OOE+00 2.10E-08 0.OOE+00 3.24E-07 O.OOE+00 2.09E-05 0.OOE+00 U-238 1.09E-03 0.OOE+00 6.49E-05 0.OOE+00 2.50E-04 0.OOE+00 5.83E-05 0.OOE+00 NP-237 1.33E-03 9.55E-05 5.85E-05 0.OOE+00 4.33E-04 0.OOE+00 8.41 E-05 0.OOE+00 NP-238 1.95E-08 5.22E-10 3.04E-10 0.OOE+00 1.79E-09 0.OOE+00 3.83E-05 0.OOE+00 NP-239 1.76E-09 1.66E-10 9.22E-11 0.OOE+00 5.21E-10 O.OOE+00 2.67E-05 0.OOE+00 PU-238 6.70E-04 8.58E-05 1.82E-05 0.OOE+00 7.80E-05 0.OOE+00 7.73E-05 0.OOE+00 PU-239 7.65E-04 9.29E-05 2.01E-05 0.OOE+00 8.57E-05 0.OOE+00 7.06E-05 0.OOE+00 PU-240 7.64E-04 9.27E-05 2.01E-05 0.OOE+00 8.56E-05 0.OOE+00 7.19E-05 0.OOE+00 PU-241 1.75E-05 8.40E-07 3.69E-07 0.OOE+00 1.71 E-06 0.OOE+00 1.48E-06 0.OOE+00 PU-242 7.09E-04 8.94E-05 1.94E-05 O.OOE+00 8.25E-05 0.OOE+00 6.92E-05 0.OOE+00 PU-244 8.28E-04 1.02E-04 2.22E-05 0.OOE+00 9.45E-05 0.OOE+00 1.03E-04 0.OOE+00 AM-241 7.98E-04 7.53E-04 5.75E-05 0.OOE+00 4.31E-04 0.OOE+00 7.87E-05 0.OOE+00 AM-242m 8.07E-04 7.11E-04 5.80E-05 O.OOE+00 4.30E-04 0.OOE+00 9.90E-05 0.OOE+00 AM-243 7.96E-04 7.35E-04 5.62E-05 0.OOE+00 4.22E-04 0.OOE+00 9.23E-05 0.OOE+00 CM-242 2.94E-05 3.10E-05 1.95E-06 0.OOE+00 8.89E-06 0.OOE+00 8.40E-05 0.OOE+00 CM-243 6.50E-04 6.03E-04 4.09E-05 0.OOE+00 1.91E-04 0.OOE+00 8.28E-05 O.OOE+00 CM-244 5.04E-04 4.77E-04 3.19E-05 0.OOE+00 1.49E-04 0.OOE+00 8.OOE-05 0.OOE+00 CM-245 9.90E-04 8.71 E-04 6.1OE-05 0.OOE+00 2.85E-04 0.OOE+00 7.46E-05 O.OOE+00 CM-246 9.82E-04 8.70E-04 6.09E-05 0.OOE+00 2.84E-04 0.OOE+00 7.33E-05 O.OOE+00 CM-247 9.57E-04 8.57E-04 6.OOE-05 O.OOE+00 2.80E-04 0.OOE+00 9.63E-05 0.OOE+00 CM-248 7.95E-03 7.06E-03 4.95E-04 O.OOE+00 2.31E-03 0.OOE+00 1.55E-03 0.OOE+00 CF-252 3.47E-04 0.OOE+00 8.37E-06 0.OOE+00 0.OOE+00 0.OOE+00 3.05E-04 0.OOE+00

CY-LG-170-301, Rev. 23 Page 125 08/07 TABLE 111-4 INGESTION DOSE FACTORS FOR CHILD (Daipj) mrem/pCi Reg. Guide 1.109 Table E-11 to E-14 and NUREG/CR - 1276 Append C Table 6 to Table 9 NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG GI-LLI SKIN H-3 0.OOE+00 2.03E-07 2.03E-07 2.03E-07 2.03E-07 2.03E-07 2.03E-07 0.OOE+00 C-14 1.21 E-05 2.42E-06 2.42E-06 2.42E-06 2.42E-06 2.42E-06 2.42E-06 0.OOE+00 NA-22 5.88E-05 5.88E-05 5.88E-05 5.88E-05 5.88E-05 5.88E-05 5.88E-05 0.OOE+00 NA-24 5.80E-06 5.80E-06 5.80E-06 5.80E-06, 5.80E-06 5.80E-06 5.80E-06 O.OOE+00 P-32 1.28E-04 3.86E-05 3.18E-05 0.OOE+00 0.OOE+00 0.OOE+00 2.28E-05 0.OOE+00 CA-41 3.47E-04 0.OOE+00 3.79E-05 0.OOE+00 0.OOE+00 0.OOE+00 1.90E-07 O.OOE+00 SC-46 1.97E-08 2.70E-08 1.04E-08 0.OOE+00 2.39E-08 0.OOE+00 3.95E-06 0.OOE+00 CR-51 0.OOE+00 0.OOE+00 8.90E-09 4.94E-09 1.35E-09 9.02E-09 4.72E-07 0.OOE+00 MN-54 0.OOE+00 1.07E-05 2.85E-06 O.OOE+00 3.OOE-06 0.OOE+00 8.98E-06 0.OOE+00 FE-55 1.15E-05 6.10E-06 1.89E-06 0.OOE+00 0.OOE+00 3.45E-06 1.13E-06 0.OOE+00 MN-56 0.OOE+00 3.34E-07 7.54E-08 0.OOE+00 4.04E-07 0.00E+00 4.84E-05 0.OOE+00 CO-57 0.OOE+00 4.93E-07 9.98E-07 0.OOE+00 0.OOE+00 0.OOE+00 4.04E-06 0.OOE+00 CO-58 0.OOE+00 1.80E-06 5.51E-06 0.OOE+00 0.OOE+00 0.OOE+00 1.05E-05 0.OOE+00 FE-59 1.65E-05 2.67E-05 1.33E-05 0.OOE+00 0.OOE+00 7.74E-06 2.78E-05 0.OOE+00 CO-60 0.OOE+00 5.29E-06 1.56E-05 0.OOE+00 O.OOE+00 O.OOE+00 2.93E-05 0.OOE+00 NI-59 4.02E-05 1.07E-05 6.82E-06 0.OOE+00 0.OOE+00 0.OOE+00 7.1OE-07 0.OOE+00 NI-63 5.38E-04 2.88E-05 1.83E-05 0.OOE+00 0.OOE+00 0.OOE+00 1.94E-06 0.OOE+00 CU-64 0.OOE+00 2.45E-07 1.48E-07 0.OOE+00 5.92E-07 O.OOE+00 1.15E-05 0.OOE+00 NI-65 2.22E-06 2.09E-07 1.22E-07 0.OOE+00 0.OOE+00 0.OOE+00 2.56E-05 0.OOE+00 ZN-65 1.37E-05 3.65E-05 2.27E-05 0.OOE+00 2.30E-05 0.OOE+00 6.41 E-06 0.OOE+00 ZN-69m 7.1OE-08 1.21E-06 1.43E-07 0.OOE+00 7.03E-07 0.OOE+00 3.94E-05 0.OOE+00 ZN-69 4.38E-08 6.33E-08 5.85E-09 0.OOE+00 3.84E-08 0.OOE+00 3.99E-06 0.00E+00 SE-79 0.OOE+00 8.43E-06 1.87E-06 0.OOE+00 1.37E-05 O.OOE+00 5.53E-07 O.OOE+00 BR-82 0.OOE+00 O.OOE+00 7.55E-06 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 BR-83 0.OOE+00 O.OOE+00 1.71E-07 0.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 BR-84 0.OOE+00 0.OOE+00 1.98E-07 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 BR-85 0.OOE+00 0.OOE+00 9.12E-09 0.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 O.OOE+00 RB-86 0.OOE+00 6.70E-05 4.12E-05 0.OOE+00 O.OOE+00 0.OOE+00 4.31 E-06 0.OOE+00 RB-87 0.OOE+00 1.83E-05 1.83E-05 0.OOE+00 0.OOE+00 0.OOE+00 5.92E-07 0.OOE+00 RB-88 O.OOE+00 1.90E-07 1.32E-07 0.OOE+00 0.OOE+00 0.OOE+00 9.32E-09 0.OOE+00 RB-89 0.OOE+00 1.17E-07 1.04E-07 0.OOE+00 0.OOE+00 0.OOE+00 1.02E-09 0.OOE+00 SR-89 1.32E-03 0.OOE+00 3.77E-05 0.OOE+00 0.OOE+00 0.OOE+00 5.11E-05 O.OOE+00 SR-90 1.70E-02 0.OOE+00 4.31E-03 0.OOE+00 0.OOE+00 0.OOE+00 2.29E-04 0.OOE+00 Y-90 4.11E-08 0.OOE+00 1.10E-09 0.OOE+00 0.OOE+00 0.OOE+00 1.17E-04 O.OOE+00 SR-91 2.40E-05 0.OOE+00 9.06E-07 0.OOE+00 0.OOE+00 O.OOE+00 5.30E-05 0.OOE+00 Y-91m 3.82E-10 O.OOE+00 1.39E-11 0.OOE+00 0.OOE+00 O.OOE+00 7.48E-07 0.OOE+00 Y-91 6.02E-07 0.OOE+00 1.61E-08 0.OOE+00 0.OOE+00 0.OOE+00 8.02E-05 0.OOE+00 SR-92 9.03E-06 0.OOE+00 3.62E-07 0.OOE+00 0.OOE+00 0.OOE+00 1.71 E-04 0.OOE+00 Y-92 3.60E-09 0.OOE+00 1.03E-10 0.OOE+00 0.OOE+00 0.OOE+00 1.04E-04 0.OOE+00 Y-93 1.14E-08 0.OOE+00 3.13E-10 0.OOE+00 0.OOE+00 0.OOE+00 1.70E-04 O.OOE+00

CY-LG-170-301, Rev. 23 Page 126 08/07 TABLE 111-4 (Continued)

INGESTION DOSE FACTORS FOR CHILD (Daipi) mrem/pCi Reg. Guide 1.109 Table E-11 to E-14 and NUREG/CR - 1276 Append C Table 6 to Table 9 NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG GI-LLI SKIN NB-93m 1.05E-07 2.62E-08 8.61 E-09 0.OOE+00 2.83E-08 0.OOE+00 3.98E-06 0.OOE+00 NB-95 2.25E-08 8.76E-09 6.26E-09 0.OOE+00 8.23E-09 O.OOE+00 1.62E-05 0.OOE+00 NB-97 2.17E-10 3.92E-11 1.83E-11 O.OOE+00 8.35E-11 0.OOE+00 1.21E-05 0.OOE+00 ZR-93 1.67E-07 6.25E-08 4.45E-08 0.OOE+00 2.42E-07 0.OOE+00 2.37E-05 0.OOE+00 ZR-95 1.16E-07 2.55E-08 2.27E-08 0.OOE+00 3.65E-08 0.OOE+00 2.66E-05 0.OOE+00 ZR-97 6.99E-09 1.01E-09 5.96E-10 0.OOE+00 1.45E-09 0.OOE+00 1.53E-04 0.OOE+00 MO-93 O.OOE+00 2.41E-05 8.65E-07 0.OOE+00 6.35E-06 0.OOE+00 1.22E-06 0.OOE+00 MO-99 0.OOE+00 1.33E-05 3.29E-06 0.OOE+00 2.84E-05 0.OOE+00 1.1OE-05 0.OOE+00 TC-99 5.35E-07 5.96E-07 2.14E-07 O.OOE+00 7.02E-06 5.27E-08 6.25E-06 0.OOE+00 TC-99m 9.23E-10 1.81E-09 3.OOE-08 0.OOE+00 2.63E-08 9.19E-10 1.03E-06 0.OOE+00 TC-101 1.07E-09 1.12E-09 1.42E-08 O.OOE+00 1.91E-08 5.92E-10 3.56E-09 O.OOE+00 RU-103 7.31E-07 O.OOE+00 2.81E-07 0.OOE+00 1.84E-06 0.OOE+00 1.89E-05 0.OOE+00 RU-105 6.45E-08 0.OOE+00 2.34E-08 0.OOE+00 5.67E-07 0.OOE+00 4.21E-05 0.OOE+00 RU-106 1.17E-05 0.OOE+00 1.46E-06 0.OOE+00 1.58E-05 0.OOE+00 1.82E-04 0.OOE+00 RH-105 5.14E-07 2.76E-07 2.36E-07 0.OOE+00 1.10E-06 0.OOE+00 1.71E-05 0.OOE+00 PD-107 0.OOE+00 4.72E-07 4.01E-08 0.OOE+00 3.95E-06 O.OOE+00 9.37E-07 O.OOE+00 PD-109 0.OOE+00 5.67E-07 1.70E-07 0.OOE+00 3.04E-06 0.OOE+00 3.33E-05 0.OOE+00 AG-110m 5.39E-07 3.64E-07 2.91E-07 0.OOE+00 6.78E-07 0.OOE+00 4.33E-05 0.OOE+00 AG-111 2.48E-07 7.76E-08 5.12E-08 0.OOE+00 2.34E-07 0.OOE+00 4.76E-05 0.OOE+00 CD-113m O.OOE+00 1.02E-05 4.34E-07 0.OOE+00 1.05E-05 0.OOE+00 2.63E-05 0.OOE+00 CD-115m 0.OOE+00 5.89E-06 2.51E-07 0.OOE+00 4.38E-06 0.OOE+00 8.01E-06 0.OOE+00 SN-123 1.33E-04 1.65E-06 3.24E-06 1.75E-06 0.OOE+00 0.OOE+00 6.52E-05 0.OOE+00 SN-125 3.55E-05 5.35E-07 1.59E-06 5.55E-07 0.O0E+00 0.OOE+00 1.1OE-04 O.OOE+00 SN-126 3.33E-04 4.15E-06 9.46E-06 1.14E-06 0.OOE+00 O.OOE+00 2.50E-05 0.OOE+00 SB-124 1.11E-05 1.44E-07 3.89E-06 2.45E-08 0.OOE+00 6.16E-06 6.94E-05 0.OOE+00 SB-125 7.16E-06 5.52E-08 1.50E-06 6.63E-09 0.OOE+00 3.99E-06 1.71E-05 0.OOE+00 SB-126 4.40E-06 6.73E-08 1.58E-06 2.38E-08 0.OOE+00 2.1OE-06 8.87E-05 0.OOE+00 SB-127 1.06E-06 1.64E-08 3.68E-07 1.18E-08 0.OOE+00 4.60E-07 5.97E-05 O.OOE+00 TE-125m 1.14E-05 3.09E-06 1.52E-06 3.20E-06 0.OOE+00 O.OOE+00 1.1OE-05 0.OOE+00 TE-127m 2.89E-05 7.78E-06 3.43E-06 6.91 E-06 8.24E-05 0.OOE+00 2.34E-05 0.OOE+00 TE-127 4.71E-07 1.27E-07 1.01E-07 3.26E-07 1.34E-06 0.OOE+00 1.84E-05 0.OOE+00 TE-129m 4.87E-05 1.36E-05 7.56E-06 1.57E-05 1.43E-04 O.OOE+00 5.94E-05 0.OOE+00 TE-129 1.34E-07 3.74E-08 3.18E-08 9.56E-08 3.92E-07 0.OOE+00 8.34E-06 0.OOE+00 TE-133m 1.87E-07 7.56E-08 9.37E-08 1.45E-07 7.13E-07 0.OOE+00 5.77E-06 0.OOE+00 TE-134 1.29E-07 5.80E-08 7.74E-08 1.02E-07 5.37E-07 0.OOE+00 5.89E-07 0.OOE+00 1-129 1.39E-05 8.53E-06 7.62E-06 5.58E-03 1.44E-05 0.OOE+00 4.29E-07 0.OOE+00 1-130 2.92E-06 5.90E-06 3.04E-06 6.50E-04 8.82E-06 0.00E+00 2.76E-06 0.OOE+00 1-131 1.72E-05 1.73E-05 9.83E-06 5.72E-03 2.84E-05 0.OOE+00 1.54E-06 0.OOE+00 TE-131m 7.20E-06 2.49E-06 2.65E-06 5.12E-06 2.41E-05 0.00E+00 1.01E-04 0.00E+00 TE-131 8.30E-08 2.53E-08 2.47E-08 6.35E-08 2.51E-07 0.OOE+00 4.36E-07 0.OOE+00

CY-LG-170-301, Rev. 23 Page 127 08/07 TABLE 111-4 (Continued)

INGESTION DOSE FACTORS FOR CHILD (Daipj) mrem/pCi Reg. Guide 1.109 Table E-1 1 to E-14 and NUREG/CR - 1276 Append C Table 6 to Table 9 NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG GI-LLI SKIN 1-132 8.00E-07 1.47E-06 6.76E-07 6.82E-05 2.25E-06 0.OOE+0O 1.73E-06 0.00E+00 TE-132 1.01 E-05 4.47E-06 5.40E-06 6.51 E-06 4.15E-05 0.00E+00 4.50E-05 0.00E+00 I-133 5.92E-06 7.32E-06 2.77E-06 I1.36E-03 1.22E-05 0.00E+00 2.95E-06 0.00E+00 CS-134m 8.44E-08 1.25E-07 8.16E-08 0.OOE+00 6.59E-08 1.09E-08 1.32E-07 0.00E+00 CS-134 2.34E-04 3.84E-04 8.10E-05 0.00E+00 1.19E-04 4.27E-05 2.07E-06 0.OOE+00 1-134 4.19E-07 7.78E-07 3.58E-07 I1.79E-05 1.19E-06 0.00E+00 5.16E-07 0.OOE+00 1-135 1.75E-06 3.15E-06 1.49E-06 2.79E-04 4.83E-06 0.00E+00 2.40E-06 0.00E+00 CS-135 8.30E-05 5.78E-05 5.93E-06 0.00E+00 2.04E-05 6.81 E-06 4.33E-07 0.OOE+00 CS-136 2.35E-05 6.46E-05 4.18E-05 0.00E+00 3.44E-05 5.13E-06 2.27E-06 0.00E+00 CS-137 3.27E-04 3.13E-04 4.62E-05 0.00E+00 1.02E-04 3.67E-05 1.96E-06 0.00E+00 CS-138 2.28E-07 3.17E-07 2.01 E-07 0.00E+00 2.23E-07 2.40E-08 1.46E-07 0.00E+00 CS- 139 1.45E-07 1.61E-07 7.74E-08 0.00E+00 1.21 E-07 1.22E-08 1.45E- 11 0.00E+00 BA-139 4.14E-07 2.21E-10 1.20E-08 0.OOE+00 1.93E-10 1.30E-10 2.39E-05 0.00E+00 BA-140 8.31E-05 7.28E-08 4.85E-06 0.OOE+00 2.37E-08 4.34E-08 4.21 E-05 0.OOE+00 LA-140 1.01E-08 3.53E-09 1.19E-09 0.OOE+00 0.00E+00 0.00E+00 9.84E-05 0.00E+00 BA-141 2.00E-07 1.12E-10 6.51 E-09 0.OOE+00 9.69E-1 1 6.58E-1 0 1.14E-07 0.00E+00 LA-141 1.36E-09 3.17E-10 6.88E-11 0.00E+00 0.00E+00 0.00E+00 7.05E-05 0.OOE+00 CE-141 3.97E-08 1.98E-08 2.94E-09 0.OOE+00 8.68E-09 0.00E+00 2.47E-05 0.OOE+00 BA-142 8.74E-08 6.29E-11 4.88E-09 0.00E+00 5.09E-1 1 3.70E-1 1 1.14E-09 0.00E+00 LA-142 5.24E-10 1.67E-10 5.23E-1 1 0.00E+00 0.00E+00 0.OOE+00 3.31 E-05 0.00E+00 CE-143 6.99E-09 3.79E-06 5.49E-10 0.OOE+00 1.59E-09 0 OOE+00 5.55E-05 0.00E+00 PR-143 3.93E-08 1.18E-08 1.95E-09 0.00E+00 6.39E-09 0.OOE+00 4.24E-05 0.00E+00 CE-144 2.08E-06 6.52E-07 1.11E-07 0.00E+00 3.61 E-07 0.OOE+00 1.70E-04 0.00E+00 PR-144 1.29E-10 3.99E-1 1 6.49E-12 0.00E+00 2.11E-11 0.OOE+00 8.59E-08 0.00E+00 ND-147 2.79E-08 2.26E&08 1.75E-09 0.OOE+00 1.24E-08 0.00E+00 3.58E-05 0.00E+00 PM-147 3.18E-07 2.27E-08 1.22E-08 0.OOE+00 4.01 E-08 0.00E+00 9.19E-06 O.OOE+00 PM-148m 1.03E-07 2.05E-08 2.05E-08 0.OOE+00 3.04E-08 0.00E+00 5.78E-05 0.00E+00 PM-148 3.02E-08 3.63E-09 2.35E-09 0.OOE+00 6.17E-09 0.00E+00 9.70E-05 0.00E+00 PM-149 6.49E-09 6.90E-10 3.74E-10 0.OOE+00 1.22E-09 0.00E+00 4.71 E-05 0.00E+00 PM-151 2.92E-09 3.55E-10 2.31 E-10 0.00E+00 6.02E-10 0.00E+00 4.03E-05 0.00E+00 SM-151 2.56E-07 3.81 E-08 1.20E-08 0.OOE+00 3.94E-08 0.00E+00 5.53E-06 0.00E+00 SM-153 3.65E-09 2.27E-09 2.19E-10 0.00E+00 6.91 E-10 0.OOE+00 3.02E-05 0.00E+00 EU-152 6.15E-07 1.12E-07 1.33E-07 0.00E+00 4.73E-07 0.OOE+00 1.84E-05 0.00E+00 EU-154 2.30E-06 2.07E-07 1.89E-07 0.00E+00 9.09E-07 0.OOE+00 4.81 E-05 0.00E+00 EU-1 55 4.82E-07 3.47E-08 2.72E-08 0.OOE+00 1.30E-07 0.00E+00 8.69E-05 0.00E+00 EU-1 56 5.62E-08 3.01 E-08 6.23E-09 0.OOE+00 1.94E-08 0.00E+00 6.83E-05 O.00E+00 TB-160 1.66E-07 O.00E+00 2.06E-08 0.OOE+00 4.94E-08 0.00E+00 3.68E-05 0.00E+00 HO-166m 1.08E-06 2.26E-07 1.91 E-07 0.00E+00 3.22E-07 0.00E+00 1.OOE-24 0.OOE+00 W-181 4.23E-08 1.04E-08 1.43E-09 0.00E+00 0.00E+00 0.00E+00 3.79E-07 0.00E+00 W-185 1.73E-06 4.32E-07 6.05E-08 0.00E+00 0.00E+00 0.OOE+00 1.61E-05 0.00E+00 W-187 4.29E-07 2.54E-07 1.14E-07 0.00E+00 0.00E+00 0.OOE+00 3.57E-05 0.OOE+00

CY-LG-170-301, Rev. 23 Page 128 08/07 TABLE 111-4 (Continued)

INGESTION DOSE FACTORS FOR CHILD (Daipj) mrem/pCi Reg. Guide 1.109 Table E-1 1 to E-14 and NUREG/CR - 1276 Append C Table 6 to Table 9 NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG GI-LLI SKIN U-232 1.76E-02 0.OOE+00 1.26E-03 0.OOE+00 1.34E-03 0.OOE+00 6.98E-05 0.OOE+00 U-233 3.72E-03 0.OOE+00 2.25E-04 0.OOE+00 6.10E-04 0.OOE+00 6.45E-05 0.OOE+00 U-234 3.57E-03 O.OOE+00 2.21 E-04 0.OOE+00 5.98E-04 0.OOE+00 6.32E-05 0.OOE+00 U-235 3.42E-03 0.OOE+00 2.07E-04 0.OOE+00 5.61E-04 0.OOE+00 8.03E-05 0.OOE+00 U-236 3.42E-03 O.OOE+00 2.12E-04 0.OOE+00 5.73E-04 0.OOE+00 5.92E-05 0.OOE+00 U-237 2.36E-07 0.OOE+00 6.27E-08 0.OOE+00 6.81 E-07 0.OOE+00 2.08E-05 0.OOE+00 U-238 3.27E-03 0.OOE+00 1.94E-04 0.OOE+00 5.24E-04 0.OOE+00 5.66E-05 O.OOE+00 NP-237 2.23E-03 1.47E-04 9.79E-05 0.OOE+00 6.05E-04 0.OOE+00 8.16E-05 0.OOE+00 NP-238 5.83E-08 1.18E-09 9.08E-10 0.OOE+00 3.76E-09 0.OOE+00 4.04E-05 O.OOE+00 NP-239 5.25E-09 3.77E-10 2.65E-10 0.OOE+00 1.09E-09 0.OOE+00 2.79E-05 0.OOE+00 PU-238 1.19E-03 1.38E-04 3.16E-05 0.OOE+00 1.15E-04 O.OOE+00 7.50E-05 0.OOE+00 PU-239 1.29E-03 1.38E-04 3.31E-05 0.OOE+00 1.22E-04 O.OOE+00 6.85E-05 O.OOE+00 PU-240 1.28E-03 1.43E-04 3.31E-05 0.OOE+00 1.22E-04 0.OOE+00 6.98E-05 0.OOE+00 PU-241 3.87E-05 1.58E-06 8.04E-07 0.OOE+00 2.96E-06 0.OOE+00 1.44E-06 0.OOE+00 PU-242 1.19E-03 1.38E-04 3.19E-05 0.OOE+00 1.17E-04 0.OOE+00 6.71E-05 0.OOE+00 PU-244 1.39E-03 1.58E-03 3.65E-05 0.OOE+00 1.35E-04 0.OOE+00 1.OOE-04 O.OOE+00 AM-241 1.36E-03 1.17E-03 1.02E-04 0.OOE+00 6.23E-04 0.OOE+00 7.64E-05 0.OOE+00 AM-242m 1.40E-03 1.12E-03 1.04E-04 O.OOE+00 6.30E-04 0.OOE+00 9.61 E-05 0.OOE+00 AM-243 1.34E-03 1.13E-03 9.83E-05 0.OOE+00 6.06E-04 0.OOE+00 8.95E-05 O.OOE+00 CM-242 8.78E-05 7.01E-05 5.84E-06 0.OOE+00 1.87E-05 0.OOE+00 8.16E-05 0.OOE+00 CM-243 1.28E-03 1.04E-03 8.24E-05 0.OOE+00 3.08E-04 0.OOE+00 8.03E-05 0.OOE+00 CM-244' 1.08E-03 8.74E-04 6.93E-05 0.OOE+00 2.54E-04 0.OOE+00 7.77E-05 0.OOE+00 CM-245 1.67E-03 1.34E-03 1.05E-04 0.OOE+00 4.11E-04 0.OOE+00 7.24E-05 O.OOE+00 CM-246 1.65E-03 1.34E-03 1.05E-04 0.OOE+00 4.1OE-04 0.OOE+00 7.11E-05 0.OOE+00 CM-247 1.61 E-03 1.32E-03 1.03E-04 0.OOE+00 4.04E-04 0.OOE+00 9.35E-05 O.OOE+00 CM-248 1.34E-02 1.09E-02 8.52E-04 0.OOE+00 3.33E-03 0.OOE+00 1.51 E-03 0.OOE+00 CF-252 1.05E-03 0.OOE+00 2.54E-05 0.OOE+00 0.OOE+00 0.OOE+00 2.96E-04 0.OOE+00

CY-LG-1 70-301, Rev. 23 Page 129 08/07 TABLE 111-5 INGESTION DOSE FACTORS FOR INFANT (Daipi) mrem/pCi Reg. Guide 1.109 Table E-11 to E-14 and NUREG/CR - 1276 Append C Table 6 to Table 9 NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG GI-LLI SKIN H-3 O.OOE+00 3.08E-07 3.08E-07 3.08E-07 3.08E-07 3.08E-07 3.08E-07 0.OOE+00 C-14 2.37E-05 5.06E-06 5.06E-06 5.06E-06 5.06E-06 5.06E-06 5.06E-06 0.OOE+00 NA-22 9.83E-05 9.83E-05 9.83E-05 9.83E-05 9.83E-05 9.83E-05 9.83E-05 0.OOE+00 NA-24 1.01E-05 1.01E-05 1.01 E-05 1.01 E-05 1.01 E-05 1.01E-05 1.01E-05 0.OOE+00 P-32 2.64E-04 1.OOE-04 6.59E-05 0.OOE+00 0.OOE+00 O.OOE+00 2.30E-05 O.OOE+00 CA-41 3.74E-04 0.OOE+00 4.08E-05 0.OOE+00 0.OOE+00 0.OOE+00 1.91 E-07 0.OOE+00 SC-46 3.75E-08 5.41E-08 1.69E-08 0.OOE+00 3.56E-08 0.OOE+00 3.53E-05 0.OOE+00 CR-51 0.OOE+00 0.OOE+00 1.41 E-08 9.20E-09 2.01E-09 1.79E-08 4.11E-07 0.OOE+00 MN-54 0.OOE+00 1.99E-05 4.51 E-06 0.OOE+00 4.41 E-06 O.OOE+00 7.31 E-06 0.OOE+00 FE-55 1.39E-05 8.98E-06 2.40E-06 O.OOE+00 0.OOE+00 4.39E-06 1.14E-06 0.OOE+00 MN-56 0.OOE+00 8.18E-07 1.41E-07 0.OOE+00 7.03E-07 0.OOE+00 7.43E-05 0.OOE+00 CO-57 0.OOE+00 1.15E-06 1.87E-06 0.OOE+00 O.OOE+00 0.OOE+00 3.92E-06 0.OOE+00 CO-58 0.OOE+00 3.60E-06 8.98E-06 0.OOE+00 0.OOE+00 0.OOE+00 8.97E-06 O.OOE+00 FE-59 3.08E-05 5.38E-05 2.12E-05 O.OOE+00 0.OOE+00 1.59E-05 2.57E-05 0.OOE+00 CO-60 0.OOE+00 1.08E-05 2.55E-05 0.OOE+00 0.OOE+00 0.OOE+00 2.57E-05 0.OOE+00 NI-59 4.73E-05 1.45E-05 8.17E-06 0.OOE+00 O.OOE+00 0.OOE+00 7.16E-07 0.OOE+00 NI-63 6.34E-04 3.92E-05 2.20E-05 0.OOE+00 O.OOE+00 O.OOE+00 1.95E-06 0.OOE+00 CU-64 O.OOE+00 6.09E-07 2.82E-07 0.OOE+00 1.03E-06 0.OOE+00 1.25E-05 O.OOE+00 NI-65 4.70E-06 5.32E-07 2.42E-07 0.OOE+00 0.OOE+00 0.OOE+00 4.05E-05 0.OOE+00 ZN-65 1.84E-05 6.31E-05 2.91E-05 0.OOE+00 3.06E-05 0.OOE+00 5.33E-05 0.OOE+00 ZN-69m 1.50E-06 3.06E-06 2.79E-07 0.OOE+00 1.24E-06 0.OOE+00 4.24E-05 0.OOE+00 ZN-69 9.33E-08 1.68E-07 1.25E-08 0.OOE+00 6.98E-08 0.OOE+00 1.37E-05 0.OOE+00 SE-79 0.OOE+00 2.1OE-05 3.90E-06 O.OOE+00 2.43E-05 0.OOE+00 5.58E-07 0.OOE+00 BR-82 0.OOE+00 0.OOE+00 1.27E-05 0.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 BR-83 0.OOE+00 0.OOE+00 3.63E-07 0.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 O.OOE+00 BR-84 0.OOE+00 O.OOE+00 3.82E-07 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 BR-85 0.OOE+00 0.OOE+00 1.94E-08 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 RB-86 0.OOE+00 1.70E-04 8.40E-05 O.OOE+00 0.OOE+00 0.OOE+00 4.35E-06 0.OOE+00 RB-87 0.OOE+00 8.88E-05 3.52E-05 O.OOE+00 0.OOE+00 0.OOE+00 5.98E-07 0.OOE+00 RB-88 0.OOE+00 4.98E-07 2.73E-07 0.OOE+00 0.OOE+00 O.0OE+00 4.85E-07 O.OOE+00 RB-89 0.OOE+00 2.86E-07 1.97E-07 0.OOE+00 0.OOE+00 0.OOE+00 9.74E-08 0.OOE+00 SR-89 2.51E-03 0.OOE+00 7.20E-05 0.OOE+00 0.OOE+00 0.OOE+00 5.16E-05 0.OOE+00 SR-90 1.85E-02 O.OOE+00 4.71 E-03 0.OOE+00 0.OOE+00 0.OOE+00 2.31 E-04 0.OOE+00 Y-90 8.69E-08 0.OOE+00 2.33E-09 O.OOE+00 0.OOE+00 0.OOE+00 1.20E-04 0.OOE+00 SR-91 5.OOE-05 0.OOE+00 1.81 E-06 0.OOE+00 O.OOE+00 0.OOE+00 5.92E-05 0.OOE+00 Y-91m 8.10E-10 0.OOE+00 2.76E-11 0.OOE+00 0.OOE+00 O.OOE+00 2.70E-06 0.OOE+00 Y-91 1.13E-06 0.OOE+00 3.01E-08 0.OOE+00 0.OOE+00 0.OOE+00 8.10E-05 0.OOE+00 SR-92 1.92E-05 0.OOE+00 7.13E-07 0.OOE+00 O.OOE+00 O.OOE+00 2.07E-04 0.OOE+00 Y-92 7.65E-09 0.OOE+00 2.15E-10 0.OOE+00 0.OOE+00 0.OOE+00 1.46E-04 0.OOE+00 Y-93 2.43E-08 0.OOE+00 6.62E-10 0.OOE+00 0.OOE+00 0.OOE+00 1.92E-04 0.OOE+00 NB-93m 1.23E-07 3.33E-08 1.04E-08 0.OOE+00 3.25E-08 0.OOE+00 3.98E-06 0.OOE+00

CY-LG-170-301, Rev. 23 Page 130 08/07 TABLE 111-5 (Continued)

INGESTION DOSE FACTORS FOR INFANT (Daipj) mrem/pCi Reg. Guide 1.109 Table E-11 to E-14 and NUREG/CR - 1276 Append C Table 6 to Table 9 NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG GI-LLI SKIN NB-95 4.20E-08 1.73E-08 1.OOE-08 0.OOE+00 1.24E-08 O.OOE+00 1.46E-05 0.OOE+00 NB-97 4.59E-10 9.79E-1 1 3.53E-1 1 0.OOE+00 7.65E-1 1 0.OOE+00 3.09E-05 O.OOE+00 ZR-93 1.93E-07 9.18E-08 5.54E-08 0.OOE+00 2.71E-07 0.OOE+00 2.39E-05 0.OOE+00 ZR-95 2.06E-07 5.02E-08 3.56E-08 0.OOE+00 5.41 E-08 O.OOE+00 2.50E-05 0.OOE+00 ZR-97 1.48E-08 2.54E-09 1.1 6E-09 0.OOE+00 2.56E-09 0.OOE+00 1.62E-04 O.OOE+00 MO-93 O.OOE+00 5.65E-05 1.82E-06 0.OOE+00 1.13E-05 0.OOE+00 1.21E-06 0.OOE+00 MO-99 O.OOE+00 3.40E-05 6.63E-06 0.OOE+00 5.08E-05 0.OOE+00 1.12E-05 0.OOE+00 TC-99 1.08E-06 1.46E-06 4.55E-07 0.OOE+00 1.23E-05 1.42E-07 6.31 E-06 0.OOE+00 TC-99m 1.92E-09 3.96E-09 5.10E-08 0.OOE+00 4.26E-08 2.07E-09 1.15E-06 0.OOE+00 TC-101 2.27E-09 2.86E-09 2.83E-08 0.OOE+00 3.40E-08 1.56E-09 4.86E-07 O.OOE+00 RU-103 1.48E-06 O.OOE+00 4.95E-07 0.OOE+00 3.08E-06 0.OOE+00 1.80E-05 O.OOE+00 RU-105 1.36E-07 0.OOE+00 4.58E-08 0.OOE+00 1.OOE-06 0.OOE+00 5.41E-05 0.OOE+00 RU-106 2.41E-05 0.OOE+00 3.01E-06 0.OOE+00 2.85E-05 0.OOE+00 1.83E-04 O.OOE+00 RH-105 1.09E-06 7.13E-07 4.79E-07 0.OOE+00 1.98E-06 0.OOE+00 1.77E-05 0.OOE+00 PD-107 0.OOE+00 1.19E-06 8.45E-08 0.OOE+00 6.79E-06 0.OOE+00 9.48E-07 0.OOE+00 PD-109 0.00E+00 1.50E-06 3.62E-07 O.OOE+00 5.51E-06 0.00E+00 3.68E-05 0.OOE+00 AG-110m 9.96E-07 7.27E-07 4.81 E-07 0.OOE+00 1.04E-06 O.00E+00 3.77E-05 0.00E+00 AG-111 5.20E-07 2.02E-07 1.07E-07 0.00E+00 4.22E-07 0.00E+00 4.82E-05 0.OOE+00 CD-113m 0.00E+00 1.77E-05 6.52E-07 0.00E+00 1.34E-05 0.00E+00 2.66E-05 0.OOE+00 CD-115m 0.OOE+00 1.42E-05 4.93E-07 0.OOE+00 7.41E-06 0.00E+00 8.09E-05 0.00E+00 SN-123 2.49E-04 3.89E-06 6.50E-06 3.91E-06 0.00E+00 0.00E+00 6.58E-05 0.00E+00 SN-125 7.41E-05 1.38E-06 3.29E-06 1.36E-06 0.00E+00 0.00E+00 1.11E-04 0.OOE+00 SN-126 5.53E-04 7.26E-06 1.80E-05 1.91E-06 O.00E+00 0.OOE+00 2.52E-05 0.OOE+00 SB-124 2.14E-05 3.15E-07 6.63E-06 5.68E-08 O.00E+00 1.34E-05 6.60E-05 O.00E+00 SB-125 1.23E-05 1.19E-07 2.53E-06 1.54E-08 0.00E+00 7.12E-06 1.64E-05 0.00E+00 SB-126 8.06E-06 1.58E-07 2.91E-06 6.19E-08 0.00E+00 5.07E-06 8.35E-05 0.00E+00 SB-127 2.23E-06 3.98E-08 6.90E-07 2.84E-08 0.00E+00 1.15E-06 5.91E-05 0.00E+00 TE-125m 2.33E-05 7.79E-06 3.15E-06 7.84E-06 0.00E+00 0.00E+00 1.11E-05 O.00E+00 TE-127m 5.85E-05 1.94E-05 7.08E-06 1.69E-05 1.44E-04 0.00E+00 2.36E-05 0.OOE+00 TE-127 1.00E-06 3.35E-07 2.15E-07 8.14E-07 2.44E-06 0.00E+00 2.10E-05 0.00E+00 TE-1 29m 1.00E-04 3.43E-05 1.54E-05 3.84E-05 2.50E-04 O.00E+00 5.97E-05 0.00E+00 TE-129 2.84E-07 9.79E-08 6.63E-08 2.38E-07 7.07E-07 0.OOE+00 2.27E-05 0.OOE+00 TE-133m 3.91E-07 1.79E-07 1.71E-07 3.45E-07 1.22E-06 0.00E+00 1.93E-05 0.OOE+00 TE-134 2.67E-07 1.34E-07 1.38E-07 2.39E-07 9.03E-07 0.00E+00 3.06E-06 0.OOE+00 1-129 2.86E-05 2.12E-05 1.55E-05 1.36E-02 2.51E-05 0.00E+00 4.24E-07 0.00E+00 1-130 6.00E-06 1.32E-05 5.30E-06 1.48E-03 1.45E-05 0.00E+00 2.83E-06 0.OOE+00 1-131 3.59E-05 4.23E-05 1.86E-05 1.39E-02 4.94E-05 0.00E+00 1.51 E-06 0.00E+00 TE-131m 1.52E-05 6.12E-06 5.05E-06 1.24E-05 4.21E-05 0.00E+00 1.03E-04 O.00E+00 TE-131 1.76E-07 6.50E-08 4.94E-08 1.57E-07 4.50E-07 0.OOE+00 7.11E-06 0.00E+00

CY-LG-170-301, Rev. 23 Page 131 08/07 TABLE 111-5 (Continued)

INGESTION DOSE FACTORS FOR INFANT (Daipj) mrem/pCi Reg. Guide 1.109 Table E-11 to E-14 and NUREG/CR - 1276 Append C Table 6 to Table 9 NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG GI-LLI SKIN 1-132 1.66E-06 3.37E-06 1.20E-06 1.58E-04 3.76E-06 0.OOE+00 2.73E-06 0.OOE+00 TE-132 2.08E-05 1.03E-05 9.61E-06 1.52E-05 6.44E-05 0.OOE+00 3.81E-05 O.OOE+00 1-133 1.25E-05 1.82E-05 5.33E-06 3.31E-03 2.14E-05 0.OOE+00 3.08E-06 0.OOE+00 CS-134m 1.76E-07 2.93E-07 1.48E-07 0.OOE+00 1.13E-07 2.60E-08 2.32E-07 0.OOE+00 CS-134 3.77E-04 7.03E-04 7.10E-05 O.OOE+00 1.81E-04 7.42E-05 1.91E-06 0.OOE+00 1-134 8.69E-07 1.78E-06 6.33E-07 4.15E-05 1.99E-06 0.OOE+00 1.84E-06 0.OOE+00 1-135 3.64E-06 7.24E-06 2.64E-06 6.49E-04 8.07E-06 0.OOE+00 2.62E-06 0.OOE+00 CS-135 1.33E-04 1.21E-04 6.30E-06 0.OOE+00 3.44E-05 1.31E-05 4.37E-07 0.OOE+00 CS-136 4.59E-05 1.35E-04 5.04E-05 0.OOE+00 5.38E-05 1.1OE-05 2.05E-06 0.OOE+00 CS-137 5.22E-04 6.11E-04 4.33E-05 0.OOE+00 1.64E-04 6.64E-05 1.91E-06 0.OOE+00 CS-138 4.81E-07 7.82E-07 3.79E-07 0.OOE+00 3.90E-07 6.09E-08 1.25E-06 0.OOE+00 CS-139 3.1OE-07 4.24E-07 1.62E-07 O.OOE+00 2.19E-07 3.30E-08 2.66E-08 0.OOE+00 BA-139 8.81E-07 5.84E-10 2.55E-08 0.OOE+00 3.51E-10 3.54E-10 5.58E-05 O.OOE+00 BA-140 1.71E-04 1.71E-07 8.81E-06 0.OOE+00 4.06E-08 1.05E-07 4.20E-05 O.OOE+00 LA-140 2.11 E-08 8.32E-09 2.14E-09 0.OOE+00 0.OOE+00 0.OOE+00 9.77E-05 0.OOE+00 BA-141 4.25E-07 2.91E-10 1.34E-08 0.OOE+00 1.75E-10 1.77E-10 5.19E-06 0.OOE+00 LA-141 2.89E-09 8.38E-10 1.46E-10 0.OOE+00 0.OOE+00 0.OOE+00 9.61E-05 0.OOE+00 CE-141 7.87E-08 4.80E-08 5.65E-09 0.OOE+00 1.48E-08 0.OOE+00 2.48E-05 0.OOE+00 BA-142 1.84E-07 1.53E-10 9.06E-09 0.OOE+00 8.81E-11 9.26E-11 7.59E-07 0.OOE+00 LA-142 1.1OE-09 4.04E-10 9.67E-11 0.OOE+00 0.OOE+00 O.OOE+00 6.86E-05 0.OOE+00 CE-143 1.48E-08 9.82E-06 1.12E-09 0.OOE+00 2.86E-09 0.OOE+00 5.73E-05 O.OOE+00 PR-143 8.13E-08 3.04E-08 4.03E-09 O.OOE+00 1.13E-08 0.OOE+00 4.29E-05 0.OOE+00 CE-144 2.98E-06 1.22E-06 1.67E-07 0.OOE+00 4.93E-07 0.OOE+00 1.71E-04 0.OOE+00 PR-144 2.74E-10 1.06E-10 1.38E-11 0.OOE+00 3.84E-11 O.OOE+00 4.93E-06 0.OOE+00 ND-147 5.53E-08 5.68E-08 3.48E-09 0.OOE+00 2.19E-08 0.OOE+00 3.60E-05 0.OOE+00 PM-147 3.88E-07 3.27E-08 1.59E-08 0.OOE+00 4.88E-08 0.OOE+00 9.27E-06 0.OOE+00 PM-148m 1.65E-07 4.18E-08 3.28E-08 0.OOE+00 4.80E-08 0.OOE+00 5.44E-05 0.OOE+00 PM-148 6.32E-08 9.13E-09 4.60E-09 0.OOE+00 1.09E-08 0.OOE+00 9.74E-05 0.OOE+00 PM-149 1.38E-08 1.81E-09 7.90E-10 0.OOE+00 2.20E-09 0.OOE+00 4.86E-05 0.OOE+00 PM-151 6.18E-09 9.01E-10 4.56E-10 0.OOE+00 1.07E-09 0.OOE+00 4.17E-05 0.OOE+00 SM-151 2.90E-07 6.67E-08 1.44E-08 O.OOE+00 4.53E-08 0.OOE+00 5.58E-06 O.OOE+00 SM-153 7.72E-09 5.97E-09 4.58E-10 0.OOE+00 1.25E-09 0.OOE+00 3.12E-05 0.OOE+00 EU-152 6.74E-07 1.79E-07 1.51E-07 0.OOE+00 5.02E-07 0.OOE+00 1.59E-05 0.OOE+00 EU-154 2.64E-06 3.67E-07 2.20E-07 0.OOE+00 9.95E-07 0.OOE+00 4.58E-05 O.OOE+00 EU-155 5.42E-07 6.25E-08 3.23E-08 0.OOE+00 1.40E-07 0.OOE+00 8.37E-05 0.OOE+00 EU-156 1.14E-07 7.06E-08 1.12E-08 0.OOE+00 3.26E-08 0.OOE+00 6.67E-05 0.OOE+00 TB-160 2.59E-07 0.OOE+00 3.24E-08 0.OOE+00 7.37E-08 0.OOE+00 3.45E-05 0.OOE+00 HO-166m 1.25E-06 2.69E-07 2.13E-07 0.OOE+00 3.57E-07 0.OOE+00 1.OOE-24 0.OOE+00 W-181 8.85E-08 2.72E-08 3.04E-09 0.OOE+00 O.OOE+00 0.OOE+00 3.82E-07 0.OOE+00 W-185 3.62E-06 1.13E-06 1.29E-07 0.OOE+00 0.OOE+00 0.OOE+00 1.62E-05 O.OOE+00 W-187 9.03E-07 6.28E-07 2.17E-07 0.OOE+00 0.OOE+00 0.OOE+00 3.69E-05 0.OOE+00

CY-LG-170-301, Rev. 23 Page 132 08/07 TABLE 111-5 (Continued)

INGESTION DOSE FACTORS FOR INFANT (Daipj) mrem/pCi Reg. Guide 1.109 Table E-11 to E-14 and NUREG/CR - 1276 Append C Table 6 to Table 9 NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG GI-LLI SKIN U-232 2.42E-02 0.OOE+00 2.16E-03 0.00E+00 2.37E-03 0.OOE+00 7.04E-05 0.OOE+00 U-233 5.08E-03 0.OOE+00 3.87E-04 0.OOE+00 1.08E-03 0.OOE+00 6.51 E-05 0.OOE+00 U-234 4.88E-03 0.OOE+00 3.80E-04 0.OOE+00 1.06E-03 0.OOE+00 6.37E-05 0.OOE+00 U-235 4.67E-03 0.OOE+00 3.56E-04 0.OOE+00 9.93E-04 0.00E+00 8.10E-05 0.OOE+00 U-236 4.67E-03 0.OOE+00 3.64E-04 0.00E+00 1.01 E-03 0.OOE+00 5.98E-05 O.00E+00 U-237 4.95E-07 0.OOE+00 1.32E-07 0.00E+00 1.23E-06 0.00E+00 2.11E-05 0.OOE+00 U-238 4.47E-03 0.OOE+00 3.33E-04 0.00E+00 9.28E-04 0.00E+00 5.71 E-05 0.00E+00 NP-237 2.40E-03 1.59E-04 1.05E-04 0.00E+00 6.34E-04 0.00E+00 8.23E-05 0.OOE+00 NP-238 1.24E-07 3.12E-09 1.92E-09 0.OOE+00 6.81E-09 0.OOE+00 4.17E-05 0.OOE+00 NP-239 1.11E-08 9.93E-10 5.61E-10 0.OOE+00 1.98E-09 0.OOE+00 2.87E-05 0.00E+00 PU-238 1.28E-03 1.50E-04 3.40E-05 0.OOE+00 1.21 E-04 0.OOE+00 7.57E-05 0.00E+00 PU-239 1.38E-03 1.55E-04 3.54E-05 0.00E+00 1.28E-04 0.OOE+00 6.91E-05 0.00E+00 PU-240 1.38E-03 1.55E-04 3.54E-05 0.OOE+00 1.28E-04 0.00E+00 7.04E-05 0.00E+00 PU-241 4.25E-05 1.76E-06 8.82E-07 0.OOE+00 3.17E-06 0.00E+00 1.45E-06 0.00E+00 PU-242 1.28E-03 1.49E-04 3.41 E-05 0.00E+00 1.23E-04 O.OOE+00 6.77E-05 0.00E+00 PU-244 1.49E-03 1.71E-04 3.91E-05 0.00E+00 1.41E-04 0.OOE+00 1.01E-04 0.OOE+00 AM-241 1.46E-03 1.27E-03 1.09E-04 0.OOE+00 6.55E-04 0.00E+00 7.70E-05 0.00E+00 AM-242m 1.51E-03 1.22E-03 1.13E-04 0.OOE+00 6.64E-04 0.OOE+00 9.69E-05 0.00E+00 AM-243 1.44E-03 1.23E-03 1.06E-04 0.OOE+00 6.36E-04 O.OOE+00 9.03E-05 0.00E+00 CM-242 1.37E-04 1.27E-04 9.1OE-06 0.OOE+00 2.62E-05 0.OOE+00 8.23E-05 0.OOE+00 CM-243 1.40E-03 1.15E-03 8.98E-05 0.OOE+00 3.27E-04 0.OOE+00 8.10E-05 0.00E+00 CM-244 1.18E-03 9.70E-04 7.59E-05 0.OOE+00 2.71E-04 0.00E+00 7.84E-05 0.OOE+00 CM-245 1.79E-03 1.45E-03 1.13E-04 0.OOE+00 4.32E-04 0.OOE+00 7.30E-05 0.OOE+00 CM-246 1.77E-03 1.45E-03 1.13E-04 0.OOE+00 4.31E-04 0.OOE+00 7.17E-05 0.OOE+00 CM-247 1.73E-03 1.43E-03 1.11E-04 0.00E+00 4.24E-04 0.00E+00 9.43E-05 0.OOE+00 CM-248 1.43E-02 1.18E-02 9.16E-04 0.00E+00 3.50E-03 0.00E+00 1.52E-03 0.00E+00 CF-252 1.22E-03 0.OOE+00 2.95E-05 0.OOE+00 0.00E+00 0.OOE+00 2.99E-04 0.00E+00

CY-LG-170-301, Rev. 23 Page 133 08/07 TABLE 111-6 EXTERNAL DOSE FACTORS FOR STANDING ON CONTAMINATED GROUND (mrem/hr per pCi/m 2 )

Reg. Guide 1.109 Table E-6 and NUREG/CR - 1276 Append C Table 1 NUCLIDE BONE LIVER THYROID KIDNEY LUNG GI-LLI SKIN T BODY H-3 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 C-14 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 NA-22 1.60E-08 1.60E-08 1.60E-08 1.60E-08 1.60E-08 1.60E-08 1.80E-08 1.60E-08 NA-24 2.50E-08 2.50E-08 2.50E-08 2.50E-08 2.50E-08 2.50E-08 2.90E-08 2.50E-08 P-32 0.OOE+00 0.OOE+00 0.00E+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 CA-41 3.41E-09 3.41E-09 3.41E-09 3.41E-09 3.41E-09 3.41E-09 4.01E-09 3.41E-09 SC-46 1.30E-08 1.30E-08 1.30E-08 1.30E-08 1.30E-08 1.30E-08 1.50E-08 1.30E-08 CR-51 2.20E-10 2.20E-10 2.20E-10 2.20E-10 2.20E-10 2.20E-10 2.60E-10 2.20E-10 MN-54 5.80E-09 5.80E-09 5.80E-09 5.80E-09 5.80E-09 5.80E-09 6.80E-09 5.80E-09 FE-55 0.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 MN-56 1.10E-08 1.10E-08 1.10E-08 1.10E-08 1.10E-08 1. i OE-08 1.30E-08 1.10E-08 CO-57 9.10E-10 9.10E-10 9.10E-10 9.10E-10 9.10E-10 9.10E-10 1.O0E-09 9.10E-10 CO-58 7.OOE-09 7.OOE-09 7.OOE-09 7.OOE-09 7.OOE-09 7.OOE-09 8.20E-09 7.OOE-09 FE-59 8.0OE-09 8.OOE-09 8.OOE-09 8.OOE-09 8.OOE-09 8.OOE-09 9.40E-09 8.OOE-09 CO-60 1.70E-08 1.70E-08 1.70E-08 1.70E-08 1.70E-08 1.70E-08 2.OOE-08 1.70E-08 NI-59 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 NI-63 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0OOE+00 CU-64 1.50E-09 1.50E-09 1.50E-09 1.50E-09 1.50E-09 1.50E-09 1.70E-09 1.50E-09 NI-65 3.70E-09 3.70E-09 3.70E-09 3.70E-09 3.70E-09 3.70E-09 4.30E-09 3.70E-09 ZN-65 4.OOE-09 4.OOE-09 4.OOE-09 4.OOE-09 4.OOE-09 4.OOE-09 4.60E-09 4.OOE-09 ZN-69m 2.90E-09 2.90E-09 2.90E-09 2.90E-09 2.90E-09 2.90E-09 3.40E-09 2.90E-09 ZN-69 0.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 SE-79 0.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 BR-82 1.90E-08 1.90E-08 1.90E-08 1.90E-08 1.90E-08 1.90E-08 2.20E-08 1.90E-08 BR-83 6.40E- 11 6.40E- 11 6.40E-1 1 6.40E- 11 6.40E-1 1 6.40E-1 1 9.30E-1 1 6.40E-1 1 BR-84 1.20E-08 1.20E-08 1.20E-08 1.20E-08 1.20E-08 1.20E-08 1.40E-08 1.20E-08 BR-85 0.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 RB-86 6.30E-10 6.30E-10 6.30E-10 6.30E-10 6.30E-10 6.30E-10 7.20E-10 6.30E-10 RB-87 O.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.O0E+00 O.OOE+00 RB-88 3.50E-09 3.50E-09 3.50E-09 3.50E-09 3.50E-09 3.50E-09 4.O0E-09 3.50E-09 RB-89 1.50E-08 1.50E-08 1.50E-08 1.50E-08 1.50E-08 1.50E-08 1.80E-08 1.50E-08 SR-89 5.60E-13 5.60E-13 5.60E-13 5.60E-13 5.60E-13 5.60E-13 6.50E-13 5.60E-13 SR-90 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 O.OOE+00 0.OE+00 Y-90 2.20E-12 2.20E-12 2.20E-12 2.20E-12 2.20E-12 2.20E-12 2.60E-12 2.20E-12 SR-91 7.1OE-09 7.10E-09 7.10E-09 7.10E-09 7.1OE-09 7.1OE-09 8.30E-09 7.10E-09 Y-91m 3.80E-09 3.80E-09 3.80E-09 3.80E-09 3.80E-09 3.80E-09 4.40E-09 3.80E-09 Y-91 2.40E-1 1 2.40E-1 1 .2.40E-1 1 2.40E-1 1 2.40E-1 1 2.40E-1 1 2.70E-1 1 2.40E-1 1 SR-92 9.OOE-09 9.OOE-09 9.OOE-09 9.OOE-09 9.OOE-09 9.OOE-09 1.OOE-08 9.00E-09 Y-92 1.60E-09 1.60E-09 1.60E-09 1.60E-09 1.60E-09 1.60E-09 1.90E-09 1.60E-09 Y-93 5.70E-10 5.70E-10 5.70E-10 5.70E-10 5.70E-10 5.70E-10 7.80E-10 5.70E-10 NB-93m 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00

CY-LG-170-301, Rev. 23 Page 134 08/07 TABLE 111-6 (Continued)

EXTERNAL DOSE FACTORS FOR STANDING ON CONTAMINATED GROUND (mrem/hr per pCi/m2)

Reg. Guide 1.109 Table E-6 and NUREG/CR - 1276 Append C Table 1 NUCLIDE BONE LIVER THYROID KIDNEY LUNG GI-LLI SKIN T BODY NB-95 5.1OE-09 5.10E-09 5.10E-09 5.1OE-09 5.1OE-09 5.10E-09 6.OOE-09 5.10E-09 NB-97 5.40E-09 5.40E-09 5.40E-09 5.40E-09 5.40E-09 5.40E-09 4.60E-09 5.40E-09 ZR-93 0.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 O.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 ZR-95 5.OOE-09 5.OOE-09 5.OOE-09 5.OOE-09 5.OOE-09 5.OOE-09 5.80E-09 5.OOE-09 ZR-97 5.50E-09 5.50E-09 5.50E-09 5.50E-09 5.50E-09 5.50E-09 6.40E-09 5.50E-09 MO-93 2.29E-11 2.29E-11 2.29E-11 2.29E-11 2.29E-11 2.29E-11 9.32E-10 2.29E-11 MO-99 1.90E-09 1.90E-09 1.90E-09 1.90E-09 1.90E-09 1.90E-09 2.20E-09 1.90E-09 TC-99 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 O.OOE+00 TC-99m 9.60E-10 9.60E-10 9.60E-10 9.60E-10 9.60E-10 9.60E-10 1.1OE-09 9.60E-10 TC-101 2.70E-09 2.70E-09 2.70E-09 2.70E-09 2.70E-09 2.70E-09 3.OOE-09 2.70E-09 RU-103 3.60E-09 3.60E-09 3.60E-09 3.60E-09 3.60E-09 3.60E-09 4.20E-09 3.60E-09 RU-105 4.50E-09 4.50E-09 4.50E-09 4.50E-09 4.50E-09 4.50E-09 5.1OE-09 4.50E-09 RU-106 1.50E-09 1.50E-09 1.50E-09 1.50E-09 1.50E-09 1.50E-09 1.80E-09 1.50E-09 RH-105 6.60E-10 6.60E-10 6.60E-10 6.60E-10 6.60E-10 6.60E-10 7.70E-10 6.60E-10 PD-107 0.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 PD-109 3.50E-11 3.50E- 11 3.50E-11 3.50E-11 3.50E-11 3.50E-11 4.OOE-11 3.50E-11 AG-110m 1.50E-08 1.50E-08 1.50E-08 1.50E-08 1.50E-08 1.50E-08 2.1OE-08 1.50E-08 AG-111 1.80E-10 1.80E-10 1.80E-10 1.80E-10 1.80E-10 1.80E-10 2.10E-10 1.80E-10 CD-113m 2.30E-12 2.30E-12 2.30E-12 2.30E-12 2.30E-12 2.30E-12 2.60E-12 2.30E-12 CD-115m 0.0OE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 SN-123 0.0OE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 6.46E-08 0.O0E+00 SN-125' 5.70E-10 5.70E-10 5.70E-10 5.70E-10 5.70E-10 5.70E-10 6.60E-10 5.70E-10 SN-126 9.OOE-09 9.OOE-09 9.OOE-09 9.OOE-09 9.OOE-09 9.OOE-09 1.OOE-08 9.OOE-09 SB-124 1.30E-08 1.30E-08 1.30E-08 1.30E-08 1.30E-08 1.30E-08 1.50E-08 1.30E-08 SB-125 3.10E-09 3.10E-09 3.1OE-09 3.10E-09 3.1OE-09 3.1OE-09 3.50E-09 3.10E-09 SB-126 8.90E-09 8.90E-09 8.90E-09 8.90E-09 8.90E-09 8.90E-09 1.OOE-08 8.90E-09 SB-127 5.70E-09 5.70E-09 5.70E-09 5.70E-09 5.70E-09 5.70E-09 6.60E-09 5.70E-09 TE-125m 3.50E- 11 3.50E-11 3.50E-11 3.50E-11 3.50E-11 3.50E-1 1 4.80E-11 3.50E-11 TE-127m 1.10E-12 1.10E-12 1.10E-12 1.10E-12 1.10E-12 1.10E-12 1.30E-12 1.10E-12 TE-127 1.OOE-11 1.OOE-11 1.OOE-11 1.OOE-11 1.OOE-11 1.OOE-11 1.10E-11 1.OOE-11 TE-129m 7.70E-10 7.70E-10 7.70E-10 7.70E-10 7.70E-10 7.70E-10 9.OOE-10 7.70E-10 TE-129 7.10E-10 7.10E-10 7.10E-10 7.10E-10 7.10E-10 7.10E-10 8.40E-10 7.10E-10 TE-133m 1.50E-08 1.50E-08 1.50E-08 1.50E-08 1.50E-08 1.50E-08 1.70E-08 1.50E-08 TE-134 1.00E-m09 1.OOE-09 1.OOE-09 1.OOE-09 1.OOE-09 1.OOE-09 1.20E-09 1.OOE-09 1-129 4.50E-10 4.50E-10 4.50E-10 4.50E-10 4.50E-10 4.50E-10 7.50E-10 4.50E-10 1-130 1.40E-08 1.40E-08 1.40E-08 1.40E-08 1.40E-08 1.40E-08 1.70E-08 1.40E-08 1-131 2.80E-09 2.80E-09 2.80E-09 2.80E-09 2.80E-09 2.80E-09 3.40E-09 2.80E-09 TE-1 31 m 8.40E-09 8.40E-09 8.40E-09 8.40E-09 8.40E-09 8.40E-09 9.90E-09 8.40E-09 TE-131 2.20E-09 2.20E-09 2.20E-09 2.20E-09 2.20E-09 2.20E-09 2.60E-06 2.20E-09 1-132 1.70E-08 1.70E-08 1.70E-08 1.70E-08 1.70E-08 1.70E-08 2.OOE-08 1.70E-08 TE-132 1.70E-09 1.70E-09 1.70E-09 1.70E-09 1.70E-09 1.70E-09 2.OOE-09 1.70E-09

CY-LG-170-301, Rev. 23 Page 135 08/07 TABLE 111-6 (Continued)

EXTERNAL DOSE FACTORS FOR STANDING ON CONTAMINATED GROUND (mrem/hr per pCi/m2)

Reg. Guide 1.109 Table E-6 and NUREG/CR - 1276 Append C Table 1 NUCLIDE BONE LIVER THYROID KIDNEY LUNG GI-LLI SKIN T BODY 1-133 3.70E-09 3.70E-09 3.70E-09 3.70E-09 3.70E-09 3.70E-09 4.50E-09 3.70E-09 CS-134m 5.20E-10 5.20E-10 5.20E-10 5.20E-10 5.20E-10 5.20E-10 7.30E-10 5.20E-10 CS-1 34 1.20E-08 1.20E-08 1.20E-08 1.20E-08 1.20E-08 1.20E-08 1.40E-08 1.20E-08 1-134 1.60E-08 1.60E-08 1.60E-08 1.60E-08 1.60E-08 1.60E-08 1.90E-08 1.60E-08 1-135 1.20E-08 1.20E-08 1.20E-08 1.20E-08 1.20E-08 1.20E-08 1.40E-08 1.20E-08 CS-135 1.50E-08 1.50E-08 1.50E-08 1.50E-08 1.50E-08 1.50E-08 1.70E-08 1.50E-08 CS-136 1.50E-08 1.50E-08 1.50E-08 1.50E-08 1.50E-08 1.50E-08 1.70E-08 1.50E-08 CS-137 4.20E-09 4.20E-09 4.20E-09 4.20E-09 4.20E-09 4.20E-09 4.90E-09 4.20E-09 CS-138 2.1OE-08 2.10E-08 2.10E-08 2.10E-08 2.10E-08 2.1OE-08 2.40E-08 2.10E-08 CS-139 6.30E-09 6.30E-09 6.30E-09 6.30E-09 6.30E-09 6.30E-09 7.20E-09 6.30E-09 BA-139 2.40E-09 2.40E-09 2.40E-09 2.40E-09 2.40E-09 2.40E-09 2.70E-09 2.40E-09 BA-140 2.10E-09 2.10E-09 2.10E-09 -2.10E-09 2.10E-09 2.1OE-09 2.40E-09 2.10E-09 LA-140 1.50E-08 1.50E-08 1.50E-08 1.50E-08 1.50E-08 1.50E-08 1.70E-08 1.50E-08 BA-141 4.30E-09 4.30E-09 4.30E-09 4.30E-09 4.30E-09 4.30E-09 4.90E-09 4.30E-09 LA-141 2.50E-10 2.50E-10 2.50E-10 2.50E-10 2.50E-10 2.50E-10 2.80E-10 2.50E-10 CE-141 5.50E-10 5.50E-10 5.50E-10 5.50E-10 5.50E-10 5.50E-10 6.20E-10 5.50E-10 BA-142 7.90E-09 7.90E-09 7.90E-09 7.90E-09 7.90E-09 7.90E-09 9.OOE-09 7.90E-09 LA-142 1.50E-08 1.50E-08 1.50E-08 1.50E-08 1.50E-08 1.50E-08 1.80E-08 1.50E-08 CE-143 2.20E-09 2.20E-09 2.20E-09 2.20E-09 2.20E-09 2.20E-09 2.50E-09 2.20E-09 PR-143 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 CE-144 3.20E-10 3.20E-10 3.20E-10 3.20E-10 3.20E-10 3.20E-10 3.70E-10 3.20E-10 PR-144 2.OOE-10 2.OOE-10 2.OOE-10 2.OOE-10 2.OOE-10 2.OOE-10 2.30E-10 2.OOE-10 ND-147 1.OOE-09 1.OOE-09 1.OOE-09 1.OOE-09 1.OOE-09 1.OOE-09 1.20E-09 1.OOE-09 PM-147 0.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 PM-148m 1.41E-08 1.41E-08 1.41E-08 1.41E-08 1.41E-08 1.41E-08 8.16E-08 1.41E-08 PM-148 4.60E-09 4.60E-09 4.60E-09 4.60E-09 4.60E-09 4.60E-09 5.30E-09 4.60E-09 PM-149 2.50E-11 2.50E-11 2.50E-11 2.50E-11 2.50E-11 2.50E-11 2.90E-11 2.50E-11 PM-151 2.20E-09 2.20E-09 2.20E-09 2.20E-09 2.20E-09 2.20E-09 2.30E-09 2.20E-09 SM-151 4.80E-11 4.80E-11 4.80E-11 4.80E-11 4.80E-11 4.80E-11 2.10E-10 4.80E-11 SM-153 2.70E-10 2.70E-10 2.70E-10 2.70E-10 2.70E-10 2.70E-10 3.OOE-10 2.70E-10 EU-152 7.37E-09 7.37E-09 7.37E-09 7.37E-09 7.37E-09 7.37E-09 8.53E-09 7.37E-09 EU-154 7.80E-09 7.80E-09 7.80E-09 7.80E-09 7.80E-09 7.80E-09 9.OOE-09 7.80E-09 EU-155 3.81E-10 3.81E-10 3.81E-10 3.81E-10 3.81E-10 3.81E-10 4.33E-10 3.81E-10 EU-156 7.60E-09 7.60E-09 7.60E-09 7.60E-09 7.60E-09 7.60E-09 8.70E-09 7.60E-09 TB-160 8.60E-09 8.60E-09 8.60E-09 8.60E-09 8.60E-09 8.60E-09 1.OOE-08 8.60E-09 HO-166m 8.90E-09 8.90E-09 8.90E-09 8.90E-09 8.90E-09 8.90E-09 1.OOE-08 8.90E-09 W-181 2.10E-12 2.10E-12 2.10E-12 2.10E-12 2.10E-12 2.10E-12 2.30E-12 2.10E-12 W-185 0.OOE+00 O.OOE+00 O.OOE+00 0.OOE+00 0.O0E+00 0.OOE+00 O.OOE+00 0.OOE+00 W-187 3.10E-09 3.10E-09 3.1OE-09 3.1OE-09 3.10E-09 3.1OE-09 3.60E-09 3.10E-09

CY-LG-170-301, Rev. 23 Page 136 08/07 TABLE 111-6 (Continued)

EXTERNAL DOSE FACTORS FOR STANDING ON CONTAMINATED GROUND (mrem/hr per pCi/m2)

Reg. Guide 1.109 Table E-6 and NUREG/CR - 1276 Append C Table 1 NUCLIDE BONE LIVER THYROID KIDNEY LUNG GI-LLI SKIN T BODY U-232 2.59E-12 2.59E-12 2.59E-12 2.59E-12 2.59E-12 2.59E-12 2.69E-11 2.59E-12 U-233 2.30E-09 2.30E-09 2.30E-09 2.30E-09 2.30E-09 2.30E-09 2.80E-09 2.30E-09 U-234 6.32E-13 6.32E-13 6.32E-13 6.32E-13 6.32E-13 6.32E-13 1.59E-10 6.32E-13 U-235 3.20E-09 3.20E-09 3.20E-09 3.20E-09 3.20E-09 3.20E-09 4.OOE-09 3.20E-09 U-236 2.10E-14 2.10E-14 2.10E-14 2.10E-14 2.10E-14 2.10E-14 1.80E-11 2.10E-14 U-237 1.OOE-09 1.OOE-09 1.OOE-09 1.OOE-09 1.OOE-09 1.0OE-09 1.30E-09 1.OOE-09 U-238 1.10E-10 1.10E-10 1.10E-10 1.10E-10 1.10E-10 1.10E-10 1.50E-10 1.10E-10 NP-237 1.40E-09 1.40E-09 1.40E-09 1.40E-09 1.40E-09 1.40E-09 1.60E-09 1.40E-09 NP-238 2.80E-09 2.80E-09 2.80E-09 2.80E-09 2.80E-09 2.80E-09 3.20E-09 2.80E-09 NP-239 9.50E-10 9.50E-10 9.50E-10 9.50E-10 9.50E-10 9.50E-10 1.1OE-09 9.50E-10 PU-238 1.30E-12 1.30E-12 1.30E-12 1.30E-12 1.30E-12 1.30E-12 1.80E-11 1.30E-12 PU-239 7.90E-13 7.90E-13 7.90E-13 7.90E-13 7.90E-13 7.90E-13 7.70E-12 7.90E-13 PU-240 1.30E-12 1.30E-12 1.30E-12 1.30E-12 1.30E-12 1.30E-12 1.80E-11 1.30E-12 PU-241 4.60E-12 4.60E-12 4.60E-12 4.60E-12 4.60E-12 4.60E-12 6.80E-12 4.60E-12 PU-242 1.10E-12 1.10E-12 1.10E-12 1.10E-12 1.10E-12 1.10E-12 1.60E-11 1.10E-12 PU-244 8.95E-10 8.95E-10 8.95E-10 8.95E-10 8.95E-10 8.95E-10 9.62E-10 8.95E-10 AM-241 1.80E-10 1.80E-10 1.80E-10 1.80E-10 1.80E-10 1.80E-10 2.60E-10 1.80E-10 AM-242M 2.60E-11 2.60E-11 2.60E-11 2.60E-11 2.60E-11 2.60E-11 1.80E-10 2.60E-11 AM-243 1.30E-09 1.30E-09 1.30E-09 1.30E-09 1.30E-09 1.30E-09 1.50E-09 1.30E-09 CM-242 5.50E-12 5.50E-12 5.50E-12 5.50E-12 5.50E-12 5.50E-12 2.30E-11 5.50E-12 CM-243 2.30E-09 2.30E-09 2.30E-09 2.30E-09 2.30E-09 2.30E-09 2.90E-09 2.30E-09 CM-244 2.90E-12 2.90E-12 2.90E-12 2.90E-12 2.90E-12 2.90E-12 1.80E-11 2.90E-12 CM-245 9.50E-10 9.50E-10 9.50E-10 9.50E-10 9.50E-10 9.50E-10 1.20E-09 9.50E-10 CM-246 1.OOE-12 1.OOE-12 1.OOE-12 1.OOE-12 1.OOE-12 1.OOE-12 1.50E-11 1.OOE-12 CM-247 2.20E-09 2.20E-09 2.20E-09 2.20E-09 2.20E-09 2.20E-09 2.60E-09 2.20E-09 CM-248 6.81E-09 6.81E-09 6.81E-09 6.81E-09 6.81E-09 6.81E-09 5.23E-09 6.81E-09 CF-252 6.60E-08 6.60E-08 6.60E-08 6.60E-08 6.60E-08 6.60E-08 7.20E-08 6.60E-08 I

CY-LG-170-301, Rev. 23 Page 137 08/07 TABLE 111-7 Usage Factors (Uap)

Pathway Infant Child Teen Adult Fish (kg/yr) -_6.9a 16a 21a Potable Water (l/yr) 330a 510a 510a 730a Shoreline Recreation (hr/yr) 90b 600b 6 00b Ref: ab Regulatory Guide 1.109, Rev 1, Table E-5 b EROL Table 5.2.A-3

CY-LG-170-301, Rev. 23 I Page 138 08/07I TABLE 111-8 Assumptions used in Limerick Liquid Effluent Dose Evaluation Symbol Description Value Reference(1) tb Period of buildup of activity in sediment(hr) 1.752E+05 Site(2)

Specific tp Envtl transit time for water ingestion (hr) 1.200E+01 A-2 A-3 (2) tp Envtl transit time for fish ingestion (hr) 2.400E+01 tp Envtl transit time for shore exposure (hr) O.OOOE+00 Site Specific Uap Water ingestion (l/yr) adult 7.300E+02 E-5 Uap Water ingestion (l/yr) teen 5.100E+02 E-5 Uap Water ingestion (l/yr) child 5.1 OOE+02 E-5 Uap Water ingestion (l/yr) infant 3.300E+02 E-5 Uap Shore exposure (hr/yr) adult 6.OOOE+02 Site Specific Uap Shore exposure (hr/yr) teen 6.OOOE+02 Site Specific Shore exposure (hr/yr) child 9.OOOE+01 Site Specific Uap Shore exposure (hr/yr) infant O.OOOE+00 Site Specific Uap Fresh water fish ingestion (kg/yr) adult 2.100E+01 E-5 Uap Fresh water fish ingestion (kg/yr) teen 1.600E+01 E-5 Uap Fresh water fish ingestion (kg/yr) child 6.900E+00 E-5 Map Fresh water fish ingestion (kg/yr) infant O.OOOE+00 E-5 W Shoreline Width Factor (dimensionless) 2.OOOE-01 A-2(3)

1) The References refer to tables contained in Regulatory Guide 1.109 unless otherwise specified.

2) Equation A-2 and A-3 from Reg. Guide 1.109, Appendix A.

3) Table A-2 from Reg. Guide 1.109, Appendix A.

CY-LG-1 70-301, Rev. 23 Page 139 08/07 TABLE 112-1 Dose Factors for Noble Gas From Table B-1 of Reg. Guide 1.109 Radionuclide Total Body Dose Beta Skin Dose Gamma Air Beta Air Dose Factor Ki Factor Li Dose Factor Mi Factor Ni (mrem/yr per (mrem/yr per (mrad/yr per (mrad/yr per pCi/m3) pCi/m 3 ) pCi/m 3 ) pCi/m3)

Ar-41 8.84E-03 2.69E-03 9.30E-03 3.28E-03 Kr-83m 7.56E-08 1.93E-05 2.88E-04 Kr-85m 1.17E-03 1.46E-03 1.23E-03 1.97E-03 Kr-85 1.61E-05 1.34E-03 1.72E-05 1.95E-03 Kr-87 5.92E-03 9.73E-03 6.17E-03 1.03E-02 Kr-88 1.47E-02 2.37E-03 1.52E-02 2.93E-03 Kr-89 1.66E-02 1.01 E-02 1.73E-02 1.06E-02 Kr-90 1.56E-02 7.29E-03 1.63E-02 7.83E-03 Xe-1 31m 9.15E-05 4.76E-04 1.56E-04 1.11E-03 Xe-1 33m 2.51 E-04 9.94E-04 3.27E-04 1.48E-03 Xe-1 33 2.94E-04 3.06E-04 3.53E-04 1.05E-03 Xe-1 35m 3.12E-03 7.11 E-04 3.36E-03 7.39E-04 Xe-135 1.81 E-03 1.86E-03 1.92E-03 2.46E-03 Xe-137 1.42E-03 1.22E-02 1.51E-03 1.27E-02 Xe-138 8.83E-03 4.13E-03 9.21E-03 4.75E-03

CY-LG-1 70-301, Rev. 23 Page 140 08/07 TABLE 112-2 INGESTION INDIVIDUAL DOSE FACTORS (Ri)

For Gaseous Effluents UNITS FOR DEPOSITION PATHWAYS (Pathway Numbers 1 to 5) are m2 -mrem/yr per gCi/sec UNITS FOR AIRBORNE PATHWAY 3 (Pathway Numbers 6) is mrem/yr per gCi/m Pathway No. Patihwa 1 Ground 2 Vegetable 3 Meat 4 Cow Milk 5 Goat Milk 6 Inhalation

CY-LG-170-301, Rev. 23 I Page 141 08/071 TABLE 112-2 Ri DOSE FACTORS Age: Adult Pathway: Ground NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG GI-LLI SKIN H-3 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 C-14 O.0OE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.0OE+00 0.OOE+00 O.OOE+00 O.OOE+00 NA-22 1.16E+10 1.16E+10 1.16E+10 1.16E+10 1.16E+10 1.16E+10 1.16E+10 1.30E+10 NA-24 1.19E+07 1.19E+07 1.19E+07 1.19E+07 1.19E+07 1.19E+07 1.19E+07 1.39E+07 P-32 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 CA-41 1.32E+10 1.32E+10 1.32E+10 1.32E+10 1.32E+10 1.32E+10 1.32E+10 1.55E+10 SC-46 8.33E+08 8.33E+08 8.33E+08 8.33E+08 8.33E+08 8.33E+08 8.33E+08 9.61E+08 CR-51 4.66E+06 4.66E+06 4.66E+06 4.66E+06 4.66E+06 4.66E+06 4.66E+06 5.51 E+06 MN-54 1.39E+09 1.39E+09 1.39E+09 1.39E+09 1.39E+09 1.39E+09 1.39E+09 1.63E+09 FE-55 0.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OE+00 O.OOE+00 O.OOE+00 O.OOE+00 MN-56 9.03E+05 9.03E+05 9.03E+05 9.03E+05 9.03E+05 9.03E+05 9.03E+05 1.07E+06 CO-57 4.92E+07 4.92E+07 4.92E+07 4.92E+07 4.92E+07 4.92E+07 4.92E+07 5.41E+07 CO-58 3.79E+08 3.79E+08 3.79E+08 3.79E+08 3.79E+08 3.79E+08 3.79E+08 4.44E+08 FE-59 2.73E+08 2.73E+08 2.73E+08 2.73E+08 2.73E+08 2.73E+08 2.73E+08 3.21E+08 CO-60 2.32E+10 2.32E+10 2.32E+10 2.32E+10 2.32E+10 2.32E+10 2.32E+10 2.73E+10 NI-59 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OQE+00 0.OOE+00 O.OOE+00 O.OOE+00 NI-63 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 CU-64 6.07E+05 6.07E+05 6.07E+05 6.07E+05 6.07E+05 6.07E+05 6.07E+05 6.88E+05 NI-65 2.97E+05 2.97E+05 2.97E+05 2.97E+05 2.97E+05 2.97E+05 2.97E+05 3.45E+05 ZN-65 7.47E+08 7.47E+08 7.47E+08 7.47E+08 7.47E+08 7.47E+08 7.47E+08 8.59E+08 ZN-69m 1.27E+06 1.27E+06 1.27E+06 1.27E+06 1.27E+06 1.27E+06 1.27E+06 1.49E+06 ZN-69 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 SE-79 O.OOE+00 O.OOE+00 O.OOE+00 O.OE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 BR-82 2.14E+07 2.14E+07 2.14E+07 2.14E+07 2.14E+07 2.14E+07 2.14E+07 2.47E+07 BR-83 4.87E+03 4.87E+03 4.87E+03 4.87E+03 4.87E+03 4.87E+03 4.87E+03 7.08E+03 BR-84 2.03E+05 2.03E+05 2.03E+05 2.03E+05 2.03E+05 2.03E+05 2.03E+05 2.36E+05 BR-85 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 RB-86 8.99E+06 8.99E+06 8.99E+06 8.99E+06 8.99E+06 8.99E+06 8.99E+06 1.03E+07 RB-87 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 RB-88 3.31E+04 3.31E+04 3.31E+04 3.31E+04 3.31E+04 3.31E+04 3.31E+04 3.78E+04 RB-89 1.23E+05 1.23E+05 1.23E+05 1.23E+05 1.23E+05 1.23E+05 1.23E+05 1.48E+05 SR-89 2.16E+04 2.16E+04 2.16E+04 2.16E+04 2.16E+04 2.16E+04 2.16E+04 2.51E+04 SR-90 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.0OE+00 O.OOE+00 O.OOE+00 Y-90 4.49E+03 4.49E+03 4.49E+03 4.49E+03 4.49E+03 4.49E+03 4.49E+03 5.31 E+03 SR-91 2.15E+06 2.15E+06 2.15E+06 2.15E+06 2.15E+06 2.15E+06 2.15E+06 2.51E+06 Y-91m 1.OOE+05 1.OOE+05 1.OOE+05 1.OOE+05 1.OOE+05 1.OOE+05 1.OOE+05 1.16E+05 Y-91 1.07E+06 1.07E+06 1.07E+06 1.07E+06 1.07E+06 1.07E+06 1.07E+06 1.21E+06 SR-92 7.77E+05 7.77E+05 7.77E+05 7.77E+05 7.77E+05 7.77E+05 7.77E+05 8.63E+05 Y-92 1.80E+05 1.80E+05 1.80E+05 1.80E+05 1.80E+05 1.80E+05 1.80E+05 2.14E+05 Y-93 1.83E+05 1.83E+05 1.83E+05 1.83E+05 1.83E+05 1.83E+05 1.83E+05 2.51E+05 NB-93m O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 0.00E+00 O.OOE+00 NB-95 1.37E+08 1.37E+08 1.37E+08 1.37E+08 1.37E+08 1.37E+08 1.37E+08 1.61E+08 NB-97 2.07E+05 2.07E+05 2.07E+05 2.07E+05 2.07E+05 2.07E+05 2.07E+05 1.76E+05, ZR-93 O.OOE+00 O.OOE+00 O.OOE+00 0.OOE+00 O.OOE+00 O.QOE+00 O.OOE+00 O.OOE+00

CY-LG-1 70-301, Rev. 23 Page 142 08/07 TABLE 112-2 Ri DOSE FACTORS Age: Adult Pathway: Ground (Continued)

NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG GI-LLI SKIN ZR-95 2.45E+08 2.45E+08 2.45E+08 2.45E+08 2.45E+08 2.45E+08 2.45E+08 2.84E+08 ZR-97 2.96E+06 2.96E+06 2.96E+06 2.96E+06 2.96E+06 2.96E+06 2.96E+06 3.44E+06 MO-93 8.84E+07 8.84E+07 8.84E+07 8.84E+07 8.84E+07 8.84E+07 8.84E+07 3.60E+09 MO-99 3.99E+06 3.99E+06 3.99E+06 3.99E+06 3.99E+06 3.99E+06 3.99E+06 4.63E+06 TC-99 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 0.00E+00 TC-99m 1.84E+05 1.84E+05 1.84E+05 1.84E+05 1.84E+05 1.84E+05 1.84E+05 2.11E+05 TC-101 2.04E+04 2.04E+04 2.04E+04 2.04E+04 2.04E+04 2.04E+04 2.04E+04 2.26E+04 RU-103 1.08E+08 1.08E+08 1.08E+08 1.08E+08 1.08E+08 1.08E+08 1.08E+08 1.26E+08 RU-105 6.36E+05 6.36E+05 6.36E+05 6.36E+05 6.36E+05 6.36E+05 6.36E+05 7.21E+05 RU-106 4.22E+08 4.22E+08 4.22E+08 4.22E+08 4.22E+08 4.22E+08 4.22E+08 5.07E+08 RH-105 2.11E+09 2.11E+09 2.11E+09 2.11E+09 2.11E+09 2.11E+09 2.11E+09 2.46E+09 PD-107 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 PD-109 1.50E+04 1.50E+04 1.50E+04 1.50E+04 1.50E+04 1.50E+04 1.50E+04 1.71 E+04 AG-110m 2.86E+09 2.86E+09 2.86E+09 2.86E+09 2.86E+09 2.86E+09 2.86E+09 4.01E+09 AG-111 1.03E+06 1.03E+06 1.03E+06 1.03E+06 1.03E+06 1.03E+06 1.03E+06 1.20E+06 CD-113m 5.60E+06 5.60E+06 5.60E+06 5.60E+06 5.60E+06 5.60E+06 5.60E+06 6.33E+06 CD-115m O.OOE+00 O.OOE+00 O.OOE+00 O.0OE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 SN-123 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 6.38E+09 SN-125 4.20E+06 4.20E+06 4.20E+06 4.20E+06 4.20E+06 4.20E+06 4.20E+06 4.86E+06 SN-126 3.48E+10 3.48E+10 3.48E+10 3.48E+10 3.48E+10 3.48E+10 3.48E+10 3.87E+10 SB-124 5.98E+08 5.98E+08 5.98E+08 5.98E+08 5.98E+08 5.98E+08 5.98E+08 6.90E+08 SB-125 2.38E+09 2.38E+09 2.38E+09 2.38E+09 2.38E+09 2.38E+09 2.38E+09 2.69E+09 SB-126 8.44E+07 8.44E+07 8.44E+07 8.44E+07 8.44E+07 8.44E+07 8.44E+07 9.48E+07 SB-127 1.68E+07 1.68E+07 1.68E+07 1.68E+07 1.68E+07 1.68E+07 1.68E+07 1.94E+07 TE-125m 1.55E+06 1.55E+06 1.55E+06 1.55E+06 1.55E+06 1.55E+06 1.55E+06 2.13E+06 TE-127m 9.16E+04 9.16E+04 9.16E+04 9.16E+04 9.16E+04 9.16E+04 9.16E+04 1.08E+05 TE-127 2.98E+03 2.98E+03 2.98E+03 2.98E+03 2.98E+03 2.98E+03 2.98E+03 3.28E+03 TE-129m 1.98E+07 1.98E+07 1.98E+07 1.98E+07 1.98E+07 1.98E+07 1.98E+07 2.31E+07 TE-129 2.62E+04 2.62E+04 2.62E+04 2.62E+04 2.62E+04 2.62E+04 2.62E+04 3.1OE+04 TE-133m 4.41E+05 4.41E+05 4.41E+05 4.41E+05 4.41E+05 4.41E+05 4.41E+05 5.OOE+05 TE-134 2.22E+04 2.22E+04 2.22E+04 2.22E+04 2.22E+04 2.22E+04 2.22E+04 2.66E+04 1-129 1.74E+09 1.74E+09 1.74E+09 1.74E+09 1.74E+09 1.74E+09 1.74E+09 2.90E+09.

1-130 5.51E+06 5.51E+06 5.51E+06 5.51E+06 5.51E+06 5.51E+06 5.51E+06 6.69E+06 1-131 1.72E+07 1.72E+07 1.72E+07 1.72E+07 1.72E+07 1.72E+07 1.72E+07 2.09E+07 TE-131m 8.03E+06 8.03E+06 8.03E+06 8.03E+06 8.03E+06 8.03E+06 8.03E+06 9.46E+06 TE-131 2.92E+04 2.92E+04 2.92E+04 2.92E+04 2.92E+04 2.92E+04 2.92E+04 3.45E+07 1-132 1.25E+06 1.25E+06 1.25E+06 1.25E+06 1.25E+06 1.25E+06 1.25E+06 1.46E+06 TE-132 4.23E+06 4.23E+06 4.23E+06 4.23E+06 4.23E+06 4.23E+06 4.23E+06 4.98E+06 1-133 2.45E+06 2.45E+06 2.45E+06 2.45E+06 2.45E+06 2.45E+06 2.45E+06 2.98E+06 CS-134m 4.80E+04 4.80E+04 4.80E+04 4.80E+04 4.80E+04 4.80E+04 4.80E+04 6.74E+04 CS-134 6.90E+09 6.90E+09 6.90E+09 6.90E+09 6.90E+09 6.90E+09 6.90E+09 8.05E+09 1-134 4.47E+05 4.47E+05 4.47E+05 4.47E+05 4.47E+05 4.47E+05 4.47E+05 5.30E+05 1-135 2.53E+06 2.53E+06 2.53E+06 2.53E+06 2.53E+06 2.53E+06 2.53E+06 2.95E+06 CS-135 5.80E+10 5.80E+10 5.80E+10 5.80E+10 5.80E+10 5.80E+10 5.80E+10 6.58E+10

CY-LG-170-301, Rev. 23 Page 143 08/07 TABLE 112-2 Ri DOSE FACTORS Age: Adult Pathway: Ground (Continued)

NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG GI-LLI SKIN CS-136 1.51E+08 1.51E+08 1.51E+08 1.51E+08 1.51E+08 1.51E+08 1.51E+08 1.71E+08 CS-137 1.30E+10 1.30E+10 1.30E+10 1.30E+10 1.30E+10 1.30E+10 1.30E+10 1.52E+10 CS-138 3.59E+05 3.59E+05 3.59E+05 3.59E+05 3.59E+05 3.59E+05 3.59E+05 4.1OE+05 CS-139 3.14E+04 3.14E+04 3.14E+04 3.14E+04 3.14E+04 3.14E+04 3.14E+04 3.59E+04 BA-139 1.06E+05 1.06E+05 1.06E+05 1,06E+05 1.06E+05 1.06E+05 1.06E+05 1.19E+05 BA-140 2.05E+07 2.05E+07 2.05E+07 2.05E+07 2.05E+07 2.05E+07 2.05E+07 2.35E+07 LA-140 1.92E+07 1.92E+07 1.92E+07 1.92E+07 1.92E+07 1.92E+07 1.92E+07 2.18E+07 BA-141 4.17E+04 4.17E+04 4.17E+04 4.17E+04 4.17E+04 4.17E+04 4.17E+04 4.75E+04 LA-141 3.14E+04 3.14E+04 3.14E+04 3.14E+04 3.14E+04 3.14E+04 3.14E+04 3.51E+04 CE-141 1.37E+07 1.37E+07 1.37E+07 1.37E+07 1.37E+07 1.37E+07 1.37E+07 1.54E+07 BA-142 4.49E+04 4.49E+04 4.49E+04 4.49E+04 4.49E+04 4.49E+04 4.49E+04 5.11E+04 LA-142 7.60E+05 7.60E+05 7.60E+05 7.60E+05 7.60E+05 7.60E+05 7.60E+05 9.11E+05 CE-143 2.31E+06 2.31E+06 2.31E+06 2.31E+06 2.31E+06 2.31E+06 2.31E+06 2.63E+06 PR-143 O.OE+00 O.OOE+00 O.O0E+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 CE-144 6.95E+07 6.95E+07 6.95E+07 6.95E+07 6.95E+07 6.95E+07 6.95E+07 8.04E+07 PR-144 1.83E+03 1.83E+03 1.83E+03 1.83E+03 1.83E+03 1.83E+03 1.83E+03 2.11E+03 ND-147 8.39E+06 8.39E+06 8.39E+06 8.39E+06 8.39E+06 8.39E+06 8.39E+06 1.01E+07 PM-147 O.OOE+00 0.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OE+00 O.OOE+00 O.OOE+00 PM-148m 4.45E+08 4.45E+08 4.45E+08 4A5E+08 4.45E+08 4.45E+08 4.45E+08 2.58E+09 PM-148 1.45E+08 1.45E+08 1.45E+08 1.45E+08 1.45E+08 1.45E+08 1.45E+08 1.67E+08 PM-149 4.23E+04 4.23E+04 4.23E+04 4.23E+04 4.23E+04 4.23E+04 4.23E+04 4.90E+04 PM-151 1.99E+06 1.99E+06 1.99E+06 1.99E+06 1.99E+06 1.99E+06 1.99E+06 2.08E+06 SM-151 1.72E+08 1.72E+08 1.72E+08 1.72E+08 1.72E+08 1.72E+08 1.72E+08 7.53E+08 SM-153 4.02E+05 4.02E+05 4.02E+05 4.02E+05 4,02E+05 4.02E+05 4.02E+05 4.46E+05 EU-152 1.79E+10 1.79E+10 1.79E+10 1.79E+10 1.79E+10 1.79E+10 1.79E+10 2.07E+10 EU-154 1.52E+10 1.52E+10 1.52E+10 1.52E+10 1.52E+10 1.52E+10 1.52E+10 1.75E+10 EU-1 55 4.95E+08 4.95E+08 4.95E+08 4.95E+08 4.95E+08 4.95E+08 4.95E+08 5.63E+08 EU-156 8.82E+07 8.82E+07 8.82E+07 8.82E+07 8.82E+07 8,82E+07 8.82E+07 1.01E+08 TB-160 4.75E+08 4.75E+08 4.75E+08 4.75E+08 4.75E+08 4.75E+08 4.75E+08 5.53E+08 HO-166m 3.42E+10 3.42E+10 3.42E+10 3.42E+10 3.42E+10 3.42E+10 3.42E+10 3.85E+10 W-181 1.94E+05 1.94E+05 1.94E+05 1.94E+05 1,94E+05 1.94E+05 1.94E+05 2.13E+05 W-185 O.OOE+00 O.OOE+00 O.OOE+00 0.OOE+00 O.OE+00 O.OOE+00 O.OOE+00 O.OOE+00 W-187 2.35E+06 2.35E+06 2.35E+06 2.35E+06 2.35E+06 2.35E+06 2.35E+06 2.73E+06 NP-239 1.71E+06 1.71E+06 1.71E+06 1.71E+06 1.71E+06 1.71E+06 1.71E+06 1.98E+06 U-232 9.12E+06 9.12E+06 9.12E+06 9.12E+06 9.12E+06 9.12E+06 9.12E+06 9.47E+07 U-233 8.90E+09 8.90E+09 8.90E+09 8.90E+09 8.90E+09 8.90E+09 8.90E+09 1.08E+10 U-234 2.45E+06 2.45E+06 2.45E+06 2.45E+06 2.45E+06 2.45E+06 2.45E+06 6.15E+08 U-235 1.24E+10 1.24E+10 1.24E+10 1.24E+10 1.24E+10 1.24E+10 1.24E+10 1.55E+10 U-236 8.13E+04 8.13E+04 8.13E+04 8.13E+04 8.13E+04 8.13E+04 8.13E+04 6.96E+07 U-237 5.16E+06 5.16E+06 5.16E+06 5.16E+06 5.16E+06 5.16E+06 5.16E+06 6.71E+06 U-238 4.26E+08 4.26E+08 4.26E+08 4.26E+08 4.26E+08 4.26E+08 4.26E+08 5.80E+08 NP-237 5.42E+09 5.42E+09 5.42E+09 5.42E+09 5.42E+09 5.42E+09 5.42E+09 6.19E+09 NP-238 4.53E+06 4.53E+06 4.53E+06 4.53E+06 4.53E+06 4.53E+06 4.53E+06 5.18E+06 PU-238 4.65E+06 4.65E+06 4.65E+06 4.65E+06 4.65E+06 4.65E+06 4.65E+06 6.44E+07

CY-LG-1 70-301, Rev. 23 I Page 144 08/071 TABLE 112-2 Ri DOSE FACTORS Age: Adult Pathway: Ground (Continued)

NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG GI-LLI SKIN PU-239 3.06E+06 3.06E+06 3.06E+06 3.06E+06 3.06E+06 3.06E+06 3.06E+06 2.98E+07 PU-240 5.02E+06 5.02E+06 5.02E+06 5.02E+06 5.02E+06 5.02E+06 '5.02E+06 6.96E+07 PU-241 1.14E+07 1.14E+07 1.14E+07 1.14E+07 1.14E+07 1.14E+07 1.14E+07 1.69E+07 PU-242 4.26E+06 4.26E+06 4.26E+06 4.26E+06 4.26E+06 4.26E+06 4.26E+06 6.19E+07 PU-244 3.46E+09 3.46E+09 3.46E+09 3.46E+09 3.46E+09 3.46E+09 3.46E+09 3.72E+09 AM-241 6.85E+08 6.85E+08 6.85E+08 6.85E+08 6.85E+08. 6.85E+08 6.85E+08 9.90E+08 AM-242m 9.62E+07 9.62E+07 9.62E+07 9.62E+07 9.62E+07 9.62E+07 9.62E+07 6.66E+08 AM-243 5.03E+09 5.03E+09 5.03E+09 5.03E+09 5.03E+09 5.03E+09 5.03E+09 5.80E+09 CM-242 6.86E+05 6.86E+05 6.86E+05 6.86E+05 6.86E+05 6.86E+05 6.86E+05 2.87E+06 CM-243 7.05E+09 7.05E+09 7.05E+09 7.05E+09 7.05E+09 7.05E+09 7.05E+09 8.89E+09 CM-244 7.84E+06 7.84E+06 7.84E+06 \ 7.84E+06 7.84E+06 7.84E+06 7.84E+06 4.87E+07 CM-245 3.67E+09 3.67E+09 3.67E+09 3.67E+09 3.67E+09 3.67E+09 3.67E+09 4.64E+09 CM-246 3.86E+06 3.86E+06 3.86E+06 3.86E+06 3.86E+06 3.86E+06 3.86E+06 5.80E+07 CM-247 8.51 E+09 8.51 E+09 8.51 E+09 8.51 E+09 8.51 E+09 8.51 E+09 8.51 E+09 1.01E+10 CM-248 2.63E+10 2.63E+10 2.63E+10 2.63E+10 2.63E+10 2.63E+10 2.63E+10 2.02E+10 CF-252 4.84E+ 10 4.84E+10 4.84E+10 4.84E+10 4.84E+10 4.84E+10 4.84E+10 5.28E+10

CY-LG-1 70-301, Rev. 23 I Page 145 08/07 I TABLE 112-2 Ri DOSE FACTORS Age: Adult Pathway: Vegetation NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG GI-LLI SKIN H-3 0.O0E+00 2.08E+03 2.08E+03 2.08E+03 2.08E+03 2.08E+03 2.08E+03 O.OOE+00 C-14 8.24E+05 1.65E+05 1.65E+05 1.65E+05 1.65E+05 1.65E+05 1.65E+05 0.OOE+00 NA-22 1.21 E+09 1.21E+09 1.21E+09 1.21E+09 1.21E+09 1.21E+09 1.21E+09 O.OOE+00 NA-24 1.12E+05 1.12E+05 1.12E+05 1.12E+05 1.12E+05 1.12E+05 1.12E+05 0.OOE+00 P-32 1.25E+08 4.99E+07 3.10E+07 0.OOE+00 0.OOE+00 0.OOE+00 9.02E+07 0.OOE+00 CA-41 1.36E+10 0.0OE+00 1.47E+09 0.00E+00' 0.OOE+00 0.OOE+00 1.36E+07 0.OOE+00 SC-46 2.20E+05 4.28E+05 1.24E+05 0.OOE+00 3.99E+05 O.OOE+00 2.08E+09 0.OOE+00 CR-51 O.OOE+00 O.0OE+00 3.53E+04 2.11E+04 7.77E+03 4.68E+04 8.87E+06 0.OOE+00 MN-54 0.OOE+00 2.85E+08 5.43E+07 O.OOE+00 8.47E+07 0.OOE+00 8.72E+08 0.OOE+00 FE-55 1.92E+08 1.33E+08 3.09E+07 0.OOE+00 0.OOE+00 7.40E+07 7.61E+07 O.OE+00 MN-56 0.OOE+00 6.48E+00 1.15E+00 0.OOE+00 8.23E+00 0.OOE+00 2.07E+02 O.OOE+00 CO-57 0.OOE+00 6.28E+06 1.04E+07 0.OOE+00 O.OOE+00 0.OOE+00 1.59E+08 0.OOE+00 CO-58 0.O0E+00 2.67E+07 5.99E+07 0.OOE+00 0.OOE+00 0.OOE+00 5.42E+08 O.OOE+00 FE-59 1.05E+08 2.47E+08 9.46E+07 0.OOE+00 O.OOE+00 6.90E+07 8.23E+08 O.OOE+00 CO-60 0.OOE+00 1.53E+08 3.38E+08 0.OOE+00 0.OOE+00 0.OOE+00 2.88E+09 0.OOE+00 NI-59 7.19E+08 2.47E+08 3.48E+08 0.OOE+00 0.OOE+00 0.OOE+00 5.08E+07 0.OOE+00 NI-63 9.56E+09 6.63E+08 3.21E+08 0.OOE+00 O.OOE+00 0.OOE+00 1.38E+08 0.OOE+00 CU-64 0.OOE+00 3.84E+03 1.80E+03 0.OOE+00 9.68E+03 0.OOE+00 3.27E+05 O.OOE+00 NI-65 2.50E+01 3.25E+00 1.48E+00 0.OOE+00 0.OOE+00 0.OOE+00 8.25E+01 0.OOE+00 ZN-65 2.88E+08 9.16E+08 4.14E+08 0.OOE+00 6.12E+08 0.OOE+00 5.77E+08 0.OOE+00 ZN-69m 9.36E+03 2.25E+04 2.05E+03 0.OOE+00 1.36E+04 0.OOE+00 1.37E+06 O.OOE+00 ZN-69 2.12E-06 4.06E-06 2.82E-07 0.OOE+00 2.64E-06 0.OOE+00 6.10E-07 0.OOE+00 SE-79 0.OOE+00 1.94E+08 3.23E+07 0.OOE+00 3.35E+08 O.OOE+00 3.96E+07 0.OOE+00 BR-82 0.OOE+00 0.OOE+00 6.29E+05 0.OOE+00 0.OOE+00 0.OOE+00 7.21 E+05 0.OOE+00 BR-83 0.00E+00 0.OOE+00 1.26E+00 0.OOE+00 0.OOE+00 0.OOE+00 1.82E+00 0.OOE+00 BR-84 0.OOE+00 0.OOE+00 8.99E-12 .OOE+00 0.OOE+00 O.OOE+00 7.06E-17 0.OOE+00 BR-85 0.OOE+00 0.OOE+00 8.70E-152 0.OOE+00 0.OOE+00 0.00E+00 0.O0E+00 O.OOE+00 RB-86 0.OOE+00 1.44E+08 6.72E+07 0.OOE+00 0.OOE+00 0.OOE+00 2.84E+07 0.OOE+00 RB-87 0.OOE+00 9.06E+08 3.15E+08 0.OOE+00 0.OOE+00 0.OOE+00 4.24E+07 0.OOE+00 RB-88 0.OOE+00 1.11E-22 5.89E-23 0.OOE+00 0.OOE+00 O.OOE+00 1.53E-33 0.O0E+00 RB-89 0.OOE+00 1.21E-26 8.51E-27 0.OOE+00 0.OOE+00 O.OOE+00 7.03E-40 0.OOE+00 SR-89 8.43E+09 0.OOE+00 2.42E+08 0.OOE+00 0.OOE+00 0.OOE+00 1.35E+09 O.OOE+00 SR-90 5.56E+11 0.0OE+00 1.36E+11 0.OOE+00 0.OOE+00 0.OOE+00 1.61E+10 0.00E+00 Y-90 5.58E+03 0.OOE+00 1.50E+02 0.OOE+00 0.OOE+00 0.OOE+00 5.91 E+07 0.OOE+00 SR-91 1.27E+05 0.OOE+00 5.13E+03 0.OOE+00 0.OOE+00 0.OOE+00 6.04E+05 0.OOE+00 Y-91m 2.OOE-09 0.OOE+00 7.73E-11 0.OOE+00 0.OOE+00 O.OOE+00 5.87E-09 0.OOE+00 Y-91 4.38E+06 0.OOE+00 1.17E+05 0.OOE+00 O.OOE+00 0.OOE+00 2.41E+09 0.OOE+00 SR-92 1.74E+02 O.OOE+00 7.53E+00 0.OOE+00 0.OOE+00 0.OOE+00 3.45E+03 0.OOE+00 Y-92 3.76E-01 0.OOE+00 1.1OE-02 0.O0E+00 O.OOE+00 0.OOE+00 6.59E+03 0.OOE+00 Y-93 7.07E+01 O.OOE+00 1.95E+00 0.OOE+00 0.OOE+00 0.OOE+00 2.24E+06 0.OOE+00 NB-93m 1.86E+06 6.07E+05 1.50E+05 0.OOE+00 6,98E+05 0.OOE+00 2.80E+08 0.OOE+00 NB-95 1.14E+05 6.35E+04 3.41E+04 0.OOE+00 6.28E+04 0.OOE+00 3.85E+08 0.OOE+00 NB-97 8.48E-07 2.15E-07 7.83E-08 0.OOE+00 2.50E-07 0.OOE+00 7.91E-04 0.OOE+00 ZR-93 3.08E+06 1.72E+05 8.03E+04 O.OOE+00 6.53E+05 0.OOE+00 1.79E+09 0.OOE+00

CY-LG-1 70-301, Rev. 23 Page 146 08/07 TABLE 112-2 Ri DOSE FACTORS Age: Adult Pathway: Vegetation (Continued)

NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG GI-LLI SKIN ZR-95 1.01E+06 3.25E+05 2.20E+05 0.OOE+00 5.11E+05 O.OOE+00 1.03E+09 0.OOE+00 ZR-97 1.41E+02 2.85E+01 1.30E+01 0.OOE+00 4.30E+01 0.OOE+00 8.81E+06 0.OOE+00 MO-93 0.OOE+00 5.53E+08 1.50E+07 0.OOE+00 1.57E+08 O.OE+00 8.99E+07 0.OOE+00 MO-99 0.OOE+00 2.58E+06 4.91 E+05 0.OOE+00 5.84E+06 O.OOE+00 5.98E+06 0.OOE+00 TC-99 9.21E+06 1.37E+07 3.70E+06 0.OOE+00 1.72E+08 1.16E+06 4.48E+08 O.OE+00 TC-99m 1.29E+00 3.64E+00 4.63E+01 0.OOE+00 5.52E+01 1.78E+00 2.15E+03 0.OOE+00 TC-101 2.49E-31 3.59E-31 3.52E-30 0.OOE+00 6.47E-30 1.83E-31 1.08E-42 0.O0E+00 RU-103 3.90E+06 0.OOE+00 1.68E+06 0.OOE+00 1.49E+07 0.OOE+00 4.56E+08 O.OOE+00 RU-105 2.22E+01 O.OOE+00 8.78E+00 0.OOE+00 2.87E+02 O.OOE+00 1.36E+04 0.OOE+00 RU-106 1.76E+08 0.OOE+00 2.22E+07 0.O0E+00 3.39E+08 0.OOE+00 1.14E+10 0.O0E+00 RH-105 8.88E+06 6.49E+06 4.28E+06 0.OOE+00 2.76E+07 0.OOE+00 1.03E+08 0.OOE+00 I PD-107 0.OOE+00 1.08E+07 6.92E+05 0.OOE+00 9.72E+07 0.OOE+00 6.71 E+07 0.OOE+00 PD-109 0.O0E+00 9.28E+03 2.09E+03 0.OOE+00 5.30E+04 0.OOE+00 1.03E+06 0.OOE+00 AG-110m 9.56E+06 8.84E+06 5.25E+06 O.OOE+00 1.74E+07 O.OOE+00 3.61E+09 O.OOE+00 AG-111 9.16E+04 3.83E+04 1.91E+04, O.OOE+00 1.24E+05 O.OOE+00 7.03E+07 O.OOE+00 CD-113m 0.OOE+00 2.32E+08 7.43E+06 O.OOE+00 2.55E+08 O.OOE+00 1.87E+09 O.OOE+00 CD-115m O.OOE+00 4.45E+07 1.42E+06 O.OOE+00 3.53E+07 O.OOE+00 1.80E+09 O.OOE+00 SN-123 1.53E+09 2.54E+07 3.74E+07 2.16E+07 O.OOE+00 O.OOE+00 3.12E+09 O.OOE+00 SN-125 1.80E+07 3.62E+05 8.16E+05 3.OOE+05 O.OOE+00 O.OOE+00 2.24E+08 O.OOE+00 SN-126 6.20E+09 1.23E+08 1.77E+08 3.62E+07 O.OOE+00 O.OOE+00 1.79E+09 O.OOE+00 SB-124 8.91E+07 1.68E+06 3.53E+07 2.16E+05 O.OOE+00 6.94E+07 2.53E+09 O.OOE+00 SB-125 1.25E+08 1.40E+06 2.98E+07 1.27E+05 O.OOE+00 9.65E+07 1.38E+09 O.OOE+00 SB-126 3.70E+06 7.53E+04 1.34E+06 2.27E+04 O.OOE+00 2.27E+06 3.03E+08 O.OOE+00 SB-127 2.18E+05 4.78E+03 8.37E+04 2.62E+03 O.OOE+00 1.29E+05 4.99E+07 O.OOE+00 TE-125m 8.27E+07 3.OOE+07 1.11E+07 2.49E+07 3.37E+08 0.OOE+00 3.30E+08 O.OOE+00 TE-127m 3.11E+08 1.11E+08 3.78E+07 7.94E+07 1.26E+09 O.OOE+00 1.04E+09 O.OOE+00 TE-127 2.36E+03 8.47E+02 5.1OE+02 1.75E+03 9.60E+03 O.OOE+00 1.86E+05 O.OOE+00 TE-129m 2.OOE+08 7.45E+07 3.16E+07 6.86E+07 8.34E+08 O.OOE+00 1.01E+09 O.OOE+00 TE-129 3.OOE-04 1.13E-04 7.30E-05 2.30E-04 1.26E-03 O.OOE+00 2.26E-04 O.OOE+00 TE-133m 8.89E-06 5.20E-06 5.01E-06 7.53E-06 5.14E-05 O.OOE+00 1.28E-05 O.OOE+00 TE-134 1.34E-08 8.77E-09 5.38E-09 1.17E-08 8.48E-08 O.OOE+00 1.48E-11 O.OOE+00 1-129 1.20E+09 1.03E+09 3.39E+09 2.66E+12 1.86E+09 O.OOE+00 1.64E+08 O.OOE+00 1-130 1.64E+05 4.83E+05 1.91E+05 4.09E+07 7.54E+05 O.OOE+00 4.16E+05 O.OOE+00 1-131 3.56E+07 5.1OE+07 2.92E+07 1.67E+10 8.74E+07 O.OOE+00 1.34E+07 O.OOE+00 TE-131m 3.82E+05 1.87E+05 1.56E+05 2.96E+05 1.89E+06 O.OOE+00 1.85E+07 O.OOE+00 TE-131 5.24E-16 2.19E-16 1.65E-16 4.31E-16 2.30E-15 O.OOE+00 7.42E-17 O.OOE+00 1-132 2.34E+01 6.26E+01 2.19E+01 2.19E+03 9.96E+01 O.OOE+00 1.18E+01 O.OOE+00 TE-132 1.80E+06 1.17E+06 1.10E+06 1.29E+06 1.12E+07 O.OOE+00 5.52E+07 O.OOE+00 1-133 8.73E+05 1.52E+06 4.63E+05 2.23E+08 2.65E+06 O.OOE+00 1.36E+06 O.OOE+00 CS-134m 2.76E+00 5.80E+00 2.97E+00 0.OOE+00 3.15E+00 4.96E-01 2.05E+00 0.OOE+00 CS-134 4.27E+09 1.02E+10 8.31E+09 0.OOE+00 3.29E+09 1.09E+09 1.78E+08 0.OOE+00 1-134 3.71E-05 1.01E-04 3.61E-05 1.75E-03 1.60E-04 0.OOE+00 8.79E-08 0.OOE+00 1-135 1.62E+04 4.24E+04 1.56E+04 2.79E+06 6.79E+04 0.OOE+00 4.79E+04 0.OOE+00 CS-135 1.44E+09 1.33E+09 5.89E+08 0.OOE+00 5.02E+08 1.50E+08 3.10E+07 0.OOE+00

CY-LG-170-301, Rev. 23 I Page 147 08/07I TABLE 112-2 Ri DOSE FACTORS Age: Adult Pathway: Vegetation (Continued)

NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG GI-LLI SKIN CS-136 2.33E+07 9.19E+07 6.62E+07 0.OOE+00 5.12E+07 7.01E+06 1.04E+07 0.OOE+00 CS-137 5.84E+09 7.99E+09 5.23E+09 0.OOE+00 2.71E+09 9.02E+08 1.55E+08 0.OOE+00 CS-138 1.42E-11 2.81E-11 1.39E-11 0.OOE+00 2.07E-11 2.04E-12 1.20E-16 O.OOE+00 CS-139 5,72E-45 8.52E-45 3.10E-45 0.OOE+00 6.82E-45 6.20E-46 1.84E-67 O.OOE+00 BA-139 1.13E-02 8.08E-06 3.32E-04 0.OOE+00 7.56E-06 4.59E-06 2.01E-02 0.OOE+00 BA-140 6.90E+07 8.67E+04 4.52E+06 0.OOE+00 2,95E+04 4.96E+04 1.42E+08 0.OOE+00 LA-140 8.29E+02 4.18E+02 1.10E+02 0.0OE+00 O.OOE+00 0.OOE+00 3.07E+07 0.OOE+00 BA-141 3,76E-22 2.84E-25 1.27E-23 0.OOE+00 2.64E-25 1.61E-25 1.77E-31 0.OOE+00 LA-141 2.54E-01 7.89E-02 1.29E-02 0.OOE+00 0.OOE+00 0.OOE+00 9.41 E+03 0.OOE+00 CE-141 1.56E+05 1.05E+05 1.19E+04 0.OOE+00 4.89E+04 O.OOE+00 4.02E+08 0.OOE+00 BA-142 1,63E-39 1.67E-42 1.02E-40 0.OOE+00 1.41E-42 9.48E-43 2.29E-57 0.OOE+00 LA-142 8,08E-05 3.68E-05 9.16E-06 0.OOE+00 0.OOE+00 0.0OE+00 2.68E-01 O.0OE+00 CE-143 4.18E+02 3.09E+05 3.42E+01 0.OOE+00 1.36E+02 0.OOE+00 1.16E+07 0.OOE+00 PR-143 3.47E+04 1.39E+04 1.72E+03 0.OOE+00 8.04E+03 0.OOE+00 1.52E+08 0.OOE+00 CE-144 2.99E+07 1.25E+07 1.60E+06 0.OOE+00 7.41E+06 O.OOE+00 1.01E+10 0.OOE+00 PR-144 9,92E-27 4.12E-27 5.04E-28 O.OOE+00 2.32E-27 0.OOE+00 1.43E-33 0.OOE+00 ND-147 1.65E+04 1.91E+04 1.14E+03 0.OOE+00 1.12E+04 0.OOE+00 9.16E+07 0.OOE+00 PM-147 5,26E+06 4.94E+05 1.96E+05 0.OOE+00 9.34E+05 0.OOE+00 6.23E+08 0.OOE+00 PM-148m 6.84E+05 1.77E+05 1.35E+05 0.OOE+00 2.67E+05 O.OOE+00 1.50E+09 0.OOE+00 PM-148 1.60E+05 2.65E+04 1.33E+04 0.OOE+00 5.01 E+04 0.OOE+00 2.08E+09 O.OOE+00 PM-149 7.11E+02 1.01E+02 4.11E+01 0.OOE+00 1.90E+02 0.OOE+00 1.89E+07 O.OOE+00 PM-151 1.42E+02 2.38E+01 1.20E+01 0.OOE+00 4.25E+01 0.OOE+00 6,55E+06 O.OOE+00 SM-1 51 5.07E+06 8.75E+05 2.10E+05 0.OOE+00 9.78E+05 0.OOE+00 3.86E+08 0.OOE+00 SM-153 3.44E+02 2.87E+02 2.09E+01 0.OOE+00 9.26E+01 0.OOE+00 1.02E+07 0.OOE+00 EU-152 1.42E+07 3.24E+06 2.84E+06 O.OOE+00 2.OOE+07 0.OOE+00 1.87E+09 0.OOE+00 EU-154 4.46E+07 5.48E+06 3.90E+06 0.OOE+00 2.62E+07 0.OOE+00 3.97E+09 0.OOE+00 EU-155 6.15E+06 8.73E+05 5.63E+05 O.OOE+00 4.03E+06 O.OOE+00 6.87E+08 0.OOE+00 EU-156 6.38E+04 4.94E+04 7.97E+03 0.OOE+00 3.30E+04 0.OOE+00 3.38E+08 0.OOE+00 TB-160 1.71E+06 0.OOE+00 2.13E+05 0.OOE+00 7.06E+05 0.OOE+00 1.58E+09 0.OOE+00 HO-166m 1.99E+07 6.21E+06 4,71E+06 0.OOE+00 9.28E+06 0,OOE+00 7.37E-11 0.OOE+00 W-181 4.76E+05 1.55E+05 1.66E+04 0.OOE+00 0.OOE+00 O.OOE+00 1.77E+07 0.OOE+00 W-185 1.51E+07 5.04E+06 5.30E+05 0.OOE+00 0.OOE+00 0.OOE+00 5.83E+08 0.OOE+00 W-187 1.59E+04 1.33E+04 4.65E+03 0.OOE+00 0.OOE+00 0.OOE+00 4,36E+06 0.OOE+00 NP-239 5.99E+02 5.89E+01 3.25E+01 0.OOE+00 1.84E+02 0.OOE+00 1.21E+07 O.OOE+00 U-232 3.04E+11 0.OOE+00 2.17E+10 0.OOE+00 3.29E+10 0.OOE+00 4.98E+09 0.OOE+00 U-233 6.42E+10 0.OOE+00 3.89E+09 0.OOE+00 1.50E+10 0.OOE+00 4.62E+09 0.OOE+00 U-234 6.16E+10 0.OOE+00 3.81E+09 0.OOE+00 1.47E+10 O.OOE+00 4.52E+09 0.OOE+00 U-235 5.90E+10 0.OOE+00 3.58E+09 0.OOE+00 1.38E+10 0.OOE+00 5,75E+09 0.OOE+00 U-236 5.90E+10 O.OOE+00 3,65E+09 O.OOE+00 1.41E+10 0.OOE+00 4.24E+09 0.OOE+00 U-237 7.86E+04 0.OOE+00 2.09E+04 0.OOE+00 3.23E+05 0.OOE+00 2.76E+07 0.OOE+00 U-238 5,65E+10 0.OOE+00 3.34E+09 O.OOE+00 1.29E+10 0.OOE+00 4.05E+09 0.OOE+00 NP-237 9,28E+10 6.60E+09 4.08E+09 0.OOE+00 3.03E+10 0.OOE+00 5.85E+09 0.OOE+00 NP-238 6,08E+03 1.64E+02 9.46E+01 0.OOE+00 5.55E+02 0.OOE+00 1.52E+07 O.OOE+00 PU-238 4.63E+10 5.87E+09 1.26E+09 0.OOE+00 5.38E+09 0.OOE+00 5.37E+09 O.OOE+00 PU-239 5,34E+10 6.42E+09 1.41 E+09 0.OOE+00 5.97E+09 0.OOE+00 4.91 E+09 O.OOE+00

CY-LG-170-301, Rev. 23 Page 148 08/07 TABLE 112-2 Ri DOSE FACTORS Age: Adult Pathway: Vegetation (Continued)

NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG GI-LLI SKIN PU-240 5.33E+10 6.41 E+09 1.41E+09 0.OOE+00 5.97E+09 0.OOE+00 4.99E+09 0.00E+00 PU-241 1.14E+09 5.43E+07 2.42E+07 0.OOE+00 1.12E+08 0.OOE+00 1.02E+08 0.00E+00 PU-242 4.95E+10 6.18E+09 1.36E+09 0.OOE+00 5.75E+09 0.OOE+00 4.81 E+09 0.00E+00 PU-244 5.78E+10 7.08E+09 1.55E+09 0.00E+00 6.59E+09 0.OOE+00 7.17E+09 0.00E+00 AM-241 5.56E+10 5.19E+10 3.98E+09 0.OOE+00 3.OOE+10 0.OOE+00 5.46E+09 0.00E+00 AM-242m 5.60E+10 4.88E+10 4.00E+09 0.00E+00 2.98E+10 0.OOE+00 6.87E+09 0.00E+00 AM-243 5.55E+10 5.08E+10 3.90E+09 0.OOE+00 2.94E+10 0.OOE+00 6.41 E+09 0.OOE+00 CM-242 1.10E+09 1.17E+09 7.34E+07 0.OOE+00 3.33E+08 0.OOE+00 4.24E+09 0.00E+00 CM-243 4.39E+10 4.02E+10 2.75E+09 O.00E+00 1.28E+10 0.OOE+00 5.72E+09 0.00E+00 CM-244 3.33E+10 3.12E+10 2.10E+09 0.OOE+00 9.79E+09 0.OOE+00 5.52E+09 O.OOE+00 CM-245 6.91E+10 6.02E+10 4.24E+09 0.OOE+00 1.98E+10 0.OOE+00 5.19E+09 O.OOE+00 CM-246 6.85E+10 6.01E+10 4.24E+09 0.OOE+00 1.97E+10 0.OOE+00 5.09E+09 0.00E+00 CM-247 6.68E+10 5.92E+10 4.18E+09 0.OOE+00 1.94E+10 0.OOE+00 6.70E+09 0.00E+00 CM-248 5.55E+11 4.88E+1 1 3.44E+10 0.OOE+00 1.61 E+11 0.OOE+00 1.08E+ 11 0.00E+00 CF-252 1.82E+10 0.00E+00 4.39E+08 0.OOE+00 0.00E+00 O.OOE+00 2.01E+10 0.00E+00

CY-LG-170-301, Rev. 23 Page 149 08/07 TABLE 112-2 Ri DOSE FACTORS Age: Adult Pathway: Meat NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG GI-LLI SKIN H-3 0.00E+00 3.25E+02 3.25E+02 3.25E+02 3.25E+02 3.25E+02 3.25E+02 0.OOE+00 C-14 3.33E+05 6.66E+04 6.66E+04 6.66E+04 6.66E+04 6.66E+04 6.66E+04 0.OOE+00 NA-22 7.29E+08 7.29E+08 7.29E+08 7.29E+08 7.29E+08 7.29E+08 7.29E+08 O.OE+00 NA-24 4.07E-04 4.07E-04 4.07E-04 4.07E-04 4.07E-04 4.07E-04 4.07E-04 0.OOE+00 P-32 2.14E+08 8.57E+07 5.33E+07 0.OOE+00 0.OOE+00 0.OOE+00 1.55E+08 O.OOE+00 CA-41 1.1OE+09 O.OOE+00 1.19E+08 0.OOE+00 O.OOE+00 0.OOE+00 1.09E+06 O.OOE+00 SC-46 7.20E+04 1.40E+05 4.07E+04 0.OOE+00 1.31E+05 0.OOE+00 6.81E+08 O.OOE+00 CR-51 0.OOE+00 0.OOE+00 2.25E+03 1.34E+03 4.95E+02 2.98E+03 5.65E+05 0.OOE+00 MN-54 0,00E+00 4.55E+06 8.68E+05 0.0OE+00 1.35E+06 0.OOE+00 1.39E+07 0.OOE+00 FE-55 1.54E+08 1.06E+08 2.48E+07 0.OOE+00 0.OOE+00 5.93E+07 6.1OE+07 0.OOE+00 MN-56 0.OOE+00 5.15E-54 9.13E-55 0.OOE+00 6.53E-54 0.OOE+00 1.64E-52 O.OOE+00 CO-57 0.OOE+00 1.69E+06 2.81E+06 0.OOE+00 0.OOE+00 0.OOE+00 4.29E+07 O.OOE+00 CO-58 0.OOE+00 7.20E+06 1.61E+07 0.OOE+00 0.0OE+00 0.OOE+00 1.46E+08 0.OOE+00 FE-59 9.40E+07 2.21E+08 8.46E+07 0.OOE+00 0.OOE+00 6.17E+07 7.36E+08 0.OOE+00 CO-60 0.00E+00 4.OOE+07 8.83E+07 0.OOE+00 0.OOE+00 0.OOE+00 7.52E+08 0.OOE+00 NI-59 7.66E+08 2.63E+08 3.71 E+08 0.OOE+00 OOOE+00 0.OOE+00 5.42E+07 0.OOE+00 NI-63 1.02E+10 7.06E+08 3142E+08 O.OOE+00 0.OOE+00 0.OOE+00 1.47E+08 0.OOE+00 CU-64 0.00E+00 8.18E-08 3.84E-08 0.OOE+00 2.06E-07 0.OOE+00 6.97E-06 0.OOE+00 NI-65 7.65E-53 9.95E-54 4.54E-54 0.OOE+00 0.OOE+00 O.OOE+00 2.52E-52 0.OOE+00 ZN-65 1.72E+08 5.48E+08 2.48E+08 0.OOE+00 3.67E+08 O.0OE+00 3.45E+08 O.OOE+00 ZN-69m 5.04E-06 1.21E-05 1.11E-06 0.OOE+00 7.32E-06 0.OOE+00 7.38E-04 0.OOE+00 ZN-69 8.02E-154 1.53E-153 1.07E-154 0.OOE+00 9.97E-154 0.OOE+00 2.31E-154 0.OOE+00 SE-79 0.OOE+00 5.84E+07 9.75E+06 0.OOE+00 1.01E+08 0.OOE+00 1.20E+07 0.OOE+00 BR-82 0.00E+00 0.OOE+00 3.61E+02 O.OOE+00 O.OOE+00 0.OOE+00 4.14E+02 O.OOE+00 BR-83 0.OOE+00 0.OOE+00 2.06E-57 0.OOE+00 0.OOE+00 0.OOE+00 2.97E-57 0.OOE+00 BR-84 0.OOE+00 0.OOE+00 4.OOE-270 0.OOE+00 0.OOE+00 0.OOE+00 3.14E-275 0.OOE+00 BR-85 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 RB-86 0.OOE+00 1.47E+08 6.84E+07 0.OOE+00 0.OOE+00 0.OOE+00 2.90E+07 0.OOE+00 RB-87 0.OOE+00 5.65E+08 1.97E+08 O.OOE+00 O.OOE+00 0.OOE+00 2.64E+07 0.OOE+00 RB-88 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 RB-89 0.OOE+00 0.OOE+00 O.OOE+00 0.0OE+00 0.OOE+00 0.OOE+00 O.OOE+00 O.OOE+00 SR-89 1.1OE+08 0.OOE+00 3.16E+06 0.OOE+00 0.OOE+00 0.OOE+00 1.76E+07 0.OOE+00 SR-90 6.70E+09 0.OOE+00 1.64E+09 0.OOE+00 0.OOE+00 0.OOE+00 1.94E+08 0.OOE+00 Y-90 3.17E+01 0.OOE+00 8.49E-01 0.OOE+00 0.OOE+00 0.OOE+00 3.36E+05 0.O0E+00 SR-91 4.63E-11 0.OOE+00 1.87E-12 0.OOE+00 0.OOE+00 0.OOE+00 2.20E-10 0.OOE+00 Y-91m 3.25E-175 0.00E+00 1.26E-176 0.OOE+00 0.OOE+00 0.OOE+00 9.54E-175 0.OOE+00 Y-91 4.28E+05 O.OOE+00 1.14E+04 O.OOE+00 0.OOE+00 0.OOE+00 2.35E+08 0.OOE+00 SR-92 3.97E-50 0.OOE+00 1.72E-51 O.OOE+00 0.OOE+00 0.OOE+00 7.87E-49 0.OOE+00 Y-92 4.95E-40 0.OOE+00 1.45E-41 0.OOE+00 0.OOE+00 0.O0E+00 8.66E-36 0.OOE+00 Y-93 1.43E-12 0.OOE+00 3.94E-14 0.OOE+00 0.OOE+00 0.OOE+00 4.52E-08 0.OOE+00 NB-93m 1.05E+07 3.41E+06 8.41E+05 0.OOE+00 3.93E+06 0.OOE+00 1.58E+09 0.OOE+00 NB-95 7.68E+05 4.27E+05 2.30E+05 0.OOE+00 4.22E+05 0.OOE+00 2.59E+09 0.OOE+00 NB-97 2.38E-119 6.01E-120 2.19E-120 0.OOE+00 7.01E-120 O.OE+00 2.22E-116 0.OOE+00 ZR-93 2.11 E+06 1.18E+05 5.49E+04 0.OOE+00 4.47E+05 O.OOE+00 1.22E+09 0.O0E+00

CY-LG-170-301, Rev. 23 Page 150 08/07 TABLE 112-2 Ri DOSE FACTORS Age: Adult Pathway: Meat (Continued)

NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG GI-LLI SKIN ZR-95 7.23E+05 2.32E+05 1.57E+05 0.OOE+00 3.64E+05 0.00E+00 7.35E+08 0.00E+00 ZR-97 6.18E-06 1.25E-06 5.71E-07 0.OOE+00 1.88E-06 0.00E+00 3.87E-01 0.00E+00 MO-93 0.00E+00 8.90E+07 2.41E+06 0.00E+00 2.52E+07 0.00E+00 1.45E+07 0.00E+00 MO-99 0.OOE+00 2.94E+04 5.60E+03 0.OOE+00 6.66E+04 0.00E+00 6.82E+04 O.00E+00 TC-99 7.41E+07 1.1OE+08 2.97E+07 0.OOE+00 1.39E+09 9.36E+06 3.60E+09 0.00E+00 TC-99m 1.39E-21 3.92E-21 4.99E-20 0.00E+00 5.95E-20 1.92E-21 2.32E-18 0.00E+00 TC-101 0.00E+00 0.00E+00 0.OOE+00 0.OOE+00 0.OOE+00 0.00E+00 0.00E+00 0.00E+00 RU-103 3.61E+07 0.00E+00 1.56E+07 0.OOE+00 1.38E+08 0.00E+00 4.22E+09 0.00E+00 RU-105 1.84E-28 O.OOE+00 7.27E-29 O.OOE+00 2.38E-27 O.OOE+00 1.13E-25 O.OOE+00 RU-106 1.40E+09 O.OOE+00 1.78E+08 O.OOE+00 2.71E+09 O.OOE+00 9.09E+10 O.OOE+00 RH-105 2.68E+05 1.96E+05 1.29E+05 O.OOE+00 8.32E+05 O.OOE+00 3.12E+06 O.OOE+00 PD-107 O.OOE+00 8.71E+05 5.57E+04 O.OOE+00 7.82E+06 O.OOE+00 5.40E+06 O.OOE+00 PD-109 O.OOE+00 3.97E-07 8.95E-08 O.OOE+00 2.27E-06 O.OOE+00 4.40E-05 0.OOE+00 AG-110m 3.24E+06 3.OOE+06 1.78E+06 O.OOE+00 5.90E+06 O.OOE+00 1.22E+09 O.OOE+00 AG-111 4.30E+04 1.80E+04 8.95E+03 O.OOE+00 5.80E+04 0.OOE+00 3.30E+07 O.OOE+00 CD-113m O.OOE+00 2.47E+06 7.92E+04 O.OOE+00 2.72E+06 O.OOE+00 1.99E+07 0.OOE+00 CD-115m O.OOE+00 5.28E+05 1.68E+04 O.OOE+00 4.19E+05 0.OOE+00 2.13E+07 0.OOE+00 SN-123 2.46E+09 4.08E+07 6.01 E+07 3.47E+07 O.OOE+00 O.OOE+00 5.01 E+09 0.OOE+00 SN-125 5.18E+07 1.04E+06 2.35E+06 8.65E+05 O.OOE+00 O.OOE+00 6.47E+08 O.OOE+00 SN-126 9.98E+09 1.98E+08 2.84E+08 5.83E+07 O.OOE+00 O.OOE+00 2.88E+09 O.OOE+00 SB-124 7.53E+06 1.42E+05 2.98E+06 1.83E+04 O.OOE+00 5.86E+06 2.14E+08 O.OOE+00 SB-125 1.OOE+07 1.12E+05 2.39E+06 1.02E+04 O.OOE+00 7.74E+06 1.10E+08 O.OOE+00 SB-126 5.70E+05 1.16E+04 2.06E+05 3.49E+03 O.OOE+00 3.49E+05 4.66E+07 O.OOE+00 SB-127 4.87E+03 1.07E+02 1.87E+03 5.86E+01 O.OOE+00 2.89E+03 1.11E+06 O.OOE+00 TE-125m 1.35E+08 4.90E+07 1.81E+07 4.07E+07 5.50E+08 O.OOE+00 5.40E+08 O.OOE+00 TE-127m 4.82E+08 1.72E+08 5.88E+07 1.23E+08 1.96E+09 O.OOE+00 1.62E+09 O.OOE+00 TE-127 6.47E-11 2.32E-11 1.40E-11 4.79E-11 2.63E-10 O.OOE+00 5.10E-09 O.OOE+00 TE-129m 3.76E+08 1.40E+08 5.95E+07 1.29E+08 1.57E+09 O.OOE+00 1.89E+09 0.OOE+00 TE-129 1.82E-121 6.84E-122 4.43E-122 1.40E-121 7.65E-121 O.OOE+00 1.37E-121 O.OOE+00 TE-133m 2.52E-153 1.47E-153 1.42E-153 2.13E-153 1.46E-152 O.OOE+00 3.62E-153 0.OOE+00 TE-134 1.62E-204 1.06E-204 6.49E-205 1.41E-204 1.02E-203 O.OOE+00 1.79E-207 0.OOE+00 1-129 7.02E+07 6.04E+07 1.98E+08 1.55E+11 1.08E+08 O.OOE+00 9.54E+06 0.OOE+00 1-130 6.36E-07 1.88E-06 7.41E-07 1.59E-04 2.93E-06 O.OOE+00 1.62E-06 0.OOE+00 1-131 3.15E+06 4.50E+06 2.58E+06 1.48E+09 7.72E+06 O.OOE+00 1.19E+06 O.OOE+00 TE-131m 1.34E+02 6.54E+01 5.45E+01 1.04E+02 6.62E+02 0.OOE+00 6.49E+03 O.OOE+00 TE-131 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 0.OOE+00 O.OOE+00 1-132 2.41 E-59 6.44E-59 2.25E-59 2.25E-57 1.03E-58 0.OOE+00 1.21 E-59 O.OOE+00 TE-132 4.17E+05 2.70E+05 2.53E+05 2.98E+05 2.60E+06 O.OOE+00 1.28E+07 O.OOE+00 1-133 1.09E-01 1.89E-01 5.77E-02 2.78E+01 3.30E-01 O.OOE+00 1.70E-01 O.OOE+00 CS-134m 8.74E-48 1.84E-47 9.39E-48 O.OOE+00 9.97E-48 1.57E-48 6.48E-48 O.OOE+00 CS-134 3.42E+08 8.14E+08 6.66E+08 O.OOE+00 2.64E+08 8.75E+07 1.43E+07 O.OOE+00 1-134 4.83E-162 1.31E-161 4.69E-162 2.27E-160 2.09E-161 O.OOE+00 1.14E-164 O.OOE+00 1-135 1.37E-17 3.59E-17 1.33E-17 2.37E-15 5.76E-17 O.OOE+00 4.06E-17 O.OOE+00 CS-135 1.16E+08 1.07E+08 4.73E+07 O.OOE+00 4.03E+07 1.21E+07 2.49E+06 O.OOE+00 CS-136 3.56E+06 1.40E+07 1.01E+07 0.OOE+00 7.81E+06 1.07E+06 1.59E+06 0.OOE+00

CY-LG-170-301, Rev. 23 Page 151 08/07 TABLE 112-2 Ri DOSE FACTORS Age: Adult Pathway: Meat (Continued)

NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG GI-LLI SKIN CS-137 4.70E+08 6.43E+08 4.21E+08 O.OOE+O0 2.18E+08 7.25E+07 1.24E+07 O.OOE+00 CS-138 1.61E-267 3.18E-267 1.57E-267 O.OOE+00 2.34E-267 2.31E-268 1.36E-272 O.OOE+00 CS-1 39 O.OE+00 O.OE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 BA-139 4.80E-102 3.42E-105 1.41E-103 O.OOE+00 3.20E-105 1.94E-105 8.51E-102 O.OOE+00 BA-140 8.47E+06 1.06E+04 5.55E+05 O.OOE+00 3.62E+03 6.09E+03 1.74E+07 O.OOE+00 LA-140 1.1OE-02 5.52E-03 1.46E-03 O.OOE+00 O.OOE+00 O.OOE+00 4.05E+02 O.OOE+00 BA-141 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 LA-141 1.26E-37 3.90E-38 6.39E-39 O.OOE+00 O.OOE+00 O.OOE+00 4.65E-33 O.OOE+00 CE-141 4.62E+03 3.13E+03 3.54E+02 O.OOE+00 1.45E+03 O.OOE+00 1.19E+07 O.OOE+00 BA-142 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 LA-142 1.28E-92 5.84E-93 1.45E-93 O.OOE+00 O.OOE+00 O.OOE+00 4.26E-89 O.OOE+00 CE-143 5.94E-03 4.39E+00 4.86E-04 O.OOE+00 1.93E-03 O.OOE+00 1.64E+02 O.OOE+00 PR-143 6.19E+03 2.48E+03 3.07E+02 O.OOE+00 1.43E+03 O.OOE+00 2.71 E+07 O.OOE+00 CE-144 7.16E+05 2.99E+05 3.85E+04 O.OOE+00 1.78E+05 O.OOE+00 2.42E+08 O.OOE+00 PR-144 O.OOE+00 O.OOE+00 O.OOE+00 0.00E+00 O.OOE+00 O.OOE+00 O.OOE+00 O.0OE+00 ND-147 2.08E+03 2.40E+03 1.44E+02 O.OOE+00 1.40E+03 O.OOE+00 1.15E+07 O.OOE+00 PM-147 5.06E+05 4.76E+04 1.89E+04 O.OOE+00 8.99E+04 O.OOE+00 5.99E+07 O.OOE+00 PM-148m 7.49E+04 1.94E+04 1.48E+04 O.OOE+00 2.93E+04 O.OOE+00 1.64E+08 O.OOE+00 PM-148 1.75E+04 2.90E+03 1.46E+03 O.OE+00 5.49E+03 O.OOE+00 2.28E+08 O.OOE+00 PM-149 1.51E+00 2.14E-01 8.74E-02 O.OOE+00 4.04E-01 O.OOE+00 4.01E+04 O.OOE+00 PM-151 1.71E-03 2.87E-04 1.45E-04 O.OOE+00 5.12E-04 O.OOE+00 7.89E+01 O.OOE+00 SM-151 5.10E+05 8.80E+04 2.11E+04 O.OOE+00 9.83E+04 O.OOE+00 3.88E+07 O.OOE+00 SM-153 3.38E-01 2.82E-01 2.06E-02 O.OOE+00 9.1OE-02 O.OOE+00 1.OOE+04 Q.OOE+00 EU-152 1.37E+06 3.12E+05 2.74E+05 O.OOE+00 1.93E+06 O.OOE+00 1.80E+08 O.OOE+00 EU-154 4.30E+06 5.28E+05 3.76E+05 O.OOE+00 2.53E+06 O.OOE+00 3.83E+08 Q.OOE+00 EU-155 5.93E+05 8.41E+04 5.42E+04 O.OOE+00 3.88E+05 O.OOE+00 6.62E+07 O.OOE+00 EU-156 1.12E+04 8.65E+03 1.39E+03 O.OOE+00 5.77E+03 O.OOE+00 5.92E+07 O.OOE+00 TB-160 1.56E+05 O.OOE+00 1.94E+04 O.OOE+00 6.43E+04 O.OOE+00 1.43E+08 O.OOE+00 HO-166m 1.76E+06 5.49E+05 4.17E+05 O.OOE+00 8.21E+05 O.OOE+00 6.52E-12 O.OOE+00 W-181 1.24E+04 4.05E+03 4.34E+02 O.OOE+00 O.OOE+00 O.OOE+00 4.62E+05 O.OOE+00 W-185 4.05E+05 1.35E+05 1.42E+04 O.OOE+00 O.OOE+00 O.OOE+00 1.56E+07 O.OOE+00 W-187 6.14E-03 5.14E-03 1.80E-03 O.OOE+00 O.0OE+00 O.OOE+00 1.68E+00 O.OOE+00 NP-239 7.63E-02 7.50E-03 4.14E-03 O.OOE+00 2.34E-02 O.OE+00 1.54E+03 O.OOE+00 U-232 2.08E+09 O.OOE+00 1.48E+08 O.OOE+00 2.25E+08 O.OOE+00 3.41 E+07 O.OOE+00 U-233 4.39E+08 O.OOE+00 2.66E+07 O.OOE+00 1.02E+08 O.OOE+00 3.16E+07 O.OOE+00 U-234 4.21E+08 0.OOE+00 2.60E+07 O.OOE+00 1.OOE+08 O.OOE+00 3.09E+07 O.OOE+00 U-235 4.03E+08 O.OOE+00 2.45E+07 O.OOE+00 9.42E+07 O.OOE+00 3.93E+07 O.OOE+00 U-236 4.03E+08 O.OOE+00 2.50E+07 O.OOE+00 9.62E+07 O.OOE+00 2.90E+07 O.OOE+00 U-237 6.28E+02 O.OOE+00 1.67E+02 O.0OE+00 2.58E+03 O.O0E+00 2.21E+05 0.OOE+00 U-238 3.86E+08 O.OOE+00 2.29E+07 O.00E+00 8.81 E+07 O.OOE+00 2.77E+07 O.OOE+00 NP-237 3.73E+08 2.65E+07 1.64E+07 O.OOE+00 1.22E+08 O.OOE+00 2.35E+07 Q.OOE+00 NP-238 4.14E-01 1.11E-02 6.43E-03 O.OOE+00 3.77E-02 O.0OE+00 1.04E+03 O.OOE+00 PU-238 1.30E+07 1.65E+06 3.54E+05 O.OOE+00 1.52E+06 O.OOE+00 1.51E+06 O.OOE+00 PU-239 1.50E+07 1.81E+06 3.96E+05 O.OOE+00 1.68E+06 O.OOE+00 1.38E+06 O.OOE+00

CY-LG-170-301, Rev. 23 Page 152 08/07 TABLE 112-2 Ri DOSE FACTORS Age: Adult Pathway: Meat (Continued)

NUCLIDE BONE LIVER T BODY THYRNII" KIliNFY I IJN Mr 1-111 SKIN PU-240 1.50E+07 1.80E+06 3.96E+05 0.OOE+00 1.68E+06 0.OOE+00 1.41E+06 0.OOE+00 PU-241 3.22E+05 1.53E+04 6.81 E+03 0.00E+00 3.14E+04 0.OOE+00 2.87E+04 0.OOE+00 PU-242 1.39E+07 1.74E+06 3.82E+05 0.OOE+00 1.62E+06 0.OOE+00 1.35E+06 0.OOE+00 PU-244 1.63E+07 1.99E+06 4.38E+05 0.OOE+00 1.86E+06 0.OOE+00 2.02E+06 0.OOE+00 AM-241 2.24E+08 2.09E+08 1.60E+07 0.OOE+00 1.2 IE+08 0.OOE+00 2.20E+07 0.OOE+00 AM-242m 2.25E+08 1.96E+08 1.61 E+07 0.OOE+00 1.20E+08 0.OOE+00 2.76E+07 0.OOE+00 AM-243 2.23E+08 2.04E+08 1.57E+07 0.OOE+00 1.18E+08 0.O0E+00 2.58E+07 0.OOE+00 CM-242 4.41 E+06 4.69E+06 2.93E+05 0.OOE+00 1.33E+06 0.OOE+00 1.70E+07 0.OOE+00 CM-243 1.76E+08 1.62E+08 1.10E+07 0.OOE+00 5.16E+07 0.OOE+00 2.30E+07 0.OOE+00 CM-244 1.34E+08 1.25E+08 8.43E+06 0.00E+00 3.94E+07 0.OOE+00 2.22E+07 0.OOE+00 CM-245 2.78E+08 2.42E+08 1.71 E+07 0.OOE+00 7.97E+07 0.00E+00 2.09E+07 0.OOE+00 CM-246 2.76E+08 2.42E+08 1.70E+07 0.OOE+00 7.94E+07 0.OOE+00 2.05E+07 0.OOE+00 CM-247 2.69E+08 2.38E+08 1.68E+07 0.OOE+00 7.82E+07 0.OOE+00 2.69E+07 0.OOE+00 CM-248 2.23E+09 1.96E+09 1.38E+08 0.OOE+00 6.46E+08 0.OOE+00 4.35E+08 0.OOE+00 CF-252 7.30E+07 0.00E+00 1.76E+06 0,00E+00 0.00E+00 0.00E+00 8.05E+07 0.OOE+00

CY-LG-170-301, Rev. 23 I Page 153 08/07I TABLE 112-2 Ri DOSE FACTORS Age: Adult Pathway: Cow Milk NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG GI-LLI SKIN H-3 O.OOE+00 7.63E+02 7.63E+02 7.63E+02 7.63E+02 7.63E+02 7.63E+02 0.OOE+00 C-14 3.63E+05 7.26E+04 7.26E+04 7.26E+04 7.26E+04 7.26E+04 7.26E+04 0.OOE+00 NA-22 2.78E+09 2.78E+09 2.78E+09 2.78E+09 2.78E+09 2.78E+09 2.78E+09 0.OOE+00 NA-24 7.13E+05 7.13E+05 7.13E+05 7.13E+05 7.13E+05 7.13E+05 7,13E+05 0.OOE+00 P-32 7.86E+08 3.14E+08 1.95E+08 0.OOE+00 0.OOE+00 0.OOE+00 5.68E+08 0.OOE+00 CA-41 6.18E+09 0.OOE+00 6.68E+08 0.OOE+00 0.OOE+00 0.OOE+00 6.14E+06 0.OOE+00 SC-46 7.36E+01 1.43E+02 4.15E+01 0.OOE+00 1.33E+02 0.OOE+00 6.96E+05 0.OOE+00 CR-51 0.O0E+00 0.OOE+00 9.1OE+03 5.44E+03 2.01E+03 1.21E+04 2.29E+06 O.OOE+00 MN-54 O.OOE+00 4.17E+06 7.95E+05 0.OOE+00 1.24E+06 0.OOE+00 1.28E+07 0.OOE+00 FE-55 1.32E+07 9.11E+06 2.12E+06 0.OOE+00 O.OOE+00 5.08E+06 5.23E+06 0.OOE+00 MN-56 0.OOE+00 1.21E-03 2.15E-04 0.OOE+00 1.54E-03 0.OOE+00 3.87E-02 0.OOE+00 CO-57 0.OOE+00 4.37E+05 7.27E+05 0.OOE+00 0.OOE+00 0.OOE+00 1.11E+07 0.OOE+00 CO-58 0.OOE+00 1.86E+06 4.17E+06 0.OOE+00 0.0OE+00 0.OOE+00 3.77E+07 0.OOE+00 FE-59 1.05E+07 2.47E+07 9.46E+06 0.OOE+00 0.OOE+00 6.90E+06 8.23E+07 0.OOE+00 CO-60 0.OOE+00 8.73E+06 1.93E+07 0.OOE+00 0.OOE+00 0.OOE+00 1.64E+08 0.OOE+00 NI-59 2.73E+08 9.37E+07 1.32E+08 0.OOE+00 0.OOE+00 O.OOE+00 1.93E+07 0.OOE+00 NI-63 3.63E+09 2.52E+08 1.22E+08 0.OOE+00 0.OOE+00 0.OOE+00 5.25E+07 0.OOE+00 CU-64 O.OOE+00 6.97E+03 3.27E+03 0.OOE+00 1.76E+04 0.OOE+00 5.94E+05 0.OOE+00 NI-65 1.08E-01 1.41E-02 6.41E-03 0.OOE+00 0.OOE+00 0.OOE+00 3.57E-01 0.OOE+00 ZN-65 6.65E+08 2.11E+09 9.56E+08 0.OOE+00 1.41E+09 0.OOE+00 1.33E+09 0.OOE+00 ZN-69m 5.23E+04 1.26E+05 1.15E+04 O.OOE+00 7.60E+04 0.OOE+00 7.67E+06 0.OOE+00 ZN-69 6.12E-13 1.17E-12 8.14E-14 0.OOE+00 7.60E-13 0.OOE+00 1.76E-13 0.OOE+00 SE-79 0.OOE+00 4.94E+08 8.25E+07 O.OOE+00 8.55E+08 0.OOE+00 1.01E+08 0.OOE+00 BR-82 0.OOE+00 0.OOE+00 9.45E+06 0.OOE+00 0.OOE+00 0.OOE+00 1.08E+07 0.OOE+00 BR-83 0.OOE+00 O.OOE+00 2.84E-02 0.OOE+00 0.OOE+00 0.OOE+00 4.09E-02 0.OOE+00 BR-84 0.OOE+00 O.OE+00 4.71 E-24, 0.OOE+00 0.OOE+00 0.00E+00 3.69E-29 0.OOE+00 BR-85 0.OOE+00 0.OOE+00 5.70E-302 0.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 RB-86 0.OOE+00 7,82E+08 3.64E+08 0.OOE+00 0.OOE+00 0.OOE+00 1.54E+08 0.OOE+00 RB-87 0.OOE+00 1.54E+09 5.36E+08 O.OOE+00 0.OOE+00 0.OOE+00 7.21E+07 0.OOE+00 RB-88 0.OOE+00 6.26E-46 3.32E-46 0.OOE+00 O.OE+00 0.OOE+00 8.64E-57 0.OOE+00 RB-89 0.OOE+00 1.27E-53 8.91E-54 O.OOE+00 0.OOE+00 0.OOE+00 7.36E-67 0.OOE+00 SR-89 5.29E+08 O.OOE+00 1.52E+07 0.OOE+00 0.OOE+00 0.OOE+00 8.48E+07 0.OOE+00 SR-90 2.52E+10 O.OOE+00 6.19E+09 0.OOE+00 0.OOE+00 0.OOE+00 7.28E+08 0.OOE+00 Y-90 2.07E+01 0.OOE+00 5.56E-01 0.OOE+00 0.OOE+00 0.OOE+00 2.20E+05 0.OOE+00 SR-91 8.46E+03 0.OOE+00 3.42E+02 0.OOE+00 0.OOE+00 0.OOE+00 4.03E+04 0.OOE+00 Y-91m 1.75E-20 O.OOE+00 6.78E-22 0.OOE+00 0.OOE+00 O.OOE+00 5.14E-20 O.OOE+00 Y-91 3.24E+03 0.OOE+00 8.67E+01 0.OOE+00 0.OOE+00 0.OOE+00 1.79E+06 O.OOE+00 SR-92 1.43E-01 0.OOE+00 6.18E-03 O.OOE+00 0.OOE+00 0.OOE+00 2.83E+00 0.OOE+00 Y-92 1.63E-05 0.OOE+00 4.77E-07 0.OOE+00 0.OOE+00 0.OOE+00 2.86E-01 0.OOE+00 Y-93 6.53E-02 0.O0E+00 1.80E-03 0.OOE+00 O.OOE+00 0.OOE+00 2.07E+03 O.OOE+00 NB-93m 2.64E+05 8.61E+04 2.12E+04 O.OOE+00 9.91E+04 0.OOE+00 3.97E+07 O.OOE+00 NB-95 2.76E+04 1.54E+04 8.25E+03 0.OOE+00 1.52E+04 0.OOE+00 9.32E+07 0.OOE+00 NB-97 9.62E-13 2.43E-13 8.89E-14 0.OOE+00 2.84E-13 0.OOE+00 8.98E-10 0.OOE+00 ZR-93 8.72E+02 4.88E+01 2.28E+01 0.OOE+00 1.85E+02 0.OOE+00 5.07E+05 O.OOE+00

CY-LG-170-301, Rev. 23 Page 154 08/07 TABLE 112-2 Ri DOSE FACTORS Age: Adult Pathway: Cow Milk (Contirnued)

NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG GI-LLI SKIN ZR-95 3.64E+02 1.17E+02 7.90E+01 0.OOE+00 1.83E+02 0.OOE+00 3.70E+05 0.OOE+00 ZR-97 1.27E-01 2.56E-02 1.17E-02 O.OOE+00 3.86E-02 0.OOE+00 7.92E+03 0.OOE+00 MO-93 O.00E+00 2.35E+08 6.36E+06 0.OOE+00 6.67E+07 0.OOE+00 3.82E+07 0.OOE+00 MO-99 O.OOE+00 7.25E+06 1.38E+06 0.OOE+00 1.64E+07 0.OOE+00 1.68E+07 0.OOE+00 TC-99 1.30E+07 1.94E+07 5.24E+06 0.OOE+00 2.44E+08 1.65E+06 6.35E+08 0.OOE+00 TC-99m 9.71 E-01 2.74E+00 3.50E+01 0.OOE+00 4.17E+01 1.34E+00 1.62E+03 0.OOE+00 TC-101 7.58E-61 1.09E-60 1.07E-59 0.OOE+00 1.97E-59 5.58E-61 3.28E-72 0.OOE+00 RU-103 3.49E+02 0.OOE+00 1.51E+02 0.OOE+00 1.33E+03 0.OOE+00 4,08E+04 0.OOE+00 RU-105 2.51 E-04 O.OOE+00 9.89E-05 0.OOE+00 3.24E-03 0.OOE+00 1.53E-01 0.OOE+00 RU-106 1.02E+04 O.OOE+00 1.29E+03 O.OOE+00 1.98E+04 0.OOE+00 6.62E+05 0.OOE+00 RH-105 5.03E+06 3.68E+06 2.43E+06 O.OOE+00 1.56E+07 0.OOE+00 5.87E+07 0.OOE+00 PD-107 O.00E+00 6.14E+06 3.92E+05 O.OOE+00 5.51 E+07 0.OOE+00 3.80E+07 0.OOE+00 PD-109 0.00E+00 1.30E+04 2.92E+03 O.OOE+00 7.39E+04 0.OOE+00 1.43E+06 0.OOE+00 AG-110m 2.83E+07 2.61 E+07 1.55E+07 O.OOE+00 5.14E+07 0.OOE+00 1.07E+10 0,OOE+00 AG-111 1.90E+06 7.93E+05 3.95E+05 O.00E+00 2.56E+06 0.OOE+00 1.46E+09 0.OOE+00 CD-1 13m 0.OOE+00 1.58E+06 5.06E+04 O.OOE+00 1.74E+06 0.OOE+00 1.27E+07 0.OOE+00 CD-1 15m 0.00E+00 4.45E+05 1.42E+04 0.OOE+00 3.53E+05 0.OOE+00 1.80E+07 0.OOE+00 SN-123 2.39E+08 3.96E+06 5.83E+06 3.36E+06 0.OOE+00 0.OOE+00 4.86E+08 0.OOE+00 SN-125 1.66E+07 3.36E+05 7.55E+05 2.78E+05 0.OOE+00 0.OOE+00 2.08E+08 0.OOE+00 SN-126 8.79E+08 1.74E+07 2.50E+07 5.13E+06 0.OOE+00 0.OOE+00 2.54E+08 0.OOE+00 SB-124 9.79E+06 1.85E+05 3.88E+06 2.37E+04 0.OOE+00 7.62E+06 2.78E+08 0.OOE+00 SB-125 1.07E+07 1.20E+05 2.56E+06 1.09E+04 0.OOE+00 8.28E+06 1.18E+08 0.OOE+00 SB-126 1.65E+06 3.35E+04 5.94E+05 1.01E+04 0.OOE+00 1.01 E+06 1.35E+08 0.OOE+00 SB-127 1.32E+05 2.88E+03 5.05E+04 1.58E+03 0.OOE+00 7.80E+04 3.01E+07 0.OOE+00 TE-125m 6.14E+06 2.22E+06 8.23E+05 1.85E+06 2.50E+07 0.OOE+00 2.45E+07 0.OOE+00 TE-127m 1.98E+07 7.07E+06 2.41 E+06 5.06E+06 8.04E+07 0.OOE+00 6.63E+07 0.OOE+00 TE-127 1.91E+02 6.86E+01 4.13E+01 1.41E+02 7.78E+02 0.OOE+00 1.51E+04 0.OOE+00 TE-129m 1.99E+07 7,44E+06 3.16E+06 6.85E+06 8.32E+07 0.OOE+00 1.OOE+08 0.OOE+00 TE-129 8.26E-1 1 3.1OE- 11 2.01 E-1 1 6.34E-1 1 3.47E-10 0.OOE+00 6.23E-11 0.OOE+00 TE-133m 6.16E-14 3.60E-14 3.46E-14 5.21 E-14 3.56E-13 0.OOE+00 8.85E-14 0.OOE+00 TE-134 2.60E-19 1.70E-19 1.04E-19 2.27E-19 1.65E-18 0.OOE+00 2.89E-22 0.OOE+00 1-129 4.10E+08 3.52E+08 1.15E+09 9.05E+11 6.31 E+08 0.OOE+00 5.56E+07 0.OOE+00 1-130 1.23E+05 3.62E+05 1.43E+05 3.07E+07 5.66E+05 0.OOE+00 3.12E+05 0.OOE+00 1-131 8.66E+07 1.24E+08 7.1 OE+07 4.06E+10 2.12E+08 0.OOE+00 3.27E+07 0.OOE+00 TE-131m 1.06E+05 5.16E+04 4.30E+04 8.18E+04 5.23E+05 0.OOE+00 5.13E+06 0.OOE+00 TE-131 1.05E-33 4.40E-34 3.33E-34 8.67E-34 4.62E-33 0.OOE+00 1.49E-34 0.OOE+00 1-132 4.80E-02 1,29E-01 4.50E-02 4.50E+00 2.05E-01 0.OOE+00 2.41 E-02 0.OOE+00 TE-132 7.02E+05 4.54E+05 4.26E+05 5.02E+05 4.38E+06 0.OOE+00 2.15E+07 O.OOE+00 1-133 1.13E+06 1.97E+06 6.OOE+05 2.89E+08 3.44E+06 0.OOE+00 1.77E+06 0.OOE+00 CS-1 34m 5.08E-02 1.07E-01 5.46E-02 0.00E+00 5.79E-02 9.13E-03 3.77E-02 O.OOE+00 CS-134 2.94E+09 7.OOE+09 5.72E+09 0.00E+00 2.27E+09 7.52E+08 1.23E+08 O.OOE+00 1-134 5.90E-13 1.60E-12 5.73E-13 2.78E-1 1 2.55E-12 0.OOE+00 1.40E-15 0.OOE+00 1-135 3.75E+03 9.83E+03 3.63E+03 6.48E+05 1.58E+04 0.OOE+00 1.11E+04 0.OOE+00 CS-135 9.77E+08 9.02E+08 4.OOE+08 0.OOE+00 3.41 E+08 1.02E+08 2.11E+07 0.OOE+00

CY-LG-1 70-301, Rev. 23 I Page 155 08/07I TABLE 112-2 Ri DOSE FACTORS Age: Adult Pathway: Cow Milk (Continued)

NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG GI-LLI SKIN CS-136 7.76E+07 3.06E+08 2.20E+08 O.OOE+00 1.70E+08 2.34E+07 3.48E+07 O.OOE+00 CS-137 3.98E+09 5.44E+09 3.56E+09 O.OOE+00 1.85E+09 6.14E+08 1.05E+08 O.OOE+00 CS-138 2.64E-24 5.22E-24 2.59E-24 Q.OOE+00 3.84E-24 3.79E-25 2.23E-29 O.OOE+00 CS-139 1.98E-90 2.95E-90 1.08E-90 O.OOE+00 2.37E-90 2.15E-91 6.40E-113 O.OOE+00 BA-139 1.29E-08 9.21E-12 3.78E-10 O.OOE+00 8.61E-12 5.22E-12 2.29E-08 O.OOE+00 BA-140 7.91E+06 9.94E+03 5,18E+05 O.OOE+00 3.38E+03 5.69E+03 1.63E+07 O.OOE+00 LA-140 1.32E+00 6.65E-01 1.76E-01 O.OOE+00 O.OOE+00 O.OOE+00 4.88E+04 O.OOE+00 BA-141 1.20E-46 9.05E-50 4.04E-48 O.OOE+00 8.41 E-50 5.14E-50 5.64E-56 O.OOE+00 LA-141 8.90E-06 2.76E-06 4.52E-07 O.OOE+00 O.OOE+00 O.OOE+00 3.29E-01 O.OOE+00 CE-141 1.59E+03 1.08E+03 1.22E+02 O.OE+00 5.OOE+02 O.OOE+00 4.12E+06 O.OOE+00 BA-142 7.77E-81 7.99E-84 4.89E-82 O.OOE+00 6.75E-84 4.53E-84 1.09E-98 O.OOE+00 LA-142 5.43E-12 2.47E-12 6.16E-13 O.OOE+00 O.OOE+00 O.OE+00 1.80E-08 O.OOE+00 CE-143 1.22E+01 8.99E+03 9.95E-01 O.OOE+00 3.96E+00 O.OE+00 3.36E+05 O.OOE+00 PR-143 4.66E+01 1.87E+01 2.31E+00 O.OOE+00 1.08E+01 O.OOE+00 2.04E+05 O.OOE+00 CE-144 1.76E+05 7.35E+04 9,44E+03 O.OOE+00 4.36E+04 O.OOE+00 5.94E+07 O.OOE+00 PR-144 1.72E-54 7.13E-55 8.73E-56 O.OOE+00 4.02E-55 O.OOE+00 2.47E-61 O.OOE+00 ND-147 2.76E+01 3.19E+01 1.91E+00 O.OOE+00 1.87E+01 O.0OE+00 1.53E+05 O.OOE+00 PM-147 1.50E+03 1.41E+02 5.61E+01 O.OOE+00 2.67E+02 O.OOE+00 1.78E+05 O.OOE+00 PM-148m 2.97E+02 7.70E+01 5.89E+01 O.OOE+00 1.16E+02 O.OOE+00 6.53E+05 O.OOE+00 PM-148 6.95E+01 1.15E+01 5.80E+00 O.OOE+00 2.18E+01 O.OOE+00 9.06E+05 O.OOE+00 PM-149 1.25E+00 1,77E-01 7.23E-02 O.OOE+00 3.34E-01 O.OOE+00 3.32E+04 O.OOE+00 PM-151 1.90E-01 3.19E-02 1.61E-02 O.OOE+00 5.70E-02 O.OOE+00 8.78E+03 O.OOE+00 SM-151 1.44E+03 2.48E+02 5.94E+01 O.OOE+00 2.77E+02 O.OQE+00 1.09E+05 0.06E+00 SM-153 5.79E-01 4.83E-01 3.53E-02 O.OOE+00 1.56E-01 0.00E+00 1.72E+04 O.OOE+00 EU-152 4.03E+03 9.19E+02 8.07E+02 O.OOE+00 5.69E+03 O.OOE+00 5.30E+05 O.OOE+00 EU-154 1.27E+04 1.56E+03 1.11E+03 O.OOE+00 7.45E+03 O.OOE+00 1.13E+06 O.OOE+00 EU-155 1.75E+03 2.49E+02 1.60E+02 O.OOE+00 1.15E+03 O.OOE+00 1.96E+05 O.OOE+00 EU-156 7.46E+01 5.77E+01 9.31E+00 O.OOE+00 3.85E+01 O.OOE+00 3.95E+05 O.OOE+00 TB-160 5.93E+02 O.OOE+00 7.39E+01 O.OOE+00 2.45E+02 O0,0E+00 5.46E+05 O.OOE+00 HO-166m 5.63E+03 1.76E+03 1.34E+03 O.OOE+00 2.63E+03 O.OOE+00 2.09E-14 O.OOE+00 W-181 1.49E+04 4.87E+03 5.22E+02 O.OOE+00 O.OOE+00 0.OOE+00 5.55E+05 O.OOE+00 W-185 5.19E+05 1.73E+05 1.82E+04 O.OOE+00 O.OE+00 O.OOE+00 2.OOE+07 O.OOE+00 W-187 1.91E+03 1.59E+03 5.57E+02 O.OOE+00 O.OOE+00 O.OOE+00 5.22E+05 O.OOE+00 NP-239 1.07E+00 1.06E-01 5.82E-02 O.OE+00 3.30E-01 O.OOE+00 2.17E+04 O.OOE+00 U-232 8.61E+09 O.OQE+00 6.15E+08 O.OOE+00 9.31E+08 O.OOE+00 1.41E+08 O.0OE+00 U-233 1.82E+09 O.OOE+00 1.10E+08 O.OOE+00 4.24E+08 OOOE+00 1.31E+08 O.OOE+00 U-234 1.74E+09 O.OOE+00 1.08E+08 O.OOE+00 4.15E+08 O.OOE+00 1.28E+08 O.OOE+00 U-235 1.67E+09 O.OOE+00 1.01E+08 O.OOE+00 3.90E+08 O.OOE+00 1.63E+08 O.OOE+00 U-236 1.67E+09 O.OOE+00 1.04E+08 O.OOE+00 3.99E+08 O.OOE+00 1.20E+08 O.OOE+00 U-237 1.65E+04 O.OOE+00 4.40E+03 O.OOE+00 6.80E+04 Q.OOE+00 5.81E+06 O.OOE+00 U-238 1.60E+09 O.OOE+00 9.48E+07 O.OOE+00 3.65E+08 O.OOE+00 1.15E+08 O.OOE+00 NP-237 2.63E+07 1.87E+06 1.16E+06 O.OOE+00 8.60E+06 O.OOE+00 1.66E+06 O.OOE+00 NP-238 1.06E+01 2.84E-01 1.64E-01 O.OOE+00 9.63E-01 O.00E+00 2.64E+04 O.OOE+00 PU-238 5.25E+06 6.65E+05 1.43E+05 O.OOE+00 6.10E+05 O.OOE+00 6.09E+05 O.OOE+00

CY-LG-1 70-301, Rev. 23 Page 156 08/07 TABLE 112-2 Ri DOSE FACTORS Age: Adult Pathway: Cow Milk (Continued)

NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG GI-LLI SKIN I PU-239 6.05E+06 7.27E+05 1.59E+05 O.OOE+00 6.77E+05 O.OOE+00 5.56E+05 O.OOE+00 PU-240 6.04E+06 7.26E+05 1.59E+05 0.OOE+00 6.76E+05 0.OOE+00 5.66E+05 0.0OE+00 PU-241 1.30E+05 6.17E+03 2.75E+03 0.OOE+00 1.27E+04 0.OOE+00 1.16E+04 0.OOE+00 PU-242 5.61 E+06 7.OOE+05 1.54E+05 0.OOE+00 6.52E+05 0.OOE+00 5.45E+05 0.OOE+00 PU-244 6.55E+06 8.02E+05 1.76E+05 0.OOE+00 7.47E+05 0.OOE+00 8.12E+05 0.OOE+00 AM-241 1.58E+07 1.47E+07 1.13E+06 0.OOE+00 8.49E+06 0.OOE+00 1.55E+06 0.OOE+00 AM-242m 1.59E+07 1.38E+07 1.13E+06 0.OOE+00 8.45E+06 O.OOE+00 1.95E+06 0.OOE+00 AM-243 1.57E+07 1.44E+07 1.11E+06 0.OOE+00 8.33E+06 O.OOE+00 1.82E+06 0.OOE+00 CM-242 3.35E+05 3.57E+05 2.23E+04 0.OOE+00 1.01E+05 O.OOE+00 1.29E+06 O.OOE+00 CM-243 1.24E+07 1.14E+07 7.79E+05 0.OOE+00 3.64E+06 0.OOE+00 1.62E+06 0OOE+00 CM-244 9.45E+06 8.85E+06 5.95E+05 0.OOE+00 2.78E+06 0.OOE+00 1.57E+06 0.OOE+00 CM-245 1.96E+07 1.71E+07 1.20E+06 O.OOE+00 5.61E+06 0.OOE+00 1.47E+06 0.OOE+00 CM-246 1.94E+07 1.70E+07 1.20E+06 0.OOE+00 5.59E+06 0.OOE+00 1.44E+06 0.0OE+00 CM-247 1.89E+07 1.68E+07 1.18E+06 0.OOE+00 5.51E+06 0.OOE+00 1.90E+06 0.OOE+00 CM-248 1.57E+08 1.38E+08 9.75E+06 0.OOE+00 4.55E+07 O.OOE+00 3.07E+07 0.0OE+00 CF-252 5.21E+06 0.OOE+00 1.26E+05 O.OOE+00 0.OOE+00 0.OOE+00 5.75E+06 0.O0E+00

CY-LG-170-301, Rev. 23 Page 157 08/07 TABLE 112-2 Ri DOSE FACTORS Age: Adult Pathway: Goat Milk NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG GI-LLI SKIN H-3 0.OOE+00 1.15E+02 1.15E+02 1.15E+02 1.15E+02 1.15E+02 1.15E+02 0.OOE+00 C-14 2.69E+04 5.39E+03 5.39E+03 5.39E+03 5.39E+03 5.39E+03 5.39E+03 0.OOE+00 NA-22 2.47E+07 2.47E+07 2.47E+07 2.47E+07 2.47E+07 2.47E+07 2.47E+07 0.00E+00 NA-24 6.35E+03 6.35E+03 6.35E+03 6.35E+03 6.35E+03 6.35E+03 6.35E+03 0.OOE+00 P-32 6.99E+07 2.80E+07 1.74E+07 0.OOE+00 0,OOE+00 0.OOE+00 5.06E+07 0.00E+00 CA-41 5.50E+07 0.OOE+00 5.95E+06 0.00E+00 0.OOE+00 0.OOE+00 5.47E+04 0.OOE+00 SC-46 6.55E-01 1.27E+00 3.70E-01 0.OOE+00 1.19E+00 0.OOE+00 6.20E+03 0.OOE+00 CR-51 0.00E+00 0.OOE+00 8.10E+01 4.84E+01 1.79E+01 1.08E+02 2.04E+04 0.OOE+00 MN-54 0.OOE+00 3.71E+04 7.08E+03 0.OOE+00 1.10E+04 0.OOE+00 1.14E+05 0.OOE+00 FE-55 1.27E+04 8.78E+03 2.05E+03 0.OOE+00 O.OOE+00 4.90E+03 5.04E+03 0.OOE+00 MN-56 O.0OE+00 1.08E-05 1.92E-06 0.OOE+00 1.37E-05 0.OOE+00 3.45E-04 0.OOE+00 CO-57 O.OOE+00 3.90E+03 6.48E+03 0.OOE+00 0.OOE+00 0.OOE+00 9.88E+04 0.OOE+00 CO-58 0.OOE+00 1.66E+04 3.72E+04 0.OOE+00 0.OOE+00 0.OOE+00 3.36E+05 0.OOE+00 FE-59 1.01 E+05 2.38E+05 9.13E+04 O.OOE+00 0.OOE+00 6.65E+04 7.94E+05 0.OOE+00 CO-60 0.00E+00 7.78E+04 1.71E+05 0.OOE+00 0.OOE+00 0.OOE+00 1.46E+06 O.OOE+00 NI-59 2.43E+06 8.34E+05 1.18E+06 0.OOE+00 0.00E+00 0.00E+00 1,72E+05 0.OOE+00 NI-63 3.23E+07 2.24E+06 1.08E+06 0.OOE+00 0.OOE+00 0.OOE+00 4.68E+05 O.OOE+00 CU-64 0.00E+00 5.76E+01 2.71E+01 0.OOE+00 1.45E+02 0.OOE+00 4.91E+03 0.OOE+00 NI-65 9.63E-04 1.25E-04 5.71E-05 0.OOE+00 0.OOE+00 0.OOE+00 3.17E-03 0.00E+00 ZN-65 5.92E+06 1.88E+07 8.51E+06 0.OOE+00 1.26E+07 0.OOE+00 1.19E+07 0.00E+00 ZN-69m 4.66E+02 1.12E+03 1.02E+02 0.OOE+00 6.77E+02 0.OOE+00 6.83E+04 0.OOE+00 ZN-69 5.45E-15 1.04E-14 7.24E-16 0.OOE+00 6.77E-15 0.OOE+00 1.57E-15 0.00E+00 SE-79 0.00E+00 4.40E+06 7.34E+05 0.OOE+00 7.61 E+06 0.00E+00 9.00E+05 0.OOE+00 BR-82 0.OOE+00 0.OOE+00 8.42E+04 0.OOE+00 0.OOE+00 0.00E+00 9.64E+04 0.OOE+00 BR-83 0.OOE+00 0.00E+00 2.53E-04 0.OOE+00 0.OOE+00 0.OOE+00 3.64E-04 0.OOE+00 BR-84 0.00E+00 0.OOE+00 4.19E-26 0.OOE+00 0.OOE+00 0.OOE+00 3.29E-31 0.00E+00 BR-85 0.00E+00 0.OOE+00 5.08E-304 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.00E+00 RB-86 0.00E+00 6.96E+06. 3.24E+06 0.OOE+00 0.OOE+00 0.OOE+00 1.37E+06 0.OOE+00 RB-87 0.00E+00 1.37E+07 4.77E+06 0.00E+00 0.O0E+00 0.OOE+00 6.42E+05 0.OOE+00 RB-88 0.00E+00 5.57E-48 2.96E-48 0.OOE+00 0.OOE+00 0.OOE+00 7.70E-59 0.00E+00 RB-89 0.OOE+00 1.13E-55 7.93E-56 0.00E+00 0.OOE+00 0.00E+00 6.55E-69 0.00E+00 SR-89 8.24E+07 0.00E+00 2.37E+06 0.00E+00 0.OOE+00 0.00E+00 1.32E+07 0.OOE+00 SR-90 3.93E+09 0.OOE+00 9.64E+08 0.00E+00 0.OOE+00 0.00E+00 1.13E+08 0.00E+00 Y-90 1.84E-01 0.OOE+00 4.95E-03 0.OOE+00 0.OOE+00 0.OOE+00 1.96E+03 0.OOE+00 SR-91 1.32E+03 0.00E+00 5.32E+01 0.OOE+00 0.OOE+00 0.OOE+00 6.28E+03 0.OOE+00 Y-91m 1.56E-22 O.OOE+00 6.03E-24 0.OOE+00 0.OOE+00 0.OOE+00 4.58E-22 0.OOE+00 Y-91 4.04E+04 0.OOE+00 1.08E+03 O.OOE+00 O.OOE+00 O.OOE+00 2.23E+07 0.OOE+00 SR-92 1.27E-03 0.00E+00 5.50E-05 0.OOE+00 0.00E+00 0.00E+00 2.52E-02 0.00E+00 Y-92 1.45E-07 0.OOE+00 4.25E-09 0.OOE+00 0.00E+00 0.00E+00 2.54E-03 0.OOE+00 Y-93 5.82E-04 0.OOE+00 1.61 E-05 0.00E+00 0.OOE+00 0.OOE+00 1.85E+01 0.00E+00 NB-93m 2.35E+03 7.67E+02 1.89E+02 0.OOE+00 8.82E+02 0.OOE+00 3.54E+05 O.00E+00 NB-95 2.46E+02 1.37E+02 7.35E+01 0.OOE+00 1.35E+02 0.00E+00 8.30E+05 O.00E+00 NB-97 8.57E-15 2.17E-15 7.91E-16 0.OOE+00 2.53E-15 0.OOE+00 7.99E-12 0.OOE+00 ZR-93 7.77E+00 4.35E-01 2.03E-01 0.OOE+00 1.65E+00 0.00E+00 4.52E+03 0.00E+00

CY-LG-170-301, Rev. 23 Page 158 08/07 TABLE 112-2 Ri DOSE FACTORS Age: Adult Pathway: Goat Milk (Continued)

NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG GI-LLI SKIN ZR-95 3.24E+00 1.04E+00 7.04E-01 O.OOE+00 1.63E+00 O.OOE+00 3.29E+03 O.OOE+00 ZR-97 1.13E-03 2.28E-04 1.04E-04 0.OOE+00 3.44E-04 0.OOE+00 7.05E+01 o.o0E+00 MO-93 O.OOE+00 2.09E+06 5.66E+04 O.OOE+00 5.94E+05 0.OOE+00 3.40E+05 O.OOE+00 MO-99 0.OOE+00 6.45E+04 1.23E+04 0.OOE+00 1.46E+05 O.OOE+00 1.50E+05 0.OOE+00 TC-99 1.16E+05 1.73E+05 4.66E+04 O.OOE+00 2.17E+06 1.47E+04 5.65E+06 O.OOE+00 TC-99m 8.65E-03 2.44E-02 3.11E-01 O.OOE+00 3.71 E-01 1.20E-02 1.45E+01 O.OOE+00 TC-101 6.75E-63 9.73E-63 9.54E-62 O.OOE+00 1.75E-61 4.97E-63 2.92E-74 O.OOE+00 RU-103 3.11E+00 O.OOE+00 1.34E+00 O.OOE+00 1.19E+01 O.OOE+00 3.63E+02 0.00E+00 RU-105 2.23E-06 O.OOE+00 8.81 E-07 O.OOE+00 2.88E-05 O.OOE+00 1.36E-03 O.OOE+00 RU-106 9.11E+01 O.OOE+00 1.15E+01 O.OOE+00 1.76E+02 0.OOE+00 5.90E+03 O.OOE+00 RH-105 4.48E+04 3.28E+04 2.16E+04 0.OOE+00 1.39E+05 O.OOE+00 5.22E+05 O.OOE+00 PD-107 O.OOE+00 5.46E+04 3.49E+03 0.OOE+00 4.91 E+05 0.OOE+00 3.39E+05 0.00E+00 PD-109 O.OOE+00 1.15E+02 2.60E+01 0.OOE+00 6.58E+02 0.00E+00 1.28E+04 O.00E+00 AG-110m 2.52E+05 2.33E+05 1.38E+05 O.OOE+00 4.58E+05 0.OOE+00 9.50E+07 O.OOE+00 AG-111 1.69E+04 7.06E+03 3.51 E+03 O.OOE+00 2.28E+04 0.OOE+00 1.30E+07 O.OOE+00 CD-113m O.OOE+00 1.41 E+04 4.51 E+02 O.OOE+00 1.55E+04 0.OOE+00 1.13E+05 0.OOE+00 CD-115m O.OOE+00 3.96E+03 1.26E+02 O.OOE+00 3.15E+03 0.OOE+00 1.60E+05 O.00E+00 SN-123 2.13E+06 3.52E+04 5.19E+04 2.99E+04 O.OOE+00 0.OOE+00 4.33E+06 0.OOE+00 SN-125 1.48E+05 2.99E+03 6.72E+03 2.47E+03 O.OOE+00 O.00E+00 1.85E+06 O.00E+00 SN-126 7.82E+06 1.55E+05 2.23E+05 4.57E+04 O.OOE+00 O.OOE+00 2.26E+06 O.OOE+00 SB-124 8.71E+04 1.65E+03 3.45E+04 2.11E+02 0.OOE+00 6.79E+04 2.47E+06 0.OOE+00 SB-125 9.56E+04 1.07E+03 2.28E+04 9.72E+01 O.OOE+00 7.37E+04 1.05E+06 O.OOE+00 SB-126 1.47E+04 2.98E+02 5.29E+03 8.97E+01 O.OOE+00 8.99E+03 1.20E+06 O.OOE+00 SB-127 1.17E+03 2.57E+01 4.50E+02 1.41E+01 O.OOE+00 6.95E+02 2.68E+05 O.OOE+00 TE-125m 5.47E+04 1.98E+04 7.32E+03 1.64E+04 2.22E+05 O.00E+00 2.18E+05 0.OOE+00 TE-127m 1.76E+05 6.30E+04 2.15E+04 4.50E+04 7.16E+05 O.OOE+00 5.91 E+05 O.00E+00 TE-127 1.70E+00 6.11E-01 3.68E-01 1.26E+00 6.92E+00 0.OOE+00 1.34E+02 O.OOE+00 TE-129m 1.78E+05 6.62E+04 2.81E+04 6.1OE+04 7.41 E+05 0.OOE+00 8.94E+05 O.OOE+00 TE-129 7.35E-13 2.76E-13 1.79E-13 5.64E-13 3.09E-12 0.OOE+00 5.55E-13 O.OOE+00 TE-133m 5.48E-16 3.20E-16 3.08E-16 4.64E-16 3.17E-15 0.OOE+00 7.88E-16 O.00E+00 TE-134 2.32E-21 1.52E-21 9.30E-22 2.03E-21 1.47E-20 0.OOE+00 2.57E-24 O.00E+00 1-129 3.65E+07 3.13E+07 1.03E+08 8.06E+10 5.62E+07 0.OOE+00 4.95E+06 O.OOE+00 1-130 1.09E+03 3.23E+03 1.27E+03 2.73E+05 5.04E+03 0.00E+00 2.78E+03 O.OOE+00 1-131 7.71 E+05 1.10E+06 6.32E+05 3.62E+08 1.89E+06 O.00E+00 2.91 E+05 0.OOE+00 TE-131m 9.40E+02 4.60E+02 3.83E+02 7.28E+02 4.66E+03 O.00E+00 4.57E+04 O.OOE+00 TE-131 9.38E-36 3.92E-36 2.96E-36 7.72E-36 4.11E-35 0.OOE+00 1.33E-36 0.OOE+00 1-132 4.28E-04 1.14E-03 4.OOE-04 4.OOE-02 1.82E-03 O.OOE+00 2.15E-04 0.OOE+00 TE-132 6.25E+03 4.05E+03 3.80E+03 4.47E+03 3.90E+04 O.OOE+00 1.91 E+05 0.00E+00 1-133 1.01E+05 1.75E+05 5.34E+04 2.58E+07 3.06E+05 0.OOE+00 1.58E+05 O.OOE+00 CS-134m 1.13E-02 2.38E-02 1.22E-02 O.00E+00 1.29E-02 2.03E-03 8.39E-03 O.OOE+00 CS- 134 6.55E+08 1.56E+09 1.27E+09 O.OOE+00 5.04E+08 1.67E+08 2.73E+07 O.OOE+00 1-134 5.25E-14 1.43E-13 5.10E-14 2.47E-12 2.27E-13 O.OOE+00 1.24E-16 Q.OOE+00 1-135 3.34E+02 8.75E+02 3.23E+02 5.77E+04 1.40E+03 0.00E+00 9.89E+02 0.OOE+00 CS-135 2.17E+08 2.01 E+08 8.91 E+07 O.OOE+00 7.59E+07 2.27E+07 4.69E+06 O.OOE+00

CY-LG-1 70-301, Rev. 23 I Page 159 08/07 I TABLE 112-2 Ri DOSE FACTORS Age: Adult Pathway: Goat Milk (Continued)

NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG GI-LLI SKIN I CS-136 1.73E+07 6.82E+07 4.91E+07 0.OE+00 3.79E+07 5.20E+06 7.74E+06 O.OE+00 I CS-137 8.85E+08 1.21E+09 7.93E+08 O.OE+00 4.11E+08 1.37E+08 2.34E+07 O.OOE+00 I CS-138 5.89E-25 1.16E-24 5.76E-25 O.OOE+00 8&54E-25 8.44E-26 4.96E-30 O.OOE+00 I CS-139 4.41E-91 6.58E-91 2.39E-91 O.OOE+00 5.27E-91 4.79E-92 1.42E-113 O.OOE+00 I BA-139 1.15E-10 8.20E-14 3.37E-12 O.OOE+00 7.66E-14 4.65E-14 2.04E-10 O.OOE+00 I BA-140 7.04E+04 8.85E+01 4.62E+03 O.OOE+00 3.01E+01 5.07E+01 1.45E+05 O.OOE+00 I LA-140 1.17E-02 5.92E-03 1.56E-03 O.OOE+00 O.OOE+00 O.OOE+00 4.35E+02 O.OE+00 I BA-141 1.07E-48 8.06E-52 3.60E-50 O.OE+00 7.49E-52 4.57E-52 5.02E-58 O.OOE+00 LA-141 7.92E-08 2.46E-08 4.02E-09 O.OOE+00 O.OOE+00 O.OOE+00 2.93E-03 O.OOE+00 CE-141 1.42E+01 9.59E+00 1.09E+00 O.OOE+00 4.45E+00 O.OOE+00 3,67E+04 O.OOE+00 BA-142 6.92E-83 7.12E-86 4.35E-84 O.OOE+00 6.01E-86 4.03E-86 9.7482E-101 O.QOE+00 LA-142 4.84E-14 2.20E-14 5.48E-15 O.OOE+00 O.OOE+00 O.OOE+00 1.61E-10 O.00E+00 CE-143 1.08E-01 8.OOE+01 8.86E-03 O.OE+00 3.52E-02 OOOE+00 2.99E+03 O.OOE+00 PR-143 4.15E-01 1,66E-01 2.06E-02 O.OOE+00 9.60E-02 O.OOE+00 1.82E+03 O.OOE+00 CE-144 1.56E+03 6.54E+02 8.40E+01 O.OOE+00 3.88E+02 O.OOE+00 5.29E+05 O.OOE+00 PR-144 1.53E-56 6.35E-57 7.77E-58 O.OOE+00 3.58E-57 O.OOE+00 2.20E-63 O.OOE+00 ND-147 2.46E-01 2.84E-01 1.70E-02 O.OOE+00 1.66E-01 O.OOE+00 1.36E+03 0.OOE+00 PM-147 1.34E+01 1.26E+00, 4.99E-01 O.OOE+00 2.38E+00 O.OOE+00 1.59E+03 O.OOE+00 PM-148m 2.65E+00 6.86E-01 5.24E-01 O.OOE+00 1.04E+00 O.OOE+00 5.81E+03 O.OOE+00 PM-148 6.18E-01 1.03E-01 5.17E-02 O.OOE+00 1.94E-01 O.OOE+00 8.07E+03 O,0E+00 PM-149 1.11E-02 1.58E-03 6.44E-04 O.OOE+00 2.98E-03 O.OOE+00 2.95E+02 O.OOE+00 PM-151 1.69E-03 2.84E-04 1.43E-04 O.OOE+00 5.07E-04 Q.OOE+00 7.82E+01 O.OOE+00 SM-151 1.28E+01 2.21E+00 5.29E-01 O.OOE+00 2.47E+00 O.OOE+00 9.74E+02 O.OOE+00 SM-153 5.16E-03 4.30E-03 3.14E-04 O.OOE+00 1.39E-03 O.OOE+00 1.53E+02 Q.OOE+00 EU-152 3.59E+01 8.18E+00 7.18E+00 O.OOE+00 5.07E+01 O.OOE+00 4.72E+03 O.OOE+00 EU-154 1.13E+02 1,39E+01 9.86E+00 O.OOE+00 6.64E+01 O.OOE+00 1.OOE+04 O.QOE+00 EU-155 1.56E+01 2.21E+00 1.43E+00 O.OOE+00 1.02E+01 O.OOE+00 1.74E+03 O.OOE+00 EU-156 6.64E-01 5.14E-01 8.29E-02 O.OOE+00 3.43E-01 O.OOE+00 3.52E+03 O.OOE+00 TB-160 5.28E+00 0.OOE+00 6,58E-01 O.OOE+00 2.18E+00 O.OOE+00 4.86E+03 O.OOE+00 HO-166m 5.02E+01 1.57E+01 1.19E+01 O.OOE+00 2.34E+01 O.OOE+00 1.86E-16 O.OOE+00 W-181 1.33E+02 4.34E+01 4.64E+00 O.OOE+00 O.OOE+00 O.OOE+00 4.94E+03 O.OOE+00 W-185 4.62E+03 1.54E+03 1.62E+02 O.OOE+00 O.OOE+00 O.OOE+00 1.78E+05 O.OOE+00 W-187 1.70E+01 1.42E+01 4.96E+00 O.OOE+00 O.OE+00 O.OE+00 4.64E+03 O.0OE+00 NP-239 9.56E-03 9.40E-04 5.18E-04 O.OOE+00 2.93E-03 O.OOE+00 1.93E+02 O.OOE+00 U-232 7.66E+07 O.OOE+00 5.47E+06 O.OE+00 8.29E+06 O.OOE+00 1.26E+06 O.OOE+00 U-233 1.62E+07 O.OOE+00 9.81E+05 O.OOE+00 3.77E+06 O.OOE+00 1.17E+06 O.OOE+00 U-234 1.55E+07 O.OOE+00 9.61 E+05 O.OOE+00 3.70E+06 O.OOE+00 1.14E+06 O.OOE+00 U-235 1.49E+07 O.OOE+00 9.03E+05 O.OOE+00 3.48E+06 O.OOE+00 1.45E+06 O.OOE+00 U-236 1.49E+07 Q.OOE+00 9.22E+05 OOOE+00 3.55E+06 O.OOE+00 1.07E+06 O.OOE+00 U-237 1.47E+02 O.OOE+00 3.92E+01 O.OOE+00 6.05E+02 O.OOE+00 5.17E+04 O.OOE+00 U-238 1.43E+07 O.OOE+00 8.44E+05 O.OOE+00 3.25E+06 O.OOE+00 1.02E+06 O.OOE+00 NP-237 2.34E+05 1.67E+04 1.03E+04 O.OOE+00 7.66E+04 O.OOE+00 1.48E+04 O.0OE+00 NP-238 9.40E-02 2.53E-03 1.46E-03 O.OOE+00 8.58E-03 O.OOE+00 2.35E+02 O.OOE+00 PU-238 4.68E+04 5.92E+03 1.27E+03 O.OE+00 5.43E+03 O.OOE+00 5.42E+03 Q.OOE+00

CY-LG-170-301, Rev. 23 I Page 160 08/07 I TABLE 112-2 Ri DOSE FACTORS Age: Adult Pathway: Goat Milk (Continued)

NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG GI-LLI SKIN PU-239 5.39E+04 6.47E+03 1.42E+03 O.OOE+00 6.03E+03 O.QOE+00 4.95E+03 O.OOE+00 PU-240 5.38E+04 6.47E+03 1.42E+03 O.OOE+00 6.02E+03 O.OOE+00 5.04E+03 O.OOE+00 PU-241 1.16E+03 5.49E+01 2.45E+01 O.OOE+00 1.13E+02 O.OOE+00 1.03E+02 O.OOE+00 PU-242 5.OOE+04 6.24E+03 1.37E+03 O.OOE+00 5.81 E+03 O.OOE+00 4.85E+03 O.OE+00 PU-244 5.83E+04 7.14E+03 1.57E+03 O.OOE+00 6.65E+03 0.0OE+00 7.23E+03 O.OOE+00 AM-241 1.40E+05 1.31 E+05 1.01E+04 O.OOE+00 7.56E+04 O.OOE+00 1.38E+04 O.OOE+00 AM-242m 1.41E+05 1.23E+05 1.01E+04 O.OOE+00 7.52E+04 O.OOE+00 1.73E+04 O.OOE+00 AM-243 1.40E+05 1.28E+05 9.85E+03 O.OOE+00 7.41E+04 O.OOE+00 1,62E+04 0.OOE+00 CM-242 2.99E+03 3.18E+03 1.99E+02 O.OOE+00 9.02E+02 O.OOE+00 1.15E+04 O.OOE+00 CM-243 1.11E+05 1.02E+05 6.94E+03 O.OOE+00 3.24E+04 O.OOE+00 1.45E+04 O.OOE+00 CM-244 8.42E+04 7.88E+04 5.30E+03 O.OOE+00 2.47E+04 O.OOE+00 1.39E+04 O.OOE+00 CM-245 1.74E+05 1.52E+05 1.07E+04 O.OOE+00 5.OOE+04 O.OOE+00 1.31 E+04 O.OOE+00 CM-246 1.73E+05 1.52E+05 1.07E+04 O.OOE+00 4.98E+04 O.OOE+00 1.28E+04 Q.OOE+00 CM-247 1.69E+05 1.49E+05 1.05E+04 O.OOE+00 4.91E+04 O.OOE+00 1.69E+04 O.OOE+00 CM-248 1.40E+06 1.23E+06 8.68E+04 O.OOE+00 4.05E+05 O.OOE+00 2.73E+05 O.OOE+00 CF-252 4.64E+04 O.OOE+00 .1.12E+03 Q.0OE+00 O.OOE+00 O.0OE+00 5.12E+04 0.QOE+00

CY-LG-170-301, Rev. 23 Page 161 08/07 TABLE 112-2 Ri DOSE FACTORS Age: Adult Pathway: Inhalation NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG GI-LLI SKIN H-3 OO0E+00 1.26E+03 1.26E+03 1.26E+03 1.26E+03 1.26E+03 1.26E+03 O.OOE+00 C-14 1,82E+04 3.41E+03 3.41E+03 3.41E+03 3.41E+03 3.41E+03 3.41E+03 O.OOE+00 NA-22 1,04E+05 1.04E+05 1.04E+05 1.04E+05 1.04E+05 1.04E+05 1.04E+05 O.QOE+00 NA-24 1,02E+04 1.02E+04 1.02E+04 1.02E+04 1.02E+04 1.02E+04 1.02E+04 O.OOE+00 P-32 1,32E+06 7.71E+04 5.01E+04 O.OOE+00 O.OOE+00 O.OOE+00 8.64E+04 O.OOE+00 CA-41 3,06E+05 O.OOE+00 3.30E+04 O.OOE+00 O.OOE+00 3.06E+04 2.29E+03 O.OOE+00 SC-46 4,41E+05 8.56E+05 2.49E+05 O.OOE+00 7.99E+05 O.OOE+00 2.58E+05 O.OOE+00 CR-51 OOOE+00 O.OOE+00 1.OOE+02 5.95E+01 2.28E+01 1.44E+04 3.32E+03 O.OOE+00 MN-54 OOOE+00 3.96E+04 6.30E+03 O.OOE+00 9.84E+03 1.40E+06 7.74E+04 O.OOE+00 FE-55 2,46E+04 1.70E+04 3.94E+03 O.OOE+00 O.OOE+00 7.21E+04 6.03E+03 O.OOE+00 MN-56 O,OOE+00 1.24E+00 1.83E-01 O.OOE+00 1.30E+00 9.44E+03 2.02E+04 0.OOE+00 CO-57 O0,0E+00 6.92E+02 6.71E+02 O.OOE+00 O.OOE+00 3.70E+05 3.14E+04 O.OOE+00 CO-58 OOOE+00 1.58E+03 2.07E+03 O.OOE+00 O.OOE+00 9.28E+05 1.06E+05 O.OQE+00 FE-59 1,18E+04 2.78E+04 1.06E+04 O.OOE+00 O.OOE+00 1.02E+06 1.88E+05 O.OOE+00 CO-60 O.OOE+00 1.15E+04 1.48E+04 O.OOE+00 O.OOE+00 5.97E+06 2.85E+05 O.OOE+00 NI-59 3.25E+04 1.17E+04 5.42E+03 O.OOE+00 O.OOE+00 6.56E+04 4.89E+03 O.OOE+00 NI-63 4,32E+05 3.14E+04 1.45E+04 O.OOE+00 O.OOE+00 1.78E+05 1.34E+04 O.OOE+00 CU-64 O.OOE+00 1.46E+00 6.15E-01 O.OOE+00 4.62E+00 6.78E+03 4.90E+04 O.OOE+00 NI-65 1.54E+00 2.10E-01 9.12E-02 O.OOE+00 O.OOE+00 5.60E+03 1.23E+04 0.OOE+00 ZN-65 3.24E+04 1.03E+05 4.66E+04 O.OOE+00 6.90E+04 8.64E+05 5.34E+04 O.OOE+00 ZN-69m 8.16E+00 1.96E+01 1.79E+00 O.OOE+00 1.18E+01 1.90E+04 1.37E+05 O.OOE+00 ZN-69 3.38E-02 6.51E-02 4.52E-03 O.0OE+00 4.22E-02 9.20E+02 1.63E+01 O.OOE+00 SE-79 O.OOE+00 3.06E+03 4.87E+02 O.OOE+00 4.55E+03 3.58E+05 2.66E+04 O.OOE+00 BR-82 O.OOE+00 O.O0E+00 1.35E+04 O.OOE+00 O.OOE+00 O.OOE+00 1.04E+04 Q.OOE+00 BR-83 O.OOE+00 O.OOE+00 2.41 E+02 O.OOE+00 O.OOE+00 O.OOE+00 2.32E+02 O.OOE+00 BR-84 O.OOE+00 O.OOE+00 3.13E+02 O.OOE+00 O.OOE+00 O.OOE+00 1.64E-03 O.OOE+00 BR-85 O.OOE+00 O.OOE+00 1.28E+01 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 RB-86 O.OOE+00 1.35E+05 5.90E+04 O.OOE+00 O.OOE+00 O.OOE+00 1.66E+04 O.OOE+00 RB-87 O.OOE+00 3.87E+02 2.57E+04 O.OOE+00 O.OOE+00 O.OOE+00 2.30E+03 O.OOE+00 RB-88 O.OOE+00 3.87E+02 1.93E+02 O.OOE+00 O.OOE+00 O.OOE+00 3.34E-09 O.OOE+00 RB-89 O.OOE+00 2.56E+02 1.70E+02 O.OOE+00 O.OOE+00 O.OOE+00 9.28E-12 0.OOE+00 SR-89 3.04E+05 O.0OE+00 8.72E+03 O.OOE+00 O.OOE+00 1.40E+06 3.50E+05 O.OOE+00 SR-90 9.92E+07 O.OOE+00 6.1OE+06 O.OOE+00 0.0OE+00 9.60E+06 7.22E+05 O.OOE+00 Y-90 2,09E+03 O.OOE+00 5.61E+01 O.OOE+00 O.OOE+00 1.70E+05 5.06E+05 O.OOE+00 SR-91 6.19E+01 O.OE+00 2.50E+00 O.OOE+00 O.OOE+00 3.65E+04 1.91E+05 Q.OOE+00 Y-91m 2.61E-01 O.OOE+00 1.02E-02 O.OOE+00 O.OOE+00 1.92E+03 1.33E+00 O.OOE+00 Y-91 4.62E+05 O.OOE+00 1.24E+04 O.OOE+00 O.OOE+00 1.70E+06 3.85E+05 O.OOE+00 SR-92 6.74E+00 O.OOE+00 2.91E-01 O.OOE+00 O.OE+00 1.65E+04 4.30E+04 O.OOE+00 Y-92 1.03E+01 O.0OE+00 3.02E-01 O.OOE+00 O.OOE+00 1.57E+04 7.35E+04 O.OOE+00 Y-93 9.44E+01 0.OOE+00 2.61 E+00 O.OOE+00 O.OOE+00 4.85E+04 4.22E+05 O.OOE+00 NB-93m 2.48E+05 8.08E+04 1.99E+04 O.OOE+00 9.28E+04, 2.49E+05 1.90E+04 O.OOE+00 NB-95 1.41E+04 7.82E+03 4.21E+03 O.OOE+00 7.74E+03 5.05E+05 1.04E+05 0.OOE+00 NB-97 2.22E-01 5.62E-02 2.05E-02 O.OOE+00 6.54E-02 2.40E+03 2.42E+02 O.OOE+00 ZR-93 4.18E+05 2.34E+04 1.10E+04 O.OOE+00 8.88E+04 1.70E+05 1.21E+04 O.OOE+00

CY-LG-170-301, Rev. 23 Page 162 08/07 TABLE 112-2 Ri DOSE FACTORS Age: Adult Pathway: Inhalation (Continued)

NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG GI-LLI SKIN ZR-95 1.07E+05 3.44E+04 2.33E+04 O.OOE+00 5.42E+04 1.77E+06 1.50E+05 0.OOE+00 ZR-97 9.68E+01 1.96E+01 9.04E+00 0.OOE+00 2.97E+01 7.87E+04 5.23E+05 0.OOE+00 MO-93 0.OOE+00 9.36E+03 2.54E+02 O.OOE+00 2.84E+03 4.09E+05 3.03E+04 O.OOE+00 MO-99 0.OE+00 1.21 E+02 2.30E+01 0.OOE+00 2.91 E+02 9.12E+04 2.48E+05 0.OOE+00 TC-99 2.50E+02 3.71E+02 1.OOE+02 O.0OE+00 4.68E+03 8.08E+05 6.03E+04 0.OOE+00 TC-99m 1.03E-03 2.91 E-03 3.70E-02 0.OOE+00 4.42E-02 7.64E+02 4.16E+03 O.0OE+00 TC-101 4.18E-05 6.02E-05 5.90E-04 O.OOE+00 1.08E-03 3.99E+02 1.09E-11 0.OOE+00 RU-103 1.53E+03 O.OOE+00 6.58E+02 0.OOE+00 5.83E+03 5.05E+05 1.10E+05 O.OOE+00 RU-105 7.90E-01 0.OOE+00 3.11E-01 0.OOE+00 1.02E+00 1.10E+04 4.82E+04 0.OOE+00 RU-106 6.91E+04 O.OOE+00 8.72E+03 0.OOE+00 1.34E+05 9.36E+06 9.12E+05 0.OOE+00 RH-105 7.39E+00 5.38E+00 3.54E+00 0.OOE+00 2.29E+01 1.93E+04 8.72E+04 0.OOE+00 PD-107 0.OOE+00 6.62E+02 4.70E+01 0.OOE+00 5.26E+03 7.58E+04 5.65E+03 0.OOE+00 PD-109 O.OOE+00 3.70E+00 9.28E-01 0.OOE+00 1.88E+01 1.48E+04 1.22E+05 O.OOE+00 AG-110m 1.08E+04 1.O0E+04 5.94E+03 O.OOE+00 1.97E+04 4.63E+06 3.02E+05 O.OOE+00 AG-111 3.40E+02 1.42E+02 7.10E+01 O.OOE+00 4.59E+02 1.86E+05 2.23E+05 O.OOE+00 CD-113m O.OOE+00 1.23E+06 3.98E+04 O.OOE+00 1.37E+06 1.66E+06 1.27E+05 O.OOE+00 CD-115m O.OOE+00 1.97E+05 6.36E+03 O.OOE+00 1.58E+05 1.41E+06 3.84E+05 O.OOE+00 SN-123 2.42E+05 5.34E+03 7.86E+03 4.54E+03 O.OE+00 2.30E+06 3.14E+05 O.OOE+00 SN-125 9.28E+03 2.50E+02 5.62E+02 2.07E+02 O.OOE+00 5.90E+05 5.45E+05 O.OOE+00 SN-126 1.26E+06 3.34E+04 4.80E+04 9.84E+03 O.OOE+00 9.36E+06 1.27E+05 O.OOE+00 SB-124 3.12E+04 5.89E+02 1.22E+04 7.55E+01 O.OOE+00 2.48E+06 4.06E+05 O.OOE+00 SB-125 5.34E+04 5.95E+02 1.26E+04 5.40E+01 O.OOE+00 1.74E+06 1.01E+05 O.OOE+00 SB-126 3.60E+03 7.30E+01 1.30E+03 2.20E+01 O.OOE+00 7.66E+05 4.81E+05 O.OOE+00 SB-127 2.64E+02 5.78E+00 1.02E+02 3.18E+00 O.OOE+00 1.64E+05 3.02E+05 O.OOE+00 TE-125m 3.42E+03 1.58E+03 4.67E+02 1.05E+03 1.24E+04 3.14E+05 7.06E+04 O.OOE+00 TE-127m 1.26E+04 5.77E+03 1.57E+03 3.29E+03 4.58E+04 9.60E+05 1.50E+05 O.OOE+00 TE-127 1.40E+00 6.42E-01 3.10E-01 1.06E+00 5.1OE+00 6.51E+03 5.74E+04 Q.OOE+00 TE-129m 9.76E+03 4.67E+03 1.58E+03 3.44E+03 3.66E+04 1.16E+06 3.83E+05 O.OOE+00 TE-129 4.98E-02 2.39E-02 1.24E-02 3.90E-02 1.87E-01 1.94E+03 1.57E+02 O.OOE+00 TE-133m 5.79E-02 4.32E-02 3.34E-02 5.02E-02 2.99E-01 4.41E+03 4.39E+02 O.OOE+00 TE-134 3.07E-02 2.58E-02 1.26E-02 2.75E-02 1.74E-01 3.47E+03 2.38E-01 O.OOE+00 1-129 1.98E+04 1.69E+04 5.53E+04 4.43E+07 3.62E+04 O.OOE+00 1.78E+03 O.OOE+00 1-130 4.58E+03 1.34E+04 5.28E+03 1.14E+06 2.09E+04 O.OOE+00 7.69E+03 O.OOE+00 1-131 2.52E+04 3.58E+04 2.05E+04 1.19E+07 6.13E+04 O.OOE+00 6.28E+03 0.OOE+00 TE-131m 6.99E+01 4.36E+01 2.90E+01 5.50E+01 3.09E+02 1.46E+05 5.56E+05 O.OOE+00 TE-131 1.11E-02 5.95E-03 3.59E-03 9.36E-03 4.37E-02 1.39E+03 1.84E+01 O.OOE+00 1-132 1.16E+03 3.26E+03 1.16E+03 1.14E+05 5.18E+03 O.OOE+00 4.06E+02 O.OOE+00 TE-132 2.60E+02 2.15E+02 1.62E+02 1.90E+02 1.46E+03 2.88E+05 5.10E+05 O.OOE+00 1-133 8.64E+03 1.48E+04 4.52E+03 2.15E+06 2.58E+04 O.OOE+00 8.88E+03 O.OOE+00 CS-134m 1.27E+02 2.56E+02 1.38E+02 O.OOE+00 1.46E+02 2.34E+01 6.34E+01 O.OOE+00 CS-1 34 3.73E+05 8.48E+05 7.28E+05 0.OOE+00 2.87E+05 9.76E+04 1.04E+04 O.OOE+00 1-134 6.44E+02 1.73E+03 6.15E+02 2.98E+04 2.75E+03 0.00E+00 1.01E+00 0.OOE+00 1-135 2.68E+03 6.98E+03 2.57E+03 4.48E+05 1.11E+04 0.OOE+00 5.25E+03 0.OOE+00 CS-135 1.17E+05 1.03E+05 4.79E+04 0.O0E+00 4.09E+04 1.26E+04 1.69E+03 0.OOE+00 CS-136 3.90E+04 1.46E+05 1.10E+05 0.OOE+00 8.56E+04 1.20E+04 1.17E+04 0.OOE+00

CY-LG-170-301, Rev. 23 Page 163 08/07 TABLE 112-2 Ri DOSE FACTORS Age: Adult Pathway: Inhalation (Continued)

NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG GI-LLI SKIN CS-137 4.78E+05 6.21E+05 4.28E+05 O.OOE+00 2.22E+05 7.52E+04 8.40E+03 O.OOE+00 CS-138 3.31E+02 6.21E+02 3.24E+02 O.OOE+00 4.80E+02 4.86E+01 1.86E-03 O.OOE+00 CS-139 2.05E+02 2.90E+02 1.11E+02 O.OOE+00 2.44E+02 2.27E+01 4.39E-21 O.OOE+00 BA-139 9.36E-01 6.66E-04 2.74E-02 O.OOE+00 6.22E-04 3.76E+03 8.96E+02 O.OOE+00 BA-140 3.90E+04 4.90E+01 2.57E+03 O.OOE+00 1.67E+01 1.27E+06 2.18E+05 O.OOE+00 LA-140 3.44E+02 1.74E+02 4.58E+01 O.OOE+00 O.OOE+00 1,36E+05 4.58E+05 O.OOE+00 BA-141 1.OOE-01 7.53E-05 3.36E-03 O.OOE+00 7.OOE-05 1.94E+03 1.16E-07 O.OOE+00 LA-141 4.27E+00 1.33E+00 2.17E-01 O.OOE+00 O.OOE+00 1.08E+04 5.85E+04 O.OOE+00 CE-141 1.99E+04 1.35E+04 1.53E+03 O.OOE+00 6.26E+03 3.62E+05 1.20E+05 O.OOE+00 BA-142 2.63E-02 2.70E-05 1.66E-03 O.OOE+00 2.29E-05 1.19E+03 1.57E-16 O.OOE+00 LA-142 6,83E-01 3.10E-01 7.72E-02 O.OOE+00 O.OE+00 6.33E+03 2.11E+03 O.OOE+00 CE-143 1.86E+02 1.38E+02 1.53E+01 O.OOE+00 6.08E+01 7.98E+04 2.26E+05 O.OOE+00 PR-143 9.36E+03 3.75E+03 4.64E+02 O.OOE+00 2.16E+03 2.81E+05 2.OOE+05 O.OOE+00 CE-144 3.43E+06 1.43E+06 1.84E+05 O.OOE+00 8.48E+05 7.78E+06 8.16E+05 O.OOEt-OO PR-144 3.01E-02 1.25E-02 1.53E-03 O.OOE+00 7.05E-03 1.02E+03 2.15E-08 O.OOE+00 ND-147 5.27E+03 6.10E+03 3.65E+02 O.OOE+00 3.56E+03 2.21E+05 1.73E+05 O.OOE+00 PM-147 6.70E+05 6.30E+04 2.55E+04 O.OOE+00 1.19E+05 5.28E+05 4.43E+04 O.OOE+00 PM-148m 7.86E+04 2.03E+04 1,55E+04 O.OOE+00 3.08E+04 1.71 E+06 3.34E+05 O.OOE+00 PM-148 3.07E+03 5.1OE+02 2.56E+02 O.OOE+00 9.60E+02 3.13E+05 4.64E+05 O.OOE+00 PM-149 2.75E+02 3.90E+01 1.59E+01 0.OOE+00 7.35E+01 5.77E+04 2.OOE+05 O.OOE+00 PM-151 6.80E+01 1.14E+01 5.77E+00 O.OOE+00 2.04E+01 3.15E+04 1.60E+05 O.OOE+00 SM-151 6.87E+05 1.18E+05 2.84E+04 O.OOE+00 1.33E+05 3.56E+05 2.60E+04 O.OOE+00 SM-153 1.36E+02 1.14E+02 8.32E+00 O.OOE+00 3.67E+01 3.31E+04 1.26E+05 O.OOE+00 EU-152 1.90E+06 4.33E+05 3.81E+05 O.OOE+00 2.68E+06 2.74E+06 1.27E+05 O.OOE+00 EU-154 5.92E+06 7.28E+05 5.18E+05 O.OOE+00 3.49E+06 4.67E+06 2.72E+05 O.OOE+00 EU-155 8.08E+05 1.14E+05 7.37E+04 O.OOE+00 5.27E+05 7.57E+05 4.76E+04 O.OOE+00 EU-156 1.54E+04 1.18E+04 1.92E+03 O.OOE+00 7.96E+03 6.85E+05 3.60E+05 O.OOE+00 TB-160 1.77E+05 O.OOE+00 2.20E+04 O.OOE+00 7.28E+04 1.54E+06 2.14E+05 O.OOE+00 HO-166m 2.70E+06 8.40E+05 6.40E+05 O.OOE+00 1.26E+06 3.15E+06 1.27E+05 0.OOE+00 W-181 4.98E+01 1.62E+01 1.74E+00 O.O0E+00 O.OOE+00 1.37E+04 2.02E+03 O.OE+00 W-185 1.56E+03 5.18E+02 5.45E+01 O.OOE+00 O.OOE+00 4.46E+05 8.56E+04 O.OOE+00 W-187 8.48E+00 7.08E+00 2.48E+00 O.OOE+00 O.OOE+00 2.90E+04 1.55E+05 O.OOE+00 NP-239 2.30E+02 2.26E+01 1.24E+01 O.OOE+00 7.OOE+01 3.76E+04 1.19E+05 O.OOE+00 U-232 4.11E+08 O.0OE+00 2.93E+07 O.OOE+00 4.45E+07 1.78E+09 3.37E+05 O.OOE+00 U-233 8.72E+07 O.OOE+00 5.28E+06 O.OOE+00 2.03E+07 4.26E+08 3.11E+05 0.OOE+00 U-234 8.32E+07 O.OOE+00 5.17E+06 O.OOE+00 1.99E+07 4.18E+08 3.05E+05 O.OOE+00 U-235 8.OOE+07 O.OOE+00 4.86E+06 O.OOE+00 1.87E+07 3.92E+08 3.87E+05 O.OOE+00 U-236 8.OOE+07 O.OOE+00 4.96E+06 O.OOE+00 1.91E+07 4.OOE+08 2.86E+05 O.OQE+00 U-237 2.94E+02 O.OOE+00 7.82E+01 O.OOE+00 1.21E+03 .8.16E+04 9.60E+04 O.OOE+00 U-238 7.66E+07 O.0OE+00 4.54E+06 O.OOE+00 1.74E+07 3.66E+08 2.73E+05 O.OOE+00 NP-237 1.25E+10 8.88E+08 5.50E+08 O.OOE+00 4.08E+09 4.18E+08 3.94E+05 O.OOE+00 NP-238 2.37E+03 6.40E+01 3.69E+01 O.OOE+00 2.18E+02 8.16E+04 1.70E+05 O.OOE+00 PU-238 1.87E+10 2.58E+09 5.52E+08 O.OOE+00 2.37E+09 1.46E+09 3.62E+05 O.OOE+00

CY-LG-1 70-301, Rev. 23 I Page 164 08/07 I TABLE 112-2 Ri DOSE FACTORS Age: Adult Pathway: Inhalation (Continued)

NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG GI-LLI SKIN PU-239 2.35E+10 2.85E+09 6.20E+08 0.OOE+00 2.64E+09 1.38E+09 3.30E+05 0.0OE+00 PU-240 2.35E+10 2.84E+09 6.18E+08 0.OOE+00 2.63E+09 1.38E+09 3.37E+05 0.OOE+00 PU-241 4.86E+08 2.32E+07 1.03E+07 0.OOE+00 4.74E+07 1.22E+06 6.92E+03 0.OOE+00 PU-242 2.18E+10 2.74E+09 5.97E+08 0.OOE+00 2.54E+09 1.32E+09 3.24E+05 O.OOE+00 PU-244 2.55E+10 3.14E+09 6.83E+08 O.OOE+00 2.91E+09 1.51E+09 4.82E+05 0.OOE+00 AM-241 7.48E+09 7.OOE+09 5.37E+08 0.OOE+00 4.03E+09 4.85E+08 3.68E+05 0.OOE+00 AM-242m 7.54E+09 6.58E+09 5.38E+08 0.OOE+00 4.01 E+09 1.95E+08 4.63E+05 0.OOE+00 AM-243 7.47E+09 6.85E+09 5.26E+08 0.OOE+00 3.96E+09 4.60E+08 4.32E+05 0.OOE+00 CM-242 1.18E+08 1.26E+08 7.87E+06 O.OOE+00 3.58E+07 3.14E+08 3.93E+05 0.OOE+00 CM-243 5.89E+09 5.41E+09 3.69E+08 0.OOE+00 1.72E+09 5.05E+08 3.87E+05 0.OOE+00 CM-244 4.46E+09 4.18E+09 2.81E+08 0.OOE+00 1.31E+09 4.85E+08 3.74E+05 0.OOE+00 CM-245 9.28E+09 8.08E+09 5.71 E+08 O.OOE+00 2.66E+09 4.68E+08 3.49E+05 0.OOE+00 CM-246 9.04E+09 8.08E+09 5.70E+08 0.OOE+00 2.66E+09 4.77E+08 3.43E+05 0.OOE+00 CM-247 8.96E+09 7.99E+09 5.62E+08 O.OOE+00 2.62E+09 4.68E+08 4.50E+05 0.OOE+00 CM-248 7.47E+10 6.58E+10 4.63E+09 0.0OE+00 2.16E+10 3.86E+09 7.27E+06 0.OOE+00 CF-252 7.72E+09 0.OOE+00 1.86E+08 0.OOE+00 0.OOE+00 1.59E+09 1.42E+06 0.OOE+00

CY-LG-170-301, Rev. 23 Page 165 08/07 TABLE 112-2 Ri DOSE FACTORS Age: Teen Pathway: Ground NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG GI-LLI SKIN H-3 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 C-14 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 O.OE+00 0.OOE+00 0.OOE+00 NA-22 1.16E+10 1.16E+10 1.16E+10 1.16E+10 1.16E+10 1.16E+10 1.16E+10 1.30E+10 NA-24 1.19E+07 1.19E+07 1.19E+07 1.19E+07 1.19E+07 1.19E+07 1.19E+07 1.39E+07 P-32 0.OOE+00 O.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 CA-41 1.32E+10 1.32E+10 1.32E+10 1.32E+10 1.32E+10 1.32E+10 1.32E+10 1.55E+10 SC-46 8.33E+08 8.33E+08 8.33E+08 8.33E+08 8.33E+08 8.33E+08 8.33E+08 9.61E+08 CR-ý51 4.66E+06 4.66E+06 4.66E+06 4.66E+06 4.66E+06 4.66E+06 4.66E+06 5.51E+06 MN-54 1.39E+09 1.39E+09 1.39E+09 1.39E+09 1.39E+09 1.39E+09 1.39E+09 1.63E+09 FE-55 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 MN-56 9.03E+05 9.03E+05 9.03E+05 9.03E+05 9.03E+05 9.03E+05 9.03E+05 1.07E+06 CO-57 4.92E+07 4.92E+07 4.92E+07 4.92E+07 4.92E+07 4.92E+07 4.92E+07 5.41 E+07 CO-58 3.79E+08 3.79E+08 3.79E+08 3.79E+08 3.79E+08 3.79E+08 3.79E+08 4.44E+08 FE-59 2.73E+08 2.73E+08 2.73E+08 2.73E+08 2.73E+08 2.73E+08 2.73E+08 3.21E+08 CO-60 2.32E+10 2.32E+10 2.32E+10 2.32E+10 2.32E+10 2.32E+10 2.32E+10 2.73E+10 NI-59 0.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 NI-63 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.00E+00 0.OOE+00 0.OOE+00 CU-64 6.07E+05 6.07E+05 6.07E+05 6.07E+05 6.07E+05 6.07E+05 6.07E+05 6.88E+05 NI-65 2.97E+05 2.97E+05 2.97E+05 2.97E+05 2.97E+05 2.97E+05 2.97E+05 3.45E+05 ZN-65 7.47E+08 7.47E+08 7.47E+08 7.47E+08 7.47E+08 7.47E+08 7.47E+08 8.59E+08 ZN-69m 1.27E+06 1.27E+06 1.27E+06 1.27E+06 1.27E+06 1.27E+06 1.27E+06 1.49E+06 ZN-69 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 SE-79 0.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 BR-82 2.14E+07 2.14E+07 2.14E+07 2.14E+07 2.14E+07 2.14E+07 2.14E+07 2.47E+07 BR-83 4.87E+03 4.87E+03 4.87E+03 4.87E+03 4.87E+03 4.87E+03 4.87E+03 7.08E+03 BR-84 2.03E+05 2.03E+05 2.03E+05 2.03E+05 2.03E+05 2.03E+05 2.03E+05 2.36E+05 BR-85 O.OOE+00 O.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.00E+00 RB-86 8.99E+06 8.99E+06 8.99E+06 .8.99E+06 8.99E+06 8.99E+06 8.99E+06 1.03E+07 RB-87 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 RB-88 3.31E+04 3.31E+04 3.31E+04 3.31E+04 3.31E+04 3.31E+04 3.31E+04 3.78E+04 RB-89 1.23E+05 1.23E+05 1.23E+05 1.23E+05 1.23E+05 1.23E+05 1.23E+05 1.48E+05 SR-89 2.16E+04 2.16E+04 2.16E+04 2.16E+04 2.16E+04 2.16E+04 2.16E+04 2.51E+04 SR-90 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 Y-90 4.49E+03 4.49E+03 4.49E+03 4.49E+03 4.49E+03 4.49E+03 4.49E+03 5.31 E+03 SR-91 2.15E+06 2.15E+06 2.15E+06 2.15E+06 2.15E+06 2.15E+06 2.15E+06 2.51E+06 Y-91m 1.OOE+05 1.00E+05 1.OOE+05 1.OOE+05 1.OOE+05 1.OOE+05 1.OOE+05 1.16E+05 Y-91 1.07E+06 1.07E+06 1.07E+06 1.07E+06 1.07E+06 1.07E+06 1.07E+06 1.21E+06 SR-92 7.77E+05 7.77E+05 7.77E+05 7.77E+05 7.77E+05 7.77E+05 7.77E+05 8.63E+05 Y-92 1.80E+05 1.80E+05 1,80E+05 1.80E+05 1.80E+05 1.80E+05 1.80E+05 2.14E+05 Y-93 1.83E+05 1.83E+05 1.83E+05 1.83E+05 1.83E+05 1.83E+05 1.83E+05 2.51E+05 NB-93m 0.OOE+00 O.OOE+00 O.OOE+00 0.O0E+00 0.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 NB-95 1.37E+08 1.37E+08 1.37E+08 1.37E+08 1.37E+08 1.37E+08 1.37E+08 1.61E+08 NB-97 2.07E+05 2.07E+05 2.07E+05 2.07E+05 2.07E+05 2.07E+05 2.07E+05 1.76E+05 ZR-93 0.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00

CY-LG-170-301, Rev. 23 I Page 166 08/07 I TABLE 112-2 Ri DOSE FACTORS Age: Teen Pathway: Ground (Continued)

NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG GI-LLI SKIN ZR-95 2.45E+08 2.45E+08 2.45E+08 2.45E+08 2.45E+08 2.45E+08 2.45E+08 2.84E+08 ZR-97 2.96E+06 2.96E+06 2.96E+06 2.96E+06 2.96E+06 2.96E+06 2.96E+06 3.44E+06 MO-93 8.84E+07 8.84E+07 8.84E+07 8.84E+07 8.84E+07 8.84E+07 8.84E+07 3.60E+09 MO-99 3.99E+06 3.99E+06 3.99E+06 3.99E+06 3.99E+06 3.99E+06 3.99E+06 4.63E+06 TC-99 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 TC-99m 1.84E+05 1.84E+05 1.84E+05 1.84E+05 1.84E+05 1.84E+05 1.84E+05 2.11E+05 TC-101 2.04E+04 2.04E+04 2.04E+04 2.04E+04 2.04E+04 2.04E+04 2.04E+04 2.26E+04 RU-103 1.08E+08 1.08E+08 1.08E+08 1.08E+08 1.08E+08 1.08E+08 1.08E+08 1.26E+08 RU-105 6.36E+05 6.36E+05 6.36E+05 6.36E+05 6.36E+05 6.36E+05 6.36E+05 7.21 E+05 RU-106 4.22E+08 4.22E+08 4.22E+08 4.22E+08 4.22E+08 4.22E+08 4.22E+08 5.07E+08 RH-105 2.11E+09 2.11E+09 2.11E+09 2.11E+09 2.11E+09 2.11E+09 2.11E+09 2.46E+09 PD-107 0.OOE+00 0.OOE+00 0.OOE+00 0.0OE+00 0.OOE+00 0.OOE+00 0.OOE+00 0,O0E+00 PD-109 1.50E+04 1.50E+04 1.50E+04 1.50E+04 1.50E+04 1.50E+04 1.50E+04 1.71E+04 AG-110m 2.86E+09 2.86E+09 2.86E+09 2.86E+09 2.86E+09 2.86E+09 2.86E+09 4.01E+09 AG-111 1.03E+06 1.03E+06 1.03E+06 1.03E+06 1.03E+06 1.03E+06 1.03E+06 1.20E+06 CD-113m 5.60E+06 5.60E+06 5.60E+06 5.60E+06 5.60E+06 5.60E+06 5.60E+06 6.33E+06 CD-115m O.OE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 0.OOE+00 O.OOE+00 O.OOE+00 SN-123 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 6.38E+09 SN-125 4,20E+06 4.20E+06 4.20E+06 4.20E+06 4.20E+06 4.20E+06 4.20E+06 4.86E+06 SN-126 3.48E+10 3.48E+10 3.48E+10 3.48E+10 3.48E+10 3.48E+10 3.48E+10 3.87E+10 SB-124 5.98E+08 5.98E+08 5.98E+08 5.98E+08 5.98E+08 5.98E+08 5.98E+08 6.90E+08 SB-125 2.38E+09 2.38E+09 2.38E+09 2.38E+09 2.38E+09 2.38E+09 2.38E+09 2.69E+09 SB-126 8.44E+07 8.44E+07 8.44E+07 8.44E+07 8.44E+07. 8.44E+07 8.44E+07 9.48E+07 SB-127 1.68E+07 1.68E+07 1.68E+07 1.68E+07 1.68E+07 1.68E+07 1.68E+07 1.94E+07 TE-125m 1.55E+06 1.55E+06 1.55E+06 1.55E+06 1.55E+06 1.55E+06 1.55E+06 2.13E+06 TE-127m 9.16E+04 9.16E+04 9.16E+04 9.16E+04 9.16E+04 9.16E+04 9.16E+04 1.08E+05 TE-127 2.98E+03 2.98E+03 2.98E+03 2.98E+03 2.98E+03 2.98E+03 2.98E+03 3.28E+03 TE-129m 1.98E+07 1.98E+07 1.98E+07 1.98E+07 1.98E+07 1.98E+07 1.98E+07 2.31E+07 TE-129 2.62E+04 2.62E+04 2.62E+04 2.62E+04 2.62E+04 2.62E+04 2.62E+04 3.10E+04 TE-133m 4.41E+05 4.41E+05 4.41E+05 4.41E+05 4.41E+05 4.41E+05 4.41E+05 5.OOE+05 TE-134 2.22E+04 2.22E+04 2.22E+04 2.22E+04 2.22E+04 2.22E+04 2.22E+04 2.66E+04 1-129 1.74E+09 1.74E+09 1.74E+09 1.74E+09 1.74E+09 1.74E+09 1.74E+09 2.90E+09 1-130 5.51E+06 5.51E+06 5.51E+06 5.51E+06 5.51E+06 5.51E+06 5.51E+06 6.69E+06 1-131 1.72E+07 1.72E+07 1.72E+07 1.72E+07 1.72E+07 1.72E+07 1.72E+07 2.09E+07 TE-131m 8.03E+06 8.03E+06 8.03E+06 8.03E+06 8.03E+06 8.03E+06 8.03E+06 9.46E+06 TE-131 2.92E+04 2.92E+04 2.92E+04 2.92E+04 2.92E+04 2.92E+04 2.92E+04 3.45E+07 1-132 1.25E+06 1.25E+06 1.25E+06 1.25E+06 1.25E+06 1.25E+06 1.25E+06 1,46E+06 TE-132 4.23E+06 4.23E+06 4.23E+06 4.23E+06 4.23E+06 4.23E+06 4.23E+06 4.98E+06 1-133 2.45E+06 2.45E+06 2.45E+06 2.45E+06 2.45E+06 2.45E+06 2.45E+06 2.98E+06 CS-134m 4.80E+04 4.80E+04 4.80E+04 4.80E+04 4.80E+04 4.80E+04 4.80E+04 6.74E+04 CS-134 6.90E+09 6.90E+09 6.90E+09 6.90E+09 6.90E+09 6.90E+09 6.90E+09 8.05E+09 1-134 4.47E+05 4.47E+05 4.47E+05 4.47E+05 4.47E+05 4.47E+05 4.47E+05 5.30E+05 1-135 2.53E+06 2.53E+06 2.53E+06 2.53E+06 2.53E+06 2.53E+06 2.53E+06 2.95E+06 CS-135 5.80E+10 5.80E+10 5.80E+10 5.80E+10 5.80E+10 5.80E+10 5.80E+10 6.58E+10

CY-LG-170-301, Rev. 23 I Page 167 08/07 I TABLE 112-2 Ri DOSE FACTORS Age: Teen Pathway: Ground (Continued)

NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG GI-LLI SKIN CS-136 1.51E+08 1.51E+08 1.51E+08 1.51E+08 1.51E+08 1.51E+08 1.51E+08 1.71E+08 CS-137 1.30E+10 1.30E+10 1.30E+10 1.30E+10 1.30E+10 1.30E+10 1.30E+10 1.52E+10 CS-138 3.59E+05 3.59E+05 3.59E+05 3.59E+05 3.59E+05 3.59E+05 3.59E+05 4.10E+05-CS-139 3.14E+04 3.14E+04 3.14E+04 3.14E+04 3.14E+04 3.14E+04 3.14E+04 3.59E+04 BA-139 1.06E+05 1.06E+05 1.06E+05 1.06E+05 1.06E+05 1.06E+05 1.06E+05 1.19E+05 BA-140 2.05E+07 2.05E+07 2.05E+07 2.05E+07 2.05E+07 2.05E+07 2.05E+07 2.35E+07 LA- 140 1.92E+07 1.92E+07 1.92E+07 1.92E+07 1.92E+07 1.92E+07 1.92E+07 2.18E+07 BA-141 4.17E+04 4.17E+04 4.17E+04 4.17E+04 4.17E+04 4.17E+04 4.17E+04 4.75E+04 LA-141 3.14E+04 3.14E+04 3.14E+04 3.14E+04 3.14E+04 3.14E+04 3.14E+04 3.51E+04 CE-141 1.37E+07 1.37E+07 1.37E+07 1.37E+07 1.37E+07 1.37E+07 1.37E+07 1.54E+07 BA-142 4.49E+04 4.49E+04 4.49E+04 4.49E+04 4.49E+04 4.49E+04 4.49E+04 5.11E+04 LA-142 7.60E+05 7.60E+05 7.60E+05 7.60E+05 7.60E+05 7.60E+05 7.60E+05 9.11E+05 CE-143 2.31E+06 2.31E+06 2.31E+06 2.31EE+06 2.31E+06 2.31E+06 2.31E+06 2.63E+06 PR-143 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 CE-144 6.95E+07 6.95E+07 6.95E+07 6.95E+07 6.95E+07 6.95E+07 6.95E+07 8.04E+07 PR-144 1.83E+03 1.83E+03 1.83E+03 1.83E+03 1.83E+03 1.83E+03 1.83E+03 2.11E+03 ND-147 8.39E+06 8.39E+06 8.39E+06 8.39E+06 8.39E+06 8.39E+06 8.39E+06 1.01E+07 PM-147 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 0.OOE+00 O.OOE+00 O.OE+00 PM-148m 4.45E+08 4.45E+08 4.45E+08 4.45E+08 4.45E+08 4.45E+08 4.45E+08 2.58E+09 PM-148 1.45E+08 1.45E+08 1.45E+08 1.45E+08 1.45E+08 1.45E+08 1.45E+08 1.67E+08 PM-149 4.23E+04 4.23E+04 4.23E+04 4.23E+04 4.23E+04 4.23E+04 4.23E+04 4.90E+04 PM-151 1.99E+06 1.99E+06 1.99E+06 1.99E+06 1.99E+06 1.99E+06 1.99E+06 2.08E+06 SM-151" 1.72E+08 1.72E+08 1.72E+08 1.72E+08 1.72E+08 1.72E+08 1.72E+08 7.53E+08 SM-153 4.02E+05 4.02E+05 4.02E+05 4.02E+05 4.02E+05 4.02E+05 4.02E+05 4.46E+05 EU-152 1.79E+10 1.79E+10 1.79E+10 1.79E+10 1.79E+10 1.79E+10 1.79E+10 2.07E+10 EU-154 1.52E+10 1.52E+10 1.52E+10 1.52E+10 1.52E+10 1.52E+10 1.52E+10 1.75E+10 EU-155 4.95E+08 4.95E+08 4.95E+08 4.95E+08 4.95E+08 4.95E+08 4.95E+08 5.63E+08 EU-156 8.82E+07 8.82E+07 8.82E+07 8.82E+07 8.82E+07 8.82E+07 8.82E+07 1.01E+08 TB-160 4.75E+08 4.75E+08 4.75E+08 4.75E+08 4.75E+08 4.75E+08 4.75E+08 5.53E+08 HO-166m 3.42E+10 3.42E+10 3.42E+10 3.42E+10 3.42E+10 3.42E+10 3.42E+10 3.85E+10 W-181 1.94E+05 1.94E+05 1.94E+05 1.94E+05 1.94E+05 1.94E+05 1.94E+05 2.13E+05 W-185 Q.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OE+00 W-187 2.35E+06 2.35E+06 2.35E+06 2.35E+06 2.35E+06 2.35E+06 2.35E+06 2.73E+06 NP-239 1.71 E+06 1.71 E+06 1.71 E+06 1.71E+06 1.71 E+06 1.71 E+06 1.71 E+06 1.98E+06 U-232 9.12E+06 9.12E+06 9.12E+06 9.12E+06 9.12E+06 9.12E+06 9.12E+06 9.47E+07 U-233 8.90E+09 8.90E+09 8.90E+09 8.90E+09 8.90E+09 8.90E+09 8.90E+09 1.08E+10 U-234 2.45E+06 2.45E+06 2.45E+06 2.45E+06 2.45E+06 2.45E+06 2.45E+06 6.15E+08 U-235 1.24E+10 1.24E+10 1.24E+10 1.24E+10 1.24E+10 1.24E+10 1.24E+10 1.55E+10 U-236 8.13E+04 8.13E+04 8.13E+04 8.13E+04 8.13E+04 8.13E+04 8.13E+04 6.96E+07 U-237 5.16E+06 5.16E+06 5.16E+06 5.16E+06 5.16E+06 5.16E+06 5.16E+06 6.71E+06 U-238 4.26E+08 4.26E+08 4.26E+08 4.26E+08 4.26E+08 4.26E+08 4.26E+08 5.80E+08 I NP-237 5.42E+09 5.42E+09 5.42E+09 5.42E+09 5.42E+09 5.42E+09 5.42E+09 6.19E+09 I NP-238 4.53E+06 4.53E+06 4.53E+06 4.53E+06 4.53E+06 4.53E+06 4.53E+06 5.18E+06 i PU-238 4.65E+06 4.65E+06 4.65E+06 4.65E+06 4.65E+06 4.65E+06 4.65E+06 6.44E+07

CY-LG-170-301, Rev. 23 Page 168 08/07 TABLE 112-2 Ri DOSE FACTORS Age: Teen Pathway: Ground (Continued)

NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG GI-LLI SKIN PU-239 3.06E+06 3.06E+06 3.06E+06 3.06E+06 3.06E+06 3.06E+06 3.06E+06 2.98E+07 PU-240 5.02E+06 5.02E+06 5.02E+06 5.02E+06 5.02E+06 5.02E+06 5.02E+06 6.96E+07 PU-241 1.14E+07 1.14E+07 1.14E+07 1.14E+07 1.14E+07 1.14E+07 1.14E+07 1.69E+07 PU-242 4.26E+06 4.26E+06 4.26E+06 4.26E+06 4.26E+06 4.26E+06 4.26E+06 6.19E+07 PU-244 3.46E+09 3.46E+09 3.46E+09 3.46E+09 3.46E+09 3.46E+09 3.46E+09 3.72E+09 AM-241 6.85E+08 6.85E+08 6.85E+08 6.85E+08 6.85E+08 6.85E+08 6.85E+08 9.90E+08 AM-242m 9.62E+07 9.62E+07 9.62E+07 9.62E+07 9.62E+07 9.62E+07 9.62E+07 6.66E+08 AM-243 5.03E+09 5.03E+09 5.03E+09 5.03E+09 5.03E+09 5.03E+09 5.03E+09 5.80E+09 CM-242 6.86E+05 6;86E+05 6.86E+05 6.86E+05 6.86E+05 6.86E+05 6.86E+05 2.87E+06 CM-243 7.05E+09 7.05E+09 7.05E+09 7.05E+09 7.05E+09 7.05E+09 7.05E+09 8.89E+09 CM-244 7.84E+06 7.84E+06 7.84E+06 7.84E+06 7.84E+06 7.84E+06 7.84E+06 4.87E+07 CM-245 3.67E+09 3.67E+09 3.67E+09 3.67E+09 3.67E+09 3.67E+09 3.67E+09 4.64E+09 CM-246 3.86E+06 3.86E+06 3.86E+06 3.86E+06 3.86E+06 3.86E+06 3.86E+06 5.80E+07 CM-247 8.51E+09 8.51E+09 8.51E+09 8.51E+09 8.51E+09 8.51E+09 8.51E+09 1.01E+10 CM-248 2.63E+10 2.63E+10 2.63E+10 2.63E+10 2.63E+10 2.63E+10 2.63E+10 2.02E+10 CF-252 4.84E+10 4.84E+10 4.84E+10 4.84E+10 4.84E+10 4.84E+10 4.84E+10 5.28E+10

CY-LG-170-301, Rev. 23 Page 169 08/07 TABLE 112-2 Ri DOSE FACTORS Age: Teen Pathway: Vegetation NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG GI-LLI SKIN H-3 0.OOE+00 2.47E+03 2.47E+03 2.47E+03 2.47E+03 2.47E+03 2.47E+03 0.OOE+00 C-14 1.39E+06 2.77E+05 2.77E+05 2.77E+05 2.77E+05 2.77E+05 2.77E+05 0.OOE+00 NA-22 1.92E+09 1.92E+09 1.92E+09 1.92E+09 1.92E+09 1.92E+09 1.92E+09 0.OOE+00 NA-24 9.98E+04 9.98E+04 9.98E+04 9.98E+04 9.98E+04 9.98E+04 9.98E+04 0.OOE+00 P-32 1.62E+08 6.47E+07 4.05E+07 0.O0E+00 0.OOE+00 O.OOE+00 8.78E+07 0.OOE+00 CA-41 1.71E+10 0.OOE+00 1.85E+09 0.00E+O0 0.OOE+00 0.OOE+00 1.69E+07 0.OOE+00 SC-46 3.35E+05 6.52E+05 1.93E+05 0.OOE+00 6.24E+05 O.OOE+00 2.22E+09 0.OOE+00 CR-51 0.OOE+00 0.OOE+00 5.18E+04 2.88E+04 1.13E+04 7.39E+04 8.70E+06 0.OOE+00 MN-54 0.OOE+00 4.31E+08 8.54E+07 O.OOE+00 1.28E+08 0.OOE+00 8.83E+08 0.OOE+00 FE-55 3.1OE+08 2.20E+08 5.13E+07 0.OOE+00 0.OOE+00 1.39E+08 9.51E+07 0.OOE+00 MN-56 0.OOE+00 5.84E+00 1.04E+00 0.OOE+00 7.40E+00 0.OOE+00 3.85E+02 0.OOE+00 CO-57 0.OOE+00 9.84E+06 1.65E+07 0.OOE+00 0.OOE+00 0.OOE+00 1.84E+08 0.OOE+00 CO-58 0.OOE+00 4.02E+07 9.26E+07 0.OOE+00, 0.OOE+00 O.OOE+00 5.54E+08 0.OOE+00 FE-59 1.61E+08 3.75E+08 1.45E+08 0.OOE+00 0.O0E+00 1.18E+08 8.87E+08 0.OOE+00 CO-60 0.OOE+00 2.37E+08 5.33E+08 0.OOE+00 0.OOE+00 0.OOE+00 3.08E+09 0.OOE+00 NI-59 1.14E+09 4.04E+08 1.94E+08 O.OOE+00 0.OOE+00 0.OOE+00 6.33E+07 O.OOE+00 NI-63 1.53E+10 1.08E+09 5.19E+08 0.OOE+00 0.OOE+00 0.OOE+00 1.72E+08 0.OOE+00 CU-64 O.OOE+00 3.48E+03 1.64E+03 0.OOE+00 8.81E+03 0.OOE+00 2.70E+05 0.OOE+00 NI-65 2.33E+01 2.98E+00 1.36E+00 0.OOE+00 0.OOE+00 0.OOE+00 1.62E+02 0.OOE+00 ZN-65 4.01E+08 1.39E+09 6.49E+08 0.OOE+00 8.91E+08 0.OOE+00 5.89E+08 0.OOE+00 ZN-69M 8.67E+03 2.04E+04 1.88E+03 0.OOE+00 1.24E+04 0.OOE+00 1.12E+06 0.OOE+00 ZN-69 1.99E-06 3.79E-06 2.65E-07 0.OOE+00 2.48E-06 O.OOE+00 6.98E-06 0.OOE+00 SE-79 0.OOE+00 3.23E+08 5.43E+07 O.OOE+00 5.63E+08 0.OOE+00 4.94E+07 0.OOE+00 BR-82 0.OOE+00 0.OOE+00 5.55E+05 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 BR-83 0.OOE+00 0.00E+00 1.18E+00 0,00E+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 BR-84 O.OOE+00 0.OOE+00 8.18E-12 0.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 BR-85 0.OOE+00 OOOE+00 8.14E-152 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 RB-86 0.OOE+00 2.04E+08 9.58E+07 0.OOE+00 0.OOE+00 0.OOE+00 3.02E+07 0.OOE+00 RB-87 0.OOE+00 1.52E+09 5.29E+08 0.OOE+00 0.OOE+00 0.OOE+00 5.29E+07 0.OOE+00 RB-88 0.OOE+00 1.03E-22 5.47E-23 O.OOE+00 0.OOE+00 0.OOE+00 8.79E-30 0.OOE+00 RB-89 0.OOE+00 1.09E-26 7.70E-27 0.OOE+00 O.OOE+00 0.OOE+00 1.67E-35 0.OOE+00 SR-89 1.37E+10 0.OOE+00 3.92E+08 0.OOE+00 O.0OE+00 0.OOE+00 1.63E+09 0.OOE+00 SR-90 7.15E+11 0.OOE+00 1.77E+11 0.OOE+00 O.OOE+00 0.OOE+00 2.01E+10 0.OOE+00 Y-90 5.21E+03 0.OOE+00 1.40E+02 0.OOE+00 0.OOE+00 O.OOE+00 4.30E+07 0.OOE+00 SR-91 1.19E+05 0.OOE+00 4.72E+03 0.OOE+00 0.OOE+00 0.OOE+00 5.38E+05 0.OOE+00 Y-91M 1,86E-09 0.OOE+00 7.11E-11 0.OOE+00 0.OOE+00 0.OOE+00 8.78E-08 0.OOE+00 Y-91 7.15E+06 O.OOE+00 1.92E+05 O.QOE+00 0.00E+00 O.OOE+00 2.93E+09 O.OOE+00 SR-92 1.62E+02 O.OOE+00 6.91E+00 0.OOE+00 0.OOE+00 0.OOE+00 4.13E+03 0.OOE+00 Y-92 3.53E-01 0.OOE+00 1.02E-02 0.OOE+00 0.OOE+00 0.OOE+00 9.70E+03 0.OOE+00 Yr93 6.63E+01 O.OOE+00 1.82E+00 0.OOE+00 0.OOE+00 0.OOE+00 2.02E+06 0.OOE+00 NB-93M 2.95E+06 9.69E+05 2.43E+05 0.OOE+00 1.13E+06 0.OOE+00 3.49E+08 0.OOE+00 NB-95 1.68E+05 9.31E+04 5.12E+04 0.OOE+00 9.02E+04 O.OOE+00 3.98E+08 0.OOE+00 NB-97 7.86E-07 1.95E-07 7.12E-08 0.OOE+00 2.28E-07 0.OOE+00 4.66E-03 0.O0E+00 ZR-93 4.79E+06 2.37E+06 1.29E+06 O.OOE+00 8.36E+06 0.OOE+00 2.24E+09 0.OOE+00

CY-LG-1 70-301, Rev. 23 I Page 170 08/07 TABLE 112-2 Ri DOSE FACTORS Age: Teen Pathway: Vegetation (Continued)

NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG GI-LLI SKIN ZR-95 1.58E+06 4.98E+05 3.43E+05 0.OOE+00 7.32E+05 0.OOE+00 1.15E+09 0.OOE+00 ZR-97 1.31E+02 2.58E+01 1.19E+01 0.OOE+00 3.92E+01 0.OOE+00 7.OOE+06 0.OOE+00 MO-93 O.OOE+00 9.18E+08 2.51 E+07 0.OOE+00 2.63E+08 0.00E+00 1.12E+08 0.OOE+00 MO-99 O.OOE+00 2.37E+06 4.52E+05 O.OOE+00 5.42E+06 0.OOE+00 4.24E+06 0.OOE+00 TC-99 1.55E+07 2.28E+07 6.21 E+06 0.OOE+00 2.89E+08 2.36E+06 5.58E+08 0.OOE+00 TC-99M 1.13E+00 3.16E+00 4.10E+01 O.OOE+00 4.72E+01 1.76E+00 2.08E+03 0.OOE+00 TC-101 2.32E-31 3.30E-31 3.24E-30 0.OOE+00 5.96E-30 2.01 E-31 5.63E-38 0.OOE+00 RU-103 6.04E+06 0.OOE+00 2.58E+06 0.OOE+00 2.13E+07 0.OOE+00 5.04E+08 0.OOE+00 RU-105 2.07E+01 O.OOE+00 8.01 E+00 0.OOE+00 2.60E+02 0.OOE+00 1.67E+04 0.O0E+00 RU-106 2.93E+08 0.OOE+00 3.70E+07 O.OOE+00 5.66E+08 0.00E+00 1.41 E+10 0.00E+00 RH-105 1.49E+07 1.08E+07 7.07E+06 0.OOE+00 4.58E+07 0.OOE+00 1.37E+09 0.OOE+00 PD-107 O.OOE+00 1.80E+07 1.16E+06 0.OOE+00 1.63E+08 0.OOE+00 8.37E+07 0.OOE+00 PD-109 O.OOE+00 8.64E+03 1.96E+03 0.OOE+00 4.99E+04 0.OOE+00 8.71 E+05 0.OOE+00 AG-110M 1.43E+07 1.36E+07 8.25E+06 0.OOE+00 2.59E+07 0.OOE+00 3.81 E+09 0.OOE+00 AG-111 9.00E+04 3.74E+04 1.88E+04 O.OOE+00 1.22E+05 0.OOE+00 5.21 E+07 0.OOE+00 CD-113M O.00E+00 3.87E+08 1.24E+07 O.OOE+00 4.28E+08 0.OOE+00 2.32E+09 0.OOE+00 CD-115M 0.00E+00 7.11E+07 2.30E+06 0.OOE+00 5.69E+07 0.OOE+00 2.25E+09 0.OOE+00 SN-123 2.55E+09 4.19E+07 6.20E+08 3.35E+07 0.OOE+00 0.OOE+00 4.73E+09 0.OOE+00 SN-125 1.93E+07 3.85E+05 8.73E+05 3.02E+05 0.OOE+00 0.OOE+00 1.82E+08 0.OOE+00 SN-126 1.01E+10 1.87E+08 2.86E+08 4.93E+07 0.OOE+00 0.OOE+00 2.24E+09 0.OOE+00 SB-124 1.41E+08 2.60E+06 5.51 E+07 3.20E+05 0.OOE+00 1.23E+08 2.84E+09 0.OOE+00 SB-125 2.04E+08 2.23E+06 4.76E+07 1.95E+05 0.OOE+00 1.79E+08 1.59E+09 0.OOE+00 SB-126 4.36E+06 8.91 E+04 1.57E+06 2.47E+04 O.OOE+00 3.13E+06 2.58E+08 0.OOE+00 SB-127 2.01 E+05 4.31 E+03 7.60E+04 2.26E+03 0.OOE+00 1.37E+05 3.42E+07 0.OOE+00 TE-125M 1.35E+08 4.88E+07 1.81E+07 3.78E+07 0.OOE+00 0.OOE+00 3.99E+08 0.OOE+00 TE-127M 5.15E+08 1.83E+08 6.13E+07 1.23E+08 2.09E+09 0.OOE+00 1.28E+09 0.OOE+00 TE-127 2.22E+03 7.88E+02 4.78E+02 1.53E+03 9.OOE+03 0.OOE+00 1.72E+05 0.OOE+00 TE-129M 3.14E+08 1.16E+08 4.97E+07 1.01E+08 1.31E+09 0.OOE+00 1.18E+09 0.OOE+00 TE-129 2.81 E-04 1.05E-04 6.83E-05 2.00E-04 1.18E-03 0.OOE+00 1.53E-03 0.OOE+00 TE-133M 8.14E-06 4.62E-06 4.50E-06 6.46E-06 4.57E-05 0.OOE+00 1.87E&05 0.OOE+00 TE-134 1.21 E-08 7.79E-09 8.14E-09 9.96E-09 -7.44E-08 0.OOE+00 4.51 E- 10 0.OOE+00 1-129 2.02E+09 1.70E+09 2.83E+09 2.07E+12 3.04E+09 0.OOE+00 1.98E+08 0.OOE+00 1-130 1.46E+05 4.24E+05 1.69E+05 3.45E+07 6.52E+05 0.OOE+00 3.26E+05 0.OOE+00 1-131 3.52E+07 4.93E+07 2.65E+07 1.44E+10 8.49E+07 O.OOE+00 9.75E+06 O.OOE+00 TE-131M 3.54E+05 1.70E+05 1.41 E+05 2.55E+05 1.77E+06 0.OOE+00 1.36E+07 0.OOE+00 TE-1 31 4.87E-16 2.01E-16 1.52E-16 3.75E-16 '2.13E-15 0.OOE+00 4.OOE-17 0.OOE+00 1-132 2.11E+O1 5.52E+01 1.98E+01 1.86E+03 8.69E+01 0.OOE+00 2.40E+01 0.OOE+00 I.

TE-132 1.64E+06 1.04E+06 9.77E+05 1.09E+06 9.96E+06 0.OOE+00 3.29E+07 0.OOE+00 1-133 8.11E+05 1.38E+06 4.19E+05 1.92E+08 2.41 E+06 0.OOE+00 1.04E+06 0.OOE+00 CS-134M 2.50E+00 5.18E+00 2.66E+00 0.OOE+00 2.88E+00 5.06E-01 3.44E+00 0.OOE+00 CS-134 6.75E+09 1.59E+10 7.37E+09 0.OOE+00 5.05E+09 1.93E+09 1.98E+08 O.OOE+00 1-134 3.36E-05 8.90E-05 3.20E-05 1.48E-03 1.40E-04 0.OOE+00 1.17E-06 O.OOE+00 1-135 1.46E+04 3.76E+04 1.40E+04 2.42E+06 5.94E+04 0.OOE+00 4.17E+04 0.OOE+00 CS-135 2.41 E+09 2.21 E+09 5.16E+08 O.OOE+00 8.43E+08 3.05E+08 3.86E+07 0.OOE+00 CS-136 2.69E+07 1.06E+08 7.12E+07 O.OOE+00 5.77E+07 9.10E+06 8.53E+06 O.OOE+00

CY-LG-170-301, Rev. 23 Page 171 08/07 TABLE 112-2 Ri DOSE FACTORS Age: Teen Pathway: Vegetation (Continued)

NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG GI-LLI SKIN CS-137 9.66E+09 1.28E+10 4.47E+09 O.OE+00 4.37E+09 1.70E+09 1.83E+08 O.OOE+00 CS-138 1.31E-11 2.52E-11 1.26E-11 O.OOE+00 1.86E-11 2.17E-12 1.14E-14 O.OOE+00 CS-139 5.36E-45 7.89E-45 2.89E-45 O.OOE+00 6.37E-45 6.98E-46 3.66E-60 O.OOE+00 BA-139 1.07E-02 7.51 E-06 3.11E-04 O.OOE+00 7.08E-06 5.17E-06 9.52E-02 O.OOE+00 BA-140 8.35E+07 1.02E+05 5.38E+06 O.OOE+00 3.47E+04 6.88E+04 1.29E+08 O.OOE+00 LA-140 7.57E+02 3.72E+02 9.90E+01 O.OOE+00 O.OOE+00 O.OOE+00 2.14E+07 O.0OE+00 BA-141 3.51E-22 2.62E-25 1.17E-23 O.OOE+00 2.43E-25 1.79E-25 7.48E-28 O.OOE+00 LA-141 2.38E-01 7.33E-02 1.21E-02 O.OOE+00 O.OOE+00 O.OOE+00 1.30E+04 O.OOE+00 CE-141 2.44E+05 1.63E+05 1.87E+04 O.OOE+00 7.68E+04 O.OOE+00 4.66E+08 O.OOE+00 BA-142 1.50E-39 1.50E-42 9.23E-41 O.OOE+00 1.27E-42 9.99E-43 4.61E-51 o0ooE+00 LA-142 7.42E-05 3.29E-05 8.21E-06 O.OOE+00 O.OOE+00 O.OOE+00 1.OOE+00 O.OOE+00 CE-143 3.91E+02 2.84E+05 3.18E+01 O.OOE+00 1.28E+02 O.OOE+00 8.55E+06 O.OOE+00 PR-143 4.40E+04 1.76E+04 2.19E+03 O.OOE+00 1.02E+04 O.OOE+00 1.45E+08 0.OOE+00 CE-144 4.99E+07 2.07E+07 2.68E+06 O.OOE+00 1.23E+07 O.OOE+00 1.26E+10 O.OOE+00 PR-144 9.30E-27 3.81E-27 4.72E-28 O.OOE+00 2.19E-27 O.OOE+00 1.03E-29 O.OOE+00 ND-147 1.97E+04 2.15E+04 1.29E+03 O.OOE+00 1.26E+04 O.OOE+00 7.74E+07 O.OOE+00 PM-147 8.60E+06 8.16E+05 3.33E+05 O.OOE+00 1.56E+06 O.OOE+00 7.76E+08 O.OOE+00 PM-148M 1.04E+06 2.63E+05 2.06E+05 O.OOE+00 3.99E+05 O.OOE+00 1.66E+09 O.OE+00 PM-148 2.56E+05 4.16E+04 2.1OE+04 O.OOE+00 7.52E+04 O.OOE+00 2.48E+09 O.OOE+00 PM-149 6.66E+02 9.36E+01 3.84E+01 O.OOE+00 1.78E+02 O.OOE+00 1.38E+07 O.OOE+00 PM-151 1.32E+02 2.18E+01 1.10E+01 O.OOE+00 3.91E+01 O.OOE+00 4.89E+06 O.OOE+00 SM-151 7.55E+06 1.45E+06 3.41E+05 O.OOE+00 1.59E+06 O.OOE+00 4.93E+08 O.OOE+00 SM-153 3.21E+02 2.66E+02 1.95E+01 O.OOE+00 8.68E+01 O.OOE+00 7.50E+06 O.OOE+00 EU-152 2.1OE+07 5.06E+06 4.46E+06 O.OOE+00 2.35E+07 O.OOE+00 1.86E+09 O.OOE+00 EU-154 6.74E+07 8.69E+06 6.13E+06 O.OOE+00 3.88E+07 O.OOE+00 4.59E+09 OOOE+00 EU-155 1.46E+07 1.41E+06 8.75E+05 O.OOE+00 5.52E+06 O.OOE+00 8.1OE+09 O.OOE+00 EU-156 8.35E+04 6.26E+04 1.02E+04 O.OOE+00 4.22E+04 O.OOE+00 3.20E+08 O.OOE+00 TB-160 2.71E+06 O.OOE+00 3.39E+05 O.OOE+00 1.07E+06 0.OOE+00 1.76E+09 O.OOE+00 HO-166M 3.09E+07 9.53E+06 6.90E+06 O.OOE+00 1.39E+07 O.OOE+00 8.66E-1 1 O.OOE+00 W-181 7.93E+05 2.56E+05 2.68E+04 O.OOE+00 O.OOE+00 O.OOE+00 2.18E+07 O.OOE+00 W-185 2.49E+07 8.23E+06 8.70E+05 O.OOE+00 O.OOE+00 O.OOE+00 7.11E+08 0.OE+00 W-187 1.48E+04 1.21E+04 4.23E+03 O.OOE+00 O.OOE+00 O.QOE+00 3.27E+06 .OOE+00 NP-239 5.81E+02 5.48E+01 3.04E+01 O.OOE+00 1.72E+02 O.OOE+00 8.82E+06 O.OOE+00 U-232 5.09E+11 O.OOE+00 3.64E+10 O.OOE+00 5.52E+10 Q.OOE+00 6.22E+09 O.OOE+00 U-233 1.07E+11 O.OOE+00 6.53E+09 O.OOE+00 2.51E+10 O.OOE+00 5.76E+09 O.OOE+00 U-234 1.03E+11 0.OOE+00 6.40E+09 O.OOE+00 2.47E+10 O.OOE+00 5.64E+09 O.OOE+00 U-235 9.88E+10 O.OOE+00 6.01E+09 O.OOE+00 2.31E+10 O.OOE+00 7.17E+09 O.OOE+00 U-236 9.88E+10 O.OOE+00 6.14E+09 O.OOE+00 2.37E+10 O.OOE+00 5.29E+09 O.OOE+00 U-237 7.58E+04 O.OOE+00 2.02E+04 O.OOE+00 3.11E+05 O.OOE+00 2.01 E+07 0.OOE+00 U-238 9.44E+10 O.OOE+00 5.62E+09 0.OOE+00 2.17E+10 O.OOE+00 5.05E+09 O.OOE+00 NP-237 1.15E+11 8.27E+09 5.07E+09 0.OOE+00 3.75E+10 O.OOE+00 7.29E+09 0.OOE+00 NP-238 5.68E+03 1.52E+02 8.86E+01 0.OOE+00 5.22E+02 O.OOE+00 1.12E+07 0.OOE+00 PU-238 5.80E+10 7.42E+09 1.57E+09 0.OOE+00 6.75E+09 0.OOE+00 6.69E+09 0.OOE+00

CY-LG-170-301, Rev. 23 Page 172 08/07 TABLE 112-2 Ri DOSE FACTORS Age: Teen Pathway: Vegetation (Continued)

NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG GI-LLI SKIN PU-239 6.63E+10 8.05E+09 1.74E+09 0.00E+00 7.42E+09 0.00E+00 6.12E+09 0.OOE+00 PU-240 6.62E+10 8.03E+09 1.74E+09 0.00E+00 7.42E+09 0.00E+00 6.23E+09 0.OOE+00 PU-241 1.50E+09 7.20E+07 3.16E+07 0.00E+00 1.47E+08 0.00E+00 1.27E+08 0.OOE+00 PU-242 6.14E+10 7.75E+09 1.68E+09 0.OOE+00 7.15E+09 0.00E+00 6.00E+09 0.OOE+00 PU-244 7.17E+10 8.84E+09 1.92E+09 0.00E+00 8.19E+09 0.00E+00 8.92E+09 0.OOE+00 AM-241 6.91E+10 6.52E+10 4.98E+09 0.00E+00 3.73E+10 0.00E+00 6.82E+09 0.OOE+00 AM-242M 6.98E+10 6.15E+10 5.02E+09 0.00E+00 3.72E+10 0.00E+00 8.57E+09 0.00E+00 AM-243 6.90E+10 6.37E+10 4.87E+09 0.OOE+00 3.66E+10 0.00E+00 8.00E+09 0.00E+00 CM-242 1.84E+09 1.94E+09 1.22E+08 0.00E+00 5.55E+08 0.00E+00 5.25E+09 0.00E+00 CM-243 5.60E+10 5.20E+10 3.53E+09 0.00E+00 1.65E+10 0.00E+00 7.14E+09 0.OOE+00 CM-244 4.33E+10 4.10E+10 2.74E+09 O.00E+00 1.28E+10 0.00E+00 6.87E+09 0.00E+00 CM-245 8.58E+10 7.55E+10 5.28E+09 0.00E+00 2.47E+10 0.00E+00 6.46E+09 0.OOE+00 CM-246 8.51E+10 7.54E+10 5.28E+09 0.00E+00 2.46E+10 0.OOE+00 6.35E+09 0.OOE+00 CM-247 8.29E+10 7.42E+10 5.20E+09 0.00E+00 2.43E+10 0.OOE+00 8.34E+09 0.OOE+00 CM-248 6.89E+11 6.12E+11 4.29E+10 O.OOE+00 2.00E+1 1 0.OOE+00 1.34E+11 0.OOE+00 CF-252 2.84E+10 0.OOE+00 6.86E+08 0.00E+00 0.00E+00 O.00E+00 2.50E+10 0.OOE+00

CY-LG-170-301, Rev. 23 Page 173 08/07 TABLE 112-2 Ri DOSE FACTORS Age: Teen Pathway: Meat NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG GI-LLI SKIN H-3 0.OOE+00 1.94E+02 1.94E+02 1.94E+02 1.94E+02 1.94E+02 1.94E+02 0.OOE+00 C-14 2.81 E+05 5.62E+04 5.62E+04 5.62E+04 5.62E+04 5.62E+04 5 62E+04 0,OOE+00 NA-22 5.79E+08 5.79E+08 5.79E+08 5.79E+08 5.79E+08 5.79E+08 5.79E+08 0.OOE+00 NA-24 3.25E-04 3.25E-04 3.25E-04 3.25E-04 3.25E-04 3.25E-04 3.25E-04 0.OOE+00 P-32 1.81 E+08 7.22E+07 4.51 E+07 0.OOE+00 0.OOE+00 O.OE+00 9.79E+07 0.OOE+00 CA-41 6.90E+08 0.OOE+00 7.46E+07 0.OOE+00 0.OOE+00 0,OOE+00 6.83E+05 0.OOE+00 SC-46 5.59E+04 1.09E+05 3.23E+04 0.OOE+00 1.04E+05 0.OOE+00 3.71E+08 0.OOE+00 CR-51 0.OOE+00 0.OOE+00 1.80E+03 9.98E+02 3.94E+02 2.56E+03 3.02E+05 0.OOE+00 MN-54 O.OOE+00 3.47E+06 6.88E+05 0.OOE+00 1.03E+06 0.OOE+00 7.11E+06 0.OOE+00 FE-55 1.25E+08 8.87E+07 2.07E+07 O.OOE+00 0.O0E+00 5.62E+07 3.84E+07 0.OOE+00 MN-56 0.OOE+00 4.18E-54 7.43E-55 0.OOE+00 5.29E-54 0.OOE+00 2.75E-52 0.OOE+00 CO-57 O.OOE+00 1.36E+06 2.28E+06 0.OOE+00 0.OOE+00 0.OOE+00 2.54E+07 O.OOE+00 CO-58 0.OOE+00 5.55E+06 1.28E+07 O.OOE+00 0.OOE+00 0.OOE+00 7.66E+07 0.OOE+00 FE-59 7.51E+07 1.75E+08 6.77E+07 0.OOE+00 0.OOE+00 5.53E+07 4.14E+08 0.OOE+00 CO-60 0.OOE+00 3.11E+07 7.OOE+07 0.OOE+00 0.OOE+00 0.OOE+00 4.04E+08 0.OOE+00 NI-59 6,12E+08 2.16E+08 1.04E+08 0.OOE+00 0.O0E+00 0.OOE+00 3.39E+07 0.OOE+00 NI-63 8.20E+09 5.79E+08 2.78E+08 0.OOE+00 0.OOE+00 0.OOE+00 9.22E+07 0.OOE+00 CU-64 0.OOE+00 6.67E-08 3.14E-08 0.0OE+00 1.69E-07 0.OOE+00 5.18E-06 0.OOE+00 NI-65 6.42E-53 8.20E-54 3.73E-54 0.OOE+00 0.OOE+00 0.OOE+00 4.45E-52 0.OOE+00 ZN-65 1.21E+08 4.21E+08 1.96E+08 0.OOE+00 2.69E+08 0.OOE+00 1.78E+08 0.OOE+00 ZN-69m 4.20E-06 9.92E-06 9.09E-07 0.OOE+00 6.03E-06 0.OOE+00 5.45E-04 0.OOE+00 ZN-69 6.77E-154 1.29E-153 9.02E-155 0.OOE+00 8.42E-154 0.OOE+00 2.38E-153 O.OOE+00 SE-79 O.OOE+00 4.90E+07 8.23E+06 O.OOE+00 8.53E+07 0.O0E+00 7.48E+06 0.00E+00 BR-82 0.OOE+00 0.OOE+00 2,87E+02 0.0OE+00 0.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 BR-83 O.OOE+00 0.OOE+00 1.74E-57 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 BR-84 0.OOE+00 0.OOE+00 3.28E-270 0.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 BR-85 0.00E+00 0.OOE+00 0.OOE+00 0.OOE+00 0.O0E+00 0.OOE+00 0.OOE+00 0.OOE+00 RB-86 0.OOE+00 1.23E+08 5.76E+07 0.OOE+00 0.OOE+00 0.OOE+00 1.81E+07 0.OOE+00 RB-87 0.OOE+00 4.75E+08 1.66E+08 0.OOE+00 0.OOE+00 0.OOE+00 1.66E+07 0.OOE+00 RB-88 0.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 RB-89 0.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 SR-89 9.28E+07 0.OOE+00 2.66E+06 0.OOE+00 0.OOE+00 0.OOE+00 1.11E+07 0.OOE+00 SR-90 4.34E+09 O.OOE+00 1.07E+09 0.O0E+00 0.OOE+00 0.OOE+00 1.22E+08 0.OOE+00 Y-90 2.67E+01 0.OOE+00 7.18E-01 0.OOE+00 0.OOE+00 0.OOE+00 2.20E+05 0.O0E+00 SR-91 3.89E-11 0.OOE+00 1.55E-12 0.OOE+00 0.OOE+00 0.OOE+00 1.76E-10 0.OOE+00 Y-91m 2.72E-175 O.OOE+00 1.04E-176 0.OOE+00 0.OOE+00 O.OOE+00 1.29E-173 0.OOE+00 Y-91 3.60E+05 O.OOE+00 9.66E+03 0.OOE+00 0.OOE+00 0.OOE+00 1.48E+08 0.OOE+00 SR-92 3.33E-50 0.OOE+00 1.42E-51 0.OOE+00 0.OOE+00 O.OE+00 8.48E-49 0.OOE+00 Y-92 4.19E-40 0.OOE+00 1.21E-41 0.OOE+00 0.OOE+00 0.OOE+00 1.15E-35 0.OOE+00 Y-93 1.20E-12 0.OOE+00 3.30E-14 0.OOE+00 0.OOE+00 0.OOE+00 3.68E-08 0.OOE+00 NB-93m 8.34E+06 2.74E+06 6.86E+05 0.OOE+00 3.20E+06 0.OOE+00 9.87E+08 0.OOE+00 NB-95 6.00E+05 3.33E+05 1.83E+05 0.OOE+00 3.23E+05 0.O0E+00 1.42E+09 O.OOE+00 NB-97 1.98E-119 4.92E-120 1.80E-120 0.OOE+00 5.76E-120 0.OOE+00 1.18E-115 0.OOE+00 ZR-93 1.65E+06 8.12E+05 4.43E+05 0.OOE+00 2.87E+06 0.OOE+00 7.68E+08 0.OOE+00

CY-LG-1 70-301, Rev. 23 I Page 174 08/07 I TABLE 112-2 Ri DOSE FACTORS Age: Teen Pathway: Meat (Continued)

NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG GI-LLI SKIN ZR-95 5.79E+05 1.83E+05 1.26E+05 0.0OE+00 2.68E+05 0.OOE+00 4.22E+08 0.O0E+00 ZR-97 5.16E-06 1.02E-06 4.70E-07 0.OOE+00 1.55E-06 0.OOE+00 2.76E-01 0.OOE+00 MO-93 0.OOE+00 7.42E+07 2.03E+06 0.00E+00 2.13E+07 0.OOE+00 9.03E+06 0.OOE+00 MO-99 0.OOE+00 2.43E+04 4.64E+03 0.OOE+00 5.57E+04 0.OOE+00 4.36E+04 0.OOE+00 TC-99 6.27E+07 9.21E+07 2.51E+07 0.O0E+00 1.17E+09 9.52E+06 2.25E+09 0.OOE+00 TC-99m 1.10E-21 3.07E-21 3.98E-20 0.OOE+00 4.58E-20 1.71E-21 2.02E-18 0.OOE+00 TC-101 0.OOE+00 0.O0E+00 0.OOE+00 0.O0E+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 RU-103 2.94E+07 0.OOE+00 1.26E+07 0.OOE+00 1.04E+08 0.OOE+00 2.46E+09 0.OOE+00 RU-105 1.54E-28 O.OE+00 5.98E-29 O.OOE+00 1.94E-27 O.OOE+00 1.24E-25 O.OOE+00 RU-106 1.18E+09 O.OOE+00 1.49E+08 O.OOE+00 2.28E+09 O.OOE+00 5.67E+10 Q.OOE+00 RH-105 2.26E+05 1.63E+05 1.07E+05 O.OOE+00 6.94E+05 O.OOE+00 2.08E+07 O.OOE+00 PD-107 O.OOE+00 7.28E+05 4.69E+04 O.OOE+00 6.58E+06 O.OOE+00 3.38E+06 O.OOE+00 PD-109 O.OOE+00 3.33E-07 7.56E-08 O.OOE+00 1.92E-06 O.OOE+00 3.35E-05 O.OOE+00 AG-110m 2.46E+06 2.32E+06 1.41E+06 O.OOE+00 4.43E+06 O.OOE+00 6.53E+08 O.OOE+00 AG-111 3.62E+04 1.50E+04 7.56E+03 O.OOE+00 4.89E+04 O.OOE+00 2.1OE+07 O.OOE+00 CD-113m O.OOE+00 2.07E+06 6.65E+04 O.OOE+00 2.29E+06 O.OOE+00 1.24E+07 O.OOE+00 CD-115m O.OOE+00 4.40E+05 1.42E+04 O.OOE+00 3.52E+05 O.OOE+00 1.39E+07 O.OOE+00 SN-123 2.08E+09 3.41E+07 5.05E+08 2.73E+07 O.OOE+00 O.OOE+00 3.85E+09 O.OOE+00 SN-125 4.37E+07 8.71E+05 1.97E+06 6.84E+05 O.OOE+00 O.OOE+00 4.12E+08 O.OOE+00 SN-126 8.12E+09 1.51E+08 2.31E+08 3.98E+07 O.OOE+00 OOOE+00 1.81E+09 O.OOE+00 SB-124 6.15E+06 1.13E+05 2.40E+06 1.40E+04 O.OOE+00 5.37E+06 1.24E+08 O.OOE+00 SB-125 8.22E+06 8.98E+04 1.92E+06 7.85E+03 O.OOE+00 7.22E+06 6.39E+07 0.00E+00 SB-126 4.65E+05 9.51E+03 1.67E+05 2.63E+03 O.OOE+00 3.34E+05 2.75E+07 O.OOE+00 SB-127 4.05E+03 8.66E+01 1.53E+03 4.56E+01 O.OOE+00 2.76E+03 6.88E+05 O.OOE+00 TE-125m 1.14E+08 4.12E+07 1.53E+07 3.19E+07 O.OOE+00 O.OOE+00 3.37E+08 O.OOE+00 TE-127m 4.07E+08 1.44E+08 4.84E+07 9.68E+07 1.65E+09 O.OOE+00 1.01E+09 O.OOE+00 TE-127 5.49E- 11 1.95E-11 1.18E-11 3.79E- 11 2.22E-10 O.OOE+00 4.24E-09 O.OOE+00 TE-129m 3.15E+08 1.17E+08 4.98E+07 1.02E+08 1.32E+09 O.OOE+00 1.18E+09 O.OOE+00 TE-129 1.53E-121 5.72E-122 3.73E-122 1.10E-121 6.44E-121 O.OOE+00 8.39E-121 O.OOE+00 TE-133m 2.07E-153 1.18E-153 1.15E-153 1.65E-153 1.17E-152 O.OOE+00 4.77E-153 O.OOE+00 TE-134 1.32E-204 8.47E-205 8.85E-205 1.08E-204 8.08E-204 O.OOE+00 4.90E-206 O.OOE+00 1-129 5.91 E+07 4.98E+07 8.30E+07 6.05E+10 8.90E+07 O.OOE+00 5.80E+06 O.OOE+00 1-130 5.12E-07 1.48E-06 5,92E-07 1.21E-04 2.28E-06 0.OOE+00 1.14E-06 O.OOE+00 1-131 2.62E+06 3.66E+06 1.97E+06 1.07E+09 6.31E+06 O.OOE+00 7.24E+05 O.OOE+00 TE-131m 1.11E+02 5.34E+01 4.46E+01 8.03E+01 5.57E+02 O.OOE+00 4.29E+03 O.OOE+00 TE-131 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 0.OOE+00 O.OOE+00 O.OOE+00 1-132 1.96E-59 5.12E-59 1.84E-59 1.73E-57 8.06E-59 O.OOE+00 2,23E-59 O.OOE+OO TE-132 3.41 E+05 2.16E+05 2.03E+05 2.28E+05 2.07E+06 O.OOE+00 6.85E+06 O.OOE+00 1-133 9.10E-02 1.54E-01 4.71E-02 2.16E+01 2.71E-01 O.OOE+00 1.17E-01 O.OOE+00 CS-134m 7.13E-48 1.48E-47 7.59E-48 O.OOE+00 8.22E-48 1.44E-48 9.82E-48 O.OOE+00 CS-134 2.72E+08 6.41E+08 2.97E+08 O.OOE+00 2.04E+08 7.77E+07 7.97E+06 O.OOE+00 1-134 3.93E-162 1.04E-161 3.74E-162 1.74E-160 1.64E-161 O.OOE+00 1.37E-163 O.OOE+00 1-135 1.12E-17 2.87E-17 1.07E-17 1.85E-15 4.54E-17 O.OOE+00 3.18E-17 O.OOE+00 CS-135 9.73E+07 8.93E+07 2.09E+07 O.OOE+00 3.41E+07 1.23E+07 1.56E+06 O.OOE+00 CS-136 2.77E+06 1.09E+07 7.33E+06 O.OOE+00 5.94E+06 9.36E+05 8.78E+05 O.OOE+00

CY-LG-170-301, Rev. 23 Page 175 08/07 TABLE 112-2 Ri DOSE FACTORS Age: Teen Pathway: Meat (Continued)

NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG GI-LLI SKIN CS-137 3.90E+08 5.19E+08 1.81EE+08 Q.OOE+00 1.77E+08 6.86E+07 7.38E+06 O.OOE+00 CS-138 1.34E-267 2.57E-267 1.28E-267 O.OOE+00 1.90E-267 2.21E-268 1.16E-270 O.OOE+00 CS-139 O.QOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 0.OOE+00 O.OOE+00 BA-139 4.07E-102 2.86E-105 1.18E-103 O.OOE+00 2.70E-105 1.97E-105 3.63E-101 O.OOE+00 BA-140 7.OOE+06 8.58E+03 4.51E+05 O.OE+00 2.91E+03 5.77E+03 1.08E+07 O.OOE+00 LA-140 9.01E-03 4.43E-03 1.18E-03 O.OOE+00 O.OOE+00 O.OOE+00 2.54E+02 O.OE+00 BA-141 O.0OE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OE+00 O0OOE+00 O.OOE+00 O.OOE+00 LA-141 1.06E-37 3.26E-38 5.38E-39 O.OOE+00 O.OOE+00 O.OOE+00 5.78E-33 O.OOE+00 CE-141 3.88E+03 2.59E+03 2.98E+02 O.OOE+00 1.22E+03 O.OOE+00 7.41E+06 O.OOE+00 BA-142 O.OE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 LA-142 1.06E-92 4.71E-93 1.17E-93 O.OE+00 O.OOE+00 O.OE+00 1.43E-88 O.OOE+00 CE-143 5.OOE-03 3.64E+00 4.06E-04 O0OOE+00 1.63E-03 O.OOE+00 1.09E+02 O.OOE+00 PR-143 5.21E+03 2.08E+03 2.59E+02 O.OOE+00 1.21E+03 O.OOE+00 1.71E+07 0.OOE+00 CE-144 6.04E+05 2.50E+05 3.24E+04 O.OOE+00 1.49E+05 O.OOE+00 1.52E+08 O.OOE+00 PR-144 O.OE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 ND-147 1.83E+03 1.99E+03 1.19E+02 Q.OOE+00 1.17E+03 O.OOE+00 7.18E+06 O.OOE+00 PM-147 4.16E+05 3.95E+04 1.61E+04 O.0OE+00 7.53E+04 O.OE+00 3.75E+07 O.0OE+00 PM-148m 5.97E+04 1.51E+04 1.18E+04 O.OOE+00 2.29E+04 O.OOE+00 9.53E+07 OOOE+00 PM-148 1.47E+04 2.39E+03 1.21E+03 O.OOE+00 4.33E+03 O.OOE+00 1.43E+08 O.OOE+00 PM-149 1.28E+00 1.79E-01 7.36E-02 O.0OE+00 3.42E-01 O.OOE+00 2.64E+04 O.OOE+00 PM-151 1.43E-03 2.36E-04 .119E-04 O.OOE+00 4.24E-04 O.OOE+00 5.30E+01 O.OOE+00 SM-151 3.81E+05 7.34E+04 1.72E+04 O.OOE+00 8.04E+04 O.OOE+00 2.49E+07 O.OOE+00 SM-153 2.84E-01 2.35E-01 1.73E-02 Q0OE+00 7.68E-02 O.OOE+00 6.64E+03 O.OOE+00 EU-152 1.02E+06 2.45E+05 2.16E+05 O.OOE+00 1.14E+06 O.OOE+00 9.01E+07 O.OOE+00 EU-154 3.27E+06 4.21E+05 2.97E+05 O.OOE+00 1.88E+06 O.OOE+00 2.23E+08 O.OOE+00 EU-1 55 7.09E+05 6.84E+04 4.24E+04 O.OOE+00 2.68E+05 O.OOE+00 3.92E+08 O.OOE+00 EU-156 9.25E+03 6.94E+03 1.13E+03 O.OOE+00 4.67E+03 O.OOE+00 3.55E+07 O.OOE+00 TB-160 1.27E+05 O.OOE+00 1.58E+04 O.OOE+00 5.01E+04 O.OOE+00 8.20E+07 O.OOE+00 HO-166m 1.37E+06 4.24E+05 3.07E+05 O.OOE+00 6.20E+05 O.OOE+00 3.85E-12 O.OOE+00 W-181 1.05E+04 3.40E+03 3.55E+02 O.OOE+00 O.OOE+00 O.OOE+00 2.89E+05 O.OOE+00 W-185 3.42E+05 1.13E+05 1.19E+04 O.OOE+00 O.OE+00 O.OOE+00 9.75E+06 O.OOE+00 W-187 5.15E-03 4.19E-03 1A7E-03 O.OOE+00 O.OOE+00 O.OOE+00 1.14E+00 O.OOE+00 NP-239 6.67E-02 6.29E-03 3149E-03 O.OOE+00 1.97E-02 O.OOE+00 1.01E+03 O.OOE+00 U-232 1.75E+09 O.OOE+00 1.25E+08 O.OOE+00 1.89E+08 O.OOE+00 2.14E+07 O.OE+00 U-233 3.69E+08 O.OOE+00 2.24E+07 O.OOE+00 8.63E+07 O.OQE+00 1.98E+07 O.OE+00 U-234 3.54E+08 O.OOE+00 2.20E+07 O.OOE+00 8.48E+07 O.OE+00 1.94E+07 O.OOE+00 U-235 3.39E+08 O.OOE+00 2.07E+07 O.OOE+00 7.95E+07 O.OOE+00 2.46E+07 O.OOE+00 U-236 3.39E+08 O.OOE+00 2.11E+07 O.OOE+00 8.12E+07 O.OOE+00 1.82E+07 O.OOE+00 U-237 5.31E+02 O.OOE+00 1.41E+02 0.O0E+00 2.18E+03 O.OOE+00 1.41E+05 O.OOE+00 U-238 3.24E+08 O.OOE+00 1.93E+07 OOOE+00 7.44E+07 O.OOE+00 1.74E+07 O.OOE+00 NP-237 2.33E+08 1.67E+07 1.02E+07 O.OOE+00 7.58E+07 O.OE+00 1.47E+07 O.OOE+00 NP-238 3.48E-01 9.31E-03 5.42E-03 O.OOE+00 3.19E-02 O.OOE+00 6.83E+02 O.OOE+00 PU-238 8.20E+06 1.05E+06 2.23E+05 0.OOE+00 9.54E+05 O.OOE+00 9.46E+05 O.OOE+00

CY-LG-1 70-301, Rev. 23 Page 176 08/07 TABLE 112-2 Ri DOSE FACTORS Age: Teen Pathway: Meat (Continued)

NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG GI-LLI SKIN PU-239 9.37E+06 1.14E+06 2:46E+05 O.OOE+00 1.05E+06 O.OOE+00 8.65E+05 0.OOE+00 PU-240 9.36E+06 1.14E+06 2.46E+05 O.OOE+00 1.05E+06 O.OOE+00 8.81E+05 O.OOE+00 PU-241 2.12E+05 1.02E+04 4.47E+03 O.OOE+00 2.07E+04 O.OQE+00 1.79E+04 O.OOE+00 PU-242 8.69E+06 1.1OE+06 2.38E+05 O.OOE+00 1.01E+06 O.OOE+00 8.48E+05 O.OOE+00 PU-244 1.01E+07 1.25E406 2.72E+05 O.OOE+00 1.16E+06 O.OOE+00 1.26E+06 O.OOE+00 AM-241 1.40E+08 1.32E+08 1.01E+07 O.OOE+00 7.54E+07 O.OOE+00 1.38E+07 O.OOE+00 AM-242m 1.41E+08 1.24E+08 1.01E+07 O.OOE+00 7.52E+07 O.OOE+00 1.73E+07 O.OOE+00 AM-243 1.39E+08 1.29E+08 9.84E+06 0.OOE+00 7.39E+07 O.OOE+00 1.62E+07 O.OOE+00 CM-242 3.72E+06 3.92E+06 2.47E+05 O.OOE+00 1.12E+06 O.OOE+00 1.06E+07 O.OOE+00 CM-243 1.13E+08 1.05E+08 7.12E+06 O.OOE+00 3.33E+07 O.OOE+00 1.44E+07 O.OOE+00 CM-244 8.75E+07 8.28E+07 5.54E+06 O.OOE+00 2.59E+07 O.OOE+00 1.39E+07 O.OOE+00 CM-245 1.73E+08 1.52E+08 1.07E+07 0.OOE+00 4.99E+07 O.OOE+00 1.31E+07 O.OE+00 CM-246 1.72E+08 1.52E+08 1.07E+07 0.OOE+00 4.97E+07 O.OOE+00 1.28E+07 O0OOE+00 CM-247 1.68E+08 1.50E+08 1.05E+07 O.OOE+00 4.90E+07 O.OOE+00 1.69E+07 O.OOE+00 CM-248 1.39E+09 1.24E+09 8.67E+07 O.OOE+00 4.04E+08 O.OOE+00 2.71E+08 O.OOE+00 CF-252 5.73E+07 O.OOE+00 1.38E+06 0.OOE+00 O.OOE+00 O.OOE+00 5.04E+07 0.OOE+00

CY-LG-1 70-301, Rev. 23 Page 177 08/07 TABLE 112-2 Ri DOSE FACTORS Age: Teen Pathway: Cow Milk NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG GI-LLI SKIN H-3 0.OOE+00 9.94E+02 9.94E+02 9.94E+02 9.94E+02 9.94E+02 9.94E+02 0.00E+00 C-14 6.70E+05 1.34E+05 1.34E+05 1.34E+05 1.34E+05 1.34E+05 1.34E+05 0.OOE+00 NA-22 4.82E+09 4.82E+09 4.82E+09 4.82E+09 4.82E+09 4.82E+09 4.82E+09 0.OOE+00 NA-24 1.24E+06 1.24E+06 1.24E+06 1.24E+06 1.24E+06 1.24E+06 1.24E+06 0.OOE+00 P-32 1.45E+09 5.78E+08 3.62E+08 0.OOE+00 0.OOE+00 0.OOE+00 7.84E+08 0.O0E+00 CA-41 8.49E+09 0.OOE+00 9.18E+08 0.OOE+00 0.OOE+00 OOOE+00 8.40E+06 O.OOE+00 SC-46 1.25E+02 2.43E+02 7.21E+01 O.OOE+00 2.33E+02 0.OOE+00 8.27E+05 O.OOE+00 CR-51 0.OOE+00 0.OOE+00 1.59E+04 8.83E+03 3.48E+03 2.27E+04 2.67E+06 0.OOE+00 MN-54 O.OOE+00 6.94E+06 1.38E+06 0.OOE+00 2.07E+06 O.OOE+00 1.42E+07 0.OOE+00 FE-55 2.34E+07 1.66E+07 3.87E+06 0.OOE+00 0.OOE+00 1.05E+07 7.18E+06 O.OOE+00 MN-56 0.OOE+00 2.15E-03 3.83E-04 O.OOE+00 2.72E-03 0.OOE+00 1.42E-01 O.OOE+00 CO-57 0.OOE+00 7.68E+05 1.29E+06 O.OOE+00 0.OOE+00 0.OOE+00 1.43E+07 0.OOE+00 CO-58 0.OOE+00 3.14E+06 7.23E+06 0.OOE+00 0.OOE+00 0.OOE+00 4.32E+07 O.OOE+00 FE-59 1.83E+07 4.28E+07 1.65E+07 0.OOE+00 O.OOE+00 1.35E+07 1.01E+08 0.OOE+00 CO-60 0.OOE+00 1.48E+07 3.33E+07 0.OOE+00 0.OOE+00 0.OOE+00 1.93E+08 0.OOE+00 NI-59 4.76E+08 1.68E+08 8.08E+07 0.OOE+00 0.OOE+00 0.OOE+00 2.64E+07 0.OOE+00 NI-63 6.38E+09 4.51 E+08 2.16E+08 0.OOE+00 0.OOE+00 0.OOE+00 7.17E+07 0.OOE+00 CU-64 O.OOE+00 1.24E+04 5.84E+03 0.OOE+00 3.14E+04 0.OOE+00 9.63E+05 0.OOE+00 NI-65 1.98E-01 2.53E-02 1.15E-02 0.OOE+00 0.OOE+00 0.OOE+00 1.37E+00 0.OOE+00 ZN-65 1.02E+09 3.54E+09 1.65E+09 0.OOE+00 2.27E+09 0.OOE+00 1.50E+09 0.OOE+00 ZN-69m 9,53E+04 2.25E+05 2.06E+04 0.0OE+00 1.37E+05 0.OOE+00 1.24E+07 0.OOE+00 ZN-69 1.13E-12 2.15E-12 1.50E-13 0.OOE+00 1.40E-12 0.OOE+00 3.95E-12 0,00E+00 SE-79 0.OOE+00 9.04E+08 1.52E+08 0.OOE+00 1.58E+09 0.OOE+00 1.38E+08 0.OOE+00 BR-82 0.OOE+00 O.0OE+00 1.64E+07 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 BR-83 0.OOE+00 O.OOE+00 5.24E-02 0.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 BR-84 0.OOE+00 O.OOE+00 8.41 E-24 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 BR-85 0.OOE+00 0.OOE+00 1.05E-301 0.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 RB-86 O.OOE+00 1.42E+09 6.69E+08 0.OOE+00 0.OOE+00 0.OOE+00 2.11E+08 0.OOE+00 RB-87 0.OOE+00 2.83E+09 9.87E+08 O.OOE+00 0.OOE+00 O.OOE+00 9.87E+07 0.OOE+00 RB-88 O.OOE+00 1.14E-45 6.06E-46 0.OOE+00 O.OOE+00 0.OOE+00 9.74E-53 O.OOE+00 RB-89 0.OOE+00 2.24E-53 1.59E-53 0.OOE+00 0.OOE+00 0.OOE+00 3.44E-62 0.OOE+00 SR-89 9.75E+08 O.OOE+00 2.79E+07 0.OOE+00 0.OOE+00 O.OOE+00 1.16E+08 0.OOE+00 SR-90 3.56E+10 O.OOE+00 8.80E+09 0.OOE+00 0.OOE+00 0.OOE+00 1.OOE+09 0.OOE+00 Y-90 3.81E+01 0.OOE+00 1.03E+00 0.OOE+00 0.OOE+00 0.OOE+00 3.14E+05 0.OOE+00 SR-91 1.55E+04 0.OOE+00 6.18E+02 0.OOE+00 0.OOE+00 0.OOE+00 7.05E+04 0.OOE+00 Y-91m 3.20E-20 O.OOE+00 1.22E-21 0.OOE+00 O.OOE+00 0.OOE+00 1.51E-18 0.OOE+00 Y-91 5.97E+03 O.OOE+00 1.60E+02 0.OOE+00 0.OOE+00 0.OOE+00 2.45E+06 0.OOE+00 SR-92 2.61 E-01 0.OOE+00 1.11E-02 0.OOE+00 0.0OE+00 0.OOE+00 6.66E+00 0.OOE+00 Y-92 3.02E-05 0.OOE+00 8.72E-07 0.OOE+00 0.OOE+00 0.OOE+00 8.27E-01 0.OOE+00 Y-93 1.20E-01 0.OOE+00 3.30E-03 0.OOE+00 O.OOE+00 0.OOE+00 3.68E+03 0.OOE+00 NB-93m 4.59E+05 1.51E+05 3.78E+04 0.OOE+00 1.76E+05 0.OOE+00 5.44E+07 0.OOE+00 NB-95 4.71E+04 2.61E+04 1.44E+04 0.OOE+00 2.53E+04 0.OOE+00 1.12E+08 0.OOE+00 NB-97 1.75E-12 4.35E-13 1.59E-13 0,OOE+00 5.09E-13 0,OOE+00 1.04E-08 0.OOE+00 ZR-93 1.49E+03 7.35E+02 4.01E+02 0.OOE+00 2.60E+03 0.OOE+00 6.95E+05 0,OOE+00

CY-LG-170-301, Rev. 23 Page 178 08/07 TABLE 112-2 Ri DOSE FACTORS Age: Teen Pathway: Cow Milk (Continued)

NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG GI-LLI SKIN ZR-95 6.37E+02 2.01E+02 1.38E+02 0.OOE+00 2.95E+02 0.OOE+00 4.64E+05 0.OOE+00 ZR-97 2.31E-01 4.56E-02 2.1OE-02 0.OOE+00 6.92E-02 0.OOE+00 1.24E+04 0.OOE+00 MO-93 0.00E+00 4.28E+08 1.17E+07 0.OOE+00 1.23E+08 0.OOE+00 5.21E+07 0.OOE+00 MO-99 0.OOE+00 1.31E+07 2.49E+06 0.OOE+00 2.99E+07 0.OOE+00 2.34E+07 0.OOE+00 TC-99 2.41E+07 3.54E+07 9.66E+06 0.OOE+00 4.50E+08 3.66E+06 8.67E+08 0.OOE+00 TC-99m 1.68E+00 4.70E+00 6.09E+01 0.O0E+00 7.OOE+01 2.61E+00 3.09E+03 0.OOE+00 TC-101 1.39E-60 1.97E-60 1.94E-59 0.OOE+00 3.57E-59 1.20E-60 3.37E-67 0.OOE+00 RU-103 6.21 E+02 0.OOE+00 2.66E+02 0.OOE+00 2.19E+03 0.OOE+00 5.19E+04 0.OOE+00 RU-105 4.58E-04 0.OOE+00 1.78E-04 0.OOE+00 5.77E-03 O.OOE+00 3.70E-01 0.OOE+00 RU-106 1.88E+04 0.OOE+00 2.37E+03 0.OOE+00 3.63E+04 0.OOE+00 9.02E+05 0.OOE+00 RH-105 9.29E+06 6.71E+06 4.40E+06 0.OOE+00 2.85E+07 0.OOE+00 8.54E+08 0.OOE+00 PD-107 0.00E+00 1.12E+07 7.22E+05 0.OOE+00 1.01E+08 0.OOE+00 5.20E+07 0.OOE+00 PD-109 0.OOE+00 2.37E+04 5.38E+03 0.OOE+00 1.37E+05 0.OOE+00 2.39E+06 0.OOE+00 AG-110m 4.67E+07 4.42E+07 2.69E+07 O.OOE+00 8.43E+07 O.OOE+00 1.24E+10 O.OOE+00 AG-111 3.49E+06 1.45E+06 7.28E+05 O.OOE+00 4.72E+06 O.OOE+00 2.02E+09 O.OOE+00 CD-113m Q.OOE+00 2.89E+06 9.29E+04 O.OOE+00 3.20E+06 O.OOE+00 1.74E+07 O.OOE+00 CD-115m 0.00E+00 8.12E+05 2.62E+04 O.OOE+00 6.49E+05 O.OOE+00 2.57E+07 O.OOE+00 SN-123 4.40E+08 7.22E+06 1.07E+08 5.79E+06 O.OOE+00 O.OOE+00 8.16E+08 O.OE+00 SN-125 3.07E+07 6.11E+05 1.38E+06 4.80E+05 0.OOE+00 O.OOE+00 2.89E+08 O.OOE+00 SN-126 1.56E+09 2.91E+07 4.44E+07 7.66E+06 O.OOE+00 O.OOE+00 3.47E+08 O.OOE+00 SB-124 1.75E+07 3.22E+05 6.81E+06 3.96E+04 O.OOE+00 1.52E+07 3.52E+08 O.OE+00 SB-125 1.92E+07 2.10E+05 4.49E+06 1.83E+04 O.OOE+00 1.69E+07 1.49E+08 O.OOE+00 SB-126 2.94E+06 6.OOE+04 1.05E+06 1.66E+04 O.OOE+00 2.11E+06 1.74E+08 O.OOE+00 SB-127 2.39E+05 5.11E+03 9.02E+04 2.68E+03 O.OOE+00 1.63E+05 4.05E+07 O.OOE+00 TE-125m 1.13E+07 4.08E+06 1.51E+06 3.16E+06 O.OOE+00 O.OOE+00 3.34E+07 O.OOE+00 TE-127m 3.65E+07 1.29E+07 4.34E+06 8.67E+06 1.48E+08 O.OOE+00 9.09E+07 O.OOE+00 TE-127 3.54E+02 1.25E+02 7.62E+01 2.44E+02 1.43E+03 O.OOE+00 2.73E+04 O.OOE+00 TE-129m 3.65E+07 1.35E+07 5.77E+06 1.18E+07 1.53E+08 0.00E+00 1.37E+08 O.OOE+00 TE-129 1.52E-10 5.67E-11 3.70E-11 1.09E-10 6.38E-10 O.OOE+00 8.31E-10 O.OOE+00 TE-133m 1.11E-13 6.29E-14 6.12E-14 8.79E-14 6.22E-13 O.OOE+00 2.54E-13 O.OOE+00 TE-134 4.64E-19 2.98E-19 3.11E-19 3.81E-19 2.84E-18 O.OOE+00 1.72E-20 O.OOE+00 1-129 7.53E+08 6.33E+08 1.06E+09 7.71E+11 1.13E+09 O.OOE+00 7.38E+07 O.OOE+00 1-130 2.16E+05 6.25E+05 2.50E+05 5.10E+07 9.63E+05 O.OOE+00 4.80E+05 O.OOE+00 1-131 1.57E+08 2.20E+08 1.18E+08 6.42E+10 3.79E+08 O.OOE+00 4.35E+07 O.OOE+00 TE-131m 1.92E+05 9.22E+04 7.69E+04 1.39E+05 9.61E+05 0.OOE+00 7.40E+06 O.OOE+00 TE-131 1.93E-33 7.94E-34 6.02E-34 1.48E-33 8.42E-33 O.OOE+00 1.58E-34 O.OE+00 1-132 8.52E-02 2.23E-01 8.OOE-02 7.51E+00 3.51E-01 O.OOE+00 9.71E-02 O.OOE+00 TE-132 1.26E+06 7.95E+05 7.48E+05 8.38E+05 7.63E+06 O.OOE+00 2.52E+07 0.OOE+00 1-133 2.07E+06 3.51E+06 1.07E+06 4.90E+08 6.15E+06 O.OOE+00 2.65E+06 O.OOE+00 CS-134m 9.05E-02 1.87E-01 9.63E-02 0.OOE+00 1.04E-01 1.83E-02 1.25E-01 0.OOE+00 CS-134 5.11E+09 1.20E+10 5.58E+09 O.OOE+00 3.82E+09 1.46E+09 1.50E+08 0.OOE+00 1-134 1.05E-12 2.78E-12 9.98E-13 4.63E-11 4.38E-12 0.OOE+00 3.66E-14 0.OOE+00 1-135 6.67E+03 1.72E+04 6.37E+03 1.o10E+06 2.71E+04 0.OOE+00 1.90E+04 0.OOE+00 CS-135 1.80E+09 1.65E+09 3.85E+08 0.OOE+00 6.29E+08 2.28E+08 2.88E+07 O.OOE+00 CS-136 1.32E+08 5.20E+08 3.49E+08 0.OOE+00 2.83E+08 4.46E+07 4.18E+07 0.OOE+00

CY-LG-170-301, Rev. 23 Page 179 08/07 TABLE 112-2 Ri DOSE FACTORS Age: Teen Pathway: Cow Milk (Continued)

NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG GI-LLI SKIN CS-137 7.21E+09 9.59E+09 3.34E+09 O.OOE+00 3.26E+09 1.27E+09 1.36E+08 O.OOE+00 CS-138 4.80E-24 9.21E-24 4.61E-24 O.OOE+00 6.80E-24 7.91E-25 4.18E-27 O.OOE+00 CS-139 3.65E-90 5.38E-90 1.97E-90 O.OOE+00 4.34E-90 4.76E-91 2.50E-105 O.OOE+00 BA-139 2.39E-08 1.68E-11 6.96E-10 O.OOE+00 1.59E-11 1.16E-11 2.13E-07 O.OOE+00 BA-140, 1.43E+07 1.75E+04 9.20E+05 O.OOE+00 5.93E+03 1.18E+04 2.20E+07 O.OOE+00 LA-140 2.37E+00 1.16E+00 3.10E-01 O.OOE+00 0.OOE+00 O.OOE+00 6.69E+04 O.OOE+00 BA-141 2.20E-46 1.64E-49 7.35E-48 O.OOE+00 1.53E-49 1.13E-49 4.69E-52 O.OOE+00 LA-141 1.64E-05 5.04E-06 8.32E-07 O.OOE+00 O.OOE+00 O.OE+00 8.93E-01 O.OOE+00 CE-141 2.92E+03 1.95E+03 2.24E+02 O.OOE+00 9.18E+02 O.OOE+00 5.58E+06 O.OOE+00 BA-142 1.41 E-80 1.41 E-83 8.67E-82 0.OOE+00 1.19E-83 9.37E-84 4.32E-92 .O.OOE+00 LA-142 9.81E-12 4.36E-12 1.08E-12 0.OOE+00 O.OOE+00 O.OOE+00 1.33E-07 O.OE+00 CE-143, 2.23E+01 1.63E+04 1.82E+00 O.OOE+00 7.29E+00 O.OOE+00 4.89E+05 O.OE+00 PR-143 8.56E+01 3.42E+01 4.26E+00 O.OOE+00 1.99E+01 O.OOE+00 2.82E+05 O.OOE+00 CE-144 3.23E+05 1.34E+05 1.74E+04 O.OOE+00 7.99E+04 O.OOE+00 8.13E+07 O.OOE+00 PR-144 3.16E-54 1.30E-54 1.60E-55 O.OOE+00 7.43E-55 O.OOE+00 3.49E-57 O.OOE+00 ND-147 5.31E+01 5.78E+01 3.46E+00 O.OOE+00 3.39E+01 O.OOE+00 2.08E+05 O.OOE+00 PM-147 2.70E+03 2.56E+02 1.05E+02 O.OOE+00 4.89E+02 O.OE+00 2.44E+05 O.OOE+00 PM-148m 5.18E+02 1.31E+02 1.03E+02 O.OOE+00 1.99E+02 O.OE+00 8.26E+05 O.OOE+00 PM-148 1.28E+02 2.08E+01 1.05E+01 O.OOE+00 3.75E+01 0.0OE+00 1.24E+06 O.OOE+00 PM-149 2.31E+00 3.24E-01 1.33E-01 O.0OE+00 6.17E-01 O.OOE+00 4.77E+04 O.OOE+00 PM-151 3.47E-01 5.73E-02 2.90E-02 O.OOE+00 1.03E-01 O.OOE+00 1.29E+04 O.0OE+00 SM-151 2.35E+03 4.52E+02 1.06E+02 O.OOE+00 4.95E+02 O.OOE+00 1.53E+05 O.0OE+00 SM-153 1.06E+00 8.81E-01 6.48E-02 O.OOE+00 2.88E-01 O.OOE+00 2.49E+04 O.OOE+00 EU-152 6.54E+03 1.58E+03 1.39E+03 O.OOE+00 7.31E+03 O.OOE+00 5.79E+05 O.OOE+00 EU-154 2.10E+04 2.71E+03 1.91E+03 O.OOE+00 1.21E+04 O.OOE+00 1.43E+06 O.OOE+00 EU-1 55 4.57E+03 4.42E+02 2.73E+02 O.OOE+00 1.73E+03 O.OE+00 2.53E+06 O.OOE+00 EU-156 1.35E+02 1.01E+02 1.65E+01 O.OOE+00 6.81E+01 O.OOE+00 5.17E+05 O.OOE+00 TB-160 1.05E+03 O.OOE+00 1.31E+02 O.OOE+00 4.16E+02 O.OOE+00 6.82E+05 O.OE+00 HO-166m 9.61E+03 2.96E+03 2.14E+03 O.OOE+00 4.34E+03 O.OOE+00 2.69E-14 0.00E+00 W-181 2.76E+04 8.91E+03 9.32E+02 O.OOE+00 O.OOE+00 O.OOE+00 7.59E+05 O.OOE+00 W-185 9.57E+05 3.16E+05 3.34E+04 O.OOE+00 O.0OE+00 O.OOE+00 2.73E+07 O.OOE+00 W-187 3.48E+03 2.84E+03 9.95E+02 O.OOE+00 O.OOE+00 O.OOE+00 7.69E+05 O.OOE+00 NP-239 2.05E+00 1.93E-01 1.07E-01 O.OOE+00 6.07E-01 O.OOE+00 3.11E+04 O.OOE+00 U-232 1.58E+10 O.OOE+00 1.13E+09 O.OOE+00 1.72E+09 O.OOE+00 1.93E+08 O.OOE+00 U-233 3.34E+09 Q.OOE+00 2.03E+08 O.OOE+00 7.81E+08 O.OOE+00 1.79E+08 O.OOE+00 U-234 3.20E+09 O.OOE+00 1.99E+08 O.OOE+00 7.68E+08 O.0OE+00 1.75E+08 O.OOE+00 U-235 3.07E+09 O.OOE+00 1.87E+08 O.OOE+00 7.19E+08 O.OOE+00 2.23E+08 O.OOE+00 U-236 3.07E+09 O.OOE+00 1.91 E+08 O.OOE+00 7.35E+08 O.OOE+00 1.65E+08 O.OOE+00 U-237 3.05E+04 O.OOE+00 8.11E+03 O.OOE+00 1.25E+05 O.OOE+00 8.07E+06 O.OOE+00 U-238 2.94E+09 O.OOE+00 1.75E+08 O.OOE+00 6.73E+08 O.OOE+00 1.57E+08 O.OOE+00 NP-237 3.58E+07 2.57E+06 1.58E+06 O.OOE+00 1.17E+07 O.OE+00 2.26E+06 O.OE+00 NP-238 1.94E+01 5.19E-01 3.02E-01 O.OOE+00 1.78E+00 O.0OE+00 3.81E+04 O.OOE+00 PU-238 7.21 E+06 9.23E+05 1.96E+05 O.OOE+00 8.39E+05 O.OOE+00 8.32E+05 O.OOE+00

CY-LG-170-301, Rev. 23 Page 180 08/07 TABLE 112-2 Ri DOSE FACTORS Age: Teen Pathway: Cow Milk (Continued)

NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG GI-LLI SKIN PU-239 8.24E+06 1.00E+06 2.17E+05 O.OOE+00 9.23E+05 O.QOE+00 7.61E+05 0.OOE+00 PU-240 8.23E+06 9.99E+05 2.17E+05 O:OOE+00 9.22E+05 O.OOE+00 7.75E+05 O.OE+00 PU-241 1.87E+05 8.97E+03 3.94E+03 O.OOE+00 1.83E+04 O.OOE+00 1.58E+04 O.OOE+00 PU-242 7.64E+06 9.63E+05 2.09E+05 O.OOE+00 8.89E+05 O.OOE+00 7.45E+05 O.OOE+00 PU-244 8.92E+06 1.10E+06 2.39E+05 O.OQE+00 1.02E+06 O.OOE+00 1.11E+06 O.0OE+00 AM-241 2.15E+07 2.03E+07 1.55E+06 O.OOE+00 1.16E+07 O.OOE+00 2.12E+06 O.OOE+00 AM-242m 2.17E+07 1.91E+07 1.56E+06 O.OOE+00 1.16E+07 O.OOE+00 2.66E+06 O.OOE+00 AM-243 2.14E+07 1.98E+07 1.51E+06 OOOE+00 1.14E+07 O.OOE+00 2.49E+06 O.OOE+00 CM-242 6.18E+05 6.51E+05 4.1OE+04 O.OOE+00 1.87E+05 O.OOE+00 1.77E+06 O.OOE+00 CM-243 1.74E+07 1.62E+07 1.1OE+06 O.OOE+00 5.12E+06 O.OOE+00 2.22E+06 OO0E+00 CM-244 1.35E+07 1.28E+07 8.53E+05 O.OOE+00 3.99E+06 O.OOE+00 2.14E+06 O.OOE+00 CM-245 2.67E+07 2.35E+07 1.64E+06 O.OOE+00 7.68E+06 O.OOE+00 2.01E+06 O.OOE+00 CM-246 2.64E+07 2.34E+07 1.64E+06 O.OOE+00 7.65E+06 O.OOE+00 1.97E+06 O.OE+00 CM-247 2.58E+07 2.31 E+07 1.62E+06 O.OOE+00 7.54E+06 O.OOE+00 2.59E+06 Q.OOE+00 CM-248 2.14E+08 1.90E+08 1.33E+07 O.OOE+00 6.22E+07 O.OOE+00 4.17E+07 O.OOE+00 CF-252 8.93E+06 O.OOE+00 2.16E+05 O.OOE+00 O.OOE+00 O.OOE+00 7.85E+06 O.OOE+00

CY-LG-170-301, Rev. 23 Page 181 08/07 TABLE 112-2 Ri DOSE FACTORS Age: Teen Pathway: Goat Milk NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG GI-LLI SKIN H-3 O.OOE+00 1.47E+02 1.47E+02 1.47E+02 1.47E+02 1.47E+02 1.47E+02 O.OOE+00 C-14 4.86E+04 9.71E+03 9.71E+03 9.71E+03 9.71E+03 9.71E+03 9.71E+03 O.OOE+00 NA-22 4.19E+07 4.19E+07 4.19E+07 4.19E+07 4.19E+07 4.19E+07 4.19E+07 O.OOE+00 NA-24 1.08E+04 1.08E+04 1.08E+04 1.08E+04 1.08E+04 1.08E+04 1.08E+04 O.OQE+00 P-32 1.26E+08 5.03E+07 3.15E+07 O.OOE+00 O.OOE+00 O.OOE+00 6.82E+07 O.OOE+00 CA-41 7.39E+07 0.OOE+00 7.99E+06 O.OOE+00 O.OOE+00 O.OOE+00 7.31E+04 O.OOE+00 SC-46 1.09E+00 2.11E+00 6.27E-01 O.OOE+00 2.02E+00 O.OOE+00 7.20E+03 O.OOE+00 CR-51 O.OOE+00 O.OOE+00 1.38E+02 7.68E+01 3.03E+01 1.97E+02 2.32E+04 O.OOE+00 MN-54 O.OOE+00 6.04E+04 1.20E+04 O.OOE+00 1.80E+04 O.OOE+00 1.24E+05 O.OOE+00 FE-55 2.20E+04 1,56E+04 3.64E+03 O.OE+00 O.OOE+00 9.91E+03 6.76E+03 O.OOE+00 MN-56 O.OOE+00 1.87E-05 3.33E-06 O.OOE+00 2.37E-05 O.OOE+00 1.23E-03 O.OOE+00 CO-57 O.OOE+00 6.68E+03 1.12E+04 0,00E+00 O.OOE+00 O.OOE+00 1.25E+05 O.OOE+00 CO-58 O.OOE+00 2.73E+04 6.29E+04 O.OOE+00 0.00E+00 O.OE+00 3.76E+05 O.OOE+00 FE-59 1.73E+05 4.03E+05 1.56E+05 O.OOE+00 O.OOE+00 1.27E+05 9.54E+05 O.OOE+00 CO-60 O.OOE+00 1.29E+05 2.90E+05 O.OOE+00 O.OOE+00 0.OE+00 1.68E+06 O.OOE+00 NI-59 4.14E+06 1.46E+06 7.03E+05 O.OOE+00 O.OOE+00 O.OOE+00 2.30E+05 O.OOE+00 NI-63 5.55E+07 3.92E+06 1.88E+06 O.OOE+00 0.OOE+00 O.OOE+00 6.24E+05 Q.OOE+00 CU-64 O.OOE+00 1.OOE+02 4.72E+01 O.OOE+00 2.54E+02 O.OOE+00 7.78E+03 O.OOE+00 NI-65 1.72E-03 2.20E-04 1.OOE-04 O.OOE+00 O.OQE+00 O.OOE+00 1.19E-02 O.OOE+00 ZN-65 8.88E+06 3.08E+07 1.44E+07 O.OOE+00 1.97E+07 0.0OE+00 1.31E+07 O.QOE+00 ZN-69m 8.29E+02 1.96E+03 1.79E+02 O.OOE+00 1.19E+03 O.OOE+00 1.07E+05 O.OOE+00 ZN-69 9.80E-15 1.87E-14 1.31E-15 O.OOE+00 1.22E-14 O.OOE+00 3.44E-14 O.QOE+00 SE-79 O.OOE+00 7.87E+06 1.32E+06 O.OOE+00 1.37E+07 O.OOE+00 1.20E+06 O.OOE+00 BR-82 O.OOE+00 O.OOE+00 1.43E+05 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 BR-83 O.OOE+00 O.OOE+00 4.56E-04 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 BR-84 O.OOE+00 O.OOE+00 7.32E-26 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 0.OOE+00 BR-85 O.OOE+00 O.OOE+00 9.13E-304 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 RB-86 O.OOE+00 1.24E+07 5.82E+06 O.OOE+00 O.OOE+00 O.OOE+00 1.83E+06 O.OOE+00 RB-87 O.OOE+00 2.46E+07 8.59E+06 O.OOE+00 O.OOE+00 O.OOE+00 8.59E+05 O.OOE+00 RB-88 O.OOE+00 9.89E-48 5.27E-48 O.OOE+00 O.OOE+00 O.OOE+00 8.47E-55 O.OOE+00 RB-89 O.OOE+00 1.95E-55 1.38E-55 O.OOE+00 O.OOE+00 O.OOE+00 2.99E-64 O.OOE+00 SR-89 1.48E+08 O.OOE+00 4.25E+06 O.OOE+00 O.OOE+00 O.OOE+00 1.77E+07 O.OOE+00 SR-90 5.42E+09 O.OOE+00 1.34E+09 O.OOE+00 O.OOE+00 O.OOE+00 1.52E+08 O.OOE+00 Y-90 3.31 E-01 O.OQE+00 8.92E-03 O.OQE+00 O.OOE+00 O.OOE+00 2.73E+03 O.OOE+00 SR-91 2.37E+03 O.OOE+00 9.41E+01 O.O0E+00 O.OOE+00 O.OOE+00 1.07E+04 O.OOE+00 Y-91m 2.79E-22 O.OOE+00 1.07E-23 O.OOE+00 O.OOE+00 O.OOE+00 1.32E-20 O.OOE+00 Y-91 7.27E+04 O.OOE+00 1.95E+03 O.OOE+00 O.OOE+00 O.0OE+00 2.98E+07 O.0OE+00 SR-92 2.27E-03 O.OOE+00 9.69E-05 O.OOE+00 0.OOE+00 O.OOE+00 5.79E-02 O.OOE+00 Y-92 2.62E-07 O.OE+00 7.59E-09 O.OOE+00 0,00E+00 O.OOE+00 7.20E-03 O.OOE+00 Y-93 1.05E-03 O.OE+00 2.87E-05 0.OOE+00 O.OOE+00 O.OOE+00 3.20E+01 O.OOE+00 NB-93m 4.0OE+03 1.31E+03 3.29E+02 O.OOE+00 1.53E+03 O.OOE+00 4.73E+05 O.OOE+00 NB-95 4.09E+02 2.27E+02 1.25E+02 O.OOE+00 2.20E+02 O.OOE+00 9.71E+05 O.OOE+00 NB-97 1.53E-14 3.79E-15 1.38E-15 O.OOE+00 4.43E715 O.OOE+00 9.04E-11 O.OOE+00 ZR-93 1.30E+01 6.40E+00 3.49E+00 0,00E+00 2.26E+01 O.OE+00 6.05E+03 O.OE+00

CY-LG-1 70-301, Rev. 23 I Page 182 08/07 TABLE 112-2 Ri DOSE FACTORS Age: Teen Pathway: Goat Milk (Continued)

NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG GI-LLI SKIN ZR-95 5.54E+00 1.75E+00 1.20E+00 0.00E+00 2.57E+00 O.OOE+00 4.03E+03 O.OOE+00 ZR-97 2.01E-03 3.97E-04 1.83E-04 0.OOE+00 6.02E-04 0.OOE+00 1.08E+02 0.OOE+00 MO-93 O.OOE+00 3.73E+06 1.02E+05 0.OOE+00 1.07E+06 O.OOE+00 4.53E+05 0.OOE+00 MO-99 0.OOE+00 1.14E+05 2.17E+04 0.OOE+00 2.60E+05 O.OOE+00 2.04E+05 0.0OE+00 TC-99 2.10E+05 3.08E+05 8.40E+04 O.OOE+00 3.91E+06 3.19E+04 7.54E+06 0.OOE+00 TC-99m 1.47E-02 4.09E-02 5.30E-01 0.O0E+00 6.09E-01 2.27E-02 2.68E+01 O.OOE+00 TC-101 1.21E-62 1.72E-62 1.69E-61 0.OOE+00 3.1OE-61 1.05E 2.93E-69 0.OOE+00 RU-103 5.41E+00 0.O0E+00 2.31E+00 0.OOE+00 1.91E+01 0.OOE+00 4.52E+02 0.OOE+00 RU-105 3.98E-06 0.00E+00 1.55E-06 O.OOE+00 5.02E-05 O.OOE+00 3.21E-03 O.OOE+00 RU-106 1.64E+02 O.OOE+00 2.06E+01 O.OQE+00 3.16E+02 O.OOE+00 7.85E+03 .0.00E+00 RH-105 8.08E+04 5.84E+04 3.83E+04 O.OOE+00 2.48E+05 O.OOE+00 7.43E+06 O.OOE+00 PD-107 O.OOE+00 9.75E+04 6.28E+03 O.OOE+00 8.81E+05 O.OOE+00 4.53E+05 O.OOE+00 PD-109 O.OOE+00 2.06E+02 4.68E+01 O.OOE+00 1.19E+03 O.OOE+00 2.08E+04 O.OOE+00 AG-110m 4.07E+05 3.85E+05 2.34E+05 O.OOE+00 7.34E+05 O.OOE+00 1.08E+08 O.OOE+00 AG-111 3.04E+04 1.26E+04 6.34E+03 O.OOE+00 4.1OE+04 O.OOE+00 1.76E+07 O.OOE+00 CD-113m O.OOE+00 2.51E+04 8.08E+02 O.OOE+00 2.78E+04 O.OOE+00 1.51E+05 OOOE+00 CD-115m O.OOE+00 7.06E+03 2.28E+02 O.OOE+00 5.65E+03 O.OOE+00 2.24E+05 O.OOE+00 SN-123 3.83E+06 6.28E+04 9.31E+05 5.03E+04 O.OOE+00 O.OOE+00 7.1OE+06 O.OOE+00 SN-125 2.67E+05 5.32E+03 1.20E+04 4.17E+03 O.OOE+00 O.OOE+00 2.51E+06 O.OOE+00 SN-126 1.36E+07 2.53E+05 3.87E+05 6.67E+04 O.OOE+00 O.OOE+00 3.02E+06 O.OOE+00 SB-124 1.52E+05 2.80E+03 5.93E+04 3.45E+02 O.OOE+00 1.33E+05 3.06E+06 O.OOE+00 SB-125 1.67E+05 1.82E+03 3.91E+04 1.60E+02 O.OOE+00 1.47E+05 1.30E+06 O.OOE+00 SB-126 2.56E+04 5.22E+02 9.18E+03 1.45E+02 O.OOE+00 1.83E+04 1.51E+06 O.OOE+00 SB-127 2.08E+03 4.44E+01 7.84E+02 2,34E+01 O.OOE+00 1.41E+03 3.53E+05 O.OOE+00 TE-125m 9.85E+04 3.55E+04 1.32E+04 2,75E+04 O.OOE+00 O.OOE+00 2.91 E+05 O.OOE+00 TE-127m 3.17E+05 1.13E+05 3.77E+04 7.55E+04 1.29E+06 O.OOE+00 7.91E+05 O.OOE+00 TE-127 3.08E+00 1.09E+00 6.63E-01 2.12E+00 1.25E+01 O.OOE+00 2.38E+02 O.OOE+00 TE-129m 3.17E+05 1.18E+05 5.02E+04 1.02E+05 .1.33E+06 O.OOE+00 1.19E+06 O.OOE+00 TE-129 1.32E-12 4.93E-13 3.22E-13 9.45E-13 5.55E-12 O.OOE+00 7.23E-12 O.OOE+00 TE-133m 9.63E-16 5.48E-16 5.33E-16 7.64E-16 5.42E-15 O.OOE+00 2.21E-15 O.OOE+00 TE-134 4.03E-21 2.59E-21 2.71E-21 3.31E-21 2.47E-20 O.OOE+00 1.50E-22 O.OOE+00 1-129 6.55E+07 5.51E+07 9.19E+07 6.71E+10 9.86E+07 O.OOE+00 6.42E+06 O.OOE+00 1-130 1.88E+03 5.44E+03 2.17E+03 4.43E+05 8.37E+03 O.OOE+00 4.18E+03 O.OOE+00 1-131 1.37E+06 1.91 E+06 1.03E+06 5.59E+08 3.30E+06 O.OOE+00 3.79E+05 O.OOE+00 TE-131m 1.67E+03 8.02E+02 6.69E+02 1.21E+03 8.36E+03 O.OOE+00 6.43E+04 O.OOE+00 TE-131 1.68E-35 6.91E-36 5.24E-36 1.29E-35 7.33E-35 O.OOE+00 1.38E-36 O.OOE+00 1-132 7.41 E-04 1,94E-03 6.96E-04 6.54E-02 3.06E-03 O.OOE+00 8.45E-04 0.OOE+00 TE-132 1.09E+04 6.92E+03 6.51 E+03 7.29E+03 6.63E+04 O.OOE+00 2.19E+05 O.OOE+00 1-133 1.80E+05 3.05E+05 9.31E+04 4.26E+07 5.35E+05 O.OOE+00 2.31E+05 O.OOE+00 CS-134m 1.97E-02 4.08E-02 2.09E-02 O.OOE+00 2.27E-02 3.98E-03 2.71E-02 O.OOE+00 CS-134 1.11E+09 2.62E+09 1.21E+09 O.OOE+00 8.31E+08 3.17E+08 3.25E+07 0.OOE+00 1-134 9.12E-14 2.42E-13 8.68E-14 4.03E-12 3.81E-13 O.OOE+00 3.19E-15 O.OOE+00 1-135 5.80E+02 1.49E+03 5.54E+02 9.61E+04 2.36E+03 O.OOE+00 1.66E+03 O.OOE+00 CS-135 3.91E+08 3.58E+08 8.38E+07 O.OOE+00 1.37E+08 4.95E+07 6.27E+06 - O.OOE+00 CS-136 2.87E+07 1.13E+08 7.59E+07 O.OOE+00 6.15E+07 9.70E+06 9.1OE+06 O.OOE+00

CY-LG-170-301, Rev. 23 Page 183 08/07 TABLE 112-2 Ri DOSE FACTORS Age: Teen Pathway: Goat Milk (Continued)

NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG GI-LLI SKIN CS-137 1.57E+09 2.09E+09 7.27E+08 O.0OE+00 7.1OE+08 2.76E+08 2.97E+07 0.00E+00 CS-138 1.04E-24 2.OOE-24 1.OOE-24 O.OOE+00 1.48E-24 1.72E-25 9.09E-28 O.OOE+00 CS-139 7.95E-91 1.17E-90 4.29E-91 0.OOE+00 9.45E-91 1.03E-91 5.44E-106 O.OOE+00 BA-139 2.08E-10 1.46E-13 6.06E-12 O.OOE+00 1.38E-13 1.01E-13 1.86E-09 O.OOE+00 BA-140 1.24E+05 1.52E+02 8.01E+03 O.OOE+00 5.16E+01 1.02E+02 1.92E+05 O.OOE+00 LA-140 2.06E-02 1.01E-02 2.70E-03 O.OOE+00 O.OOE+00 O.OOE+00 5.82E+02 O.OOE+00 BA-141 1.91E-48 1.43E-51 6.39E-50 O.OOE+00 1.33E-51 9.79E-52 4.08E-54 O.OOE+00 LA-141 1.43E-07 4.39E-08 7.24E-09 O.OOE+00 0,00E+00 O.OOE+00 7.77E-03 O.OOE+00 CE-141 2.54E+01 1.70E+01 1.95E+00 O.OOE+00 7.99E+00 O.OOE+00 4.85E+04 O.OOE+00 BA-142 1.23E-82 1.23E-85 7.54E-84 O.OOE+00 1.04E-85 8.15E-86 3.76E-94 O.OOE+00 LA-142 8.53E-14 3.79E-14 9.44E-15 O.OOE+00 O.OOE+00 O.OOE+00 1.15E-09 O.OOE+00 CE-143 1.94E-01 1.41E+02 1.58E-02 O.OOE+00 6.34E-02 O.OOE+00 4.25E+03 O.OE+00 PR-143 7.45E-01 2.97E-01 3.71E-02 O.OOE+00 1.73E-01 O.OOE+00 2.45E+03 O.OOE+00 CE-144 2.81E+03 1.16E+03 1.51E+02 O.O0E+00 6.95E+02 O.OOE+00 7.08E+05 O.OOE+00 PR-144 2.75E-56 1.13E-56 1.40E-57 0.OOE+00 6.47E-57 O.OOE+00 3.03E-59 O.OOE+00 ND-147 4.62E-01 5.03E-01 3.01E-02 O.OOE+00 2.95E-01 O0O0E+00 1.81E+03 O.OOE+00 PM-147 2.35E+01 2.23E+00 9.09E-01 O.OOE+00 4.26E+00 O.OOE+00 2.12E+03 O.OOE+00 PM-148m 4.50E+00 1.14E+00 8.93E-01 O.OOE+00 1.73E+00 O.OOE+00 7.19E+03 O.OOE+00 PM-148 1.11E+00 1.81E-01 9.09E-02 O.OOE+00 3.26E-01 O.OOE+00 1.08E+04 O.OOE+00 PM-149 2.01E-02 2.82E-03 1.16E-03 O.OOE+00 5.37E-03 O.0OE+00 4.15E+02 O.OOE+00 PM-151 3.02E-03 4.99E-04 2.52E-04 O.OOE+00 8.97E-04 O.OOE+00 1.12E+02 O.OE+00 SM-151 2.04E+01 3.93E+00 9.22E-01 O.OOE+00 4.31E+00 O.0OE+00 1.33E+03 O.OOE+00 SM-153 9.26E-03 7.66E-03 5.64E-04 O.OOE+00 2.50E-03 O.OOE+00 2.16E+02 O.OOE+00 EU-152 5.69E+01 1.37E+01 1.21E+01 O.OOE+00 6.36E+01 O.OOE+00 5.04E+03 O.OOE+00 EU-154 1.83E+02 2.36E+01 1.66E+01 O.OOE+00 1.05E+02 O.OOE+00 1.25E+04 O.OOE+00 EU-155 3.98E+01 3.84E+00 2.38E+00 O.OOE+00 1.50E+01 O.OOE+00 2.20E+04 O.OOE+00 EU-156 1.17E+00 8.80E-01 1.44E-01 O.OOE+00 5.92E-01 O.OOE+00 4.50E+03 O.OOE+00 TB-160 9.16E+00 O.OOE+00 1.14E+00 O.OOE+00 3,62E+00 O.OOE+00 5.93E+03 O.OOE+00 HO-166m 8,36E+01 2.58E+01 1.86E+01 O.OOE+00 3.77E+01 O.OOE+00 2.34E-16 O.OOE+00 W-181 2.40E+02 7.75E+01 8.11E+00 O.OOE+00 O.OOE+00 O.OOE+00 6.60E+03 O.OOE+00 W-185 8.32E+03 2.75E+03 2.90E+02 O.OOE+00 O.OOE+00 O.OOE+00 2.37E+05 O.OOE+00 W-187 3.03E+01 2.47E+01 8.66E+00 O.OOE+00 O.OOE+00 O.OOE+00 6.69E+03 O.OOE+00 NP-239 1.78E-02 1.68E-03 9.34E-04 O.OOE+00 5.28E-03 O.OOE+00 2.71E+02 O.OOE+00 U-232 1.38E+08 O.OOE+00 9.85E+06 O.OOE+00 1.49E+07 O.OOE+00 1.68E+06 O.OOE+00 U-233 2.91E+07 O.OOE+00 1.77E+06 O.OOE+00 6.79E+06 O.OOE+00 1.56E+06 O.OOE+00 U-234 2.79E+07 O.OOE+00 1.73E+06 O.OOE+00 6.68E+06 O.OOE+00 1.53E+06 O.OQE+00 U-235 2.67E+07 O.OOE+00 1.63E+06 O.OE+00 6.26E+06 O.OOE+00 1.94E+06 O.OOE+00 U-236 2.67E+07 O.OOE+00 1.66E+06 O.OE+00 6.40E+06 O.OOE+00 1.43E+06 O.OOE+00 U-237 2.65E+02 O.OOE+00 7.06E+01 O.OOE+00 1.09E+03 O.OOE+00 7.02E+04 0.00E+06 U-238 2.55E+07 0.OOE+00 1.52E+06 O.OOE+00 5.86E+06 O.OOE+00 1.37E+06 O.OOE+00 NP-237 3.12E+05 2.24E+04 1.37E+04 O.OOE+00 1.01E+05 O.OOE+00 1.97E+04 O.OOE+00 NP-238 1.69E-01 4.52E-03 2.63E-03 O.00E+00 1.55E-02 O.OOE+00 3.31E+02 O.OOE+00 PU-238 6.27E+04 8.03E+03 1.70E+03 O.OOE+00 7.30E+03 O.OOE+00 7.23E+03 O.OOE+00

CY-LG-1 70-301, Rev. 23 I Page 184 08/07I TABLE 112-2 Ri DOSE FACTORS Age: Teen Pathway: Goat Milk (Continued)

NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG GI-LLI SKIN PU-239 7.17E+04 8.71E+03 1.88E+03 0.OOE+00 8.03E+03 0.OOE+00 6.62E+03 O.OOE+00 PU-240 7.16E+04 8.69E+03 1.88E+03 0.OOE+00 8.02E+03 O.OOE+00 6.74E+03 O.OOE+00 PU-241 1.63E+03 7.81E+01 3.43E+01 O.OOE+00 1.59E+02 O.OOE+00 1.38E+02 O.OOE+00 PU-242 6.65E+04 8.38E+03 1.82E+03 O.OOE+00 7.73E+03 O.OOE+00 6.49E+03 O.OQE+00 PU-244 7.76E+04 9.56E+03 2.08E+03 O.OE+00 8.86E+03 O.OOE+00 9.65E+03 O.OQE+00 AM-241 1.87E+05 1.76E+05 1.35E+04 O.OE+00 1.01E+05 O.OOE+00 1.84E+04 O.OOE+00 AM-242m 1.89E+05 1.66E+05 1.36E+04 O.OOE+00 1.01E+05 O.OOE+00 2.32E+04 O.OOE+00 AM-243 1.87E+05 1.72E+05 1.32E+04 O.OOE+00 9.89E+04 O.OOE+00 2.16E+04 O.OOE+00 CM-242 5.37E+03 5.67E+03 3.56E+02 O.OOE+00 1.63E+03 O.OOE+00 1.54E+04 O.OOE+00 CM-243 1.52E+05 1.41 E+05 9.54E+03 O.OOE+00 4.46E+04 O.OOE+00 1.93E+04 O.OOE+00 CM-244 1.17E+05 1.11E+05 7.43E+03 O.OOE+00 3.47E+04 O.OOE+00 1.86E+04 O.OOE+00 CM-245 2.32E+05 2.04E+05 1.43E+04 O.OOE+00 6.68E+04 O.OOE+00 1.75E+04 O.OOE+00 CM-246 230E+05 2.04E+05 1.43E+04 O.OOE+00 6.65E+04 0.OOE+00 1.72E+04 O.OOE+00 CM-247 2.24E+05 2.01E+05 1.41E+04 O.OOE+00 6.56E+04 O.OOE+00 2.26E+04 O.OOE+00 CM-248 1.86E+06 1.65E+06 1.16E+05 O.OOE+00 5.41E+05 O.OOE+00 3.63E+05 O.OOE+00 CF-252 7.77E+04 O.OOE+00 1.87E+03 O.OOE+00 O.OOE+00 O.OOE+00 6.83E+04 O.OOE+00

CY-LG-1 70-301, Rev. 23 Page 185 08/07 TABLE 112-2 Ri DOSE FACTORS Age: Teen Pathway: Inhalation NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG GI-LLI SKIN H-3 0.00E+00 1.27E+03 1.27E+03 1.27E+03 1.27E+03 1.27E+03 1.27E+03 0.OOE+00 C-14 2.60E+04 4.87E+03 4.87E+03 4.87E+03 4.87E+03 4.87E+03 4.87E+03 0.OOE+00 NA-22 1.41 E+05 1.41 E+05 1.41 E+05 1.41 E+05 1.41E+05 1.41 E+05 1.41E+05 0.OOE+00 NA-24 1.38E+04 1.38E+04 1.38E+04 1.38E+04 1.38E+04 1.38E+04 1.38E+04 0.OOE+00 P-32 1.89E+06 1.10E+05 7.16E+04 0,OOE+00 0.00E+00 0.OOE+00 9.28E+04 0.OOE+00 CA-41 3.24E+05 0.OOE+00 3.50E+04 0.OOE+00 1.08E+06 8.08E+08 2.38E+05 0.OOE+00 SC-46 5.79E+05 1.13E+06 3.34E+05 7.50E+01 3.07E+01 2.1OE+04 3.00E+03 0.OOE+00 CR-51 0.OOE+00 O.OOE+00 1.35E+02 7.50E+01 3.07E+01 2.1OE+04 3.OOE+03 0.OOE+00 MN-54 0.OOE+00 5.11 E+04 8.40E+03 0.OOE+00 1.27E+04 1.98E+06 6.68E+04 0.OOE+00 FE-55 3.34E+04 2.38E+04 5.54E+03 OOOE+00 0.OOE+00 1.24E+05 6.39E+03 0.OOE+00 MN-56 0.OOE+00 1.70E+00 2.52E-01 0.OOE+00 1.79E+00 1.52E+04 5.74E+04 0.OOE+00 CO-57 0.00E+00 9.44E+02 9.20E+02 0.00E+00 0.OOE+00 5.86E+05 3.14E+04 0.OOE+00 CO-58 O.00E+00 2.07E+03 2.78E+03 O.00E+00 0.00E+00 1,34E+06 9.52E+04 0.OOE+00 FE-59 1 "59E+04 3.70E+04 1.43E+04 0.00E+00 0.00E+00 1.53E+06 1.78E+05 0.OOE+00 CO-60 0.00E+00 1.51 E+04 1.98E+04 0.00E+00 O.00E+00 8.72E+06 2.59E+05 0.OOE+00 NI-59 4.35E+04 1.62E+04 7.39E+03 0.OOE+00 0.OOE+00 1.13E+05 5.18E+03 0.OOE+00 NI-63 5.80E+05 4.34E+04 1.98E+04 0.OOE+00 O.OOE+00 3.07E+05 1.42E+04 0.OOE+00 CU-64 0.OOE+00 2.03E+00 8.48E-01 0.OOE+00 6.41 E+00 1.11E+04 6.14E+04 0.OOE+00 NI-65 2.18E+00 2.93E-01 1.27E-01 0.00E+00 0.OOE+00 9.36E+03 3.67E+04 0.OOE+00 ZN-65 3.86E+04 1.34E+05 6.24E+04 O.OOE+00 8.64E+04 1.24E+06 4.66E+04 0.OOE+00 ZN-69m 1.15E+01 2.47E+01 2.49E+00 0.OOE+00 1.65E+01 3.14E+04 1.71E+05 0.OOE+00 ZN-69 4.83E-02 9.20E-02 6.46E-03 0.OOE+00 6.02E-02 1,58E+03 2.85E+02 0.OOE+00 SE-79 0.OOE+00 4.34E+03 6.97E+02 0.OOE+00 6.50E+03 6.17E+05 2,82E+04 0.OOE+00 BR-82 0.O0E+00 0.0OE+00 1.82E+04 0.OOE+00 0.OOE+00 0.OOE+00 8.OOE-1 5 0.OOE+00 BR-83 0.00E+00 O.00E+00 3.44E+02 0.00E+00 0.00E+00 0.OOE+00 0.OOE+00 0.OOE+00 BR-84 O.OOE+00 0.OOE+00 4.33E+02 0.00E+00 0.OOE+00 O.00E+00 0.OOE+00 0.OOE+00 0.OOE+00 BR-85 O.OOE+00 0.00E+00 1.83E+01 O.0OE+00 0.00E+00 0.OOE+00 0.OOE+00 0.OOE+00 RB-86 0.OOE+00 1.90E+05 8.40E+04 0.OOE+00 0.00E+00 1.77E+04 0.OOE+00 O.00E+00 RB-87 0.OOE+00 1.12E+05 3.66E+04 0.00E+00 0.OOE+00 2.44E+03 0.OOE+00 0.OOE+00 RB-88 0.00E+00 5.46E+02 2.72E+02 0.OOE+00 0.OOE+00 2.92E-05 0.OOE+00 0.OOE+00 RB-89 0.00E+00 3.52E+02 2.33E+02 0.OOE+00 0.OOE+00 3.38E-07 0.OOE+00 0.00E+00 SR-89 4.34E+05 0.OOE+00 1.25E+04 0.OOE+00 2.42E+06 3.71 E+05 0.OOE+00 0.OOE+00 SR-90 1.08E+08 0.00E+00 6.68E+06 0.OOE+00 1.65E+07 7.65E+05 0.0OE+00 0.OOE+00 Y-90 2.98E+03 0.00E+00 8.OOE+01 0.OOE+00 2.93E+05 5.59E+05 0.OOE+00 0.O0E+00 SR-91 8.80E+01 0.OOE+00 3.51 E+00 0.OOE+00 6.07E+04 2.59E+05 0.OOE+00 0.O0E+00 Y-91m 3.70E-01 0.OOE+00 1.42E-02 0.00E+00 3.20E+03 3.02E+01 0.OOE+00 0.OOE+00 Y-91 6.61 E+05 0.OOE+00 1.77E+04 O.0OE+00 2.94E+06 4.09E+05 0.OOE+00 0.OOE+00 SR-92 9.52E+00 0.OOE+00 4.06E-01 0.OOE+00 2.74E+04 1.19E+05 0.OOE+00 0.OOE+00 Y-92 1.47E+01 0.00E+00 4.29E-01 0.OOE+00 2.68E+04 1.65E+05 0.OOE+00 0.OOE+00 Y-93 1.35E+02 O.OOE+00 3.72E+00 0.OOE+00 8.32E+04 5.79E+05 0.OOE+00 0.00E+00 NB-93m 3.31 E+05 1.09E+05 2.73E+04 1.27E+05 4.29E+05 2.02E+04 0.OOE+00 0.OOE+00 NB-95 1.86E+04 1.03E+04 5.66E+03 1.00E+04 7.51 E+05 9.68E+04 0.OOE+00 0.00E+00 NB-97 3.14E-01 7.78E-02 2.84E-02 9.12E-02 3.93E+03 2.17E+03 0.OOE+00 O.OOE+0O 1.28E+05 0.OOE+00 ZR-93 5.46E+05 2.70E+05 1.47E+05 0,00E+00 9.28E+05 2.94E+06 ZR-95 1.46E+05 4.58E+04 3.15E+04 0.00E+00 6.74E+04 2.69E+06 1.49E+05 0.OOE+00

CY-LG-170-301, Rev. 23 Page 186 08/07 TABLE 112-2 Ri DOSE FACTORS Age: Teen Pathway: Inhalation (Continued)

NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG GI-LLI SKIN ZR-97 1.38E+02 2.72E+01 1.26E+01 0.OOE+00 4.12E+01 1.30E+05 6.30E+05 0.00E+00 MO-93 0.OOE+00 1.33E+04 3.62E+02 O.OOE+00 4.05E+03 7.05E+05 3.19E+04 0.OOE+00 MO-99 0.OOE+00 1.69E+02 3.22E+01 0.OOE+00 4.11E+02 1.54E+05 2.69E+05 0.OOE+00 TC-99 3.58E+02 5.26E+02 1.43E+02 0.OOE+00 6.68E+03 1.39E+06 6.39E+04 0.OOE+00 TC-99m 1.38E-03 3.86E-03 4.99E-02 0.OOE+00 5.76E-02 1.15E+03 6.13E+03 0.OOE+00 TC-101 5.92E-05 8.40E-05 8.24E-04 O.OOE+00 1.52E-03 6.67E+02 8.72E-07 0.OOE+00 RU-103 2.10E+03 0.OOE+00 8.96E+02 O.OOE+00 7.43E+03 7.83E+05 1.09E+05 0.OOE+00 RU-105 1.12E+00 0.OOE+00 4.34E-01 0.OOE+00 1.41E+00 1.82E+04 9.04E+04 0.OOE+00 RU-106 9.84E+04 0.OOE+00 1.24E+04 0.OOE+00 1.90E+05 1.61E+07 9.60E+05 0.O0E+00 RH-105 1.06E+01 7.58E+00 4.99E+00 0.OOE+00 3.23E+01 3.27E+04 9.84E+04 0.OOE+00 PD-107 O.OOE+00 9.36E+02 6.71E+01 0,00E+00 7.51E+03 1.30E+05 5.99E+03 0.OOE+00 PD-109 O.OOE+00 5.25E+00 1.33E+00 0,00E+00 2.69E+01 2.55E+04 1.57E+05 0.OOE+00 AG-110m 1.38E+04 1.31E+04 7.99E+03 O.OOE+00 2.50E+04 6.75E+06 2.73E+05 O.OOE+00 AG-111 4.86E+02 2.02E+02 1.02E+02 O.OOE+00 6.54E+02 3.20E+05 2.40E+05 O.OOE+00 CD-113m O.OOE+00 1.74E+06 5.68E+04 O.OOE+00 1.94E+06 2.87E+06 1.34E+05 O.OOE+00 CD-115m O.OOE+00 2.78E+05 9.12E+03 O.OOE+00 2.26E+05 2.42E+06 4.08E+05 O.OOE+00 SN-123 3.45E+05 7.55E+03 1.12E+04 6.04E+03 O.OOE+00 3.97E+05 3.33E+05 O.OOE+00 SN-125 1.33E+04 3.54E+02 7.99E+02 2.76E+02 O.OOE+00 1.01E+06 5.83E+05 O.OOE+00 SN-126 1.74E+06 4.31E+04 6.59E+04 1.14E+04 O.OOE+00 1.38E+07 1.34E+05 O.OOE+00 SB-124 4.30E+04 7.94E+02 1.68E+04 9.76E+01 O.OOE+00 3.85E+06 3.98E+05 O.OOE+00 SB-125 7.38E+04 8.08E+02 1.72E+04 7.04E+01 O.OOE+00 2.74E+06 9.92E+04 O.OOE+00 SB-126 4,95E+03 1.02E+02 1.78E+03 2.80E+01 O0OOE+00 1.24E+06 4.81E+05 O.OOE+00 SB-127 3.71E+02 7.94E+00 1.40E+02 4.17E+00 O.OOE+00 2.65E+05 3.15E+05 O.OOE+00 TE-125m 4.88E+03 2.24E+03 6.67E+02 1.40E+03 O.OOE+00 5.36E+05 7.50E+04 O.OOE+00 TE-127m 1.80E+04 8.16E+03 2.18E+03 4.38E+03 6.54E+04 1.66E+06 1.59E+05 O.OOE+00 TE-127 2.01E+00 9.12E-01 4,42E-01 1.42E+00 7.28E+00 1.12E+04 8.08E+04 O.OOE+00 TE-129m 1.39E+04 6.58E+03 2.25E+03 4.58E+03 5.19E+04 1.98E+06 4.05E+05 O.OOE+00 TE-129 7.1OE-02 3.38E-02 1.76E-02 5.18E-02 2.66E-01 3.30E+03 1.62E+03 O.OOE+00 TE-133m 8.08E-02 5.86E-02 4.57E-02 6.54E-02 2.46E-01 6.97E+03 9.84E+02 O.OOE+00 TE-134 4.25E-02 3.48E-02 2.91E-02 3.57E-02 2.33E-01 5.38E+03 1.10E+01 O.OOE+00 1-129 2.82E+04 2.35E+04 7.12E+04 2.93E+07 4.21E+04 O.OOE+00 1.83E+03 O.OOE+00 1-130 6.24E+03 1.79E+04 7.17E+03 1.49E+06 2.75E+04 O.OOE+00 9.12E+03 O.OOE+00 1-131 3.54E+04 4.91E+04 2.64E+04 1.46E+07 8.40E+04 O.OOE+00 6.49E+03 0.00E+00 TE-131m 9.84E+01 6.01E+01 4.02E+01 7.25E+01 4.39E+02 2.38E+05 6.21E+05 O.OOE+00 TE-131 1.58E-02 8.32E-03 5.04E-03 1.24E-02 6.18E-02 2.34E+03 1.51E+01 0.OOE+00 1-132 1.59E+03 4.38E+03 1.58E+03 1.51 E+05 6.92E+03 O.OOE+00 1.27E+03 O.OOE+00 TE-132 3.60E+02 2.90E+02 2.19E+02 2.46E+02 1.95E+03 4.49E+05 4.63E+05 O.OOE+00 1-133 1.22E+04 2.05E+04 6.22E+03 2.92E+06 3.59E+04 0.OOE+00 1.03E+04 0.OOE+00 CS-134m 1.76E+02 3.48E+02 1.88E+02 O.OOE+00 2.03E+02 3.65E+01 1.62E+02 0.OOE+00 CS-134 5.02E+05 1.13E+06 5.49E+05 0.OOE+00 3.75E+05 1.46E+05 9.76E+03 0,OOE+00 1-134 8.88E+02 2.32E+03 8.40E+02 3.95E+04 3.66E+03 0.OOE+00 2.04E+01 0.OOE+00 1-135 3.70E+03 9.44E+03 3.49E+03 6.21E+05 1.49E+04 0.OOE+00 6.95E+03 0.OOE+00 CS-135 1.66E+05 1.46E+05 3.58E+04 0.OOE+00 5.84E+04 2.16E+04 1.78E+03 0.OOE+00 CS-136 5.15E+04 1.94E+05 1.37E+05 0.OOE+00 1.1OE+05 1.78E+04 1.09E+04 0.OOE+00 CS-137 6.70E+05 8.48E+05 3.11E+05 0.OOE+00 3.04E+05 1.21E+05 8.48E+03 0.OOE+00

CY-LG-1 70-301, Rev. 23 I Page 187 08/07 TABLE 112-2 Ri DOSE FACTORS Age: Teen Pathway: Inhalation (Continued)

NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG GI-LLI SKIN CS-138 4.66E+02 8.56E+02 4.46E+02 0.OOE+00 6.62E+02 7.87E+01 2.70E-01 0.00E+00 CS-139 2.92E+02 4.10E+02 1.58E+02 0.OOE+00 3.47E+02 3.89E+01 1.33E-13 0.OOE+00 BA-139 1.34E+00 9.44E-04 3.90E-02 0.OOE+00 8.88E-04 6.46E+03 6.45E+03 0.OOE+00 BA-140 5.47E+04 6.70E+01 3.52E+03 0.OOE+00 2.28E+01 2.03E+06 2.29E+05 O.OOE+00 LA-140 4.79E+02 2.36E+02 6.26E+01 0.OOE+00 0.OOE+00 2.14E+05 4.87E+05 0.0OE+00 BA-141 1.42E-01 1.06E-04 4.74E-03 0.OOE+00 9.84E-05 3.29E+03 7.46E-04 0.OOE+00 LA-141 6.10E+00 1.88E+00 3.10E-01 0.OOE+00 O.OOE+00 1.85E+04 1.23E+05 O.OOE+00 CE-141 2.84E+04 1.90E+04 2.17E+03 O.OOE+00 8.88E+03 6.14E+05 1.26E+05 0.OOE+00 BA-142 3.70E-02 3,70E-05 2.27E-03 0.OOE+00 3.14E-05 1.91E+03 4.79E-10 0.OOE+00 LA-142 9.60E-01 4.25E-01 1.06E-01 0.OOE+00 0.OOE+00 1.02E+04 1.20E+04 0.OOE+00 CE-143 2.66E+02 1.94E+02 2.16E+01 0.OOE+00 8.64E+01 1.30E+05 2.55E+05 0.OOE+00 PR-143 1.34E+04 5.31E+03 6.62E+02 O.OOE+00 3.09E+03 4.83E+05 2.14E+05 0.OOE+00 CE-144 4.89E+06 2.02E+06 2.62E+05 0.OOE+00 1.21E+06 1.34E+07 8.64E+05 0.OOE+00 PR-144 4.30E-02 1.76E-02 2.18E-03 0.OOE+00 1.01E-02 1,75E+03 2.35E-04 OOOE+00 ND-147 7.86E+03 8.56E+03 5.13E+02 0.OOE+00 5.02E+03 3.72E+05 1.82E+05 0.OOE+00 PM-147 9.20E+05 8.80E+04 3.60E+04 0.OOE+00 1.68E+05 9.12E+05 4.70E+04 0.OOE+00 PM-148m 1.06E+05 2.68E+04 2.10E+04 0.OOE+00 4.06E+04 2.56E+06 3.28E+05 0.OOE+00 PM-148 4.35E+03 7.1OE+02 3.58E+02 0.OOE+00 1.28E+03 5.22E+05 4.91E+05 0.OOE+00 PM-149 3.93E+02 5.51E+01 2.27E+01 0.OOE+00 1.05E+02 9,92E+04 2.23E+05 0.OOE+00 PM-151 9.60E+01 1.59E+01 8.08E+00 0.OOE+00 2.86E+01 4.52E+04 1.82E+05 0.OOE+00 SM-151 8.56E+05 1.68E+05 3.89E+04 0.OOE+00 1.82E+05 6.14E+05 2.82E+04 O.OOE+00 SM-153 1.94E+02 1.61E+02 1.18E+01 0.OOE+00 5.25E+01 5.69E+04 1.42E+05 0.OOE+00 EU-1 52 2.37E+06 5.75E+05 5.04E+05 0.OOE+00 2.67E+06 4.01 E+06 1.08E+05 0.OOE+00 EU-154 7.54E+06 9.84E+05 6.88E+05 0.OOE+00 4.35E+06 7.30E+06 2.67E+05 0.OOE+00 EU-155 1.60E+06 1.57E+05 9.68E+04 0.OOE+00 6.12E+05 1.21E+07 4.78E+05 0.OOE+00 EU-156 2.16E+04 1.62E+04 2,64E+03 0.OOE+00 1.09E+04 1.10E+06 3.65E+05 O.OOE+00 TB-160 2.43E+05 0.OOE+00 3.03E+04 0.OOE+00 9.60E+04 3.18E+06 2.08E+05 0.OOE+00 HO-166m 3.52E+06 1.25E+06 7.90E+05 0.OOE+00 1.60E+06 4.99E+06 1.34E+05 0.OOE+00 W-181 7.12E+01 2.30E+01 2.41E+00 0.OOE+00 0.OOE+00 2.36E+04 2.15E+03 0.OOE+00 W-185 2.22E+03 7.34E+02 7.78E+01 0.OOE+00 0.OOE+00 7.68E+05 9.12E+04 O.OOE+00 W-187 1.20E+01 9.76E+00 3.43E+00 0.OOE+00 0.OOE+00 4.74E+04 1.77E+05 0.OOE+00 NP-239 3.38E+02 3.19E+01 1.77E+01 0.OOE+00 1.00E+02 6.49E+04 1.32E+05 0.OOE+00 U-232 5.85E+08 0.OOE+00 4.18E+07 0.OOE+00 6.35E+07 3.07E+09 3.57E+05 0.OOE+00 U-233 1.24E+08 0.OOE+00 7.54E+06 0.OOE+00 2.90E+07 7.34E+08 3.30E+05 0.OOE+00 U-234 1.18E+08 O.OOE+00 7.38E+06 0.OOE+00 2.84E+07 7.19E+08 3.23E+05 0.OOE+00 U-235 1.14E+08 0.OOE+00 6.94E+06 0.OOE+00 2.67E+07 6.75E+08 4.1OE+05 0.OOE+00 U-236 1.14E+08 0.OOE+00 7.09E+06 0.OOE+00 2.73E+07 6.90E+08 3.03E+05 0.OOE+00 U-237 4.20E+02 0.OOE+00 1.12E+02 0.OOE+00 1.73E+03 1.41E+05 1.03E+05 0.OOE+00 U-238 1.09E+08 0.OOE+00 6.48E+06 0.OOE+00 2.50E+07 6.31 E+08 2.90E+05 0.OOE+00 NP-237 1.31E+10 9.44E+08 5.77E+08 O.OOE+00 2.68E+09 7.19E+08 4.18E+05 0.OOE+00 NP-238 3.38E+03 9.04E+01 5.27E+01 0.OOE+00 3.1OE+02 1.40E+05 1.90E+05 0.OOE+00 PU-238 2.14E+10 2,74E+09 5.78E+08 0.OOE+00 2.48E+09 2.50E+09 3.83E+05 0.OOE+00 PU-239 2.46E+10 2.99E+09 6.44E+08 0,OOE+00 2.75E+09 2.34E+09 3.50E+05 0.OOE+00

CY-LG-170-301, Rev. 23 Page 188 08/07 TABLE 112-2 Ri DOSE FACTORS Age: Teen Pathway: Inhalation (Continued)

NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG GI-LLI SKIN PU-240 2.45E+10 2.98E+09 6.43E+08 O.OOE+00 2.74E+09 2.34E+09 3.57E+05 O.OOE+00 PU-241 5.31 E+08 2.55E+07 1.12E+07 O.OOE+00 5.18E+07 2.08E+06 7.34E+03 O.OOE+00 PU-242 2.27E+10 2.88E+09 6.20E+08 O.OOE+00 2.65E+09 2.26E+09 3.43E+05 O.OOE+00 PU-244 2.66E+10 3.30E+09 7.10E+08 O.OOE+00 3.03E+09 2.58E+09 5.11 E+05 O.OOE+00 AM-241 7.87E+09 7.44E+09 5.68E+08 0.OOE+00 4.26E+09 8.40E+08 3.90E+05 O.OE+00 AM-242m 7.96E+09 7.02E+09 5.72E+08 0.OOE+00 4.24E+09 3.37E+08 4.91 E+05 O.OOE+00 AM-243 7.86E+09 7.26E+09 5.56E+08 O.OOE+00 4.17E+09 7.93E+08 4.58E+05 O.OOE+00 CM-242 1.69E+08 1.78E+08 1.13E+07 O.OOE+00 5.12E+07 5.41E+08 4.17E+05 O.OOE+00 CM-243 6.36E+09 5.90E+09 4.OOE+08 O.OOE+00 1.87E+09 8.72E+08 4.1OE+05 O.OOE+00 CM-244 4.90E+09 4.64E+09 3.10E+08 O.OOE+00 1.45E+09 8.40E+08 3.97E+05 O.OOE+00 CM-245 9.76E+09 8.64E+09 6.02E+08 O.OOE+00 2.82E+09 8.08E+08 3.70E+05 O.OOE+00 CM-246 9.68E+09 8.64E+09 6.02E+08 O.OOE+00 2.81 E+09 8.24E+08 3.63E+05 O.OOE+00 CM-247 9.44E+09 8.48E+09 5.93E+08 O.OOE+00 2.77E+09 8.08E+08 4.78E+05 O.OOE+00 CM-248 7.85E+10 6.98E+10 4.89E+09 O.OOE+00 2.28E+10 6.66E+09 7.70E+06 O.OOE+00 CF-252 1.03E+10 O.OOE+00 2.46E+08 O.OOE+00 O.OOE+00 2.74E+09 1.51E+06 O.OOE+00

CY-LG-170-301, Rev. 23 Page 189 08/07 TABLE 112-2 Ri DOSE FACTORS Age: Child Pathway: Ground NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG GI-LLI SKIN H-3 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 C-14 O.0OE+00 O.OOE+00 O.QOE+00 O.OOE+00 O.OOE+00 O.00E+00 Q.OOE+00 0.00E+00 NA-22 1.16E+10 1,16E+10 1.16E+10 1.16E+10 1.16E+10 1.16E+10 1.16E+10 1.30E+10 NA-24 1.19E+07 1.19E+07 1.19E+07 1.19E+07 1.19E+07 1.19E+07 1.19E+07 1.39E+07 P-32 O.OOE+00 O.OOE+00 O.0OE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 Q.OOE+00 CA-41 1.32E+10 1,32E+10 1.32E+10 1.32E+10 1.32E+10 1.32E+10 1.32E+10 1.55E+10 SC-46 8.33E+08 8.33E+08 8.33E+08 8.33E+08 8.33E+08 8.33E+08 8.33E+08 9.61E+08 CR-51 4.66E+06 4M66E+06 4.66E+06 4.66E+06 4.66E+06 4.66E+06 4.66E+06 5.51E+06 MN-54 1.39E+09 1.39E+09 1.39E+09 1.39E+09 1.39E+09 1.39E+09 1.39E+09 1.63E+09 FE-55 O.OOE+00 O.0OE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 .O.OOE+00 MN-56 9.03E+05 9.03E+05 9.03E+05 9.03E+05 9.03E+05 9.03E+05 9.03E+05 1.07E+06 CO-57 4.92E+07 4.92E+07 4.92E+07 4.92E+07 4.92E+07 4.92E+07 4.92E+07 5.41E+07 CO-58 3.79E+08 3.79E+08 3.79E+08 3.79E+08 3.79E+08 3.79E+08 3.79E+08 4.44E+08 FE-59 2.73E+08 2.73E+08 2.73E+08 2.73E+08 2.73E+08 2.73E+08 2.73E+08 3.21E+08 CO-60 2.32E+10 2.32E+10 2.32E+10 2.32E+10 2.32E+10 2.32E+10 2.32E+10 2.73E+10 NI-59 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 NI-63 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 0.OOE+00 O.OOE+00 CU-64 '6.07E+05 6.07E+05 6.07E+05 6.07E+05 6.07E+05 6.07E+05 6.07E+05 6.88E+05 NI-65 2.97E+05 2.97E+05 2.97E+05 2.97E+05 2.97E+05 2.97E+05 2.97E+05 3.45E+05 ZN-65 7.47E+08 7.47E+08 7.47E+08 7.47E+08 7.47E+08 7.47E+08 7.47E+08 8.59E+08 ZN-69m 1.27E+06 1.27E+06 1.27E+06 1.27E+06 1.27E+06 1.27E+06 1.27E+06 1.49E+06 ZN-69 O.OOE+00 O.OOE+00 OOOE+00 O.OOE+00 O.0OE+00 O.OOE+00 O.OOE+00 O.OOE+00 SE-79 O.OOE+00 O.OOE+00 0,00E+00 O.OOE+00 O.OOE+00 0.00E+00 O.OOE+00 O.OOE+00 BR-82 2.14E+07 2.14E+07 2.14E+07 2.14E+07 2.14E+07 2.14E+07 2.14E+07 2.47E+07 BR-83 4.87E+03 4.87E+03 4.87E+03 4.87E+03 4.87E+03 4.87E+03 4.87E+03 7.08E+03 BR-84 2.03E+05 2.03E+05 2.03E+05 2.03E+05 2.03E+05 2.03E+05 2.03E+05 2.36E+05 BR-85 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 RB-86 8.99E+06 8.99E+06 8.99E+06 8.99E+06 8.99E+06 8.99E+06 8.99E+06 1.03E+07 RB-87 O.OOE+00 O.OOE+00 O.OE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 RB-88 3.31E+04 3.31E+04 3.31E+04 3.31E+04 3.31E+04 3.31E+04 3.31E+04 3.78E+04 RB-89 1.23E+05 1.23E+05 1.23E+05 1.23E+05 1.23E+05 1.23E+05 1.23E+05 1.48E+05 SR-89 2.16E+04 2.16E+04 2.16E+04 2.16E+04 2.16E+04 2.16E+04 2.16E+04 2.51E+04 SR-90 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 Y-90 4.49E+03 4.49E+03 4.49E+03 4.49E+03 4.49E+03 4.49E+03 4.49E+03 5.31E+03 SR-91 2.15E+06 2.15E+06 2.15E+06 2.15E+06 2.15E+06 2.15E+06 2.15E+06 2.51E+06 Y-91m 1.o0E+05 1,OOE+05 1.OOE+05 1.OOE+05 1.00E+05 1.OOE+05 1.OOE+05 1.16E+05 Y-91 1.07E+06 1.07E+06 1.07E+06 1.07E+06 1.07E+06 1.07E+06 1.07E+06 1.21E+06 SR-92 7.77E+05 7.77E+05 7.77E+05 7.77E+05 7.77E+05 7.77E+05 7.77E+05 8.63E+05 Y-92 1.80E+05 1.80E+05 1.80E+05 1.80E+05 1.80E+05 1.80E+05 1.80E+05 2.14E+05 Y-93 1.83E+05 1.83E+05 1.83E+05 1.83E+05 1.83E+05 1.83E+05 1.83E+05 2.51E+05 NB-93m O.OOE+00 Q.0OE+00 0.OOE+00 O.OOE+00 O.0OE+00 0.00E+00 O.OOE+00 O.OOE+00 NB-95 1.37E+08 1.37E+08 1.37E+08 1.37E+08 1.37E+08 1.37E+08 1.37E+08 1.61E+08 NB-97 2.07E+05 2.07E+05 2.07E+05 2.07E+05 2.07E+05 2.07E+05 2.07E+05 1.76E+05 ZR-93 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 0.OOE+00 O.OOE+00 ZR-95 2.45E+08 2.45E+08 2.45E+08 2.45E+08 2.45E+08 2.45E+08 2.45E+08 2.84E+08

CY-LG-170-301, Rev. 23 Page 190 08/07 TABLE 112-2 Ri DOSE FACTORS Age: Child Pathway: Ground (Continued)

NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG GI-LLI SKIN ZR-97 2.96E+06 2.96E+06 2.96E+06 2.96E+06 2.96E+06 2.96E+06 2.96E+06 3.44E+06 MO-93 8.84E+07 8.84E+07 8.84E+07 8.84E+07 8.84E+07 8.84E+07 8.84E+07 3.60E+09 MO-99 3.99E+06 3.99E+06 3.99E+06 3.99E+06 3.99E+06 3.99E+06 3.99E+06 4.63E+06 TC-99 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 TC-99m 1.84E+05 1.84E+05 1.84E+05 1.84E+05 1.84E+05 1.84E+05 1.84E+05 2.11E+05 TC-101 2.04E+04 2.04E+04 2.04E+04 2.04E+04 2.04E+04 2.04E+04 2.04E+04 2.26E+04 RU-103 1.08E+08 1.08E+08 1.08E+08 1.08E+08 1.08E+08 1.08E+08 1.08E+08 1.26E+08 RU-105 6.36E+05 6.36E+05 6.36E+05 6.36E+05 6.36E+05 6.36E+05 6.36E+05 7.21E+05 RU-106 4.22E+08 4.22E+08 4.22E+08 4.22E+08 4.22E+08 4.22E+08 4.22E+08 5.07E+08 RH-105 2.11E+09 2.11E+09 2.11E+09 2.11E+09 2.11E+09 2.11E+09 2.11E+09 2.46E+09 PD-107 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 PD-109 1.50E+04 1.50E+04 1.50E+04 1.50E+04 1.50E+04 1.50E+04 1.50E+04 1.71E+04 AG-110m 2.86E+09 2.86E+09 2.86E+09 2.86E+09 2.86E+09 2.86E+09 2.86E+09 4.01E+09 AG-111 1.03E+06 1.03E+06 1.03E+06 1.03E+06 1.03E+06 1.03E+06 1.03E+06 1.20E+06 CD-113m 5.60E+06 5.60E+06 5.60E+06 5.60E+06 5.60E+06 5.60E+06 5.60E+06 6.33E+06 CD-115m O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 SN-123 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 6.38E+09 SN-125 4.20E+06 4.20E+06 4.20E+06 4.20E+06 4.20E+06 4.20E+06 4.20E+06 4.86E+06 SN-126 3.48E+10 3.48E+10 3.48E+10 3.48E+10 3.48E+10 3.48E+10 3.48E+10 3.87E+10 SB-124 5.98E+08 5.98E+08 5.98E+08 5.98E+08 5.98E+08 5.98E+08 5.98E+08 6.90E+08 SB-125 2.38E+09 2.38E+09 2.38E+09 2.38E+09 2.38E+09 2.38E+09 2.38E+09 2.69E+09 SB-126 8.44E+07 8.44E+07 8.44E+07 8.44E+07 8.44E+07 8.44E+07 8.44E+07 9.48E+07 SB-127 1.68E+07 1.68E+07 1.68E+07 1.68E+07 1.68E+07 1.68E+07 1.68E+07 1.94E+07 TE-125m 1.55E+06 1.55E+06 1.55E+06 1.55E+06 1.55E+06 1.55E+06 1.55E+06 2.13E+06 TE-127m 9.16E+04 9.16E+04 9.16E+04 9.16E+04 9.16E+04 9.16E+04 9.16E+04 1.08E+05 TE-127 2.98E+03 2.98E+03 2.98E+03 2.98E+03 2.98E+03 2.98E+03 2.98E+03 3.28E+03 TE-129m 1.98E+07 1.98E+07 1.98E+07 1.98E+07 1.98E+07 1.98E+07 1.98E+07 2.31E+07 TE-129 2.62E+04 2.62E+04 2.62E+04 2.62E+04 2.62E+04 2.62E+04 2.62E+04 3.1OE+04 TE-133m 4.41E+05 4.41E+05 4.41E+05 4.41E+05 4.41E+05 4.41E+05 4.41E+05 5.OOE+05 TE-134 2.22E+04 2.22E+04 2.22E+04 2.22E+04 2.22E+04 2.22E+04 2.22E+04 2.66E+04 1-129 1.74E+09 1.74E+09 1.74E+09 1.74E+09 1.74E+09 1.74E+09 1.74E+09 2.90E+09 1-130 5.51E+06 5.51E+06 5.51E+06 5.51E+06 5.51E+06 5.51E+06 5.51E+06 6.69E+06 1-131 1.72E+07 1.72E+07 1.72E+07 1.72E+07 1.72E+07 1.72E+07 1.72E+07 2.09E+07 TE-131m 8.03E+06 8.03E+06 8.03E+06 8.03E+06 8.03E+06 8.03E+06 8.03E+06 9.46E+06 TE-131 2.92E+04 2.92E+04 2.92E+04 2.92E+04 2.92E+04 2.92E+04 2.92E+04 3.45E+07 1-132 1.25E+06 1.25E+06 1.25E+06 1.25E+06 1.25E+06 1.25E+06 1.25E+06 1.46E+06 TE-132 4.23E+06 4.23E+06 4.23E+06 4.23E+06 4.23E+06 4.23E+06 4.23E+06 4.98E+06 1-133 2.45E+06 2.45E+06 2.45E+06 2.45E+06 2.45E+06 2.45E+06 2.45E+06 2.98E+06 CS-134m 4.80E+04 4.80E+04 4.80E+04 4.80E+04 4.80E+04 4.80E+04 4.80E+04 6.74E+04 CS-134 6.90E+09 6.90E+09 6.90E+09 6.90E+09 6.90E+09 6.90E+09 6.90E+09 8.05E+09 1-134 4.47E+05 4.47E+05 4.47E+05 4.47E+05 4.47E+05 4.47E+05 4.47E+05 5.30E+05 1-135 2.53E+06 2.53E+06 2.53E+06 2.53E+06 2.53E+06 2.53E+06 2.53E+06 2.95E+06 CS-135 5.80E+10 5.80E+10 5.80E+10 5.80E+10 5.80E+10 5.80E+10 5.80E+10 6.58E+10 CS-136 1.51E+08 1.51E+08 1.51E+08 1.51E+08 1.51E+08 1.51E+08 1.51E+08 1.71E+08 CS-137 1.30E+10 1.30E+10 1.30E+10 1.30E+10 1.30E+10 1.30E+10 1.30E+10 1.52E+10

CY-LG-170-301, Rev. 23 I Page 191 08/07I TABLE 112-2 Ri DOSE FACTORS Age: Child Pathway: Ground (Continued)

NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG GI-LLI SKIN CS-138 3.59E+05 3.59E+05 3.59E+05 3.59E+05 3.59E+05 3.59E+05 3.59E+05 4.10E+05 CS-139 3.14E+04 3.14E+04 3.14E+04 3.14E+04 3.14E+04 3.14E+04 3.14E+04 3.59E+04 BA-139 1.06E+05 1.06E+05 1.06E+05 1.06E+05 1,06E+05 1.06E+05 1.06E+05 1.19E+05 BA-140 2.05E+07 2.05E+07 2.05E+07 2.05E+07 2.05E+07 2.05E+07 2.05E+07 2.35E+07 LA- 140 1.92E+07 1.92E+07 1.92E+07 1.92E+07 1.92E+07 1.92E+07 1.92E+07 2.18E+07 BA-141 4.17E+04 4.17E+04 4.17E+04 4.17E+04 4.17E+04 4.17E+04 4.17E+04 4.75E+04 LA-141 3.14E+04 3.14E+04 3.14E+04 3.14E+04 3.14E+04 3.14E+04 3.14E+04 3.51E+04 CE-141 1.37E+07 1.37E+07 1.37E+07 1.37E+07 1.37E+07 1,37E+07 1.37E+07 1.54E+07 BA-142 4.49E+04 4.49E+04 4.49E+04 4.49E+04 4.49E+04 4.49E+04 4.49E+04 5.11E+04 LA-142 7.60E+05 7.60E+05 7.60E+05 7.60E+05 7.60E+05 7.60E+05 7.60E+05 9.11E+05 CE-143 2.31E+06 2.31E+06 2.31E+06 2.31E+06 2.31E+06 2.31E+06 2.31E+06 2.63E+06 PR-143 O.QOE+00 O.OOE+00 O.OOE+00 O.0OE+00 O.OOE+00 O.OOE+00 O.OOE+00 0.OE+00 CE-144 6.95E+07 6.95E+07 6.95E+07 6.95E+07 6.95E+07 6.95E+07 6.95E+07 8.04E+07 PR-144 1.83E+03 1.83E+03 1.83E+03 1.83E+03 1.83E+03 1.83E+03 1.83E+03 2.11E+03 ND-147 8.39E+06 8.39E+06 8.39E+06 8.39E+06 8.39E+06 8.39E+06 8.39E+06 1.01E+07 PM-147 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.0OE+00 O.OOE+00 O.OOE+00 PM-148m 4.45E+08 4.45E+08 4.45E+08 4.45E+08 4.45E+08 4.45E+08 4.45E+08 2.58E+09 PM-148 1.45E+08 1.45E+08 1.45E+08 1.45E+08 1.45E+08 1.45E+08 1.45E+08 1.67E+08 PM-149 4.23E+04 4.23E+04 4.23E+04 4.23E+04 4.23E+04 4.23E+04 4.23E+04 4.90E+04 PM-151 1.99E+06 1.99E+06 1.99E+06 1.99E+06 1.99E+06 1.99E+06 1.99E+06 2.08E+06 SM-151 1.72E+08 1.72E+08 1.72E+08 1.72E+08 1.72E+08 1.72E+08 1.72E+08 7.53E+08 SM-153 4.02E+05 4.02E+05 4.02E+05 4.02E+05 4.02E+05 4.02E+05 4.02E+05 4.46E+05 EU-152 1.79E+10 1.79E+10 1.79E+10 1.79E+10 1.79E+10 1.79E+10 1.79E+10 2.07E+10 EU-154 1.52E+10 1.52E+10 1.52E+10 1.52E+10 1.52E+10 1.52E+10 1.52E+10 1.75E+10 EU-1 55 4.95E+08 4.95E+08 4.95E+08 4.95E+08 4.95E+08 4.95E+08 4.95E+08 5.63E+08 EU-156 8.82E+07 8.82E+07 8.82E+07 8.82E+07 8.82E+07 8.82E+07 8.82E+07 1.01E+08 TB-160 4.75E+08 4.75E+08 4.75E+08 4.75E+08 4.75E+08 4.75E+08 4.75E+08 5.53E+08 HO-166m 3.42E+10 3.42E+10 3.42E+10 3.42E+10 3.42E+10 3.42E+10 3.42E+10 3.85E+10 W-181 1.94E+05 1.94E+05 1.94E+05 1.94E+05 1.94E+05 1.94E+05 1.94E+05 2.13E+05 W-185 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 0.OOE+00 O.OOE+00 O.OOE+00 W-187 2.35E+06 2.35E+06 2,35E+06 2.35E+06 2.35E+06 2.35E+06 2.35E+06 2.73E+06 NP-239 1.71E+06 1.71E+06 1.71E+06 1.71E+06 1.71E+06 1.71E+06 1.71E+06 1.98E+06 U-232 9.12E+06 9.12E+06 9.12E+06 9.12E+06 9.12E+06 9.12E+06 9.12E+06 9.47E+07 U-233 8.90E+09 8.90E+09 8.90E+09 8.90E+09 8.90E+09 8.90E+09 8.90E+09 1.08E+10 U-234 2.45E+06 2.45E+06 2.45E+06 2.45E+06 2.45E+06 2.45E+06 2.45E+06 6.15E+08 U-235 1.24E+10 1,24E+10 1.24E+10 1,24E+10 1.24E+10 1.24E+10 1.24E+10 1.55E+10 U-236 8.13E+04 8.13E+04 8.13E+04 8.13E+04 8.13E+04 8.13E+04 8.13E+04 6.96E+07 U-237 5.16E+06 5.16E+06 5.16E+06 5.16E+06 5.16E+06 5.16E+06 5.16E+06 6.71E+06 U-238 4.26E+08 4.26E+08 4.26E+08 4.26E+08 4.26E+08 4.26E+08 4.26E+08 5.80E+08 NP-237 5.42E+09 5.42E+09 5.42E+09 5.42E+09 5.42E+09 5.42E+09 5.42E+09 6.19E+09 NP-238 4.53E+06 4.53E+06 4,53E+06 4.53E+06 4.53E+06 4.53E+06 4.53E+06 5.18E+06 PU-238 4.65E+06 4.65E+06 4.65E+06 4.65E+06 4.65E+06 4.65E+06 4.65E+06 6.44E+07 PU-239 3.06E+06 3.06E+06 3.06E+06 3.06E+06 3.06E+06 3.06E+06 3.06E+06 2.98E+07

CY-LG-170-301, Rev. 23 Page 192 08/07 TABLE 112-2 Ri DOSE FACTORS Age: Child Pathway: Ground (Continued)

NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG GI-LLI SKIN PU-240 5.02E+06 5.02E+06 5.02E+06 5.02E+06 5.02E+06 5.02E+06 5.02E+06 6.96E+07 PU-241 1,14E+07 1.14E+07 1.14E+07 1.14E+07 1.14E+07 1.14E+07 1.14E+07 1.69E+07 PU-242 4.26E+06 4.26E+06 4.26E+06 4.26E+06 4.26E+06 4.26E+06 4.26E+06 6.19E+07 PU-244 3.46E+09 3.46E+09 3.46E+09 3.46E+09 3.46E+09 3.46E+09 3.46E+09 3.72E+09 AM-241 6.85E+08 6.85E+08 6.85E+08 6.85E+08 6.85E+08 6.85E+08 6.85E+08 9.90E+08 AM-242m 9.62E+07 9.62E+07 9.62E+07 9.62E+07 9.62E+07 9.62E+07 9.62E+07 6.66E+08 AM-243 5.03E+09 5.03E+09 5.03E+09 5.03E+09 5.03E+09 5.03E+09 5.03E+09 5.80E+09 CM-242 6.86E+05 6.86E+05 6.86E+05 6.86E+05 6.86E+05 6.86E+05 6.86E+05 2.87E+06 CM-243 7.05E+09 7.05E+09 7.05E+09 7.05E+09 7.05E+09 7.05E+09 7.05E+09 8.89E+09 CM-244 7.84E+06 7.84E+06 7.84E+06 7.84E+06 7.84E+06 7.84E+06 7.84E+06 4.87E+07 CM-245 3.67E+09 3.67E+09 3.67E+09 3.67E+09 3.67E+09 3.67E+09 3.67E+09 4.64E+09 CM-246 3.86E+06 3.86E+06 3.86E+06 3.86E+06 3.86E+06 3.86E+06 3.86E+06 5.80E+07 CM-247 8.51E+09 8.51E+09 8.51E+09 8.51E+09 8.51E+09 8.51E+09 8.51E+09 1.01E+10 CM-248 2.63E+10 2.63E+10 2.63E+10 2.63E+10 2.63E+10 2.63E+10 2.63E+10 2.02E+10 CF-252 4.84E+10 4.84E+10 4.84E+10 4.84E+10 4.84E+10 4,84E+10 4.84E+10 5.28E+10

CY-LG-170-301, Rev. 23 Page 193 08/07 TABLE 112-2 Ri DOSE FACTORS Age: Child Pathway: Vegetation NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG GI-LLI SKIN H-3 O.OOE+00 3.86E+03 3.86E+03 3.86E+03 3.86E+03 3.86E+03 3.86E+03 0.OOE+00 C-14 3.38E+06 6.76E+05 6.76E+05 6.76E+05 6.76E+05 6.76E+05 6.76E+05 O.OOE+00 NA-22 3.94E+09 3.94E+09 3.94E+09 3.94E+09 3.94E+09 3.94E+09 3.94E+09 O.OE+00 NA-24 1.56E+05 1.56E+05 1.56E+05 1.56E+05 1.56E+05 1.56E+05 1.56E+05 O.OOE+00 P-32 3.61 E+08 1.09E+08 8.96E+07 O.OOE+00 0.OOE+00 O.OOE+00 6.43E+07 O.OOE+00 CA-41 2.46E+10 O.OOE+00 2.69E+09 O.OE+00 O.OOE+00 O.OOE+00 1.35E+07 O.OOE+00 SC-46 7.41E+05 1.02E+06 3.91E+05 O.OOE+00 8.99E+05 O.OQE+00 1.49E+08 O.OOE+00 CR-51 O.OOE+00 O.OOE+00 1.02E+05 5.66E+04 1.55E+04 1.03E+05 5.41E+06 O.OOE+00 MN-54 O.OOE+00 6.38E+08 1.70E+08 O.OOE+00 1.79E+08 O.OOE+00 5.35E+08 O.OE+00 FE-55 7.71E+08 4.09E+08 1.27E+08 O0,0E+00 O.OOE+00 2.31E+08 7.58E+07 O.OOE+00 MN-56 O.OOE+00 7.65E+00 1.73E+00 O.OOE+00 9.25E+00 O.OOE+00 1.11E+03 O.OOE+00 CO-57 O.OOE+00 1.66E+07 3.35E+07 O.OOE+00 O.OOE+00 O.OOE+00 1.36E+08 O0,0E+00 CO-58 O.OOE+00 6.05E+07 1.85E+08 O.OOE+00 O.OOE+00 O.OOE+00 3.53E+08 0.OOE+00 FE-59 3.65E+08 5.91E+08 2.94E+08 O.OOE+00 O.OOE+00 1.71E+08 6.15E+08 O.OOE+00 CO-60 O.OOE+00 3.64E+08 1.07E+09 O.OOE+00 O.OOE+00 O.0OE+00 2.02E+09 O.OOE+00 NI-59 2.85E+09 7.58E+08 4.83E+08 O.OOE+00 O.OOE+00 O.OOE+00 .5.03E+07 O.OOE+00 NI-63 3.81E+10 2.04E+09 1.30E+09 O.OOE+00 O.OOE+00 O.OOE+00 1.37E+08 0.OOE+00 CU-64 O.OOE+00 4.59E+03 2.77E+03 O.OOE+00 1.11E+04 O.OOE+00 2.15E+05 O.OOE+00 NI-65 4.28E+01 4.03E+00 2.35E+00 O.OOE+00 O.OOE+00 0.OOE+00 4.93E+02 O.OOE+00 ZN-65 7.79E+08 2.07E+09 1.29E+09 O.OOE+00 1.31E+09 O.OOE+00 3.64E+08 O.OOE+00 ZN-69m 1.59E+03 2.71E+04 3.20E+03 O.OOE+00 1.57E+04 O.OOE+00 8.81E+05 O.OOE+00 ZN-69 3.67E-06 5.30E-06 4.90E-07 O.OOE+00 3.22E-06 O.OOE+00 3.34E-04 O.OOE+00 SE-79 O.OOE+00 5.97E+08 1.33E+08 O.OOE+00 9.71E+08 O.OOE+00 3.92E+07 O.OOE+00 BR-82 OOOE+00 O.OOE+00 8.54E+05 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 BR-83 O.OOE+00 O.OOE+00 2.18E+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 BR-84 O.OOE+00 O.OOE+00 1.39E-1 1 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 BR-85 O.OOE+00 O.OOE+00 1.5E-151 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 RB-86 O.OOE+00 3.55E+08 2.18E+08 O.OOE+00 O.OOE+00 O.OOE+00 2.28E+07 O.OOE+00 RB-87 O.OOE+00 1.30E+09 1.30E+09 O.OOE+00 O.OOE+00 O.OOE+00 4.20E+07 O.OOE+00 RB-88 O.OOE+00 1.42E-22 9.84E-23 O.OOE+00 O.OOE+00 O.OOE+00 6.95E-24 O.OOE+00 RB-89 O.OOE+00 1.43E-26 1.28E-26 O.OOE+00 O.OOE+00 O.OOE+00 1.25E-28 O.OOE+00 SR-89 3.33E+10 O.OOE+00 9.50E+08 O.OOE+00 O.0OE+00 O.OOE+00 1.29E+09 O.OOE+00 SR-90 '1.20E+12 O.0OE+00 3.04E+11 O.OOE+00 O.OOE+00 O.OOE+00 1.61E+10 O.OOE+00 Y-90 9.68E+03 O.OOE+00 2.59E+02 O.OOE+00 O.OOE+00 O.OOE+00 2.76E+07 O.OOE+00 SR-91 2.18E+05 Q.OOE+00 8.24E+03 O.OOE+00 O.OOE+00 O.OE+00 4.82E+05 O.OQE+00 Y-91m 3.41E-09 O.OOE+00 1.24E-10 O.OOE+00 O.OOE+00 O.OOE+00 6.68E-06 O.0OE+00 Y-91 1.74E+07 O.OOE+00 4.65E+05 O.OOE+00 O.OOE+00 O.OOE+00 2.32E+09 O.OOE+00 SR-92 2.97E+02 O.OOE+00 1.19E+01 O.OOE+00 O.OOE+00 O.OOE+00 5.63E+03 O.OOE+00 Y-92 6.51 E-01 O.OOE+00 1,86E-02 O.OOE+00 O.OOE+00 O.OOE+00 1,88E+04 O.OE+00 Y-93 1.22E+02 O.OOE+00 3.35E+00 O.OOE+00 O.OOE+00 O.OOE+00 1.82E+06 O.OOE+00 NB-93m 7.37E+06 1.84E+06 6.04E+05 O.OOE+00 1.99E+06 O.OOE+00 2.79E+08 O.OOE+00 NB-95' 3.69E+05 1.44E+05 1.03E+05 O.OOE+00 1.35E+05 O.OOE+00 2.66E+08 O.OOE+00 NB-97 1.43E-06 2.59E-07 1.21E-07 O.OE+00 5.51E-07 O.OE+00 7.99E-02 O.OOE+00 ZR-93 1.18E+07 4.43E+06 3.15E+06 0.OOE+00 1.72E+07 O.OOE+00 1.68E+09 O.OOE+00 ZR-95 3.61 E+06 7.93E+05 7.06E+05 O.OOE+00 1.14E+06 O.OOE+00 8.28E+08 O.OOE+00

CY-LG-1 70-301, Rev. 23 Page 194 08/07 TABLE 112-2 Ri DOSE FACTORS Age: Child Pathway: Vegetation (Continued)

NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG GI-LLI SKIN ZR-97 2.38E+02 3.44E+01 2.03E+01 0.OOE+00 4.94E+01 0.OOE+00 5.22E+06 0.OOE+00 MO-93 O.OOE+00 1.71E+09 6.13E+07 0.OOE+00 4.50E+08 0.OOE+00 8.65E+07 0.OOE+00 MO-99 0.OOE+00 3.24E+06 8.OOE+05 0.OOE+00 6.91 E+06 0.OOE+00 2.68E+06 0.OOE+00 TC-99 3.79E+07 4.22E+07 1.52E+07 0.OOE+00 4.98E+08 3.74E+06 4.43E+08 0.O0E+00 TC-99m 1.95E+00 3.83E+00 6.35E+01 0.OOE+00 5.56E+01 1.94E+00 2.18E+03 0.OOE+00 TC-101 4.27E-31 4.46E-31 5.66E-30 0.OOE+00 7.61E-30 2.36E-31 1.42E-30 0.OOE+00 RU-103 1.39E+07 0.OOE+00 5.36E+06 0.OOE+00 3.51E+07 0.OOE+00 3.61E+08 0.OOE+00 RU-105 3.78E+01 0.OOE+00 1.37E+01 0.OOE+00 3.32E+02 0.OOE+00 2.47E+04 0.OOE+00 RU-106 7'.16E+08 0.OOE+00 8.93E+07 0.OOE+00 9.67E+08 0.OOE+00 1.11E+10 0.OOE+00 RH-105 3.63E+07 1.95E+07 1.67E+07 O.OE+00 7.76E+07 0.OOE+00 1.21E+09 0.OOE+00 PD-107 0.OOE+00 3.35E+07 2.84E+06 0.OOE+00 2.80E+08 0.OOE+00 6.64E+07 0.OOE+00 PD-109 0.OOE+00 1.21E+04 3.62E+03 0.OOE+00 6.48E+04 0.OOE+00 7.09E+05 0.OOE+00 AG-110m 3.08E+07 2.08E+07 1.66E+07 O.QOE+00 3.87E+07 O.OE+00 2.47E+09 O.OOE+00 AG-111 1.72E+05 5.39E+04 3.56E+04 O.OOE+00 1.63E+05 O.OOE+00 3.31E+07 O.OOE+00 CD-113m O.OOE+00 7.15E+08 3.04E+07 O.OOE+00 7.36E+08 O.OOE+00 1.84E+09 O.OOE+00 CD-115m O.OOE+00 1.30E+08 5.55E+06 O.OOE+00 9.68E+07 0.OOE+00 1.77E+08 O.OOE+00 SN-123 6.23E+09 7.73E+07 1.52E+08 8.19E+07 O.OOE+00 0.O0E+00 3.05E+09 O.0OE+00 SN-125 3.91E+07 5.89E+05 1.75E+06 6.11E+05 O.OOE+00 O.OOE+00 1.21E+08 O.OOE+00 SN-126 2.36E+10 2.94E+08 6.70E+08 8.08E+07 O.OOE+00 0.OOE+00 1.77E+09 O.OOE+00 SB-124 3.28E+08 4.26E+06 1.15E+08 7.25E+05 O.OOE+00 1.82E+08 2.05E+09 O.OOE+00 SB-125 4.81E+08 3.71E+06 1.01E+08 4.45E+05 O.OOE+00 2.68E+08 1.15E+09 O.OOE+00 SB-126 8.72E+06 1.33E+05 3.13E+06 4.72E+04 O.OOE+00 4.16E+06 1.76E+08 O.OE+00 SB-127 3.64E+05 5.64E+03 1.26E+05 4.05E+03 O.OOE+00 1.58E+05 2.05E+07 O.OOE+00 TE-125m 3.27E+08 8.85E+07 4.36E+07 9.17E+07 O.OOE+00 O.OOE+00 3.15E+08 O.OOE+00 TE-127m 1.25E+09 3.38E+08 1.49E+08 3.OOE+08 3.58E+09 O.OOE+00 1.02E+09 O.OOE+00 TE-127 4.10E+03 1.11E+03 8.79E+02 2.84E+03 1.17E+04 O.OOE+00 1.60E+05 O.OOE+00 TE-129m 7.52E+08 2.10E+08 1.17E+08 2.43E+08 2.21 E+09 O.OOE+00 9.18E+08 O.OE+00 TE-129 5.19E-04 1.45E-04 1.23E-04 3.71E-04 1.52E-03 O.OOE+00 3.23E-02 O.OOE+00 TE-133m 1.46E-05 5.91E-06 7.33E-06 1.13E-05 5.58E-05 0.00E+00 4.51E-04 O.OOE+00 TE-134 2.17E-08 9.75E-09 1.30E-08 1.71 E-08 9.02E-08 O.OOE+00 9.90E-08 O.OOE+00 1-129 4.93E+09 3.02E+09 2.70E+09 1.98E+12 5.1OE+09 O.OOE+00 1.52E+08 O.OOE+00 1-130 2.57E+05 5.19E+05 2.68E+05 5.72E+07 7.76E+05 O.OOE+00 2.43E+05 O.OOE+00 1-131 6.72E+07 6.76E+07 3.84E+07 2.23E+10 1.11E+08 O.OOE+00 6.01E+06 O.OOE+00 TE-131m 6.46E+05 2.23E+05 2.38E+05 4.59E+05 2.16E+06 O.OOE+00 9.06E+06 O.OOE+00 TE-131 8.97E-16 2.73E-16 2.67E-16 6.86E-16 2.71E-15 O.OOE+00 4.71E-15 0.OOE+00 1-132 3.74E+01 6.88E+01 3.16E+01 3.19E+03 1.05E+02 O.OOE+00 8.10E+01 O.OOE+00 TE-132 2.94E+06 1.30E+06 1.57E+06 1.89E+06 1.21E+07 O.OOE+00 1.31E+07 O.OOE+00 1-133 1.48E+06 1.83E+06 6.91E+05 3.40E+08 3.05E+06 O.OOE+00 7.36E+05 O.OOE+00 CS-134m 4.44E+00 6.58E+00 4.29E+00 0.OOE+00 3.47E+00 5.73E-01 6.94E+00 0.OOE+00 CS-134 1.54E+10 2.53E+10 5.34E+09 0.OOE+00 7.85E+09 2.82E+09 1.37E+08 O.OOE+00 1-134 5.96E-05 1.11E-04 5.09E-05 2.55E-03 1.69E-04 0.OOE+00 7.34E-05 0.OOE+00 1-135 2.60E+04 4.67E+04 2.21E+04 4.14E+06 7.17E+04 O.OOE+00 3.56E+04 0.OOE+00 CS-135 5.88E+09 4.1OE+09 4.20E+08 0.OOE+00 1.45E+09 4.83E+08 3.07E+07 O.OOE+00 CS-136 5.40E+07 1.48E+08 9.60E+07 O.OOE+00 7.90E+07 1.18E+07 5.21E+06 0.OOE+00 CS-137 2.31E+10 2.21E+10 3.26E+09 O.OOE+00 7.19E+09 2.59E+09 1.38E+08 0,OOE+00

CY-LG-170-301,, Rev. 23 Page 195 08/07 TABLE 112-2 Ri DOSE FACTORS Age: Child Pathway: Vegetation (Continued)

NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG GI-LLI SKIN CS-138 2.39E-11 3.32E-11 2.11E-11 0.OOE+00 2.34E-11 2.52E-12 1.53E-11 O.OOE+00 CS-139 9.88E-45 1.1OE-44 5.27E-45 O.OOE+00 8.24E-45 8.31E-46 9.88E-49 O.OOE+00 BA-139 1.97E-02 1.05E-05 5.70E-04 O.OOE+00 9.17E-06 6.18E-06 1.14E+00 O.OOE+00 BA-140 1.78E+08 1.56E+05 1.04E+07 O.OOE+00 5.07E+04 9.28E+04 9.01E+07 O.OOE+00 LA- 140 1.36E+03 4.76E+02 1.60E+02 O.OOE+00 O.OOE+00 O.OOE+00 1.33E+07 O.OOE+00 BA-141 6.48E-22 3.63E-25 2.11E-23 O.OOE+00 3.14E-25 2.13E-24 3.69E-22 O.OOE+00 LA-141 4.41 E-01 1.03E-01 2.23E-02 O.OOE+00 O.OOE+00 O.OOE+00 2.28E+04 O.OOE+00 CE-141 5.85E+05 2.92E+05 4.33E+04 O.OOE+00 1.28E+05 O.OOE+00 3.64E+08 O.OOE+00 BA-142 2.71E-39 1.95E-42 1.52E-40 O.OOE+00 1.58E-42 1.15E-42 3.54E-41 O.OOE+00 LA-142 1.34E-04 4.28E-05 1.34E-05 O.OOE+00 O.OOE+00 O.OOE+00 8.49E+00 O.OOE+00 CE-143 7.20E+02 3.90E+05 5.65E+01 O.OOE+00 1.64E+02 O.OOE+00 5.71 E+06 O.OOE+00 PR-143 9.73E+04 2.92E+04 4.83E+03 O.OOE+00 1.58E+04 O.OOE+00 1.05E+08 O.OOE+00 CE-144 1.22E+08 3.82E+07 6.51E+06 O.OOE+00 2.12E+07 O.OOE+00 9.96E+09 0.OOE+00 PR-144 1.73E-26 5.34E-27 8.69E-28 O.OOE+00 2.83E-27 O.OOE+00 1.15E-23 O.OOE+00 ND-147 4.12E+04 3.33E+04 2.58E+03 O.OOE+00 1.83E+04 O.OOE+00 5.28E+07 O.OOE+00 PM-147 2.13E+07 1.52E+06 8.17E+05 O.OOE+00 2.69E+06 O.OOE+00 6.16E+08 O.OOE+00 PM-148m 2.08E+06 4.15E+05 4.15E+05 O.OOE+00 6.15E+05 O.OOE+00 1.17E+09 0.OOE+00 PM-148 6.11E+05 7.34E+04 4.75E+04 O.OOE+00 1.25E+05 O.OOE+00 1.96E+09 O.OOE+00 PM-149 1.23E+03 1.31E+02 7.11E+01 O.OOE+00 2.32E+02 O.OOE+00 8.95E+06 O.OOE+00 PM-151 2.41E+02 2.94E+01 1.91E+01 O.OOE+00 4.98E+01 O.OOE+00 3.33E+06 O.OOE+00 SM-151 1.81E+07 2.70E+06 8.49E+05 O.OOE+00 2.79E+06 O.OOE+00 3.91E+08 O.OOE+00 SM-153 5.94E+02 3.70E+02 3.57E+01 O.OOE+00 1.13E+02 O.OOE+00 4.92E+06 O.OOE+00 EU-152 4.31 E+07 7.85E+06 9.32E+06 O.OOE+00 3.32E+07 0.OOE+00 1.29E+09 O.OOE+00 EU-154 1.60E+08 1.44E+07 1.32E+07 O.OOE+00 6.33E+07 O.OOE+00 3.35E+09 O.OOE+00 EU-155 3.32E+07 2.39E+06 1.87E+06 OOOE+00 8.94E+06 O.OOE+00 5.98E+09 O.OOE+00 EU-156 1.84E+05 9.86E+04 2.04E+04 O.OOE+00 6.35E+04 O.OOE+00 2.24E+08 O.OOE+00 TB-160 5.66E+06 O.OOE+00 7.03E+05 O.OOE+00 1.68E+06 O.OOE+00 1.25E+09 O.OOE+00 HO-166m 7.65E+07 1.60E+07 1.35E+07 O.OOE+00 2.28E+07 O.OOE+00 7.09E-11 O.OOE+00 W-181 1.93E+06 4.74E+05 6.51E+04 O.OOE+00 O.OOE+00 O.OOE+00 1.73E+07 O.OOE+00 W-185 6.06E+07 1.51E+07 2.12E+06 O.OOE+00 O.OOE+00 O.OOE+00 5.64E+08 O.OOE+00 W-187 2.69E+04 1.59E+04 7.16E+03 O.OOE+00 O.OOE+00 O.OOE+00 2.24E+06 O.OOE+00 NP-239 1.07E+03 7.71E+01 5.42E+01 O.OOE+00 2.23E+02 O.OOE+00 5.70E+06 O.OOE+00 U-232 1.24E+12 O.OOE+00 8.91E+10 O.OOE+00 9.48E+10 O.OOE+00 4.94E+09 O.OOE+00 U-233 2.64E+11 O.OOE+00 1.59E+10 O.OOE+00 4.32E+10 O.OOE+00 4.57E+09 O.OOE+00 U-234 2.53E+11 0.0OE+00 1.57E+10 O.OQE+00 4.24E+10 O.OE+00 4.48E+09 O.OOE+00 U-235 2.42E+11 0.OOE+00 1.47E+10 O.OE+00 3.98E+10 O.OOE+00 5.69E+09 O.OOE+00 U-236 2.42E+11 O.OOE+00 1.50E+10 O.OOE+00 4.06E+10 O.OOE+00 4.20E+09 O.OOE+00 U-237 1.43E+05 O.OOE+00 3.81E+04 O.OOE+00 4.13E+05 O.OOE+00 1.26E+07 O.OOE+00 U-238 2.32E+11 O.OOE+00 1.37E+10 O.OOE+00 3.71E+10 O.OOE+00 4.01E+09 O.OOE+00 NP-237 1.58E+11 1.04E+10 6.94E+09 O.OOE+00 4.29E+10 O.OOE+00 5.78E+09 O.OOE+00 NP-238 1.05E+04 2.13E+02 1.64E+02 O.OOE+00 6.78E+02 O.OOE+00 7.29E+06 O.OOE+00 PU-238 8.42E+10 9.76E+09 2.24E+09 O.OQE+00 8.14E+09 O.OE+00 5.31E+09 O.OOE+00 PU-239 9.14E+10 9.78E+09 2.35E+09 O.OQE+00 8.65E+09 O.OOE+00 4.85E+09 O.OOE+00 PU-240 9.07E+10 1.01E+10 2.35E+09 O.OOE+00 8.65E+09 O.OOE+00 4.95E+09 O.OOE+00

CY-LG-170-301, Rev. 23 Page 196 08/07 TABLE 112-2 Ri DOSE FACTORS Age: Child Pathway: Vegetation (Continued)

NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG GI-LLI SKIN PU-241 2.71E+09 1.11E+08 5.64E+07 0.0OE+00 2.08E+08 0.OOE+00 1.01E+08 0.OOE+00 PU-242 8.43E+10 9.78E+09 2.26E+09 0.OOE+00 8.29E+09 O.OE+00 4.76E+09 0.OOE+00 PU-244 9.85E+10 1.12E+11 2.59E+09 0.OOE+00 9.57E+09 0.OOE+00 7.09E+09 0.OOE+00 AM-241 9.64E+10 8.29E+10 7.23E+09 0.OOE+00 4.41E+10 0.OOE+00 5.41 E+09 0.OOE+00 AM-242m 9.91E+10 7.93E+10 7.36E+09 0.OOE+00 4.46E+10 0.OOE+00 6.80E+09 0.OOE+00 AM-243 9.50E+10 8.01E+10 6.97E+09 0.OOE+00 4.30E+10 0.OOE+00 6.34E+09 O.OOE+00 CM-242 4.48E+09 3.57E+09 2.98E+08 0.OOE+00 9.53E+08 O.OOE+00 4.16E+09 0.OOE+00 CM-243 9.02E+10 7.33E+10 5.81 E+09 O.OOE+00 2.17E+10 0.OOE+00 5.66E+09 0.OOE+00 CM-244 7.59E+10 6.14E+10 4.87E+09 0.OOE+00 1.79E+10 0.OOE+00 5.46E+09 0.OOE+00 CM-245 1.18E+11 9.50E+10 7.44E+09 O.OOE+00 2.91E+10 0.OOE+00 5.13E+09 0.OOE+00 CM-246 1.17E+11 9.50E+10 7.44E+09 0.OOE+00 2.91E+10 0.OOE+00 5.04E+09 0.OOE+00 CM-247 1.14E+11 9.36E+10 7.30E+09 O.OOE+00 2.86E+10 0.OOE+00 6.63E+09 0.OOE+00 CM-248 9.50E+11 7.73E+11 6.04E+10 0.OOE+00 2.36E+11 0.OOE+00 1.07E+11 0.OOE+00 CF-252 7.03E+10 0.OOE+00 1.70E+09 0.OOE+00 0.O0E+00 0.OOE+00 1.98E+10 0.OOE+00

CY-LG-1 70-301, Rev. 23 I Page 197 08/07[

TABLE 112-2 Ri DOSE FACTORS Age: Child Pathway: Meat NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG GI-LLI SKIN H-3 O.OOE+00 2.34E+02 2.34E+02 2.34E+02 2.34E+02 2.34E+02 2.34E+02 O.OOE+00 C-14 5.29E+05 1.06E+05 1.06E+05 1.06E+05 1.06E+05 1.06E+05 1.06E+05 O.OOE+00 NA-22 9.18E+08 9.18E+08 9.18E+08 9.18E+08 9.18E+08 9.18E+08 9.18E+08 O.OOE+00 NA-24 5.18E-04 5.18E-04 5.18E-04 5.18E-04 5.18E-04 5.18E-04 5.18E-04 O.OOE+00 P-32 3.41E+08 1.03E+08 8.46E+07 O.OOE+00 O.OOE+00 O.OOE+00 6.07E+07 O.OOE+00 CA-41 7.66E+08 O.OOE+00 8.37E+07 O.OOE+00 O.OOE+00 O.OOE+00 4.20E+05 O.OOE+00 SC-46 9.60E+04 1.32E+05 5.07E+04 O.OE+00 1.16E+05 O.OOE+00 1.92E+07 O.OOE+00 CR-51 O.OOE+00 O.OOE+00 2.80E+03 1.55E+03 4.25E+02 2.84E+03 1.49E+05 O.OOE+00 MN-54 O.OOE+00 3.97E+06 1.06E+06 O.OOE+00 1.11E+06 O.OOE+00 3.33E+06 O.OOE+00 FE-55 2.40E+08 1.27E+08 3.94E+07 0.OOE+00 O.OOE+00 7.20E+07 2.36E+07 O.OOE+00 MN-56 O.OOE+00 5.57E-54 1.26E-54 O.OOE+00 6.74E-54 O.0OE+00 8.07E-52 O.OOE+00 CO-57 O.OOE+00 1.78E+06 3.60E+06 0.00E+00 O.0OE+00 O.OOE+00 1.46E+07 O.OE+00 CO-58 O.OOE+00 6.49E+06 1.99E+07 O.OE+00 O.OOE+00 O.OOE+00 3.78E+07 O.OOE+00 FE-59 1.33E+08 2.15E+08 1.07E+08 O.OOE+00 O.OOE+00 6.25E+07 2.24E+08 O.OOE+00 CO-60 O.OOE+00 3.69E+07 1.09E+08 O.OOE+00 O.OOE+00 O.OOE+00 2.04E+08 O.OOE+00 NI-59 1.18E+09 3.13E+08 2.OOE+08 O.0OE+00 O.OOE+00 O.OOE+00 2.08E+07 O.OOE+00 NI-63 1.57E+10 8.41E+08 5.35E+08 0.00E+00 O.OOE+00 O.OOE+00 5.67E+07 OO0E+00 CU-64 O.OE+00 8.97E-08 5.42E-08 O.OOE+00 2.17E-07 O.OOE+00 4.21E-06 O.OOE+00 NI-65 1.20E-52 1.13E-53 6.59E-54 O.OOE+00 O.OOE+00 O.OOE+00 1.38E-51 O.OOE+00 ZN-65 1.82E+08 4.84E+08 3.01E+08 O.OOE+00 3.05E+08 O.OE+00 8.51E+07 O.OOE+00 ZN-69M 7.85E-07 1.34E-05 1.58E-06 O.OOE+00 7.77E-06 O.OOE+00 4.35E-04 O.OOE+00 ZN-69 1.27E-153 1.84E-153 1.70E-154 O.OOE+00 1.11E-153 O.OOE+00 1.16E-151 O.OOE+00 SE-79 O.QOE+00 6.98E+07 1.55E+07 O.OOE+00 1.13E+08 O.OOE+00 4.58E+06 O.OOE+00 BR-82 O.OOE+00 O.OOE+00 4.50E+02 O.OOE+00 O.OOE+00 O.OOE+00 O.OE+00 O.OOE+00 BR-83 O.OOE+00 O.OOE+00 3.27E-57 O.OOE+00 O.OOE+00 O.OOE+00 O.OE+00 O.OOE+00 BR-84 O.OOE+00 O.OOE+00 5.67E-270 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 BR-85 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.0OE+00 O.OOE+00 O.OOE+00 RB-86 O.OOE+00 1.74E+08 1.07E+08 O.OOE+00 0.OOE+00 O.OOE+00 1.12E+07 O.OOE+00 RB-87 O.OOE+00 3.13E+08 3.13E+08 O.OOE+00 O.OOE+00 O.OOE+00 1.01E+07 O.OOE+00 RB-88 O.OOE+00 O.OOE+00 O.OOE+00 0.00E+00 O.OOE+00 O.OOE+00 O.OOE+00 " O.OOE+00 RB-89 O.OE+00 O.OOE+00 Q.OQE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 SR-89 1.76E+08 O.OOE+00 5.02E+06 O.OOE+00 O.OOE+00 O.OOE+00 6.80E+06 O.OOE+00 SR-90 5.60E+09 O.OOE+00 1.42E+09 O.OOE+00 O.OOE+00 O.OOE+00 7.55E+07 O.OOE+00 Y-90 5.04E+01 O.OOE+00 1.35E+00 O.OOE+00 O.OOE+00 O.OOE+00 1.44E+05 O.OOE+00 SR-91 7.30E-11 O.OOE+00 2.76E-12 O.OOE+00 O.OOE+00 O.OOE+00 1.61E-10 O.OOE+00 Y-91M 5.09E-175 O.OOE+00 1.85E-176 O.OOE+00 O.OOE+00 O.OOE+00 9.96E-172 O.OOE+00 Y-91 6.81E+05 O.OOE+00 1.82E+04 O.OOE+00 O.OOE+00 O.OOE+00 9.07E+07 O.OOE+00 SR-92 6.22E-50 O.OOE+00 2.49E-51 O.OQE+00 O.OOE+00 O.OOE+00 1.18E-48 O.OOE+00 Y-92 7.86E-40 O.OOE+00 2.25E-41 O.OOE+00 O.OOE+00 O.OOE+00 2.27E-35 O.OOE+00 Y-93 2.26E-12 O.OOE+00 6.20E-14 O.OOE+00 O.OOE+00 O.OOE+00 3.37E-08 O.OOE+00 NB-93M 1.61E+07 4.01E+06 1.32E+06 0.00E+00 4.33E+06 O.OOE+00 6.09E+08 O.OOE+00 NB-95 1,04E+06 4.03E+05 2.88E+05 O.OE+00 3.79E+05 O.OOE+00 7.46E+08 O.OOE+00 NB-97 3.68E-119 6.65E-120 3.11E-120 O.OOE+00 1.42E-119 O.OOE+00 2.05E-114 O.OOE+00 ZR-93 3.13E+06 1.17E+06 8.35E+05 0.00E+00 4.54E+06 O.0OE+00 4.45E+08 O.OOE+00

CY-LG-170-301, Rev. 23 Page 198 08/07 TABLE 112-2 Ri DOSE FACTORS Age: Child Pathway: Meat (Continued)

NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG GI-LLI SKIN ZR-95 1.03E+06 2.26E+05 2.01E+05 0.00E+00 3.24E+05 0.00E+00 2.36E+08 0.OOE+00 ZR-97 9.59E-06 1.39E-06 8.18E-07 0.OOE+00 1.99E-06 0.O0E+00 2.10E-01 0.O0E+00 MO-93 0.OOE+00 1.06E+08 3.82E+06 0.OOE+00 2.80E+07 0.OOE+00 5.39E+06 0.OOE+00 MO-99 O.OOE+00 3.38E+04 8.37E+03 O.OOE+00 7.22E+04 O.OOE+00 2.80E+04 0.OOE+00 TC-99 1.18E+08 1.32E+08 4.73E+07 0.OOE+00 1.55E+09 1.16E+07 1.38E+09 0.OOE+00 TC-99M 1.93E-21 3.79E-21 6.28E-20 0.OOE+00 5.51E-20 1.92E-21 2.16E-18 0.OOE+00 TC-101 0.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 RU-103 5.32E+07 0.OOE+00 2.04E+07 0.OOE+00 1.34E+08 0.00E+00 1.38E+09 0.OOE+00 RU-105 2.88E-28 O.OOE+00 1.04E-28 0.OOE+00 2.53E-27 0.OOE+00 1.88E-25 0.OOE+00 RU-106 2.23E+09 0.OOE+00 2.78E+08 0.OOE+00 3.01E+09 0.OOE+00 3.46E+10 0.OOE+00 RH-105 4.24E+05 2.28E+05 1.95E+05 0.O0E+00 9.07E+05 0.OOE+00 1.41E+07 0.OOE+00 PD-107 0.OOE+00 1.04E+06 8.86E+04 0.OOE+00 8.72E+06 O.OOE+00 2.07E+06 0.00E+00 PD-109 0.OOE+00 4.74E-07 1.42E-07 0.OOE+00 2.54E-06 0.OOE+00 2.79E-05 0.OOE+00 AG-110M 4.07E+06 2.75E+06 2.20E+06 0.OOE+00 5.12E+06 0.OOE+00 3.27E+08 0.OOE+00 AG-111 6.83E+04 2.14E+04 1.41E+04 O.OOE+00 6.45E+04 0.OOE+00 1.31E+07 0.OOE+00 CD-113M 0.OOE+00 2.95E+06 1.26E+05 0.OOE+00 3.04E+06 0.OOE+00 7.61E+06 0.OOE+00 CD-115M 0.OOE+00 6.29E+05 2.68E+04 0.OOE+00 4.68E+05 0.OOE+00 8.56E+05 0.OOE+00 SN-123 3.92E+09 4.87E+07 9.56E+07 5.16E+07 0.OOE+00 0.00E+00 1.92E+09 0.OOE+00 SN-125 8.23E+07 1.24E+06 3.69E+06 1.29E+06 0.OOE+00 0.OOE+00 2.55E+08 0.OOE+00 SN-126 1.47E+10 1.83E+08 4.18E+08 5.04E+07 0.OOE+00 0.OOE+00 1.1OE+09 0.OOE+00 SB-124 1.11E+07 1.44E+05 3.90E+06 2.46E+04 0.OOE+00 6.17E+06 6.96E+07 0.OOE+00 SB-125 1.50E+07 1.15E+05 3.13E+06 1.39E+04 0.OOE+00 8.34E+06 3.57E+07 0.OOE+00 SB-126 8.13E+05 1.24E+04 2.92E+05 4.40E+03 0.OOE+00 3.88E+05 1.64E+07 0.OOE+00 SB-127 7.47E+03 1.15E+02 2.59E+03 8.31E+01 0.OOE+00 3.24E+03 4.20E+05 0.OOE+00 TE-125M 2.15E+08 5.82E+07 2.86E+07 6.02E+07 O.OOE+00 0.00E+00 2.07E+08 0.OOE+00 TE-127M 7,67E+08 2.07E+08 9.11E+07 1.83E+08 2.19E+09 0.OOE+00 6.21 E+08 0.OOE+00 TE-127 1.03E-10 2.78E-11 2.21E-11 7.14E-11 2.94E-10 0.OOE+00 4.03E-09 0.OOE+00 TE-129M 5.93E+08 1.66E+08 9.21E+07 1.91 E+08 1.74E+09 0.OOE+00 7.23E+08 0.OOE+00 TE-129 2.90E-121 8.08E-122 6.87E-122 2.07E-121 8.47E-121 0.OOE+00 1.80E-119 0.OOE+00 TE-133M 3.80E-153 1.54E-153 1.90E-153 2.95E-153 1.45E-152 0.OOE+00 1.17E-151 0.OOE+00 TE-134 2.40E-204 1.08E-204 1.44E-204 1.90E-204 9.99E-204 0.OOE+00 1.1OE-203 0.OOE+00 1-129 1.11E+08 6.83E+07 6.1OE+07 4.47E+10 1.15E+08 0.OOE+00 3.43E+06 0.OOE+00 1-130 9.16E-07 1.85E-06 9.54E-07 2.04E-04 2.77E-06 O.OOE+00 8.66E-07 0.OOE+00 1-131 4.85E+06 4.88E+06 2.77E+06 1.61E+09 8.01E+06 0.OOE+00 4.34E+05 0.OOE+00 TE-131M 2.07E+02 7.17E+01 7.63E+01 1.47E+02 6.94E+02 0.OOE+00 2.91E+03 0.OOE+00 TE-131 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 1-132 3.54E-59 6.50E-59 2.99E-59 3.02E-57 9.95E-59 O.OOE+00 7.65E-59 0.OOE+00 TE-132 6.23E+05 2.76E+05 3.33E+05 4.02E+05 2.56E+06 0.OOE+00 2.78E+06 O.OOE+00 1-133 1.69E-01 2.09E-01 7.91 E-02 3.88E+01 3.48E-01 O.OOE+00 8.43E-02 0.OOE+00 CS-134M 1.29E-47 1.91E-47 1.25E-47 0.OOE+00 1.01E-47 1.67E-48 2.02E-47 0.OOE+00 CS-134 4.80E+08 7.88E+08 1.66E+08 0.OOE+00 2.44E+08 8,76E+07 4.25E+06 0.OOE+00 1-134 7.11E-162 1.32E-161 6.08E-162 3.04E-160 2.02E-161 0.OOE+00 8.76E-162 0.OOE+00 1-135 2.02E-17 3.64E-17 1.72E-17 3.22E-15 5.58E-17 0.OOE+00 2.77E-17 O.OOE+00 CS-135 1.83E+08 1.28E+08 1.31E+07 0.OOE+00 4.51E+07 1.50E+07 9.56E+05 0.OOE+00 CS-136 4.78E+06 1.32E+07 8.51E+06 0.OOE+00 7.OOE+06 1.04E+06 4.62E+05 0.OOE+00

CY-LG-170-301, Rev. 23 Page 199 08/07 TABLE 112-2 Ri DOSE FACTORS Age: Child Pathway: Meat (Continued)

NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG GI-LLI SKIN CS-137 7.18E+08 6.88E+08 1.02E+08 O.OOE+00 2.24E+08 8.06E+07 4.31E+06 0.OOE+00 CS-138 2.48E-267 3.45E-267 2.18E-267 0.OOE+00 2.42E-267 2.61E-268 1.59E-267 0.OOE+00 CS-139 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 +.OOE+0O.OQE+000.OOE+00 BA-139 7.64E-102 4.08E-105 2.21E-103 0.OOE+00 3.56E-105 2.40E-105 4.41E-100 0.OOE+00 BA-140 1.29E+07 1.13E+04 7.54E+05 0.OOE+00 3.69E+03 6.75E+03 6.55E+06 O.OOE+00 LA-140 1.65E-02 5.77E-03 1.94E-03 0.OOE+00 0.OOE+00 0.OOE+00 1.61E+02 0.OOE+00 BA-141 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 0.OOE+00 LA-141 2.0OE-37 4.66E-38 1.01 E-38 0.OOE+00 0.OOE+00 O.OE+00 1.04E-32 0.OOE+00 CE-141 7.31E+03 3.64E+03 5.41E+02 0.OOE+00 1.60E+03 0.OOE+00 4.55E+06 0.OOE+00 BA-142 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 LA-142 1.96E-92 6.24E-93 1.96E-93 0.OOE+00 0.OOE+00 0.OOE+00 1.24E-87 0.OOE+00 CE-143 9.38E-03 5.09E+00 7.37E-04 0.OOE+00 2.13E-03 0.OOE+00 7.45E+01 O.OOE+00 PR-143 9.86E+03 2.96E+03 4.89E+02 0.OOE+00 1.60E+03 O.OOE+00 1.06E+07 O.OOE+00 CE-144 1.14E+06 3.57E+05 6.07E+04 0.0OE+00 1.97E+05 0.OOE+00 9.30E+07 0.00E+00 PR-144 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 ND-147 3.43E+03 2.78E+03 2.15E+02 0.OOE+00 1.53E+03 0.OOE+00 4.41E+06 0.OOE+00 PM-147 7.95E+05 5.68E+04 3.05E+04 0.OOE+00 1.OOE+05 0.OOE+00 2.30E+07 0.OOE+00 PM-148M 9.37E+04 1.86E+04 1.86E+04 0.OOE+00 2.76E+04 0.OOE+00 5.26E+07 0.OOE+00 PM-148 2.75E+04 3.30E+03 2.14E+03 0.OOE+00 5.61 E+03 O.OOE+00 8.82E+07 0.OOE+00 PM-149 2.41 E+00 2.56E-01 1.39E-01 0.OOE+00 4.53E-01 0.OOE+00 1.75E+04 O.OOE+00 PM-151 2.67E-03 3.24E-04 2.11E-04 0.OOE+00 5.50E-04 0.OOE+00 3.68E+01 0.OOE+00 SM-151 7.05E+05 1.05E+05 3.31E+04 0.OOE+00 1.09E+05 0.OOE+00 1.52E+07 0.OOE+00 SM-153 5.36E-01 3.33E-01 3.22E-02 0.OOE+00 1.01E-01 0.OOE+00 4.44E+03 0.OOE+00 EU-152 1.61 E+06 2.93E+05 3.48E+05 0.OOE+00 1.24E+06 0.OOE+00 4.82E+07 0.OOE+00 EU-154 5.99E+06 5.39E+05 4.92E+05 0.OOE+00 2.37E+06 O.OOE+00 1.25E+08 O.OOE+00 EU-155 1.24E+06 8.92E+04 6.99E+04 0.OOE+00 3.34E+05 0.OOE+00 2.23E+08 0.OOE+00 EU-156 1.71E+04 9.15E+03 1.89E+03 0.OOE+00 5.90E+03 O.OOE+00 2.08E+07 0.0OE+00 TB-160 2.05E+05 0.OOE+00 2.54E+04 0.OOE+00 6.1OE+04 0.OOE+00 4.54E+07 0.OOE+00 HO-166M 2.62E+06 5.49E+05 4.64E+05 0.OOE+00 7.82E+05 0.OOE+00 2.43E-12 0.OOE+00 W-181 1.98E+04 4.86E+03 6.69E+02 O.OOE+00 0.OOE+00 O.OOE+00 1.77E+05 0.OOE+00 W-185 6.45E+05 1.61E+05 2.26E+04 0.OOE+00 0.OOE+00 0.OOE+00 6.00E+06 0.OOE+00 W-187 9.54E-03 5.65E-03 2.53E-03 0.OOE+00 0.0OE+00 O.OOE+00 7.94E-01 0.OOE+00 NP-239 1.26E-01 9.01E-03 6.33E-03 0.OOE+00 2.61E-02 0.OOE+00 6.67E+02 0.OOE+00 U-232 3.30E+09 0.OOE+00 2.36E+08 0.OOE+00 2.51E+08 0.OOE+00 1.31E+07 0.OOE+00 U-233 6.98E+08 O.OOE+00 4.22E+07 0.OOE+00 1.15E+08 0.O0E+00 1.21E+07 0.OOE+00 U-234 6.70E+08 0.OOE+00 4.15E+07 0.OOE+00 1.12E+08 O.OOE+00 1.19E+07 O.OOE+00 U-235 6.42E+08 0.OOE+00 3.89E+07 0.OOE+00 1.05E+08 O.OOE+00 1.51 E+07 0.OOE+00 U-236 6.42E+08 0.OOE+00 3.98E+07 0.OOE+00 1.08E+08 0.OOE+00 1.11E+07 0.OOE+00 U-237 1.O0E+03 0.OOE+00 2.66E+02 0.OOE+00 2.89E+03 O.OOE+00 8.82E+04 0.OOE+00 U-238 6.14E+08 0.OOE+00 3.64E+07 O.OOE+00 9.84E+07 0.OOE+00 1.06E+07 0.OOE+00 NP-237 2.46E+08 1.62E+07 1.08E+07 0.OOE+00 6.68E+07 0.OOE+00 9.01E+06 0.OOE+00 NP-238 6.56E-01 1.33E-02 1.02E-02 0.OOE+00 4.23E-02 0.OOE+00 4.55E+02 0.OOE+00 PU-238 9.18E+06 1.06E+06 2.44E+05 0.OOE+00 8.87E+05 0.OOE+00 5.79E+05 0.O0E+00 PU-239 9.97E+06 1.07E+06 2.56E+05 0.OOE+00 9.43E+05 0.OOE+00 5.29E+05 O.OOE+00 PU-240 9.89E+06 1.11 E+06 2.56E+05 0.OOE+00 9.43E+05 0.OOE+00 5.40E+05 0.OOE+00

CY-LG-170-301, Rev. 23 I Page 200 08/07 I TABLE 112-2 Ri DOSE FACTORS Age: Child Pathway: Meat (Continued)

NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG GI-LLI SKIN PU-241 2.96E+05 1.21E+04 6.15E+03 O.OOE+00 2.26E+04 O.OOE+00 1.10E+04 O.OOE+00 PU-242 9.20E+06 1.07E+06 2.47E+05 O.OQE+00 9.04E+05 O.OOE+00 5.19E+05 O.OOE+00 PU-244 1.07E+07 1.22E+07 2.82E+05 O.OOE+00 1.04E+06 O.OOE+00 7.73E+05 O.OOE+00 AM-241 1.50E+08 1.29E+08 1.13E+07 O.OOE+00 6.88E+07 O.OOE+00 8.43E+06 O.OOE+00 AM-242M 1.54E+08 1.24E+08 1.15E+07 O.OOE+00 6.95E+07 O.OOE+00 1.06E+07 O.OOE+00 AM-243 1.48E+08 1.25E+08 1.09E+07 O.OOE+00 6.69E+07 O.OOE+00 9.88E+06 O.OOE+00 CM-242 7.01E+06 5.59E+06 4.66E+05 O.OOE+00 1.49E+06 O.0OE+00 6.51 E+06 O.OOE+00 CM-243 1.41 E+08 1.14E+08 9.05E+06 O.OOE+00 3.38E+07 O.OOE+00 8.82E+06 O.OOE+00 CM-244 1.18E+08 9.57E+07 7.59E+06 0.OOE+00 2.78E+07 O.OOE+00 8.51 E+06 O.OE+00 CM-245 1.84E+08 1.48E+08 1.16E+07 O.OOE+00 4.54E+07 O.OOE+00 7.99E+06 O.OOE+00 CM-246 1.82E+08 1.48E+08 1.16E+07 0.OE+00 4.53E+07 O.OOE+00 7.85E+06 O.OOE+00 CM-247 1.78E+08 1.46E+08 1.14E+07 O.OOE+00 4.46E+07 O.OOE+00 1.03E+07 O.OOE+00 CM-248 1.48E+09 1.20E+09 9.41E+07 O.OE+00 3.68E+08 O.OOE+00 1.67E+08 O.OOE+00 CF-252 1.09E+08 O.OOE+00 2.65E+06 O.OOE+00 O.OOE+00 O.OOE+00 3.08E+07 O.OOE+00

CY-LG-170-301, Rev. 23 Page 201 08/07 TABLE 112-2 Ri DOSE FACTORS Age: Child Pathway: Cow Milk NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG GI-LLI SKIN H-3 O.OQE+00 1.57E+03 1.57E+03 1.57E+03 1.57E+03 1.57E+03 1.57E+03 O.OOE+00 C-14 1.65E+06 3.29E+05 3.29E+05 3.29E+05 3.29E+05 3.29E+05 3.29E+05 O.OOE+00 NA-22 9.99E+09 9.99E+09 9.99E+09 9.99E+09 9.99E+09 9.99E+09 9.99E+09 O.OOE+00 NA-24 2.59E+06 2.59E+06 2.59E+06 2.59E+06 2.59E+06 2.59E+06 2.59E+06 O.OOE+00 P-32 3.57E+09 1.08E+09 8.86E+08 O.OOE+00 O.OOE+00 O.OOE+00 6.35E+08 O.OOE+00 CA-41 1.23E+10 O.OOE+00 1.35E+09 O.OOE+00 O.OOE+00 O.OOE+00 6.75E+06 O.OOE+00 SC-46 2.80E+02 3.84E+02 1.48E+02 O.OOE+00 3.40E+02 O.OOE+00 5.62E+04 O.OOE+00 CR-51 O.OOE+00 O.OOE+00 3.24E+04 1.80E+04 4.92E+03 3.29E+04 1.72E+06 O.OOE+00 MN-54 O.OOE+00 1.04E+07 2.77E+06 O.OOE+00 2.91 E+06 O.OE+00 8.72E+06 O.OOE+00 FE-55 5.87E+07 3.11E+07 9.64E+06 O.OOE+00 O.OOE+00 1.76E+07 5.77E+06 O.OOE+00 MN-56 O.QOE+00 3.75E-03 8.47E-04 O.OOE+00 4.54E-03 O.OE+00 5.44E-01 O.OOE+00 CO-57 O.OOE+00 1.31E+06 2.66E+06 O.OOE+00 O.OOE+00 O.0OE+00 1,08E+07 O.OOE+00 CO-58 O.OOE+00 4.79E+06 1.47E+07 O.OOE+00 O.OOE+00 O.OOE+00 2.79E+07 O.OOE+00 FE-59 4.25E+07 6.88E+07 3.43E+07 O.OOE+00 O.OOE+00 1,99E+07 7.16E+07 O.OOE+00 CO-60 O.OOE+00 2.30E+07 6.78E+07 O.OOE+00 O.OOE+00 O.OOE+00 1.27E+08 O.OOE+00 NI-59 1.20E+09 3.19E+08 2.03E+08 O.OOE+00 O.OOE+00 O.OOE+00 2.11E+07 O.00E+00 NI-63 1.60E+10 8.56E+08 5.44E+08 0.00E+00 O.OOE+00 O.OOE+00 5.77E+07 O.OOE+00 CU-64 O.OOE+00 2.18E+04 1.32E+04 O.OOE+00 5.27E+04 O.0OE+00 1.02E+06 O.OOE+00 NI-65 4.84E-01 4.56E-02 2.66E-02 O.OOE+00 O.OOE+00 O.OOE+00 5.58E+00 O.OOE+00 ZN-65 2.OOE+09 5.33E+09 3.32E+09 O.OOE+00 3.36E+09 O.OOE+00 9.37E+08 O.OQE+00 ZN-69M 2.33E+04 3.97E+05 4.69E+04 O.OOE+00 2.30E+05 O.OOE+00 1.29E+07 O.00E+00 ZN-69 2.77E-12 4.OOE-12 3.70E-13 O.OOE+00 2.43E-12 O.OOE+00 2.52E-10 O.OOE+00 SE-79 O.OOE+00 1.69E+09 3.74E+08 O.OOE+00 2.74E+09 O.OOE+00 1.11E+08 O.OOE+00 BR-82 O.OOE+00 O.OOE+00 3.36E+07 O.OOE+00 0.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 BR-83 O.OOE+00 O.OOE+00 1.29E-01 O.OOE+00 O.OOE+00 O.OOE+00 O.0OE+00 O.OOE+00 BR-84 O.OOE+00 O.OOE+00 1,90E-23 0.00E+00 O.OOE+00 0.OOE+00 O.OOE+00 O.OOE+00 BR-85 O.OOE+00 O.OOE+00 2.6E-301 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 RB-86 O.OOE+00 2.64E+09 1.62E+09 O.OOE+00 O.OOE+00 O.OOE+00 1.70E+08 O.OOE+00 RB-87 O.OOE+00 2.44E+09 2.44E+09 O.OOE+00 O.OOE+00 O.OOE+00 7.89E+07 O.OOE+00 RB-88 O.OOE+00 2.09E-45 1.45E-45 O.OOE+00 O.OOE+00 O.OOE+00 1.03E-46 O.OOE+00 RB-89 O.OOE+00 3.93E-53 3.50E-53 O.OE+00 O.OOE+00 O.OOE+00 3.43E-55 O.OOE+00 SR-89 2.41 E+09 O.OOE+00 6.89E+07 O.OOE+00 O.OOE+00 O.OOE+00 9.34E+07 0.OOE+00 SR-90 6.02E+10 O.OOE+00 1.53E+10 O.OOE+00 O.OOE+00 O.OE+00 8.11E+08 O.OOE+00 Y-90 9.42E+01 O.OOE+00 2.52E+00 O.OOE+00 0.OOE+00 O.OOE+00 2.68E+05 O.OOE+00 SR-91 3.81E+04 O.OOE+00 1.44E+03 O.OOE+00 O.OOE+00 O.OOE+00 8.42E+04 O.OOE+00 Y-91M 7.83E-20 O.OOE+00 2.85E-21 O.OOE+00 O.OOE+00 O.OOE+00 1.53E-16 O.OOE+00 Y-91 1.47E+04 O.OOE+00 3.94E+02 O.OOE+00 O.OOE+00 0.OOE+00 1.96E+06 O.OOE+00 SR-92 6.39E-01 O.OOE+00 2.56E-02 O.OOE+00 O.OOE+00 O.OOE+00 1.21E+01 O.OOE+00 Y-92 7.40E-05 O.OOE+00 2.12E-06 O.OOE+00 O.OOE+00 O.OOE+00 2.14E+00 O.OOE+00 Y-93 2.96E-01 O.OOE+00 8.12E-03 O.OOE+00 O.OOE+00 O.OOE+00 4.41 E+03 O.OOE+00 NB-93M 1.16E+06 2.89E+05 9.49E+04 O.0OE+00 3.12E+05 O.QOE+00 4.39E+07 O.OOE+00 NB-95 1.06E+05 4.14E+04 2.96E+04 O.OOE+00 3.89E+04 O.OE+00 7.65E+07 O.OE+00 NB-97 4.26E-12 7.69E-13 3.59E-13 O.OOE+00 1.64E-12 O.OOE+00 2.37E-07 O.0OE+00 ZR-93 3.71 E+03 1.39E+03 9.89E+02 O.OOE+00 5.38E+03 O.OOE+00 5.27E+05 O.OOE+00

CY-LG-170-301, Rev. 23 Page 202 08/07 TABLE 112-2 Ri DOSE FACTORS Age: Child Pathway: Cow Milk (Continued)

NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG GI-LLI SKIN ZR-95 1.48E+03 3.25E+02 2.89E+02 0.OOE+00 4.65E+02 0.OOE+00 3.39E+05 0.OOE+00 ZR-97 5.61E-01 8.11E-02 4.78E-02 0.OOE+00 1.16E-01 O.OOE+00 1.23E+04 0.OOE+00 MO-93 O.OOE+00 8.03E+08 2.88E+07 0.OOE+00 2.12E+08 0,OOE+00 4.07E+07 0.O0E+00 MO-99 O.OOE+00 2.38E+07 5.89E+06 0.OOE+00 5.08E+07 0.OOE+00 1.97E+07 0.OOE+00 TC-99 5.94E+07 6.62E+07 2.38E+07 0.OOE+00 7.80E+08 5.85E+06 6.94E+08 0.OOE+00 TC-99M 3.86E+00 7.58E+00 1.26E+02 0.OOE+00 1.10E+02 3.85E+00 4.31E+03 0.OOE+00 TC-101 3.40E-60 3.56E-60 4.51E-59 0.OOE+00 6.07E-59 1.88E-60 1.13E-59 0.OOE+00 RU-103 1.47E+03 O.OOE+00 5.65E+02 0.O0E+00 3.70E+03 0.OOE+00 3.80E+04 0.OOE+00 RU-105 1.12E-03 O.OOE+00 4.05E-04 0.OOE+00 9.82E-03 0.OOE+00 7.29E-01 0.OOE+00 RU-106 4.63E+04 0.OOE+00 5.78E+03 0.OOE+00 6.26E+04 0.OOE+00 7.21E+05 0.OOE+00 RH-105 2.28E+07 1.22E+07 1.05E+07 0.OOE+00 4.87E+07 0.OOE+00 7.57E+08 0.OOE+00 PD-107 0.O0E+00 2.10E+07 1.78E+06 O.OOE+00 1.76E+08 0.OOE+00 4.16E+07 0.OOE+00 PD-109 0.OOE+00 4.42E+04 1.32E+04 0.OOE+00 2.37E+05 0.OOE+00 2.59E+06 0.OOE+00 AG-110M 1.01E+08 6.84E+07 5.47E+07 0.OOE+00 1.27E+08 0.OOE+00 8.14E+09 0.OOE+00 AG-111 8.61E+06 2.70E+06 1.78E+06 0.OOE+00 8.13E+06 0.OOE+00 1.65E+09 0.OOE+00 CD-113M 0.OOE+00 5.39E+06 2.29E+05 0.OOE+00 5.55E+06 0.OOE+00 1.39E+07 0.OOE+00 CD-115M 0.OOE+00 1.52E+06 6.47E+04 O.OOE+00 1.13E+06 O.OOE+00 2.06E+06 0.O0E+00 SN-123 1.09E+09 1.35E+07 2.65E+07 1.43E+07 O.OOE+00 O.OOE+00 5.33E+08 0.OOE+00 SN-125 7.55E+07 1.14E+06 3.38E+06 1.18E+06 0.OOE+00 O.OOE+00 2.34E+08 0.OOE+00 SN-126 3.70E+09 4.61E+07 1.05E+08 1.27E+07 0.OOE+00 0.OOE+00 2.78E+08 0.OOE+00 SB-124 4.13E+07 5.36E+05 1.45E+07 9.12E+04 0.OOE+00 2.29E+07 2.58E+08 0.OOE+00 SB-125 4.57E+07 3.52E+05 9.58E+06 4.23E+04 0.OOE+00 2.55E+07 1.09E+08 0.OOE+00 SB-126 6.71E+06 1.03E+05 2.41E+06 3.63E+04 0.OOE+00 3.20E+06 1.35E+08 0.OOE+00 SB-127 5.75E+05 8.90E+03 2.OOE+05 6.41 E+03 0.OOE+00 2.50E+05 3.24E+07 O.OOE+00 TE-125M 2.78E+07 7.54E+06 3.71E+06 7.81 E+06 0.0OE+00 0.OOE+00 2.68E+07 0.OOE+00 TE-127M 8.99E+07 2.42E+07 1.07E+07 2.15E+07 2.56E+08 0.OOE+00 7.28E+07 0.OOE+00 TE-127 8.70E+02 2.35E+02 1.87E+02 6.02E+02 2.48E+03 0.OOE+00 3.40E+04 0.OOE+00 TE-129M 8.99E+07 2.51E+07 1.40E+07 2.90E+07 2.64E+08 0.OOE+00 1.10OE+08 0.OOE+00 TE-129 3.75E-10 1.05E-10 8.90E-11 2.68E-10 1.1OE-09 0.OOE+00 2.34E-08 0.OOE+00 TE-133M 2.65E-13 1.07E-13 1.33E-13 2.06E-13 1.01E-12 0.OOE+00 8.19E-12 0.OOE+00 TE-134 1.10E-18 4.96E-19 6.62E-19 8.73E-19 4.60E-18 O.OOE+00 5.04E-18 0.OOE+00 1-129 1.85E+09 1.14E+09 1.02E+09 7.44E+11 1.92E+09 0.OOE+00 5.72E+07 O.OOE+00 1-130 5.05E+05 1.02E+06 5.26E+05 1.12E+08 1.53E+06 0.O0E+00 4.78E+05 0.OOE+00 1-131 3.81E+08 3.84E+08 2.18E+08 1.27E+11 6.30E+08 0.OOE+00 3.41 E+07 0.OOE+00 TE-131M 4.68E+05 1.62E+05 1.72E+05 3.33E+05 1.57E+06 0.O0E+00 6.56E+06 0.OOE+00 TE-131 4.73E-33 1.44E-33 1.41E-33 3.62E-33 1.43E-32 0.OOE+00 2.48E-32 O.OOE+00 1-132 2.02E-01 3.70E-01 1.70E-01 1.72E+01 5.67E-01 0.OOE+00 4.36E-01 0.OOE+00 TE-132 3.OOE+06 1.33E+06 1.60E+06 1.93E+06 1.23E+07 0.OOE+00 1.34E+07 O.OOE+00 1-133 5.02E+06 6.21E+06 2.35E+06 1.15E+09 1.04E+07 0.OOE+00 2.50E+06 O.OOE+00 CS-134M 2.14E-01 3.17E-01 2.07E-01 0.OOE+00 1.67E-01 2.77E-02 3.35E-01 O.OOE+00 CS-134 1.18E+10 1.93E+10 4.08E+09 0.OOE+00 5.99E+09 2.15E+09 1.04E+08 0.OOE+00 1-134 2.48E-12 4.61E-12 2.12E-12 1.06E-10 7.05E-12 0.OOE+00 3.06E-12 0.OOE+00 1-135 1.58E+04 2.84E+04 1.34E+04 2.52E+06 4.36E+04 0.OOE+00 2.17E+04 0.OE+00 CS-135 4.43E+09 3.08E+09 3.16E+08 0.OOE+00 1.09E+09 3.63E+08 2.31E+07 0.OOE+00 CS-136 2.98E+08 8.19E+08 5.30E+08 0.OOE+00 4.36E+08 6.51E+07 2.88E+07 O.OOE+00

CY-LG-170-301, Rev. 23 Page 203 08/07 TABLE 112-2 Ri DOSE FACTORS Age: Child Pathway: Cow Milk (Continued)

NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG GI-LLI SKIN CS-137 1.74E+10 1.66E+10 2.45E+09 O.OOE+00 5.42E+09 1.95E+09 1.04E+08 O.OOE+00 CS-138 1.16E-23 1.62E-23 1.03E-23 O.OOE+00 1.14E-23 1.22E-24 7.45E-24 O.OOE+00 CS-139 8.98E-90 9.97E-90 4.79E-90 O.OOE+00 7.49E-90 7.55E-91 8.98E-94 O.OOE+00 BA-139 5.87E-08 3.14E-11 1.70E-09 O.OOE+00 2.74E-11 1.84E-11 3.39E-06 O.OOE+00 BA-140 3.45E+07 3.02E+04 2.01E+06 O.OOE+00 9.83E+03 1.80E+04 1.75E+07 O.OOE+00 LA-140 5.68E+00 1.98E+00 6.69E-01 O.OOE+00 O.OOE+00 O.OOE+00 5.53E+04 O.OOE+00 BA-141 5.41E-46 3.03E-49 1.76E-47 O.OOE+00 2.62E-49 1.78E-48 3.08E-46 O.0OE+00 LA-141 4.04E-05 9.42E-06 2.04E-06 O.OOE+00 0.OOE+00 O.OOE+00 2.09E+00 O.OOE+00 CE-141 7.19E+03 3.59E+03 5.33E+02 O.OOE+00 1.57E+03 O.OOE+00 4.48E+06 O.OOE+00 BA-142 3.40E-80 2.44E-83 1.90E-81 O.OOE+00 1.98E-83 1.44E-83 4.43E-82 O.OOE+00 LA-142 2.37E-11 7.55E-12 2.36E-12 O.OOE+00 O.OOE+00 O.OOE+00 1.50E-06 O.OOE+00 CE-143 5.48E+01 2.97E+04 4.31E+00 O.OOE+00 1.25E+01 O.OOE+00 4.35E+05 O.OOE+00 PR-143 2.12E+02 6.36E+01 1.05E+01 O.OOE+00 3.44E+01 O.OOE+00 2.29E+05 O.OOE+00 CE-144 7.97E+05 2.50E+05 4.26E+04 O.OOE+00 1.38E+05 O.OOE+00 6.52E+07 O.OOE+00 PR-144 7.83E-54 2.42E-54 3.94E-55 O.OOE+00 1.28E-54 O.OOE+00 5.22E-51 O.OOE+00 ND-147 1.30E+02 1.06E+02 8.18E+00 O.OOE+00 5.80E+01 O.OOE+00 1.67E+05 0.00E+00 PM-147 6.75E+03 4,82E+02 2.59E+02 O.OOE+00 8,52E+02 O.OOE+00 1.95E+05 O.OOE+00 PM-148M 1.06E+03 2.11E+02 2.11E+02 O.OOE+00 3.14E+02 O.OOE+00 5.96E+05 O.OOE+00 PM-148 3.11E+02 3.74E+01 2.42E+01 O.OOE+00 6.36E+01 O.OOE+00 1.OOE+06 O.OE+00 PM-149 5.69E+00 6.05E-01 3.28E-01 O.OOE+00 1.07E+00 O.OOE+00 4.13E+04 O.OOE+00 PM-151 8.47E-01 1.03E-01 6.70E-02 O.OOE+00 1.75E-01 O.OOE+00 1.17E+04 O.OOE+00 SM-151 5.68E+03 8.45E+02 2.66E+02 O.OOE+00 8.74E+02 O.OOE+00 1.23E+05 O.OOE+00 SM-153 2.63E+00 1.63E+00 1.58E-01 0.OOE+00 4.97E-01 O.OOE+00 2.17E+04 0.OOE+00 EU-152 1.35E+04 2.47E+03 2.93E+03 O.OOE+00 1.04E+04 O.OOE+00 4.05E+05 O.OOE+00 EU-154 5.04E+04 4.54E+03 4.14E+03 O.OOE+00 1.99E+04 O.OOE+00 1.05E+06 O.OOE+00 EU-155 1.05E+04 7.53E+02 5.90E+02 O.OOE+00 2.82E+03 O.OOE+00 1.88E+06 O.OOE+00 EU-156 3.26E+02 1.74E+02 3.61E+01 O.OOE+00 1.12E+02 O.OOE+00 3.96E+05 O.OOE+00 TB-160 2.23E+03 O.OOE+00 2.76E+02 O.OOE+00 6.63E+02 O.OOE+00 4.94E+05 O.OOE+00 HO-166M 2.40E+04 5.02E+03 4.24E+03 O.OOE+00 7.15E+03 O.OOE+00 2.22E-14 O.OOE+00 W-181 6.79E+04 1.67E+04 2.30E+03 0.OOE+00 O.OOE+00 O.OOE+00 6.08E+05 0.OOE+00 W-185 2.36E+06 5.89E+05 8.25E+04 O.OOE+00 O.OOE+00 O.OOE+00 2.19E+07 O.OOE+00 W-187 8.45E+03 5.OOE+03 2.24E+03 O.OOE+00 O.OOE+00 O.OOE+00 7.03E+05 OOOE+00 NP-239 5.05E+00 3.62E-01 2.55E-01 O.OOE+00 1.05E+00 O.OOE+00 2.68E+04 O.OE+00 U-232 3.90E+10 O.OOE+00 2.79E+09 O.OOE+00 2.97E+09 O.OOE+00 1.55E+08 O.OOE+00 U-233 8.27E+09 O.OOE+00 5.OOE+08 O.OOE+00 1.36E+09 O.00E+00 1.43E+08 O.OOE+00 U-234 7.93E+09 O.OOE+00 4.91E+08 O.OOE+00 1.33E+09 O.OOE+00 1.40E+08 0.OOE+00 U-235 7.60E+09 O.OOE+00 4.60E+08 O.OOE+00 1.25E+09 OOOE+00 1.78E+08 O.OOE+00 U-236 7.60E+09 O.OOE+00 4.71E+08 O.OOE+00 1.27E+09 O.OOE+00 1.32E+08 O.OOE+00 U-237 7.52E+04 O.OOE+00 2.OOE+04 O.OOE+00 2.17E+05 O.OOE+00 6.63E+06 O.OOE+00 U-238 7.27E+09 O.OOE+00 4.31E+08 O.OOE+00 1.16E+09 O.OOE+00 1.26E+08 O.OOE+00 NP-237 4.95E+07 3.27E+06 2.18E+06 O.OOE+00 1.34E+07 O.OOE+00 1.81E+06 O.OOE+00 NP-238 4.78E+01 9.68E-01 7.45E-01 O.OOE+00 3.08E+00 O.OOE+00 3.31 E+04 O.OOE+00 PU-238 1.06E+07 1.22E+06 2.80E+05 O.OOE+00 1.02E+06 O.OOE+00 6.66E+05 OOOE+00 PU-239 1.15E+07 1.23E+06 2.94E+05 0.OOE+00 1.08E+06 O.OOE+00 6.09E+05 O.OOE+00 PU-240 1.14E+07 1.27E+06 2.94E+05 O.OOE+00 1.08E+06 O.OE+00 6.20E+05 O.OOE+00

CY-LG-1 70-301, Rev. 23 Page 204 08/07 TABLE 112-2 Ri DOSE FACTORS Age: Child Pathway: Cow Milk (Continued)

NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG ' GI-LLI SKIN PU-241 3.41E+05 1.39E+04 7,09E+03 O.OOE+00 2.61E+04 O.OOE+OO 1.27E+04 O.OOE+00 PU-242 1.06E+07 1.23E+06 2.84E+05 O.OE+00 1.04E+06 O.OOE+O0 5.96E+05 O.OOE+OO PU-244 1.24E+07 1.40E+07 3.24E+05 O.O0E+00 1.20E+06 O.OOE+00 8.89E+05 O.OOE+0O AM-241 3.02E+07 2.60E+07 2.27E+06 O.OOE+00 1.38E+07 O.OOE+O0 1.70E+06 O.OOE+O0 AM-242M 3.11E+07 2.49E+07 2.31E+06 O.OOE+O0 1.40E+07 O.OOE+O0 2.13E+06 O.OOE+00 AM-243 2.98E+07 2.51E+07 2.18E+06 O.OOE+00 1.35E+07 O.OOE+O0 1.99E+06 O.OOE+00 CM-242 1.52E+06 1.22E+06 1.01E+05 O.OOE+00 3.24E+05 O.OOE+00 1.41E+06 O.OOE+00 CM-243 2.83E+07 2.30E+07 1.82E+06 O.OOE+00 6.81E+06 O.OOE+00 1.78E+06 O.OOE+00 CM-244 2.38E+07 1.93E+07 1.53E+06 O.OOE+0O 5.61E+06 O.OOE+00 1.72E+06 O.OOE+00 CM-245 3.71E+07 2.98E+07 2.33E+06 O.OOE+00 9.13E+06 O.OOE+0O 1.61E+06 O.OOE+00 CM-246 3.67E+07 2.98E+07 2.33E+06 O.OQE+00 9.11E+06 O.OOE+00 1.58E+06 O.O0E+00 CM-247 3.58E+07 2.93E+07 2.29E+06 O.OOE+00 8.98E+06 O0OOE+00 2.08E+06 O.OOE+00 CM-248 2.98E+08 2.42E+08 1.89E+07 O.OOE+00 7.40E+07 O.OOE+00 3.36E+07 O.OOE+0Q CF-252 2.23E+07 O.OOE+0O 5,40E+05 O.OOE+00 O.OOE+00 O.OOE+0O 6.29E+06 O.OOE+0O

CY-LG-170-301, Rev. 23 Page 205 08/07 TABLE 112-2 Ri DOSE FACTORS Age: Child Pathway: Goat Milk NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG GI-LLI SKIN H-3 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 C-14 0.O0E+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 NA-22 0.O0E+00 0.OOE+00 0.OOE+00 O.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 0.O0E+00 NA-24 0.O0E+00 0.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 P-32 0.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 CA-41 O.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 SC-46 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 CR-51 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 MN-54 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 FE-55 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 MN-56 0.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 CO-57 0.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 CO-58 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 FE-59 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 O000E+00 0.OOE+00 0.OOE+00 CO-60 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 NI-59 0.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 NI-63 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 CU-64 0.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 NI-65 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 ZN-65 0.OOE+00 0.OOE+00 0.OOE+00 O.00E+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 ZN-69M O.OOE+00 0.OOE+00 0.0OE+00 0.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 ZN-69 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 SE-79 0.00DE00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 BR-82 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 BR-83 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 BR-84 0.OOE+00 O.OOE+00 O0O0E+00 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 BR-85 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 RB-86 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 RB-87 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 RB-88 0.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 RB-89 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 SR-89 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.0OE+00 0.0OE+00 0.OOE+00 SR-90 0,00E+00 0.OOE+00 O.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 Y-90 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 0.00E+00 O.OOE+00 0.O0E+00 SR-91 0.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 0.O0E+00 Y-91M 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 Y-91 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 SR-92 0.OOE+00 0.OOE+00 0.OOE+00 0.00E+00 0.OOE+00 O.OOE+00 0.OOE+00 0.0OE+00 Y-92 0.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 Y-93 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 NB-93M 0.00E+00 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 O.OE+00 0.OOE+00 NB-95 0.00E+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 NB-97 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 ZR-93 0.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 0.O0E+00 0.00E+00

CY-LG-170-301, Rev. 23 Page 206 08/07 TABLE 112-2 Ri DOSE FACTORS Age: Child Pathway: Goat Milk (Continued)

NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG GI-LLI SKIN ZR-95 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 ZR-97 0.OOE+00 0.OOE+00 0.OOE+00 O.00E+00 0.OOE+00 0.OOE+00 0.0OE+00 0.OOE+00 MO-93 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.00E+00 0.OOE+00 MO-99 0.OOE+00 O.OOE+00 0,00E+00 0.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 TC-99 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 TC-99M 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 TC-101 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 RU-103 0.OOE+00 0.OOE+00 O.OOE+00 O.OOE+00 0,OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 RU-105 0.OOE+00 0.00E+00 O.OOE+00 0.OOE+00 O.OOE+00 0.O0E+00 0.OOE+00 0.00E+00 RU-106 0.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00> 0.OOE+00 RH-105 0.OOE+00 0.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 PD-107 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 PD-109 0.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.O0E+00 0.OOE+00 AG-110M 0.0OE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 AG-111 0.OOE+00 O.OOE+00 O.OE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+0 0. OOE+00 CD-113M 0.0OE+00 0.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 CD-115M 0.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 SN-123 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE++/-0 0.OOE+00 0.OOE+00 O.OOE+00 SN-125 0.OOE+00 O.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 SN-126 0.0OE+00 O.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 SB-124 O.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 SB-125 0.O0E+00 0.O0E+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 SB-126 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 0.00E+00 0.OOE+00 SB-127 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 TE-125M 0.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 0,00E+00 0.OOE+00 0.OOE+00 TE-127M 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 TE-127 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 O.OOE+00 0.OOE+00 TE-129M 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0,OOE+00 TE-129 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 TE-133M 0.OOE+00 O.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 TE-134 0.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 O.OOE+00 1-129 0.O0E+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 1-130 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 1-131 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 TE-131M 0.00E+00 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 TE-131 0.OOE+00 0.OOE+00 0.OOE+00 0.0OE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 1-132 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 OOOE+00 0.OOE+00 0.OOE+00 0.OOE+00 TE-132 0.OOE+0O 0.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 1-133 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 CS-134M 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 CS-134 0.OOE+00 0.0OE+00 0.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 1-134 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.0OE+00 1-135 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 CS-135 0.OOE+00 0.0OE+00 0.OOE+00 0.O0E+00 0.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 CS-136 0.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 0.00E+00 0.OOE+00 0.OOE+00 0.OOE+00

CY-LG-170-301, Rev. 23 I Page 207 08/07 I TABLE 112-2 Ri DOSE FACTORS Age: Child Pathway: Goat Milk (Continued)

NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG GI-LLI SKIN CS-137 O.QOE+00 O.OOE+00 0.OOE+00 O.OOE+00 O.OOE+00 O.0OE+00 Q.OOE+00 O.OOE+00 CS-138 Q.OOE+00 O.OOE+00 O.0OE+00 O.OOE+00 O.OE+00 O.OOE+00 O.OOE+00 O.OOE+00 CS-139 Q.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 BA-139 Q.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 BA-140 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 LA-140 Q.OOE+00 0.00E+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 BA-141 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 0.00E+00 LA-141 O.OOE+00 O.OOE+00 O.OOE+00 OOOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 CE-141 O.OOE+00 O.OOE+00 O.OOE+00 O.OE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 BA-142 0.00E+00 0.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 LA-142 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OQE+00 O.OE+00 CE-143 O.QOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 0.OOE+00 O.OOE+00 O.OOE+00 PR-143 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OQE+00 O.OOE+00 CE-144 O.QOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 PR-144 O.OOE+00 O.OOE+00 Q.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 ND-147 O.QOE+00 O.OOE+00 O.0OE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.O0E+00 O.OOE+00 PM-147 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 PM-148M O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.QOE+00 PM-148 Q.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 PM-149 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 PM-151 Q.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 SM-151 O.OOE+00 O.OE+00 0.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 SM-153 O.QOE+00 O.OOE+00 O.0OE+00 O.0OE+00 O.OOE+00 O.OOE+00 O0OOE+00 O.OOE+00 EU-152 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 EU-154 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 EU-155 Q.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 EU-156 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 TB-160 O.OOE+00 O.OOE+00 O.OOE+00 0,00E+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 HO-166M O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OE+00 W-181 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O0OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 W-185 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 W-187 Q.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O0O0E+00 O.OOE+00 NP-239 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 U-232 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 0.OOE+00 O.OOE+00 U-233 O.OOE+00 O.OOE+00 0.OOE+00 O.OOE+00 O.OE+00 O.OOE+00 O.OOE+00 O.OOE+00 U-234 O.OOE+00 0.0OE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00, O.OOE+00 U-235 O.OOE+00 O.0OE+00 0.00E+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 U-236 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.00E+00 O.OOE+00 O.OOE+00 U-237 O.OOE+00 O.OOE+00 O.OE+00 0.OOE+00 O.OOE+00 O.OOE+00 0,OOE+00 O.OOE+00 U-238 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 NP-237 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 0.OOE+00 O.OE+00 O.OOE+00 NP-238 O.OOE+00 O.OE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OE+00 PU-238 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 0.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 PU-239 Q.OE+00 O.OOE+00 O.OE+00 O.OOE+00 0.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 PU-240 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OE+00

CY-LG-170-301, Rev. 23 Page 208 08/07 TABLE 112-2 Ri DOSE FACTORS Age: Child Pathway: Goat Milk (Continued)

NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG GI-LLI SKIN PU-241 O.OOE+00 0.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 PU-242 Q.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 PU-244 O.OOE+00 O.QOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 AM-241 O.OE+00 O.OOE+00 O.OOE+00 0.00E+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 AM-242M O.OOE+00 O.OOE+O0 O.OOE+00 O.OOE+00 0.OOE+00 O.OOE+00 O.OOE+00 0.00E+00 AM-243 O.OE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 CM-242 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 CM-243 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OE+00 O.OOE+00 O.OOE+00 O.OOE+00 CM-244 O.OOE+00 O.OE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 CM-245 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OE+00 O.OOE+00 O.OOE+00 0.OOE+00 CM-246 O.OOE+00 O.OOE+00 O.OOE+00 O.OE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 CM-247 O.OOE+00 O.OOE+00 0.OE+00 O.0OE+00 O.OOE+00 O.OE+00 O.OOE+00 O.OOE+00 CM-248 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.0OE+00 O.OOE+00 O.OOE+00 CF-252 O.OOE+00 O.OOE+00 O.OOE+00 O.0OE+00 O.OOE+00 O.OOE+00 O.OOE+00 0.OOE+00

CY-LG-170-301, Rev. 23 Page 209 08/07 TABLE 112-2 Ri DOSE FACTORS Age: Child Pathway: Inhalation NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG GI-LLI SKIN H-3 0.OOE+00 1.13E+03 1.13E+03 1.13E+03 1.13E+03 1.13E+03 1.13E+03 0.OOE+00 C-14 3.59E+04 6.73E+03 6.73E+03 6.73E+03 6.73E+03 6.73E+03 6.73E+03 0.O0E+00 NA-22 1.63E+05 1.63E+05 1.63E+05 1.63E+05 1.63E+05 1.63E+05 1.63E+05 O.OE+00 NA-24 1.61E+04 1.61E+04 1.61E+04 1.61E+04 1.61E+04 1.61E+04 1.61E+04 O0OOE+00 P-32 2.61E+06 1.14E+05 9.88E+04 0.OOE+00 0.OOE+00 O.OOE+00 4.22E+04 0.00E+00 CA-41 2.61E+05 0.OOE+00 2.85E+04 0.OOE+00 0.OOE+00 2.67E+08 1.09E+03 0.OOE+00 SC-46 7.29E+05 9.99E+05 3.85E+05 0.OOE+00 8.84E+05 0.OOE+00 9.07E+04 0.OOE+00 CR-51 0.OOE+00 O.OOE+00 1.54E+02 8.55E+01 2.43E+01 1.70E+04 1.08E+03 0.OOE+00 MN-54 0.OOE+00 4.29E+04 9.51E+03 0.OOE+00 1.OOE+04 1.58E+06 2.29E+04 0.0OE+00 FE-55 4.74E+04 2.52E+04 7.77E+03 0.OOE+00 0.OOE+00 1.11E+05 2.87E+03 0.OOE+00 MN-56 0.OOE+00 1.66E+00 3.12E-01 0.OOE+00 1.67E+00 1.31E+04 1.23E+05 0.OOE+00 CO-57 0.OOE+00 9.03E+02 1.07E+03 O.OOE+00 O.OOE+00 5.07E+05 1.32E+04 0.OOE+00 CO-58 0.OOE+00 1.77E+03 3.16E+03 0.OOE+00 0.OOE+00 1.11E+06 3.44E+04 0.OOE+00 FE-59 2.07E+04 3.35E+04 1.67E+04 0.OOE+00 0.OOE+00 1.27E+06 7.07E+04 0.OOE+00 CO-60 0.OOE+00 1.31E+04 2.26E+04 O.OE+00 0.OOE+00 7.07E+06 9.62E+04 0.OOE+00 NI-59 6.14E+04 1.73E+04 1.05E+04 0.OOE+00 0.OOE+00 1.01E+05 2.33E+03 O.OOE+00 NI-63 8.21E+05 4.63E+04 2.80E+04 0.OOE+00 0.OOE+00 2.75E+05 6.33E+03 0.OOE+00 CU-64 O.OOE+00 1.99E+00 1.07E+00 0.OOE+00 6.03E+00 9.58E+03 3.67E+04 0.OOE+00 NI-65 2.99E+00 2.96E-01 1.64E-01 0.OOE+00 0.OOE+00 8.18E+03 8.40E+04 0.OOE+00 ZN-65 4.26E+04 1.13E+05 7.03E+04 0.OOE+00 7.14E+04 9.95E+05 1.63E+04 0.OOE+00 ZN-69M 1.58E+01 2.69E+01 3.18E+00 O.OOE+00 1.56E+01 2.72E+04 1.OOE+05 O.OOE+00 ZN-69 6.70E-02 9.66E-02 8.92E-03 0.OOE+00 5.85E-02 1.42E+03 1.02E+04 0.OOE+00 SE-79 O.OOE+00 4.55E+03 9.62E+02 0.OOE+00 6.33E+03 5.51E+05 1.27E+04 0.OOE+00 BR-82 0.OOE+00 O.OOE+00 2.09E+04 0.OOE+00 0.OOE+00 0.OOE+00 3.70E-15 0.OOE+00 BR-83 0.OOE+00 0.OOE+00 4.74E+02 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 BR-84 0.OOE+00 0.OOE+00 5.48E+02 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 BR-85 0.OOE+00 0.OOE+00 2.53E+01 0.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 RB-86 0.OOE+00 1.98E+05 1.14E+05 0.OOE+00 0.OOE+00 0.OOE+00 7.99E+03 O.OOE+00 RB-87 0.OOE+00 1.17E+05 5.07E+04 0.OOE+00 0.OOE+00 O.OOE+00 1.10E+03 0.OOE+00 RB-88 0.OOE+00 5.62E+02 3.66E+02 0.OOE+00 O.OOE+00 0.OOE+00 1.72E+01 0.OOE+00 RB-89 0.OOE+00 3.45E+02 2.90E+02 O.OOE+00 0.OOE+00 0.OOE+00 1.89E+00 0.O0E+00 SR-89 5.99E+05 0.OOE+00 1.72E+04 0.OOE+00 0.OOE+00 2.16E+06 1.67E+05 0.OOE+00 SR-90 1.01E+08 O.OOE+00 6.44E+06 0.OOE+00 0,OOE+00 1.48E+07 3.43E+05 0.OOE+00 Y-90 4.11E+03 0.0OE+00 1.11E+02 O.OOE+00 0.OOE+00 2.62E+05 2.68E+05 0.OOE+00 SR-91 1.21E+02 0.OOE+00 4.59E+00 0.OOE+00 0.OOE+00 5.33E+04 1.74E+05 0.OOE+00 Y-91M 5.07E-01 0.OOE+00 1.84E-02 0.OOE+00 0.OOE+00 2.81E+03 1.72E+03 0.O0E+00 Y-91 9.14E+05 Q.OOE+00 2.44E+04 0.OOE+00 O.OOE+00 2.63E+06 1.84E+05 0.OOE+00 SR-92 1.31E+01 0.OOE+00 5.25E-01 0.OOE+00 0.OOE+00 2.40E+04 2.42E+05 O.OOE+00 Y-92 2.04E+01 0.OOE+00 5.81 E-01 O.OOE+00 0.OOE+00 2.39E+04 2.39E+05 0.OOE+00 Y-93 1.87E+02 0.OOE+00 5.11E+00 0.OOE+00 0.OOE+00 7.44E+04 3.89E+05 O.OOE+00 NB-93M 4.70E+05 1.17E+05 3.85E+04 0.OOE+00 1.26E+05 3.85E+05 9.07E+03 0.OOE+00 NB-95 2.35E+04 9.18E+03 6.55E+03 0.OOE+00 8.62E+03 6.14E+05 3.70E+04 O.OE+00 NB-97 4.29E-01 7.70E-02 3.60E-02 0.O0E+00 8.55E-02 3.42E+03 2.78E+04 0,00E+00

CY-LG-170-301, Rev. 23 Page 210 08/07 TABLE 112-2 Ri DOSE FACTORS Age: Child Pathway: Inhalation (Continued)

NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG GI-LLI SKIN ZR-93 7.66E+05 2.89E+05 2.05E+05 0.OOE+00 1.11E+06 2.63E+06 5.44E+04 0.0OE+00 ZR-95 1.90E+05 4.18E+04 3.70E+04 0.OOE+00 5.96E+04 2.23E+06 6.11E+04 0.OOE+00 ZR-97 1.88E+02 2.72E+01 1.60E+01 O.OOE+00 3.89E+01 1.13E+05 3.51E+05 O.OOE+00 MO-93 0.O0E+00 1.39E+04 5.OOE+02 0.OOE+00 3.92E+03 6.29E+05 1.40E+04 0.OOE+00 MO-99 0.OOE+00 1.72E+02 4.26E+01 0.OOE+00 3.92E+02 1.35E+05 1.27E+05 0.OOE+00 TC-99 4.96E+02 5.51E+02 1.98E+02 0.OOE+00 6.48E+03 1.25E+06 2.87E+04 0.OOE+00 TC-99M 1.78E-03 3.48E-03 5.77E-02 0.OOE+00 5.07E-02 9.51E+02 4.81E+03 0.OOE+00 TC-101 8.1OE-05 8.51E-05 1.08E-03 0.OOE+00 1.45E-03 5.85E+02 1.63E+01 O.OOE+00 RU-103 2.79E+03 0.OOE+00 1.07E+03 0.OOE+00 7.03E+03 6.62E+05 4.48E+04 0.OOE+00 RU-105 1.53E+00 0.OOE+00 5.55E-01 0.OOE+00 1.34E+00 1.59E+04 9.95E+04 O.OOE+00 RU-106 1.36E+05 0.OOE+00 1.69E+04 0.OOE+00 1.84E+05 1.43E+07 4.29E+05 O.OOE+00 RH-105 1.45E+01 7.77E+00 6.62E+00 0.OOE+00 3.10E+01 2.89E+04 4.92E+04 0.OOE+00 PD-107 O.OOE+00 9.81E+02 9.29E+01 0.OOE+00 7.29E+03 1.17E+05 2.69E+03 0.OOE+00 PD-109 0.OOE+00 5.48E+00 1.83E+00 0.OOE+00 2.61E+01 2.28E+04 9.58E+04 0.OOE+00 AG-110M 1.69E+04 1.14E+04 9.14E+03 0.OOE+00 2.12E+04 5.48E+06 1.OOE+05 0.OOE+00 AG-111 6.70E+02 2.10E+02 1.39E+02 0.OOE+00 6.33E+02 2.86E+05 1.10E+05 0.OOE+00 CD-113M 0.O0E+00 1.82E+06 7.84E+04 O.OOE+00 1.90E+06 2.57E+06 6.03E+04 0.OOE+00 CD-115M 0.OOE+00 2.92E+05 1.25E+04 0.OOE+00 2.19E+05 2.17E+06 1.84E+05 0.OOE+00 SN-123 4.77E+05 7.92E+03 1.55E+04 8.40E+03 0.OOE+00 3.55E+06 1.50E+05 0.OOE+00 SN-125 1.83E+04 3.68E+02 1.09E+03 3.81 E+02 O.OOE+00 8.99E+05 2.65E+05 0.OOE+00 SN-126 2.31E+06 3.85E+04 8.73E+04 1.05E+04 0.OOE+00 1.12E+07 6.03E+04 0.OOE+00 SB-124 5.66E+06 7.40E+02 2.OOE+04 1.26E+02 O.OOE+00 3.24E+06 1.64E+05 0.OOE+00 SB-125 9.84E+04 7.59E+02 1.99E+04 9.10E+01 0.OOE+00 2.32E+06 4.03E+04 0.O0E+00 SB-126 6.36E+03 9.69E+01 2.28E+03 3.70E+01 O.OOE+00 1.06E+06 2.10E+05 O.OOE+00 SB-127 5.03E+02 7.73E+00 1.74E+02 5.59E+00 0.OOE+00 2.28E+05 1.41E+05 0.OOE+00 TE-125M 6.73E+03 2.33E+03 9.14E+02 1.92E+03 0.OOE+00 4.77E+05 3.38E+04 0.OOE+00 TE-127M 2.49E+04 8.55E+03 3.02E+03 6.07E+03 6.36E+04 1.48E+06 7.14E+04 O.OOE+00 TE-127 2.77E+00 9.51E-01 6.11E-01 1.96E+00 7.07E+00 1.OOE+04 5.62E+04 O.OOE+00 TE-129M 1.92E+04 6.85E+03 3.04E+03 6.33E+03 5.03E+04 1.76E+06 1.82E+05 O.OOE+00 TE-129 9.77E-02 3.50E-02 2.38E-02 7.14E-02 2.57E-01 2.93E+03 2.55E+04 0.OOE+00 TE-133M 1.08E-01 5.59E-02 5.55E-02 8.58E-02 3.74E-01 5.92E+03 1.76E+04 0.OOE+00 TE-134 5.66E-02 3.26E-02 3.48E-02 4.59E-02 2.11E-01 4.55E+03 1.80E+03 0.OOE+00 1-129 3.89E+04 2.37E+04 2.11E+04 1.58E+07 4.OOE+04 0.OOE+00 7.96E+02 0.OOE+00 1-130 8.18E+03 1.64E+04 8.44E+03 1.85E+06 2.45E+04 0.OOE+00 5.11E+03 0.OOE+00 1-131 4.81E+04 4.81E+04 2.73E+04 1.62E+07 7.88E+04 0.OOE+00 2.84E+03 0.OOE+00 TE-131M 1.34E+02 5.92E+01 5.07E+01 9.77E+01 4.0OE+02 2.06E+05 3.08E+05 0.OOE+00 TE-131 2.17E-02 8.44E-03 6.59E-03 1.70E-02 5.88E-02 2.05E+03 1.33E+03 O.OOE+00 1-132 2.12E+03 4.07E+03 1.88E+03 1.94E+05 6.25E+03 0.OOE+00 3.20E+03 0.OOE+00 TE-132 4.81E+02 2.72E+02 2.63E+02 3.18E+02 1.77E+03 3.77E+05 1.38E+05 0.OOE+00 1-133 1.66E+04 2.03E+04 7.70E+03 3.85E+06 3.38E+04 0.OOE+00 5.48E+03 0.OOE+00 CS-134M 2.34E+02 3.30E+02 2.26E+02 0.OOE+00 1.83E+02 3.09E+01 2.93E+02 0.OOE+00 CS-134 6.51E+05 1.01E+06 2.25E+05 0.OOE+00 3.30E+05 1.21E+05 3.85E+03 0.OOE+00 1-134 1-17E+03 2.16E+03 9.95E+02 5.07E+04 3.30E+03 0.OOE+00 9.55E+02 0.OOE+00 1-135 4.92E+03 8.73E+03 4.14E+03 7.92E+05 1.34E+04 0.OOE+00 4.44E+03 0.OOE+00 CS-135 2.31 E+05 1.53E+05 1.65E+04 O.OOE+00 5.66E+04 1.93E+04 8.03E+02 0.OOE+00

CY-LG-1 70-301, Rev. 23 I Page 211 08/07 I TABLE 112-2 Ri DOSE FACTORS Age: Child Pathway: Inhalation (Continued)

NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG GI-LLI SKIN CS-136 6.51E+04 1.71E+05 1.16E+05 O.OOE+00 9.55E+04 1.45E+04 4.18E+03 O.OOE+00 CS-137 9.07E+05 8.25E+05 1.28E+05 O.OOE+00 2.82E+05 1.04E+05 3.62E+03 O.0OE+00 CS-138 6.33E+02 8.40E+02 5.55E+02 O.OOE+00 6.22E+02 6.81E+01 2.70E+02 O.OOE+00 CS-139 4.03E+02 4.26E+02 2.15E+02 O.OOE+00 3.36E+02 3.46E+01 2.68E-02 O.OOE+00 BA-139 1.84E+00 9.84E-04 5.37E-02 O.OOE+00 8.62E-04 5.77E+03 5.77E+04 O.OOE+00 BA-140 7.40E+04 6.48E+01 4.33E+03 O.OOE+00 2.11E+01 1.74E+06 1.02E+05 O.OOE+00 LA-140 6.44E+02 2.25E+02 7.55E+01 O.OOE+00 O.OOE+00 1.83E+05 2.26E+05 O.OOE+00 BA-141 1.96E-01 1.09E-04 6.36E-03 O.OOE+00 9.47E-05 2.92E+03 2.75E+02 O.OOE+00 LA-141 8.47E+00 1.96E+00 4.26E-01 O.OOE+00 O.OOE+00 1.66E+04 1.62E+05 O.OOE+00 CE-141 3.92E+04 1.95E+04 2.90E+03 O.OOE+00 8.55E+03 5.44E+05 5.66E+04 O.OOE+00 BA-142 5.00E-02 3.60E-05 2.79E-03 O.OOE+00 2.91 E-05 1.64E+03 2.74E+00 O.OOE+00 LA- 142 1.30E+00 4.11E-01 1.29E-01 O.OOE+00 0.OOE+00 8.70E+03 7.59E+04 O.OOE+00 CE-143 3.66E+02 1.99E+02 2.88E+01 O.OOE+00 8.36E+01 1.15E+05 1.27E+05 O.OE+00 PR-143 1.85E+04 5.55E+03 9.14E+02 O.OOE+00 3.OOE+03 4.33E+05 9.73E+04 O.OOE+00 CE-144 6.77E+06 2.12E+06 3.62E+05 O.OOE+00 1.17E+06 1.20E+07 3.89E+05 O.OOE+00 PR-144 5.96E-02 1.85E-02 3.OOE-03 O.OOE+00 9.77E-03 1.57E+03 1.97E+02 O.OOE+00 ND-147 1.08E+04 8.73E+03 6.81E+02 O.OE+00 4.81E+03 3.28E+05 8.21E+04 O.OOE+00 PM-147 1.30E+06 9.32E+04 5.03E+04 O.OOE+00 1.65E+05 8.14E+05 2.11E+04 O.OOE+00 PM-148M 1.22E+05 2.42E+04 2.42E+04 O.OOE+00 3.60E+04 2.12E+06 1.32E+05 O.OOE+00 PM-148 5.96E+03 7.18E+02 4.63E+02 O.OOE+00 1.22E+03 4.59E+05 2.22E+05 O.OOE+00 PM-149 5.44E+02 5.77E+01 3.13E+01 O.OOE+00 1.02E+02 8.88E+04 1.08E+05 O.OOE+00 PM-151 1.32E+02 1.60E+01 1.04E+01 O.OOE+00 2.72E+01 4.59E+04 9.55E+04 O.OOE+00 SM-151 1.16E+06 1.76E+05 5.51E+04 O.OOE+00 1.81E+05 5.48E+05 1.27E+04 O.OOE+00 SM-153 2.68E+02 1.67E+02 1.61E+01 O.OE+00 5.07E+01 5.07E+04 6.92E+04 O.00E+00 EU-152 2.75E+06 5.07E+05 5.96E+05 O.OOE+00 2.12E+06 3.33E+06 4.22E+04 O.OOE+00 EU-154 1.01E+07 9.21E+05 8.40E+05 O.OOE+00 4.03E+06 6.14E+06 1.10E+05 O.OOE+00 EU-155 2.07E+06 1.50E+05 1.18E+05 O.OOE+00 5.59E+05 1.03E+06 1.99E+05 O.OOE+00 EU-156 2.92E+04 1.57E+04 3.24E+03 O.OOE+00 1.01E+04 9.40E+05 1.57E+05 O.OOE+00 TB-160 2.88E+05 O.OOE+00 3.58E+04 O.OOE+00 8.58E+04 1.98E+06 8.44E+04 O.OOE+00 HO-166M 4.96E+06 1.04E+06 8.77E+05 O.OOE+00 1.48E+06 4.18E+06 6.03E+04 O.OOE+00 W-181 9.84E+01 2.41E+01 3.33E+00 O.OOE+00 O.OOE+00 2.11E+04 9.66E+02 O.OOE+00 W-185 3.07E+03 7.70E+02 1.08E+02 0.O0E+00 O.OOE+00 6.88E+05 4.11E+04 0.00E+00 W-187 1.63E+01 9.66E+00 4.33E+00 O.OOE+00 O.OOE+00 4.11E+04 9.10E+04 O.OOE+00 NP-239 4.66E+02 3.35E+01 2.35E+01 O.OOE+00 9.73E+01 5.81 E+04 6.40E+04 0.00E+00 U-232 8.1OE+08 O.OOE+00 5.77E+07 O.OOE+00 6.18E+07 2.75E+09 1.60E+05 O.OOE+00 U-233 1.72E+08 O.OOE+00 1.04E+07 O.OOE+00 2.82E+07 6.55E+08 1.48E+05 O.0OE+00 U-234 1.65E+08 O.OOE+00 1.02E+07 O.OOE+00 2.76E+07 6.44E+08 1.45E+05 O.OOE+00 U-235 1.58E+08 O.OOE+00 9.58E+06 O.OOE+00 2.59E+07 6.03E+08 1.84E+05 O.OOE+00 U-236 1.58E+08 O.OOE+00 9.81E+06 O.OOE+00 2.65E+07 6.18E+08 1.36E+05 O.OOE+00 U-237 5.81E+02 O.OOE+00 1.54E+02 O.OOE+00 1.68E+03 1.26E+05 4.77E+04 O.OOE+00 U-238 1.51 E+08 O.OOE+00 8.95E+06 O.OOE+00 2.42E+07 5.66E+08 1.30E+05 O.OOE+00 NP-237 1.01E+10 6.66E+08 4.40E+08 O.OOE+00 2.74E+09 6.44E+08 1.87E+05 O.OOE+00 NP-238 4.66E+03 9.47E+01 7.29E+01 O.OOE+00 3.02E+02 1.25E+05 9.25E+04 O.OOE+00 PU-238 1.68E+10 1.97E+09 4.48E+08 O.OOE+00 1.65E+09 2.25E+09 1.72E+05 O.OOE+00 PU-239 1.84E+10 2.07E+09 4.74E+08 O.OOE+00 1.77E+09 2.12E+09 1.57E+05 O.OOE+00

CY-LG-170-301, Rev. 23 Page 212 08/07 TABLE 112-2 Ri DOSE FACTORS Age: Child Pathway: Inhalation (Continued)

NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG GI-LLI SKIN PU-240 1.83E+10 2.07E+09 4.70E+08 0.OOE+00 1.76E+09 2.11E+09 1.60E+05 0.OOE+00 PU-241 5.22E+08 2.16E+07 1.08E+07 0.OOE+00 4.07E+07 1.87E+06 3.29E+03 0.0OE+00 PU-242 1.70E+10 1.99E+09 4.55E+08 0.OOE+00 1.70E+09 2.04E+09 1.54E+05 0.OOE+00 PU-244 1.99E+10 2.28E+09 5.22E+08 0.OOE+00 1.95E+09 2.33E+09 2.29E+05 0.OOE+00 AM-241 6.11E+09 5.29E+09 4.59E+08 0.OOE+00 2.82E+09 7.47E+08 1.75E+05 0.OOE+00 AM-242M 6.29E+09 5.07E+09 4.70E+08 0,OOE+00 2.85E+09 3.01 E+08 2.21E+05 O.OOE+00 AM-243 6.03E+09 5.14E+09 4.44E+08 0.OOE+00 2.75E+09 7.10E+08 2.05E+05 0.OOE+00 CM-242 2.33E+08 1.87E+08 1.55E+07 0.OOE+00 4.96E+07 4.85E+08 1.87E+05 0.OOE+00 CM-243 5.74E+09 4.70E+09 3.68E+08 0.OOE+00 1.38E+09 7.77E+08 1.84E+05 0.OOE+00 CM-244 4.77E+09 3.89E+09 3.07E+08 0.OOE+00 1.13E+09 7.47E+08 1.78E+05 0.OOE+00 CM-245 7.51E+09 6.07E+09 4.74E+08 0.OOE+00 1.86E+09 7.22E+08 1.66E+05 0.OOE+00 CM-246 7.44E+09 6.07E+09 4.74E+08 0.OOE+00 1.86E+09 7.36E+08 1,63E+05 0.OOE+00 CM-247 7.25E+09 5.99E+09 4.66E+08 0.OOE+00 1.83E+09 7.22E+08 2.15E+05 0.OOE+00 CM-248 6.03E+10 4.92E+10 3.85E+09 0.OOE+00 1.51E+10 5.96E+09 3.46E+06 0.OOE+00 CF-252 1.43E+10 0.OOE+00 3.45E+08 0.OOE+00 0.OOE+00 2.45E+09 6.81E+05 0.OOE+00

CY-LG-170-301, Rev. 23 Page 213 08/07 TABLE 112-2 Ri DOSE FACTORS Age: Infant Pathway: Ground NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG GI-LLI SKIN H-3 0.OOE+00 O.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 C-14 0.OOE+00 0.OOE+00 0.0OE+00 0.OOE+00 0.OOE+00 0.00E+00 0.OOE+00 0.OOE+00 NA-22 1.16E+10 1.16E+10 1.16E+10 1.16E+10 1.16E+10 1.16E+10 1.16E+10 1.30E+10 NA-24 1.19E+07 1.19E+07 1.19E+07 1.19E+07 1.19E+07 1.19E+07 1.19E+07 1.39E+07 P-32 O.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 CA-41 1.32E+10 1.32E+10 1.32E+10 1.32E+10 1.32E+10 1.32E+10 1.32E+10 1.55E+10 SC-46 8.33E+08 8.33E+08 8.33E+08 8.33E+08 8.33E+08 8.33E+08 8.33E+08 9.61E+08 CR-51 4.66E+06 4.66E+06 4.66E+06 4.66E+06 4.66E+06 4.66E+06 4.66E+06 5.51E+06 MN-54 1.39E+09 1.39E+09 1.39E+09 1.39E+09 1.39E+09 1.39E+09 1.39E+09 1.63E+09 FE-55 O.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 MN-56 9.03E+05 9.03E+05 9.03E+05 9.03E+05 9.03E+05 9.03E+05 9.03E+05 1.07E+06 CO-57 4.92E+07 4.92E+07 4.92E+07 4.92E+07 4.92E+07 4.92E+07 4.92E+07 5.41 E+07 CO-58 3.79E+08 3.79E+08 3.79E+08 3.79E+08 3.79E+08 3.79E+08 3.79E+08 4.44E+08 FE-59 2.73E+08 2.73E+08 2.73E+08 2.73E+08 2.73E+08 2.73E+08 2.73E+08 3.21 E+08 CO-60 2.32E+10 2.32E+10 2.32E+10 2.32E+10 2.32E+10 2.32E+10 2.32E+10 2.73E+10 NI-59 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 O.0OE+00 0.OOE+00 0.OOE+00 NI-63 0.OOE+00 0.OOE+00 O.0OE+00 0.OOE+00 0.OOE+00 0.O0E+00 0.OOE+00 O.OOE+00 CU-64 6.07E+05 6.07E+05 6.07E+05 6.07E+05 6.07E+05 6.07E+05 6.07E+05 6.88E+05 NI-65 2.97E+05 2.97E+05 2.97E+05 2.97E+05 2.97E+05 2.97E+05 2.97E+05 3.45E+05 ZN-65 7.47E+08 7.47E+08 7.47E+08 7.47E+08 7.47E+08 7.47E+08 7.47E+08 8.59E+08 ZN-69M 1.27E+06 1.27E+06 1.27E+06 1.27E+06 1.27E+06 1.27E+06 1.27E+06 1.49E+06 ZN-69 0.OOE+00 0.OOE+00 0.O0E+00 0.OOE+00 0.OOE+00 O.0OE+00 0.OOE+00 0.OOE+00 SE-79 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 BR-82 2.14E+07 2.14E+07 2.14E+07 2.14E+07 2.14E+07 2.14E+07 2.14E+07 2.47E+07 BR-83 4.87E+03 4.87E+03 4.87E+03 4.87E+03 4.87E+03 4.87E+03 4.87E+03 7.08E+03 BR-84 2.03E+05 2.03E+05 2.03E+05 2.03E+05 2.03E+05 2.03E+05 2.03E+05 2.36E+05 BR-85 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.00E+00 0.OOE+00 0.OOE+00 RB-86 8.99E+06 8.99E+06 8.99E+06 8.99E+06 8.99E+06 8.99E+06 8.99E+06 1.03E+07 RB-87 0.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 RB-88 3.31E+04 3.31 E+04 3.31E+04 3.31 E+04 3.31 E+04 3.31E+04 3.31E+04 3.78E+04 RB-89 1.23E+05 1.23E+05 1.23E+05 1.23E+05 1.23E+05 1.23E+05 1.23E+05 1.48E+05 SR-89 2.16E+04 2.16E+04 2.16E+04 2.16E+04 2.16E+04 2.16E+04 2.16E+04 2.51E+04 SR-90 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 Y-90 4.49E+03 4.49E+03 4.49E+03 4.49E+03 4.49E+03 14.49E+03 4.49E+03 5.31 E+03 SR-91 2.15E+06 2.15E+06 2.15E+06 2.15E+06 2.15E+06 2.15E+06 2.15E+06 2.51E+06 Y-91M 1.OOE+05 1.OOE+05 1.00E+05 1.0OE+05 1.OOE+05 1.OOE+05 1.OOE+05 1.16E+05 Y-91 1.07E+06 1.07E+06 1.07E+06 1:07E+06 1.07E+06 1.07E+06 1.07E+06 1.21E+06 SR-92 7.77E+05 7.77E+05 7.77E+05 7.77E+05 7.77E+05 7.77E+05 7.77E+05 8.63E+05 Y-92 1.80E+05 1.80E+05 1.80E+05 1.80E+05 1.80E+05 1.80E+05 1.80E+05 .2.14E+05 Y-93 1.83E+05 1.83E+05 1.83E+05 1.83E+05 1.83E+05 1.83E+05 1.83E+05 2.51E+05 NB-93M 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 NB-95 1.37E+08 1.37E+08 1.37E+08 1.37E+08 1.37E+08 1.37E+08 1.37E+08 1.61E+08 NB-97 2.07E+05 2.07E+05 2.07E+05 2.07E+05 2.07E+05 2.07E+05 2.07E+05 1.76E+05 ZR-93 0.OOE+00 O.OOE+00 O.OOE+00 -0.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00

CY-LG-1 70-301, Rev. 23 I Page 214 08/07 I TABLE 112-2 Ri DOSE FACTORS Age: Infant Pathway: Ground (Continued)

NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG GI-LLI SKIN ZR-95 2.45E+08 2.45E+08 2.45E+08 2.45E+08 2.45E+08 2.45E+08 2.45E+08 2.84E+08 ZR-97 2.96E+06 2.96E+06 2.96E+06 2.96E+06 2.96E+06 2.96E+06 2.96E+06 3.44E+06 MO-93 8.84E+07 8.84E+07 8.84E+07 8.84E+07 8.84E+07 8.84E+07 8.84E+07 3.60E+09 MO-99 3.99E+06 3.99E+06 3.99E+06 3.99E+06 3.99E+06 3.99E+06 3.99E+06 4.63E+06 TC-99 0.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 TC-99M 1.84E+05 1.84E+05 1.84E+05 1.84E+05 1.84E+05 1.84E+05 1.84E+05 2.11 E+05 TC-101 2.04E+04 2.04E+04 2.04E+04 2.04E+04 2.04E+04 2.04E+04 2.04E+04 2.26E+04 RU-103 1.08E+08 1.08E+08 1.08E+08 1.08E+08 1.08E+08 1.08E+08 1.08E+08 1.26E+08 I RU-105 6.36E+05 6.36E+05 6:36E+05 6.36E+05 6.36E+05 6.36E+05 6.36E+05 7.21E+05 RU-106 4.22E+08 4.22E+08 4.22E+08 4.22E+08 4.22E+08 4.22E+08 4.22E+08 5.07E+08 RH-105 2.11E+09 2.11E+09 2.11E+09 2.11E+09 2.11E+09 2.11E+09 2.11E+09 2.46E+09 PD-107 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 PD-109 1.50E+04 1.50E+04 1.50E+04 1.50E+04 1.50E+04 1.50E+04 1.50E+04 1.71E+04 AG-110M 2.86E+09 2.86E+09 2.86E+09 2.86E+09 2.86E+09 2.86E+09 2.86E+09 4.01E+09 AG-1 11 1.03E+06 1.03E+06 1.03E+06 1.03E+06 1.03E+06 1.03E+06 1.03E+06 1.20E+06 CD-1 13M 5.60E+06 5.60E+06 5.60E+06 5.60E+06 5.60E+06 5.60E+06 5.60E+06 6.33E+06 CD-115M O.OOE+00 O.OOE+00 O.OOE+00 0.00E+O0 O.OOE+00 O.OOE+00 O.OOE+00 0.OOE+00 SN-123 O.OOE+00 O.OOE+00 O.OOE+00 O.00E+00 O.OOE+00 O.OOE+00 O.OOE+00 6.38E+09 SN-125 4.20E+06 4.20E+06 4.20E+06 4.20E+06 4.20E+06 4.20E+06 4.20E+06 4.86E+06 SN-126 3.48E+10 3.48E+10 3.48E+10 3.48E+10 3.48E+10 3.48E+10 3.48E+10 3.87E+10 SB-124 5.98E+08 5.98E+08 5.98E+08 5.98E+08 5.98E+08 5.98E+08 5.98E+08 6.90E+08 SB-125 2.38E+09 2.38E+09 2.38E+09 2.38E+09 2.38E+09 2.38E+09 2.38E+09 2.69E+09 SB-126 8.44E+07 8.44E+07 8.44E+07 8.44E+07 8,44E+07 8.44E+07 8.44E+07 9.48E+07 SB-127 1.68E+07 1.68E+07 1.68E+07 1,68E+07 1.68E+07 1.68E+07 1.68E+07 1.94E+07 TE-125M 1.55E+06 1.55E+06 1.55E+06 1.55E+06 1.55E+06 1.55E+06 1.55E+06 2.13E+06 TE-127M 9.16E+04 9.16E+04 9.16E+04 9.16E+04 9.16E+04 9.16E+04 9.16E+04 1.08E+05 TE-127 2.98E+03 2.98E+03 2.98E+03 2.98E+03 2.98E+03 2.98E+03 2.98E+03 3.28E+03 TE-129M 1.98E+07 1.98E+07 1*98E+07 1.98E+07 1.98E+07 1.98E+07 1.98E+07 2.31E+07 TE-129 2.62E+04 2.62E+04 2.62E+04 2.62E+04 2.62E+04 2.62E+04 2.62E+04 3.1OE+04 TE-133M 4.41E+05 4.41E+05 4.41E+05 4.41E+05 4.41E+05 4.41E+05 4.41E+05 5.OOE+05 TE-134 2.22E+04 2.22E+04 2.22E+04 2.22E+04 2.22E+04 2.22E+04 2.22E+04 2.66E+04 1-129 1.74E+09 1.74E+09 1.74E+09 1.74E+09 1.74E+09 1.74E+09 1.74E+09 2.90E+09 1-130 5.51 E+06 5.51 E+06 5.51 E+06 5.51 E+06 5.51 E+06 5.51 E+06 5.51 E+06 6.69E+06 1-131 1.72E+07 1.72E+07 1.72E+07 1.72E+07 1.72E+07 1.72E+07 1.72E+07 2.09E+07 TE-131M 8.03E+06 8.03E+06 8.03E+06 8.03E+06 8.03E+06 8.03E+06 8.03E+06 9.46E+06 TE-131 2.92E+04 2.92E+04 2.92E+04 2.92E+04 2.92E+04 2.92E+04 2.92E+04 3.45E+07 1-132 1.25E+06 1.25E+06 1.25E+06 1.25E+06 1.25E+06 1.25E+06 1.25E+06 1.46E+06 TE-132 4.23E+06 4.23E+06 4.23E+06 4.23E+06 4.23E+06 4.23E+06 4.23E+06 4.98E+06 1-133 2.45E+06 2.45E+06 2.45E+06 2.45E+06 2.45E+06 2.45E+06 2.45E+06 2.98E+06 CS-134M 4.80E+04 4.80E+04 4.80E+04 4.80E+04 4.80E+04 4.80E+04 4.80E+04 6.74E+04 CS-134 6.90E+09 6.90E+09 6.90E+09 6.90E+09 6.90E+09 6.90E+09 6.90E+09 8.05E+09 1-134 4.47E+05 4.47E+05 4.47E+05 4.47E+05 4.47E+05 4.47E+05 4.47E+05 5.30E+05 1-135 2.53E+06 2.53E+06 2.53E+06 2.53E+06 2.53E+06 2.53E+06 2.53E+06 2.95E+06 CS-135 5.80E+10 5.80E+10 5.80E+10 5.80E+10 5.80E+10 5.80E+10 5.80E+10 6.58E+10 CS-136 1.51E+08 1.51E+08 1.51E+08 1.51E+08 1.51E+08 1.51E+08 1.51E+08 1.71E+08

CY-LG-170-301, Rev. 23 Page 215 08/07 TABLE 112-2 Ri DOSE FACTORS Age: Infant Pathway: Ground (Continued)

NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG GI-LLI SKIN CS-137 1.30E+10 1.30E+10 1.30E+10 1.30E+10 1.30E+10 1.30E+10 1.30E+10 1.52E+10 CS-138 3.59E+05 3.59E+05 3.59E+05 3.59E+05 3.59E+05 3.59E+05 3.59E+05 4.1OE+05 CS-139 3.14E+04 3.14E+04 3.14E+04 3.14E+04 3.14E+04 3.14E+04 3.14E+04 3.59E+04 BA-139 1.06E+05 1.06E+05 1.06E+05 1.06E+05 1.06E+05 1.06E+05 1.06E+05 1.19E+05 BA-140 2.05E+07 2.05E+07 2.05E+07 2.05E+07 2.05E+07 2.05E+07 2.05E+07 2.35E+07 LA- 140 1.92E+07 1.92E+07 1.92E+07 1.92E+07 1.92E+07 1.92E+07 1.92E+07 2.18E+07 BA-141 4.17E+04 4.17E+04 4.17E+04 4.17E+04 4.17E+04 4.17E+04 4.17E+04 4.75E+04 LA-141 3.14E+04 3.14E+04 3.14E+04 3.14E+04 3.14E+04 3.14E+04 3.14E+04 3.51E+04 CE-141 1.37E+07 1.37E+07 1.37E+07 1.37E+07 1.37E+07 1.37E+07 1.37E+07 1.54E+07 BA-142 4.49E+04 4.49E+04 4.49E+04 4.49E+04 4.49E+04 4.49E+04 4.49E+04 5.11 E+04 LA-142 7.60E+05 7.60E+05 7.60E+05 7.60E+05 7.60E+05 7.60E+05 7.60E+05 9.11E+05 CE-143 2.31E+06 2.31E+06 2.31E+06 2.31E+06 2.31E+06 2.31E+06 2.31E+06 2.63E+06 PR-143 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 CE-144 6.95E+07 6.95E+07 6.95E+07 6.95E+07 6.95E+07 6.95E+07 6.95E+07 8.04E+07 PR-144 1.83E+03 1.83E+03 1.83E+03 1.83E+03 1.83E+03 1.83E+03 1.83E+03 2.11E+03 ND-147 8.39E+06 8.39E+06 8.39E+06 8.39E+06 8.39E+06 8.39E+06 8.39E+06 1.01E+07 PM-147 O.OOE+00 O.OOE+00 0.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 PM-148M 4.45E+08 4.45E+08 4.45E+08 4.45E+08 4.45E+08 4.45E+08 4.45E+08 2.58E+09 PM-148 1.45E+08 1.45E+08 1.45E+08 1.45E+08 1.45E+08 1.45E+08 1.45E+08 1,67E+08 PM-149 4.23E+04 4.23E+04 4.23E+04 4.23E+04 4.23E+04 4.23E+04 4.23E+04 4.90E+04 PM-151 1.99E+06 1.99E+06 1.99E+06 1.99E+06 1.99E+06 1.99E+06 1.99E+06 2.08E+06 SM-151 1.72E+08 1.72E+08 1.72E+08 1,72E+08 1.72E+08 1.72E+08 1.72E+08 7.53E+08 SM-153 4.02E+05 4.02E+05 4.02E+05 4.02E+05 4.02E+05 4.02E+05 4.02E+05 4.46E+05 EU-152 1.79E+10 1.79E+10 1.79E+10 1.79E+10 1.79E+10 1.79E+10 1.79E+10 2.07E+10 EU-154 1.52E+10 1.52E+10 1.52E+10 1.52E+10 1.52E+10 1.52E+10 1.52E+10 1.75E+10 EU-155 4.95E+08 4.95E+08 4.95E+08 4.95E+08 4,95E+08 4.95E+08 4.95E+08 5.63E+08 EU-156 8.82E+07 8.82E+07 8.82E+07 8.82E+07 8.82E+07 8.82E+07 8.82E+07 1.01E+08 TB-160 4.75E+08 4.75E+08 4.75E+08 4.75E+08 4.75E+08 4.75E+08 4.75E+08 5.53E+08 HO-166M 3.42E+10 3.42E+10 3.42E+10 3.42E+10 3.42E+10 3.42E+10 3.42E+10 3.85E+10 W-181 1.94E+05 1.94E+05 1.94E+05 1.94E+05 1.94E+05 1.94E+05 1.94E+05 2.13E+05 W-185 O.OE+00 O.OOE+00 O.OOE+00 O.OOE+00 0.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 W-187 2.35E+06 2.35E+06 2.35E+06 2.35E+06 2.35E+06 2.35E+06 2.35E+06 2.73E+06 NP-239 1.71E+06 1.71E+06 1.71E+06 1.71E+06 1.71E+06 1.71E+06 1.71E+06 1.98E+06 U-232 9.12E+06 9.12E+06 9.12E+06 9.12E+06 9.12E+06 9.12E+06 9.12E+06 9.47E+07 U-233 8.90E+09 8.90E+09 8.90E+09 8.90E+09 8.90E+09 8.90E+09 8.90E+09 1.08E+10 U-234 2.45E+06 2.45E+06 2.45E+06 2.45E+06 2.45E+06 2.45E+06 2.45E+06 6.15E+08 U-235 1.24E+10 1.24E+10 1.24E+10 1.24E+10 1.24E+10 1.24E+10 1.24E+10 1.55E+10 U-236 8.13E+04 8.13E+04 8.13E+04 8.13E+04 8.13E+04 8.13E+04 8.13E+04 6.96E+07 U-237 5.16E+06 5.16E+06 5.16E+06 5.16E+06 5.16E+06 5.16E+06 5.16E+06 6.71E+06 U-238 4.26E+08 4.26E+08 4.26E+08 4.26E+08 4.26E+08 4.26E+08 4.26E+08 5.80E+08 NP-237 5.42E+09 5.42E+09 5.42E+09 5.42E+09 5.42E+09 5.42E+09 5.42E+09 6.19E+09 NP-238 4.53E+06 4.53E+06 4.53E+06 4.53E+06 4.53E+06 4.53E+06 4.53E+06 5.18E+06 PU-238 4.65E+06 4.65E+06 4.65E+06 4.65E+06 4.65E+06 4.65E+06 4.65E+06 6.44E+07 PU-239 3.06E+06 3.06E+06 3.06E+06 3.06E+06 3.06E+06 3.06E+06 3.06E+06 2.98E+07

CY-LG-1 70-301, Rev. 23 I Page 216 08/07 TABLE 112-2 Ri DOSE FACTORS Age: Infant Pathway: Ground (Continued)

NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG GI-LLI SKIN PU-240 5.02E+06 5.02E+06 5.02E+06 5.02E+06 5.02E+06 5.02E+06 5.02E+06 6.96E+07 PU-241 1,14E+07 1.14E+07 1.14E+07 1.14E+07 1.14E+07 1.14E+07 1.14E+07 1.69E+07 PU-242 4.26E+06 4.26E+06 4.26E+06 4.26E+06 4.26E+06 4.26E+06 4.26E+06 6.19E+07 PU-244 3.46E+09 3.46E+09 3.46E+09 3.46E+09 3.46E+09 3.46E+09 3.46E+09 3.72E+09 AM-241 6.85E+08 6.85E+08 6.85E+08 6.85E+08 6.85E+08 6.85E+08 6.85E+08 9.90E+08 AM-242M 9.62E+07 9.62E+07 9.62E+07 9.62E+07 9.62E+07 9.62E+07 9.62E+07 6.66E+08 AM-243 5.03E+09 5.03E+09 5.03E+09 5.03E+09 5.03E+09 5.03E+09 5.03E+09 5.80E+09 CM-242 6.86E+05 6.86E+05 6.86E+05 6.86E+05 6.86E+05 6.86E+05 6.86E+05 2.87E+06 CM-243 7.05E+09 7.05E+09 7.05E+09 7.05E+09 7.05E+09 7.05E+09 7.05E+09 8.89E+09 CM-244 7.84E+06 7.84E+06 7.84E+06 7.84E+06 7.84E+06 7.84E+06 7.84E+06 4.87E+07 CM-245 3.67E+09 3.67E+09 3.67E+09 3.67E+09 3.67E+09 3.67E+09 3.67E+09 4.64E+09 CM-246 3.86E+06 3.86E+06 3.86E+06 3.86E+06 3.86E+06 3.86E+06 3.86E+06 5.80E+07 CM-247 8.51E+09 8.51E+09 8.51E+09 8.51E+09 8.51E+09 8.51E+09 8.51E+09 1.01E+10 CM-248 2.63E+10 2.63E+10 2.63E+10 2.63E+10 2.63E+10 2.63E+10 2.63E+10 2.02E+10 CF-252 4.84E+10 4.84E+10 4.84E+10 4.84E+10 4.84E+10 4.84E+10 4.84E+10 5.28E+10

CY-LG-1 70-301, Rev. 23 I Page 217 08/07 I TABLE 112-2 Ri DOSE FACTORS Age: Infant Pathway: Vegetation NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG GI-LLI SKIN I H-3 0.OOE+00 O.OOE+00 0.OOE+00 0.O0E+00 #VALUE! 0.OOE+00 O.OOE+00 0.0OE+00 I C-14 0.OOE+00 00OE+00 0.OOE+00 0.00E+00 0.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 I NA-22 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 O.OOE+00 0.OOE+00 I NA-24 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 I P-32 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.0OE+00 CA-41 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 SC-46 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 CR-51 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 MN-54 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 FE-55 0.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 MN-56 0,O0E+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.00E+00 0.OOE+00 O.OOE+00 CO-57 0,OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 CO-58 0.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 FE-59 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 CO-60 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 0.O0E+00 NI-59 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.O0E+00 0.OOE+00 0.OOE+00 0.OOE+00 NI-63 0.OOE+00 0.OOE+00 0.00E+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 CU-64 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 NI-65 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 ZN-65 O.0OE+00 O.OOE+00 0.OOE+00 0.OOE+00 0O00E+00 O.OOE+00 0.OOE+00 0.00E+00 ZN-69M O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.00E+00 ZN-69 0.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 SE-79 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 BR-82 0.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 BR-83 0.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 BR-84 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 O.OOE+0.0 BR-85 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 RB-86 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 RB-87 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 RB-88 0.OOE+00 0.OOE+00 O.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 RB-89 0.OOE+00 0.OOE+00 O.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 SR-89 0.OOE+00 O.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 SR-90 0.OOE+00 O.OE+00 0.OOE+00 0.OOE+00 O.OOE+00 0.0OE+00 0.OOE+00 0.OOE+00 Y-90 0.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.0OE+00 0.OOE+00 O.OOE+00 SR-91 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 Y-91 M O.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 Y-91 0.O0E+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 SR-92 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 0.0OE+00 Y-92 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 Y-93 O.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.O0E+00 0.OOE+00 0.OOE+00 NB-93M 0.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 NB-95 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 NB-97 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 ZR-93 0.OOE+00 0.OOE+00 0.OOE+00 0.00E+00' 0.O0E+00 0.OOE+00 0.OOE+00 0.OOE+00

CY-LG-170-301, Rev. 23 I Page 218 08/07 I TABLE 112-2 Ri DOSE FACTORS Age: Infant Pathway: Vegetation (Continued)

NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG GI-LLI SKIN ZR-95 0.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 ZR-97 0.OOE+00 O.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.O0E+00 O.OOE+00 MO-93 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 MO-99 O.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 TC-99 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 TC-99M 0.OOE+00 0.OOE+00 O.OOE+00 O.OOE+00 0.0OE+00 0.OOE+00 0.OOE+00 0.OOE+00 TC-101 0.0OE+00 0.OOE+00 O.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 RU-103 0.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 RU-105 0.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 RU-106 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 RH-105 0.OOE+00 0.OOE+00 O.OOE+00 0.00E+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 PD-107 0.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 PD-109 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 AG-110M O.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 AG-1 11 0.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 CD-1 13M 0.00E+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.0OE+00 0.OOE+00 CD-1 15M 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.0OE+00 0.OOE+00 SN-123 0.OOE+00 0.OOE+00 0.00E+00 O.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 SN-125 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 SN-126 0.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 SB-124 O.OOE+00 O.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 SB-125 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 SB-126 0.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 SB-127 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 TE-125M 0.OOE+00 0.OOE+00 O.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 TE-127M 0.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 TE-127 O.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 TE-129M 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 TE-129 0.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 TE-133M O.OOE+00 O.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 TE-134 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 1-129 0.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 1-130 0.OOE+00 0.OOE+00 O.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 00OE+00 0.OOE+00 1-131 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 0.O0E+00 O.OOE+00 TE-131M O.OOE+00 O.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 O.00E+00 0.O0E+00 O.0OE+00 TE-131 0.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.0OE+00 1-132 O.OOE+00 O.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 0o00E+00 0.OOE+00 O.OOE+00 TE-132 0.OOE+00 0.00E+00 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 1-133 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 CS-134M 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 CS-134 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 1-134 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 1-135 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 CS-135 O.OOE+00 0.OOE+00 0,00E+00 0.OOE+00 O.OOE+00 O.OOE+00 0.OOE+00 0,OOE+00 CS-136 0.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00

CY-LG-1 70-301, Rev. 23 Page 219 08/07 TABLE 112-2 Ri DOSE FACTORS Age: Infant Pathway: Vegetation (Continued)

NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG GI-LLI SKIN CS-137 O.0OE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 CS-138 O.OOE+00 O.OOE+00 O.OOE+00 O0OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 CS-139 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 BA-139 O.OOE+00 O.OE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 BA-140 O.OOE+00 O.OOE+00 O.0OE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 LA-140 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OE+00 O.OOE+00 O.OOE+00 O.OOE+00 BA-141 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 Q.OOE+00 O.OOE+00 O.OOE+00 LA-141 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OQE+00 CE-141 O.OOE+00 O.OOE+00 O.OOE+00 O.0OE+00 O.OOE+00 O.OOE+00 O0OOE+00 O.OOE+00 BA-142 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 LA-142 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 CE-143 O.OOE+00 O.OOE+00 O0OOE+00 O.OOE+00 O.OOE+00 O.0OE+00 O.OOE+00 O.OE+00 PR-143 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 0.OOE+00 000E+00 CE-144 O.OOE+00 0.00E+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 OOQE+00 PR-144 O.OE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 ND-147 O.OOE+00 O.OOE+00 O.OOE+00 O.OE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 PM-147 O.OQE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OE+00 O.OOE+00 PM-148M O.OE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 PM-148 O.OOE+00 O.OOE+00 O.OE+00 O.OOE+00 O.OOE+00 O.OOE+00 0.OOE+00 O.OOE+00 PM-149 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 PM-151 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 0.OOE+00 O.OOE+00 O.OQE+00 SM-151 O.0OE+00 O.QOE+00 O.OOE+00 O.OOE+00 O.OE+00 O.OOE+00 O.OOE+00 O.OOE+00 SM-153 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 Q.OOE+00 EU-152 O.OOE+00 O.OOE+00 O.OOE+00 0.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 Q.OOE+00 EU-154 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 EU-155 O.OOE+00 O.OOE+00 O.0OE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 EU-156 O.OOE+00 O.OOE+00 O.0OE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 TB-160 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OE+00 HO-166M O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 W-181 OOOE+00 O.OOE+00 O.OOE+00 O.OOE+00 0.OE+00 O.OOE+00 O.OOE+00 O.OOE+00 W-185 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 W-187 O.OOE+00 O.OOE+00 O.OOE+00 0.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 NP-239 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 U-232 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 U-233 O.OE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 U-234 0.00E+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OE+00 O.OOE+00 O.OOE+00 O.OOE+00 U-235 G.OOE+00 O.OOE+00 O.OOE+00 O.0OE+00 O.QOE+00 0.OOE+00 O.OOE+00 O.0OE+00 U-236 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.0OE+00 O.OOE+00 O.OOE+00 O.OOE+00 U-237 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OE+00 O.OOE+00 U-238 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.0OE+00 O.OOE+00 NP-237 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OE+00 O.OOE+00 O.OOE+00 O.OOE+00 NP-238 O.OOE+00 O.OE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 PU-238 O.OOE+00 O.OOE+00 O.OOE+00 O.00E+00 O.OOE+00 O.0OE+00 O.OOE+00 O.OOE+00 PU-239 O.0OE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OQE+00 O.OOE+00 O.OOE+00

CY-LG-170-301, Rev. 23 Page 220 08/07 TABLE 112-2 Ri DOSE FACTORS Age: Infant Pathway: Vegetation (Continued)

NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG GI-LLI SKIN PU-240 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OE+00 O.OOE+00 O.OOE+00 PU-241 O.OOE+00 O.OOE+00 O.0OE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 PU-242 0.OOE+00 O.OOE+00 O.0OE+00 O.OOE+00 O.OOE+00 O.OE+00 O.OOE+00 O.OOE+00 PU-244 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.0OE+00 O.OOE+00 O.OOE+00 AM-241 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 AM-242M O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 AM-243 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 CM-242 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.0OE+00 O.OOE+00 CM-243 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 CM-244 O.OOE+00 O.OOE+00 O.OOE+00 O.QOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 CM-245 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 CM-246 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 CM-247 O.OOE+00 0.OOE+00 O.OOE+00 O.00E+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 CM-248 O.OOE+00 0.OOE+00 O.OE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 CF-252 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 Q.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00

CY-LG-170-301, Rev. 23 Page 221 08/07 TABLE 112-2 Ri DOSE FACTORS Age: Infant Pathway: Meat NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG GI-LLI SKIN H-3 O.OOE+00 Q.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 C-14 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 0.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 NA-22 O.OOE+00 0.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 NA-24 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OE+00 P-32 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OE+00 O0OOE+00 O.OOE+00 CA-41 O.OOE+00 O.OOE+00 0.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OE+00 SC-46 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 CR-51 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 MN-54 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 OOOE+00 O.OOE+00 O.OOE+00 FE-55 O.OOE+00 O.OOE+00 O.OOE+00 O.0OE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 MN-56 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 CO-57 O.OE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OE+00 O.OOE+00 O.OOE+00 O.OOE+00 CO-58 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OE+00 O.OOE+00 O.OOE+00 0.OOE+00 FE-59 O.OE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 CO-60 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 NI-59 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 Q.0OE+00 O.OE+00 O.OOE+00 NI-63 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 CU-64 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OE+00 O.OOE+00 O.OOE+00 NI-65 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 ZN-65 O.QOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE00 O.OOE+00 O.OOE+00 O.OOE+00 ZN-69M O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 0.OOE+00 O.OE+00 O.OOE+00 ZN-69 O.OOE+00 O.0OE+00 O.OOE+00 O.OOE+00 O.OOE+00 0.00E+00 O.OOE+00 O.OOE+00 SE-79 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 BR-82 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 BR-83 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 BR-84 O.OOE+00 O.OOE+00 0.00E+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 BR-85 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 RB-86 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 RB-87 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 RB-88 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 RB-89 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 SR-89 O.0OE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 SR-90 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 Y-90 O.OOE+00 0.00E+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 SR-91 O.OOE+00 O.OOE+00 O.OOE+00 O0OOE+00 O.OOE+00 O.OOE+00 Q.OOE+00 O.OOE+00 Y-91M O.OOE+00 O.OOE+00 O.0OE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 Y-91 O.OOE+00 0.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OE+00 O.OOE+00 SR-92 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 Y-92 O.OOE+00 O.OE+00 O.OOE+00 O.OOE+00 0.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 Y-93 O.OOE+00 O.OE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 NB-93M O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 NB-95 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 NB-97 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 ZR-93 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00

CY-LG-170-301, Rev. 23 Page 222 08/07 TABLE 112-2 Ri DOSE FACTORS Age: Infant Pathway: Meat (Continued)

NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG GI-LLI SKIN ZR-95 0.OOE+00 O.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 ZR-97 0.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 MO-93 0.00E+00 0.OOE+00 0.O0E+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 MO-99 0.00E+00 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 TC-99 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 TC-99M 0.0OE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 O.OOE+00 TC-101 0.00E+00 0.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.0OE+00 RU-103 0.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 RU-105 0-00E+00 0.00E+00 0.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 RU-106 0.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 RH-105 0.OOE+00 O.OOE+00 0.OOE+00 0.OOE+0O 0.OOE+00 0.OOE+00 O.OOE+00 O.OOE+00 PD-107 0.OOE+00 O.OOE+00 0.OOE+00 O.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 PD-109 0.OOE+00 0.OOE+00 O.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 AG-110M 0.OOE+00 O.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 0.00E+00 0.OOE+00 0.OOE+00 AG-111 O.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 CD-113M O.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 CD-115M 0.OOE+00 O.0OE+00 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 SN-123 O.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 SN-125 0.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 SN-126 0.00E+00 0.OOE+00 0.OOE+00 0.00E+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 SB-124 0-00E+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 SB-125 0.00E+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 SB-126 0.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 0O.0E+00 0.OOE+00 0.OOE+00 O.OOE+00 SB-127 0.0E+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.0OE+00 0.OOE+00 TE-125M O.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 TE-127M 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 TE-127 0.00E+00 0.OOE+00 0.OOE+00 0.OOE+00 0.O0E+00 0.OOE+00 0.OOE+00 0.OOE+00 TE-129M 0.00E+00 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 TE-129 O.OOE+00 O.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 TE-133M 0.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 TE-134 0.00E+00 0.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 1-129 0.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 1-130 0.00E+00 0.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 1-131 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 O.OE+00 0.OOE+00 TE-131M O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 TE-131 0.00E+0 0.OO00E+00 0.00E+00 0.00E+00 0,00E+0O 0.OOE+00 0.OOE+00 0.OOE+00 1-132 0.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 TE-132 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 1-133 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 CS-134M 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 CS-134 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.0OE+00 0.OOE+00 0.OOE+00 0.OOE+00 1-134 0.00E+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 1-135 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 CS-135 0.00E+00 0.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 CS-136 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00

CY-LG-170-301, Rev. 23 Page 223 08/07 TABLE 112-2 Ri DOSE FACTORS Age: Infant Pathway: Meat (Continued)

NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG GI-LLI SKIN CS-1 37 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 0.OOE+00 CS-1 38 O.OOE+00 O.OOE+00 O.0OE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 CS-1 39 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 BA-139 O.OOE+00 O.OOE+00 O.OE+00 O.OOE+00 O.OOE+00 0,OQE+00 O.OOE+00 O.OOE+00 BA-140 O.OE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 0.OQE+00 O.OOE+00 O.OOE+00 LA-140 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 0.OOE+00 O.OOE+00 O:OOE+00 BA-141 O.OOE+00 O.0OE+00 O.OOE+00 O.OOE+00 O.OOE+00 O0OOE+00 O.OOE+00 O.OE+00 LA-141 O.OQE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 CE-141 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 BA-142 O.OOE+00 O.00E+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 .0.00E+00 LA-142 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 OOOE+00 O.OOE+00 O.OOE+00 CE-143 O.OOE+00 0.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 PR-143 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 0.OOE+00 O.OOE+00 O.OOE+00 CE-144 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 PR-144 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 ND-147 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 0.OOE+00 PM-147 O.OOE+00 O.OOE+00 O.0OE+00 O.OOE+00 O.OE+00 O.OOE+00 Q.OOE+00 O.OOE+00 PM-148M O.OE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 PM-148 O.OOE+00 O.OOE+00 O.OOE+00 O.OE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.0OE+00 PM-149 O.OOE+00 O.OOE+00 O.OOE+00 O.OE+00 O.OOE+00 O.OOE+00 0.00E+00 O.OOE+00 PM-151 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.0OE+00 O.OOE+00 O.OOE+00 SM-151 O.OOE+00 O.OOE+00 O.OOE+00 O0OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 SM-153 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 OO0E+00 EU-1 52 O.OOE+00 O.OOE+00 0.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 EU-154 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 EU-155 O.0OE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OE+00 O.OOE+00 O.OOE+00 O.OOE+00 EU-156 O.OOE+00 0.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 0.00E+00 TB-160 O.OOE+00 O.OOE+00 O.OOE+00 O.OE+00 0.OOE+00 O.OOE+00 O.OOE+00 0.OOE+00 HO-166M O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 OOOE+00 O.OOE+00 O.OOE+00 O.OOE+00 W-181 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 W-185 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 W-187 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 NP-239 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 U-232 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.QOE+00 O.OOE+00 O.OOE+00 O.OOE+00 U-233 O.OOE+00 Q.OOE+00 O.OOE+00 O.OOE+00 O.0OE+00 O.OOE+00 O.OOE+00 O.OOE+00 U-234 O.OOE+00 O.OOE+00 O.OOE+00 O.0OE+00 0.0OE+00 O.OOE+00 O.OOE+00 O.0OE+00 U-235 .OOE+00 O.OOE+00 O.OOE+00 O.0OE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 U-236 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 U-237 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 U-238 O.OOE+00 OOOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 NP-237 0.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 Q.OOE+00 O.OOE+00 O.OOE+00 NP-238 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 PU-238 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 PU-239 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 0.OOE+00 O.OOE+00 O.OOE+00

CY-LG-170-301, Rev. 23 Page 224 08/07 TABLE 112-2 Ri DOSE FACTORS Age: Infant Pathway: Meat (Continued)

NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG GI-LLi SKIN PU-240 O.OOE+00 O.OE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 0.OOE+00 PU-241 O.OOE+00 O.OOE+00 O.OOE+00 O.0OE+00 O.OOE+00 O0OOE+00 O.OOE+00 O.0OE+00 PU-242 O.OOE+00 O.OE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.0OE+00 O.0OE+00 PU-244 O.OOE+00 O.OOE+00 O.OOE+00 0.00E+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 AM-241 O.OOE+00 O.OE+00 O.OOE+00 0.00E+00 O.OOE+00 O.OOE+00 0,00E+00 O.OOE+00 AM-242M O.OOE+00 O.OE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OE+00 O.OOE+00 O.OOE+00 AM-243 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 0.OOE+00 O.OE+00 O.OOE+00 O.OOE+00 CM-242 O.OOE+00 O.OE+00 O.OOE+00 O.OOE+00 0.OOE+00 OOOE+00 0.00E+00 O.OQE+00 CM-243 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 0.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 CM-244 Q.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 0.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 CM-245 0.OOE+00 O.OOE+00 O.OOE+00 O.OQE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 CM-246 0.OOE+00 0.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 CM-247 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 CM-248 O.OOE+00 ' O.OOE+00 O.OOE+00 O.OQE+00 O.OOE+00 O.OOE+00 0.00E+00 O.OOE+00 CF-252 O.OOE+00 O.OOE+00 O.OOE+00 0.00E+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00

CY-LG-170-301, Rev. 23 Page 225 08/07 TABLE 112-2 Ri DOSE FACTORS Age: Infant Pathway: Cow Milk NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG GI-LLI SKIN H-3 0.00E+00 2.38E+03 2.38E+03 2.38E+03 2.38E+03 2.38E+03 2.38E+03 0.00E+00 C-14 3.23E+06 6.89E+05 6.89E+05 6.89E+05 6.89E+05 6.89E+05 6.89E+05 0.OOE+00 NA-22 1.67E+10 1.67E+10 1.67E+10 1.67E+10 1.67E+10 1.67E+10 1.67E+10 0.OOE+00 NA-24 4.51E+06 4.51 E+06 4.51 E+06 4.51 E+06 4.51 E+06 4.51 E+06 4.51 E+06 0.OOE+00 P-32 7.37E+09 2.79E+09 1.84E+09 0.OOE+00 0.OOE+00 0.OOE+00 6.41 E+08 0.OOE+00 CA-41 1.33E+10 0.OOE+00 1.45E+09 0.OOE+00 0.OOE+00 0.OOE+00 6.79E+06 0.OOE+00 SC-46 5.33E+02 7.69E+02 2.40E+02 0.OOE+00 5.06E+02 0.OOE+00 5.02E+05 0.OOE+00 CR-51 0.00E+00 0.OOE+00 5.14E+04 3.35E+04 7.32E+03 6.52E+04 1.50E+06 0.OOE+00 MN-54 0.00E+00 1.93E+07 4.38E+06 0.OOE+00 4.28E+06 0.OOE+00 7.10E+06 0.OOE+00 FE-55 7.09E+07 4.58E+07 1.22E+07 0.OOE+00 0.OOE+00 2.24E+07 5.82E+06 0.00E+00 MN-56 0.00E+00 9.19E-03 1.58E-03 0.OOE+00 7.90E-03 0.00E+00 8.35E-01 0.00E+00 CO-57 0.00E+00 3.06E+06 4.98E+06 0.OOE+00 0.OOE+00 0.00E+00 1.04E+07 0.OOE+00 CO-58 0.00E+00 9.58E+06 2.39E+07 0.OOE+00 0.OOE+00 0.OOE+00 2.39E+07 0.OOE+00 FE-59 7.94E+07 1.39E+08 5.46E+07 0.OOE+00 0.OOE+00 4.1 OE+07 6.62E+07 0.O0E+00 CO-60 0.00E+00 4.69E+07 1.11E+08 0.OOE+00 0.OOE+00 0.OOE+00 1.12E+08 0.OOE+00 NI-59 1.41 E+09 4.32E+08 2.43E+08 0.OOE+00 0.OOE+00 0.OOE+00 2.13E+07 0.OOE+00 NI-63 1,89E+10 1.17E+09 6.54E+08 0.OOE+00 0.OOE+00 0.OOE+00 5.80E+07 0.OOE+00 CU-64 0.00E+00 5.43E+04 2.51 E+04 0.OOE+00 9.18E+04 0.00E+00 1.11E+06 0.OOE+00 NI-65 1.03E+00 1.16E-01 5.28E-02 0.OOE+00 0.OOE+00 0.OOE+00 8.83E+00 0.OOE+00 ZN-65 2.69E+09 9.22E+09 4.25E+09 0.00E+00 4.47E+09 0.OOE+00 7.79E+09 0.OOE+00 ZN-69M 4.92E+05 1.OOE+06 9.14E+04 0.OOE+00 4.06E+05 0.OOE+00 1.39E+07 0.OOE+00 ZN-69 5.90E-12 1.06E-11 7.90E-1 3 0.OOE+00 4.41 E-12 0.OOE+00 8.66E-10 0.OOE+00 SE-79 0.OOE+00 4.20E+09 7.80E+08 0.OOE+00 4.86E+09 0.OOE+00 1.12E+08 0.OOE+00 BR-82 0.00E+00 0.OOE+00 5.65E+07 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 BR-83 0.00E+00 0.OOE+00 2.73E-01 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 BR-84 0.OOE+00 0.OOE+00 3.67E-23 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 BR-85 0.00E+00 0.OOE+00 5.5E-301 0.OOE+00 0.OOE+00 0.OOE+00 0.00E+00 0.OOE+00 RB-86 0.00E+00 6.70E+09 3.31 E+09 0.OOE+00 0.OOE+00 0.OOE+00 1.72E+08 0.00E+00 RB-87 0.OOE+00 1.18E+10 4.69E+09 0.OOE+00 0.OOE+00 0.OOE+00 7.97E+07 0.00E+00 RB-88 0.00E+00 5.48E-45 3.00E-45 0.OOE+00 0.OOE+00 0.00E+00 5.34E-45 0.OOE+00 RB-89 0.00E+00 9.62E-53 6.62E-53 0.OOE+00 0.OOE+00 0.OOE+00 3.27E-53 0.OOE+00 SR-89 4.59E+09 0.OOE+00 1.32E+08 0.00E+00 0.OOE+00 0.OOE+00 9.43E+07 0.OOE+00 SR-90 6.55E+10 0.OOE+00 1.67E+10 0.OOE+00 0.OOE+00 0.OOE+00 8.18E+08 0.OOE+00 Y-90 1.99E+02 0.00E+00 5.34E+00 0.OOE+00 0.OOE+00 0.OOE+00 2.75E+05 0.OOE+00 SR-91 7.94E+04 0.OOE+00 2.88E+03 0.OOE+00 0,00E+00 0.OOE+00 9.40E+04 0.OOE+00 Y-91 M 1.66E-19 0.OOE+00 5.66E-21 0.OOE+00 0,O0E+00 0.OOE+00 5.53E-16 0.OOE+00 Y-91 2,77E+04 O.OOE+00 7.37E+02 0.OOE+00 0.00E+00 0.OOE+00 1.98E+06 0.OOE+00 SR-92 1.36E+00 0.OOE+00 5.04E-02 0.OOE+00 0.OOE+00 0.OOE+00 1.46E+01 0.OOE+00 Y-92 1.57E-04 0.OOE+00 4.42E-06 0.OOE+00 0.OOE+00 0.OOE+00 3.OOE+00 0.OOE+00 Y-93 6.31E-01 0.OOE+00 1.72E-02 0.OOE+00 0.OOE+00 0.00E+00 4.98E+03 0.OOE+00 NB-93M 1.36E+06 3.67E+05 1.15E+05 0.OOE+00 3.58E+05 0.00E+00 4.39E+07 0.OOE+00 NB-95 1.98E+05 8.17E+04 4.72E+04 0.OOE+00 5.86E+04 0.OOE+00 6.90E+07 0.OOE+00 NB-97 9.01E-12 1.92E-12 6.93E-13 0.OOE+00 1.50E-12 0.OOE+00 6.06E-07 0.OOE+00 ZR-93 4.29E+03 2.04E+03 1.23E+03 0.OOE+00 6.02E+03 0.OOE+00 5.31 E+05 0.OOE+00

CY-LG-1 70-301, Rev. 23 Page 226 08/07 TABLE 112-2 Ri DOSE FACTORS Age: Infant Pathway: Cow Milk (Continued)

NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG GI-LLI SKIN ZR-95 2.63E+03 6.40E+02 4.54E+02 0.OOE+00 6.90E+02 0.OOE+00 3.19E+05 0.OOE+00 ZR-97 1.19E+00 2.04E-01 9.31E-02 0.OOE+00 2.06E-01 0.OOE+00 1.30E+04 0.0OE+00 MO-93 O.OOE+00 1.88E+09 6.07E+07 0.OOE+00 3.77E+08 0.OOE+00 4.03E+07 0.OOE+00 MO-99 0.OOE+00 6.08E+07 1.19E+07 0.OOE+00 9.09E+07 0.OOE+00 2.00E+07 0.OOE+00 TC-99 1.20E+08 1.62E+08 5.05E+07 0.OOE+00 1.37E+09 1.58E+07 7.01E+08 O.OOE+00 TC-99M 8.04E+00 1.66E+01 2.13E+02 O.OOE+00 1.78E+02 8.67E+00 4.81E+03 0.OOE+00 TC-101 7.21E-60 9.09E-60 8.99E-59 0.OOE+00 1.08E-58 4.96E-60 1.54E-57 O.OOE+00 RU-103 2.98E+03 O.OOE+00 9.95E+02 0.OOE+00 6.19E+03 0.OOE+00 3.62E+04 O.OOE+00 RU-105 2.36E-03 O.OOE+00 7.93E-04 0.OOE+00 1.73E-02 0.OOE+00 9.37E-01 O.OOE+00 RU-106 9.54E+04 O.OOE+00 1.19E+04 0.OOE+00 1.13E+05 0.OOE+00 7.25E+05 .0.00E+00 RH-105 4.83E+07 3.16E+07 2.12E+07 0.OOE+00 8.77E+07 0.OOE+00 7.84E+08 0,OOE+00 PD-107 0.OOE+00 5.29E+07 3.76E+06 0.OOE+00 3.02E+08 0.OOE+00 4.21E+07 0.OOE+00 PD-109 0.OOE+00 1.17E+05 2.82E+04 0.OOE+00 4.29E+05 O.OOE+00 2.87E+06 O.OOE+00 AG-110M 1.87E+08 1.37E+08 9.04E+07 0.OOE+00 1.96E+08 0.OOE+00 7.09E+09 O.OOE+00 AG-111 1.81E+07 7.02E+06 3.72E+06 0.OOE+00 1.47E+07 0.OOE+00 1.67E+09 0.OOE+00 CD-113M 0.OOE+00 9.36E+06 3.45E+05 0.OOE+00 7.08E+06 0.OOE+00 1.41E+07 OOOE+00 CD-115M O.OOE+00 3.66E+06 1.27E+05 0.OOE+00 1.91E+06 0.OOE+00 2.08E+07 0.OOE+00 SN-123 2.04E+09 3.18E+07 5.31E+07 3.20E+07 0.OOE+00 0.OOE+00 5.38E+08 0.OOE+00 SN-125 1.58E+08 2.94E+06 7.OOE+06 2.89E+06 0.OOE+00 0.00E+00 2.36E+08 O.OOE+00 SN-126 6.14E+09 8.07E+07 2.0OE+08 2.12E+07 0.OOE+00 0.OOE+00 2.80E+08 O.OE+00 SB-124 7.96E+07 1.17E+06 2.47E+07 2.11E+05 O.OOE+00 4.99E+07 2.46E+08 0.O0E+00 SB-125 7.85E+07 7.60E+05 1.62E+07 9.83E+04 0.O0E+00 4.55E+07 1.05E+08 O.OOE+00 SB-126 1.23E+07 2.41E+05 4.44E+06 9.44E+04 0.OOE+00 7.73E+06 1.27E+08 O.OOE+00 SB-127 1.21E+06 2.16E+04 3.75E+05 1.54E+04 0.OOE+00 6.24E+05 3.21E+07 O.OOE+00 TE-125M 5.68E+07 1.90E+07 7.68E+06 1.91E+07 0.OOE+00 0.OOE+00 2.71E+07 O.OOE+00 TE-127M 1.82E+08 6.04E+07 2.20E+07 5.26E+07 4.48E+08 0.OOE+00 7.34E+07 0.OOE+00 TE-127 1.85E+03 6.19E+02 3.97E+02 1.50E+03 4.51E+03 0.OOE+00 3.88E+04 O.OOE+00 TE-129M 1.85E+08 6.33E+07 2.84E+07 7.09E+07 4.61E+08 0.OOE+00 1.10E+08 O.OOE+00 TE-129 7.95E-10 2.74E-10 1.86E-10 6.66E-10 1.98E-09 0.OOE+00 6.36E-08 0.OOE+00 TE-133M 5.55E-13 2.54E-13 2.43E-13 4.89E-13 1.73E-12 0.OOE+00 2.74E- 11 O.OOE+00 TE-134 2.28E-18 1.15E-18 1.18E-18 2.05E-18 7.73E-18 0.OOE+00 2.62E-17 O.OOE+00 1-129 3.81E+09 2.83E+09 2.07E+09 1.81E+12 3.35E+09 0.OOE+00 5.65E+07 0.OOE+00 1-130 1.04E+06 2.28E+06 9.17E+05 2.56E+08 2.51E+06 0.OOE+00 4.90E+05 0.OOE+00 1-131 7.96E+08 9.38E+08 4.12E+08 3.08E+ 11 1.10E+09 0.OOE+00 3.35E+07 0.OOE+00 TE-131M 9.88E+05 3.98E+05 3.28E+05 8.06E+05 2.74E+06 0.OOE+00 6.69E+06 0.OOE+00 TE-131 1.OOE-32 3.70E-33 2.81 E-33 8.94E-33 2.56E-32 O.0OE+00 4.05E-31 0.OOE+00 1-132 4.18E-01 8.49E-01 3.02E-01 3.98E+01 9.47E-01 0.OOE+00 6.88E-01 0.OOE+00 TE-132 6.17E+06 3.06E+06 2.85E+06 4.51E+06 1.91E+07 0.O0E+00 1.13E+07 0.OOE+00 1-133 1.06E+07 1.54E+07 4.52E+06 2.81E+09 1.82E+07 0.OOE+00 2.61E+06 0.OOE+00 CS-134M 4.47E-01 7.44E-01 3.76E-01 0.OOE+00 2.87E-01 6.60E-02 5.89E-01 0.OOE+00 CS-134 1.90E+1,0 3.54E+10 3.57E+09 0.OOE+00 9.11E+09 3.74E+09 9.62E+07 0.OOE+00 1-134 5.15E-12 1.05E-11 3.75E-12 2.46E-10 1.18E-11 0.OOE+00 1.09E-11 0.OOE+00 1-135 3.28E+04 6.53E+04 2.38E+04 5.86E+06 7.28E+04 O.OOE+00 2.36E+04 0.OOE+00 CS-135 7.09E+09 6.45E+09 3.36E+08 0.OOE+00 1.83E+09 6.99E+08 2.33E+07 0.OOE+00 CS-136 5.82E+08 1.71E+09 6.39E+08 0.OOE+00 6.82E+08 1.40E+08 2.60E+07 0.OOE+00

CY-LG-170-301, Rev. 23 I Page 227 08/07 I TABLE 112-2 Ri DOSE FACTORS Age: Infant Pathway: Cow Milk (Continued)

NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG GI-LLI SKIN CS-137 2.77E+10 3.25E+10 2.30E+09 O.OOE+00 8.71E+09 3.53E+09 1.01E+08 O.OOE+00 CS-138 2.45E-23 3.99E-23 1.93E-23 0.OOE+00 1.99E-23 3.11E-24 6.38E-23 O.OOE+00 CS-139 1.92E-89 2.62E-89 1.OOE-89 O.OOE+00 1.36E-89 2.04E-90 1.65E-90 O.OOE+00 BA-139 1.25E-07 8.28E-11 3.62E-09 O.OOE+00 4.98E-11 5.02E-11 7.92E-06 O.OOE+00 BA-140 7.1OE+07 7.10E+04 3.66E+06 O.OOE+00 1.68E+04 4.36E+04 1.74E+07 O.OOE+00 LA-140 1.19E+01 4.67E+00 1.20E+00 O.OOE+00 O.OOE+00 O.OOE+00 5.49E+04 O.OOE+00 BA-141 1.15E-45 7.87E-49 3.63E-47 O.OOE+00 4.74E-49 4.79E-49 1.40E-44 O.OOE+00 LA-141 8.58E-05 2.49E-05 4.34E-06 O.OOE+00 O.OOE+00 O.OOE+00 2.85E+00 O.OOE+00 CE-141 1.43E+04 8.70E+03 1.02E+03 O.OOE+00 2.68E+03 O.OOE+00 4.49E+06 O.OOE+00 BA-142 7.15E-80 5.94E-83 3.52E-81 O.OOE+00 3.42E-83 3.60E-83 2.95E-79 O.OOE+00 LA-142 4.97E-11 1.83E-11 4.37E-12 O.OOE+00 O.OOE+00 O.OOE+00 3.1OE-06 O.OOE+00 CE-143 1.16E+02 7.70E+04 8.78E+00 O.OOE+00 2.24E+01 O.OOE+00 4.49E+05 O.OOE+00 PR-143 4.38E+02 1.64E+02 2.17E+01 O.OOE+00 6.09E+01 O.OOE+00 2.31E+05 O.OOE+00 CE-144 1.14E+06 4.68E+05 6.40E+04 O.OOE+00 1.89E+05 0.OOE+00 6.56E+07 O.OOE+00 PR-144 1.66E-53 6.44E-54 8.38E-55 O.OOE+00 2.33E-54 O.OOE+00 2.99E-49 O.OOE+00 ND-147 2.58E+02 2.65E+02 1.63E+01 O.OOE+00 1.02E+02 O.OOE+00 1.68E+05 O.OOE+00 PM-147 8.24E+03 6.95E+02 3.38E+02 O.OOE+00 1.04E+03 O.OOE+00 1.97E+05 O.OOE+00 PM-148M 1.70E+03 4.31E+02 3.38E+02 O.OE+00 4.95E+02 O.OOE+00 5.61E+05 O.OOE+00 PM-148 6.52E+02 9.42E+01 4.74E+01 O.OOE+00 1.12E+02 O.OOE+00 1.00E+06 O.OOE+00 PM-149 1.21 E+01 1.59E+00 6.92E-01 O.OOE+00 1.93E+00 O.OOE+00 4.26E+04 O.OOE+00 PM-151 1.79E+00 2.61E-01 1.32E-01 O.OOE+00 3.11E-01 O.OOE+00 1.21E+04 O.OOE+00 SM-151 6.43E+03 1.48E+03 3.20E+02 O.OOE+00 1.01E+03 O.OOE+00 1.24E+05 O.OOE+00 SM-153 5.55E+00 4.30E+00 3.30E-01 O.OOE+00 8.99E-01 O.OOE+00 2.24E+04 O.OOE+00 EU-152 1.48E+04 3.94E+03 3.33E+03 O.OOE+00 1.11E+04 O.OOE+00 3.50E+05 O.OOE+00 EU-154 5.79E+04 8.04E+03 4.82E+03 O.OOE+00 2.18E+04 O.OOE+00 1.OOE+06 O.OOE+00 EU-155 1.18E+04 1.36E+03 7.01E+02 O.OE+00 3.04E+03 O.OOE+00 1.82E+06 O.OOE+00 EU-1 56 6.61 E+02 4.09E+02 6.49E+01 O.OOE+00 1.89E+02 O.OOE+00 3.86E+05 O.OOE+00 TB-160 3.48E+03 O.OOE+00 4.35E+02 O.OOE+00 9.89E+02 O.OOE+00 4.63E+05 O.OOE+00 HO-166M 2.78E+04 5.98E+03 4.73E+03 O.OOE+00 7.93E+03 O.OOE+00 2.22E-14 O.OOE+00 W-181 1.42E+05 4.37E+04 4.88E+03 O.OOE+00 O.OOE+00 O.OOE+00 6.13E+05 O.OOE+00 W-185 4.93E+06 1.54E+06 1.76E+05 O.OOE+00 O.OOE+00 O.OOE+00 2.21E+07 O.OOE+00 W-187 1.78E+04 1.24E+04 4.27E+03 O.OOE+00 O.OOE+00 O.OOE+00 7.27E+05 O.OOE+00 NP-239 1.07E+01 9.54E-01 5.39E-01 O.OOE+00 1.90E+00 O.OOE+00 2.76E+04 O.OOE+00 U-232 5,37E+10 O.OOE+00 4.79E+09 O.OE+00 5.26E+09 O.OOE+00 1.56E+08 O.OOE+00 U-233 1.13E+10 Q.OOE+00 8.60E+08 O.OOE+00 2.40E+09 0.OOE+00 1.45E+08 O.OOE+00 U-234 1.08E+10 O.OOE+00 8.44E+08 O.OOE+00 2.36E+09 O.OOE+00 1.42E+08 O.OOE+00 U-235 1.04E+10 O.OOE+00 7.91E+08 O.OOE+00 2.21E+09 O.OOE+00 1.80E+08 O.OOE+00 U-236 1.04E+10 O.OOE+00 8.09E+08 O.OOE+00 2.24E+09 O.OOE+00 1.33E+08 O.OOE+00 U-237 1.58E+05 O.OE+00 4.21E+04 O.OOE+00 3.92E+05 O.OOE+00 6.72E+06 O.OOE+00 U-238 9.93E+09 O.OE+00 7.40E+08 O.OOE+00 2.06E+09 O.OOE+00 1.27E+08 O.OOE+00 NP-237 5.33E+07 3.53E+06 2.33E+06 O.OOE+00 1.41E+07 O.OOE+00 1.83E+06 O.OOE+00 NP-238 1.02E+02 2.56E+00 1.58E+00 O.OOE+00 5.59E+00 O.OOE+00 3.42E+04 O.OOE+00 PU-238 1.14E+07 1.33E+06 3.02E+05 O.OOE+00 1.07E+06 O.OOE+00 6.72E+05 O.OOE+00 PU-239 1.23E+07 1.38E+06 3.15E+05 O.OOE+00 1.14E+06 O.OOE+00 6.14E+05 O.OOE+00

CY-LG-170-301, Rev. 23 Page 228 08/07 TABLE 112-2 Ri DOSE FACTORS Age: Infant Pathway: Cow Milk (Continued)

NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG GI-LLI SKIN PU-240 1.23E+07 1.38E+06 3.15E+05 0.OOE+00 1.14E+06 0.OOE+00 6.26E+05 0.OOE+00 PU-241 3.75E+05 1.55E+04 7.77E+03 0.OOE+00 2.79E+04 0.OOE+00 1.28E+04 0.OOE+00 PU-242 1.14E+07 1.32E+06 3.03E+05 0.OOE+00 1.09E+06 0.OOE+00 6.02E+05 0.OOE+00 PU-244 1.32E+07 1.52E+06 3.48E+05 0.OOE+00 1.25E+06 0.OOE+00 8.98E+05 0.OOE+00 AM-241 3.24E+07 2.82E+07 2.42E+06 0.OOE+00 1.45E+07 0.OOE+00 1.71E+06 0.0OE+00 AM-242M 3.35E+07 2.71E+07 2.51E+06 0.OOE+00 1.47E+07 0.OOE+00 2.15E+06 O.OOE+00 AM-243 3.20E+07 2.73E+07 2.36E+06 0.OOE+00 1.41 E+07 0.OOE+00 2.01 E+06 0.OOE+00 CM-242 2.37E+06 2.20E+06 1.58E+05 0.OOE+00 4.54E+05 0.OOE+00 1.43E+06 O.OOE+00 CM-243 3.1OE+07 2.54E+07 1.99E+06 0.0OE+00 7.24E+06 0.OOE+00 1.79E+06 0.OOE+00 CM-244 2.60E+07 2.14E+07 1.68E+06 0.OOE+00 5.98E+06 0.OOE+00 1.73E+06 0.OOE+00 CM-245 3.98E+07 3.22E+07 2.51E+06 0.0OE+00 9.60E+06 0.OOE+00 1.62E+06 0.OOE+00 CM-246 3.93E+07 3.22E+07 2.51E+06 O.OOE+00 9.58E+06 O.OOE+00 1.59E+06 0.OOE+00 CM-247 3.84E+07 3.18E+07 2.47E+06 O.OOE+00 9.42E+06 0.OOE+00 2.1OE+06 0.OOE+00 CM-248 3.18E+08 2.62E+08 2.04E+07 0.O0E+00 7.78E+07 0.0OE+00 3.38E+07 0.OOE+00 CF-252 2.59E+07 0.OOE+00 6.27E+05 0.OOE+00 O.OOE+00 0.OOE+00 6.35E+06 0.OOE+00

CY-LG-1 70-301, Rev. 23 I Page 229 08/07 I TABLE 112-2 Ri DOSE FACTORS Age: Infant Pathway: Goat Milk NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG GI-LLI SKIN H-3 O.OOE+00 O.OOE+00 0.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 C-14 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 NA-22 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 NA-24 O.OE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 P-32 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 CA-41 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OQE+00 SC-46 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 CR-51 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 MN-54 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OE+00 O.OOE+00 O.OOE+00 FE-55 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 OOOE+00 MN-56 O.OOE+00 0.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 CO-57 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OE+00 O.OOE+00 CO-58 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OE+00 O.OOE+00 O.OOE+00 O.OOE+00 FE-59 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 CO-60 O.OOE+00 O.OOE+00 O.OQE+00 O.OOE+00 0.00E+00 O.OOE+00 O.OOE+00 0.00E+00 NI-59 O.OOE+00 O.OE+00 O.OOE+00 O.0OE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 NI-63 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.0OE+00 O.OOE+00 CU-64 O.OOE+00 O.OOE+00 O.OQE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 NI-65 0,00E+00 O.OOE+00 Q.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 ZN-65 O.OE+00 0:00E+00 0.OE+00 O.OOE+00 O.OOE+00 0OOE+00 O.OOE+00 O.OOE+00 ZN-69M O.OOE+00 O.OOE+00 0.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 ZN-69 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 SE-79 0.00E+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 0.00E+00 O.OOE+00 O.OOE+00 BR-82 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 0.OOE+00 O.OOE+00 BR-83 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.0OE+00 O.OOE+00 O.OOE+00 BR-84 O.OOE+00 O.OOE+00 0.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 BR-85 O.OOE+00 O.OOE+00 O.0OE+00 O.OOE+00 O0,0E+00 O.OOE+00 O.OOE+00 O.OOE+00 RB-86 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 Q.OOE+00 O.OOE+00 RB-87 O.OOE+00 O.OE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 RB-88 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 RB-89 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 SR-89 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 SR-90 O.OOE+00 O.OOE+00 Q.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 Y-90 O.0OE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 SR-91 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 0.00E+00 O.OOE+00 Y-91M O.OOE+00 O.0OE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 0.OOE+00 O.OOE+00 Y-91 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 SR-92 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 Y-92 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 OOOE+00 O.OOE+00 O.OOE+00 Y-93 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OE+00 NB-93M O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 NB-95 0.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 NB-97 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 ZR-93 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00

CY-LG-170-301, Rev. 23 Page 230 08/07 TABLE 112-2 Ri DOSE FACTORS Age: Infant Pathway: Goat Milk (Continued)

NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG GI-LLI SKIN ZR-95 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.00E+00 0.OOE+00 0.OOE+00 ZR-97 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 MO-93 0.OOE+00 000E+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 MO-99 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 TC-99 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 TC-99M O.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 TC-101 0.OOE+00 0.00E+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 RU-103 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 RU-105 0.00E+00 0.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 RU-106 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 RH-105 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 PD-107 0.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 PD-109 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 AG-110M 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 AG-111 O.OOE+00 0.OOE+00 0.OOE+00 O.00E+00 0.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 CD-113M 0.OOE+00 0-OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 CD-115M O.OOE+00 0.OOE+00 O.0OE+00 0.OOE+00 0.OOE+00 O.OOE+00 O.OOE+00 0.OOE+00 SN-123 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 SN-125 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 SN-126 0.OOE+00 0.OOE+00 0.0OE+00 O.OOE+00 0.OOE+00 0.OOE+00 0.0OE+00 0.OOE+00 SB-124 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 SB-125 0.OOE+00 0.OOE+00 0.0OE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 SB-126 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 SB-127 0.OOE+00 O.OOE+00 0.0OE+00 0.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 O.OOE+00 TE-125M 0.00E+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0,OOE+00 TE-127M 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 O.OE+00 0.OOE+00 O.OOE+00 0.OOE+00 TE-127 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 TE-129M O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 TE-129 O.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 TE-133M 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 TE-134 0.OOE+00 0.OOE+00 0.O0E+00 0.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 O.OOE+00 1-129 0.OOE+00 O.OOE+00 0.O0E+00 O.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 O.OOE+00 1-130 0.OOE+00 0.OOE+00 0.O0E+00 0.OOE+0O 0.OOE+00 0.OOE+00 0.O0E+00 0.OOE+00 1-131 0.OOE+00 0.OOE+00 O.OE+00 0.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 TE-131M O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 0.O0E+00 0.OOE+00 TE-131, 0.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 1-132 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 0.O0E+00 0.OOE+00 TE-132 0.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 1-133 0.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 CS-134M O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 CS-134 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 1-134 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 1-135 0.OOE+00 O.OOE+00 0.OOE+00 O.OOE+00 O.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 CS-135 0.OOE+00 O.OOE+00 0.OOE+00 O.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 CS-136 0.OOE+00 O.OOE+00 0.OOE+00 O.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00 0.OOE+00

CY-LG-170-301, Rev. 23 Page 231 08/07 TABLE 112-2 Ri DOSE FACTORS Age: Infant Pathway: Goat Milk (Continued)

NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG GI-LLI SKIN CS-137 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 CS-i 38 O.0OE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 CS-139 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 BA-139 Q.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 BA-140 O.OE+00 O.OOE+00 O.OOE+00 O.0OE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 LA-140 0.OOE+00 O.OOE+00 O.0OE+00 O.OOE+00 O.OOE+00 0.OOE+00 O.OOE+00 O.OOE+00 BA-141 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.0OE+00 O.OOE+00 O.OOE+00 O.OOE+00 LA-141 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 CE-141 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 BA-142 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 .0.00E+00 LA-142 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OE+00 O.OOE+00 O.OOE+00 O.OOE+00 CE-143 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 Q.OOE+00 O.OOE+00 PR-143 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 CE-144 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 0.OOE+00 O.OOE+00 PR-144 O.OOE+00 O.OOE+00 O.OOE+00 O.0OE+00 O.OOE+00 O.OOE+00 O.OOE+00 0.OOE+00 ND-147 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 PM-147 O.OOE+00 O.OOE+00 O.OE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 PM-148M O.OOE+00 O.OOE+00 0.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 Q.OOE+00 PM-148 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.0OE+00 0.OOE+00 O.OOE+00 O.OOE+00 PM-149 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 PM-151 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 SM-151 O.OQE+00 0.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.0OE+00 O.OOE+00 0.OOE+00 SM-153 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 EU-152 O.OOE+00 O.OOE+00 0.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 EU-154 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 .OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 EU-155 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 0.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 EU-156 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 0.00E+00 O.OOE+00 TB-160 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 HO-166M O.OE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 W-181 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 W-185 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.0OE+00 O.OOE+00 W-187 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 NP-239 0.OOE+00 O.OE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 U-232 O.OOE+00 0.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 U-233 O.OOE+00 O.OOE+00 O.0OE+00 O.OOE+00 O.Q0E+00 O.OOE+00 O.OOE+00 O.OOE+00 U-234 O.0OE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.00E+00 O.OOE+00 O.OOE+00 O.OOE+00 U-235 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 U-236 0.OOE+00 O.OE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 U-237 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 U-238 O.OE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 NP-237 O.0OE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 0.OOE+00 O.OOE+00 O.OOE+00 NP-238 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 PU-238 O.OOE+00 O.OOE+00 O.OQE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 PU-239 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 o.00E+00

CY-LG-170-301, Rev. 23 Page 232 08/07 TABLE 112-2 Ri DOSE FACTORS Age: Infant Pathway: Goat Milk (Continued)

NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG GI-LLI SKIN PU-240 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 PU-241 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 PU-242 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 PU-244 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 AM-241 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 AM-242M 0.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 AM-243 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 CM-242 O.OOE+00 O.OOE+00 O.OOE+00 0,00E+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 CM-243 0.00E+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 CM-244 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 CM-245 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 CM-246 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 CM-247 O.OOE+00 O.QOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 CM-248 O.OOE+00 O.0OE+00 O0OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 CF-252 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00 O.OOE+00

CY-LG-170-301, Rev. 23 Page 233 08/07 TABLE 112-2 Ri DOSE FACTORS Age: Infant Pathway: Inhalation NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG GI-LLI SKIN H-3 O.OOE+00 6.47E+02 6.47E+02 6.47E+02 6.47E+02 6.47E+02 6.47E+02 0.00E+00 C-14 2.65E+04 5.31E+03 5.31E+03 5.31E+03 5.31E+03 5.31E+03 5.31E+03 O.OOE+00 NA-22 1.03E+05 1.03E+05 1.03E+05 1.03E+05 1.03E+05 1.03E+05 1.03E+05 O.OOE+00 NA-24 1.06E+04 1.06E+04 1.06E+04 1.06E+04 1.06E+04 1.06E+04 1.06E+04 O.OOE+00 P-32 2.03E+06 1.12E+05 7.74E+04 O.OOE+00 O.OOE+00 O.OOE+00 1.61E+04 O.OOE+00 CA-41 1.05E+05 O.OOE+00 1.14E+04 O.OOE+00 O.OOE+00 9.72E+07 4.14E+02 O.OOE+00 SC-46 5.25E+05 7.57E+05 2.37E+05 O.OOE+00 4.98E+05 O.OOE+00 3.07E+04 O.OOE+00 CR-51 O.OOE+00 O.OOE+00 8.95E+01 5.75E+01 1.32E+01 1.28E+04 3.57E+02 O.OOE+00 MN-54 O.OOE+00 2.53E+04 4.98E+03 O.OOE+00 4.98E+03 1.OOE+06 7.06E+03 O.OOE+00 FE-55 1.97E+04 1.18E+04 3.33E+03 O.OOE+00 O.OOE+00 8.69E+04 1.1OE+03 O.OE+00 MN-56 O.OOE+00 1.54E+00 2.21E-01 O.OOE+00 1.1OE+00 1.25E+04 7.17E+04 O.OOE+00 CO-57 O.OOE+00 6.51E+02 6.41E+02 O.OOE+00 O.OOE+00 3.79E+05 4.86E+03 O.OOE+00 CO-58 O.0OE+00 1.22E+03 1.82E+03 O.QOE+00 O.OOE+00 7.77E+05 1.11 E+04 O.OOE+00 FE-59 1.36E+04 2.35E+04 9.48E+03 O.OOE+00 O.OOE+00 1.02E+06 2.48E+04 O.OOE+00 CO-60 O.OOE+00 8.02E+03 1.18E+04 O.OOE+00 O.OOE+00 4.51E+06 3.19E+04 O.OOE+00 NI-59 2.53E+04 7.62E+03 4.34E+03 O.OOE+00 O.OOE+00 7.67E+04 8.88E+02 O.OOE+00 NI-63 3.39E+05 2.04E+04 1.16E+04 O.OOE+00 O.OOE+00 2.09E+05 2.42E+03 O.OOE+00 CU-64 O.0OE+00 1.88E+00 7.74E-01 O.OOE+00 3.98E+00 9.30E+03 1.50E+04 O.OOE+00 NI-65 2.39E+00 2.84E-01 1.23E-01 O.OOE+00 O.OOE+00 8.12E+03 5.01E+04 O.OE+00 ZN-65 1.93E+04 6.26E+04 3.11E+04 O.OOE+00 3.25E+04 6.47E+05 5.14E+04 O.OOE+00 ZN-69M 1.26E+01 2.58E+01 2.34E+00 O.OOE+00 1.04E+01 2.67E+04 4.09E+04 O.OOE+00 ZN-69 5.39E-02 9.67E-02 7.18E-03 O.OOE+00 4.02E-02 1.47E+03 1.32E+04 O.OOE+00 SE-79 O.OOE+00 3.15E+03 5.88E+02 O.OOE+00 3.46E+03 4.19E+05 4.84E+04 O.OOE+00 BR-82 O.OOE+00 O.OOE+00 1.33E+04 O.OOE+00 O.OOE+00 O.OOE+00 1.40E-15 0.OOE+00 BR-83 O.OOE+00 O.OOE+00 3.81 E+02 O.OOE+00 O.OOE+00 O.OOE+00 0.OOE+00 O.OE+00 BR-84 O.OOE+00 O.OOE+00 4.OOE+02 O.OOE+00 O.OOE+00 O.OOE+00 O.OE+00 O.OOE+00 BR-85 O.OOE+00 O.OOE+00 2.04E+01 O.OOE+00 O.OOE+00 O.OE+00 O.OOE+00 O.OOE+00 RB-86 O.OOE+00 1.90E+05 8.82E+04 O.OOE+00 O.OOE+00 O.OOE+00 3.04E+03 O.OOE+00 RB-87 O.OOE+00 1.24E+05 4.93E+04 O.OOE+00 O.OOE+00 O.OOE+00 8.37E+02 O.OOE+00 RB-88 O.OOE+00 5.57E+02 2.87E+02 O.OOE+00 O.OOE+00 O.OOE+00 3.39E+02 O.OOE+00 RB-89 O.OOE+00 3.21 E+02 2.06E+02 O.OOE+00 O.OOE+00 O.OE+00 6.82E+01 O.OOE+00 SR-89 3.98E+05 O.OOE+00 1.14E+04 0.OOE+00 O.OOE+00 2.03E+06 6.40E+04 O.OOE+00 SR-90 4.09E+07 O.OOE+00 2.59E+06 O.OOE+00 O.0OE+00 1.12E+07 1.31E+05 O.OOE+00 Y-90 3.29E+03 O.OOE+00 8.82E+01 O.OOE+00 O.0OE+00 2.69E+05 1.04E+05 O.OOE+00 SR-91 9.56E+01 O.OOE+00 3.46E+00 O.OOE+00 0.OOE+00 5.26E+04 7.34E+04 O.OOE+00 Y-91M 4.07E-01 O.OOE+00 1.39E-02 O.OOE+00 O.OOE+00 2.79E+03 2.35E+03 O.OOE+00 Y-91 5.88E+05 O.OOE+00 1.57E+04 O.OE+00 O.OOE+00 2.45E+06 7.03E+04 O.OOE+00 SR-92 1.05E+01 O.OOE+00 3.91E-01 O.OOE+00 O.OOE+00 2.38E+04 1.40E+05 O.OOE+00 Y-92 1.64E+01 O.OOE+00 4.61 E-01 O.OOE+00 O.OOE+00 2.45E+04 1.27E+05 O.OOE+00 Y-93 1.50E+02 O.OOE+00 4.07E+00 Q.0OE+00 O.OOE+00 7.64E+04 1.67E+05 O.OOE+00 NB-93M 1.93E+05 5.03E+04 1.61 E+04 O.OOE+00 5.15E+04 2.93E+05 3.46E+03 O.OOE+00 NB-95 1.57E+04 6.43E+03 3.78E+03 O.OOE+00 4.72E+03 4.79E+05 1.27E+04 O.OOE+00 NB-97 3.42E-01 7.29E-02 2.63E-02 O.OOE+00 5.70E-02 3.32E+03 2.69E+04 O.OOE+00 ZR-93 3.14E+05 1.33E+05 8.65E+04 O.OOE+00 4.47E+05 1.92E+06 2.07E+04 O.OOE+00

CY-LG-170-301, Rev. 23 Page 234 08/07 TABLE 112-2 Ri DOSE FACTORS Age: Infant Pathway: Inhalation (Continued)

NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG GI-LLI SKIN ZR-95 1.15E+05 2.79E+04 2.03E+04 0.OOE+00 3.11E+04 1.75E+06 2.17E+04 0.OOE+00 ZR-97 1.50E+02 2.56E+01 1.17E+01 0.OOE+00 2.59E+01 1.10E+05 1.40E+05 O.OOE+00 MO-93 0.OOE+00 9.04E+03 3.11E+02 0.OOE+00 2.16E+03 4.76E+05 5.26E+03 0.OOE+00 MO-99 0.OOE+00 1.65E+02 3.23E+01 O.OOE+00 2,65E+02 1.35E+05 4.87E+04 O.OOE+00 TC-99 2.93E+02 3.75E+02 1.24E+02 0.OOE+00 3.49E+03 9.48E+05 1.09E+04 O.OOE+00 TC-99M 1.40E-03 2.88E-03 3.72E-02 0.OOE+00 3.11E-02 8.11E+02 2.03E+03 O.OOE+00 TC-101 6.51E-05 8.23E-05 8.12E-04 0.OOE+00 9.79E-04 5.84E+02 8.44E+02 0.OOE+00 RU-103 2.02E+03 0.OOE+00 6.79E+02 0.OOE+00 4.24E+03 5.52E+05 1.61E+04 0.OOE+00 RU-105 1.22E+00 0.OOE+00 4.10E-01 0.OOE+00 8.99E-01 1.57E+04 4.84E+04 0.OOE+00 RU-106 8.68E+04 0.OOE+00 1.09E+04 0.OOE+00 1.07E+05 1.16E+07 1.64E+05 . 0.OOE+00 RH-105 1.16E+01 7.57E+00 5.08E+00 O.OOE+00 2.10E+01 2.91E+04 1.92E+04 O.OOE+00 PD-107 O.OOE+00 6.89E+01 5.75E+01 O.OOE+00 3.85E+03 8.88E+04 1.03E+03 O.OOE+00 PD-109 O.QOE+00 5.49E+00 1.47E+00 O.OOE+00 1.79E+01 2.35E+04 3.99E+04 O.OOE+00 AG-110M 9.98E+03 7.22E+03 5.OOE+03 O.OOE+00 1.09E+04 3.67E+06 3.30E+04 O.OOE+00 AG-111 5.25E+02 2.03E+02 1.09E+02 O.OOE+00 4.27E+02 2.88E+05 4.23E+04 O.OOE+00 CD-113M O.OOE+00 9.34E+05 3.70E+04 O.OOE+00 8.12E+05 1.96E+06 2.31 E+04 O.OOE+00 CD-115M O.OOE+00 2.42E+05 8.67E+03 O.OOE+00 1.32E+05 2.06E+06 7.03E+04 O.OOE+00 SN-123 2.93E+05 5.89E+03 1.02E+04 5.98E+03 O.OOE+00 3.11E+06 5.71E+04 O.OOE+00 SN-125 1.41E+04 3.51E+02 8.40E+02 3.46E+02 O.OOE+00 9.OOE+05 1.02E+05 O.OOE+00 SN-126 1.16E+06 2.02E+04 4.93E+04 5.38E+03 O.OOE+00 6.90E+06 2.31E+04 O.OOE+00 SB-124 3.79E+04 5.56E+02 1.20E+04 1.01E+02 O.OOE+00 2.65E+06 5.91E+04 O.OOE+00 SB-125 5.45E+04 4.77E+02 1.09E+04 6.23E+01 O.OOE+00 1.64E+06 1.47E+04 O.OOE+00 SB-126 4.31E+03 8.41E+01 1.55E+02 3.29E+01 O.OOE+00 9.63E+05 7,46E+04 O.OOE+00 SB-127 3.95E+02 7.06E+00 1.23E+02 5.04E+00 O.OOE+00 2.16E+05 5.29E+04 O.OOE+00 TE-125M 4.76E+03 1.99E+03 6.58E+02 1.62E+03 O.OOE+00 4.47E+05 1.29E+04 O.OOE+00 TE-127M 1.67E+04 6.90E+03 2.07E+03 4.87E+03 3.75E+04 1.31E+06 2.73E+04 O.OOE+00 TE-127 2.23E+00 9.53E-01 4.89E-01 1.85E+00 4.86E+00 1.04E+04 2.44E+04 O.OOE+00 TE-129M 1.41E+04 6.09E+03 2.23E+03 5.47E+03 3.18E+04 1.68E+06 6.90E+04 O.OOE+00 TE-129 7.88E-02 3.47E-02 1.88E-02 6.75E-02 1.75E-01 3.OOE+03 2.63E+04 O.OOE+00 TE-133M 8.58E-02 5.03E-02 3.84E-02 7.73E-02 2.41E-01 5.49E+03 2.23E+04 O.OOE+00 TE-134 4.45E-02 2.86E-02 2.35E-02 4.07E-02 1.34E-01 4.10E+03 3.54E+03 O.OOE+00 1-129 3.02E+04 2.23E+04 1.62E+04 1.46E+07 2.63E+04 O.OOE+00 2.97E+02 O.OOE+00 1-130 6.36E+03 1.39E+04 5.57E+03 1.60E+06 1.53E+04 O.OOE+00 1.99E+03 O.OOE+00 1-131 3.79E+04 4.44E+04 1.96E+04 1.48E+07 5.18E+04 O.OOE+00 1.06E+03 0.OOE+00 TE-131M 1.07E+02 5.50E+01 3.63E+01 8.93E+01 2.65E+02 1.99E+05 1.19E+05 O.OOE+00 TE-131 1.74E-02 8.22E-03 5.OOE-03 1.58E-02 3.99E-02 2.06E+03 8.22E+03 0.OOE+00 1-132 1.69E+03 3.54E+03 1.26E+03 1.69E+05 3.95E+03 O.OOE+00 1.90E+03 O.OOE+00 TE-132 3.72E+02 2.37E+02 1.76E+02 2.79E+02 1.04E+03 3.40E+05 4.41E+04 0.OOE+00 1-133 1.32E+04 1.92E+04 5.60E+03 3.56E+06 2.24E+04 O.OOE+00 2.16E+03 O.OOE+00 CS-134M 1.85E+02 2.94E+02 1.55E+02 0.OOE+00 1.19E+02 2.80E+01 1.62E+02 0.OOE+00 CS-134 3.96E+05 7.03E+05 7.45E+04 0.O0E+00 1.90E+05 7.97E+04 1.33E+03 O.OOE+00 1-134 9.21E+02 1.88E+03 6.65E+02 4.45E+04 2.09E+03 0.OOE+00 1.29E+03 0.OOE+00 1-135 3.86E+03 7.60E+03 2.77E+03 6.96E+05 8.47E+03 0.OOE+00 1.83E+03 0.OOE+00 CS-135 1.40E+05 1.21E+05 6.62E+03 0.OOE+00 3.61E+04 1.41E+04 3.05E+02 0.OOE+00 CS-136 4.83E+04 1.35E+05 5.29E+04 O.OOE+00 5.64E+04 1.18E+04 1.43E+03 O.OOE+00

CY-LG-170-301, Rev. 23 Page 235 08/07 TABLE 112-2 Ri DOSE FACTORS Age: Infant Pathway: Inhalation (Continued)

NUCLIDE 'BONE LIVER T BODY THYROID KIDNEY LUNG GI-LLI SKIN CS-137 5.49E+05 6.12E+05 4.55E+04 0.OOE+00 1.72E+05 7.13E+04 1.33E+03 0.OOE+00 CS-138 5.05E+02 7.81E+02 3.98E+02 0.OOE+00 4.1OE+02 6.54E+01 8.76E+02 0.OOE+00 CS-139 3.25E+02 4.24E+02 1.71E+02 0.OOE+00 2.31E+02 3.54E+01 1.86E+01' 0.OOE+00 BA-139 1.48E+00 9.84E-04 4.30E-02 0.OOE+00 5.92E-04 5.95E+03 5.1OE+04 0.O0E+00 BA-140 5,60E+04 5.60E+01 2.90E+03 0.OOE+00 1.34E+01 1.60E+06 3.84E+04 0.OOE+00 LA-140 5.05E+02 2.OOE+02 5.15E+01 0.OOE+00 0.0OE+00 1.68E+05 8.48E+04 0.OOE+00 BA-141 1.57E-01 1.08E-04 4.97E-03 0.00E+00 6.50E-05 2.97E+03 4.75E+03 0.OOE+00 LA-141 6.79E+00 1.96E+00 3.43E-01 0.OOE+00 0.00E+00 1.71E+04 8.34E+04 0.OOE+00 CE-141 2.77E+04 1.67E+04 1.99E+03 0.OOE+00 5.25E+03 5.17E+05 2.16E+04 0.OOE+00 BA-142 3.98E-02 3.30E-05 1.96E-03 0.OOE+00 1.90E-05 1.55E+03 6.93E+02 0.OOE+00 LA-142 1.03E+00 3.77E-01 9.04E-02 0.OOE+00 0.OOE+00 8.22E+03 5.95E+04 0.OOE+00 CE-143 2.93E+02 1.93E+02 2.21E+01 0.OOE+00 5.64E+01 1.16E+05 4.97E+04 0.0OE+00 PR-143 1.40E+04 5.24E+03 6.99E+02 0.OOE+00 1.97E+03 4.33E+05 3.72E+04 0.OOE+00 CE-144 3.19E+06 1.21E+06 1.76E+05 0.OOE+00 5.38E+05 9.84E+06 1.48E+05 0.OOE+00 PR-144 4.79E-02 1.85E-02 2.41E-03 0.OOE+00 6.72E-03 1.61E+03 4.28E+03 0.OOE+00 ND-147 7.94E+03 8.13E+03 5.OOE+02 0.OOE+00 3.15E+03 3.22E+05 3.12E+04 0.OOE+00 PM-147 5.47E+05 4.30E+04 2.18E+04 0.OOE+00 6.90E+04 6.37E+05 8.05E+03 0.OOE+00 PM-148M 7.O0E+04 1.74E+04 1.39E+04 0.0OE+00 2.03E+04 1.71E+06 4.72E+04 0.OOE+00 PM-148 4.68E+03 6.75E+01 3.42E+02 0.00E+00 8.06E+02 4.48E+05 8.46E+04 0.00E+00 PM-149 4.34E+02 5.71E+01 2.49E+01 0.OOE+00 6.94E+01 9.1OE+04 4.21E+04 0.00E+00 PM-151 1.05E+02 1.54E+01 7.77E+00 0.OOE+00 1.82E+01 4.55E+04 3.61E+04 0.OOE+00 SM-151 4.73E+05 9,03E+04 2.28E+04 0.OOE+00 7.34E+04 4.17E+05 4.84E+03 0.OOE+00 SM-153 2.14E+02 1.65E+02 1.27E+01 0.OOE+00 3.46E+01 5.18E+04 2,70E+04 0.OOE+00 EU-152 1.10E+06 2.48E+05 2.41E+05 0.OOE+00 8.32E+05 2.07E+06 1.38E+04 0.OOE+00 EU-1 54 4.14E+06 4.84E+05 3.43E+05 0.OOE+00 1.60E+06 4.27E+06 3.98E+04 0.OOE+00 EU-1 55 8.36E+05 8.01 E+04 4.84E+04 0.OOE+00 2.21E+05 7.28E+05 7.27E+04 0.OOE+00 EU-156 2,18E+04 1.34E+04 2.16E+03 0.OOE+00 6.27E+03 8.57E+05 5.80E+04 0.OOE+00 TB-160 1.57E+05 0.OOE+00 1.96E+04 0.OOE+00 4.48E+04 1.55E+06 3.OOE+04 0.OOE+00 HO-166M 2.03E+05 4.30E+05 3.51 E+05 0.OOE+00 5.91 E+05 2.87E+06 2.31 E+04 0.OOE+00 W-181 6.80E+01 2.04E+01 2.34E+00 0.OOE+00 0.OOE+00 1.86E+04 3.68E+02 0.OOE+00 W-185 2.20E+03 6.76E+02 7.81E+01 0.OOE+00 0.OOE+00 6.27E+05 1.57E+04 0.OOE+00 W-187 1.30E+01 9.02E+00 3.12E+00 0.OOE+00 0.OOE+00 3.96E+04 3.56E+04 0.O0E+00 NP-239 3.71 E+02 3.32E+01 1.88E+01 0.OOE+00 6.62E+01 5.95E+04 2.49E+04 0.O0E+00 U-232 3.60E+08 0.00E+00 2.98E+07 0.OOE+00 3.36E+07 2.09E+09 6.10E+04 0.OOE+00 U-233 7.62E+07 0.OOE+00 5.36E+06 0.OOE+00 1.53E+07 4.98E+08 5.64E+04 0.00E+00 U-234 7T31E+07 0.OOE+00 5.25E+06 0.OOE+00 1.50E+07 4.89E+08 5.53E+04 0.00E+00 U-235 7.01 E+07 0.OOE+00 4.93E+06 0.O0E+00 1.41 E+07 4.59E+08 7.03E+04 0.OOE+00 U-236 7.01 E+07 0.OOE+00 5.04E+06 0.00E+00 1.44E+07 4.69E+08 5.19E+04 0.OOE+00 U-237 4.55E+02 0.00E+00 1.21E+02 0.00E+00 1.13E+03 1.28E+05 1.83E+04 0.OOE+00 U-238 6.71E+07 0.0OE+00 4.61E+06 0.OOE+00 1.32E+07 4.28E+08 4.96E+04 0.OOE+00 NP-237 4.03E+09 2.66E+08 1,76E+08 0.OOE+00 1.08E+09 4.89E+08 7.14E+04 0.OOE+00 NP-238 3.74E+03 9.41E+01 5.82E+01 0.OOE+00 2.06E+02 1.29E+05 3.61E+04 0.OOE+00 PU-238 6.69E+09 7.81E+08 1.78E+08 0.OOE+00 6.50E+08 1.26E+09 6.57E+04 0.00E+00 PU-239 7.29E+09 8.20E+08 1.88E+08 0.OOE+00 6.93E+08 1.19E+09 5.99E+04 0.OOE+00

CY-LG-170-301, Rev. 23 I Page 236 08/07I TABLE 112-2 Ri DOSE FACTORS Age: Infant Pathway: Inhalation (Continued)

NUCLIDE BONE LIVER T BODY THYROID KIDNEY LUNG GI-LLI SKIN PU-240 7.29E+09 8.19E+08 1.88E+08 O.OOE+00 6.92E+08 1.19E+09 6.1OE+04 0.00E+00 PU-241 2.1OE+08 8.64E+06 4.35E+06 O.OOE+00 1.61E+07 1.07E+06 1.26E+03 O.OOE+00 PU-242 6.76E+09 7.90E+08 1.81E+08 O.OOE+00 6.68E+08 1.14E+09 5.88E+04 O.OOE+00 PU-244 7.90E+09 9.03E+08 2.07E+08 O.OOE+00 7.64E+08 1.31 E+09 8.76E+04 O.OOE+00 AM-241 2.45E+09 2.11E+09 1.83E+08 O.OOE+00 1.11E+09 5.68E+08 6.69E+04 O.OOE+00 AM-242M 2.52E+09 2.03E+09 1.89E+08 O.0OE+00 1.12E+09 2.30E+08 8.41 E+04 O.OOE+00 AM-243 2.41E+09 2.06E+09 1.78E+08 O.OQE+00 1.08E+09 5;39E+08 7.84E+04 O.OOE+00 CM-242 1.20E+08 1.08E+08 7.98E+06 O.OOE+00 2.37E+07 4.16E+08 7.14E+04 O.OOE+00 CM-243 2.31E+09 1.89E+09 1.48E+08 O.OOE+00 5.47E+08 5.94E+08 7.03E+04 O.OOE+00 CM-244 1.93E+09 1.58E+09 1.24E+08 O.OOE+00 4.49E+08 5.71 E+08 6.80E+04 O.OOE+00 CM-245 3.01E+09 2.44E+09 1.90E+08 O.OOE+00 7.32E+08 5.49E+08 6.34E+04 O.OOE+00 CM-246 2.98E+09 2.44E+09 1.90E+08 O.OOE+00 7.32E+08 5.59E+08 6.23E+04 O.OOE+00 CM-247 2.90E+09 2.39E+09 1.86E+08 O.OOE+00 7.21E+08 5.49E+08 8.19E+04 O.OE+00 CM-248 2.41E+10 1.97E+10 1.54E+09 O.OOE+00 5.94E+09 4.52E+09 1.32E+06 O.OOE+00 CF-252 5.89E+09 O.OOE+00 1.41E+08 O.OOE+00 O.OOE+00 1.92E+09 2.59E+05 O.OOE+00

CY-LG-170-301, Rev. 23 Page 237 08/07 Table 112-3 STABLE ELEMENT TRANSFER DATA NUCLIDE VEG/SOIL COW MILK (D/L) MEAT (D/KG) GOAT MILK (D/L)

H-3 4.8E+00 1.OE-02 1.2E-02 1.7E-01 C-14 5.5E+00 1.2E-02 3.1E-02 1.OE-01 NA-22 5.2E-02 4.OE-02 3.OE-02 4.OE-02 NA-24 5.2E-02 4.OE-02 3.OE-02 4.OE-02 P-32 1.1 E+00 2.5E-02 4.6E-02 2.5E-01 CA-41 3.6E-02 8.OE-03 4.OE-03 8.OE-03 SC-46 1.1E-03 5.OE-06 1.6E-02 5.OE-06 CR-51 2.5E-04 2.2E-03 2.4E-03 2.2E-03 MN-54 2.9E-02 2.5E-04 8.OE-04 2.5E-04 FE-55 6.6E-04 1.2E-03 4.OE-02 1.3E-04 MN-56 2.9E-02 2.5E-04 8.OE-04 2.5E-04 CO-57 9.4E-03 1.OE-03 1.3E-02 1.OE-03 CO-58 9.4E-03 1.OE-03 1.3E-02 1.OE-03 FE-59 6.6E-04 1.2E-03 4.OE-02 1.3E-03 CO-60 94E-03 1.OE-03 1.3E-02 1.OE-03 NI-59 1.9E-02 6.7E-03 5.3E-02 6.7E-03 NI-63 1.9E-02 6.7E-03 5.3E-02 6.7E-03 CU-64 1.2E-01 1.4E-02 8.OE-03 1.3E-02 NI-65 1.9E-02 6.7E-03 5.3E-02 6.7E-03 ZN-65 4.OE-01 3.9E-02 3.OE-02 3.9E-02 ZN-69m 4.OE-01 3.9E-02 3.0E-02 3.9E-02 ZN-69 4.OE-01 3.9E-02 3.OE-02 3.9E-02 SE-79 1.3E+00 4.5E-02 1.5E-02 4.5E-02 BR-82 7.6E-01 5.OE-02 2.6E-02 5.OE-02 BR-83 7.6E-01 5.OE-02 2.6E-02 5.0E-02 BR-84 7.6E-01 5.OE-02 2.6E-02 5.OE-02 BR-85 7.6E-01 5.OE-02 2.6E-02 5.OE-02 RB-86 1.3E-01 3.OE-02 3.1 E-02 3.OE-02 RB-87 1.3E-01 3.OE-02 3.1 E-02 3.OE-02 RB-88 1.3E-01 3.OE-02 3.1 E-02 3.OE-02 RB-89 1.3E-01 3.OE-02 3.1 E-02 3.OE-02 SR-89 1.7E-02 8.OE-04 6.OE-04 1.4E-02 SR-90 1.7E-02 8.0E-04 6.OE-04 1.4E-02 Y-90 2.6E-03 1.OE-05 4.6E-03 1.OE-05 SR-91 1.7E-02 8.OE-04 6.OE-04 1.4E-02 Y-91 m 2.6E-03 1.OE-05 4.6E-03 1.OE-05 Y-91 2.6E-03 1.OE-05 4.6E-03 1.4E-02 SR-92 1.7E-02 8.OE-04 6.OE-04 8.OE-04 Y-92 2.6E-03 1.OE-05 4.6E-03 1.OE-05 Y-93 2.6E-03 I.OE-05 4.6E-03 1.OE-05 NB-93m 9.4E-03 2.5E-03 2.8E-01 2.5E-03 NB-95 9.4E-03 2.5E-03 2.8E-01 2.5E-03 NB-97 9.4E-03 2.5E-03 2.8E-01 2.5E-03 ZR-93 1.7E-04 5.OE-06 3.4E-02 5.OE-06

CY-LG-170-301, Rev. 23 Page 238 08/07 Table 112-3 STABLE ELEMENT TRANSFER DATA*

NUCLIDE VEG/SOIL COW MILK (D/L) MEAT (D/KG) GOAT MILK (D/L)

ZR-95 1.7E-04 5.0E-06 3.4E-02 5.0E-06 ZR-97 1.7E-04 5.0E-06 3.4E-02 5.0E-06 MO-93 1.2E-01 7.5E-03 8.0E-03 7.5E-03 MO-99 1.2E-01 7.5E-03 8.0E-03 7.5E-03 TC-99 2.5E-01 2.5E-02 4.0E-01 2.5E-02 TC-99m 2.5E-01 2.5E-02 4.0E-01 2.5E-02 TC-101 2.5E-01 2.5E-02 4.0E-01 2.5E-02 RU-103 5.0E-02 1.0E-06 4.0E-01 1.0E-06 RU-105 5.0E-02 1.0E-06 4.0E-01 1.OE-06 RU-106 5.0E-02 1.0E-06 4.0E-01 1.0E-06 RH-105 1.3E+01 1.OE-02 1.5E-03 1.OE-02 PD-107 5.0E+00 1.OE-02 4.0E-03 1.0E-02 PD-109 5.0E+00 1.0E-02 4.OE-03 1.0E-02 AG-110m 1.5E-01 5.OE-02 1.7E-02 5.OE-02 AG-111 1.5E-01 5.OE-02 1.7E-02 5.OE-02 CD-113m 3.0E-01 1.2E-04 5.3E-04 1.2E-04 CD-115m 3.OE-01 1.2E-04 5.3E-04 1.2E-04 SN-123 2.5E-03 2.5E-03 8.OE-02 2.5E-03 SN-125 2.5E-03 2.5E-03 8.OE-02 2.5E-03 SN-126 2.5E-03 2.5E-03 8.OE-02 2.5E-03 SB-124 1.1 E-02 1.5E-03 4.OE-03 1.5E-03 SB-125 1.1E-02 1.5E-03 4.OE-03 1.5E-03 SB-126 1.1 E-02 1.5E-03 4.OE-03 1.5E-03 SB-127 1.1 E-02 1.5E-03 4.OE-03 1.5E-03 TE-125m 1.3E+00 1.OE-03 7.7E-02 1.OE-03 TE-127m 1.3E+00 1.0E-03 7.7E-02 1.0E-03 TE-127 1.3E+00 1.OE-03 7.7E-02 1.0E-03 TE-129m 1.3E+00 1.OE-03 7.7E-02 1.OE-03 TE-129 1.3E+00 1.OE-03 7.7E-02 1.0E-03 TE-133m 1.3E+00 1.OE-03 7.7E-02 1.OE-03 TE-134 1.3E+00 1.0E-03 7.7E-02 1.OE-03 1-129 2.OE-02 6.OE-03 2.9E-03 6.OE-02 1-130 2.OE-02 6.OE-03 2.9E-03 6.OE-03 1-131 2.OE-02 6.OE-03 2.9E-03 6.0E-03 TE-131m 1.3E+00 1.OE-03 7.7E-02 1.0E-03 TE-131 1.3E+00 1.OE-03 7.7E-02 1.0E-03 1-132 2.OE-02 6.OE-03 2.9E-03 6.OE-03 TE-132 1.3E+00 1.OE-03 7.7E-02 1.0E-03 1-133 2.OE-02 6.OE-03 2.9E-03 6.0E-02 CS-134m 1.OE-02 1.2E-02 4.OE-03 3.0E-01 CS-134 1.OE-02 1.2E-02 4.OE-03 3.OE-01 1-134 2.OE-02 6.OE-03 2.9E-03 6.OE-02 1-135 2.OE-02 6.OE-03 2.9E-03 6.OE-02 CS-135 1.OE-02 1.2E-02 4.OE-03 3.OE-01 CS-136 1.OE-02 1.2E-02 4.OE-03 3.OE-01

CY-LG-170-301, Rev. 23 Page 239 08/07 Table 112-3 STABLE ELEMENT TRANSFER DATA*

NUCLIDE VEG/SOIL COW MILK (D/L) MEAT (D/KG) GOAT MILK (D/L)

CS-137 1.OE-02 1.2E-02 4.OE-03 3.OE-01 CS-138 1.OE-02 1.2E-02 4.OE-03 3.OE-01 CS-139 1.OE-02 1.2E-02 4.OE-03 3.OE-01 BA-139 5.OE-03 4.OE-04 3.2E-03 4.0E-04 BA-140 5.OE-03 4.OE-04 3.2E-03 4.OE-04 LA-140 2.5E-03 5.OE-06 2.OE-04 5.OE-06 BA-141 5.OE-03 4.OE-04 3.2E-03 4.OE-04 LA-141 2.5E-03 5.OE-06 2.OE-04 5.OE-06 CE-141 2.5E-03 1.OE-04 1.2E-03 1.OE-04 BA-142 5.OE-03 4.0E-04 3.2E-03 4.OE-04 LA-142 2.5E-03 5.OE-06 2.OE-04 5.OE-06 CE-143 2.5E-03 1.OE-04 1.2E-03 1.0E-04 PR-143 2.5E-03 5.OE-06 4.7E-03 5.0E-06 CE-144 2.5E-03 1.OE-04 1.2E-03 1.OE-04 PR-144 2.5E-03 5.OE-06 4.7E-03 5.OE-06 ND-147 2.4E-03 5.OE-06 3.3E-03 5.OE-06 PM-147 2.5E-03 5.OE-06 4.8E-03 5.0E-06 PM-148m 2.5E-03 5.OE-06 4.8E-03 5.OE-06 PM-148 2.5E-03 5.OE-06 4.8E-03 5.OE-06 PM-149 2.5E-03 5.OE-06 4.8E-03 5.OE-06 PM-151 2.5E-03 5.OE-06 4.8E-03 5.OE-06 SM-151 2.5E-03 5.OE-06 5.OE-03 5.OE-06 SM-153 2.5E-03 5.OE-06 5.OE-03 5.OE-06 EU-152 2.5E-03 5.OE-06 4.8E-03 5.OE-06 EU-154 2.5E-03 5.OE-06 4.8E-03 5.OE-06 EU-155 2.5E-03 5.OE-06 4.8E-03 5.OE-06 EU-1 56 2.5E-03 5.OE-06 4.8E-03 5.OE-06 TB-160 2.6E-03 5.OE-06 4.4E-03 5.OE-06 HO-166m 2.6E-03 5.OE-06 4.4E-03 5.OE-06 W-181 1.8E-02 5.OE-04 1.3E-03 5.OE-04 W-185 1.8E-02 5.OE-04 1.3E-03 5.OE-04 W-187 1.8E-02 5.OE-04 I.3E-03 5.OE-04 NP-239 2.5E-03 5.OE-06 2.OE-04 5.OE-06 U-232 2.5E-03 5.OE-04 3.4E-04 5.OE-04 U-233 2.5E-03 5.OE-04 3.4E-04 5.OE-04 U-234 2.5E-03 5.OE-04 3.4E-04 5.OE-04 U-235 2.5E-03 5.OE-04 3.4E-04 5.OE-04 U-236 2.5E-03 5.OE-04 3.4E-04 5.OE-04 U-237 2.5E-03 5.OE-04 3.4E-04 5.OE-04 U-238 2.5E-03 5.OE-04 3.4E-04 5.OE-04 NP-237 2.5E-03 5.OE-06 2.OE-04 5.OE-06 NP-238 2.5E-03 5.OE-06 2.OE-04 5.0E-06 PU-238 2.5E-04 2.OE-06 1.4E-05 2.OE-06 PU-239 2.5E-04 2.OE-06 1.4E-05 2.OE-06

CY-LG-170-301, Rev. 23 Page 240 08/07 Table 112-3 STABLE ELEMENT TRANSFER DATA*

NUCLIDE VEG/SOIL COW MILK (D/L) MEAT (D/KG) GOAT MILK (D/L)

PU-240 2.5E-04 2.OE-06 1.4E-05 2.OE-06 PU-241 2.5E-04 2.OE-06 1.4E-05 2.OE-06 PU-242 2.5E-04 2.OE-06 1.4E-05 2.OE-06 PU-244 2.5E-04 2.OE-06 1.4E-05 2.OE-06 AM-241 2.5E-04 5.OE-06 2.OE-04 5.OE-06 AM-242m 2.5E-04 5.OE-06 2.OE-04 5.OE-06 AM-243 2.5E-04 5.OE-06 2.OE-04 5.OE-06 CM-242 2.5E-03 5.OE-06 2.OE-04 5.OE-06 CM-243 2.5E-03 5.OE-06 2.OE-04 5.OE-06 CM-244 2.5E-03 5.OE-06 2.OE-04 5.OE-06 CM-245 2.5E-03 5.OE-06 2.0E-04 5.OE-06 CM-246 2.5E-03 5.OE-06 2.OE-04 5.OE-06 CM-247 2.5E-03 5.OE-06 2.OE-04 5.OE-06 CM-248 2.5E-03 5.OE-06 2.OE-04 5.OE-06 CF-252 2.5E-03 5.0E-06 2.OE-04 5.OE-06 Reg. Guide 1.109 Table E-1, E-2 and NUREG/CR - 1276 Append D Columns 19, 20 and 21

CY-LG-170-301, Rev. 23 Page 241 08/07 TABLE 112-4 1

Assumptions Used in Limerick Gaseous Effluent Ri Calculations( )

Symbol Description Value Reference(2) f

Fraction of annual intake of fresh, leafy vegetation grown locally 0.42 Site Spec.

fg Fraction of annual intake of stored vegetation grown locally 0.76 E-15 YV Vegetation area density (kg/mr2) 2.0 E-15 r Fraction of deposited particulates retained on vegetation 0.20 E-1 5 r Fraction of deposited iodines retained on vegetation 1.0 E-15 SF Shielding factor of residential structures 0.7 E-15 t Period of buildup of activity in soil (sec) 6.31 E08 Site Spec.

tf Transport time milkman (sec) 1.73E05 E-15 th Delay time for ingestion of stored feed by animals (sec) 7.78E06 E-15 th Delay time for ingestion of leafy vegetable by man (sec) 8.64E04 E-15 th Delay time for ingestion of other vegetable by man (sec) 5.18E06 E-15 ts Time between slaughter and consumption of meat animal (sec) 1.73E06 E-15 Yp Grass yield (kg/m**2) 0.7 E-15 Ys Stored feed yield (kg/m**2) 2.0 E-15

w Weathering rate constant for activity on veg (sece1 ) 5.73E-07 E-15 QF Milk cow feed consumption rate (kg/day wet) 50.0 E-3 QF Beef cattle consumption rate (kg/day wet) 50.0 E-3 QF Goat feed consumption rate (kg/day wet) 6.0 E-3 K Ground exposure (all age groups) (hr/yr) 8760.0 C-2(3)

BR Breathing Rate adult (m**3/yr) 8000.0 E-5 BR Breathing Rate teen (m*3/yr) 8000.0 E-5 BR Breathing Rate child (m**3/yr) 3700.0 E-5 BR Breathing Rate infant (m**3/yr) 1400.0 E-5 L Leafy veg onsumption rate adult (kg/yr) 64.0 E-5 U- Leafy veg consumption rate teen (kg/yr 42.0 E-5 L Leafy veg onsumption rate child (kg/yr) 26.0 E-5 UA Leafy veg consumption rate infant (kg/yr) 0.0 E-5 U Stored veg consumption rate adult (kg/yr) 520.0 E-5 U Stored veg consumption rate adult (kg/yr) 630.0 E-5 Stored veg consumption rate adult (kg/yr) 520.0 E-5 U, Stored veg consumption rate adult (kg/yr) 0.0 E-5 Uap Cow milk consumption rate adult (l/yr) 310.0 E-5 Uap Cow milk consumption rate teen (l/yr) 400.0 E-5 Uap Cow milk consumption rate child (l/yr) 330.0 E-5 Uap Cow milk consumption rate infant (l/yr) 330.0 E-5 Uap Goat milk consumption rate adult (l/yr) 23.0 Site Spec.

Uap Goat milk consumption rate teen (l/yr) 29.0 Site Spec.

Uap Goat milk consumption rate child (I/yr) 0.0 Site Spec.

Uap Goat milk consumption rate infant (l/yr) 0.0 Site Spec.

Uap Meat consumption rate adult (kg/yr) 110.0 E-5 Uap Meat consumption rate teen (kg/yr) 65.0 E-5 Uap Meat consumption rate child (kg/yr) 41.0 E-5 Uap Meat consumption rate infant (kg/yr) 0.0 E-5 fp Fraction of year animals on pasture 0.75 Site Spec.

fs Fraction of feed from pasture when on pasture 0.39 Site Spec.

H Atmosphere absolute humidity (gm/m**3) 8.0 (4)

NOTES

1) Ri values are calculated in accordance with the methodologies given in NUREG-0133.

2) The References refer to tables contained in Regulatory Guide 1.109 unless otherwise specified.

3) From Reg. Guide 1.109, Appendix C, Equation C-2

4) From NUREG-01 33, Section 5.3.1.3.

CY-LG-170-301, Rev. 23 Page 242 08/07 TABLE 112-5 Nearest Gaseous Effluent Dose Receptor Distances (Meters)

Plume Ground Vegetation Cow Direction Inhalation Pathway Meat Pathway Pathway Goat Pathway Pathways N 948 2867 3414 7565 0 NNE 825 825 1585 0 0 NE 1057 2540 1097 0 0 ENE 985 1130 3871 0 0 E 873 1076 1890 0 0 ESE 1047 1721 4511 0 0 SE 1557 2224 7241 0 0 SSE 1647 1724 7224 0 0 S 1325 1860 3018 6781 0 SSW 1543 1622 1433 3145 0 SW 991 946 2835 0 0 WSW 1158 3731 2134 4336 0 W 1105 1283 4084 4467 0 WNW 1198 1333 0 0 0 NW 1104 2498 6660 0 0 NNW 1540 2612 6325 0 0

CY-LG-1 70-301, Rev. 23 Page 243 08/07 FIGURES

CY-LG-170-301, Rev. 23 Page 244 08/07 LGS DILUTION FACTOR (Mp) vs. RIVER FLOW STATION OUTFALL 100 0

10 E 11 + . . . 1.E+0.-- -+4 1.E+01 1 E+02 .. ~1. E+03 1.E+04 r-LLVV JCTS)

Figure 111.3.1-1

CY-LG-170-301, Rev. 23 Page 245 08/07 LGS DILUTION FACTOR (Mp) vs. RIVER FLOW 110 13w0 PENNSYLVANIA

!o AMERICAN I . WATER

.. COMPANY I I* "

10000,

1000

. .. ..... . . .. . I-1 ..

10 &I 1.E+1 1E+02 1.E+03 1.E+4 rL6%Jfl %uIa Figure 111.3.1-2

CY-LG-A70-301, Rev. 23 Page 246 08/07 LGS DILUTION FACTOR (Mp) vs. RIVER FLOW PHOENIXVILLE 1000 0 E"01 1 IL. 100-* ... . . . .. .. 7 1 7.1.....

. . . ......-. . .. . ......... ... . ... . . .. .. ... I.. .. IT I""

-j

.,, i 'L ....................................... .i

"_ 7i '

1*; I:

1 i _ _ _ _ _

1. E+01 1. E+02 ..... 1.E+03 1. E+04 f-LUVV tCTS)

Figure 111.3.1-3

CY-LG-1 70-301, Rev. 23 Page 247 08/07 LGS DILUTION FACTOR (Mp) vs. RIVER FLOW PHILADELPHIA SURBURBAN 1000 S100

-0. ... ..... . 1 7

......... ..7 *..... . __

. - - .'-r---

............. ... 71 C--

i . -...... .~........ . . . . . -....--- ---.- -

.E÷01 1.E+02 1.E+03 1 .E+04 FLOW (cfs)

Figure 111.3.1-4

CY-LG-1 70-301, Rev. 23 I Page 248 08/07I LGS DILUTION FACTOR (Mp) vs. RIVER FLOW CREW COURSE 1000 CL100 0

I-I.)

M U--

-J 10 1

1.E+01 1. E+02 1.E+03 1.E+04 FLOW (cfs)

Figure 111.3.1-5

CY-LG-170-301, Rev. 23 Page 249 08/07 To FOOT

F.3.0.83 fltl.618-63012 OK04 Chem Waste (Cw) TANK Subsyslem

'I Figure I11-1

CY-LG-170-301, Rev. 23 I Page 250 08/07[

North Vent a Monitor Wide Unit* I S Elov 41' Mid HighRange Spartic ulate "nesMoito Accident.

end Iodine Low flangeMonitor P--lMoulae4 Iodine &R . Firer Noble Gas Normal flange Monitors Gas Monitor Pump

43) Turbine Enclosure Exhaust 004.000 CPM Turbine Enclosure Turbine Enclosure Exhaust + (2) Equip Comport Exhaust Turbine Enclosure (2) (2) 4-- (2) Battey Room Exhaust

~Min.

Equip. Comport Exhaust 1mP S03.000 Rom xhus Mach. Vac. Pump Steam Packing Exhausier Steam Peak. Eshauster 4R-dwasl Enal Exhaust D/W Pugs'oJ Radwaote Encl. Equip.

Compattment Exhauster S ta ndb yG asT r o st. 8 . 143G as e Sbu s Mad w a tes Tre a tm e n t 1 eUnit i Condenser Oltgas Fume Hood Exhausi 1[1.Uttodsrf1

_oo APhiladelphia Electric Comp.

Control Area E2haut) Limerick Oonerating Stailon is) Units I & 2 Gaseots, Effluents, Flow Diagram Norlh Slack Unit I Charcoal System Exhaust Fan Filter Unii2 CharoaloSystem Figure 112-1

CY-LG-170-301, Rev. 23 Page 251 08/07 Relueling Floor Exhaust Reactor EncIosure Exhaust Equipment Compartment Exhaust Philadelphia Eleotric Camp.

LImerick Generating Stklton IJtsl I A, Gaseaou Elnuent Flow Diagram South Stock Figure 112-2

CY-LG-170-301, Rev. 23 Page 252 08/07 UNIT 2 Reactor Encl.

East Exhaust Stack El 416' 7000 cdm Particulate/Iodine Radiation Monitor Bag Fllter (typical) P T

General Repair Area I E

EXHAUSR FAN _FILTER Figure 112-3

CY-LG-1 70-301, Rev. 23 Page 253 08/07 APPENDIX A RADIOLOGICAL ENVIRONMENTAL MONITORING PROGRAM -

SAMPLE TYPE, LOCATION, AND ANALYSIS

CY-LG-170-301, Rev. 23 Page 254 08/07 TABLE A-1 Page 1 of 3 ODCM - Limerick Generating Station Radiological Environmental Monitoring Program Pathway Station Code Location Collection Method Analyses 1 set of four (4) TLDs from each Inrect 36S2 3,183 feet N of site location at least quarterly Gamma dose quarterly (1) Inner Ring 3S1 2,301 feet NNE of site 5S1 2,350 feet NE of site 7S1 3,099 feet ENE of site 10S3 2,648 feet E of site 11S1 2,017 feet ESE of site 13S2 2,149 feet SE of site 14S1 3,319 feet SSE of site 18S2 1,390 feet S of site 21S2 977 feet SSW of site 23S2 2,793 feet SW of site 25S2 2,445 feet WSW of site 26S3 2,088 feet W of site 29S1 2,886 feet WNW of site 31S1 1,395 feet NW of site 34S2 3,071 feet NNW of site (2) Outer Ring 36D1 18,527 feet N of site 2E1 25,112 feet NNE of site 4E1 25,221 feet NE of site 7E1 22,489 feet ENE of site 10E1 20,826 feet E of site 10F3 29,442 feet ESE of site 13E1 22,772 feet SE of site 16F1 26,608 feet SSE of site 19D1 18,439 feet S of site 20F1 27,648 feet SSW of site 24D1 20,972 feet SW of site 25D1 21,044 feet WSW of site 28D2 20,231 feet W of site 29E1 26,110 feet WNW of site 31 D2 20,446 feet NW of site 34E1 24,243 feet NNW of site

CY-LG-170-301, Rev. 23 Page 255 08/07 T Rl 1: -1 (r-rnfin"ar41 Dn-' 9 nf '

Pathway Station Code Location Collection Method Analyses (3) Controls and 5H1 C 130,742 feet NE of site Special Interest 6C1 11,305 feet NE of site 9C1 11,377 feet E of site 13C1 14,980 feet SE of site 15D1 16,877 feet SE of site 177B1 8,462 feet S of site 20D1 16,157 feet SSW of site 31D1 15,853 feet WNW of site II. Airborn 10S3 2,648 feet E of site Approximately 1 cfm continuous flow Gross beta analysis on each weekly Particulates 11Sl 2,017 feet ESE of site through glass fiber filter which is collected sample. Gamma spectrometry shall be 14S1 3,319 feet SSE of site weekly. done when gross beta exceeds ten times 13Cl 14,980 feet SE of site the yearly mean of control station value.

22G1 C 93,619 feet SW of site Gross beta analysis done 24 hr after sampling to allow for Radon and Thoron daughter decay.

Gamma Spec on quarterly composite.

Iodine 10S3 2,648 feet E of site A TEDA impregnated flow-through Iodine 131 analysis on each weekly 11SI 2,017 feet ESE of site cartridge is connected to air sampler and sample.

14S1 3,319 feet SSE of site is collected weekly at site filter change.

13C1 14,980 feet SE of site 22G1 C 93,619 feet SW of site Ill. WVtA 24SI C 1,058 feet SW of site Sample collected from a continuous water Gamma isotopic analysis monthly.

a. Surface 13BI 9,225 feet SE of site sampler, monthly. In event sampler is inoperable, weekly grab samples will be H-3 on quarterly composite collected until sampler retumed to service.

b. Ground No Ground water is sampled and analyzed, because ground water flow is to the rlver per UFSAR Section 2.4.13

c. Drinking 15F7 33,400 feet SSE of site Sample collected from a continuous water Gross beta and gamma isotopic 15F4 45,514 feet SE of site sampler monthly. In event sampler is monthly, 16C2 14,034 feet SSE of site inoperable, weekly grab samples.will be 28F3 C 30,811 feet WNW of site collected until sampler retumed to service. H-3 on quarterly composite TABLE A-1 (Continued) Page 3 of 3

CY-LG-1 70-301, Rev. 23 Page 256 08/07 Pathway Station Code Location Collection Method Analyses Ill. Watt (Continued) 16C4 11,510 feet SSE of site A sediment sample is taken down stream Gamma isotopic analysis each

d. Sediment from of discharge semi-annually sample shoreline IV. lngtin 18E1 22,704 feet S of site Sample of fresh milk is collected from Gamma isotopic and 1-131 analyses

a. Milk 19B1 10,317 feet SSW of site each farm biweekly when cows are on on each sample 25C1 14,224 feet WSW of site pasture (April) through October), monthly 23F1 C 26,505 feet SW of site at other times.

b. Fish and 16C5 9,251 feet SE of site Two species of recreationally Gamma isotopic analyses on edible Invertebrates 29C1 C 13,725 feet WNW of site important fish (Predator and bottom portions.

feeder) sampled in season or semiannuall if not seasonal.

Seasons are Spring and Fall There are no commercially or recreationally important species of invertebrates. Therefore no invertebrates are sampid.

c. Food Products There are no downstream food products that are irrigated by water in which liquid plant wastes have been discharged.

No broad leaf vegetation sampling is performed, because milk sampling is performed.

C = Control Location

CY-LG-170-301, Rev. 23 Page 257 08/07 Figure A-1 Environmental Sampling Locations On Site or Near the Limerick Generatinq Station

CY-LG-170-301, Rev. 23 Page 258 08/07 Figure A-2 Environmental Sampling Locations at Distances Less Than Five Miles from the Limerick Generatinq Station.

CY-LG-170-301, Rev. 23 I Page 259 08/07I Figure A-3 Environmental Sampling Locations at Distances Greater Than Five Miles from the Limerick Generating Station.

CY-LG-170-301, Rev. 23 Page 260 08/07 REFERENCES

1. Regulatory Guide 1.109, "Calculation of Annual Doses to Man from Routine Releases of Reactor Effluents for the Purpose of Evaluating Compliance with 10 CFR Part 50, Appendix I," Revision 1, U.S. Nuclear Regulatory Commission, Washington, D.C.

20555, October 1977.

2. Regulatory Guide 1.111, "Methods for Estimating Atmospheric Transport and Dispersion of Gaseous Effluents in Routine Releases from Light-Water-Cooled Reactors," Revision 1, U.S. Nuclear Regulatory Commission, Washington, D.C. 20555, July 1977.

3. Regulatory Guide 1.112, "Calculation of Releases of Radioactive Materials in Gaseous and Liquid Effluents from Light-Water-Cooled Power Reactors," U.S. Nuclear Regulatory Commission, Washington, D.C. 20555, April 1976.

4. Regulatory Guide 1.113, "Estimating Aquatic Dispersion of Effluents from Accidental and Routine Reactor Releases for the Purpose of Implementing Appendix I," Revision 1, U.S. Nuclear Regulatory Commission, Washington, D.C. 20555, April 1977.

5. U.S. Nuclear Regulatory Commission, "Calculation of Releases of Radioactive Materials in Gaseous and Liquid Effluents from Boiling Water Reactors (BWR-GALE Code)," USNRC Report NUREG-0016, Washington, D.C. 20555, April 1976.

6. U.S. Nuclear Regulatory Commission, "XOQDOQ, Program for the Methodological Evaluation of Routine Effluent Releases at Nuclear Power Stations," USNRC Report NUREG-0324, Washington, D.C. 20555, September, 1977.

7. Title 10, "Energy," Chapter I, Code of Federal Regulations; Part 20, Appendix B, U.S.

Government Printing Office, Washington, D.C. 20402, January 1, 1977.

8. Title 10, "Energy," Chapter I, Code of Federal Regulations; Part 100, U.S. Government Printing Office, Washington, D.C. 20404, January 1, 1977.

9. Title 40, "Protection of Environment," Chapter I, Code of Federal Regulations, Part 141, U.S. Government Printing Office, Washington, D.C. 20402, January 1, 1977.

10. Regulatory Guide 1.21, "Measuring, Evaluating, and Reporting Radioactivity in Solid Wastes and Releases of Radioactive Materials in Liquid and Gaseous Effluents from Light-Water-Cooled Nuclear Power Plants," Revision 1, U.S. Nuclear Regulatory Commission, Washington, D.C. 20555, June 1974.

11. Title 40, "Protection of Environment," Chapter I, Code of Federal Regulations, Part 190, Federal Register, Vol. 42, No. 9, Washington, D.C. 20402, January 13, 1977.

12. U.S. Nuclear Regulatory Commission, "Short Term Diffusion Estimates," Section 2.3.4, Standard Review Plan for the Review of Safety Analysis Reports for Nuclear Power Plants - LWR Edition, USNRC Report NUREG-75/087, Washington, D.C. 20555, November 1975.

CY-LG-170-301, Rev. 23 Page 261 08/07

13. U.S. Nuclear Regulatory Commission, "Preparation of Radiological Effluent Technical Specifications for Nuclear Power Plants," USNRC Report NUREG-0133, Washington, D.C. 20555, October 1978.

14. Letter From Thomas E. Marley, Director Office of Nuclear Reactor Regulations, To Thomas E. Tipton Vice President and Director Operations, Nuclear Management and Resources Council, 6/30/93.

15. ANSI N42.14-1991 (Revision of ANSI N42.14-1978) "Calibration and Use of Germanium Spectrometers For the Measurement of Gamma-Ray Emission Rates of Radionuclides", Sect. 6.2.2

16. EML Procedures Manual, H.L. Volchok and G. dePlangue, Editors, U.S. Dept. Of Energy (Revised Annually)

17. L.A. Currie, "Limits For Qualitative Detection and Quantitative Determination -

Application to Radiochemistry", Analytical Chemistry, Vol. 40, pp. 586-593 (TABLE II),

1968

18. NUREG/CR-4007, "Lower Limit of Detection: Definition and Elaboration of a Proposed Position for Radiological Effluent and Environmental Measurements", prepared by NRC by L.A. Currie (Chapter II, Sect. D.2; Chapter III, Sect. C.1), September 1984

19. Tech. Spec. Section 1.24 (Definitions)

20. USNRC Generic Letter, 89-01

21. Tech. Spec. Section 6.14.

22. Tech. Spec. Section 6.5.1.6m.

23. Tech. Spec. Section 6.5.3.

24. Tech. Spec. Section 6.8.4d, e and f.

25. Tech. Spec. Section 6.9.1.8/ODCM Control 1.3.6.

26. Tech. Spec. Section 6.10.3m and n.

27. UFSAR, Section 11.5.6.

28. Bechtel, Inc., "Dilution Studies for Routine and Accidental Releases from Limerick Nuclear Plant into the Schuylkill River", March, 1996.

29. ANSI/ANS-6.6.1-1979 "calculation and measurement of direct and scattered gamma radiation from LWR nuclear power plants, Section 7

30. Hartwell, J.K., "Detection Limits for Radioanalytical Counting Techniques,"Atlantic Richfield Hanford Company Report ARH-SA-215 (June, 1975).

31. NUREG 1276 - LADTAP II Users Manual

ML081260684

Text

Navigation menu

Search